{"PMC7309926": [["Effects of DFs in control of chronic diseases ::: IntroductionAs stated earlier, diets with high fiber contents are asserted to present significant protective effects against chronic diseases such as metabolic syndrome including type 2 diabetes (M. M\u00fcller, Canfora, & Blaak, 2018), CVD and obesity (M. M\u00fcller et al., 2018).", [["DFs", "CHEMICAL", 11, 14], ["chronic diseases", "DISEASE", 29, 45], ["chronic diseases", "DISEASE", 175, 191], ["metabolic syndrome", "DISEASE", 200, 218], ["type 2 diabetes", "DISEASE", 229, 244], ["CVD", "DISEASE", 282, 285], ["obesity", "DISEASE", 290, 297], ["DFs", "PROBLEM", 11, 14], ["chronic diseases", "PROBLEM", 29, 45], ["high fiber contents", "TREATMENT", 92, 111], ["chronic diseases", "PROBLEM", 175, 191], ["metabolic syndrome", "PROBLEM", 200, 218], ["type 2 diabetes", "PROBLEM", 229, 244], ["CVD", "PROBLEM", 282, 285], ["obesity", "PROBLEM", 290, 297], ["chronic", "OBSERVATION_MODIFIER", 29, 36], ["diseases", "OBSERVATION", 37, 45], ["significant protective", "OBSERVATION_MODIFIER", 136, 158], ["metabolic syndrome", "OBSERVATION", 200, 218], ["obesity", "OBSERVATION", 290, 297]]], ["Substantial research has been carried out so far stating DFs as important formulation in the control and treatment of these pathologies (Prasad & Bondy, 2019).", [["DFs", "SIMPLE_CHEMICAL", 57, 60], ["these pathologies", "PROBLEM", 118, 135]]], ["In this context, in our previous review we also presented the health benefits of DFs particularly konjac glucomannan (KGM) with critical focus on its role in control of diabetes (Shah et al., 2015).", [["konjac glucomannan", "CHEMICAL", 98, 116], ["KGM", "CHEMICAL", 118, 121], ["diabetes", "DISEASE", 169, 177], ["konjac glucomannan", "CHEMICAL", 98, 116], ["KGM", "CHEMICAL", 118, 121], ["DFs", "SIMPLE_CHEMICAL", 81, 84], ["konjac glucomannan", "SIMPLE_CHEMICAL", 98, 116], ["KGM", "SIMPLE_CHEMICAL", 118, 121], ["konjac glucomannan (KGM", "TREATMENT", 98, 121], ["diabetes", "PROBLEM", 169, 177]]], ["It is thought that the benefit of DFs in control of diabetes is connected with their fermentation by gut microbiota to short chain fatty acids (SCFAs), the deficiency of which may lead to the development and progression of the disease (L. Zhao et al., 2018).", [["gut", "ANATOMY", 101, 104], ["DFs", "CHEMICAL", 34, 37], ["diabetes", "DISEASE", 52, 60], ["fatty acids", "CHEMICAL", 131, 142], ["SCFAs", "CHEMICAL", 144, 149], ["fatty acids", "CHEMICAL", 131, 142], ["SCFAs", "CHEMICAL", 144, 149], ["DFs", "SIMPLE_CHEMICAL", 34, 37], ["gut", "ORGANISM_SUBDIVISION", 101, 104], ["fatty acids", "SIMPLE_CHEMICAL", 131, 142], ["SCFAs", "SIMPLE_CHEMICAL", 144, 149], ["DFs", "PROBLEM", 34, 37], ["diabetes", "PROBLEM", 52, 60], ["short chain fatty acids", "PROBLEM", 119, 142], ["the deficiency", "PROBLEM", 152, 166], ["the disease", "PROBLEM", 223, 234], ["progression", "OBSERVATION_MODIFIER", 208, 219]]], ["Although most of the research community assumes that the detailed mood of actions of DFs in safeguarding against these pathologies is up to some extent complicated and not fully known, still there are evidences describing the presence of \u03b2-glucans in some DFs (e.g.oats) linked to curb the levels of total cholesterol and low density lipoprotein (LDL) cholesterol (Korcz et al., 2018).", [["DFs", "CHEMICAL", 85, 88], ["\u03b2-glucans", "CHEMICAL", 238, 247], ["cholesterol", "CHEMICAL", 306, 317], ["cholesterol", "CHEMICAL", 352, 363], ["\u03b2-glucans", "CHEMICAL", 238, 247], ["cholesterol", "CHEMICAL", 306, 317], ["cholesterol", "CHEMICAL", 352, 363], ["\u03b2-glucans", "SIMPLE_CHEMICAL", 238, 247], ["DFs", "SIMPLE_CHEMICAL", 256, 259], ["cholesterol", "SIMPLE_CHEMICAL", 306, 317], ["low density lipoprotein (LDL) cholesterol", "SIMPLE_CHEMICAL", 322, 363], ["LDL", "PROTEIN", 347, 350], ["these pathologies", "PROBLEM", 113, 130], ["\u03b2-glucans", "PROBLEM", 238, 247], ["total cholesterol", "TEST", 300, 317], ["cholesterol", "TEST", 352, 363], ["pathologies", "OBSERVATION", 119, 130]]], ["In particular instance, SDFs being more viscous are known to control and lower postprandial blood cholesterol and sugar rises by influencing their absorption from the small intestine because of the formation of gels by these fibers (Mackie, Bajka, & Rigby, 2016).", [["blood", "ANATOMY", 92, 97], ["small intestine", "ANATOMY", 167, 182], ["fibers", "ANATOMY", 225, 231], ["cholesterol", "CHEMICAL", 98, 109], ["cholesterol", "CHEMICAL", 98, 109], ["sugar", "CHEMICAL", 114, 119], ["SDFs", "SIMPLE_CHEMICAL", 24, 28], ["blood", "ORGANISM_SUBSTANCE", 92, 97], ["cholesterol", "SIMPLE_CHEMICAL", 98, 109], ["sugar", "SIMPLE_CHEMICAL", 114, 119], ["small intestine", "ORGAN", 167, 182], ["fibers", "CELLULAR_COMPONENT", 225, 231], ["SDFs", "PROBLEM", 24, 28], ["lower postprandial blood cholesterol and sugar rises", "PROBLEM", 73, 125], ["the small intestine", "PROBLEM", 163, 182], ["small intestine", "ANATOMY", 167, 182]]], ["Similarly, another mechanism in lowering blood cholesterol levels by SDFs involve their capability to attenuate the quantity of bile reabsorbed in the intestines thereby elevating the excretion of bile in feces (Threapleton et al., 2013).", [["blood", "ANATOMY", 41, 46], ["bile", "ANATOMY", 128, 132], ["intestines", "ANATOMY", 151, 161], ["bile", "ANATOMY", 197, 201], ["cholesterol", "CHEMICAL", 47, 58], ["cholesterol", "CHEMICAL", 47, 58], ["blood", "ORGANISM_SUBSTANCE", 41, 46], ["cholesterol", "SIMPLE_CHEMICAL", 47, 58], ["SDFs", "SIMPLE_CHEMICAL", 69, 73], ["bile", "SIMPLE_CHEMICAL", 128, 132], ["intestines", "ORGAN", 151, 161], ["bile", "SIMPLE_CHEMICAL", 197, 201], ["feces", "ORGANISM_SUBSTANCE", 205, 210], ["lowering blood cholesterol levels", "TEST", 32, 65], ["bile reabsorbed in the intestines", "PROBLEM", 128, 161], ["bile", "ANATOMY", 128, 132], ["reabsorbed", "OBSERVATION", 133, 143], ["intestines", "ANATOMY", 151, 161], ["excretion", "OBSERVATION_MODIFIER", 184, 193], ["bile", "ANATOMY", 197, 201]]], ["And in order to cope with this loss, the liver stimulates the release of extra bile salts via enhancing the production of LDL cholesterol receptors, which skillfully perform separation of LDL molecules in the blood stream (Jesch & Carr, 2017).", [["liver", "ANATOMY", 41, 46], ["bile", "ANATOMY", 79, 83], ["blood stream", "ANATOMY", 209, 221], ["bile salts", "CHEMICAL", 79, 89], ["cholesterol", "CHEMICAL", 126, 137], ["bile salts", "CHEMICAL", 79, 89], ["cholesterol", "CHEMICAL", 126, 137], ["liver", "ORGAN", 41, 46], ["bile salts", "SIMPLE_CHEMICAL", 79, 89], ["LDL", "SIMPLE_CHEMICAL", 122, 125], ["LDL", "SIMPLE_CHEMICAL", 188, 191], ["blood", "ORGANISM_SUBSTANCE", 209, 214], ["LDL cholesterol receptors", "PROTEIN", 122, 147], ["LDL molecules", "PROTEIN", 188, 201], ["this loss", "PROBLEM", 26, 35], ["extra bile salts", "TREATMENT", 73, 89], ["LDL cholesterol receptors", "TEST", 122, 147], ["LDL molecules", "PROBLEM", 188, 201], ["liver", "ANATOMY", 41, 46]]], ["Consequently, the elevated bile salts production by the liver causes isolation of more LDL molecules from the blood.", [["bile", "ANATOMY", 27, 31], ["liver", "ANATOMY", 56, 61], ["blood", "ANATOMY", 110, 115], ["bile salts", "CHEMICAL", 27, 37], ["bile salts", "CHEMICAL", 27, 37], ["bile salts", "SIMPLE_CHEMICAL", 27, 37], ["liver", "ORGAN", 56, 61], ["LDL", "SIMPLE_CHEMICAL", 87, 90], ["blood", "ORGANISM_SUBSTANCE", 110, 115], ["LDL molecules", "PROTEIN", 87, 100], ["the elevated bile salts production", "PROBLEM", 14, 48], ["more LDL molecules", "PROBLEM", 82, 100], ["the blood", "TEST", 106, 115], ["elevated", "OBSERVATION_MODIFIER", 18, 26], ["bile", "ANATOMY", 27, 31], ["salts production", "OBSERVATION", 32, 48], ["liver", "ANATOMY", 56, 61], ["more LDL", "OBSERVATION_MODIFIER", 82, 90], ["blood", "ANATOMY", 110, 115]]], ["Furthermore, in another way SDFs and indigestible starch molecules go through fermentation by intestinal bacterial flora resulting in the productions of SCFAs, which in turn aid in attenuating circulating cholesterol levels in blood (Threapleton et al., 2013).Effects of DFs in control of chronic diseases ::: IntroductionNo doubt while speaking about CVD, the term \u201cobesity\u201d can't be ignored as it is one of the main reasons for CVD related morbidities and mortalities.", [["blood", "ANATOMY", 227, 232], ["SCFAs", "CHEMICAL", 153, 158], ["cholesterol", "CHEMICAL", 205, 216], ["DFs", "CHEMICAL", 271, 274], ["chronic diseases", "DISEASE", 289, 305], ["CVD", "DISEASE", 352, 355], ["obesity", "DISEASE", 367, 374], ["CVD", "DISEASE", 430, 433], ["SCFAs", "CHEMICAL", 153, 158], ["cholesterol", "CHEMICAL", 205, 216], ["SDFs", "SIMPLE_CHEMICAL", 28, 32], ["SCFAs", "SIMPLE_CHEMICAL", 153, 158], ["cholesterol", "SIMPLE_CHEMICAL", 205, 216], ["blood", "ORGANISM_SUBSTANCE", 227, 232], ["another way SDFs", "PROBLEM", 16, 32], ["indigestible starch molecules", "PROBLEM", 37, 66], ["intestinal bacterial flora", "PROBLEM", 94, 120], ["the productions of SCFAs", "PROBLEM", 134, 158], ["attenuating circulating cholesterol levels", "TEST", 181, 223], ["DFs", "PROBLEM", 271, 274], ["chronic diseases", "PROBLEM", 289, 305], ["obesity", "PROBLEM", 367, 374], ["CVD related morbidities", "PROBLEM", 430, 453], ["indigestible", "OBSERVATION", 37, 49], ["starch molecules", "OBSERVATION", 50, 66], ["intestinal", "ANATOMY", 94, 104], ["bacterial flora", "OBSERVATION", 105, 120], ["chronic", "OBSERVATION_MODIFIER", 289, 296], ["diseases", "OBSERVATION", 297, 305]]], ["Till date, a substantial amount of research work has been reported dealing with interventional human trials to determine the potential effects of DFs rich diets or DFs supplements in weight loss management.", [["DFs", "CHEMICAL", 146, 149], ["DFs", "CHEMICAL", 164, 167], ["weight loss", "DISEASE", 183, 194], ["human", "ORGANISM", 95, 100], ["DFs", "SIMPLE_CHEMICAL", 146, 149], ["DFs", "SIMPLE_CHEMICAL", 164, 167], ["human", "SPECIES", 95, 100], ["human", "SPECIES", 95, 100], ["interventional human trials", "TREATMENT", 80, 107], ["DFs rich diets", "TREATMENT", 146, 160], ["DFs supplements", "TREATMENT", 164, 179], ["weight loss management", "TREATMENT", 183, 205], ["substantial", "OBSERVATION_MODIFIER", 13, 24], ["amount", "OBSERVATION_MODIFIER", 25, 31]]], ["The reason could be the indigestible characteristic of DFs which prolong their transit time in the intestinal lumen and thereby induce greater satiety compared with simple and digestible polysaccharides which are readily digested.", [["intestinal lumen", "ANATOMY", 99, 115], ["DFs", "SIMPLE_CHEMICAL", 55, 58], ["intestinal lumen", "MULTI-TISSUE_STRUCTURE", 99, 115], ["DFs", "PROBLEM", 55, 58], ["greater satiety", "PROBLEM", 135, 150], ["simple and digestible polysaccharides", "PROBLEM", 165, 202], ["DFs", "OBSERVATION", 55, 58], ["transit time", "OBSERVATION", 79, 91], ["intestinal lumen", "ANATOMY", 99, 115], ["greater", "OBSERVATION_MODIFIER", 135, 142]]], ["Furthermore, DFs could also be involved in prolongation of meal intervals and induce an enhanced mastication with presumable cephalic and peripheral effects on satiety.", [["cephalic", "ANATOMY", 125, 133], ["DFs", "SIMPLE_CHEMICAL", 13, 16], ["DFs", "PROTEIN", 13, 16], ["DFs", "PROBLEM", 13, 16], ["an enhanced mastication", "PROBLEM", 85, 108], ["presumable cephalic and peripheral effects on satiety", "PROBLEM", 114, 167], ["enhanced mastication", "OBSERVATION", 88, 108], ["cephalic", "ANATOMY", 125, 133], ["peripheral effects", "OBSERVATION", 138, 156]]], ["Interestingly and more healthfully diets rich in DFs have a lesser energy bulk and could influence palatability of foods, which could ultimately lead to a lower calories intake (Benton & Young, 2017).", [["DFs", "SIMPLE_CHEMICAL", 49, 52], ["lesser energy bulk", "OBSERVATION_MODIFIER", 60, 78]]], ["Another mechanism related to appetite reducing effects of DFs, is based on stimulating the signaling of GIT satiation peptide hormones such as glucagon-like peptide (GLP-1) and peptide YY (PYY) or glucose dependent insulinotropic peptide (GIP) by DFs which result from their fermentation in the large intestine by gut microbiota (Lim & Poppitt, 2019).", [["intestine", "ANATOMY", 301, 310], ["gut", "ANATOMY", 314, 317], ["DFs", "CHEMICAL", 58, 61], ["glucose", "CHEMICAL", 197, 204], ["glucose", "CHEMICAL", 197, 204], ["DFs", "SIMPLE_CHEMICAL", 58, 61], ["GIT", "ORGANISM_SUBDIVISION", 104, 107], ["glucagon-like peptide", "GENE_OR_GENE_PRODUCT", 143, 164], ["GLP-1", "GENE_OR_GENE_PRODUCT", 166, 171], ["peptide YY", "GENE_OR_GENE_PRODUCT", 177, 187], ["PYY", "GENE_OR_GENE_PRODUCT", 189, 192], ["glucose dependent insulinotropic peptide", "SIMPLE_CHEMICAL", 197, 237], ["GIP", "GENE_OR_GENE_PRODUCT", 239, 242], ["DFs", "SIMPLE_CHEMICAL", 247, 250], ["intestine", "ORGAN", 301, 310], ["gut", "ORGANISM_SUBDIVISION", 314, 317], ["DFs", "PROBLEM", 58, 61], ["GIT satiation peptide hormones", "TREATMENT", 104, 134], ["glucagon", "TEST", 143, 151], ["GLP", "TEST", 166, 169], ["glucose dependent insulinotropic peptide", "PROBLEM", 197, 237], ["DFs", "PROBLEM", 247, 250], ["large intestine", "ANATOMY", 295, 310], ["gut microbiota", "ANATOMY", 314, 328]]], ["Han et al. (2017) found that both oat and wheat fiber significantly reduced body and adipose tissues weight in the rats fed with high fat diet (HFD).", [["wheat fiber", "ANATOMY", 42, 53], ["body", "ANATOMY", 76, 80], ["adipose tissues", "ANATOMY", 85, 100], ["oat", "ORGANISM_SUBDIVISION", 34, 37], ["wheat fiber", "CELL", 42, 53], ["body", "ORGANISM_SUBDIVISION", 76, 80], ["adipose tissues", "TISSUE", 85, 100], ["rats", "ORGANISM", 115, 119], ["oat", "SPECIES", 34, 37], ["wheat", "SPECIES", 42, 47], ["rats", "SPECIES", 115, 119], ["wheat", "SPECIES", 42, 47], ["adipose tissues", "OBSERVATION", 85, 100]]], ["Also compared to HFD group, cereal DFs increased protein expressions involved in the lipolysis and browning process.", [["cereal DFs", "PROTEIN", 28, 38], ["cereal DFs increased protein expressions", "PROBLEM", 28, 68], ["the lipolysis", "PROBLEM", 81, 94], ["browning process", "PROBLEM", 99, 115], ["protein expressions", "OBSERVATION", 49, 68], ["lipolysis", "ANATOMY", 85, 94], ["browning process", "OBSERVATION", 99, 115]]], ["From their results, they concluded that cereal DFs promoted adipocyte lipolysis by the cAMP\u2013PKA\u2013HSL pathway and enhanced WAT browning by activation of UCP1, and consequently reduced visceral fat mass in response to HFD feeding (Han et al., 2017).", [["adipocyte", "ANATOMY", 60, 69], ["WAT", "ANATOMY", 121, 124], ["visceral fat", "ANATOMY", 182, 194], ["DFs", "CHEMICAL", 47, 50], ["DFs", "SIMPLE_CHEMICAL", 47, 50], ["adipocyte", "CELL", 60, 69], ["cAMP\u2013PKA", "GENE_OR_GENE_PRODUCT", 87, 95], ["HSL", "GENE_OR_GENE_PRODUCT", 96, 99], ["WAT", "TISSUE", 121, 124], ["UCP1", "GENE_OR_GENE_PRODUCT", 151, 155], ["visceral fat", "TISSUE", 182, 194], ["cAMP\u2013PKA", "PROTEIN", 87, 95], ["HSL", "PROTEIN", 96, 99], ["UCP1", "PROTEIN", 151, 155], ["adipocyte lipolysis", "TREATMENT", 60, 79], ["enhanced WAT browning", "PROBLEM", 112, 133], ["UCP1", "TEST", 151, 155], ["consequently reduced visceral fat mass", "PROBLEM", 161, 199], ["WAT browning", "OBSERVATION", 121, 133], ["UCP1", "ANATOMY", 151, 155], ["reduced", "OBSERVATION_MODIFIER", 174, 181], ["visceral fat", "ANATOMY", 182, 194], ["mass", "OBSERVATION", 195, 199]]], ["It is crucial to mention here that although research studies conducted on animal experimental models usually have more pronounced effects, however, the amount of fibers generally used in these studies are also higher compared to the levels used in human clinical trials, particularly in cases for prebiotics, where the dose is generally 40-fold higher on the basis of body weight (Makki, Deehan, Walter, & B\u00e4ckhed, 2018).Effects of DFs in control of chronic diseases ::: IntroductionThe preceding results imply that DFs have shown significant effects in control and treatment of different pathological conditions, still there are reports where contradictory results have been observed in the treatment groups in comparison to the control ones.", [["fibers", "ANATOMY", 162, 168], ["body", "ANATOMY", 368, 372], ["DFs", "CHEMICAL", 432, 435], ["chronic diseases", "DISEASE", 450, 466], ["fibers", "CELLULAR_COMPONENT", 162, 168], ["human", "ORGANISM", 248, 253], ["body", "ORGANISM_SUBDIVISION", 368, 372], ["DFs", "SIMPLE_CHEMICAL", 516, 519], ["human", "SPECIES", 248, 253], ["human", "SPECIES", 248, 253], ["research studies", "TEST", 44, 60], ["these studies", "TEST", 187, 200], ["prebiotics", "TREATMENT", 297, 307], ["DFs", "PROBLEM", 432, 435], ["chronic diseases", "PROBLEM", 450, 466], ["DFs", "PROBLEM", 516, 519], ["treatment", "TREATMENT", 566, 575], ["different pathological conditions", "PROBLEM", 579, 612], ["more pronounced", "OBSERVATION_MODIFIER", 114, 129], ["higher", "OBSERVATION_MODIFIER", 210, 216], ["chronic", "OBSERVATION_MODIFIER", 450, 457], ["diseases", "OBSERVATION", 458, 466], ["significant", "OBSERVATION_MODIFIER", 531, 542], ["effects", "OBSERVATION_MODIFIER", 543, 550]]], ["For example, in a study conducted to evaluate the effects of fibers intake on inflammatory markers (IM) in post-menopausal women, it was found that women in the higher fibers intake group (24.7 g/day) had lower plasma IL-6 and TNF-\u03b1-R2 (receptor 2 of the TNF-\u03b1) levels as compared to those with lower ingestion (7.7 g/day).", [["fibers", "ANATOMY", 61, 67], ["fibers", "ANATOMY", 168, 174], ["plasma", "ANATOMY", 211, 217], ["fibers", "TISSUE", 61, 67], ["women", "ORGANISM", 123, 128], ["women", "ORGANISM", 148, 153], ["plasma", "ORGANISM_SUBSTANCE", 211, 217], ["IL-6", "GENE_OR_GENE_PRODUCT", 218, 222], ["TNF-\u03b1-R2", "GENE_OR_GENE_PRODUCT", 227, 235], ["receptor 2", "GENE_OR_GENE_PRODUCT", 237, 247], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 255, 260], ["inflammatory markers", "PROTEIN", 78, 98], ["plasma IL-6", "PROTEIN", 211, 222], ["TNF", "PROTEIN", 227, 230], ["\u03b1-R2", "PROTEIN", 231, 235], ["TNF", "PROTEIN", 255, 258], ["women", "SPECIES", 123, 128], ["women", "SPECIES", 148, 153], ["a study", "TEST", 16, 23], ["inflammatory markers", "TREATMENT", 78, 98], ["lower plasma IL", "TEST", 205, 220], ["TNF", "TEST", 227, 230], ["receptor", "TEST", 237, 245], ["the TNF-\u03b1) levels", "TEST", 251, 268]]], ["However, there was no association between fibers and c-reactive protein (CRP) in both the groups (Grundy, Brewer, Cleeman, Smith, & Lenfant, 2004).", [["fibers", "ANATOMY", 42, 48], ["fibers", "CELLULAR_COMPONENT", 42, 48], ["c-reactive protein", "GENE_OR_GENE_PRODUCT", 53, 71], ["CRP", "GENE_OR_GENE_PRODUCT", 73, 76], ["c-reactive protein", "PROTEIN", 53, 71], ["CRP", "PROTEIN", 73, 76], ["c-reactive protein", "TEST", 53, 71], ["CRP", "TEST", 73, 76], ["no association between", "UNCERTAINTY", 19, 41]]], ["Likewise, in another study individuals from different ethnical groups, who consumed more fibers (1.39 g/serving of food) compared to those with the less consumption (0.02 g/serving) were favored with lower CRP values (King et al., 2007).", [["CRP", "GENE_OR_GENE_PRODUCT", 206, 209], ["CRP", "PROTEIN", 206, 209], ["another study", "TEST", 13, 26], ["lower CRP values", "PROBLEM", 200, 216]]], ["Even higher intake of DFs (43.8 g/day) as compared to lower intake (8.2 g/day) didn't show significant effects on IM in the two experimental groups, except for the lower values of homocysteine among several individuals analyzed in the study.", [["DFs", "CHEMICAL", 22, 25], ["homocysteine", "CHEMICAL", 180, 192], ["homocysteine", "CHEMICAL", 180, 192], ["DFs", "SIMPLE_CHEMICAL", 22, 25], ["homocysteine", "SIMPLE_CHEMICAL", 180, 192], ["significant effects on IM", "PROBLEM", 91, 116], ["homocysteine", "TREATMENT", 180, 192], ["the study", "TEST", 231, 240]]], ["And hence, the authors of the study concluded that there could be many influential factors such as group homogeneity, better conditions of the subjects assessed to get fiber-rich diets, statistical errors in the measures of randomization, that affected outcomes of the study (Jensen et al., 2006).", [["the study", "TEST", 26, 35], ["fiber-rich diets", "TREATMENT", 168, 184], ["randomization", "TREATMENT", 224, 237], ["the study", "TEST", 265, 274]]], ["As human trials with consumption of DFs dosage greater than 50 g/day exhibited significant improvements in the assessed health markers (S. J. O'Keefe et al., 2015; L. Zhao et al., 2018), it could be postulated that the health benefits of DFs are strongly co-related with their daily intake and it is suggested to be greater than 50 g, which could be achieved not only by regular food but also with the addition of supplements (S. J. D. O'Keefe, 2018).", [["DFs", "CHEMICAL", 36, 39], ["human", "ORGANISM", 3, 8], ["DFs", "SIMPLE_CHEMICAL", 36, 39], ["DFs", "SIMPLE_CHEMICAL", 238, 241], ["human", "SPECIES", 3, 8], ["human", "SPECIES", 3, 8], ["DFs dosage", "TREATMENT", 36, 46], ["significant", "OBSERVATION_MODIFIER", 79, 90], ["improvements", "OBSERVATION", 91, 103]]], ["However, in modern world there could be problems in tolerating such a higher dose and could lead to a number of gut related undesirable conditions like flatulence, bloating, stomach pain, diarrhea, and constipation (Grabitske & Slavin, 2009).Colonic microflora and fermentation of DFs ::: IntroductionAs stated earlier, the human gut is a natural habitat for trillion of microorganisms which not only contribute a significant role in promoting GIT health itself but also play their potential part in general health well beings.", [["gut", "ANATOMY", 112, 115], ["stomach", "ANATOMY", 174, 181], ["Colonic", "ANATOMY", 242, 249], ["gut", "ANATOMY", 330, 333], ["GIT", "ANATOMY", 444, 447], ["flatulence", "DISEASE", 152, 162], ["bloating", "DISEASE", 164, 172], ["stomach pain", "DISEASE", 174, 186], ["diarrhea", "DISEASE", 188, 196], ["constipation", "DISEASE", 202, 214], ["gut", "ORGANISM_SUBDIVISION", 112, 115], ["stomach", "ORGANISM_SUBDIVISION", 174, 181], ["Colonic microflora", "PATHOLOGICAL_FORMATION", 242, 260], ["human", "ORGANISM", 324, 329], ["gut", "ORGANISM_SUBDIVISION", 330, 333], ["GIT", "ORGAN", 444, 447], ["human", "SPECIES", 324, 329], ["human", "SPECIES", 324, 329], ["undesirable conditions", "PROBLEM", 124, 146], ["flatulence", "PROBLEM", 152, 162], ["bloating", "PROBLEM", 164, 172], ["stomach pain", "PROBLEM", 174, 186], ["diarrhea", "PROBLEM", 188, 196], ["constipation", "PROBLEM", 202, 214], ["Colonic microflora", "TREATMENT", 242, 260], ["microorganisms", "PROBLEM", 371, 385], ["flatulence", "OBSERVATION", 152, 162], ["stomach", "ANATOMY", 174, 181], ["diarrhea", "OBSERVATION", 188, 196]]], ["The diversity and constitution of bacterial flora residing in the GIT significantly differ from person to person and is greatly affected by many factors including age (Mariat et al., 2009), genetics (Khachatryan et al., 2008) and Neolithic settlements (Larsen et al., 2010).", [["GIT", "ANATOMY", 66, 69], ["GIT", "ORGAN", 66, 69], ["person", "SPECIES", 96, 102], ["person", "SPECIES", 106, 112], ["bacterial flora", "PROBLEM", 34, 49], ["diversity", "OBSERVATION_MODIFIER", 4, 13], ["bacterial flora", "OBSERVATION", 34, 49]]], ["However, among them, dietary habits are regarded as one of the most crucial factors which can be modified accordingly by selecting the diets rich in complex undigestible components (resistant starches), unable to be digested by human enzymes but rather by these bacteria for their growth and energy (Milani et al., 2017).", [["human", "ORGANISM", 228, 233], ["human enzymes", "PROTEIN", 228, 241], ["human", "SPECIES", 228, 233], ["human", "SPECIES", 228, 233], ["complex undigestible components", "PROBLEM", 149, 180], ["resistant starches", "PROBLEM", 182, 200], ["human enzymes", "TEST", 228, 241], ["these bacteria", "PROBLEM", 256, 270]]], ["As schematically shown in Fig. 3, these undigested complex and resistant starches arriving the colon of large intestine encounter anaerobic fermentation producing vital SCFAs (mainly acetate, propionate and butyrate) (Canfora, Meex, Venema, & Blaak, 2019).", [["colon", "ANATOMY", 95, 100], ["intestine", "ANATOMY", 110, 119], ["SCFAs", "CHEMICAL", 169, 174], ["acetate, propionate", "CHEMICAL", 183, 202], ["butyrate", "CHEMICAL", 207, 215], ["SCFAs", "CHEMICAL", 169, 174], ["acetate", "CHEMICAL", 183, 190], ["propionate", "CHEMICAL", 192, 202], ["butyrate", "CHEMICAL", 207, 215], ["colon", "ORGAN", 95, 100], ["intestine", "ORGAN", 110, 119], ["SCFAs", "SIMPLE_CHEMICAL", 169, 174], ["acetate", "SIMPLE_CHEMICAL", 183, 190], ["propionate", "SIMPLE_CHEMICAL", 192, 202], ["butyrate", "SIMPLE_CHEMICAL", 207, 215], ["these undigested complex and resistant starches", "PROBLEM", 34, 81], ["anaerobic fermentation", "TREATMENT", 130, 152], ["vital SCFAs", "TREATMENT", 163, 174], ["mainly acetate", "TREATMENT", 176, 190], ["propionate and butyrate", "TREATMENT", 192, 215], ["Canfora", "TREATMENT", 218, 225], ["resistant starches", "OBSERVATION", 63, 81], ["colon", "ANATOMY", 95, 100], ["large", "OBSERVATION_MODIFIER", 104, 109], ["intestine", "ANATOMY", 110, 119]]], ["Broadly speaking, each of the produced SCFAs has a different and individual role in exerting healthy effects but in general they perform a fundamental collective role.", [["SCFAs", "CHEMICAL", 39, 44], ["SCFAs", "CHEMICAL", 39, 44], ["SCFAs", "SIMPLE_CHEMICAL", 39, 44]]], ["For example being weak acids, all of the produced SCFAs cause in decreasing the colonic pH which is of potential advantage to prohibit the growth of harmful pathogenic bacteria such as Enterobacteraciae due to their sensitivity to low pH (den Besten et al., 2013).", [["colonic", "ANATOMY", 80, 87], ["SCFAs", "CHEMICAL", 50, 55], ["Enterobacteraciae", "CHEMICAL", 185, 202], ["SCFAs", "CHEMICAL", 50, 55], ["SCFAs", "SIMPLE_CHEMICAL", 50, 55], ["colonic", "ORGAN", 80, 87], ["Enterobacteraciae", "SIMPLE_CHEMICAL", 185, 202], ["weak acids", "PROBLEM", 18, 28], ["decreasing the colonic pH", "PROBLEM", 65, 90], ["harmful pathogenic bacteria", "PROBLEM", 149, 176], ["Enterobacteraciae", "PROBLEM", 185, 202], ["low pH", "PROBLEM", 231, 237], ["weak", "OBSERVATION_MODIFIER", 18, 22], ["acids", "OBSERVATION_MODIFIER", 23, 28], ["SCFAs", "OBSERVATION", 50, 55], ["decreasing", "OBSERVATION_MODIFIER", 65, 75], ["colonic", "ANATOMY", 80, 87]]], ["More specifically, on individual scale, it has been researched that after being transported to liver, propionate efficiently contribute in gluconeogenesis to produce glucose from non-carbohydrate sources (i.e. proteins or lipids).", [["liver", "ANATOMY", 95, 100], ["propionate", "CHEMICAL", 102, 112], ["glucose", "CHEMICAL", 166, 173], ["propionate", "CHEMICAL", 102, 112], ["glucose", "CHEMICAL", 166, 173], ["liver", "ORGAN", 95, 100], ["propionate", "SIMPLE_CHEMICAL", 102, 112], ["glucose", "SIMPLE_CHEMICAL", 166, 173], ["non-carbohydrate", "SIMPLE_CHEMICAL", 179, 195], ["lipids", "SIMPLE_CHEMICAL", 222, 228], ["glucose", "TEST", 166, 173], ["non-carbohydrate sources", "PROBLEM", 179, 203], ["liver", "ANATOMY", 95, 100]]], ["Similarly, acetate is carried in the blood to the peripheral tissues, where it is involved in enhancing ATPs production via citric acid cycle thereby scaling up fermentation proficiency (Gonzalez-Garcia et al., 2017).", [["blood", "ANATOMY", 37, 42], ["peripheral tissues", "ANATOMY", 50, 68], ["acetate", "CHEMICAL", 11, 18], ["citric acid", "CHEMICAL", 124, 135], ["acetate", "CHEMICAL", 11, 18], ["citric acid", "CHEMICAL", 124, 135], ["acetate", "SIMPLE_CHEMICAL", 11, 18], ["blood", "ORGANISM_SUBSTANCE", 37, 42], ["peripheral tissues", "TISSUE", 50, 68], ["ATPs", "SIMPLE_CHEMICAL", 104, 108], ["citric acid", "SIMPLE_CHEMICAL", 124, 135], ["acetate", "TREATMENT", 11, 18], ["citric acid cycle", "TREATMENT", 124, 141], ["peripheral tissues", "ANATOMY", 50, 68], ["enhancing ATPs", "OBSERVATION", 94, 108]]], ["On the other hand, butyrate is known as an important calorie source for the colonic epithelial cells instead of other energy sources like glucose and glutamine.", [["colonic epithelial cells", "ANATOMY", 76, 100], ["butyrate", "CHEMICAL", 19, 27], ["glucose", "CHEMICAL", 138, 145], ["glutamine", "CHEMICAL", 150, 159], ["butyrate", "CHEMICAL", 19, 27], ["glucose", "CHEMICAL", 138, 145], ["glutamine", "CHEMICAL", 150, 159], ["butyrate", "SIMPLE_CHEMICAL", 19, 27], ["colonic epithelial cells", "CELL", 76, 100], ["glucose", "SIMPLE_CHEMICAL", 138, 145], ["glutamine", "AMINO_ACID", 150, 159], ["colonic epithelial cells", "CELL_TYPE", 76, 100], ["the colonic epithelial cells", "PROBLEM", 72, 100], ["glucose and glutamine", "TREATMENT", 138, 159], ["colonic", "ANATOMY", 76, 83], ["epithelial cells", "OBSERVATION", 84, 100]]], ["Butyrate is thought to be a fundamental nutrient executing the metabolic activity and growth of colonocytes and may work as a prime safeguarding factor against colonic disturbances (Murugesan et al., 2018).", [["colonocytes", "ANATOMY", 96, 107], ["colonic", "ANATOMY", 160, 167], ["Butyrate", "CHEMICAL", 0, 8], ["colonic disturbances", "DISEASE", 160, 180], ["Butyrate", "CHEMICAL", 0, 8], ["Butyrate", "SIMPLE_CHEMICAL", 0, 8], ["colonocytes", "CELL", 96, 107], ["colonic", "ORGAN", 160, 167], ["colonocytes", "CELL_TYPE", 96, 107], ["growth of colonocytes", "PROBLEM", 86, 107], ["colonic disturbances", "PROBLEM", 160, 180], ["thought to be", "UNCERTAINTY", 12, 25], ["metabolic activity", "OBSERVATION", 63, 81]]], ["These claims were further backed by the results stating a significant reduction in butyrate-producing bacteria in feces of individuals suffering from ulcerative colitis and colon cancers in comparison to the healthy subjects (Sivaprakasam et al., 2016; L.; Zhao et al., 2018).", [["feces", "ANATOMY", 114, 119], ["ulcerative", "ANATOMY", 150, 160], ["colon cancers", "ANATOMY", 173, 186], ["butyrate", "CHEMICAL", 83, 91], ["ulcerative colitis", "DISEASE", 150, 168], ["colon cancers", "DISEASE", 173, 186], ["butyrate", "CHEMICAL", 83, 91], ["butyrate", "SIMPLE_CHEMICAL", 83, 91], ["feces", "ORGANISM_SUBSTANCE", 114, 119], ["ulcerative colitis", "PATHOLOGICAL_FORMATION", 150, 168], ["colon cancers", "CANCER", 173, 186], ["a significant reduction in butyrate", "PROBLEM", 56, 91], ["bacteria in feces of individuals", "PROBLEM", 102, 134], ["ulcerative colitis", "PROBLEM", 150, 168], ["colon cancers", "PROBLEM", 173, 186], ["significant", "OBSERVATION_MODIFIER", 58, 69], ["reduction", "OBSERVATION_MODIFIER", 70, 79], ["ulcerative", "OBSERVATION_MODIFIER", 150, 160], ["colitis", "OBSERVATION", 161, 168], ["colon", "ANATOMY", 173, 178], ["cancers", "OBSERVATION", 179, 186]]], ["Also, butyrate has shown the capability of promoting metabolic disorders (CVD and related disorders) via seral mechanisms including AMPK activation and GLUT4 expression in the adipose tissue, combating high fat diet (HFD) incited gut microbiome dysbiosis, and stimulating resolvin E1 and lipoxin biosynthesis (Gao et al., 2019).", [["seral", "ANATOMY", 105, 110], ["adipose tissue", "ANATOMY", 176, 190], ["gut", "ANATOMY", 230, 233], ["butyrate", "CHEMICAL", 6, 14], ["metabolic disorders", "DISEASE", 53, 72], ["CVD", "DISEASE", 74, 77], ["butyrate", "CHEMICAL", 6, 14], ["lipoxin", "CHEMICAL", 288, 295], ["butyrate", "SIMPLE_CHEMICAL", 6, 14], ["seral", "GENE_OR_GENE_PRODUCT", 105, 110], ["AMPK", "GENE_OR_GENE_PRODUCT", 132, 136], ["GLUT4", "GENE_OR_GENE_PRODUCT", 152, 157], ["adipose tissue", "TISSUE", 176, 190], ["gut", "ORGANISM_SUBDIVISION", 230, 233], ["resolvin E1", "GENE_OR_GENE_PRODUCT", 272, 283], ["lipoxin", "SIMPLE_CHEMICAL", 288, 295], ["AMPK", "PROTEIN", 132, 136], ["GLUT4", "PROTEIN", 152, 157], ["promoting metabolic disorders", "PROBLEM", 43, 72], ["CVD", "PROBLEM", 74, 77], ["related disorders", "PROBLEM", 82, 99], ["seral mechanisms", "PROBLEM", 105, 121], ["AMPK activation", "PROBLEM", 132, 147], ["GLUT4 expression in the adipose tissue", "PROBLEM", 152, 190], ["gut microbiome dysbiosis", "PROBLEM", 230, 254], ["stimulating resolvin E1", "TREATMENT", 260, 283], ["lipoxin biosynthesis", "TREATMENT", 288, 308], ["metabolic disorders", "OBSERVATION", 53, 72], ["GLUT4 expression", "OBSERVATION", 152, 168], ["adipose tissue", "ANATOMY", 176, 190], ["gut", "ANATOMY", 230, 233], ["microbiome dysbiosis", "OBSERVATION", 234, 254]]], ["Its noteworthy to mention that the roles and actions of SCFAs are also highly controversial.", [["SCFAs", "CHEMICAL", 56, 61], ["SCFAs", "CHEMICAL", 56, 61], ["SCFAs", "SIMPLE_CHEMICAL", 56, 61]]], ["And it has been known that in mice, SCFAs usually evoke positive effects on disease phenotype but in humans, this effect is not as straightforward (Chambers, Preston, Frost, & Morrison, 2018).", [["SCFAs", "CHEMICAL", 36, 41], ["SCFAs", "CHEMICAL", 36, 41], ["mice", "ORGANISM", 30, 34], ["SCFAs", "SIMPLE_CHEMICAL", 36, 41], ["humans", "ORGANISM", 101, 107], ["mice", "SPECIES", 30, 34], ["humans", "SPECIES", 101, 107], ["mice", "SPECIES", 30, 34], ["humans", "SPECIES", 101, 107], ["disease phenotype", "PROBLEM", 76, 93]]], ["Also, SCFA turnover is very high and local, hence measures of SCFA in plasma/feces should be interpreted with great caution since it is unlikely to be an accurate representation of SCFAs metabolism (Venegas et al., 2019).Effects of DFs on composition of gut microbiome ::: IntroductionPrevious literature has acknowledged that the kind of dietary substrate as well as the overall DFs in the diet are the two factors that potentially affect the composition of gut microbiota.", [["plasma", "ANATOMY", 70, 76], ["gut microbiome", "ANATOMY", 254, 268], ["gut microbiota", "ANATOMY", 459, 473], ["SCFA", "CHEMICAL", 6, 10], ["SCFA", "CHEMICAL", 62, 66], ["SCFAs", "CHEMICAL", 181, 186], ["DFs", "CHEMICAL", 232, 235], ["SCFA", "CHEMICAL", 6, 10], ["SCFA", "CHEMICAL", 62, 66], ["SCFAs", "CHEMICAL", 181, 186], ["SCFA", "SIMPLE_CHEMICAL", 6, 10], ["SCFA", "SIMPLE_CHEMICAL", 62, 66], ["plasma", "ORGANISM_SUBSTANCE", 70, 76], ["feces", "ORGANISM_SUBSTANCE", 77, 82], ["SCFAs", "SIMPLE_CHEMICAL", 181, 186], ["DFs", "SIMPLE_CHEMICAL", 232, 235], ["gut", "ORGANISM_SUBDIVISION", 254, 257], ["DFs", "SIMPLE_CHEMICAL", 380, 383], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 459, 473], ["SCFA turnover", "PROBLEM", 6, 19], ["SCFA in plasma/feces", "TEST", 62, 82], ["SCFAs metabolism", "PROBLEM", 181, 197], ["dietary substrate", "TREATMENT", 339, 356], ["SCFA turnover", "OBSERVATION", 6, 19], ["very", "OBSERVATION_MODIFIER", 23, 27], ["high", "OBSERVATION_MODIFIER", 28, 32], ["SCFAs metabolism", "OBSERVATION", 181, 197]]], ["Consequently, this alteration in bacterial composition in the gut by DFS in turn influences several important processes such as pH and amounts of SCFAs, which can ultimately even have a strong impact on the bacterial composition itself.", [["gut", "ANATOMY", 62, 65], ["DFS", "CHEMICAL", 69, 72], ["SCFAs", "CHEMICAL", 146, 151], ["SCFAs", "CHEMICAL", 146, 151], ["gut", "ORGANISM_SUBDIVISION", 62, 65], ["SCFAs", "SIMPLE_CHEMICAL", 146, 151], ["this alteration", "PROBLEM", 14, 29], ["bacterial composition", "PROBLEM", 33, 54], ["pH and amounts of SCFAs", "PROBLEM", 128, 151], ["bacterial composition", "OBSERVATION", 33, 54], ["bacterial composition", "OBSERVATION_MODIFIER", 207, 228]]], ["This provided scientists around the world with an interesting background to identify and comprehensively understand the relationship between different kinds of DFs and the gut microbiota.", [["gut microbiota", "ANATOMY", 172, 186], ["DFs", "GENE_OR_GENE_PRODUCT", 160, 163], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 172, 186]]], ["One research group analyzed and compared the fecal bacterial contents of children from two different ethnic groups i.e European children (EU) and children from a rural African village of Burkina Faso (BF), which is the area where the diet is generally believed to contain higher amounts of fibers, as occurred during the early human settlements from the time when agriculture came into being.", [["fibers", "ANATOMY", 290, 296], ["children", "ORGANISM", 73, 81], ["children", "ORGANISM", 128, 136], ["children", "ORGANISM", 146, 154], ["fibers", "CELLULAR_COMPONENT", 290, 296], ["human", "ORGANISM", 327, 332], ["children", "SPECIES", 73, 81], ["children", "SPECIES", 128, 136], ["children", "SPECIES", 146, 154], ["human", "SPECIES", 327, 332], ["human", "SPECIES", 327, 332], ["fecal bacterial", "OBSERVATION_MODIFIER", 45, 60]]], ["They found significant differences in the gut microbiota of the two selected groups as analyzed by high-throughput 16S rDNA sequencing and biochemical analyses.", [["gut", "ANATOMY", 42, 45], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 42, 56], ["16S rDNA", "DNA", 115, 123], ["rDNA sequencing", "TEST", 119, 134], ["biochemical analyses", "TEST", 139, 159], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["differences", "OBSERVATION", 23, 34]]], ["Furthermore, they also determined a significant difference in the production of short-chain fatty acids (P < 0.001) in BF than in EU children (De Filippo et al., 2010).", [["fatty acids", "CHEMICAL", 92, 103], ["short-chain fatty acids", "CHEMICAL", 80, 103], ["chain fatty acids", "SIMPLE_CHEMICAL", 86, 103], ["children", "ORGANISM", 133, 141], ["children", "SPECIES", 133, 141], ["short-chain fatty acids", "PROBLEM", 80, 103], ["significant", "OBSERVATION_MODIFIER", 36, 47], ["difference", "OBSERVATION_MODIFIER", 48, 58]]], ["Another research group described the same phenomenon by determining the effects of a highly branched randomly linked polysaccharide i.e Polydextrose, and a SDF derived from corn containing oligosaccharides with random glycosyl bonds.", [["Polydextrose", "CHEMICAL", 136, 148], ["Polydextrose", "CHEMICAL", 136, 148], ["glycosyl", "CHEMICAL", 218, 226], ["Polydextrose", "SIMPLE_CHEMICAL", 136, 148], ["glycosyl bonds", "SIMPLE_CHEMICAL", 218, 232], ["SDF", "PROTEIN", 156, 159], ["corn", "SPECIES", 173, 177], ["corn", "SPECIES", 173, 177], ["Polydextrose", "TREATMENT", 136, 148], ["a SDF", "PROBLEM", 154, 159], ["random glycosyl bonds", "TREATMENT", 211, 232]]], ["Performing 454 pyrosequencing, these fibers exhibited a favorable move in the gut microbiota of the adult population thereby hallmarking them with potential application as prebiotics (Hooda et al., 2012).", [["fibers", "ANATOMY", 37, 43], ["gut microbiota", "ANATOMY", 78, 92], ["fibers", "CELLULAR_COMPONENT", 37, 43], ["gut", "ORGANISM_SUBDIVISION", 78, 81], ["favorable", "OBSERVATION_MODIFIER", 56, 65]]], ["Inulin a potential DF based prebiotic is a carbohydrate formed by \u03b2-D (2 \u2192 1) linked fructose oligomers with terminal \u03b2-D fructose or \u03b1-D glucose units joined by \u03b1-D (1 \u2192 2) linkage which has gained tremendous attention in functional foods development (Alvarez-Sabatel, de Mara\u00f1\u00f3n, & Arboleya, 2018; J.; Xu et al., 2016).", [["Inulin", "CHEMICAL", 0, 6], ["DF", "CHEMICAL", 19, 21], ["\u03b2-D", "CHEMICAL", 66, 69], ["fructose", "CHEMICAL", 85, 93], ["\u03b2-D fructose", "CHEMICAL", 118, 130], ["\u03b1-D glucose", "CHEMICAL", 134, 145], ["\u03b1-D", "CHEMICAL", 162, 165], ["carbohydrate", "CHEMICAL", 43, 55], ["fructose", "CHEMICAL", 85, 93], ["fructose", "CHEMICAL", 122, 130], ["\u03b1-D glucose", "CHEMICAL", 134, 145], ["Inulin", "SIMPLE_CHEMICAL", 0, 6], ["carbohydrate", "SIMPLE_CHEMICAL", 43, 55], ["\u03b2-D (2 \u2192 1) linked fructose oligomers", "SIMPLE_CHEMICAL", 66, 103], ["terminal \u03b2-D fructose", "SIMPLE_CHEMICAL", 109, 130], ["\u03b1-D glucose", "SIMPLE_CHEMICAL", 134, 145], ["\u03b1-D (1 \u2192 2)", "SIMPLE_CHEMICAL", 162, 173], ["Inulin", "TREATMENT", 0, 6], ["fructose oligomers", "TREATMENT", 85, 103], ["terminal \u03b2-D fructose", "TREATMENT", 109, 130], ["\u03b1-D glucose units", "TREATMENT", 134, 151], ["functional foods", "OBSERVATION", 223, 239]]], ["On large industrial scale, inulin obtained from dahlia, chicory and Jerusalem artichoke and is well known prebiotic having astonishing beneficial characteristics which made it interesting candidate to be extensively used in formulating functional foods (W. Xu et al., 2018).", [["inulin", "CHEMICAL", 27, 33], ["inulin", "SIMPLE_CHEMICAL", 27, 33], ["chicory", "ORGANISM_SUBDIVISION", 56, 63], ["Jerusalem artichoke", "ORGANISM", 68, 87], ["chicory", "SPECIES", 56, 63], ["large", "OBSERVATION_MODIFIER", 3, 8], ["industrial scale", "OBSERVATION", 9, 25]]], ["It has shown to aid in the prevention of diarrhea associated with enteral nutrition and to boost up GIT health (Esmaeilnejad Moghadam, Keivaninahr, Fouladi, Rezaei Mokarram, & Nazemi, 2019; Silva, Guimar\u00e3es, Costa, Cruz, & Meireles, 2019), to enhance stability and protection of probiotics (Krithika & Preetha, 2019; Peredo, Beristain, Pascual, Azuara, & Jimenez, 2016), to reduce fat contents of the food products (Glisic et al., 2019) etc. The principal product obtained by inulin fermentation is butyrate, which is thought to be the result of two different mechanisms.", [["fat", "ANATOMY", 381, 384], ["diarrhea", "DISEASE", 41, 49], ["inulin", "CHEMICAL", 476, 482], ["butyrate", "CHEMICAL", 499, 507], ["butyrate", "CHEMICAL", 499, 507], ["GIT", "ORGANISM_SUBDIVISION", 100, 103], ["fat", "TISSUE", 381, 384], ["inulin", "SIMPLE_CHEMICAL", 476, 482], ["butyrate", "SIMPLE_CHEMICAL", 499, 507], ["diarrhea", "PROBLEM", 41, 49], ["enteral nutrition", "TREATMENT", 66, 83], ["Esmaeilnejad Moghadam", "TREATMENT", 112, 133], ["Keivaninahr", "TREATMENT", 135, 146], ["Fouladi", "TREATMENT", 148, 155], ["probiotics", "TREATMENT", 279, 289], ["diarrhea", "OBSERVATION", 41, 49], ["thought to be", "UNCERTAINTY", 518, 531]]], ["The first pathway involves the condensation of two molecules of acetyl coenzyme A and the reduction of them to butyryl-CoA.", [["acetyl coenzyme A", "CHEMICAL", 64, 81], ["butyryl-CoA", "CHEMICAL", 111, 122], ["acetyl coenzyme A", "CHEMICAL", 64, 81], ["butyryl-CoA", "CHEMICAL", 111, 122], ["acetyl coenzyme A", "SIMPLE_CHEMICAL", 64, 81], ["butyryl-CoA", "SIMPLE_CHEMICAL", 111, 122], ["acetyl coenzyme A", "TREATMENT", 64, 81], ["acetyl coenzyme", "OBSERVATION", 64, 79], ["CoA", "ANATOMY", 119, 122]]], ["In the other connected metabolic pathway, the generated butyryl-CoA:acetate CoA transferase can move the CoA to extrinsic acetate, resulting in the production of butyrate and acetyl-CoA (Karimi, Azizi, Ghasemlou, & Vaziri, 2015).", [["butyryl-CoA", "CHEMICAL", 56, 67], ["acetate", "CHEMICAL", 68, 75], ["extrinsic acetate", "CHEMICAL", 112, 129], ["butyrate", "CHEMICAL", 162, 170], ["acetyl-CoA", "CHEMICAL", 175, 185], ["butyryl-CoA", "CHEMICAL", 56, 67], ["acetate CoA", "CHEMICAL", 68, 79], ["CoA", "CHEMICAL", 105, 108], ["acetate", "CHEMICAL", 122, 129], ["butyrate", "CHEMICAL", 162, 170], ["acetyl-CoA", "CHEMICAL", 175, 185], ["Karimi", "CHEMICAL", 187, 193], ["butyryl-CoA", "SIMPLE_CHEMICAL", 56, 67], ["acetate CoA transferase", "SIMPLE_CHEMICAL", 68, 91], ["CoA", "SIMPLE_CHEMICAL", 105, 108], ["acetate", "SIMPLE_CHEMICAL", 122, 129], ["butyrate", "SIMPLE_CHEMICAL", 162, 170], ["acetyl-CoA", "SIMPLE_CHEMICAL", 175, 185], ["Karimi", "SIMPLE_CHEMICAL", 187, 193], ["butyryl-CoA:acetate CoA transferase", "PROTEIN", 56, 91], ["acetate CoA transferase", "TREATMENT", 68, 91], ["extrinsic acetate", "TREATMENT", 112, 129], ["butyrate", "TEST", 162, 170], ["CoA", "ANATOMY", 182, 185]]], ["In earlier times Hannah et al. determined the influence of agave inulin on gut microbiome.", [["gut microbiome", "ANATOMY", 75, 89], ["inulin", "CHEMICAL", 65, 71], ["inulin", "SIMPLE_CHEMICAL", 65, 71], ["gut microbiome", "MULTI-TISSUE_STRUCTURE", 75, 89], ["agave inulin", "TREATMENT", 59, 71]]], ["Agave inulin, which is consisted of linear and branched fructose chains, connected with \u03b2-2,1 and \u03b2 \u22122,6 linkages, is considered different from other inulin kinds of fibers both in chemical composition as well as botanical origin.", [["fibers", "ANATOMY", 166, 172], ["inulin", "CHEMICAL", 6, 12], ["fructose", "CHEMICAL", 56, 64], ["\u03b2-2,1 and \u03b2 \u22122,6", "CHEMICAL", 88, 104], ["fructose", "CHEMICAL", 56, 64], ["inulin", "SIMPLE_CHEMICAL", 6, 12], ["fructose chains", "SIMPLE_CHEMICAL", 56, 71], ["\u03b2-2,1", "SIMPLE_CHEMICAL", 88, 93], ["\u03b2 \u22122,6 linkages", "SIMPLE_CHEMICAL", 98, 113], ["inulin", "SIMPLE_CHEMICAL", 150, 156], ["fibers", "CELLULAR_COMPONENT", 166, 172], ["Agave inulin", "TREATMENT", 0, 12], ["linear and branched fructose chains", "PROBLEM", 36, 71], ["linear", "OBSERVATION_MODIFIER", 36, 42], ["branched", "OBSERVATION_MODIFIER", 47, 55], ["fructose chains", "OBSERVATION", 56, 71], ["inulin kinds", "OBSERVATION_MODIFIER", 150, 162], ["fibers", "OBSERVATION_MODIFIER", 166, 172], ["chemical composition", "OBSERVATION", 181, 201], ["botanical origin", "OBSERVATION", 213, 229]]], ["After feeding to healthy individuals with different doses in a randomized, double-blind, placebo-controlled, 3-period, crossover trial, it was concluded that agave inulin supplementation significantly altered the GIT microbiota composition and activity in the selected healthy individuals (Holscher et al., 2015).", [["GIT", "ANATOMY", 213, 216], ["inulin", "CHEMICAL", 164, 170], ["inulin", "SIMPLE_CHEMICAL", 164, 170], ["GIT microbiota", "MULTI-TISSUE_STRUCTURE", 213, 227], ["different doses", "TREATMENT", 42, 57], ["double-blind", "TREATMENT", 75, 87], ["placebo", "TREATMENT", 89, 96], ["agave inulin supplementation", "TREATMENT", 158, 186]]], ["In the next year, Birgitte and colleagues., evaluated the effects of dietary inulin, cellulose or brewers spent grain (BSG) on intestinal tumorigenesis and cecal microbiota.", [["intestinal", "ANATOMY", 127, 137], ["cecal microbiota", "ANATOMY", 156, 172], ["inulin", "CHEMICAL", 77, 83], ["BSG", "CHEMICAL", 119, 122], ["inulin", "SIMPLE_CHEMICAL", 77, 83], ["cellulose", "SIMPLE_CHEMICAL", 85, 94], ["intestinal", "ORGAN", 127, 137], ["cecal microbiota", "PATHOLOGICAL_FORMATION", 156, 172], ["dietary inulin", "TREATMENT", 69, 83], ["cellulose", "TREATMENT", 85, 94], ["intestinal tumorigenesis", "TREATMENT", 127, 151], ["cecal microbiota", "TREATMENT", 156, 172], ["intestinal", "ANATOMY", 127, 137], ["tumorigenesis", "OBSERVATION", 138, 151], ["cecal microbiota", "ANATOMY", 156, 172]]], ["Their results demonstrated that the type of DF contributes a potential role in the progression of colorectal cancer; however the protective effects of dietary inulin against colonic tumorigenesis is strongly linked with the profound alterations in the ceacal microbiota profile (Moen et al., 2016).", [["colorectal cancer", "ANATOMY", 98, 115], ["colonic", "ANATOMY", 174, 181], ["ceacal", "ANATOMY", 252, 258], ["DF", "DISEASE", 44, 46], ["colorectal cancer", "DISEASE", 98, 115], ["inulin", "CHEMICAL", 159, 165], ["colonic tumorigenesis", "DISEASE", 174, 195], ["colorectal cancer", "CANCER", 98, 115], ["inulin", "SIMPLE_CHEMICAL", 159, 165], ["colonic", "ORGAN", 174, 181], ["DF", "PROBLEM", 44, 46], ["colorectal cancer", "PROBLEM", 98, 115], ["dietary inulin", "TREATMENT", 151, 165], ["colonic tumorigenesis", "PROBLEM", 174, 195], ["the profound alterations", "PROBLEM", 220, 244], ["progression", "OBSERVATION_MODIFIER", 83, 94], ["colorectal", "ANATOMY", 98, 108], ["cancer", "OBSERVATION", 109, 115], ["profound", "OBSERVATION_MODIFIER", 224, 232], ["alterations", "OBSERVATION", 233, 244]]], ["Nevertheless, the impact of different dietary trials in clinical practice have shown controversial results due to a significant variability in individual response against the tested diet, which could be linked to variations in their gut microbiome as stated earlier that gut microbiome vary from person to person.", [["gut microbiome", "ANATOMY", 233, 247], ["gut microbiome", "ANATOMY", 271, 285], ["gut", "ORGANISM_SUBDIVISION", 233, 236], ["gut microbiome", "MULTI-TISSUE_STRUCTURE", 271, 285], ["person", "SPECIES", 296, 302], ["person", "SPECIES", 306, 312], ["different dietary trials", "TREATMENT", 28, 52], ["a significant variability", "PROBLEM", 114, 139]]], ["Last year Biesiekierski and colleagues published a comprehensive review on these issues by citing studies dealing with the predictive dimensions of baseline microbiome for clinical response to dietary trials in two particular pathological conditions, i.e. obesity and IBS (Biesiekierski, Jalanka, & Staudacher, 2019).", [["obesity", "DISEASE", 256, 263], ["IBS", "DISEASE", 268, 271], ["dietary trials", "TREATMENT", 193, 207], ["obesity", "PROBLEM", 256, 263], ["IBS", "PROBLEM", 268, 271], ["obesity", "OBSERVATION", 256, 263], ["IBS", "OBSERVATION", 268, 271]]], ["Therefore, it is still a challenging task and needs further large-scale interventions to address and provide solid grounds for these claims that can be significantly undertaken in clinical practices.Whole grains and gut microbiome ::: IntroductionAccording to AACCI, the whole grains (WGs) can be defined as the \u201cintegral, ground, cracked or flaked fruit of the grain whose original three parts, the starchy endosperm, germ and bran, are present in the same relative proportions as they exist in the intact grain\u201d (AACCI & (American Association of Cereal Chemists International), 1999).", [["grains", "ANATOMY", 205, 211], ["gut", "ANATOMY", 216, 219], ["whole grains", "ANATOMY", 271, 283], ["endosperm", "ANATOMY", 408, 417], ["germ", "ANATOMY", 419, 423], ["bran", "ANATOMY", 428, 432], ["gut", "ORGANISM_SUBDIVISION", 216, 219], ["grain", "ORGANISM_SUBDIVISION", 362, 367], ["starchy endosperm", "TISSUE", 400, 417], ["germ", "TISSUE", 419, 423], ["bran", "ORGANISM_SUBDIVISION", 428, 432], ["bran", "SPECIES", 428, 432], ["further large-scale interventions", "TREATMENT", 52, 85], ["cracked or flaked fruit of the grain", "PROBLEM", 331, 367], ["cracked", "OBSERVATION_MODIFIER", 331, 338], ["flaked fruit", "OBSERVATION", 342, 354], ["starchy endosperm", "OBSERVATION", 400, 417], ["intact", "OBSERVATION", 500, 506]]], ["Generally speaking, the WGs constitute a huge group of staple foods that includes wheat, corn, rice, oats, barley, rye and so on (Hui et al., 2019).", [["wheat, corn, rice, oats, barley, rye", "CHEMICAL", 82, 118], ["wheat", "ORGANISM_SUBDIVISION", 82, 87], ["corn", "ORGANISM_SUBDIVISION", 89, 93], ["rice", "ORGANISM_SUBDIVISION", 95, 99], ["oats", "ORGANISM_SUBDIVISION", 101, 105], ["barley", "ORGANISM_SUBDIVISION", 107, 113], ["rye", "ORGANISM_SUBDIVISION", 115, 118], ["wheat", "SPECIES", 82, 87], ["corn", "SPECIES", 89, 93], ["rice", "SPECIES", 95, 99], ["oats", "SPECIES", 101, 105], ["barley", "SPECIES", 107, 113], ["rye", "SPECIES", 115, 118], ["wheat", "SPECIES", 82, 87], ["corn", "SPECIES", 89, 93], ["rice", "SPECIES", 95, 99], ["barley", "SPECIES", 107, 113]]], ["It is evident from the available literature that WGs confer a broad spectrum of potential health benefits due to their richness in bioactive compounds which may significantly affect processes like energy metabolism, weight regulation and food intake (Koecher, McKeown, Sawicki, Menon, & Slavin, 2019).", [["WGs", "SIMPLE_CHEMICAL", 49, 52], ["their richness in bioactive compounds", "PROBLEM", 113, 150], ["bioactive compounds", "OBSERVATION", 131, 150]]], ["One possible mechanism by which WGs confer benefits maybe be associated with their capability of modulation gut microbiota where DFs are regarded as the fundamental factor to stimulate this modulation.", [["gut microbiota", "ANATOMY", 108, 122], ["WGs", "SIMPLE_CHEMICAL", 32, 35], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 108, 122], ["DFs", "SIMPLE_CHEMICAL", 129, 132], ["the fundamental factor", "PROBLEM", 149, 171], ["possible", "UNCERTAINTY", 4, 12]]], ["It is postulated that the fiber contents of the WGs imparts enhanced viscosity to the digesta and lower glucose as well as cholesterol levels by binding to the bile acids in the small intestine (Wu, Inui, & Chen, 2020), thereby implying DFs and whole grains based diets very important in diabetes management to aid in glycaemic, cholestrol as well as body weight, and inflammation controls (Reynolds, Akerman, & Mann, 2020; Wang et al., 2020).", [["fiber", "ANATOMY", 26, 31], ["WGs", "ANATOMY", 48, 51], ["digesta", "ANATOMY", 86, 93], ["small intestine", "ANATOMY", 178, 193], ["body", "ANATOMY", 351, 355], ["WGs", "CHEMICAL", 48, 51], ["glucose", "CHEMICAL", 104, 111], ["cholesterol", "CHEMICAL", 123, 134], ["bile acids", "CHEMICAL", 160, 170], ["diabetes", "DISEASE", 288, 296], ["cholestrol", "CHEMICAL", 329, 339], ["inflammation", "DISEASE", 368, 380], ["glucose", "CHEMICAL", 104, 111], ["cholesterol", "CHEMICAL", 123, 134], ["bile acids", "CHEMICAL", 160, 170], ["WGs", "SIMPLE_CHEMICAL", 48, 51], ["digesta", "ORGANISM_SUBSTANCE", 86, 93], ["glucose", "SIMPLE_CHEMICAL", 104, 111], ["cholesterol", "SIMPLE_CHEMICAL", 123, 134], ["bile acids", "SIMPLE_CHEMICAL", 160, 170], ["intestine", "ORGAN", 184, 193], ["DFs", "SIMPLE_CHEMICAL", 237, 240], ["cholestrol", "SIMPLE_CHEMICAL", 329, 339], ["body", "ORGANISM_SUBDIVISION", 351, 355], ["cholesterol levels", "TEST", 123, 141], ["the bile acids", "TEST", 156, 170], ["diabetes management", "TREATMENT", 288, 307], ["cholestrol", "TREATMENT", 329, 339], ["body weight", "TEST", 351, 362], ["bile", "ANATOMY", 160, 164], ["small intestine", "ANATOMY", 178, 193], ["inflammation", "OBSERVATION", 368, 380]]], ["Similarly, another pivotal role of WGs involve their ability to curb protein fermentation by the gut microbiota, which can ultimately lead to protein fermentation accountable for unwanted fermentation metabolites and harmful impacts on the host (Russell et al., 2011).", [["gut microbiota", "ANATOMY", 97, 111], ["WGs", "GENE_OR_GENE_PRODUCT", 35, 38], ["gut", "ORGANISM_SUBDIVISION", 97, 100], ["WGs", "PROTEIN", 35, 38], ["protein fermentation", "TEST", 142, 162], ["unwanted fermentation metabolites", "PROBLEM", 179, 212]]], ["Also, another noteworthy characteristic of the WGs is their richness in resistant starch (RS) which is particularly butyrogenic and thus scale up the increased production of butyrate by the bacterial fermentation (Gong et al., 2018).", [["butyrate", "CHEMICAL", 174, 182], ["butyrate", "CHEMICAL", 174, 182], ["starch", "SIMPLE_CHEMICAL", 82, 88], ["butyrate", "SIMPLE_CHEMICAL", 174, 182], ["the WGs", "PROBLEM", 43, 50], ["resistant starch", "PROBLEM", 72, 88], ["the bacterial fermentation", "PROBLEM", 186, 212], ["richness", "OBSERVATION_MODIFIER", 60, 68], ["resistant", "OBSERVATION_MODIFIER", 72, 81], ["starch", "OBSERVATION_MODIFIER", 82, 88], ["butyrogenic", "OBSERVATION_MODIFIER", 116, 127], ["increased", "OBSERVATION_MODIFIER", 150, 159], ["production", "OBSERVATION_MODIFIER", 160, 170]]], ["And the bacterial fermentation of the undigestible components of WGs in the GIT has been agreed upon to be partly associated with the healthful effects of WGs (Koecher et al., 2019).", [["GIT", "ANATOMY", 76, 79], ["WGs", "CHEMICAL", 65, 68], ["WGs", "SIMPLE_CHEMICAL", 65, 68], ["GIT", "ORGAN", 76, 79], ["WGs", "SIMPLE_CHEMICAL", 155, 158], ["the bacterial fermentation", "TEST", 4, 30], ["bacterial fermentation", "OBSERVATION", 8, 30]]], ["In addition, the WGs have also demonstrated an anti-inflammatory activity and hence can be of significant benefit in lessening of metabolic inflammation responsible for metabolic disorders (McCarty & Assanga, 2018) as has been mentioned in a meta-analysis of 9 randomized trials (Y. Xu et al., 2018).", [["metabolic inflammation", "DISEASE", 130, 152], ["metabolic disorders", "DISEASE", 169, 188], ["WGs", "SIMPLE_CHEMICAL", 17, 20], ["the WGs", "TEST", 13, 20], ["metabolic inflammation", "PROBLEM", 130, 152], ["metabolic disorders", "PROBLEM", 169, 188], ["anti-inflammatory activity", "OBSERVATION", 47, 73], ["metabolic inflammation", "OBSERVATION", 130, 152]]], ["This specific significance of WGs become particularly applicable in light of recent research that designated a strong connection of gut bacteria involvement in metabolic disorders (Gregor & Hotamisligil, 2011).", [["gut", "ANATOMY", 132, 135], ["metabolic disorders", "DISEASE", 160, 179], ["gut", "ORGANISM_SUBDIVISION", 132, 135], ["WGs", "PROBLEM", 30, 33], ["gut bacteria involvement", "PROBLEM", 132, 156], ["metabolic disorders", "PROBLEM", 160, 179], ["gut", "ANATOMY", 132, 135], ["bacteria", "OBSERVATION", 136, 144], ["metabolic disorders", "OBSERVATION", 160, 179]]], ["Therefore, in 2013, a research group evaluated the influence of the diet supplemented with WGs on gut microbiota in healthy human subjects.", [["gut microbiota", "ANATOMY", 98, 112], ["WGs", "CHEMICAL", 91, 94], ["WGs", "SIMPLE_CHEMICAL", 91, 94], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 98, 112], ["human", "ORGANISM", 124, 129], ["human", "SPECIES", 124, 129], ["human", "SPECIES", 124, 129]]], ["Their results stated that short-term utilization of the WGs significantly modified the composition of the gut microbiota which as a consequence interestingly supported in excelling host physiological actions connected with metabolic dysfunctions in humans (Mart\u00ednez et al., 2013).", [["gut microbiota", "ANATOMY", 106, 120], ["metabolic dysfunctions", "DISEASE", 223, 245], ["WGs", "SIMPLE_CHEMICAL", 56, 59], ["gut microbiota", "ORGANISM_SUBDIVISION", 106, 120], ["humans", "ORGANISM", 249, 255], ["humans", "SPECIES", 249, 255], ["humans", "SPECIES", 249, 255], ["the WGs", "TEST", 52, 59], ["metabolic dysfunctions", "PROBLEM", 223, 245], ["gut microbiota", "ANATOMY", 106, 120], ["metabolic dysfunctions", "OBSERVATION", 223, 245]]], ["In the year 2017, Sally and his research group evaluated the effects of two different types of diets 1) rich in WGs and 2) rich in refined grains (RGs) on immune and inflammatory responses, gut microbiota, and microbial products in healthy adults while maintaining subject body weights.", [["gut microbiota", "ANATOMY", 190, 204], ["body", "ANATOMY", 273, 277], ["RGs", "CHEMICAL", 147, 150], ["grains", "ORGANISM_SUBDIVISION", 139, 145], ["RGs", "SIMPLE_CHEMICAL", 147, 150], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 190, 204], ["body", "ORGANISM_SUBDIVISION", 273, 277], ["immune and inflammatory responses", "PROBLEM", 155, 188], ["inflammatory", "OBSERVATION", 166, 178]]], ["Presenting their results, they stated that the short-term consumption of WGs had significant effect on the studied parameters in comparison to the RGs diets.", [["WGs", "CHEMICAL", 73, 76], ["WGs", "SIMPLE_CHEMICAL", 73, 76], ["the short-term consumption of WGs", "PROBLEM", 43, 76]]], ["The WGs maintenance diet increased stool weight and frequency and had modest positive impacts on gut microbiota, SCFAs, effector memory T cells, and the acute innate immune response and no effect on other markers of cell-mediated immunity or systemic and gut inflammation (Vanegas et al., 2017).", [["WGs", "ANATOMY", 4, 7], ["stool", "ANATOMY", 35, 40], ["gut microbiota", "ANATOMY", 97, 111], ["effector memory T cells", "ANATOMY", 120, 143], ["cell", "ANATOMY", 216, 220], ["gut", "ANATOMY", 255, 258], ["WGs", "CHEMICAL", 4, 7], ["SCFAs", "CHEMICAL", 113, 118], ["inflammation", "DISEASE", 259, 271], ["WGs", "SIMPLE_CHEMICAL", 4, 7], ["stool", "ORGANISM_SUBSTANCE", 35, 40], ["gut", "ORGANISM_SUBDIVISION", 97, 100], ["SCFAs", "SIMPLE_CHEMICAL", 113, 118], ["effector memory T cells", "CELL", 120, 143], ["cell", "CELL", 216, 220], ["gut", "ORGANISM_SUBDIVISION", 255, 258], ["effector memory T cells", "CELL_TYPE", 120, 143], ["stool weight", "TEST", 35, 47], ["the acute innate immune response", "PROBLEM", 149, 181], ["cell-mediated immunity", "PROBLEM", 216, 238], ["systemic and gut inflammation", "PROBLEM", 242, 271], ["acute", "OBSERVATION_MODIFIER", 153, 158], ["gut", "ANATOMY", 255, 258], ["inflammation", "OBSERVATION", 259, 271]]], ["In the following year, researchers from Japan in a randomized double-blind study investigated the effects of WGs wheat bread on visceral fat obesity in Japanese individuals.", [["visceral fat", "ANATOMY", 128, 140], ["WGs wheat bread", "CHEMICAL", 109, 124], ["visceral fat obesity", "DISEASE", 128, 148], ["bread", "ORGANISM_SUBDIVISION", 119, 124], ["visceral fat", "TISSUE", 128, 140], ["wheat", "SPECIES", 113, 118], ["wheat", "SPECIES", 113, 118], ["blind study", "TEST", 69, 80], ["visceral fat obesity", "PROBLEM", 128, 148], ["visceral fat", "ANATOMY", 128, 140], ["obesity", "OBSERVATION", 141, 148]]], ["After 12 weeks of experimental trials, the subjects who consumed WG wheat bread showed significant and safe reductions in visceral fat areas (Kikuchi et al., 2018).", [["visceral fat", "ANATOMY", 122, 134], ["visceral fat", "TISSUE", 122, 134], ["wheat", "SPECIES", 68, 73], ["wheat", "SPECIES", 68, 73], ["experimental trials", "TREATMENT", 18, 37], ["significant and safe reductions in visceral fat areas", "PROBLEM", 87, 140], ["significant", "OBSERVATION_MODIFIER", 87, 98], ["safe", "OBSERVATION_MODIFIER", 103, 107], ["reductions", "OBSERVATION_MODIFIER", 108, 118], ["visceral fat", "ANATOMY", 122, 134]]], ["Similar phenomenon was also described by another group in a randomized control showing the role of WGs to promote gastrointestinal health in overweight and obese individuals (Kopf et al., 2018).", [["gastrointestinal", "ANATOMY", 114, 130], ["overweight and obese", "DISEASE", 141, 161], ["WGs", "SIMPLE_CHEMICAL", 99, 102], ["gastrointestinal", "ORGAN", 114, 130], ["Similar phenomenon", "PROBLEM", 0, 18], ["a randomized control", "TREATMENT", 58, 78], ["phenomenon", "OBSERVATION", 8, 18], ["gastrointestinal", "ANATOMY", 114, 130]]], ["In the following year, the effects of dietary WG, fruit, and vegetables on weight and inflammatory biomarkers in 75 overweight and obese women were assessed in a randomized control trial.", [["fruit", "ANATOMY", 50, 55], ["vegetables", "ANATOMY", 61, 71], ["WG, fruit, and vegetables", "CHEMICAL", 46, 71], ["fruit", "ORGANISM_SUBDIVISION", 50, 55], ["vegetables", "ORGANISM_SUBDIVISION", 61, 71], ["women", "ORGANISM", 137, 142], ["women", "SPECIES", 137, 142], ["weight", "TEST", 75, 81], ["inflammatory biomarkers", "TEST", 86, 109], ["a randomized control trial", "TREATMENT", 160, 186], ["inflammatory", "OBSERVATION_MODIFIER", 86, 98]]], ["Significant modifications in serum biomarkers (CRP, TNF-\u03b1, IL-6, D-dimer, and serum fibrinogen) after consuming the trial diet for 10 weeks suggested WG based diet to support in attenuating inflammatory degrees and control following unpleasant health outcomes (Arabzadegan et al., 2019, pp. 1\u20139).", [["serum", "ANATOMY", 29, 34], ["serum", "ANATOMY", 78, 83], ["serum", "ORGANISM_SUBSTANCE", 29, 34], ["CRP", "GENE_OR_GENE_PRODUCT", 47, 50], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 52, 57], ["IL-6", "GENE_OR_GENE_PRODUCT", 59, 63], ["D-dimer", "GENE_OR_GENE_PRODUCT", 65, 72], ["serum", "ORGANISM_SUBSTANCE", 78, 83], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 84, 94], ["CRP", "PROTEIN", 47, 50], ["TNF", "PROTEIN", 52, 55], ["IL-6", "PROTEIN", 59, 63], ["D-dimer", "PROTEIN", 65, 72], ["serum fibrinogen", "PROTEIN", 78, 94], ["Significant modifications", "PROBLEM", 0, 25], ["serum biomarkers", "TEST", 29, 45], ["CRP", "TEST", 47, 50], ["TNF", "TEST", 52, 55], ["IL", "TEST", 59, 61], ["D-dimer", "TEST", 65, 72], ["serum fibrinogen", "TEST", 78, 94], ["the trial diet", "TREATMENT", 112, 126], ["attenuating inflammatory degrees", "TREATMENT", 178, 210], ["inflammatory degrees", "OBSERVATION_MODIFIER", 190, 210]]], ["WG millet has also shown significant impact on lipid metabolism in both the in vitro cells and the in vivo rats (fed with high fat diet) experimental models.", [["cells", "ANATOMY", 85, 90], ["lipid", "SIMPLE_CHEMICAL", 47, 52], ["cells", "CELL", 85, 90], ["rats", "ORGANISM", 107, 111], ["fat", "ORGANISM_SUBDIVISION", 127, 130], ["in vitro cells", "CELL_LINE", 76, 90], ["millet", "SPECIES", 3, 9], ["rats", "SPECIES", 107, 111], ["lipid metabolism", "PROBLEM", 47, 63], ["high fat diet", "TREATMENT", 122, 135], ["significant", "OBSERVATION_MODIFIER", 25, 36], ["lipid metabolism", "OBSERVATION", 47, 63], ["vitro cells", "OBSERVATION", 79, 90]]], ["Associated with its lowering lipid storage, total cholesterol and triglyceride contents in the cells, it was found that WG millet exhibit hypolipidemic characteristics by modulating lipid metabolism concomitant genes expression or composition of gut microflora (Li et al., 2019).", [["cells", "ANATOMY", 95, 100], ["gut microflora", "ANATOMY", 246, 260], ["cholesterol", "CHEMICAL", 50, 61], ["triglyceride", "CHEMICAL", 66, 78], ["cholesterol", "CHEMICAL", 50, 61], ["triglyceride", "CHEMICAL", 66, 78], ["lipid", "SIMPLE_CHEMICAL", 29, 34], ["cholesterol", "SIMPLE_CHEMICAL", 50, 61], ["triglyceride", "SIMPLE_CHEMICAL", 66, 78], ["cells", "CELL", 95, 100], ["lipid", "SIMPLE_CHEMICAL", 182, 187], ["gut", "ORGANISM_SUBDIVISION", 246, 249], ["its lowering lipid storage", "PROBLEM", 16, 42], ["total cholesterol", "TEST", 44, 61], ["triglyceride contents in the cells", "PROBLEM", 66, 100], ["WG millet", "PROBLEM", 120, 129], ["hypolipidemic characteristics", "PROBLEM", 138, 167], ["modulating lipid metabolism concomitant genes expression", "PROBLEM", 171, 227], ["hypolipidemic", "OBSERVATION_MODIFIER", 138, 151], ["lipid metabolism", "OBSERVATION", 182, 198]]], ["However, in the same year another research group found that whole barley had the potential in preventing obesity and dyslipidemia in germ free C57BL/6J obese mice with or without the involvement of gut microbiota related mechanisms (Gong, Wang, Sun, Wang, & Sun, 2019).", [["gut", "ANATOMY", 198, 201], ["obesity", "DISEASE", 105, 112], ["dyslipidemia", "DISEASE", 117, 129], ["barley", "ORGANISM_SUBDIVISION", 66, 72], ["germ free C57BL/6J obese mice", "ORGANISM", 133, 162], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 198, 212], ["mice", "SPECIES", 158, 162], ["barley", "SPECIES", 66, 72], ["mice", "SPECIES", 158, 162], ["obesity", "PROBLEM", 105, 112], ["dyslipidemia", "PROBLEM", 117, 129], ["obesity", "OBSERVATION", 105, 112], ["dyslipidemia", "OBSERVATION", 117, 129]]], ["These observations were further supported by another randomized cross-over trial stating body weight and systemic low-grade inflammation lowering effects of WG without major modifications in the composition of gut microbiota (Roager et al., 2019; Wu et al., 2020).", [["body", "ANATOMY", 89, 93], ["gut", "ANATOMY", 210, 213], ["inflammation", "DISEASE", 124, 136], ["WG", "CHEMICAL", 157, 159], ["body", "ORGANISM_SUBDIVISION", 89, 93], ["gut", "ORGANISM_SUBDIVISION", 210, 213], ["body weight", "TEST", 89, 100], ["systemic low-grade inflammation lowering effects of WG", "PROBLEM", 105, 159], ["low-grade", "OBSERVATION_MODIFIER", 114, 123], ["inflammation", "OBSERVATION", 124, 136]]], ["Nevertheless, most recently, Zhu and colleagues found that a fiber rich Med diet changed human gut microbiota composition and its metabolites after consumption of just 4 days in comparison to an animal fat\u2013rich, low-fiber fast food diet (Zhu et al., 2020).", [["gut", "ANATOMY", 95, 98], ["human", "ORGANISM", 89, 94], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 95, 109], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 89, 94], ["a fiber rich", "TREATMENT", 59, 71], ["human gut microbiota composition", "TREATMENT", 89, 121], ["an animal fat\u2013rich", "TREATMENT", 192, 210], ["low-fiber fast food diet", "TREATMENT", 212, 236]]], ["In order to elucidate the extent to which WGs offer these healthy impacts, Hui et al. categorized the lipid monitoring effects of different WGs by performing a network meta-analysis of fifty-five studies including a total of 3900 participants.", [["participants", "SPECIES", 230, 242]]], ["They found oat bran to be the most effective than barley, brown rice, wheat and wheat bran which were not reported with significant effects on blood lipid profiles (Hui et al., 2019).", [["blood", "ANATOMY", 143, 148], ["barley", "ORGANISM_SUBDIVISION", 50, 56], ["brown rice", "ORGANISM", 58, 68], ["wheat", "ORGANISM_SUBDIVISION", 70, 75], ["wheat bran", "ORGANISM", 80, 90], ["blood", "ORGANISM_SUBSTANCE", 143, 148], ["bran", "SPECIES", 15, 19], ["barley", "SPECIES", 50, 56], ["rice", "SPECIES", 64, 68], ["wheat", "SPECIES", 70, 75], ["wheat", "SPECIES", 80, 85], ["bran", "SPECIES", 86, 90], ["barley", "SPECIES", 50, 56], ["brown rice", "SPECIES", 58, 68], ["wheat", "SPECIES", 70, 75], ["wheat", "SPECIES", 80, 85], ["oat bran", "PROBLEM", 11, 19], ["wheat and wheat bran", "PROBLEM", 70, 90], ["blood lipid profiles", "TEST", 143, 163], ["oat bran", "OBSERVATION", 11, 19]]], ["Moreover, the efficacy of WGs in prevention of cancer has also been extensively research previously.", [["cancer", "ANATOMY", 47, 53], ["WGs", "CHEMICAL", 26, 29], ["cancer", "DISEASE", 47, 53], ["WGs", "SIMPLE_CHEMICAL", 26, 29], ["cancer", "CANCER", 47, 53], ["cancer", "PROBLEM", 47, 53], ["cancer", "OBSERVATION", 47, 53]]], ["In this perspective, in the cancer prevention study-II nutrition cohort, it has been found that higher WGs intake was linked with lower incidence of colorectal cancer risks in older US men (Um et al., 2019) and gastric cancer risks as summarized in a meta-analysis of observational data from a registered study (Y. Xu, Yang, Du, Li, & Zhou, 2019).Prebiotic effects of DFs ::: IntroductionPrebiotics are known as the \u201cselectively fermented food ingredients that allow particular modifications both in the composition and/or performance of the gut microflora, thereby imparting health benefits to the host\u201d (Gibson et al., 2010).", [["cancer", "ANATOMY", 28, 34], ["colorectal cancer", "ANATOMY", 149, 166], ["gastric cancer", "ANATOMY", 211, 225], ["gut microflora", "ANATOMY", 542, 556], ["cancer", "DISEASE", 28, 34], ["WGs", "CHEMICAL", 103, 106], ["colorectal cancer", "DISEASE", 149, 166], ["gastric cancer", "DISEASE", 211, 225], ["cancer", "CANCER", 28, 34], ["WGs", "SIMPLE_CHEMICAL", 103, 106], ["colorectal cancer", "CANCER", 149, 166], ["men", "ORGANISM", 185, 188], ["gastric cancer", "CANCER", 211, 225], ["DFs", "SIMPLE_CHEMICAL", 368, 371], ["gut microflora", "MULTI-TISSUE_STRUCTURE", 542, 556], ["men", "SPECIES", 185, 188], ["higher WGs intake", "PROBLEM", 96, 113], ["colorectal cancer", "PROBLEM", 149, 166], ["gastric cancer risks", "PROBLEM", 211, 231], ["observational data", "TEST", 268, 286], ["a registered study", "TEST", 292, 310], ["cancer", "OBSERVATION", 28, 34], ["colorectal", "ANATOMY", 149, 159], ["cancer", "OBSERVATION", 160, 166], ["gastric", "ANATOMY", 211, 218], ["cancer", "OBSERVATION", 219, 225], ["Li", "ANATOMY", 329, 331]]], ["This definition elaborates that not all DFs can be put together in the group of prebiotics; however, most of the prebiotics can be regarded as DFs (Slavin, 2013).", [["DFs", "SIMPLE_CHEMICAL", 40, 43], ["prebiotics", "TREATMENT", 80, 90]]], ["Scientifically, food constituents can be classified as prebiotics if they proficiently perform these actions; (i) must resist gastric acidity, hydrolysis by human enzymes, and gastrointestinal absorption; (ii) must be fermented by the gut microflora; (iii) must stimulate the growth and activity of gut microflora associated with health (Davani-Davari et al., 2019).", [["gastric", "ANATOMY", 126, 133], ["gastrointestinal", "ANATOMY", 176, 192], ["gut microflora", "ANATOMY", 235, 249], ["gut microflora", "ANATOMY", 299, 313], ["gastric", "ORGAN", 126, 133], ["human", "ORGANISM", 157, 162], ["gastrointestinal", "ORGANISM_SUBDIVISION", 176, 192], ["gut microflora", "ORGANISM_SUBDIVISION", 235, 249], ["gut microflora", "MULTI-TISSUE_STRUCTURE", 299, 313], ["human enzymes", "PROTEIN", 157, 170], ["human", "SPECIES", 157, 162], ["human", "SPECIES", 157, 162], ["gastric acidity", "PROBLEM", 126, 141], ["human enzymes", "TEST", 157, 170], ["gastric", "ANATOMY", 126, 133], ["acidity", "OBSERVATION", 134, 141], ["gastrointestinal", "ANATOMY", 176, 192]]], ["Till date a substantial research has stamped prebiotics as important formulations contributing to the well-being of human health.", [["human", "ORGANISM", 116, 121], ["human", "SPECIES", 116, 121], ["human", "SPECIES", 116, 121], ["stamped prebiotics", "TREATMENT", 37, 55]]], ["For example, they have been claimed to promote gut epithelial barrier concerns, prevent apoptosis of intestinal epithelial cells, and attenuate intestinal inflammation and carcinogenesis (Baliou et al., 2019).", [["gut epithelial barrier", "ANATOMY", 47, 69], ["intestinal epithelial cells", "ANATOMY", 101, 128], ["intestinal", "ANATOMY", 144, 154], ["inflammation", "DISEASE", 155, 167], ["carcinogenesis", "DISEASE", 172, 186], ["gut epithelial barrier", "TISSUE", 47, 69], ["intestinal epithelial cells", "CELL", 101, 128], ["intestinal", "ORGAN", 144, 154], ["intestinal epithelial cells", "CELL_TYPE", 101, 128], ["intestinal epithelial cells", "PROBLEM", 101, 128], ["intestinal inflammation", "PROBLEM", 144, 167], ["epithelial", "ANATOMY_MODIFIER", 51, 61], ["intestinal epithelial cells", "OBSERVATION", 101, 128], ["intestinal", "ANATOMY", 144, 154], ["inflammation", "OBSERVATION", 155, 167]]], ["Similarly, prebiotics were also found to lower down obesity in experimental obese mice by affecting the gene expression style occurring in their white adipose tissues, and therefore resulting in increasing lipolysis, a decreased adipogenesis and elevated metabolic response to leptin (E. M. Dewulf et al., 2011).", [["white adipose tissues", "ANATOMY", 145, 166], ["obesity", "DISEASE", 52, 59], ["mice", "ORGANISM", 82, 86], ["adipose tissues", "TISSUE", 151, 166], ["leptin", "GENE_OR_GENE_PRODUCT", 277, 283], ["mice", "SPECIES", 82, 86], ["mice", "SPECIES", 82, 86], ["prebiotics", "TREATMENT", 11, 21], ["lower down obesity", "PROBLEM", 41, 59], ["increasing lipolysis", "PROBLEM", 195, 215], ["a decreased adipogenesis", "PROBLEM", 217, 241], ["elevated metabolic response", "PROBLEM", 246, 273], ["obesity", "OBSERVATION", 52, 59], ["obese", "OBSERVATION", 76, 81], ["expression style", "OBSERVATION", 109, 125], ["adipose tissues", "ANATOMY", 151, 166], ["increasing", "OBSERVATION_MODIFIER", 195, 205], ["lipolysis", "OBSERVATION", 206, 215], ["decreased adipogenesis", "OBSERVATION", 219, 241], ["elevated", "OBSERVATION_MODIFIER", 246, 254], ["metabolic response", "OBSERVATION", 255, 273]]], ["Furthermore, prebiotics potentially contribute in ameliorating metabolic disorders e.g. type 2 diabetes and CVD via promoting and stimulating gut microbiota, which in turn stimulates insulin-signaling and cholesterol-lowering characteristics (Yoo & Kim, 2016).", [["gut microbiota", "ANATOMY", 142, 156], ["metabolic disorders", "DISEASE", 63, 82], ["type 2 diabetes", "DISEASE", 88, 103], ["CVD", "DISEASE", 108, 111], ["cholesterol", "CHEMICAL", 205, 216], ["cholesterol", "CHEMICAL", 205, 216], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 142, 156], ["insulin", "GENE_OR_GENE_PRODUCT", 183, 190], ["cholesterol", "SIMPLE_CHEMICAL", 205, 216], ["prebiotics", "TREATMENT", 13, 23], ["ameliorating metabolic disorders", "PROBLEM", 50, 82], ["type 2 diabetes", "PROBLEM", 88, 103], ["CVD", "PROBLEM", 108, 111], ["stimulating gut microbiota", "PROBLEM", 130, 156], ["stimulates insulin", "TREATMENT", 172, 190], ["cholesterol", "TEST", 205, 216], ["metabolic disorders", "OBSERVATION", 63, 82]]], ["It is believed that the suggested pathways could comprise the secretion of gut peptides with incretin role, such as glucagon-like peptide 1, which takes part in the development of hepatic insulin resistance (T. D. M\u00fcller et al., 2019).", [["gut", "ANATOMY", 75, 78], ["hepatic", "ANATOMY", 180, 187], ["incretin", "GENE_OR_GENE_PRODUCT", 93, 101], ["glucagon-like peptide 1", "GENE_OR_GENE_PRODUCT", 116, 139], ["hepatic", "ORGAN", 180, 187], ["insulin", "GENE_OR_GENE_PRODUCT", 188, 195], ["the secretion of gut peptides", "PROBLEM", 58, 87], ["incretin role", "TREATMENT", 93, 106], ["glucagon", "TREATMENT", 116, 124], ["hepatic insulin resistance", "TREATMENT", 180, 206], ["hepatic", "ANATOMY", 180, 187], ["insulin resistance", "OBSERVATION", 188, 206]]], ["Prebiotics have also exhibited shielding effects on liver, because of their capability to prevent the hepatic storage of TAG and/or cholesterol in the liver tissue known as steatosis (Loman, Hern\u00e1ndez-Saavedra, An, & Rector, 2018).Prebiotic effects of DFs ::: IntroductionIn light of the preceding discussion, it can be stated that consumption of prebiotics in addition to DFs is considered as an avenue in the modulation of gut microbiota.", [["liver", "ANATOMY", 52, 57], ["hepatic", "ANATOMY", 102, 109], ["liver tissue", "ANATOMY", 151, 163], ["gut microbiota", "ANATOMY", 425, 439], ["Prebiotics", "CHEMICAL", 0, 10], ["TAG", "CHEMICAL", 121, 124], ["cholesterol", "CHEMICAL", 132, 143], ["steatosis", "DISEASE", 173, 182], ["DFs", "CHEMICAL", 373, 376], ["TAG", "CHEMICAL", 121, 124], ["cholesterol", "CHEMICAL", 132, 143], ["liver", "ORGAN", 52, 57], ["hepatic", "ORGAN", 102, 109], ["TAG", "SIMPLE_CHEMICAL", 121, 124], ["cholesterol", "SIMPLE_CHEMICAL", 132, 143], ["liver tissue", "TISSUE", 151, 163], ["DFs", "SIMPLE_CHEMICAL", 252, 255], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 425, 439], ["Prebiotics", "TREATMENT", 0, 10], ["shielding effects on liver", "PROBLEM", 31, 57], ["the hepatic storage of TAG", "PROBLEM", 98, 124], ["cholesterol in the liver tissue", "PROBLEM", 132, 163], ["steatosis", "PROBLEM", 173, 182], ["prebiotics", "TREATMENT", 347, 357], ["DFs", "PROBLEM", 373, 376], ["shielding effects", "OBSERVATION", 31, 48], ["liver", "ANATOMY", 52, 57], ["hepatic", "ANATOMY", 102, 109], ["liver", "ANATOMY", 151, 156], ["tissue", "ANATOMY_MODIFIER", 157, 163], ["steatosis", "OBSERVATION", 173, 182]]], ["The natural sources of prebiotics with their ample quantities include foods such as asparagus, leeks, garlic, onion, Jerusalem artichokes, oats and soybeans so on (Davani-Davari et al., 2019).", [["leeks, garlic, onion, Jerusalem artichokes", "CHEMICAL", 95, 137], ["asparagus", "ORGANISM_SUBDIVISION", 84, 93], ["garlic", "SIMPLE_CHEMICAL", 102, 108], ["onion", "TISSUE", 110, 115], ["oats", "ORGANISM_SUBDIVISION", 139, 143], ["soybeans", "ORGANISM_SUBDIVISION", 148, 156], ["garlic", "SPECIES", 102, 108], ["onion", "SPECIES", 110, 115], ["oats", "SPECIES", 139, 143], ["soybeans", "SPECIES", 148, 156], ["prebiotics", "TREATMENT", 23, 33]]], ["Popular prebiotics, such as lactulose, galacto oligosaccharides and inulin-type fructans (eg, inulin, oligofructose and fructo-oligosaccharides), have been shown to perform a critical role in stimulating beneficial alternation in the gut microbiota composition as well as function including SCFAs production and modulating appetite and satiety) (Bindels, Delzenne, Cani, & Walter, 2015).", [["gut", "ANATOMY", 234, 237], ["lactulose", "CHEMICAL", 28, 37], ["inulin-type fructans", "CHEMICAL", 68, 88], ["inulin", "CHEMICAL", 94, 100], ["oligofructose", "CHEMICAL", 102, 115], ["fructo-oligosaccharides", "CHEMICAL", 120, 143], ["SCFAs", "CHEMICAL", 291, 296], ["lactulose", "CHEMICAL", 28, 37], ["SCFAs", "CHEMICAL", 291, 296], ["lactulose", "SIMPLE_CHEMICAL", 28, 37], ["galacto oligosaccharides", "SIMPLE_CHEMICAL", 39, 63], ["inulin-type fructans", "SIMPLE_CHEMICAL", 68, 88], ["eg", "SIMPLE_CHEMICAL", 90, 92], ["inulin", "SIMPLE_CHEMICAL", 94, 100], ["oligofructose", "SIMPLE_CHEMICAL", 102, 115], ["fructo-oligosaccharides", "SIMPLE_CHEMICAL", 120, 143], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 234, 248], ["SCFAs", "SIMPLE_CHEMICAL", 291, 296], ["Popular prebiotics", "TREATMENT", 0, 18], ["lactulose", "TREATMENT", 28, 37], ["galacto oligosaccharides", "TREATMENT", 39, 63], ["inulin", "TREATMENT", 68, 74], ["type fructans", "PROBLEM", 75, 88], ["inulin", "TREATMENT", 94, 100], ["oligofructose and fructo-oligosaccharides", "TREATMENT", 102, 143], ["SCFAs production", "TREATMENT", 291, 307]]], ["Earlier studies have recognized the reality that oligosaccharides, particularly fructo oligosaccharides (FOS) and inulin are key candidates acknowledged for their prebiotic roles.", [["inulin", "CHEMICAL", 114, 120], ["oligosaccharides", "SIMPLE_CHEMICAL", 49, 65], ["fructo oligosaccharides", "SIMPLE_CHEMICAL", 80, 103], ["FOS", "SIMPLE_CHEMICAL", 105, 108], ["inulin", "SIMPLE_CHEMICAL", 114, 120], ["Earlier studies", "TEST", 0, 15], ["oligosaccharides", "PROBLEM", 49, 65], ["inulin", "TREATMENT", 114, 120]]], ["Outcomes of randomized control trials have revealed that these oligosaccharides enhance production of Bifidobacterium (a genus of oligosaccharides fermenting gut microflora) as well as Lactobacillus species (Tojo et al., 2014).", [["gut microflora", "ANATOMY", 158, 172], ["Bifidobacterium", "CHEMICAL", 102, 117], ["Bifidobacterium", "SIMPLE_CHEMICAL", 102, 117], ["gut microflora", "ORGANISM", 158, 172], ["randomized control trials", "TREATMENT", 12, 37], ["these oligosaccharides", "PROBLEM", 57, 79], ["Bifidobacterium", "PROBLEM", 102, 117], ["oligosaccharides fermenting gut microflora", "PROBLEM", 130, 172], ["Lactobacillus species", "PROBLEM", 185, 206]]], ["Nevertheless, lately some other bacterial species such as Roseburia intestinalis, Ruminococcus bromii and Faecalibacterium prausnitzii are evolving as bacteria linked with good health (Conlon & Bird, 2015).", [["Roseburia intestinalis", "ORGANISM", 58, 80], ["Ruminococcus bromii", "ORGANISM", 82, 101], ["Faecalibacterium prausnitzii", "ORGANISM", 106, 134], ["Roseburia intestinalis", "SPECIES", 58, 80], ["Ruminococcus bromii", "SPECIES", 82, 101], ["Faecalibacterium prausnitzii", "SPECIES", 106, 134], ["Roseburia intestinalis", "SPECIES", 58, 80], ["Ruminococcus bromii", "SPECIES", 82, 101], ["Faecalibacterium prausnitzii", "SPECIES", 106, 134], ["some other bacterial species", "PROBLEM", 21, 49], ["Roseburia intestinalis", "PROBLEM", 58, 80], ["Ruminococcus bromii", "PROBLEM", 82, 101], ["Faecalibacterium prausnitzii", "PROBLEM", 106, 134], ["bacterial species", "OBSERVATION", 32, 49], ["Faecalibacterium prausnitzii", "OBSERVATION", 106, 134]]], ["This assures that prebiotic treatment is not involved just in boosting Bifidobacterium, but also endorses other species displaying anti-inflammatory characteristics (Faecalibacterium prausnitzii) and weight control (Akkermansia muciniphila) (Zhang, Li, Cheng, Buch, & Zhang, 2019).", [["Bifidobacterium", "SIMPLE_CHEMICAL", 71, 86], ["Faecalibacterium prausnitzii", "ORGANISM", 166, 194], ["Akkermansia muciniphila", "ORGANISM", 216, 239], ["Faecalibacterium prausnitzii", "SPECIES", 166, 194], ["Akkermansia muciniphila", "SPECIES", 216, 239], ["Faecalibacterium prausnitzii", "SPECIES", 166, 194], ["Akkermansia muciniphila", "SPECIES", 216, 239], ["prebiotic treatment", "TREATMENT", 18, 37], ["Faecalibacterium prausnitzii", "TREATMENT", 166, 194], ["weight control (Akkermansia muciniphila)", "PROBLEM", 200, 240]]], ["This claim was further supported by the findings of Dewulf et al. presenting human subjects.", [["human", "ORGANISM", 77, 82], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 77, 82]]], ["They issued their results with a statement that even though the rise in Bifidobacteria remains the foremost and common signature of the prebiotic approach, a complex modulation of the gut microbial ecology also happens upon prebiotic treatment in obese individuals (E. Dewulf et al., 2012).", [["gut", "ANATOMY", 184, 187], ["Bifidobacteria", "CHEMICAL", 72, 86], ["Bifidobacteria", "SIMPLE_CHEMICAL", 72, 86], ["gut", "ORGANISM_SUBDIVISION", 184, 187], ["Bifidobacteria", "PROBLEM", 72, 86], ["the prebiotic approach", "TREATMENT", 132, 154], ["prebiotic treatment", "TREATMENT", 224, 243], ["Bifidobacteria", "OBSERVATION", 72, 86], ["prebiotic approach", "OBSERVATION", 136, 154], ["gut", "ANATOMY", 184, 187]]], ["A summary of clinical trials based on pre & probiotics applications conducted in aim to treat different diseases during the past decade mostly during the last five years has been outlined in Table 1.Anti-viral efficacy of prebiotics & probiotics ::: IntroductionNowadays a strong and efficient inner defense mechanism (immunity) is more and more important than ever before.", [["inner", "ANATOMY", 294, 299], ["inner", "TISSUE", 294, 299], ["clinical trials", "TREATMENT", 13, 28], ["pre & probiotics applications", "TREATMENT", 38, 67], ["different diseases", "PROBLEM", 94, 112], ["Anti-viral efficacy of prebiotics", "TREATMENT", 199, 232], ["diseases", "OBSERVATION", 104, 112]]], ["In this perspective, balanced nutrition and wise selection of nutrients can be a crucial strategy to significantly aid in excelling our immune system.", [["immune system", "ANATOMY", 136, 149], ["immune system", "ANATOMICAL_SYSTEM", 136, 149], ["balanced nutrition", "TREATMENT", 21, 39], ["a crucial strategy", "TREATMENT", 79, 97]]], ["These facts are backed by different research works which have shown that prebiotics and probiotics modulate the gut microbiota and interact with innate and adaptive immunity.", [["gut microbiota", "ANATOMY", 112, 126], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 112, 126], ["prebiotics", "TREATMENT", 73, 83], ["probiotics", "TREATMENT", 88, 98]]], ["This could be due to the existence of the major part of immune systems in the large intestine which is home to trillions of beneficial micro-organisms (microbiome) (Wells, 2011).", [["immune systems", "ANATOMY", 56, 70], ["intestine", "ANATOMY", 84, 93], ["intestine", "ORGAN", 84, 93], ["could be due to", "UNCERTAINTY", 5, 20], ["immune systems", "OBSERVATION", 56, 70], ["large", "OBSERVATION_MODIFIER", 78, 83], ["intestine", "ANATOMY", 84, 93]]], ["A substantial research work has been done in this area to provide scientific proofs for these claims.", [["substantial", "OBSERVATION_MODIFIER", 2, 13]]], ["For example, in a randomized placebo-control trial, it was hypothesized that early prebiotic or probiotic supplementation would reduce the risk of virus-associated respiratory tract infections (RTIs) during the first year of life in a cohort of preterm infants.", [["respiratory tract", "ANATOMY", 164, 181], ["respiratory tract infections", "DISEASE", 164, 192], ["RTIs", "DISEASE", 194, 198], ["respiratory tract", "ORGANISM_SUBDIVISION", 164, 181], ["infants", "ORGANISM", 253, 260], ["infants", "SPECIES", 253, 260], ["a randomized placebo-control trial", "TREATMENT", 16, 50], ["probiotic supplementation", "TREATMENT", 96, 121], ["virus", "PROBLEM", 147, 152], ["respiratory tract infections", "PROBLEM", 164, 192], ["virus", "OBSERVATION", 147, 152], ["respiratory tract", "ANATOMY", 164, 181], ["infections", "OBSERVATION", 182, 192]]], ["The results concluded that supplementation with prebiotics galacto oligosaccharide and polydextrose mixture at ratio1:1 and a probiotic (Lactobacillus rhamnosus GG, ATCC 53103) significantly reduced the incidence of (RTIs) in these children as compared to the control placebo group receiving (microcrystalline cellulose).", [["galacto oligosaccharide", "CHEMICAL", 59, 82], ["polydextrose", "CHEMICAL", 87, 99], ["ratio1:1", "CHEMICAL", 111, 119], ["Lactobacillus rhamnosus GG", "CHEMICAL", 137, 163], ["ATCC 53103", "CHEMICAL", 165, 175], ["RTIs", "DISEASE", 217, 221], ["microcrystalline cellulose", "CHEMICAL", 293, 319], ["polydextrose", "CHEMICAL", 87, 99], ["galacto oligosaccharide", "SIMPLE_CHEMICAL", 59, 82], ["polydextrose", "SIMPLE_CHEMICAL", 87, 99], ["ratio1:1", "SIMPLE_CHEMICAL", 111, 119], ["Lactobacillus rhamnosus GG", "ORGANISM", 137, 163], ["ATCC 53103", "CELL", 165, 175], ["children", "ORGANISM", 232, 240], ["microcrystalline cellulose", "SIMPLE_CHEMICAL", 293, 319], ["Lactobacillus rhamnosus", "SPECIES", 137, 160], ["children", "SPECIES", 232, 240], ["Lactobacillus rhamnosus GG, ATCC 53103", "SPECIES", 137, 175], ["supplementation", "TREATMENT", 27, 42], ["prebiotics galacto oligosaccharide", "TREATMENT", 48, 82], ["polydextrose mixture", "TREATMENT", 87, 107], ["a probiotic (Lactobacillus rhamnosus GG", "TREATMENT", 124, 163], ["ATCC", "TEST", 165, 169], ["the control placebo group receiving (microcrystalline cellulose", "TREATMENT", 256, 319]]], ["And hence it was suggested that gut microbiota modification with specific prebiotics and probiotics might offer a novel and cost-effective means to reduce the risk of rhinovirus infections (Luoto et al., 2014).", [["gut", "ANATOMY", 32, 35], ["rhinovirus infections", "DISEASE", 167, 188], ["gut", "ORGANISM_SUBDIVISION", 32, 35], ["rhinovirus", "ORGANISM", 167, 177], ["gut microbiota modification", "TREATMENT", 32, 59], ["specific prebiotics", "TREATMENT", 65, 84], ["probiotics", "TREATMENT", 89, 99], ["a novel and cost-effective means", "TREATMENT", 112, 144], ["rhinovirus infections", "PROBLEM", 167, 188], ["rhinovirus", "OBSERVATION", 167, 177]]], ["The same probiotic bacterium (Lactobacillus rhamnosus) also showed to enhance macrophage viability for HSV-1 (herpes simplex virus type 1) elimination and activation against HSV-1 more effectively than non-probiotic Escherichia coli (Khani, Motamedifar, Golmoghaddam, Hosseini, & Hashemizadeh, 2012).", [["macrophage", "ANATOMY", 78, 88], ["Lactobacillus rhamnosus", "CHEMICAL", 30, 53], ["herpes simplex virus type 1)", "CHEMICAL", 110, 138], ["Lactobacillus rhamnosus", "ORGANISM", 30, 53], ["macrophage", "CELL", 78, 88], ["HSV-1 (", "ORGANISM", 103, 110], ["herpes simplex virus type 1", "ORGANISM", 110, 137], ["HSV-1", "ORGANISM", 174, 179], ["Escherichia coli", "ORGANISM", 216, 232], ["Lactobacillus rhamnosus", "SPECIES", 30, 53], ["HSV-1", "SPECIES", 103, 108], ["herpes simplex virus", "SPECIES", 110, 130], ["HSV-1", "SPECIES", 174, 179], ["Escherichia coli", "SPECIES", 216, 232], ["Lactobacillus rhamnosus", "SPECIES", 30, 53], ["HSV-1", "SPECIES", 103, 108], ["herpes simplex virus type 1", "SPECIES", 110, 137], ["HSV-1", "SPECIES", 174, 179], ["Escherichia coli", "SPECIES", 216, 232], ["The same probiotic bacterium (Lactobacillus rhamnosus", "TEST", 0, 53], ["macrophage viability", "TEST", 78, 98], ["HSV", "TEST", 103, 106], ["herpes simplex virus type", "PROBLEM", 110, 135], ["HSV", "TEST", 174, 177], ["non-probiotic Escherichia coli", "PROBLEM", 202, 232], ["macrophage viability", "OBSERVATION", 78, 98], ["Escherichia coli", "OBSERVATION", 216, 232]]], ["Another study determined the anti-influenza virus effects of both live and non-live Lactobacillus acidophilus L-92 accompanied by the activation of innate immunity.", [["Lactobacillus acidophilus L-92", "CHEMICAL", 84, 114], ["Lactobacillus acidophilus L-92", "ORGANISM", 84, 114], ["Lactobacillus acidophilus", "SPECIES", 84, 109], ["anti-influenza virus", "SPECIES", 29, 49], ["Lactobacillus acidophilus L-92", "SPECIES", 84, 114], ["Another study", "TEST", 0, 13], ["the anti-influenza virus effects", "TREATMENT", 25, 57], ["non-live Lactobacillus acidophilus", "TEST", 75, 109], ["anti-influenza virus", "OBSERVATION", 29, 49]]], ["The results concluded potential protective effects of the orally administrated (10 mg/mouse per d) probiotics bacteria against influenza virus infection in mouse model infected intranasally with influenza virus (H1N1) (Goto et al., 2013).", [["intranasally", "ANATOMY", 177, 189], ["influenza virus infection", "DISEASE", 127, 152], ["influenza virus", "DISEASE", 195, 210], ["mouse", "ORGANISM", 86, 91], ["influenza virus", "ORGANISM", 127, 142], ["mouse", "ORGANISM", 156, 161], ["influenza virus", "ORGANISM", 195, 210], ["mouse", "SPECIES", 86, 91], ["influenza virus", "SPECIES", 127, 142], ["mouse", "SPECIES", 156, 161], ["influenza virus", "SPECIES", 195, 210], ["mouse", "SPECIES", 86, 91], ["influenza virus", "SPECIES", 127, 142], ["mouse", "SPECIES", 156, 161], ["probiotics bacteria", "TREATMENT", 99, 118], ["influenza virus infection", "PROBLEM", 127, 152], ["influenza virus", "PROBLEM", 195, 210]]], ["Rotavirus (RV) infection, the underlying cause of diarrhea and vomiting leads to sever dehydration in patients specially children and therefore is consider the second leading cause of mortality in children < 5 years of age (Yen et al., 2014).", [["Rotavirus (RV) infection", "DISEASE", 0, 24], ["diarrhea", "DISEASE", 50, 58], ["vomiting", "DISEASE", 63, 71], ["dehydration", "DISEASE", 87, 98], ["Rotavirus", "ORGANISM", 0, 9], ["patients", "ORGANISM", 102, 110], ["children", "ORGANISM", 121, 129], ["children", "ORGANISM", 197, 205], ["patients", "SPECIES", 102, 110], ["children", "SPECIES", 121, 129], ["children", "SPECIES", 197, 205], ["RV", "SPECIES", 11, 13], ["Rotavirus (RV) infection", "PROBLEM", 0, 24], ["diarrhea", "PROBLEM", 50, 58], ["vomiting", "PROBLEM", 63, 71], ["sever dehydration", "PROBLEM", 81, 98], ["RV", "ANATOMY", 11, 13], ["infection", "OBSERVATION", 15, 24], ["diarrhea", "OBSERVATION", 50, 58]]], ["One of the possible biological pathways inducing diarrhea due to the infection is nonstructural protein (NSP4) production that causes Ca2+ -dependent transepithelial secretion.", [["transepithelial", "ANATOMY", 150, 165], ["diarrhea", "DISEASE", 49, 57], ["infection", "DISEASE", 69, 78], ["Ca2", "CHEMICAL", 134, 137], ["Ca2+", "CHEMICAL", 134, 138], ["NSP4", "GENE_OR_GENE_PRODUCT", 105, 109], ["Ca2+", "SIMPLE_CHEMICAL", 134, 138], ["transepithelial", "MULTI-TISSUE_STRUCTURE", 150, 165], ["nonstructural protein", "PROTEIN", 82, 103], ["NSP4", "PROTEIN", 105, 109], ["Ca2", "PROTEIN", 134, 137], ["diarrhea", "PROBLEM", 49, 57], ["the infection", "PROBLEM", 65, 78], ["nonstructural protein (NSP4) production", "PROBLEM", 82, 121], ["dependent transepithelial secretion", "PROBLEM", 140, 175], ["possible", "UNCERTAINTY", 11, 19], ["diarrhea", "OBSERVATION", 49, 57], ["infection", "OBSERVATION", 69, 78], ["dependent", "OBSERVATION_MODIFIER", 140, 149], ["transepithelial secretion", "OBSERVATION", 150, 175]]], ["Therefore, the antiviral activity of four probiotic metabolites (Lactobacillus casei and Bifidobacterium species) was evaluated using in vitro RV infection model.", [["Lactobacillus casei", "CHEMICAL", 65, 84], ["RV infection", "DISEASE", 143, 155], ["Lactobacillus casei", "ORGANISM", 65, 84], ["Bifidobacterium species", "ORGANISM", 89, 112], ["Lactobacillus casei", "SPECIES", 65, 84], ["Lactobacillus casei", "SPECIES", 65, 84], ["four probiotic metabolites", "TREATMENT", 37, 63], ["Lactobacillus casei", "TREATMENT", 65, 84], ["Bifidobacterium species", "TREATMENT", 89, 112], ["vitro RV infection model", "TREATMENT", 137, 161], ["RV", "ANATOMY", 143, 145], ["infection", "OBSERVATION", 146, 155]]], ["The findings demonstrated that probiotic metabolites were capable to interfere with the final amount of intracellular NSP4 protein and a successful Ca2+ regulation, thereby suggesting probiotics based novel approach against the RV infection (Olaya Galan et al., 2016).", [["intracellular", "ANATOMY", 104, 117], ["Ca2", "CHEMICAL", 148, 151], ["RV infection", "DISEASE", 228, 240], ["Ca2+", "CHEMICAL", 148, 152], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 104, 117], ["NSP4", "GENE_OR_GENE_PRODUCT", 118, 122], ["Ca2+", "SIMPLE_CHEMICAL", 148, 152], ["intracellular NSP4 protein", "PROTEIN", 104, 130], ["Ca2", "PROTEIN", 148, 151], ["probiotic metabolites", "PROBLEM", 31, 52], ["intracellular NSP4 protein", "TREATMENT", 104, 130], ["probiotics", "TREATMENT", 184, 194], ["the RV infection", "PROBLEM", 224, 240], ["RV", "ANATOMY", 228, 230], ["infection", "OBSERVATION", 231, 240]]], ["In 2017, researchers from China evaluated the effects of probiotic bacteria Lactobacillus plantarum strain N4(Lp) against transmissible gastroenteritis coronavirus.", [["gastroenteritis coronavirus", "DISEASE", 136, 163], ["Lactobacillus plantarum strain N4(Lp)", "ORGANISM", 76, 113], ["transmissible gastroenteritis coronavirus", "ORGANISM", 122, 163], ["Lactobacillus plantarum", "SPECIES", 76, 99], ["transmissible gastroenteritis coronavirus", "SPECIES", 122, 163], ["Lactobacillus plantarum", "SPECIES", 76, 99], ["transmissible gastroenteritis coronavirus", "SPECIES", 122, 163], ["probiotic bacteria Lactobacillus plantarum strain N4(Lp)", "TREATMENT", 57, 113], ["transmissible gastroenteritis coronavirus", "PROBLEM", 122, 163], ["gastroenteritis coronavirus", "OBSERVATION", 136, 163]]], ["The results found a significant viral yields reduction in the treatment groups due to the optimal inhibition of viral RNA replication (Yang et al., 2017).", [["a significant viral yields reduction", "TREATMENT", 18, 54], ["the treatment groups", "TREATMENT", 58, 78], ["viral RNA replication", "TREATMENT", 112, 133], ["significant", "OBSERVATION_MODIFIER", 20, 31], ["viral yields", "OBSERVATION", 32, 44], ["reduction", "OBSERVATION_MODIFIER", 45, 54], ["viral RNA replication", "OBSERVATION", 112, 133]]], ["Last year in another randomized, placebo-controlled trial with 258 healthy children aged 3\u20136 years consuming 6 g/day prebiotic inulin-type fructans or maltodextrina, it was found that supplementing these children during a cold season with the prebiotic significantly reduced febrile episodes requiring medical attention and lowered the incidence of sinusitis, which could be attributed to the modulation of specific gut microbiota by this prebiotic (Soldi et al., 2019).", [["gut", "ANATOMY", 416, 419], ["inulin-type fructans", "CHEMICAL", 127, 147], ["febrile", "DISEASE", 275, 282], ["sinusitis", "DISEASE", 349, 358], ["children", "ORGANISM", 75, 83], ["inulin-type fructans", "SIMPLE_CHEMICAL", 127, 147], ["maltodextrina", "SIMPLE_CHEMICAL", 151, 164], ["children", "ORGANISM", 204, 212], ["sinusitis", "PATHOLOGICAL_FORMATION", 349, 358], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 416, 430], ["children", "SPECIES", 75, 83], ["children", "SPECIES", 204, 212], ["the prebiotic significantly reduced febrile episodes", "PROBLEM", 239, 291], ["medical attention", "TREATMENT", 302, 319], ["sinusitis", "PROBLEM", 349, 358], ["sinusitis", "OBSERVATION", 349, 358]]], ["In the same year, another research group evaluated the in vitro immunomodulatory and anti- Campylobacter jejuni activities of probiotic lactobacilli spp.", [["Campylobacter jejuni", "ORGANISM", 91, 111], ["Campylobacter jejuni", "SPECIES", 91, 111], ["Campylobacter jejuni", "SPECIES", 91, 111], ["vitro immunomodulatory", "TREATMENT", 58, 80], ["anti- Campylobacter jejuni activities", "TREATMENT", 85, 122], ["probiotic lactobacilli spp", "TREATMENT", 126, 152], ["Campylobacter jejuni", "ANATOMY", 91, 111]]], ["(L. salivarius, L. johnsonii, L. reuteri, L. crispatus, and L. gasseri).", [["L. salivarius", "ORGANISM", 1, 14], ["L. johnsonii", "ORGANISM", 16, 28], ["L. reuteri", "ORGANISM", 30, 40], ["L. crispatus", "ORGANISM", 42, 54], ["L. gasseri", "ORGANISM", 60, 70], ["L. salivarius", "SPECIES", 1, 14], ["L. johnsonii", "SPECIES", 16, 28], ["L. reuteri", "SPECIES", 30, 40], ["L. crispatus", "SPECIES", 42, 54], ["L. gasseri", "SPECIES", 60, 70], ["L. salivarius", "SPECIES", 1, 14], ["L. johnsonii", "SPECIES", 16, 28], ["L. reuteri", "SPECIES", 30, 40], ["L. crispatus", "SPECIES", 42, 54], ["L. gasseri", "SPECIES", 60, 70], ["salivarius", "ANATOMY", 4, 14], ["L. johnsonii", "ANATOMY", 16, 28], ["L. crispatus", "ANATOMY", 42, 54], ["L. gasseri", "ANATOMY", 60, 70]]], ["The results demonstrated that lactobacilli carry differential antagonistic effects against C. jejuni and vary in their ability to trigger off innate responses (Taha-Abdelaziz et al., 2019).Prebiotics and probiotics based formulations (emulsions & nano, microparticles) ::: IntroductionIn recent years a greater attention has been attracted by different kinds of prebiotic formulations.", [["lactobacilli", "CHEMICAL", 30, 42], ["Prebiotics", "CHEMICAL", 189, 199], ["lactobacilli", "SIMPLE_CHEMICAL", 30, 42], ["C. jejuni", "ORGANISM", 91, 100], ["Prebiotics", "SIMPLE_CHEMICAL", 189, 199], ["C. jejuni", "SPECIES", 91, 100], ["C. jejuni", "SPECIES", 91, 100], ["lactobacilli", "TREATMENT", 30, 42], ["C. jejuni", "PROBLEM", 91, 100], ["Prebiotics", "TREATMENT", 189, 199], ["probiotics based formulations", "TREATMENT", 204, 233], ["prebiotic formulations", "TREATMENT", 362, 384]]], ["Encapsulation is a versatile technique used to enclose the encapsulants within polymeric solid, liquid or semi-solid shells in order to protect them from the harsh environments (e.g light, oxygen, pH, heat etc) as well as to control their release.", [["oxygen", "CHEMICAL", 189, 195], ["oxygen", "CHEMICAL", 189, 195], ["oxygen", "SIMPLE_CHEMICAL", 189, 195], ["a versatile technique", "TREATMENT", 17, 38], ["the encapsulants within polymeric solid, liquid or semi-solid shells", "TREATMENT", 55, 123], ["oxygen", "TREATMENT", 189, 195], ["semi-solid shells", "OBSERVATION", 106, 123]]], ["For example, Vito et al. produced emulsion filled gels (EFG) based on inulin and extra virgin olive oil, by means of both mechanical shearing and ultrasound homogenization (Paradiso et al., 2015).", [["olive oil", "ANATOMY", 94, 103], ["EFG", "CHEMICAL", 56, 59], ["inulin", "CHEMICAL", 70, 76], ["EFG", "SIMPLE_CHEMICAL", 56, 59], ["inulin", "SIMPLE_CHEMICAL", 70, 76], ["oil", "ORGANISM_SUBSTANCE", 100, 103], ["inulin and extra virgin olive oil", "TREATMENT", 70, 103], ["both mechanical shearing", "TREATMENT", 117, 141], ["ultrasound homogenization", "TREATMENT", 146, 171]]], ["Similar study was also conducted by another research group which evaluated the stability, consistency, and oil oxidation of emulsion filled gel prepared by inulin and rice bran oil using ultrasonic radiation (Nourbehesht, Shekarchizadeh, & Soltanizadeh, 2018).", [["oil", "ANATOMY", 107, 110], ["bran oil", "ANATOMY", 172, 180], ["inulin and rice bran oil", "CHEMICAL", 156, 180], ["oil", "SIMPLE_CHEMICAL", 107, 110], ["inulin", "SIMPLE_CHEMICAL", 156, 162], ["rice", "SPECIES", 167, 171], ["bran", "SPECIES", 172, 176], ["rice", "SPECIES", 167, 171], ["Similar study", "TEST", 0, 13], ["oil oxidation of emulsion filled gel", "TREATMENT", 107, 143], ["rice bran oil", "TREATMENT", 167, 180], ["ultrasonic radiation", "TREATMENT", 187, 207]]], ["In order to enhance microbiological, nutritional, and sensory quality of strawberry juices after 2 weeks of refrigerated storage, another study group reported the enrichment of the juices with prebiotic fiber (inulin and oligofructose) and their preservation treatment (with ultrasound and geraniol).", [["juices", "ANATOMY", 84, 90], ["juices", "ANATOMY", 181, 187], ["inulin", "CHEMICAL", 210, 216], ["oligofructose", "CHEMICAL", 221, 234], ["geraniol", "CHEMICAL", 290, 298], ["geraniol", "CHEMICAL", 290, 298], ["strawberry", "ORGANISM", 73, 83], ["juices", "ORGANISM_SUBSTANCE", 84, 90], ["juices", "ORGANISM_SUBSTANCE", 181, 187], ["inulin", "SIMPLE_CHEMICAL", 210, 216], ["oligofructose", "SIMPLE_CHEMICAL", 221, 234], ["geraniol", "SIMPLE_CHEMICAL", 290, 298], ["strawberry", "SPECIES", 73, 83], ["refrigerated storage", "TREATMENT", 108, 128], ["another study", "TEST", 130, 143], ["prebiotic fiber (inulin and oligofructose)", "TREATMENT", 193, 235], ["their preservation treatment", "TREATMENT", 240, 268], ["ultrasound", "TEST", 275, 285]]], ["As a result, combining preservation treatment (geraniol) with prebiotics (inulin and oligofructose) showed to be an efficient strategy to control the native microflora, as well as, to inhibit inoculated pathogens in strawberry juice during 2 weeks of refrigerated storage (Cassani, Tomadoni, Moreira, & Ag\u00fcero, 2018).", [["strawberry juice", "ANATOMY", 216, 232], ["geraniol", "CHEMICAL", 47, 55], ["inulin", "CHEMICAL", 74, 80], ["oligofructose", "CHEMICAL", 85, 98], ["geraniol", "CHEMICAL", 47, 55], ["geraniol", "SIMPLE_CHEMICAL", 47, 55], ["inulin", "SIMPLE_CHEMICAL", 74, 80], ["oligofructose", "SIMPLE_CHEMICAL", 85, 98], ["juice", "ORGANISM_SUBSTANCE", 227, 232], ["strawberry", "SPECIES", 216, 226], ["strawberry", "SPECIES", 216, 226], ["combining preservation treatment (geraniol)", "TREATMENT", 13, 56], ["prebiotics (inulin and oligofructose", "TREATMENT", 62, 98], ["inoculated pathogens in strawberry juice", "PROBLEM", 192, 232]]], ["Gum odina (GOd) a plant-derived gum, which is non-toxic in nature and is capable of enhancing immune system of the body due to its prebiotic action (Mitra et al., 2016).", [["immune system", "ANATOMY", 94, 107], ["body", "ANATOMY", 115, 119], ["Gum odina", "CHEMICAL", 0, 9], ["GOd", "CHEMICAL", 11, 14], ["Gum odina", "SIMPLE_CHEMICAL", 0, 9], ["GOd", "SIMPLE_CHEMICAL", 11, 14], ["gum", "ORGANISM", 32, 35], ["immune system", "ANATOMICAL_SYSTEM", 94, 107], ["body", "ORGANISM_SUBDIVISION", 115, 119], ["Gum odina", "SPECIES", 0, 9], ["non-toxic", "OBSERVATION_MODIFIER", 46, 55], ["body", "ANATOMY", 115, 119]]], ["Aditya et al. developed a multiple emulsion (W/O/W) of lamivudine using a GOd to increase bioavailability and patient compliances of the encapsulated drug.", [["lamivudine", "CHEMICAL", 55, 65], ["GOd", "CHEMICAL", 74, 77], ["lamivudine", "CHEMICAL", 55, 65], ["lamivudine", "SIMPLE_CHEMICAL", 55, 65], ["GOd", "SIMPLE_CHEMICAL", 74, 77], ["patient", "ORGANISM", 110, 117], ["patient", "SPECIES", 110, 117], ["a multiple emulsion", "PROBLEM", 24, 43], ["lamivudine", "TREATMENT", 55, 65], ["the encapsulated drug", "TREATMENT", 133, 154], ["multiple", "OBSERVATION_MODIFIER", 26, 34], ["emulsion", "OBSERVATION", 35, 43]]], ["GOd was employed to stabilize both the interfaces of liquid membrane in both the external and internal aqueous phases.", [["liquid membrane", "ANATOMY", 53, 68], ["GOd", "SIMPLE_CHEMICAL", 0, 3], ["GOd", "PROTEIN", 0, 3], ["liquid membrane", "OBSERVATION", 53, 68]]], ["Their results provided a promising scope for GOd stabilized W/O/W multiple emulsions in antiviral therapies (Jena, Nayak, De, Mitra, & Samanta, 2018).", [["GOd", "CHEMICAL", 45, 48], ["GOd", "SIMPLE_CHEMICAL", 45, 48], ["multiple emulsions", "TREATMENT", 66, 84], ["antiviral therapies", "TREATMENT", 88, 107]]], ["Addition of prebiotic ingredients also reduce the health risk of certain foods associated with their high contents of sodium, fats, fatty acid fatty acid profile rich in saturated fatty acids and cholesterol, which can increase the incidence of chronic disease such as coronary heart disease (CVD), obesity, high blood cholesterol and cancer.", [["coronary", "ANATOMY", 269, 277], ["heart", "ANATOMY", 278, 283], ["blood", "ANATOMY", 313, 318], ["cancer", "ANATOMY", 335, 341], ["sodium", "CHEMICAL", 118, 124], ["fatty acid fatty acid", "CHEMICAL", 132, 153], ["fatty acids", "CHEMICAL", 180, 191], ["cholesterol", "CHEMICAL", 196, 207], ["chronic disease", "DISEASE", 245, 260], ["coronary heart disease", "DISEASE", 269, 291], ["CVD", "DISEASE", 293, 296], ["obesity", "DISEASE", 299, 306], ["cholesterol", "CHEMICAL", 319, 330], ["cancer", "DISEASE", 335, 341], ["sodium", "CHEMICAL", 118, 124], ["fatty acid fatty acid", "CHEMICAL", 132, 153], ["saturated fatty acids", "CHEMICAL", 170, 191], ["cholesterol", "CHEMICAL", 196, 207], ["cholesterol", "CHEMICAL", 319, 330], ["sodium", "SIMPLE_CHEMICAL", 118, 124], ["fats", "SIMPLE_CHEMICAL", 126, 130], ["fatty acid fatty acid", "SIMPLE_CHEMICAL", 132, 153], ["saturated fatty acids", "SIMPLE_CHEMICAL", 170, 191], ["cholesterol", "SIMPLE_CHEMICAL", 196, 207], ["coronary heart", "MULTI-TISSUE_STRUCTURE", 269, 283], ["blood", "ORGANISM_SUBSTANCE", 313, 318], ["cholesterol", "SIMPLE_CHEMICAL", 319, 330], ["cancer", "CANCER", 335, 341], ["prebiotic ingredients", "TREATMENT", 12, 33], ["fatty acid fatty acid profile", "PROBLEM", 132, 161], ["cholesterol", "TEST", 196, 207], ["chronic disease", "PROBLEM", 245, 260], ["coronary heart disease", "PROBLEM", 269, 291], ["CVD", "PROBLEM", 293, 296], ["obesity", "PROBLEM", 299, 306], ["high blood cholesterol", "PROBLEM", 308, 330], ["cancer", "PROBLEM", 335, 341], ["prebiotic ingredients", "OBSERVATION", 12, 33], ["chronic", "OBSERVATION_MODIFIER", 245, 252], ["disease", "OBSERVATION", 253, 260], ["coronary heart", "ANATOMY", 269, 283], ["disease", "OBSERVATION", 284, 291], ["obesity", "OBSERVATION", 299, 306], ["high blood cholesterol", "OBSERVATION", 308, 330], ["cancer", "OBSERVATION", 335, 341]]], ["Within this context Maria et al. evaluated the effect of the addition of various prebiotic fibers on the rheological and technological properties and the microstructure of an emulsified meat product (bologna).", [["meat", "ANATOMY", 186, 190], ["meat", "ORGANISM_SUBDIVISION", 186, 190], ["various prebiotic fibers", "TREATMENT", 73, 97]]], ["They concluded that the simultaneous addition of a partial level of cassava starch and the prebiotic fibers would improve the stability of the meat emulsions, allowing the reliable production of a healthier bologna sausage (Felisberto, Galv\u00e3o, Picone, Cunha, & Pollonio, 2015).Prebiotics and probiotics based formulations (emulsions & nano, microparticles) ::: IntroductionInterestingly, this technology has shown promising effects not only for the prebiotics but also for probiotics simultaneously.", [["meat", "ANATOMY", 143, 147], ["cassava starch", "CHEMICAL", 68, 82], ["Prebiotics", "CHEMICAL", 277, 287], ["cassava", "ORGANISM", 68, 75], ["starch", "SIMPLE_CHEMICAL", 76, 82], ["meat", "ORGANISM_SUBDIVISION", 143, 147], ["Prebiotics", "SIMPLE_CHEMICAL", 277, 287], ["cassava", "SPECIES", 68, 75], ["a partial level of cassava starch", "TREATMENT", 49, 82], ["the prebiotic fibers", "TREATMENT", 87, 107], ["Prebiotics", "TREATMENT", 277, 287], ["probiotics based formulations", "TREATMENT", 292, 321], ["the prebiotics", "TREATMENT", 445, 459], ["probiotics", "TREATMENT", 473, 483], ["stability", "OBSERVATION_MODIFIER", 126, 135], ["meat emulsions", "OBSERVATION", 143, 157]]], ["Probiotics derived from a Greek word meaning \u201cfor life\u201d and are living organisms which confer potential health benefits including the alleviation of digestive discomfort, reduction of the duration of childhood diarrhea, regulation of intestinal immunity, and improvement of symptoms of the irritable bowel syndrome (Hill et al., 2014).", [["digestive", "ANATOMY", 149, 158], ["intestinal", "ANATOMY", 234, 244], ["bowel", "ANATOMY", 300, 305], ["digestive discomfort", "DISEASE", 149, 169], ["diarrhea", "DISEASE", 210, 218], ["irritable bowel syndrome", "DISEASE", 290, 314], ["digestive", "ORGAN", 149, 158], ["intestinal", "ORGAN", 234, 244], ["bowel", "ORGAN", 300, 305], ["Probiotics", "TREATMENT", 0, 10], ["digestive discomfort", "PROBLEM", 149, 169], ["childhood diarrhea", "PROBLEM", 200, 218], ["intestinal immunity", "TREATMENT", 234, 253], ["symptoms", "PROBLEM", 274, 282], ["the irritable bowel syndrome", "PROBLEM", 286, 314], ["intestinal", "ANATOMY", 234, 244], ["irritable", "OBSERVATION_MODIFIER", 290, 299], ["bowel", "ANATOMY", 300, 305]]], ["However, to significantly achieve these health benefits associated with probiotics, their protection against processing and storage conditions as well as those encountered during passage through human gut is inevitable.", [["gut", "ANATOMY", 201, 204], ["human", "ORGANISM", 195, 200], ["gut", "ORGANISM_SUBDIVISION", 201, 204], ["human", "SPECIES", 195, 200], ["human", "SPECIES", 195, 200], ["probiotics", "TREATMENT", 72, 82]]], ["At this point, encapsulation technology has been proven to be effective in protecting probiotics from these adverse conditions, while maintaining their viability and functionality (Raddatz et al., 2020; M.; Zhao et al., 2020).", [["encapsulation technology", "TREATMENT", 15, 39], ["protecting probiotics", "TREATMENT", 75, 96], ["these adverse conditions", "PROBLEM", 102, 126]]], ["So far a number of different encapsulation based formulations have been implied in food industry to enhance protection and viability of the encapsulated probiotic bacteria and thereby scale up the nutritional value and functional properties of the produced products.", [["different encapsulation based formulations", "TREATMENT", 19, 61], ["the encapsulated probiotic bacteria", "PROBLEM", 136, 171], ["nutritional value", "OBSERVATION_MODIFIER", 197, 214]]], ["The presence of prebiotics in these systems perform several pivotal roles.", [["prebiotics", "TREATMENT", 16, 26], ["prebiotics", "OBSERVATION", 16, 26]]], ["For example, these prebiotics increase stability of the synthesized systems, aid in developing of novel food products with reduced fats and salt contents and enhance protection and viability of the encapsulated probiotics bacteria.", [["fats", "SIMPLE_CHEMICAL", 131, 135], ["salt", "SIMPLE_CHEMICAL", 140, 144], ["these prebiotics", "TREATMENT", 13, 29], ["reduced fats and salt contents", "PROBLEM", 123, 153], ["enhance protection", "TREATMENT", 158, 176], ["the encapsulated probiotics bacteria", "PROBLEM", 194, 230], ["increase", "OBSERVATION_MODIFIER", 30, 38], ["stability", "OBSERVATION_MODIFIER", 39, 48], ["food products", "OBSERVATION", 104, 117], ["reduced", "OBSERVATION_MODIFIER", 123, 130], ["fats", "OBSERVATION_MODIFIER", 131, 135], ["salt contents", "OBSERVATION", 140, 153]]], ["These approaches are of particular importance in the production of novel functional foods the demands for which have increased significantly in recent years.", [["increased", "OBSERVATION_MODIFIER", 117, 126]]], ["A summary of these formulations developed in recent years with their respective potentials has been given in Table 1.ConclusionsFrom the above detailed descriptions, a conclusion can be withdrawn with the facts that DFs and complex resistant undigestible carbohydrates, that withstand digestion by host enzymes in the upper GIT play a pivotal role in driving bacterial fermentation in the large intestine.", [["upper GIT", "ANATOMY", 318, 327], ["intestine", "ANATOMY", 395, 404], ["carbohydrates", "CHEMICAL", 255, 268], ["DFs", "SIMPLE_CHEMICAL", 216, 219], ["upper GIT", "ORGAN", 318, 327], ["intestine", "ORGAN", 395, 404], ["host enzymes", "PROTEIN", 298, 310], ["these formulations", "TREATMENT", 13, 31], ["DFs", "PROBLEM", 216, 219], ["complex resistant undigestible carbohydrates", "PROBLEM", 224, 268], ["host enzymes", "TEST", 298, 310], ["resistant", "OBSERVATION_MODIFIER", 232, 241], ["undigestible carbohydrates", "OBSERVATION", 242, 268], ["upper", "ANATOMY_MODIFIER", 318, 323], ["GIT", "ANATOMY", 324, 327], ["large", "ANATOMY_MODIFIER", 389, 394], ["intestine", "ANATOMY", 395, 404]]], ["It could be due to the production of SCFAs from these DFs by the gut microbiota, which in turn paly significant roles in promoting health and well-being.", [["gut microbiota", "ANATOMY", 65, 79], ["SCFAs", "CHEMICAL", 37, 42], ["SCFAs", "CHEMICAL", 37, 42], ["SCFAs", "SIMPLE_CHEMICAL", 37, 42], ["DFs", "SIMPLE_CHEMICAL", 54, 57], ["gut", "ORGANISM_SUBDIVISION", 65, 68], ["SCFAs", "PROBLEM", 37, 42], ["could be due to", "UNCERTAINTY", 3, 18], ["gut microbiota", "ANATOMY", 65, 79]]], ["The production of SCFAs mainly depends on dietary substrate, which affects the composition of the bacterial flora, transit time through the colon and luminal pH (which are all interlinked variables).", [["flora", "ANATOMY", 108, 113], ["colon", "ANATOMY", 140, 145], ["luminal", "ANATOMY", 150, 157], ["SCFAs", "CHEMICAL", 18, 23], ["luminal", "CHEMICAL", 150, 157], ["SCFAs", "CHEMICAL", 18, 23], ["SCFAs", "SIMPLE_CHEMICAL", 18, 23], ["colon", "ORGAN", 140, 145], ["luminal", "MULTI-TISSUE_STRUCTURE", 150, 157], ["The production of SCFAs", "PROBLEM", 0, 23], ["dietary substrate", "TREATMENT", 42, 59], ["the bacterial flora", "PROBLEM", 94, 113], ["SCFAs", "OBSERVATION_MODIFIER", 18, 23], ["bacterial flora", "OBSERVATION", 98, 113], ["colon", "ANATOMY", 140, 145], ["luminal pH", "ANATOMY", 150, 160]]], ["In short, the type of DFs arriving the colon has a remarkable impact on the performance and composition of bacterial communities, thereby influencing the production of SCFAs, the balance of which is vital to maintain gut health.", [["colon", "ANATOMY", 39, 44], ["communities", "ANATOMY", 117, 128], ["gut", "ANATOMY", 217, 220], ["SCFAs", "CHEMICAL", 168, 173], ["SCFAs", "CHEMICAL", 168, 173], ["colon", "ORGAN", 39, 44], ["SCFAs", "SIMPLE_CHEMICAL", 168, 173], ["gut", "ORGANISM_SUBDIVISION", 217, 220], ["bacterial communities", "PROBLEM", 107, 128], ["short", "OBSERVATION_MODIFIER", 3, 8], ["colon", "ANATOMY", 39, 44], ["bacterial communities", "OBSERVATION", 107, 128]]], ["Among all the produced SCFAs, butyrate may be regarded as the most beneficial one for colonic health, which could be due to is principal energy source for the colonycytes as well as its role in modulating cell turnover in the colon.", [["colonic", "ANATOMY", 86, 93], ["colonycytes", "ANATOMY", 159, 170], ["cell", "ANATOMY", 205, 209], ["colon", "ANATOMY", 226, 231], ["SCFAs", "CHEMICAL", 23, 28], ["butyrate", "CHEMICAL", 30, 38], ["SCFAs", "CHEMICAL", 23, 28], ["butyrate", "CHEMICAL", 30, 38], ["SCFAs", "SIMPLE_CHEMICAL", 23, 28], ["butyrate", "SIMPLE_CHEMICAL", 30, 38], ["colonic", "ORGAN", 86, 93], ["cell", "CELL", 205, 209], ["colon", "ORGAN", 226, 231], ["the colonycytes", "PROBLEM", 155, 170], ["modulating cell turnover in the colon", "PROBLEM", 194, 231], ["colonic", "ANATOMY", 86, 93], ["modulating cell turnover", "OBSERVATION", 194, 218], ["colon", "ANATOMY", 226, 231]]], ["This implies that ensuring an adequate supply of DFs, such that to maintain raised butyrate levels is throughout the entire length of the large intestine, can be a beneficial strategy in the prevention of colon cancer, usually originated in the distal colon.", [["intestine", "ANATOMY", 144, 153], ["colon cancer", "ANATOMY", 205, 217], ["distal colon", "ANATOMY", 245, 257], ["butyrate", "CHEMICAL", 83, 91], ["colon cancer", "DISEASE", 205, 217], ["butyrate", "CHEMICAL", 83, 91], ["DFs", "SIMPLE_CHEMICAL", 49, 52], ["butyrate", "SIMPLE_CHEMICAL", 83, 91], ["intestine", "ORGAN", 144, 153], ["colon cancer", "CANCER", 205, 217], ["colon", "ORGAN", 252, 257], ["DFs", "PROBLEM", 49, 52], ["raised butyrate levels", "PROBLEM", 76, 98], ["a beneficial strategy", "TREATMENT", 162, 183], ["colon cancer", "PROBLEM", 205, 217], ["adequate", "OBSERVATION_MODIFIER", 30, 38], ["supply", "OBSERVATION_MODIFIER", 39, 45], ["large intestine", "ANATOMY", 138, 153], ["colon", "ANATOMY", 205, 210], ["cancer", "OBSERVATION", 211, 217], ["distal", "ANATOMY_MODIFIER", 245, 251], ["colon", "ANATOMY", 252, 257]]], ["However, interestingly maintaining an optimal levels of all the three SCFAs may have a broader range of health benefits including impacting the progressions of metabolic syndrome such as type 2 diabetes, obesity and CVD.", [["SCFAs", "CHEMICAL", 70, 75], ["metabolic syndrome", "DISEASE", 160, 178], ["type 2 diabetes", "DISEASE", 187, 202], ["obesity", "DISEASE", 204, 211], ["CVD", "DISEASE", 216, 219], ["SCFAs", "CHEMICAL", 70, 75], ["SCFAs", "SIMPLE_CHEMICAL", 70, 75], ["metabolic syndrome", "PROBLEM", 160, 178], ["type 2 diabetes", "PROBLEM", 187, 202], ["obesity", "PROBLEM", 204, 211], ["CVD", "PROBLEM", 216, 219], ["metabolic syndrome", "OBSERVATION", 160, 178], ["diabetes", "OBSERVATION", 194, 202], ["obesity", "OBSERVATION", 204, 211]]], ["Profound knowledge of particular DFs that develop and stimulate SCFAs particularly butyrate and propionate production, with reducing secondary bile acid conversion and elevating bile acid binding and excretion, would ultimately lead to enhanced defense against both colon cancer and metabolic syndrome.", [["colon cancer", "ANATOMY", 266, 278], ["SCFAs", "CHEMICAL", 64, 69], ["butyrate", "CHEMICAL", 83, 91], ["propionate", "CHEMICAL", 96, 106], ["bile acid", "CHEMICAL", 143, 152], ["bile acid", "CHEMICAL", 178, 187], ["colon cancer", "DISEASE", 266, 278], ["metabolic syndrome", "DISEASE", 283, 301], ["SCFAs", "CHEMICAL", 64, 69], ["butyrate", "CHEMICAL", 83, 91], ["propionate", "CHEMICAL", 96, 106], ["bile acid", "CHEMICAL", 143, 152], ["bile acid", "CHEMICAL", 178, 187], ["DFs", "GENE_OR_GENE_PRODUCT", 33, 36], ["SCFAs", "SIMPLE_CHEMICAL", 64, 69], ["butyrate", "SIMPLE_CHEMICAL", 83, 91], ["propionate", "SIMPLE_CHEMICAL", 96, 106], ["bile acid", "SIMPLE_CHEMICAL", 143, 152], ["bile acid", "SIMPLE_CHEMICAL", 178, 187], ["colon cancer", "CANCER", 266, 278], ["particular DFs", "PROBLEM", 22, 36], ["propionate production", "TREATMENT", 96, 117], ["reducing secondary bile acid conversion", "PROBLEM", 124, 163], ["elevating bile acid binding", "PROBLEM", 168, 195], ["both colon cancer", "PROBLEM", 261, 278], ["metabolic syndrome", "PROBLEM", 283, 301], ["bile", "ANATOMY", 143, 147], ["bile", "ANATOMY", 178, 182], ["colon", "ANATOMY", 266, 271], ["cancer", "OBSERVATION", 272, 278], ["metabolic syndrome", "OBSERVATION", 283, 301]]], ["Furthermore, weight loss formulas that are based on lowered carbohydrate and calories intake should maintain ample amounts of DFs to sustain gut health.", [["gut", "ANATOMY", 141, 144], ["weight loss", "DISEASE", 13, 24], ["carbohydrate", "CHEMICAL", 60, 72], ["carbohydrate", "SIMPLE_CHEMICAL", 60, 72], ["calories", "SIMPLE_CHEMICAL", 77, 85], ["gut", "ORGANISM_SUBDIVISION", 141, 144], ["weight loss formulas", "PROBLEM", 13, 33], ["lowered carbohydrate and calories intake", "TREATMENT", 52, 92]]], ["In addition, being prebiotics and as a food for probiotics, DFs play inevitable role in the development of novel functional foods and hence various formulations have been focused tremendously in recent years.", [["DFs", "CHEMICAL", 60, 63], ["DFs", "SIMPLE_CHEMICAL", 60, 63], ["prebiotics", "TREATMENT", 19, 29], ["probiotics", "TREATMENT", 48, 58], ["various formulations", "TREATMENT", 140, 160]]], ["These pre and probiotics-based formulations are aimed to enhance stability of the synthesized systems, protect the encapsulants and promote viability and functionality of the encapsulated probiotics.", [["probiotics-based formulations", "TREATMENT", 14, 43], ["the encapsulants", "TREATMENT", 111, 127], ["the encapsulated probiotics", "TREATMENT", 171, 198], ["viability", "OBSERVATION_MODIFIER", 140, 149]]], ["Therefore, it is strongly recommended that future work is needed to; i) develop novel pre & probiotic based formulations with promising characteristics, ii) evaluate the in vivo efficacy as well as dosage optimization of the designed systems in animal models and iii) carry out clinical trials to find out the significance of these formulations in human subjects suffering from different pathologies.Uncited section", [["human", "ORGANISM", 348, 353], ["human", "SPECIES", 348, 353], ["human", "SPECIES", 348, 353], ["novel pre & probiotic based formulations", "TREATMENT", 80, 120], ["dosage optimization", "TREATMENT", 198, 217], ["different pathologies", "PROBLEM", 378, 399], ["different", "OBSERVATION_MODIFIER", 378, 387], ["pathologies", "OBSERVATION", 388, 399]]]], "49021648e861b97bee9f78268b75ab80a4a8995f": [["Au fil des d\u00e9cennies, des savants prestigieux, mais aussi des hommes de terrain ont contribu\u00e9 \u00e0 son succ\u00e8s et \u00e0 celui de son Bulletin, dans lequel ont \u00e9t\u00e9 publi\u00e9es plusieurs d\u00e9couvertes m\u00e9dicales majeures.", [["Au", "CHEMICAL", 0, 2]]]], "4bf8dc8f39812506722699d56119bbd9e836cd18": [["IntroductionThe actual Coronavirus Disease (COVID 19) pandemic is due to Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a member of the coronavirus family.", [["Coronavirus Disease", "DISEASE", 23, 42], ["acute respiratory syndrome coronavirus", "DISEASE", 80, 118], ["Severe acute respiratory syndrome coronavirus 2", "ORGANISM", 73, 120], ["SARS-CoV-2", "ORGANISM", 122, 132], ["coronavirus", "ORGANISM", 151, 162], ["coronavirus", "SPECIES", 151, 162], ["Severe acute respiratory syndrome coronavirus", "SPECIES", 73, 118], ["SARS-CoV-2", "SPECIES", 122, 132], ["The actual Coronavirus Disease", "PROBLEM", 12, 42], ["pandemic", "PROBLEM", 54, 62], ["Severe acute respiratory syndrome coronavirus", "PROBLEM", 73, 118], ["Coronavirus Disease", "OBSERVATION", 23, 42], ["due to", "UNCERTAINTY", 66, 72], ["Severe", "OBSERVATION_MODIFIER", 73, 79], ["acute", "OBSERVATION_MODIFIER", 80, 85], ["respiratory syndrome", "OBSERVATION", 86, 106]]], ["It is a single strain RNA-virus that enters human cells through the binding between the viral structural spike (S) protein and the angiotensin-converting enzyme 2 (ACE2) receptor [1] .", [["cells", "ANATOMY", 50, 55], ["angiotensin", "CHEMICAL", 131, 142], ["human", "ORGANISM", 44, 49], ["cells", "CELL", 50, 55], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 131, 162], ["ACE2", "GENE_OR_GENE_PRODUCT", 164, 168], ["human cells", "CELL_TYPE", 44, 55], ["viral structural spike (S) protein", "PROTEIN", 88, 122], ["angiotensin-converting enzyme 2 (ACE2) receptor", "PROTEIN", 131, 178], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 44, 49], ["a single strain RNA-virus", "PROBLEM", 6, 31], ["protein", "TEST", 115, 122], ["the angiotensin-converting enzyme", "TREATMENT", 127, 160], ["virus", "OBSERVATION", 26, 31], ["viral structural spike", "OBSERVATION", 88, 110]]], ["ACE 2 is mainly expressed on the surface of alveolar type II epithelial cells, cardiac myocytes and vascular endothelial cells (EC).", [["surface", "ANATOMY", 33, 40], ["alveolar type II epithelial cells", "ANATOMY", 44, 77], ["cardiac myocytes", "ANATOMY", 79, 95], ["vascular endothelial cells", "ANATOMY", 100, 126], ["EC", "ANATOMY", 128, 130], ["ACE 2", "GENE_OR_GENE_PRODUCT", 0, 5], ["surface", "CELLULAR_COMPONENT", 33, 40], ["alveolar type II epithelial cells", "CELL", 44, 77], ["cardiac myocytes", "CELL", 79, 95], ["vascular endothelial cells", "CELL", 100, 126], ["EC", "CELL", 128, 130], ["ACE 2", "PROTEIN", 0, 5], ["alveolar type II epithelial cells", "CELL_TYPE", 44, 77], ["cardiac myocytes", "CELL_TYPE", 79, 95], ["vascular endothelial cells", "CELL_TYPE", 100, 126], ["EC", "CELL_TYPE", 128, 130], ["alveolar type II epithelial cells", "PROBLEM", 44, 77], ["cardiac myocytes and vascular endothelial cells", "PROBLEM", 79, 126], ["surface", "ANATOMY_MODIFIER", 33, 40], ["alveolar", "ANATOMY_MODIFIER", 44, 52], ["epithelial cells", "OBSERVATION", 61, 77], ["cardiac myocytes", "ANATOMY", 79, 95], ["vascular", "ANATOMY", 100, 108], ["endothelial cells", "OBSERVATION", 109, 126]]], ["Viral entry is facilitated by a type 2 transmembrane serine protease, TMPRSS2, via the S protein as well [2] .IntroductionSARS-CoV-2 has rapidly spread worldwide, so far that in March 2020 the World Health Organization (WHO) has declared it a global pandemic and public health emergency.", [["IntroductionSARS-CoV-2", "CHEMICAL", 110, 132], ["serine", "CHEMICAL", 53, 59], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 70, 77], ["type 2 transmembrane serine protease", "PROTEIN", 32, 68], ["TMPRSS2", "PROTEIN", 70, 77], ["S protein", "PROTEIN", 87, 96], ["a type 2 transmembrane serine protease", "TREATMENT", 30, 68], ["TMPRSS2", "TREATMENT", 70, 77], ["IntroductionSARS", "TEST", 110, 126]]], ["COVID-19 has a wide spectrum of possible clinical features, ranging from asymptomatic patients to severe pulmonary disease with multiorgan failure (MOF) [3] .", [["pulmonary", "ANATOMY", 105, 114], ["multiorgan", "ANATOMY", 128, 138], ["COVID-19", "CHEMICAL", 0, 8], ["pulmonary disease", "DISEASE", 105, 122], ["multiorgan failure", "DISEASE", 128, 146], ["MOF", "DISEASE", 148, 151], ["patients", "ORGANISM", 86, 94], ["pulmonary", "ORGAN", 105, 114], ["patients", "SPECIES", 86, 94], ["COVID", "TEST", 0, 5], ["clinical features", "PROBLEM", 41, 58], ["severe pulmonary disease", "PROBLEM", 98, 122], ["multiorgan failure", "PROBLEM", 128, 146], ["wide spectrum", "OBSERVATION_MODIFIER", 15, 28], ["severe", "OBSERVATION_MODIFIER", 98, 104], ["pulmonary", "ANATOMY", 105, 114], ["disease", "OBSERVATION", 115, 122], ["multiorgan failure", "OBSERVATION", 128, 146]]], ["Asymptomatic Vincenzo Carfora and Giorgio Spiniello have contributed equally to the paper. infection may be present in up to 85% of confirmed cases [4, 5] .IntroductionThere is a growing evidence of a procoagulant state in COVID 19 patients, with important prognostic implications.", [["infection", "DISEASE", 91, 100], ["patients", "ORGANISM", 232, 240], ["patients", "SPECIES", 232, 240], ["Asymptomatic", "PROBLEM", 0, 12], ["Giorgio Spiniello", "TREATMENT", 34, 51], ["infection", "PROBLEM", 91, 100], ["procoagulant", "OBSERVATION_MODIFIER", 201, 213]]], ["Lungs are the most affected organs and critically ill patients often show thrombotic lesions in pulmonary microvessels, with a prevalence twice higher than critical non-COVID 19 patients [6] .", [["Lungs", "ANATOMY", 0, 5], ["organs", "ANATOMY", 28, 34], ["thrombotic lesions", "ANATOMY", 74, 92], ["pulmonary microvessels", "ANATOMY", 96, 118], ["critically ill", "DISEASE", 39, 53], ["thrombotic lesions", "DISEASE", 74, 92], ["Lungs", "ORGAN", 0, 5], ["organs", "ORGAN", 28, 34], ["patients", "ORGANISM", 54, 62], ["thrombotic lesions", "PATHOLOGICAL_FORMATION", 74, 92], ["pulmonary microvessels", "TISSUE", 96, 118], ["patients", "ORGANISM", 178, 186], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 178, 186], ["thrombotic lesions in pulmonary microvessels", "PROBLEM", 74, 118], ["thrombotic", "OBSERVATION_MODIFIER", 74, 84], ["lesions", "OBSERVATION", 85, 92], ["pulmonary microvessels", "ANATOMY", 96, 118]]], ["Therefore, the correct management of the anticoagulant therapy in COVID 19 patients has a fundamental role.IntroductionThis narrative review will summarize the knowledge on the coagulative state in patients with COVID-19 and its therapeutic management.", [["COVID-19", "CHEMICAL", 212, 220], ["COVID-19", "CHEMICAL", 212, 220], ["patients", "ORGANISM", 75, 83], ["patients", "ORGANISM", 198, 206], ["patients", "SPECIES", 75, 83], ["patients", "SPECIES", 198, 206], ["the anticoagulant therapy", "TREATMENT", 37, 62], ["COVID", "TEST", 212, 217], ["its therapeutic management", "TREATMENT", 225, 251]]], ["The article is addressed particularly to physicians having in care patients with COVID-19 in their clinical practice.MethodsA narrative review was performed using MEDLINE and Google Scholar from January 2020 up to 28th May 2020, in order to identify the coagulative state in patients with COVID-19.", [["patients", "ORGANISM", 67, 75], ["patients", "ORGANISM", 275, 283], ["patients", "SPECIES", 67, 75], ["patients", "SPECIES", 275, 283], ["COVID", "TREATMENT", 81, 86], ["COVID", "TEST", 289, 294]]], ["We included the following search terms: \"COVID-19\" and \"SARS-CoV-2\" in combination with \"Thrombosis\" and \"Anticoagulation\".", [["SARS", "DISEASE", 56, 60], ["Thrombosis", "DISEASE", 89, 99], ["Thrombosis", "PROBLEM", 89, 99], ["Anticoagulation", "TREATMENT", 106, 121], ["Thrombosis", "OBSERVATION", 89, 99]]], ["The reference lists of all studies included were manually searched to identify any other study that might merit inclusion.", [["all studies", "TEST", 23, 34], ["any other study", "TEST", 79, 94]]], ["We excluded articles in non-English-language.Biochemical and clinical manifestations of hyper-coagulable state in Covid 19The autoptic evidence of diffuse microvascular thrombi in the lungs of patients died from COVID-19 support the theory of a hypercoagulable state.", [["diffuse microvascular thrombi", "ANATOMY", 147, 176], ["lungs", "ANATOMY", 184, 189], ["microvascular thrombi", "DISEASE", 155, 176], ["COVID-19", "CHEMICAL", 212, 220], ["microvascular thrombi", "PATHOLOGICAL_FORMATION", 155, 176], ["lungs", "ORGAN", 184, 189], ["patients", "ORGANISM", 193, 201], ["patients", "SPECIES", 193, 201], ["hyper-coagulable state", "PROBLEM", 88, 110], ["diffuse microvascular thrombi", "PROBLEM", 147, 176], ["COVID", "TEST", 212, 217], ["a hypercoagulable state", "PROBLEM", 243, 266], ["diffuse", "OBSERVATION_MODIFIER", 147, 154], ["microvascular", "OBSERVATION_MODIFIER", 155, 168], ["thrombi", "OBSERVATION", 169, 176], ["lungs", "ANATOMY", 184, 189], ["hypercoagulable", "OBSERVATION", 245, 260]]], ["Carsana et al. [7] examined lungs tissues of 38 patients who died for COVID-19, with histologic evidence of platelet-fibrin thrombi in 33 out of 38 cases.", [["lungs tissues", "ANATOMY", 28, 41], ["platelet", "ANATOMY", 108, 116], ["platelet-fibrin thrombi", "DISEASE", 108, 131], ["lungs tissues", "TISSUE", 28, 41], ["patients", "ORGANISM", 48, 56], ["platelet", "CELL", 108, 116], ["fibrin", "GENE_OR_GENE_PRODUCT", 117, 123], ["patients", "SPECIES", 48, 56], ["COVID", "TEST", 70, 75], ["platelet", "TEST", 108, 116], ["fibrin thrombi", "PROBLEM", 117, 131], ["lungs", "ANATOMY", 28, 33], ["platelet", "ANATOMY", 108, 116], ["fibrin thrombi", "OBSERVATION", 117, 131]]], ["Tables 1 and 2 show the biochemical and clinical evidences, respectively, of hyper-coagulable status in COVID-19 (Tables 1, 2 ).Biochemical and clinical manifestations of hyper-coagulable state in Covid 19In COVID-19-patients it is common to observe relative thrombocytopenia with increased fibrinogen and D-Dimer levels [8] and variable levels of prothrombin time (PT), activated partial thromboplastin time (aPTT) and International standardized ratio (INR) [9] .", [["thrombocytopenia", "DISEASE", 259, 275], ["patients", "ORGANISM", 217, 225], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 291, 301], ["D-Dimer", "SIMPLE_CHEMICAL", 306, 313], ["prothrombin", "GENE_OR_GENE_PRODUCT", 348, 359], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 389, 403], ["fibrinogen", "PROTEIN", 291, 301], ["prothrombin", "PROTEIN", 348, 359], ["patients", "SPECIES", 217, 225], ["hyper-coagulable status", "PROBLEM", 77, 100], ["COVID", "TEST", 104, 109], ["hyper-coagulable state", "PROBLEM", 171, 193], ["COVID", "TEST", 208, 213], ["relative thrombocytopenia", "PROBLEM", 250, 275], ["increased fibrinogen", "PROBLEM", 281, 301], ["D-Dimer levels", "TEST", 306, 320], ["prothrombin time", "TEST", 348, 364], ["PT", "TEST", 366, 368], ["activated partial thromboplastin time", "TREATMENT", 371, 408], ["aPTT", "TEST", 410, 414], ["International standardized ratio", "TEST", 420, 452], ["INR", "TEST", 454, 457], ["thrombocytopenia", "OBSERVATION", 259, 275]]], ["Moreover, there is evidence of direct correlation between D-Dimer levels and poor prognosis [10] .", [["D-Dimer", "CHEMICAL", 58, 65], ["D-Dimer", "GENE_OR_GENE_PRODUCT", 58, 65], ["Dimer", "PROTEIN", 60, 65], ["D-Dimer levels", "TEST", 58, 72]]], ["Tang et al. [11] enrolled 183 consecutive COVID-19 patients and performed routine coagulation tests [PT, [8] In COVID-19-patients it is common to observe increased fibrinogen and D-Dimer levels Chen, 2020 [9] In COVID-19-patients it is common to observe variable levels of prothrombin time (PT), activated partial thromboplastin time (aPTT) and International standardized ratio (INR) Qin, 2020 [15] In COVID-19 the hyperinflammation mediated by IL-1, TNF-alfa and IL-6 leads to an increase of plasma concentrations of fibrinogen and plasminogen activator inhibitor-1 (PAI-1) Campbell, 2020 [19] In a murine model of MERS-CoV infection, increased concentrations of C5a and C5b-9 were found in sera and lung tissues.", [["plasma", "ANATOMY", 493, 499], ["sera", "ANATOMY", 692, 696], ["lung tissues", "ANATOMY", 701, 713], ["hyperinflammation", "DISEASE", 415, 432], ["MERS-CoV infection", "DISEASE", 616, 634], ["C5b-9", "CHEMICAL", 672, 677], ["patients", "ORGANISM", 51, 59], ["patients", "ORGANISM", 121, 129], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 164, 174], ["D-Dimer", "SIMPLE_CHEMICAL", 179, 186], ["patients", "ORGANISM", 221, 229], ["prothrombin", "GENE_OR_GENE_PRODUCT", 273, 284], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 314, 328], ["IL-1", "GENE_OR_GENE_PRODUCT", 445, 449], ["TNF-alfa", "GENE_OR_GENE_PRODUCT", 451, 459], ["IL-6", "GENE_OR_GENE_PRODUCT", 464, 468], ["plasma", "ORGANISM_SUBSTANCE", 493, 499], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 518, 528], ["plasminogen activator inhibitor-1", "GENE_OR_GENE_PRODUCT", 533, 566], ["PAI-1", "GENE_OR_GENE_PRODUCT", 568, 573], ["murine", "ORGANISM", 600, 606], ["MERS-CoV", "ORGANISM", 616, 624], ["C5a", "GENE_OR_GENE_PRODUCT", 664, 667], ["C5b-9", "GENE_OR_GENE_PRODUCT", 672, 677], ["sera", "ORGANISM_SUBSTANCE", 692, 696], ["lung tissues", "TISSUE", 701, 713], ["fibrinogen", "PROTEIN", 164, 174], ["prothrombin", "PROTEIN", 273, 284], ["IL", "PROTEIN", 445, 447], ["TNF", "PROTEIN", 451, 454], ["IL-6", "PROTEIN", 464, 468], ["fibrinogen", "PROTEIN", 518, 528], ["C5a", "PROTEIN", 664, 667], ["C5b", "PROTEIN", 672, 675], ["patients", "SPECIES", 51, 59], ["patients", "SPECIES", 121, 129], ["patients", "SPECIES", 221, 229], ["murine", "SPECIES", 600, 606], ["MERS-CoV", "SPECIES", 616, 624], ["routine coagulation tests", "TEST", 74, 99], ["PT", "TEST", 101, 103], ["COVID", "TEST", 112, 117], ["increased fibrinogen", "PROBLEM", 154, 174], ["D-Dimer levels", "TEST", 179, 193], ["COVID", "TEST", 212, 217], ["prothrombin time", "TEST", 273, 289], ["PT", "TEST", 291, 293], ["activated partial thromboplastin time", "TREATMENT", 296, 333], ["aPTT", "TEST", 335, 339], ["International standardized ratio", "TEST", 345, 377], ["INR", "TEST", 379, 382], ["COVID", "TEST", 402, 407], ["IL", "TEST", 445, 447], ["TNF", "TEST", 451, 454], ["alfa and IL", "TREATMENT", 455, 466], ["plasma concentrations", "TEST", 493, 514], ["fibrinogen", "TEST", 518, 528], ["plasminogen activator inhibitor", "TREATMENT", 533, 564], ["MERS", "PROBLEM", 616, 620], ["CoV infection", "PROBLEM", 621, 634], ["increased concentrations", "PROBLEM", 636, 660], ["C5a", "TEST", 664, 667], ["C5b", "TEST", 672, 675], ["CoV", "ANATOMY", 621, 624], ["infection", "OBSERVATION", 625, 634], ["increased", "OBSERVATION_MODIFIER", 636, 645], ["concentrations", "OBSERVATION_MODIFIER", 646, 660], ["lung tissues", "ANATOMY", 701, 713]]], ["Blocking C5a with a murine antibody alleviated lung and spleen damage with decreased cytokine response and viral replication [7] Evidence of platelet-fibrin thrombi in lungs tissues of patients who died for COVID-19 Tang, 2020 [11] 183 consecutive COVID 19 patients have been enrolled and 15 of 21 non survivors had a ISTH-DIC score \u2265 5 Varga, 2020 [34] Evidence of viral elements within endothelial cells in histological analyses,.", [["lung", "ANATOMY", 47, 51], ["spleen", "ANATOMY", 56, 62], ["platelet", "ANATOMY", 141, 149], ["lungs tissues", "ANATOMY", 168, 181], ["endothelial cells", "ANATOMY", 388, 405], ["lung and spleen damage", "DISEASE", 47, 69], ["DIC", "DISEASE", 323, 326], ["C5a", "GENE_OR_GENE_PRODUCT", 9, 12], ["murine", "ORGANISM", 20, 26], ["lung", "ORGAN", 47, 51], ["spleen", "ORGAN", 56, 62], ["platelet", "CELL", 141, 149], ["fibrin", "GENE_OR_GENE_PRODUCT", 150, 156], ["lungs tissues", "TISSUE", 168, 181], ["patients", "ORGANISM", 185, 193], ["patients", "ORGANISM", 257, 265], ["endothelial cells", "CELL", 388, 405], ["C5a", "PROTEIN", 9, 12], ["murine antibody", "PROTEIN", 20, 35], ["cytokine", "PROTEIN", 85, 93], ["platelet", "CELL_TYPE", 141, 149], ["viral elements", "DNA", 366, 380], ["endothelial cells", "CELL_TYPE", 388, 405], ["murine", "SPECIES", 20, 26], ["patients", "SPECIES", 185, 193], ["patients", "SPECIES", 257, 265], ["Blocking C5a", "PROBLEM", 0, 12], ["a murine antibody alleviated lung", "PROBLEM", 18, 51], ["spleen damage", "PROBLEM", 56, 69], ["decreased cytokine response", "PROBLEM", 75, 102], ["viral replication", "TREATMENT", 107, 124], ["platelet", "TEST", 141, 149], ["fibrin thrombi in lungs tissues", "PROBLEM", 150, 181], ["COVID", "TEST", 207, 212], ["a ISTH", "TEST", 316, 322], ["DIC score", "TEST", 323, 332], ["viral elements within endothelial cells", "PROBLEM", 366, 405], ["histological analyses", "TEST", 409, 430], ["lung", "ANATOMY", 47, 51], ["spleen", "ANATOMY", 56, 62], ["decreased", "OBSERVATION_MODIFIER", 75, 84], ["cytokine response", "OBSERVATION", 85, 102], ["platelet", "ANATOMY", 141, 149], ["fibrin thrombi", "OBSERVATION", 150, 164], ["lungs", "ANATOMY", 168, 173], ["viral elements", "OBSERVATION", 366, 380], ["endothelial cells", "OBSERVATION", 388, 405]]], ["These findings suggest that SARS-CoV-2 infection facilitates the induction of endothelitis in several organs as a direct consequence of viral involvement and of the host inflammatory response, leading to a prothrombotic state aPTT, Fibrinogen, D-Dimer and fibrin degradation product (FDP)].", [["organs", "ANATOMY", 102, 108], ["SARS", "DISEASE", 28, 32], ["infection", "DISEASE", 39, 48], ["endothelitis", "DISEASE", 78, 90], ["SARS-CoV-2", "ORGANISM", 28, 38], ["organs", "ORGAN", 102, 108], ["aPTT", "GENE_OR_GENE_PRODUCT", 226, 230], ["Fibrinogen", "GENE_OR_GENE_PRODUCT", 232, 242], ["D-Dimer", "SIMPLE_CHEMICAL", 244, 251], ["fibrin degradation product", "SIMPLE_CHEMICAL", 256, 282], ["FDP", "SIMPLE_CHEMICAL", 284, 287], ["aPTT", "PROTEIN", 226, 230], ["Fibrinogen", "PROTEIN", 232, 242], ["Dimer", "PROTEIN", 246, 251], ["fibrin", "PROTEIN", 256, 262], ["FDP", "PROTEIN", 284, 287], ["SARS-CoV-2", "SPECIES", 28, 38], ["SARS", "PROBLEM", 28, 32], ["CoV-2 infection", "PROBLEM", 33, 48], ["endothelitis in several organs", "PROBLEM", 78, 108], ["viral involvement", "PROBLEM", 136, 153], ["the host inflammatory response", "PROBLEM", 161, 191], ["a prothrombotic state aPTT", "PROBLEM", 204, 230], ["Fibrinogen", "TEST", 232, 242], ["D-Dimer", "TEST", 244, 251], ["fibrin degradation product", "PROBLEM", 256, 282], ["SARS", "OBSERVATION", 28, 32], ["infection", "OBSERVATION", 39, 48], ["fibrin degradation", "OBSERVATION", 256, 274]]], ["The 21 non-survivors (11.5%) showed significantly prolonged PT and aPTT and elevated D-Dimer, and 15 (71.4%) of these matched the grade of overt-DIC according to the International Society on Thrombosis and Hemostasis (ISTH) scoring system (ISTH-DIC score \u2265 5).", [["DIC", "DISEASE", 145, 148], ["Thrombosis", "DISEASE", 191, 201], ["D-Dimer", "GENE_OR_GENE_PRODUCT", 85, 92], ["aPTT", "PROTEIN", 67, 71], ["The 21 non-survivors", "TEST", 0, 20], ["significantly prolonged PT", "PROBLEM", 36, 62], ["aPTT", "TEST", 67, 71], ["elevated D-Dimer", "PROBLEM", 76, 92], ["overt-DIC", "PROBLEM", 139, 148], ["Thrombosis", "PROBLEM", 191, 201], ["scoring system", "TEST", 224, 238], ["ISTH", "TEST", 240, 244], ["DIC score", "TEST", 245, 254], ["Thrombosis", "OBSERVATION", 191, 201]]], ["These findings support the growing use of ISTH-DIC score as a prognostic score in COVID-19 patients.", [["ISTH", "SIMPLE_CHEMICAL", 42, 46], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["DIC score", "PROBLEM", 47, 56], ["growing", "OBSERVATION_MODIFIER", 27, 34]]], ["Thus, the hemostasis dysregulation leads to a prothrombotic state in COVID-19 patients and to microthrombosis formation in pulmonary small vessels of critical patients [12] .", [["pulmonary small vessels", "ANATOMY", 123, 146], ["microthrombosis", "DISEASE", 94, 109], ["patients", "ORGANISM", 78, 86], ["pulmonary small vessels", "MULTI-TISSUE_STRUCTURE", 123, 146], ["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 159, 167], ["the hemostasis dysregulation", "PROBLEM", 6, 34], ["a prothrombotic state", "PROBLEM", 44, 65], ["COVID", "TEST", 69, 74], ["microthrombosis formation", "PROBLEM", 94, 119], ["pulmonary", "ANATOMY", 123, 132], ["small vessels", "OBSERVATION", 133, 146]]], ["It is acknowledged that, regardless of etiology, critically ill patients have an increased risk of venous thromboembolism (VTE) [13] and this is particularly clear in severe COVID-19 patients.", [["venous", "ANATOMY", 99, 105], ["critically ill", "DISEASE", 49, 63], ["venous thromboembolism", "DISEASE", 99, 121], ["VTE", "DISEASE", 123, 126], ["COVID", "DISEASE", 174, 179], ["patients", "ORGANISM", 64, 72], ["venous thromboembolism", "PATHOLOGICAL_FORMATION", 99, 121], ["patients", "ORGANISM", 183, 191], ["patients", "SPECIES", 64, 72], ["patients", "SPECIES", 183, 191], ["venous thromboembolism", "PROBLEM", 99, 121], ["increased", "OBSERVATION_MODIFIER", 81, 90], ["venous", "ANATOMY", 99, 105], ["thromboembolism", "OBSERVATION", 106, 121], ["clear", "OBSERVATION", 158, 163], ["severe", "OBSERVATION_MODIFIER", 167, 173]]], ["Poissy et al. [6] published a case series of 107 patients admitted in intensive care unit (ICU) for COVID 19 related pneumonia, showing that pulmonary embolism (PE) had an unexpectedly high frequency (20.6%), being twice higher than what was observed in influenza patients admitted in ICU for respiratory failure in 2019.", [["pulmonary", "ANATOMY", 141, 150], ["respiratory", "ANATOMY", 293, 304], ["COVID", "DISEASE", 100, 105], ["pneumonia", "DISEASE", 117, 126], ["pulmonary embolism", "DISEASE", 141, 159], ["PE", "DISEASE", 161, 163], ["influenza", "DISEASE", 254, 263], ["respiratory failure", "DISEASE", 293, 312], ["patients", "ORGANISM", 49, 57], ["pulmonary", "ORGAN", 141, 150], ["patients", "ORGANISM", 264, 272], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 264, 272], ["COVID 19 related pneumonia", "PROBLEM", 100, 126], ["pulmonary embolism", "PROBLEM", 141, 159], ["PE", "PROBLEM", 161, 163], ["respiratory failure", "PROBLEM", 293, 312], ["pneumonia", "OBSERVATION", 117, 126], ["pulmonary", "ANATOMY", 141, 150], ["embolism", "OBSERVATION", 151, 159], ["PE", "OBSERVATION", 161, 163], ["high", "OBSERVATION_MODIFIER", 185, 189], ["respiratory", "ANATOMY", 293, 304], ["failure", "OBSERVATION", 305, 312]]], ["Furthermore, in the reported PE cases there was a low number of associated deep vein thrombosis (DVT) suggesting that they had pulmonary thrombosis rather than pulmonary embolism from peripheral veins.Biochemical and clinical manifestations of hyper-coagulable state in Covid 19Because of the high PE incidence reported in critical COVID-19 patients, clinicians should suspect PE when there is hypoxemia disproportionate to respiratory disease, with or without acute unexplained right ventricular dysfunction, even in absence of typical DVT symptoms.", [["deep vein", "ANATOMY", 75, 84], ["pulmonary", "ANATOMY", 127, 136], ["pulmonary", "ANATOMY", 160, 169], ["peripheral veins", "ANATOMY", 184, 200], ["respiratory", "ANATOMY", 424, 435], ["right ventricular", "ANATOMY", 479, 496], ["PE", "DISEASE", 29, 31], ["deep vein thrombosis", "DISEASE", 75, 95], ["DVT", "DISEASE", 97, 100], ["pulmonary thrombosis", "DISEASE", 127, 147], ["pulmonary embolism", "DISEASE", 160, 178], ["PE", "DISEASE", 298, 300], ["PE", "DISEASE", 377, 379], ["hypoxemia", "DISEASE", 394, 403], ["respiratory disease", "DISEASE", 424, 443], ["right ventricular dysfunction", "DISEASE", 479, 508], ["DVT", "DISEASE", 537, 540], ["deep vein", "MULTI-TISSUE_STRUCTURE", 75, 84], ["pulmonary", "ORGAN", 127, 136], ["pulmonary", "ORGAN", 160, 169], ["peripheral veins", "MULTI-TISSUE_STRUCTURE", 184, 200], ["patients", "ORGANISM", 341, 349], ["ventricular", "MULTI-TISSUE_STRUCTURE", 485, 496], ["patients", "SPECIES", 341, 349], ["associated deep vein thrombosis", "PROBLEM", 64, 95], ["DVT", "PROBLEM", 97, 100], ["pulmonary thrombosis", "PROBLEM", 127, 147], ["pulmonary embolism from peripheral veins", "PROBLEM", 160, 200], ["hyper-coagulable state", "PROBLEM", 244, 266], ["the high PE incidence", "PROBLEM", 289, 310], ["PE", "PROBLEM", 377, 379], ["hypoxemia", "PROBLEM", 394, 403], ["respiratory disease", "PROBLEM", 424, 443], ["acute unexplained right ventricular dysfunction", "PROBLEM", 461, 508], ["typical DVT symptoms", "PROBLEM", 529, 549], ["PE", "OBSERVATION", 29, 31], ["low number", "OBSERVATION_MODIFIER", 50, 60], ["deep", "ANATOMY_MODIFIER", 75, 79], ["vein", "ANATOMY", 80, 84], ["thrombosis", "OBSERVATION", 85, 95], ["DVT", "OBSERVATION", 97, 100], ["pulmonary", "ANATOMY", 127, 136], ["thrombosis", "OBSERVATION", 137, 147], ["pulmonary", "ANATOMY", 160, 169], ["embolism", "OBSERVATION", 170, 178], ["peripheral", "ANATOMY_MODIFIER", 184, 194], ["veins", "ANATOMY", 195, 200], ["high", "OBSERVATION_MODIFIER", 293, 297], ["PE", "OBSERVATION", 298, 300], ["PE", "OBSERVATION", 377, 379], ["hypoxemia", "OBSERVATION", 394, 403], ["respiratory disease", "OBSERVATION", 424, 443], ["right ventricular", "ANATOMY", 479, 496], ["dysfunction", "OBSERVATION", 497, 508], ["typical", "OBSERVATION_MODIFIER", 529, 536], ["DVT", "OBSERVATION", 537, 540]]], ["Figure 1 shows the possible mechanisms of the hyper-coagulable state in COVID-19 (Fig. 1) .Mechanisms of hyper-coagulable state in COVID-19COVID-19 patients can experience a hyper-inflammation phase, with a systemic response and a cytokine storm, that has a prothrombotic action [14] .", [["COVID-19", "CHEMICAL", 72, 80], ["patients", "ORGANISM", 148, 156], ["cytokine", "PROTEIN", 231, 239], ["patients", "SPECIES", 148, 156], ["the hyper-coagulable state", "PROBLEM", 42, 68], ["COVID", "TEST", 72, 77], ["hyper-coagulable state", "PROBLEM", 105, 127], ["COVID", "TEST", 131, 136], ["a hyper-inflammation phase", "PROBLEM", 172, 198], ["a systemic response", "PROBLEM", 205, 224], ["a cytokine storm", "PROBLEM", 229, 245], ["hyper", "OBSERVATION", 46, 51], ["hyper", "OBSERVATION", 105, 110]]], ["In fact, as outlined by Qin et al. [15] , in COVID-19 the hyperinflammation mediated by IL-1, tumor necrosis factor-alpha (TNF-\u03b1) and IL-6 leads to an increase of plasma concentrations of fibrinogen, lactate dehydrogenase (LDH), plasminogen activator inhibitor-1 (PAI-1) and neutrophil to lymphocytes ratio (NLR), mainly due to T CD4+ lymphocytes reduction.", [["plasma", "ANATOMY", 163, 169], ["neutrophil", "ANATOMY", 275, 285], ["lymphocytes", "ANATOMY", 289, 300], ["T CD4+ lymphocytes", "ANATOMY", 328, 346], ["hyperinflammation", "DISEASE", 58, 75], ["necrosis", "DISEASE", 100, 108], ["lactate", "CHEMICAL", 200, 207], ["lactate", "CHEMICAL", 200, 207], ["COVID-19", "CELL", 45, 53], ["IL-1", "GENE_OR_GENE_PRODUCT", 88, 92], ["tumor necrosis factor-alpha", "GENE_OR_GENE_PRODUCT", 94, 121], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 123, 128], ["IL-6", "GENE_OR_GENE_PRODUCT", 134, 138], ["plasma", "ORGANISM_SUBSTANCE", 163, 169], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 188, 198], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 200, 221], ["LDH", "GENE_OR_GENE_PRODUCT", 223, 226], ["plasminogen activator inhibitor-1", "GENE_OR_GENE_PRODUCT", 229, 262], ["PAI-1", "GENE_OR_GENE_PRODUCT", 264, 269], ["neutrophil", "CELL", 275, 285], ["lymphocytes", "CELL", 289, 300], ["NLR", "GENE_OR_GENE_PRODUCT", 308, 311], ["T CD4", "GENE_OR_GENE_PRODUCT", 328, 333], ["IL-1", "PROTEIN", 88, 92], ["tumor necrosis factor-alpha", "PROTEIN", 94, 121], ["TNF", "PROTEIN", 123, 126], ["IL-6", "PROTEIN", 134, 138], ["fibrinogen", "PROTEIN", 188, 198], ["lactate dehydrogenase", "PROTEIN", 200, 221], ["LDH", "PROTEIN", 223, 226], ["plasminogen activator inhibitor-1 (PAI-1", "PROTEIN", 229, 269], ["NLR", "PROTEIN", 308, 311], ["CD4", "PROTEIN", 330, 333], ["COVID", "TEST", 45, 50], ["IL", "TEST", 88, 90], ["tumor necrosis factor", "PROBLEM", 94, 115], ["alpha (TNF", "TEST", 116, 126], ["IL", "TEST", 134, 136], ["plasma concentrations", "TEST", 163, 184], ["fibrinogen", "TEST", 188, 198], ["lactate dehydrogenase", "TEST", 200, 221], ["LDH", "TEST", 223, 226], ["plasminogen activator inhibitor", "TEST", 229, 260], ["PAI", "TEST", 264, 267], ["neutrophil", "TEST", 275, 285], ["lymphocytes ratio", "TEST", 289, 306], ["NLR", "TEST", 308, 311], ["lymphocytes reduction", "TREATMENT", 335, 356], ["tumor", "OBSERVATION_MODIFIER", 94, 99], ["necrosis", "OBSERVATION", 100, 108], ["lymphocytes reduction", "OBSERVATION", 335, 356]]], ["There is a close molecular interaction between inflammatory cytokines and coagulation.", [["inflammatory cytokines", "PROTEIN", 47, 69], ["inflammatory cytokines", "PROBLEM", 47, 69], ["inflammatory cytokines", "OBSERVATION", 47, 69]]], ["IL-6, IL-8, and TNF-\u03b1 contribute to a pro-coagulant state promoting the activation of platelets, EC and the expression of tissue factor [16] .", [["platelets", "ANATOMY", 86, 95], ["EC", "ANATOMY", 97, 99], ["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["IL-8", "GENE_OR_GENE_PRODUCT", 6, 10], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 16, 21], ["platelets", "CELL", 86, 95], ["EC", "CELL", 97, 99], ["tissue", "TISSUE", 122, 128], ["IL-6", "PROTEIN", 0, 4], ["IL-8", "PROTEIN", 6, 10], ["TNF-\u03b1", "PROTEIN", 16, 21], ["platelets", "CELL_TYPE", 86, 95], ["EC", "CELL_TYPE", 97, 99], ["tissue factor", "PROTEIN", 122, 135], ["IL", "TEST", 0, 2], ["IL", "TEST", 6, 8], ["TNF", "TEST", 16, 19], ["a pro-coagulant state", "PROBLEM", 36, 57], ["platelets", "TREATMENT", 86, 95]]], ["Furthermore, during inflammation there is a reduction in natural anticoagulants production such as antithrombin III, tissue factor inhibitor and Protein C, favoring a prothrombotic state [17] .", [["inflammation", "DISEASE", 20, 32], ["antithrombin III", "GENE_OR_GENE_PRODUCT", 99, 115], ["tissue factor", "GENE_OR_GENE_PRODUCT", 117, 130], ["Protein C", "GENE_OR_GENE_PRODUCT", 145, 154], ["antithrombin III", "PROTEIN", 99, 115], ["tissue factor inhibitor", "PROTEIN", 117, 140], ["Protein C", "PROTEIN", 145, 154], ["inflammation", "PROBLEM", 20, 32], ["a reduction", "PROBLEM", 42, 53], ["natural anticoagulants production", "TREATMENT", 57, 90], ["antithrombin III", "TREATMENT", 99, 115], ["tissue factor inhibitor", "TREATMENT", 117, 140], ["Protein C", "PROBLEM", 145, 154], ["a prothrombotic state", "PROBLEM", 165, 186], ["inflammation", "OBSERVATION", 20, 32], ["reduction", "OBSERVATION_MODIFIER", 44, 53], ["natural anticoagulants", "OBSERVATION", 57, 79]]], ["Coagulation cascade can promote inflammation as well.", [["inflammation", "DISEASE", 32, 44], ["Coagulation cascade", "PROBLEM", 0, 19], ["inflammation", "PROBLEM", 32, 44], ["inflammation", "OBSERVATION", 32, 44]]], ["In fact, thrombin is a major activator of protease-activated receptor 1 (PAR 1), a seven-transmembrane G-protein coupled receptor.", [["thrombin", "GENE_OR_GENE_PRODUCT", 9, 17], ["protease-activated receptor 1", "GENE_OR_GENE_PRODUCT", 42, 71], ["PAR 1", "GENE_OR_GENE_PRODUCT", 73, 78], ["G-protein coupled receptor", "GENE_OR_GENE_PRODUCT", 103, 129], ["thrombin", "PROTEIN", 9, 17], ["protease-activated receptor 1", "PROTEIN", 42, 71], ["PAR 1", "PROTEIN", 73, 78], ["seven-transmembrane G-protein coupled receptor", "PROTEIN", 83, 129], ["thrombin", "TREATMENT", 9, 17], ["thrombin", "OBSERVATION", 9, 17]]], ["PAR1 promotes the release of IL-1, IL-2, IL-6, IL-8, TNF\u03b1 and increases the expression of adhesion molecules such as E-and P-selectin and ICAM-1 on the endothelial surface [18] .Mechanisms of hyper-coagulable state in COVID-19Another pathogenetic key-point in the pro-thrombotic effect of COVID-19 could be the pathological complement-activation, such as occurs in thrombotic micro-angiopathy (TMA) [19] .", [["endothelial surface", "ANATOMY", 152, 171], ["COVID-19", "CHEMICAL", 289, 297], ["thrombotic micro-angiopathy", "DISEASE", 365, 392], ["TMA", "DISEASE", 394, 397], ["COVID-19", "CHEMICAL", 289, 297], ["PAR1", "GENE_OR_GENE_PRODUCT", 0, 4], ["IL-1", "GENE_OR_GENE_PRODUCT", 29, 33], ["IL-2", "GENE_OR_GENE_PRODUCT", 35, 39], ["IL-6", "GENE_OR_GENE_PRODUCT", 41, 45], ["IL-8", "GENE_OR_GENE_PRODUCT", 47, 51], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 53, 57], ["E", "GENE_OR_GENE_PRODUCT", 117, 118], ["P-selectin", "GENE_OR_GENE_PRODUCT", 123, 133], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 138, 144], ["endothelial surface", "CELLULAR_COMPONENT", 152, 171], ["COVID-19Another", "GENE_OR_GENE_PRODUCT", 218, 233], ["COVID-19", "GENE_OR_GENE_PRODUCT", 289, 297], ["PAR1", "PROTEIN", 0, 4], ["IL-8", "PROTEIN", 47, 51], ["TNF\u03b1", "PROTEIN", 53, 57], ["adhesion molecules", "PROTEIN", 90, 108], ["E-and P-selectin", "PROTEIN", 117, 133], ["ICAM-1", "PROTEIN", 138, 144], ["IL", "TEST", 29, 31], ["IL", "TEST", 35, 37], ["IL", "TEST", 41, 43], ["IL", "TEST", 47, 49], ["TNF", "TREATMENT", 53, 56], ["adhesion molecules", "PROBLEM", 90, 108], ["E", "TEST", 117, 118], ["ICAM", "TEST", 138, 142], ["hyper-coagulable state", "PROBLEM", 192, 214], ["COVID", "TEST", 218, 223], ["COVID", "TEST", 289, 294], ["thrombotic micro-angiopathy", "PROBLEM", 365, 392], ["endothelial", "ANATOMY", 152, 163], ["hyper", "OBSERVATION", 192, 197], ["pro-thrombotic", "OBSERVATION", 264, 278], ["thrombotic", "OBSERVATION_MODIFIER", 365, 375], ["micro-angiopathy", "OBSERVATION", 376, 392]]], ["TMA can occur in different scenarios, as in Atypical Hemolytic Uremic Syndrome (aHUS), a rare disorder characterized by uncontrolled complement activation with hemolytic anemia, thrombocytopenia, and acute renal failure.", [["renal", "ANATOMY", 206, 211], ["TMA", "DISEASE", 0, 3], ["Hemolytic Uremic Syndrome", "DISEASE", 53, 78], ["aHUS", "DISEASE", 80, 84], ["hemolytic anemia", "DISEASE", 160, 176], ["thrombocytopenia", "DISEASE", 178, 194], ["acute renal failure", "DISEASE", 200, 219], ["renal", "ORGAN", 206, 211], ["TMA", "PROBLEM", 0, 3], ["Atypical Hemolytic Uremic Syndrome", "PROBLEM", 44, 78], ["aHUS", "PROBLEM", 80, 84], ["a rare disorder", "PROBLEM", 87, 102], ["uncontrolled complement activation", "PROBLEM", 120, 154], ["hemolytic anemia", "PROBLEM", 160, 176], ["thrombocytopenia", "PROBLEM", 178, 194], ["acute renal failure", "PROBLEM", 200, 219], ["different scenarios", "OBSERVATION_MODIFIER", 17, 36], ["Atypical", "OBSERVATION_MODIFIER", 44, 52], ["Hemolytic", "OBSERVATION_MODIFIER", 53, 62], ["Uremic Syndrome", "OBSERVATION", 63, 78], ["uncontrolled", "OBSERVATION_MODIFIER", 120, 132], ["hemolytic", "OBSERVATION_MODIFIER", 160, 169], ["anemia", "OBSERVATION", 170, 176], ["thrombocytopenia", "OBSERVATION", 178, 194], ["acute", "OBSERVATION_MODIFIER", 200, 205], ["renal", "ANATOMY", 206, 211], ["failure", "OBSERVATION", 212, 219]]], ["In severe COVID-19, the reported elevated levels of LDH, d-dimer, and bilirubin, the mild thrombocytopenia and anaemia, the diffuse microvascular thrombi with renal and cardiac injury make the complement cascade hyperactivation a conceivable pathogenetic mechanism.", [["microvascular thrombi", "ANATOMY", 132, 153], ["renal", "ANATOMY", 159, 164], ["cardiac", "ANATOMY", 169, 176], ["bilirubin", "CHEMICAL", 70, 79], ["thrombocytopenia", "DISEASE", 90, 106], ["anaemia", "DISEASE", 111, 118], ["thrombi", "DISEASE", 146, 153], ["cardiac injury", "DISEASE", 169, 183], ["bilirubin", "CHEMICAL", 70, 79], ["LDH", "GENE_OR_GENE_PRODUCT", 52, 55], ["d-dimer", "GENE_OR_GENE_PRODUCT", 57, 64], ["bilirubin", "SIMPLE_CHEMICAL", 70, 79], ["microvascular thrombi", "PATHOLOGICAL_FORMATION", 132, 153], ["renal", "ORGAN", 159, 164], ["cardiac", "ORGAN", 169, 176], ["LDH", "PROTEIN", 52, 55], ["severe COVID", "TEST", 3, 15], ["elevated levels of LDH, d-dimer", "PROBLEM", 33, 64], ["bilirubin", "TEST", 70, 79], ["the mild thrombocytopenia", "PROBLEM", 81, 106], ["anaemia", "PROBLEM", 111, 118], ["the diffuse microvascular thrombi", "PROBLEM", 120, 153], ["renal and cardiac injury", "PROBLEM", 159, 183], ["the complement cascade hyperactivation", "PROBLEM", 189, 227], ["severe", "OBSERVATION_MODIFIER", 3, 9], ["bilirubin", "ANATOMY", 70, 79], ["mild", "OBSERVATION_MODIFIER", 85, 89], ["thrombocytopenia", "OBSERVATION", 90, 106], ["anaemia", "OBSERVATION", 111, 118], ["diffuse", "OBSERVATION_MODIFIER", 124, 131], ["microvascular", "OBSERVATION_MODIFIER", 132, 145], ["thrombi", "OBSERVATION", 146, 153], ["renal", "ANATOMY", 159, 164], ["cardiac", "ANATOMY", 169, 176], ["injury", "OBSERVATION", 177, 183]]], ["Complement cascade activation converges in the activation of the C3 convertase that then cleaves C3 into C3a and C3b.", [["Complement", "GENE_OR_GENE_PRODUCT", 0, 10], ["C3 convertase", "GENE_OR_GENE_PRODUCT", 65, 78], ["C3", "GENE_OR_GENE_PRODUCT", 97, 99], ["C3a", "GENE_OR_GENE_PRODUCT", 105, 108], ["C3b", "GENE_OR_GENE_PRODUCT", 113, 116], ["C3 convertase", "PROTEIN", 65, 78], ["C3", "PROTEIN", 97, 99], ["C3a", "PROTEIN", 105, 108], ["C3b", "PROTEIN", 113, 116], ["Complement cascade activation", "TREATMENT", 0, 29], ["the C3 convertase", "TREATMENT", 61, 78]]], ["C3b activates C5 convertase, which cleaves C5 into C5a and C5b.", [["C3b", "GENE_OR_GENE_PRODUCT", 0, 3], ["C5 convertase", "GENE_OR_GENE_PRODUCT", 14, 27], ["C5a", "GENE_OR_GENE_PRODUCT", 51, 54], ["C5b", "GENE_OR_GENE_PRODUCT", 59, 62], ["C3b", "PROTEIN", 0, 3], ["C5 convertase", "PROTEIN", 14, 27], ["C5", "PROTEIN", 43, 45], ["C5a", "PROTEIN", 51, 54], ["C5b", "PROTEIN", 59, 62]]], ["Thereafter, C5b forms a complex with other complement proteins, the C5b-9 membrane attack complex (MAC) that leads to cell lysis [20] .", [["C5b-9 membrane", "ANATOMY", 68, 82], ["cell", "ANATOMY", 118, 122], ["C5b", "GENE_OR_GENE_PRODUCT", 12, 15], ["C5b-9 membrane attack complex", "GENE_OR_GENE_PRODUCT", 68, 97], ["cell", "CELL", 118, 122], ["C5b", "PROTEIN", 12, 15], ["complement proteins", "PROTEIN", 43, 62], ["C5b-9 membrane attack complex", "PROTEIN", 68, 97], ["MAC", "PROTEIN", 99, 102], ["other complement proteins", "TEST", 37, 62], ["the C5b", "TEST", 64, 71], ["cell lysis", "TREATMENT", 118, 128], ["cell lysis", "OBSERVATION", 118, 128]]], ["Complement cascade activation can lead to coagulation activation.", [["Complement", "GENE_OR_GENE_PRODUCT", 0, 10], ["Complement cascade activation", "PROBLEM", 0, 29], ["coagulation activation", "PROBLEM", 42, 64]]], ["In fact, C5a can increase tissue factor activity on EC, thus promoting coagulation cascade activation [21] .", [["tissue", "ANATOMY", 26, 32], ["EC", "ANATOMY", 52, 54], ["C5a", "GENE_OR_GENE_PRODUCT", 9, 12], ["tissue", "TISSUE", 26, 32], ["EC", "CELL", 52, 54], ["C5a", "PROTEIN", 9, 12], ["tissue factor", "PROTEIN", 26, 39], ["EC", "CELL_TYPE", 52, 54]]], ["Furthermore, platelets have receptors for C3a that can promote their activation [22] , while MAC adhesion on EC promotes the secretion of von Willebrand factor on their surface.Mechanisms of hyper-coagulable state in COVID-19Thus, because of the prothrombotic role of the cytokine storm and of the probable complement cascade hyperactivation, humanized monoclonal antibodies (hMAbs) that target and inhibit these pathways are being used in COVID-19 clinical trials: Tocilizumab (hMAb that targets IL-6 receptor) and Eculizumab (hMAb that targets complement component 5 protein-C5).Mechanisms of hyper-coagulable state in COVID-19As regards the endothelial disfunction, SARS-CoV-2 determines an endothelium damage with a pro-thrombotic effect.", [["platelets", "ANATOMY", 13, 22], ["EC", "ANATOMY", 109, 111], ["surface", "ANATOMY", 169, 176], ["endothelial", "ANATOMY", 644, 655], ["endothelium", "ANATOMY", 694, 705], ["COVID-19Thus", "CHEMICAL", 217, 229], ["Tocilizumab", "CHEMICAL", 466, 477], ["Eculizumab", "CHEMICAL", 516, 526], ["COVID-19As", "CHEMICAL", 621, 631], ["COVID-19Thus", "CHEMICAL", 217, 229], ["Tocilizumab", "CHEMICAL", 466, 477], ["Eculizumab", "CHEMICAL", 516, 526], ["platelets", "CELL", 13, 22], ["C3a", "GENE_OR_GENE_PRODUCT", 42, 45], ["EC", "CELL", 109, 111], ["von Willebrand factor", "GENE_OR_GENE_PRODUCT", 138, 159], ["surface", "CELLULAR_COMPONENT", 169, 176], ["COVID-19Thus", "CELL", 217, 229], ["humanized monoclonal antibodies", "GENE_OR_GENE_PRODUCT", 343, 374], ["Tocilizumab", "SIMPLE_CHEMICAL", 466, 477], ["hMAb", "SIMPLE_CHEMICAL", 479, 483], ["IL-6 receptor", "GENE_OR_GENE_PRODUCT", 497, 510], ["Eculizumab", "SIMPLE_CHEMICAL", 516, 526], ["hMAb", "SIMPLE_CHEMICAL", 528, 532], ["complement component 5 protein-C5", "GENE_OR_GENE_PRODUCT", 546, 579], ["COVID-19As", "GENE_OR_GENE_PRODUCT", 621, 631], ["endothelial", "CELL", 644, 655], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 669, 679], ["endothelium", "TISSUE", 694, 705], ["platelets", "CELL_TYPE", 13, 22], ["C3a", "PROTEIN", 42, 45], ["EC", "CELL_TYPE", 109, 111], ["von Willebrand factor", "PROTEIN", 138, 159], ["cytokine", "PROTEIN", 272, 280], ["humanized monoclonal antibodies", "PROTEIN", 343, 374], ["hMAbs", "PROTEIN", 376, 381], ["IL-6 receptor", "PROTEIN", 497, 510], ["Eculizumab", "PROTEIN", 516, 526], ["hMAb", "PROTEIN", 528, 532], ["complement component 5 protein", "PROTEIN", 546, 576], ["C5", "PROTEIN", 577, 579], ["platelets", "TEST", 13, 22], ["C3a", "TEST", 42, 45], ["hyper-coagulable state", "PROBLEM", 191, 213], ["complement cascade hyperactivation", "PROBLEM", 307, 341], ["humanized monoclonal antibodies", "TREATMENT", 343, 374], ["Tocilizumab (hMAb", "TREATMENT", 466, 483], ["IL", "TEST", 497, 499], ["Eculizumab (hMAb", "TREATMENT", 516, 532], ["hyper-coagulable state", "PROBLEM", 595, 617], ["COVID", "TEST", 621, 626], ["the endothelial disfunction", "PROBLEM", 640, 667], ["SARS", "PROBLEM", 669, 673], ["CoV", "TEST", 674, 677], ["an endothelium damage", "PROBLEM", 691, 712], ["a pro-thrombotic effect", "PROBLEM", 718, 741], ["hyper", "OBSERVATION", 191, 196], ["prothrombotic", "OBSERVATION", 246, 259], ["probable", "UNCERTAINTY", 298, 306], ["cascade hyperactivation", "OBSERVATION", 318, 341], ["hyper", "OBSERVATION", 595, 600], ["endothelial", "ANATOMY", 644, 655], ["disfunction", "OBSERVATION", 656, 667], ["endothelium", "ANATOMY", 694, 705], ["damage", "OBSERVATION", 706, 712], ["pro-thrombotic", "OBSERVATION", 720, 734]]], ["During the last few years, literature data demonstrated the association between endothelial dysfunction and thrombotic phenomena, since the endothelium plays an active role in the regulation of vascular tone and platelets activity, especially in case of hypoxia.Mechanisms of hyper-coagulable state in COVID-19However, endothelium's response to hypoxia varies in systemic and pulmonary circulation.", [["endothelial", "ANATOMY", 80, 91], ["endothelium", "ANATOMY", 140, 151], ["vascular", "ANATOMY", 194, 202], ["platelets", "ANATOMY", 212, 221], ["endothelium", "ANATOMY", 319, 330], ["pulmonary", "ANATOMY", 376, 385], ["endothelial dysfunction", "DISEASE", 80, 103], ["thrombotic phenomena", "DISEASE", 108, 128], ["hypoxia", "DISEASE", 254, 261], ["hypoxia", "DISEASE", 345, 352], ["endothelial", "TISSUE", 80, 91], ["endothelium", "TISSUE", 140, 151], ["vascular", "MULTI-TISSUE_STRUCTURE", 194, 202], ["platelets", "CELL", 212, 221], ["COVID-19However", "CELL", 302, 317], ["endothelium", "TISSUE", 319, 330], ["pulmonary", "ORGAN", 376, 385], ["platelets", "CELL_TYPE", 212, 221], ["literature data", "TEST", 27, 42], ["endothelial dysfunction", "PROBLEM", 80, 103], ["thrombotic phenomena", "PROBLEM", 108, 128], ["platelets activity", "TEST", 212, 230], ["hypoxia", "PROBLEM", 254, 261], ["hyper-coagulable state", "PROBLEM", 276, 298], ["COVID", "TEST", 302, 307], ["hypoxia varies in systemic and pulmonary circulation", "PROBLEM", 345, 397], ["endothelial dysfunction", "OBSERVATION", 80, 103], ["thrombotic phenomena", "OBSERVATION", 108, 128], ["active", "OBSERVATION_MODIFIER", 161, 167], ["vascular tone", "ANATOMY", 194, 207], ["platelets activity", "OBSERVATION", 212, 230], ["hypoxia", "OBSERVATION", 254, 261], ["hyper", "OBSERVATION", 276, 281], ["hypoxia", "OBSERVATION", 345, 352], ["systemic", "OBSERVATION", 363, 371], ["pulmonary circulation", "ANATOMY", 376, 397]]], ["In systemic circulation, hypoxia induces vasodilation by releasing nitric oxide (NO), while in pulmonary circulation, hypoxia induces vasoconstriction in order to reduce the perfusion of the unventilated lung areas [23] .Mechanisms of hyper-coagulable state in COVID-19SARS-CoV-2 binds the ACE-2 receptor, which is widely expressed on both alveolar type II epithelial cells and EC of the pulmonary microvessels.", [["pulmonary", "ANATOMY", 95, 104], ["lung", "ANATOMY", 204, 208], ["alveolar type II epithelial cells", "ANATOMY", 340, 373], ["EC", "ANATOMY", 378, 380], ["pulmonary microvessels", "ANATOMY", 388, 410], ["hypoxia", "DISEASE", 25, 32], ["nitric oxide", "CHEMICAL", 67, 79], ["NO", "CHEMICAL", 81, 83], ["hypoxia", "DISEASE", 118, 125], ["nitric oxide", "CHEMICAL", 67, 79], ["NO", "CHEMICAL", 81, 83], ["nitric oxide", "SIMPLE_CHEMICAL", 67, 79], ["NO", "SIMPLE_CHEMICAL", 81, 83], ["pulmonary", "ORGAN", 95, 104], ["lung", "ORGAN", 204, 208], ["COVID-19SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 261, 279], ["ACE-2 receptor", "GENE_OR_GENE_PRODUCT", 290, 304], ["alveolar type II epithelial cells", "CELL", 340, 373], ["EC", "CELL", 378, 380], ["pulmonary microvessels", "TISSUE", 388, 410], ["ACE-2 receptor", "PROTEIN", 290, 304], ["alveolar type II epithelial cells", "CELL_TYPE", 340, 373], ["EC", "CELL_TYPE", 378, 380], ["hypoxia", "PROBLEM", 25, 32], ["vasodilation", "TREATMENT", 41, 53], ["releasing nitric oxide", "TREATMENT", 57, 79], ["hypoxia", "PROBLEM", 118, 125], ["vasoconstriction", "PROBLEM", 134, 150], ["the perfusion of the unventilated lung areas", "PROBLEM", 170, 214], ["hyper-coagulable state", "PROBLEM", 235, 257], ["COVID", "TEST", 261, 266], ["CoV", "TEST", 274, 277], ["systemic circulation", "ANATOMY", 3, 23], ["hypoxia", "OBSERVATION", 25, 32], ["pulmonary circulation", "ANATOMY", 95, 116], ["hypoxia", "OBSERVATION", 118, 125], ["vasoconstriction", "OBSERVATION", 134, 150], ["perfusion", "OBSERVATION_MODIFIER", 174, 183], ["lung", "ANATOMY", 204, 208], ["hyper", "OBSERVATION", 235, 240], ["both", "ANATOMY_MODIFIER", 335, 339], ["alveolar", "ANATOMY_MODIFIER", 340, 348], ["epithelial cells", "OBSERVATION", 357, 373], ["pulmonary microvessels", "ANATOMY", 388, 410]]], ["Lung epithelial cells act as oxygen concentration sensors, while EC modulate vascular tone through the release of vasoconstriction mediators like endothelin, superoxide radicals, arachidonic acid-derivatives, endoperoxides, thromboxane A2 and vasodilators like NO [produced by endothelial nitric oxide synthase 3 (NOS-3)].", [["Lung epithelial cells", "ANATOMY", 0, 21], ["EC", "ANATOMY", 65, 67], ["vascular", "ANATOMY", 77, 85], ["oxygen", "CHEMICAL", 29, 35], ["superoxide", "CHEMICAL", 158, 168], ["arachidonic acid", "CHEMICAL", 179, 195], ["thromboxane", "CHEMICAL", 224, 235], ["NO", "CHEMICAL", 261, 263], ["nitric oxide", "CHEMICAL", 289, 301], ["oxygen", "CHEMICAL", 29, 35], ["superoxide", "CHEMICAL", 158, 168], ["arachidonic acid", "CHEMICAL", 179, 195], ["thromboxane A2", "CHEMICAL", 224, 238], ["NO", "CHEMICAL", 261, 263], ["nitric oxide", "CHEMICAL", 289, 301], ["Lung epithelial cells", "CELL", 0, 21], ["oxygen", "SIMPLE_CHEMICAL", 29, 35], ["EC", "CELL", 65, 67], ["vascular", "MULTI-TISSUE_STRUCTURE", 77, 85], ["endothelin", "GENE_OR_GENE_PRODUCT", 146, 156], ["superoxide radicals", "SIMPLE_CHEMICAL", 158, 177], ["arachidonic acid-derivatives", "SIMPLE_CHEMICAL", 179, 207], ["endoperoxides", "SIMPLE_CHEMICAL", 209, 222], ["thromboxane A2", "SIMPLE_CHEMICAL", 224, 238], ["vasodilators", "SIMPLE_CHEMICAL", 243, 255], ["NO", "SIMPLE_CHEMICAL", 261, 263], ["endothelial nitric oxide synthase 3", "GENE_OR_GENE_PRODUCT", 277, 312], ["NOS-3", "GENE_OR_GENE_PRODUCT", 314, 319], ["Lung epithelial cells", "CELL_TYPE", 0, 21], ["EC", "CELL_TYPE", 65, 67], ["endothelial nitric oxide synthase 3", "PROTEIN", 277, 312], ["NOS", "PROTEIN", 314, 317], ["Lung epithelial cells", "PROBLEM", 0, 21], ["oxygen concentration sensors", "TEST", 29, 57], ["vasoconstriction mediators", "TREATMENT", 114, 140], ["endothelin", "TREATMENT", 146, 156], ["superoxide radicals", "TREATMENT", 158, 177], ["arachidonic acid-derivatives", "TREATMENT", 179, 207], ["endoperoxides", "TREATMENT", 209, 222], ["thromboxane A2", "TREATMENT", 224, 238], ["vasodilators", "TREATMENT", 243, 255], ["endothelial nitric oxide synthase", "TREATMENT", 277, 310], ["epithelial cells", "OBSERVATION", 5, 21], ["vascular", "ANATOMY", 77, 85]]], ["The virus-related damage on EC leads to microvascular dysfunction, thus shifting the vascular equilibrium towards vasoconstriction with subsequent organ ischemia and inflammation, favoring a pro-coagulant state [24] .", [["EC", "ANATOMY", 28, 30], ["microvascular", "ANATOMY", 40, 53], ["vascular", "ANATOMY", 85, 93], ["organ", "ANATOMY", 147, 152], ["microvascular dysfunction", "DISEASE", 40, 65], ["ischemia", "DISEASE", 153, 161], ["inflammation", "DISEASE", 166, 178], ["EC", "CELL", 28, 30], ["microvascular", "TISSUE", 40, 53], ["vascular", "MULTI-TISSUE_STRUCTURE", 85, 93], ["organ", "ORGAN", 147, 152], ["EC", "CELL_TYPE", 28, 30], ["The virus", "PROBLEM", 0, 9], ["related damage", "PROBLEM", 10, 24], ["microvascular dysfunction", "PROBLEM", 40, 65], ["shifting the vascular equilibrium", "PROBLEM", 72, 105], ["vasoconstriction", "PROBLEM", 114, 130], ["subsequent organ ischemia", "PROBLEM", 136, 161], ["inflammation", "PROBLEM", 166, 178], ["a pro-coagulant state", "PROBLEM", 189, 210], ["virus", "OBSERVATION", 4, 9], ["damage", "OBSERVATION", 18, 24], ["microvascular dysfunction", "OBSERVATION", 40, 65], ["vascular", "ANATOMY", 85, 93], ["organ", "ANATOMY", 147, 152], ["ischemia", "OBSERVATION", 153, 161], ["inflammation", "OBSERVATION", 166, 178]]], ["Vasoconstriction slows blood flow, thus favoring platelet activation and aggregation, while EC damage impairs their anticoagulant and fibrinolytic function, leading to platelet adhesion and coagulation cascade activation [25, 26] .", [["blood", "ANATOMY", 23, 28], ["platelet", "ANATOMY", 49, 57], ["EC", "ANATOMY", 92, 94], ["platelet", "ANATOMY", 168, 176], ["blood", "ORGANISM_SUBSTANCE", 23, 28], ["platelet", "CELL", 49, 57], ["EC", "CELL", 92, 94], ["platelet", "CELL", 168, 176], ["EC", "CELL_TYPE", 92, 94], ["Vasoconstriction", "PROBLEM", 0, 16], ["blood flow", "TEST", 23, 33], ["platelet activation", "PROBLEM", 49, 68], ["aggregation", "PROBLEM", 73, 84], ["EC damage", "PROBLEM", 92, 101], ["their anticoagulant", "TREATMENT", 110, 129], ["fibrinolytic function", "TEST", 134, 155], ["platelet adhesion", "TREATMENT", 168, 185], ["coagulation cascade activation", "TEST", 190, 220], ["blood flow", "OBSERVATION", 23, 33], ["platelet activation", "OBSERVATION", 49, 68], ["platelet adhesion", "OBSERVATION", 168, 185]]], ["One of the mechanisms involved is the impairment of the glycocalyx that covers EC surface of the vascular bed.", [["glycocalyx", "ANATOMY", 56, 66], ["EC surface", "ANATOMY", 79, 89], ["vascular bed", "ANATOMY", 97, 109], ["glycocalyx", "CELLULAR_COMPONENT", 56, 66], ["EC surface", "CELLULAR_COMPONENT", 79, 89], ["vascular bed", "MULTI-TISSUE_STRUCTURE", 97, 109], ["EC", "CELL_TYPE", 79, 81], ["the impairment of the glycocalyx", "PROBLEM", 34, 66], ["impairment", "OBSERVATION", 38, 48], ["glycocalyx", "ANATOMY_MODIFIER", 56, 66], ["surface", "OBSERVATION_MODIFIER", 82, 89], ["vascular bed", "ANATOMY", 97, 109]]], ["EC glycocalyx plays an important role in nitric oxide-mediated vasodilation, and disruption of the glycocalyx results in thrombin generation and platelet adhesion [27] .", [["EC glycocalyx", "ANATOMY", 0, 13], ["glycocalyx", "ANATOMY", 99, 109], ["platelet", "ANATOMY", 145, 153], ["nitric oxide", "CHEMICAL", 41, 53], ["nitric oxide", "CHEMICAL", 41, 53], ["EC", "CELL", 0, 2], ["nitric oxide", "SIMPLE_CHEMICAL", 41, 53], ["glycocalyx", "CELLULAR_COMPONENT", 99, 109], ["thrombin", "GENE_OR_GENE_PRODUCT", 121, 129], ["platelet", "CELL", 145, 153], ["EC", "CELL_TYPE", 0, 2], ["thrombin", "PROTEIN", 121, 129], ["EC glycocalyx", "TREATMENT", 0, 13], ["nitric oxide", "TREATMENT", 41, 53], ["mediated vasodilation", "TREATMENT", 54, 75], ["the glycocalyx", "PROBLEM", 95, 109], ["thrombin generation", "TREATMENT", 121, 140], ["platelet adhesion", "TEST", 145, 162]]], ["Moreover, patients with cardiovascular disease and dyslipidemia have high levels of circulating asymmetric di-methyl-arginine (ADMA) [28] , an analogue of L-arginine that inhibits NOS-3 activity [29] , and this leads to lower NO levels; this explains why endothelial dysfunction and the pro-coagulant state are more severe in this cohort of patients.Mechanisms of hyper-coagulable state in COVID-19According to these assumptions, statins [30] and ACE inhibitors (ACE-I) [31] , because of their effect on reducing endothelial dysfunction, might find a rationale in the management of COVID-19 patients, as well as the reduction of low density lipoprotein (which reduces eNOS activity) [32] and the increased consumption of resveratrol (which induces eNOS activity and expression) [33] .Mechanisms of hyper-coagulable state in COVID-19Thus, thrombotic events observed in COVID-19 may be explained by the endothelial dysfunction, due to both direct virus-induced damage [34] and systemic inflammatory state, which has a pro-thrombotic effect [35] .", [["cardiovascular", "ANATOMY", 24, 38], ["endothelial", "ANATOMY", 255, 266], ["endothelial", "ANATOMY", 513, 524], ["endothelial", "ANATOMY", 901, 912], ["cardiovascular disease", "DISEASE", 24, 46], ["dyslipidemia", "DISEASE", 51, 63], ["asymmetric di-methyl-arginine", "CHEMICAL", 96, 125], ["ADMA", "CHEMICAL", 127, 131], ["L-arginine", "CHEMICAL", 155, 165], ["NO", "CHEMICAL", 226, 228], ["endothelial dysfunction", "DISEASE", 255, 278], ["statins", "CHEMICAL", 430, 437], ["ACE-I", "CHEMICAL", 463, 468], ["endothelial dysfunction", "DISEASE", 513, 536], ["COVID", "DISEASE", 582, 587], ["resveratrol", "CHEMICAL", 721, 732], ["COVID-19Thus", "CHEMICAL", 824, 836], ["thrombotic", "DISEASE", 838, 848], ["endothelial dysfunction", "DISEASE", 901, 924], ["asymmetric di-methyl-arginine", "CHEMICAL", 96, 125], ["L-arginine", "CHEMICAL", 155, 165], ["NO", "CHEMICAL", 226, 228], ["statins", "CHEMICAL", 430, 437], ["resveratrol", "CHEMICAL", 721, 732], ["COVID-19Thus", "CHEMICAL", 824, 836], ["COVID-19", "CHEMICAL", 868, 876], ["patients", "ORGANISM", 10, 18], ["cardiovascular", "ANATOMICAL_SYSTEM", 24, 38], ["asymmetric di-methyl-arginine", "SIMPLE_CHEMICAL", 96, 125], ["ADMA", "SIMPLE_CHEMICAL", 127, 131], ["[28]", "SIMPLE_CHEMICAL", 133, 137], ["L-arginine", "SIMPLE_CHEMICAL", 155, 165], ["NOS-3", "GENE_OR_GENE_PRODUCT", 180, 185], ["NO", "SIMPLE_CHEMICAL", 226, 228], ["endothelial", "CELL", 255, 266], ["patients", "ORGANISM", 341, 349], ["statins", "SIMPLE_CHEMICAL", 430, 437], ["ACE inhibitors", "SIMPLE_CHEMICAL", 447, 461], ["ACE-I", "SIMPLE_CHEMICAL", 463, 468], ["endothelial", "CELL", 513, 524], ["patients", "ORGANISM", 591, 599], ["low density lipoprotein", "SIMPLE_CHEMICAL", 629, 652], ["NOS", "GENE_OR_GENE_PRODUCT", 669, 672], ["resveratrol", "SIMPLE_CHEMICAL", 721, 732], ["eNOS", "GENE_OR_GENE_PRODUCT", 748, 752], ["COVID-19Thus", "SIMPLE_CHEMICAL", 824, 836], ["COVID-19", "GENE_OR_GENE_PRODUCT", 868, 876], ["endothelial", "TISSUE", 901, 912], ["NOS", "PROTEIN", 180, 183], ["low density lipoprotein", "PROTEIN", 629, 652], ["NOS", "PROTEIN", 669, 672], ["eNOS", "PROTEIN", 748, 752], ["patients", "SPECIES", 10, 18], ["patients", "SPECIES", 341, 349], ["patients", "SPECIES", 591, 599], ["cardiovascular disease", "PROBLEM", 24, 46], ["dyslipidemia", "PROBLEM", 51, 63], ["high levels", "PROBLEM", 69, 80], ["circulating asymmetric di-methyl-arginine (ADMA)", "PROBLEM", 84, 132], ["an analogue of L-arginine", "TREATMENT", 140, 165], ["NOS", "TEST", 180, 183], ["endothelial dysfunction", "PROBLEM", 255, 278], ["the pro-coagulant state", "PROBLEM", 283, 306], ["hyper-coagulable state", "PROBLEM", 364, 386], ["COVID", "TEST", 390, 395], ["statins", "TREATMENT", 430, 437], ["ACE inhibitors", "TREATMENT", 447, 461], ["ACE-I", "TREATMENT", 463, 468], ["reducing endothelial dysfunction", "PROBLEM", 504, 536], ["COVID", "TEST", 582, 587], ["low density lipoprotein", "PROBLEM", 629, 652], ["resveratrol", "TREATMENT", 721, 732], ["hyper-coagulable state", "PROBLEM", 798, 820], ["COVID", "TEST", 824, 829], ["thrombotic events", "PROBLEM", 838, 855], ["COVID", "TEST", 868, 873], ["the endothelial dysfunction", "PROBLEM", 897, 924], ["both direct virus", "PROBLEM", 933, 950], ["induced damage", "PROBLEM", 951, 965], ["systemic inflammatory state", "PROBLEM", 975, 1002], ["a pro-thrombotic effect", "PROBLEM", 1014, 1037], ["cardiovascular", "ANATOMY", 24, 38], ["disease", "OBSERVATION", 39, 46], ["dyslipidemia", "OBSERVATION", 51, 63], ["hyper", "OBSERVATION", 364, 369], ["low density", "OBSERVATION_MODIFIER", 629, 640], ["hyper", "OBSERVATION", 798, 803], ["thrombotic", "OBSERVATION", 838, 848], ["endothelial dysfunction", "OBSERVATION", 901, 924], ["systemic", "OBSERVATION_MODIFIER", 975, 983], ["inflammatory", "OBSERVATION", 984, 996]]], ["This procoagulant state could explain the frequently observed pulmonary thrombi in COVID 19 patients that probably form in pulmonary vessels and are not the consequence of embolic propagation of peripheral venous thrombi [36] .Management of hyper-coagulable in COVID-19As stated before, cytokine storm and complement cascade hyperactivation probably play an important role in the hypercoagulable state of COVID-19 patients and are the rationale for the use of anti-inflammatory drugs like hMAb that target and inhibit IL-6 pathway and complement cascade activation (tocilizumab and eculizumab, respectively).", [["pulmonary thrombi", "ANATOMY", 62, 79], ["pulmonary vessels", "ANATOMY", 123, 140], ["peripheral venous thrombi", "ANATOMY", 195, 220], ["pulmonary thrombi", "DISEASE", 62, 79], ["peripheral venous thrombi", "DISEASE", 195, 220], ["eculizumab", "CHEMICAL", 582, 592], ["eculizumab", "CHEMICAL", 582, 592], ["pulmonary thrombi", "PATHOLOGICAL_FORMATION", 62, 79], ["patients", "ORGANISM", 92, 100], ["pulmonary vessels", "MULTI-TISSUE_STRUCTURE", 123, 140], ["peripheral venous", "MULTI-TISSUE_STRUCTURE", 195, 212], ["COVID-19As", "CELL", 261, 271], ["patients", "ORGANISM", 414, 422], ["hMAb", "SIMPLE_CHEMICAL", 489, 493], ["IL-6", "GENE_OR_GENE_PRODUCT", 518, 522], ["tocilizumab", "SIMPLE_CHEMICAL", 566, 577], ["eculizumab", "SIMPLE_CHEMICAL", 582, 592], ["cytokine", "PROTEIN", 287, 295], ["IL-6", "PROTEIN", 518, 522], ["patients", "SPECIES", 92, 100], ["patients", "SPECIES", 414, 422], ["the frequently observed pulmonary thrombi", "PROBLEM", 38, 79], ["peripheral venous thrombi", "PROBLEM", 195, 220], ["hyper", "PROBLEM", 241, 246], ["cytokine storm", "TREATMENT", 287, 301], ["complement cascade hyperactivation", "PROBLEM", 306, 340], ["anti-inflammatory drugs", "TREATMENT", 460, 483], ["complement cascade activation (tocilizumab and eculizumab", "TREATMENT", 535, 592], ["pulmonary", "ANATOMY", 62, 71], ["thrombi", "OBSERVATION", 72, 79], ["probably form", "UNCERTAINTY", 106, 119], ["pulmonary vessels", "ANATOMY", 123, 140], ["not the consequence of", "UNCERTAINTY", 149, 171], ["embolic", "OBSERVATION", 172, 179], ["peripheral", "ANATOMY_MODIFIER", 195, 205], ["venous", "ANATOMY", 206, 212], ["thrombi", "OBSERVATION", 213, 220], ["hyper", "OBSERVATION", 241, 246]]], ["Xu et al. [37] treated 21 severe or critical COVID-19 patients with tocilizumab with routine therapy: fever ceased in all patients; 15 patients lowered their oxygen demand within 5 days after tocilizumab administration; C-reactive protein (CRP) levels decreased significantly in most patients; Computed tomography (CT) showed improvement of the lung opacities.", [["lung", "ANATOMY", 345, 349], ["tocilizumab", "CHEMICAL", 68, 79], ["fever", "DISEASE", 102, 107], ["oxygen", "CHEMICAL", 158, 164], ["lung opacities", "DISEASE", 345, 359], ["oxygen", "CHEMICAL", 158, 164], ["patients", "ORGANISM", 54, 62], ["tocilizumab", "SIMPLE_CHEMICAL", 68, 79], ["patients", "ORGANISM", 122, 130], ["patients", "ORGANISM", 135, 143], ["oxygen", "SIMPLE_CHEMICAL", 158, 164], ["tocilizumab", "SIMPLE_CHEMICAL", 192, 203], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 220, 238], ["CRP", "GENE_OR_GENE_PRODUCT", 240, 243], ["patients", "ORGANISM", 284, 292], ["lung", "ORGAN", 345, 349], ["C-reactive protein", "PROTEIN", 220, 238], ["CRP", "PROTEIN", 240, 243], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 122, 130], ["patients", "SPECIES", 135, 143], ["patients", "SPECIES", 284, 292], ["tocilizumab", "TREATMENT", 68, 79], ["routine therapy", "TREATMENT", 85, 100], ["fever", "PROBLEM", 102, 107], ["their oxygen demand", "TREATMENT", 152, 171], ["tocilizumab administration", "TREATMENT", 192, 218], ["C-reactive protein (CRP) levels", "TEST", 220, 251], ["Computed tomography (CT)", "TEST", 294, 318], ["the lung opacities", "PROBLEM", 341, 359], ["fever", "OBSERVATION", 102, 107], ["improvement", "OBSERVATION_MODIFIER", 326, 337], ["lung", "ANATOMY", 345, 349], ["opacities", "OBSERVATION", 350, 359]]], ["Diurno et al. [38] published a case series on 4 severe COVID-19 patients treated with eculizumab: CPR values diminished in all patients, with evidence of lung lesions' reduction on CT scans performed 48 h after Eculizumab administration in 3 out of 4 patients.", [["lung lesions", "ANATOMY", 154, 166], ["COVID", "DISEASE", 55, 60], ["eculizumab", "CHEMICAL", 86, 96], ["Eculizumab", "CHEMICAL", 211, 221], ["eculizumab", "CHEMICAL", 86, 96], ["Eculizumab", "CHEMICAL", 211, 221], ["patients", "ORGANISM", 64, 72], ["eculizumab", "SIMPLE_CHEMICAL", 86, 96], ["patients", "ORGANISM", 127, 135], ["lung lesions", "PATHOLOGICAL_FORMATION", 154, 166], ["Eculizumab", "SIMPLE_CHEMICAL", 211, 221], ["patients", "ORGANISM", 251, 259], ["patients", "SPECIES", 64, 72], ["patients", "SPECIES", 127, 135], ["patients", "SPECIES", 251, 259], ["eculizumab", "TREATMENT", 86, 96], ["CPR values", "TEST", 98, 108], ["lung lesions", "PROBLEM", 154, 166], ["CT scans", "TEST", 181, 189], ["Eculizumab administration", "TREATMENT", 211, 236], ["lung", "ANATOMY", 154, 158], ["lesions", "OBSERVATION", 159, 166]]], ["Ongoing multicenter studies are further investigating Tocilizumab and Eculizumab use in COVID-19.", [["Tocilizumab", "CHEMICAL", 54, 65], ["Eculizumab", "CHEMICAL", 70, 80], ["Tocilizumab", "CHEMICAL", 54, 65], ["Eculizumab", "CHEMICAL", 70, 80], ["Tocilizumab", "SIMPLE_CHEMICAL", 54, 65], ["Eculizumab", "SIMPLE_CHEMICAL", 70, 80], ["Ongoing multicenter studies", "TEST", 0, 27], ["Tocilizumab", "TREATMENT", 54, 65], ["Eculizumab use", "TREATMENT", 70, 84], ["COVID", "TEST", 88, 93]]], ["NCT04317092 is a multicenter, open label, single arm study with primary endpoint of overall mortality reduction 1 month after registration and includes patients with SARS-CoV-2-induced interstitial pneumonia with respiratory insufficiency (O2sat \u2264 93% or PaO 2 /FiO 2 ratio \u2264 300) treated with Tocilizumab.", [["interstitial", "ANATOMY", 185, 197], ["respiratory", "ANATOMY", 213, 224], ["interstitial pneumonia", "DISEASE", 185, 207], ["respiratory insufficiency", "DISEASE", 213, 238], ["Tocilizumab", "CHEMICAL", 294, 305], ["Tocilizumab", "CHEMICAL", 294, 305], ["patients", "ORGANISM", 152, 160], ["Tocilizumab", "SIMPLE_CHEMICAL", 294, 305], ["patients", "SPECIES", 152, 160], ["single arm study", "TEST", 42, 58], ["overall mortality reduction", "TREATMENT", 84, 111], ["SARS", "PROBLEM", 166, 170], ["CoV", "TEST", 171, 174], ["interstitial pneumonia", "PROBLEM", 185, 207], ["respiratory insufficiency", "PROBLEM", 213, 238], ["O2sat", "TEST", 240, 245], ["PaO", "TEST", 255, 258], ["FiO", "TEST", 262, 265], ["Tocilizumab", "TREATMENT", 294, 305], ["interstitial", "ANATOMY_MODIFIER", 185, 197], ["pneumonia", "OBSERVATION", 198, 207], ["respiratory insufficiency", "OBSERVATION", 213, 238]]], ["NCT04288713 (SOLID-C19) is a multicenter study investigating Eculizumab use in severe COVID-19 patients admitted in ICU with acute respiratory insufficiency, having as endpoints the reduction of mortality, time in ICU and time on a ventilator.", [["respiratory", "ANATOMY", 131, 142], ["Eculizumab", "CHEMICAL", 61, 71], ["COVID", "DISEASE", 86, 91], ["acute respiratory insufficiency", "DISEASE", 125, 156], ["Eculizumab", "CHEMICAL", 61, 71], ["Eculizumab", "SIMPLE_CHEMICAL", 61, 71], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["a multicenter study", "TEST", 27, 46], ["acute respiratory insufficiency", "PROBLEM", 125, 156], ["a ventilator", "TREATMENT", 230, 242], ["acute", "OBSERVATION_MODIFIER", 125, 130], ["respiratory insufficiency", "OBSERVATION", 131, 156]]], ["VTE risk assessment in non-COVID-19 inpatients relies on clinical validated scores like Caprini, Improve and Padua scores [39, 40] .", [["VTE", "DISEASE", 0, 3], ["VTE risk assessment", "TEST", 0, 19], ["non-COVID", "TEST", 23, 32], ["Padua scores", "TEST", 109, 121]]], ["However, it is not clear if these VTE risk scores should be used for COVID-19 patients or if these patients should routinely be treated with thrombus-prophylaxis because of their prothrombotic state.", [["thrombus", "ANATOMY", 141, 149], ["VTE", "DISEASE", 34, 37], ["thrombus", "DISEASE", 141, 149], ["patients", "ORGANISM", 78, 86], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 99, 107], ["these VTE risk scores", "PROBLEM", 28, 49], ["COVID", "TEST", 69, 74], ["thrombus", "PROBLEM", 141, 149], ["prophylaxis", "TREATMENT", 150, 161], ["their prothrombotic state", "PROBLEM", 173, 198], ["thrombus", "OBSERVATION", 141, 149], ["prothrombotic", "OBSERVATION", 179, 192]]], ["Tang et al. [41] retrospectively enrolled 449 severe COVID-19-patients and 99 (22.0%) patients received Low Molecular Weight Heparin (LMWH) treatment (4000-6000 IU q24h) for at least 7 days.", [["Heparin", "CHEMICAL", 125, 132], ["LMWH", "CHEMICAL", 134, 138], ["patients", "ORGANISM", 62, 70], ["patients", "ORGANISM", 86, 94], ["Low Molecular Weight Heparin", "SIMPLE_CHEMICAL", 104, 132], ["LMWH", "SIMPLE_CHEMICAL", 134, 138], ["patients", "SPECIES", 62, 70], ["patients", "SPECIES", 86, 94], ["severe COVID", "TEST", 46, 58], ["Low Molecular Weight Heparin (LMWH) treatment", "TREATMENT", 104, 149]]], ["D-dimer, PT and age were directly correlated with 28-day mortality, while low platelet count correlated with a worse outcome.", [["platelet", "ANATOMY", 78, 86], ["D-dimer", "GENE_OR_GENE_PRODUCT", 0, 7], ["platelet", "CELL", 78, 86], ["D-dimer", "TEST", 0, 7], ["PT", "TEST", 9, 11], ["low platelet count", "PROBLEM", 74, 92]]], ["LMWH treatment was associated with lower mortality in patients with sepsis-induced coagulopathy (SIC) score \u2265 4 and in patients with D-dimer exceeding 3.0 \u03bcg/ mL (6 times the upper limit of normal (ULN)).", [["LMWH", "CHEMICAL", 0, 4], ["sepsis", "DISEASE", 68, 74], ["coagulopathy", "DISEASE", 83, 95], ["SIC", "DISEASE", 97, 100], ["LMWH", "SIMPLE_CHEMICAL", 0, 4], ["patients", "ORGANISM", 54, 62], ["patients", "ORGANISM", 119, 127], ["D-dimer", "SIMPLE_CHEMICAL", 133, 140], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 119, 127], ["LMWH treatment", "TREATMENT", 0, 14], ["lower mortality", "PROBLEM", 35, 50], ["sepsis", "PROBLEM", 68, 74], ["induced coagulopathy", "PROBLEM", 75, 95], ["SIC) score", "TEST", 97, 107], ["D-dimer", "TEST", 133, 140], ["sepsis", "OBSERVATION", 68, 74], ["coagulopathy", "OBSERVATION", 83, 95], ["upper limit", "OBSERVATION_MODIFIER", 175, 186], ["normal", "OBSERVATION", 190, 196]]], ["Lin et al. [42] suggest using LMWH at anticoagulant dose (100 IU/ kg q12h) for at least 3-5 days in severe COVID-19 patients when D-dimer is higher than 4 times the ULN.", [["LMWH", "CHEMICAL", 30, 34], ["COVID", "DISEASE", 107, 112], ["LMWH", "SIMPLE_CHEMICAL", 30, 34], ["patients", "ORGANISM", 116, 124], ["D-dimer", "SIMPLE_CHEMICAL", 130, 137], ["patients", "SPECIES", 116, 124], ["LMWH at anticoagulant dose", "TREATMENT", 30, 56], ["severe COVID", "TEST", 100, 112], ["D-dimer", "TEST", 130, 137]]], ["Moreover, in support of routine use of LMWH, there is the evidence of the anti-inflammatory [43] and the protective action on endothelial function [44] exerted by LMWH.Management of hyper-coagulable in COVID-19Nowadays, clinicians agree on the use of LMWH in severe and critically ill COVID-19-patients, regardless of VTE risk scores.", [["endothelial", "ANATOMY", 126, 137], ["LMWH", "CHEMICAL", 39, 43], ["LMWH", "CHEMICAL", 163, 167], ["LMWH", "CHEMICAL", 251, 255], ["VTE", "DISEASE", 318, 321], ["LMWH", "SIMPLE_CHEMICAL", 39, 43], ["endothelial", "CELL", 126, 137], ["LMWH", "SIMPLE_CHEMICAL", 163, 167], ["patients", "ORGANISM", 294, 302], ["patients", "SPECIES", 294, 302], ["LMWH", "TREATMENT", 39, 43], ["endothelial function", "TEST", 126, 146], ["hyper", "PROBLEM", 182, 187], ["LMWH", "TREATMENT", 251, 255], ["VTE risk scores", "PROBLEM", 318, 333], ["anti-inflammatory", "OBSERVATION_MODIFIER", 74, 91], ["LMWH", "OBSERVATION", 163, 167], ["hyper", "OBSERVATION", 182, 187], ["severe", "OBSERVATION_MODIFIER", 259, 265]]], ["On the other hand, there are conflicting strategies on routine LMWH therapy in patients with mild and moderate COVID 19.", [["LMWH", "CHEMICAL", 63, 67], ["LMWH", "SIMPLE_CHEMICAL", 63, 67], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["routine LMWH therapy", "TREATMENT", 55, 75], ["mild and moderate COVID 19", "PROBLEM", 93, 119], ["LMWH therapy", "OBSERVATION", 63, 75], ["mild", "OBSERVATION_MODIFIER", 93, 97], ["moderate", "OBSERVATION_MODIFIER", 102, 110]]], ["For example, Zhai et al. [40] suggest that VTE risk-scores should be calculated in mild and moderate inpatients and routine thrombus-prophylaxis should be routinely used in severe and critically ill COVID-19-patients.", [["thrombus", "ANATOMY", 124, 132], ["VTE", "DISEASE", 43, 46], ["thrombus", "DISEASE", 124, 132], ["patients", "ORGANISM", 208, 216], ["patients", "SPECIES", 208, 216], ["VTE risk-scores", "PROBLEM", 43, 58], ["mild and moderate inpatients", "PROBLEM", 83, 111], ["routine thrombus", "PROBLEM", 116, 132], ["prophylaxis", "TREATMENT", 133, 144], ["mild", "OBSERVATION_MODIFIER", 83, 87], ["moderate", "OBSERVATION_MODIFIER", 92, 100], ["thrombus", "OBSERVATION", 124, 132]]], ["Conversely, Cattaneo et al. [36] suggest a routine thrombi-prophylaxis with LMWH (4000-6000 IU q24h) in COVID-19 inpatients in absence of contraindications.Management of hyper-coagulable in COVID-19We propose the following algorithm for anticoagulation management in COVID 19 patients (Fig. 2) . in Mild cases, Padua or Caprini scores should be evaluated; if Padua score is \u2265 4 and/or Caprini score is \u2265 10, LMWH (4000 IU q24h) should be started in the absence of contraindications.Management of hyper-coagulable in COVID-19In Moderate cases, LMWH (4000-6000 IU q24h) should be started, irrespective of VTE risk assessment scores, in the absence of contraindications.", [["LMWH", "CHEMICAL", 76, 80], ["LMWH", "CHEMICAL", 408, 412], ["LMWH", "CHEMICAL", 543, 547], ["VTE", "DISEASE", 603, 606], ["LMWH", "SIMPLE_CHEMICAL", 76, 80], ["patients", "ORGANISM", 276, 284], ["LMWH", "SIMPLE_CHEMICAL", 408, 412], ["LMWH", "SIMPLE_CHEMICAL", 543, 547], ["patients", "SPECIES", 276, 284], ["a routine thrombi-prophylaxis", "TREATMENT", 41, 70], ["LMWH", "TREATMENT", 76, 80], ["hyper", "PROBLEM", 170, 175], ["anticoagulation management", "TREATMENT", 237, 263], ["Mild cases", "PROBLEM", 299, 309], ["Padua or Caprini scores", "PROBLEM", 311, 334], ["Padua score", "TEST", 359, 370], ["Caprini score", "TEST", 385, 398], ["LMWH", "TREATMENT", 408, 412], ["hyper", "PROBLEM", 496, 501], ["COVID", "TEST", 516, 521], ["LMWH", "TREATMENT", 543, 547], ["VTE risk assessment scores", "TEST", 603, 629], ["hyper", "OBSERVATION", 170, 175], ["hyper", "OBSERVATION", 496, 501]]], ["In Severe and Critical cases: ISTH-DIC score should be evaluated; in case of ISTH-DIC score < 5, LMWH (4000-6000 IU q24h) should be started, in the absence of contraindications; if the ISTH-DIC score is \u2265 5, we suggest to use full-dose LMWH (100 IU/Kg q12h), in the absence of contraindications.ConclusionsThe whole scientific community is focusing on COVID-19 pandemic to face the hardest health emergency of the last years.", [["DIC", "DISEASE", 82, 85], ["LMWH", "CHEMICAL", 97, 101], ["LMWH", "CHEMICAL", 236, 240], ["LMWH", "SIMPLE_CHEMICAL", 97, 101], ["LMWH", "SIMPLE_CHEMICAL", 236, 240], ["DIC score", "PROBLEM", 35, 44], ["ISTH", "TEST", 77, 81], ["DIC score", "TEST", 82, 91], ["LMWH", "TREATMENT", 97, 101], ["the ISTH", "TEST", 181, 189], ["DIC score", "TEST", 190, 199], ["full-dose LMWH", "TREATMENT", 226, 240], ["Severe", "OBSERVATION_MODIFIER", 3, 9]]], ["The rapid and often sudden clinical deterioration of COVID-19-patients and the reported correlation between disease severity and D-Dimer levels often induce to search for PE in rapidly deteriorating patients.", [["PE", "DISEASE", 171, 173], ["patients", "ORGANISM", 62, 70], ["D-Dimer", "GENE_OR_GENE_PRODUCT", 129, 136], ["patients", "ORGANISM", 199, 207], ["patients", "SPECIES", 62, 70], ["patients", "SPECIES", 199, 207], ["COVID", "TEST", 53, 58], ["disease severity", "PROBLEM", 108, 124], ["D-Dimer levels", "TEST", 129, 143], ["PE", "PROBLEM", 171, 173], ["rapid", "OBSERVATION_MODIFIER", 4, 9], ["PE", "OBSERVATION", 171, 173]]], ["There is growing evidence that pulmonary thrombi directly form in situ, as a consequence of virus-induced inflammation and endothelial dysfunction, and this is particularly evident in patients with previous cardiovascular disease.", [["pulmonary thrombi", "ANATOMY", 31, 48], ["endothelial", "ANATOMY", 123, 134], ["cardiovascular", "ANATOMY", 207, 221], ["pulmonary thrombi", "DISEASE", 31, 48], ["inflammation", "DISEASE", 106, 118], ["endothelial dysfunction", "DISEASE", 123, 146], ["cardiovascular disease", "DISEASE", 207, 229], ["pulmonary thrombi", "MULTI-TISSUE_STRUCTURE", 31, 48], ["endothelial", "TISSUE", 123, 134], ["patients", "ORGANISM", 184, 192], ["patients", "SPECIES", 184, 192], ["pulmonary thrombi", "PROBLEM", 31, 48], ["virus", "PROBLEM", 92, 97], ["inflammation", "PROBLEM", 106, 118], ["endothelial dysfunction", "PROBLEM", 123, 146], ["previous cardiovascular disease", "PROBLEM", 198, 229], ["pulmonary", "ANATOMY", 31, 40], ["thrombi", "OBSERVATION", 41, 48], ["virus", "OBSERVATION", 92, 97], ["inflammation", "OBSERVATION", 106, 118], ["endothelial dysfunction", "OBSERVATION", 123, 146], ["cardiovascular", "ANATOMY", 207, 221], ["disease", "OBSERVATION", 222, 229]]], ["Thus, the management of this hyper-coagulable status may have several treatment approaches.ConclusionsSince SARS-CoV2 induces high IL-6 levels and complement cascade activation contributing to the prothrombotic state of COVID 19 patients, the use of anti-inflammatory drugs like corticosteroids and hMAb that target and inhibit IL-6 pathway and complement cascade activation (Tocilizumab and Eculizumab, respectively) may be useful [45, 46] .", [["SARS", "DISEASE", 108, 112], ["hMAb", "CHEMICAL", 299, 303], ["Tocilizumab", "CHEMICAL", 376, 387], ["Eculizumab", "CHEMICAL", 392, 402], ["corticosteroids", "CHEMICAL", 279, 294], ["Tocilizumab", "CHEMICAL", 376, 387], ["Eculizumab", "CHEMICAL", 392, 402], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 108, 117], ["IL-6", "GENE_OR_GENE_PRODUCT", 131, 135], ["patients", "ORGANISM", 229, 237], ["corticosteroids", "SIMPLE_CHEMICAL", 279, 294], ["hMAb", "SIMPLE_CHEMICAL", 299, 303], ["IL-6", "GENE_OR_GENE_PRODUCT", 328, 332], ["Tocilizumab", "SIMPLE_CHEMICAL", 376, 387], ["Eculizumab", "SIMPLE_CHEMICAL", 392, 402], ["IL-6", "PROTEIN", 131, 135], ["IL-6", "PROTEIN", 328, 332], ["patients", "SPECIES", 229, 237], ["this hyper-coagulable status", "PROBLEM", 24, 52], ["several treatment approaches", "TREATMENT", 62, 90], ["ConclusionsSince SARS", "TEST", 91, 112], ["high IL", "TREATMENT", 126, 133], ["complement cascade activation", "PROBLEM", 147, 176], ["the prothrombotic state", "PROBLEM", 193, 216], ["anti-inflammatory drugs", "TREATMENT", 250, 273], ["corticosteroids", "TREATMENT", 279, 294], ["hMAb", "TREATMENT", 299, 303], ["complement cascade activation (Tocilizumab and Eculizumab", "TREATMENT", 345, 402]]], ["Likewise, drugs that reduce endothelial dysfunction, like Statins and ACE-I, could also play a role.", [["endothelial", "ANATOMY", 28, 39], ["endothelial dysfunction", "DISEASE", 28, 51], ["ACE-I", "CHEMICAL", 70, 75], ["endothelial", "CELL", 28, 39], ["ACE-I", "GENE_OR_GENE_PRODUCT", 70, 75], ["ACE", "PROTEIN", 70, 73], ["drugs", "TREATMENT", 10, 15], ["endothelial dysfunction", "PROBLEM", 28, 51], ["Statins", "TREATMENT", 58, 65], ["endothelial dysfunction", "OBSERVATION", 28, 51]]], ["Finally, LMWH is widely used in COVID-19 patients to prevent thrombi formation, but further studies are needed to assess the optimal anticoagulant regimen and to investigate other therapeutic strategies like platelet aggregation inhibitors.ConclusionsOpen Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.", [["thrombi", "ANATOMY", 61, 68], ["platelet", "ANATOMY", 208, 216], ["LMWH", "CHEMICAL", 9, 13], ["thrombi", "DISEASE", 61, 68], ["platelet aggregation", "DISEASE", 208, 228], ["LMWH", "SIMPLE_CHEMICAL", 9, 13], ["patients", "ORGANISM", 41, 49], ["thrombi", "PATHOLOGICAL_FORMATION", 61, 68], ["platelet", "CELL", 208, 216], ["patients", "SPECIES", 41, 49], ["LMWH", "TREATMENT", 9, 13], ["thrombi formation", "PROBLEM", 61, 78], ["further studies", "TEST", 84, 99], ["the optimal anticoagulant regimen", "TREATMENT", 121, 154], ["platelet aggregation inhibitors", "TREATMENT", 208, 239], ["LMWH", "OBSERVATION", 9, 13], ["widely", "OBSERVATION_MODIFIER", 17, 23], ["thrombi", "OBSERVATION", 61, 68]]], ["The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material.", [["The images", "TEST", 0, 10]]], ["To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.", [["licen", "ORGANISM", 68, 73]]]], "b849d1a59b6961ea842a1901143602c646a79b8c": [["IntroductionWe study pricing problems in a game-theoretic model known as Stackelberg games or Stackelberg pricing problems.", [["Stackelberg pricing problems", "PROBLEM", 94, 122]]], ["We are interested in the complexity of computing leader-optimal prices depending on the constraints of the followers.IntroductionOne line of research studies Stackelberg pricing problems where the followers' constraints are given by a combinatorial optimization problem.", [["optimal prices", "TREATMENT", 56, 70], ["research studies", "TEST", 141, 157], ["a combinatorial optimization problem", "TREATMENT", 233, 269]]], ["A well-motivated example of such a pricing problem was introduced by Labb\u00e9 et al. [15] to compute optimal road-tolls: A road network is modeled by a graph where the edges have costs that have to be paid when traveling along an edge.", [["road network", "MULTI-TISSUE_STRUCTURE", 120, 132], ["a pricing problem", "TREATMENT", 33, 50]]], ["Each follower is given by two nodes s and t in the graph and chooses a minimalcost path connecting s and t.", [["nodes", "OBSERVATION", 30, 35]]], ["On the other hand, a large toll might cause the followers to avoid a road entirely resulting in zero revenue.", [["large", "OBSERVATION", 21, 26]]], ["Since the followers \"buy\" a shortest path, this variant is called Stackelberg shortest path.IntroductionStackelberg minimum spanning tree was analyzed by Cardinal et al. and Bil\u00f2 et al. [3, 11, 12] .", [["IntroductionStackelberg minimum spanning tree", "TREATMENT", 92, 137]]], ["The followers are again interested in subsets of a graph's edges, but the subsets have to form a spanning tree.", [["a graph's edges", "TREATMENT", 49, 64]]], ["The leader charges additional costs for some of the edges and collects revenue if they are used by a follower (internet service provider).", [["The leader charges additional costs", "TREATMENT", 0, 35]]], ["Stackelberg shortest path is hard to approximate within a factor of less than 2 (see Briest et al. [7] ) and Stackelberg minimum spanning tree was shown to be APX-hard.", [["APX", "GENE_OR_GENE_PRODUCT", 159, 162], ["APX", "PROTEIN", 159, 162]]], ["The constraints are a bit technical and we spare them for the next section.", [["the next section", "TREATMENT", 58, 74]]], ["As an example, for a matroid, we can think of the subsets of a graph's edges that are acyclic.", [["a graph's edges", "TREATMENT", 61, 76], ["acyclic", "PROBLEM", 86, 93]]], ["The inclusion-wise maximal subsets of a matroid are its bases.", [["bases", "ANATOMY_MODIFIER", 56, 61]]], ["If the elements of the ground set are associated with weights, then a minimal weight basis can be computed by the greedy algorithm.", [["a minimal weight basis", "TEST", 68, 90]]], ["The minimal weight bases of a graphic matroid are the minimum weight spanning trees of the associated graph.IntroductionFor a Stackelberg pricing problem based on a matroid, the ground set is partitioned into two blocks.", [["a Stackelberg pricing problem", "TREATMENT", 124, 153], ["minimal", "OBSERVATION_MODIFIER", 4, 11], ["weight", "OBSERVATION_MODIFIER", 12, 18], ["bases", "ANATOMY_MODIFIER", 19, 24]]], ["One block contains items 1 that have fixed-costs.", [["One block", "PROBLEM", 0, 9], ["fixed", "OBSERVATION_MODIFIER", 37, 42]]], ["Think of these fixed-cost items as being offered by the leader's competitors.", [["fixed", "OBSERVATION_MODIFIER", 15, 20]]], ["The second block contains the priceable items for which the leader chooses prices.", [["The second block", "PROBLEM", 0, 16], ["the priceable items", "PROBLEM", 26, 45]]], ["The leader's goal is to maximize her revenue.IntroductionFinding a minimum weight basis of a matroid can be regarded as a rather simple problem since it can be done with the greedy algorithm.", [["a rather simple problem", "PROBLEM", 120, 143], ["the greedy algorithm", "TEST", 170, 190]]], ["Therefore, it is surprising that the pricing problem based on the graphic matroid, Stackelberg minimum spanning tree, is APX-hard.", [["APX", "GENE_OR_GENE_PRODUCT", 121, 124], ["APX", "PROTEIN", 121, 124], ["the pricing problem", "PROBLEM", 33, 52], ["tree", "OBSERVATION_MODIFIER", 112, 116]]], ["To find cases that can be solved in polynomial time, we have to resort to even simpler matroids.IntroductionWe study three different classes of matroids in two scenarios.", [["IntroductionWe study", "TEST", 96, 116]]], ["Note that this scenario was studied in most of the literature on Stackelberg pricing problems so far.", [["Stackelberg pricing problems", "TREATMENT", 65, 93]]], ["For the second scenario, there are multiple followers which implies a few questions regarding the availability of items and coordination between followers.", [["multiple", "OBSERVATION_MODIFIER", 35, 43]]], ["The leader sets one price for each item that is valid for all the followers.IntroductionThe first class are uniform matroids.", [["uniform matroids", "OBSERVATION", 108, 124]]], ["Here, followers are interested in buying a set of items that has a given size.", [["size", "OBSERVATION_MODIFIER", 73, 77]]], ["Different followers may come with different sizes.", [["sizes", "OBSERVATION_MODIFIER", 44, 49]]], ["There is no additional structure on the items and a follower buys a subset of his given size with minimum total weight.", [["no", "UNCERTAINTY", 9, 11], ["additional", "OBSERVATION_MODIFIER", 12, 22], ["structure", "OBSERVATION", 23, 32]]], ["While the single follower scenario is quite simple, the multiple followers scenario requires a dynamic programming approach.IntroductionSecond, we consider partition matroids which generalize uniform matroids.", [["a dynamic programming approach", "TREATMENT", 93, 123], ["partition matroids", "TREATMENT", 156, 174], ["multiple", "OBSERVATION_MODIFIER", 56, 64], ["uniform matroids", "OBSERVATION", 192, 208]]], ["For each block, the follower buys a subset of a given size.", [["size", "OBSERVATION_MODIFIER", 54, 58]]], ["Different followers may be associated with different partitions and sizes.", [["may be associated with", "UNCERTAINTY", 20, 42], ["sizes", "OBSERVATION_MODIFIER", 68, 73]]], ["We show that computing leaderoptimal prices for a single follower can be done in polynomial time.", [["computing leaderoptimal prices", "TREATMENT", 13, 43]]], ["For the multiple followers, this computational task is NP-hard.", [["multiple", "OBSERVATION_MODIFIER", 8, 16]]], ["The third class are laminar matroids which generalize partition matroids.", [["laminar matroids", "PROBLEM", 20, 36], ["laminar matroids", "OBSERVATION", 20, 36], ["partition matroids", "OBSERVATION", 54, 72]]], ["A laminar matroid is based on a hierarchical family of subsets of the ground set, i.e., two subsets of the family are either disjoint or one is contained in the other.", [["laminar matroid", "OBSERVATION", 2, 17]]], ["For each of the subsets of the laminar family, a follower has an upper bound on the number of items that he wants to buy from this subset.", [["an upper bound", "PROBLEM", 62, 76], ["upper bound", "OBSERVATION_MODIFIER", 65, 76]]], ["Finding leader-optimal prices has the same complexity for laminar matroids as it has for partition matroids.", [["laminar matroids", "TREATMENT", 58, 74], ["laminar matroids", "OBSERVATION", 58, 74]]], ["In the next section, we give a more careful definition of matroids and Stackelberg pricing problems.", [["matroids", "TREATMENT", 58, 66], ["Stackelberg pricing problems", "PROBLEM", 71, 99]]], ["3 and 4, we show how to solve Stackelberg uniform matroid with multiple followers and Stackelberg laminar matroid with one follower, respectively.", [["multiple", "OBSERVATION_MODIFIER", 63, 71], ["laminar", "ANATOMY_MODIFIER", 98, 105], ["matroid", "ANATOMY", 106, 113]]], ["Section 5 shows that Stackelberg partition matroid is hard with multiple followers.", [["Stackelberg partition matroid", "PROBLEM", 21, 50]]], ["Additional literature includes surveys on Stackelberg shortest path by van Hoesel [20] and Labb\u00e9 and Violin [16] .", [["Labb\u00e9", "TEST", 91, 96]]], ["Roche et al. [18] present an algorithm with logarithmic approximation guarantee.", [["logarithmic approximation guarantee", "TREATMENT", 44, 79]]], ["The best lower bound is due to Briest et al. [7] showing approximation hardness within a factor of less than 2.", [["approximation hardness", "PROBLEM", 57, 79]]], ["This is an improvement over APX-hardness by Joret [13] .IntroductionA Stackelberg shortest path tree game was studied by Bilo et al. [4] and Cabello [10] .", [["APX", "SIMPLE_CHEMICAL", 28, 31], ["APX", "PROTEIN", 28, 31], ["improvement", "OBSERVATION_MODIFIER", 11, 22]]], ["Briest et al. [9] give a polynomial time algorithm for Stackelberg bipartite vertex cover game which was later improved by Ba\u00efou and Barahona [1] .IntroductionBriest et al. [9] give a log(k) approximation algorithm for Stackelberg pricing games where k is the number of items.", [["a polynomial time algorithm", "TREATMENT", 23, 50], ["a log(k) approximation algorithm", "TREATMENT", 182, 214]]], ["Their algorithms use a single price strategy which was studied in a more general setting by B\u00f6hnlein et al. [5] .IntroductionBriest et al. [8] study Stackelberg pricing games where the follower is based on a NP-hard optimization problem and runs a known approximation algorithm.PreliminariesStackelberg Pricing Problems.", [["a single price strategy", "TREATMENT", 21, 44], ["a NP-hard optimization problem", "TREATMENT", 206, 236]]], ["Let E = E f\u222a E p be a finite set of items which consists of two blocks E f and E p .", [["E f and E p", "DNA", 71, 82]]], ["E f contains the fixed-cost items and E p contains the priceable items.", [["E f", "DNA", 0, 3], ["fixed", "OBSERVATION_MODIFIER", 17, 22]]], ["Hence, given a price function p, we compose a weight function w : E \u2192 R:PreliminariesEach follower i is determined by a family of feasible subsets S i \u2286 2 E which contains the subsets that he is interested in buying.", [["E \u2192 R", "GENE_OR_GENE_PRODUCT", 66, 71]]], ["Hence, follower i buys the following feasible subset:PreliminariesThe revenue from follower i is rev(S * i (p)) and the leader's total revenue isPreliminariesThe leader's objective is to determine a price function p that maximizes rev(p).", [["rev(p)", "PROTEIN", 231, 237]]], ["A follower's decision is the solution to an optimization problem (given a price function).", [["an optimization problem", "TREATMENT", 41, 64]]], ["If there are multiple followers, we assume that items are available in unlimited supply.stackelberg pricingObjective: Find prices p : E p \u2192 R maximizing rev(p).stackelberg pricingNote that stackelberg pricing captures the problems mentioned in the introduction.stackelberg pricingMatroids.", [["E p \u2192 R", "DNA", 134, 141], ["rev(p)", "DNA", 153, 159], ["stackelberg pricing", "TREATMENT", 189, 208], ["the problems", "PROBLEM", 218, 230], ["multiple", "OBSERVATION_MODIFIER", 13, 21]]], ["Given a ground set E, a family of subsets S \u2282 2 E is a matroid if it satisfies the following conditions:stackelberg pricingMatroids are a well-studied combinatorial structure (cf. [17] ).", [["stackelberg pricingMatroids", "TREATMENT", 104, 131]]], ["The bases of a matroid S are its inclusion-wise maximal elements.", [["matroid S", "CELL_LINE", 15, 24], ["inclusion-wise maximal elements", "DNA", 33, 64], ["bases", "ANATOMY_MODIFIER", 4, 9]]], ["For example, the acyclic subsets of the edges of a graph G form a matroid.", [["acyclic subsets", "OBSERVATION", 17, 32], ["edges", "OBSERVATION_MODIFIER", 40, 45]]], ["It is called the graphic matroid and its bases are the spanning forests of G.stackelberg pricingGiven weights w : E \u2192 R on the ground sets, a minimum weight basis B can be computed using a greedy algorithm: To compute B, we (starting with B = \u2205) consider the elements of E sorted by their weights in non-decreasing order and add an element e to B if B \u222a e \u2208 S.stackelberg pricingStackelberg Matroid is an instance of stackelberg pricing where followers are given by a matroid and buy a minimum weight basis.", [["E \u2192 R", "GENE_OR_GENE_PRODUCT", 114, 119], ["E \u2192 R", "DNA", 114, 119], ["G.stackelberg pricing", "TREATMENT", 75, 96], ["bases", "ANATOMY_MODIFIER", 41, 46]]], ["Cardinal et al. [11] show that stackelberg pricing based on the graphic matroid is APX-hard.", [["APX", "GENE_OR_GENE_PRODUCT", 83, 86], ["APX", "PROTEIN", 83, 86], ["stackelberg pricing", "TREATMENT", 31, 50]]], ["Theorem 2.1 (Cardinal et al. [11] ). stackelberg matroid with one follower is APX-hard.stackelberg pricingCardinal et al. observe that an optimal price function uses only values that appear as fixed-costs in c.", [["APX", "GENE_OR_GENE_PRODUCT", 78, 81], ["APX", "PROTEIN", 78, 81], ["Theorem", "TEST", 0, 7], ["et al", "OBSERVATION", 115, 120]]], ["Given an instance of stackelberg matroid and a price function p, then E = {e 1 , . . . , e m+n } are the elements of E sorted nondecreasingly by their weights w.", [["stackelberg matroid", "PROTEIN", 21, 40], ["stackelberg matroid", "TREATMENT", 21, 40], ["a price function", "TEST", 45, 61]]], ["Hence, the optimistic follower computes his solution greedily based on this order.", [["his solution", "TREATMENT", 40, 52]]], ["If p assigns a price that is not a fixed-cost, increasing this price to the next larger fixed-cost does not change the ordering but increases the leader's revenue.", [["a fixed-cost", "PROBLEM", 33, 45]]], ["This observation also holds if there are multiple followers.", [["This observation", "TEST", 0, 16], ["multiple", "OBSERVATION_MODIFIER", 41, 49]]], ["Lemma 2.1 (Cardinal et al. [11] ).", [["Lemma", "TEST", 0, 5]]], ["There is an optimal price function that uses only values of the cost function c.stackelberg pricingWe close this section with some more notation.", [["this section", "TREATMENT", 108, 120], ["optimal", "OBSERVATION_MODIFIER", 12, 19], ["price function", "OBSERVATION", 20, 34]]], ["Similarly, given a price function p, let E p = {h 1 , . . . , h n } be the elements of E p sorted non-decreasingly by their price.", [["a price function", "TEST", 17, 33]]], ["Usually, the price function is clear from the context and we write p(h i ) = p i .Uniform MatroidIn light of Theorem 2.1, we consider an arguably simple class of matroids, namely uniform matroids.", [["Theorem", "TEST", 109, 116], ["clear", "OBSERVATION", 31, 36], ["uniform matroids", "OBSERVATION", 179, 195]]], ["Given a ground set E and an integer s \u2265 1, the uniform matroid S (of rank s) contains all subsets of E that have size at most s.", [["a ground set E", "TREATMENT", 6, 20], ["an integer s", "TEST", 25, 37], ["the uniform matroid S", "TEST", 43, 64], ["size", "OBSERVATION_MODIFIER", 113, 117]]], ["Formally,Uniform MatroidThe bases of the uniform matroid are the subsets of size exactly s.Stackelberg Uniform Matroid with One Follower.Let the follower be based on a uniform matroid of rank s.", [["matroid", "CANCER", 49, 56], ["Uniform", "OBSERVATION_MODIFIER", 9, 16], ["Matroid", "OBSERVATION_MODIFIER", 17, 24], ["bases", "ANATOMY_MODIFIER", 28, 33], ["uniform", "OBSERVATION_MODIFIER", 41, 48], ["matroid", "OBSERVATION_MODIFIER", 49, 56], ["subsets", "OBSERVATION_MODIFIER", 65, 72], ["size", "OBSERVATION_MODIFIER", 76, 80], ["Stackelberg", "OBSERVATION_MODIFIER", 91, 102], ["Uniform", "OBSERVATION_MODIFIER", 103, 110], ["Matroid", "OBSERVATION_MODIFIER", 111, 118]]], ["Since E has no structure, the follower only cares about the weight of an element.", [["no", "UNCERTAINTY", 12, 14], ["structure", "OBSERVATION_MODIFIER", 15, 24]]], ["Given a price function p, the follower buys the set S * (p) = {e 1 , . . . , e s }.Stackelberg Uniform Matroid with One Follower.With the next lemma we analyze the conditions when the follower buys a fixed number a \u2208 N of the priceable items, for a \u2264 min{s, n}.", [["Matroid", "OBSERVATION_MODIFIER", 103, 110], ["One Follower", "OBSERVATION_MODIFIER", 116, 128]]], ["It follows that |S * (p) \u2229 E f | = s \u2212 a, g s\u2212a+1 \u2208 S * (p), g s\u2212a \u2208 S * (p), and that h a \u2208 S * (p).", [["a", "TEST", 39, 40], ["g", "TEST", 61, 62]]], ["Hence, we must have that p a \u2264 c s\u2212a+1 and c s\u2212a < p a+1 .", [["a \u2264 c s\u2212a", "TEST", 27, 36]]], ["It follows that |S * (p)\u2229E p | \u2265 a and thatStackelberg Uniform Matroid with One Follower.To gain maximum revenue when selling a items, the leader chooses the largest prices that satisfy the conditions of Lemma 3.1.", [["a", "TEST", 33, 34], ["largest", "OBSERVATION_MODIFIER", 158, 165]]], ["It follows that an optimal price function assigns prices c s\u2212a+1 for a many items while the prices of the remaining items must be larger.", [["larger", "OBSERVATION_MODIFIER", 130, 136]]], ["The revenue of such a price function is a \u00b7 c s\u2212a+1 , and the maximum revenue rev * can be computed as follows:Stackelberg Uniform Matroid with One Follower.B\u00f6hnlein et al. [5] showed that constant functions are optimal for stackelberg uniform matroid.", [["stackelberg uniform matroid", "PROBLEM", 224, 251]]], ["The second part of Observation 1 follows from Lemma 3.1.Stackelberg Uniform Matroid with One Follower.To convince ourselves that an optimal price function does not have to be constant when there are more than one followers, we consider a small example.", [["Matroid", "OBSERVATION_MODIFIER", 76, 83], ["One Follower", "OBSERVATION_MODIFIER", 89, 101]]], ["Verify that the constant price functions with values 3 and 5 each yield a revenue of 15.", [["values", "TEST", 46, 52]]], ["But the price function that assigns prices (3, 5, 5, 5) yields a revenue of 16.Stackelberg Uniform Matroid with One Follower.From the small example, we get the intuition that an optimal price function p can have several steps (assuming a non-decreasing ordering of the function's values).", [["Matroid", "OBSERVATION_MODIFIER", 99, 106], ["One Follower", "OBSERVATION_MODIFIER", 112, 124], ["small", "OBSERVATION_MODIFIER", 134, 139]]], ["To determine these steps or equivalently the step-lengths, we use dynamic programming.", [["dynamic programming", "TREATMENT", 66, 85]]], ["The set of all price functions that satisfy these conditions isStackelberg Uniform Matroid with One Follower.for a, b \u2208 N. With the next lemma we characterize optimal price functions under these conditions.Stackelberg Uniform Matroid with One Follower.Proof.", [["Matroid", "OBSERVATION_MODIFIER", 226, 233], ["One Follower", "OBSERVATION_MODIFIER", 239, 251]]], ["Suppose towards a contradiction that p a+1 < c si\u2212(a+b)+1 .", [["si\u2212", "TEST", 47, 50]]], ["But this implies that p a+1 can be increased to c si\u2212(a+b)+1 without changing the followers' decision and increasing the leader's revenue, contradicting that p was optimal.Stackelberg Uniform Matroid with One Follower.For i \u2264 and a \u2264 s i+1 , we compute recursively the maximum revenue that the items h a+1 , . . . , h n can yield under the conditions of P i a,b .Stackelberg Uniform Matroid with One Follower.Note that P i a,b can be empty, and for a sound definition max is replaced by sup.", [["c si\u2212", "GENE_OR_GENE_PRODUCT", 48, 53], ["P", "DNA", 419, 420], ["Matroid", "OBSERVATION_MODIFIER", 192, 199], ["One Follower", "OBSERVATION_MODIFIER", 205, 217], ["Matroid", "OBSERVATION_MODIFIER", 383, 390], ["One Follower", "OBSERVATION_MODIFIER", 396, 408], ["empty", "OBSERVATION", 434, 439]]], ["For a practical algorithm, we define \u03bb i a,b = \u2212\u221e in these cases.", [["a practical algorithm", "TEST", 4, 25]]], ["The main technical feat of this section is the next lemma which derives a recursive formula for \u03bb i a,b .Lemma 3.4.", [["this section", "TREATMENT", 27, 39], ["Lemma", "TEST", 105, 110], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["The leader's maximum revenue can be computed as follows:max p rev(p) = max b\u2264min{s ,n} \u03bb 0,b .Lemma 3.4.", [["max b\u2264min{s", "TEST", 71, 82], ["Lemma", "TEST", 94, 99]]], ["The leader's maximum revenue can be computed as follows:The lemmas above imply an algorithm to compute the leader's optimal revenue for stackelberg uniform matroid when there are multiple followers.", [["multiple", "OBSERVATION_MODIFIER", 179, 187]]], ["Hence, the main result of this section is as follows.Laminar MatroidWe continue with positive results showing that stackelberg matroid based on laminar matroids can be solved in polynomial time if there is only one follower.Laminar MatroidLet E be a ground set.", [["stackelberg matroid", "PROBLEM", 115, 134], ["laminar matroids", "TREATMENT", 144, 160], ["main", "OBSERVATION_MODIFIER", 11, 15], ["laminar matroids", "OBSERVATION", 144, 160]]], ["Then, F \u2286 2 E is a laminar family if for all U, V \u2208 F, either U \u2286 V , V \u2286 U or U \u2229V = \u2205.", [["U \u2286 V", "GENE_OR_GENE_PRODUCT", 62, 67], ["F \u2286 2 E", "DNA", 6, 13], ["U, V \u2208 F", "CELL_LINE", 45, 53], ["U \u2286 V , V \u2286 U", "CELL_LINE", 62, 75]]], ["Each element of F has a capacity \u03d5 : F \u2192 N. The laminar matroid S based on F and \u03d5 is defined as followsLaminar MatroidWithout loss of generality, we assume that E \u2208 F. In case E \u2208 F, we add E to F and set \u03d5(E) = |E| without changing the matroid.Laminar MatroidLetLaminar MatroidObserve that laminar families have a hierarchical structure.", [["E|", "PROTEIN", 214, 216], ["laminar", "ANATOMY_MODIFIER", 48, 55], ["MatroidLetLaminar MatroidObserve", "OBSERVATION", 254, 286], ["laminar", "ANATOMY_MODIFIER", 292, 299], ["hierarchical structure", "OBSERVATION", 316, 338]]], ["We can associate a laminar family with a rooted tree where we identify the nodes of the tree with the elements of the laminar family.", [["nodes", "OBSERVATION", 75, 80]]], ["Set E is the root.", [["root", "ANATOMY", 13, 17], ["root", "TISSUE", 13, 17], ["root", "ANATOMY_MODIFIER", 13, 17]]], ["The children of a node are its direct subsets and the minimal subsets are leafs.Laminar MatroidWe say thatLaminar MatroidObserve that F i is again a laminar family on E. Moreover, we define S i to be the laminar matroid based on F i and \u03d5| Fi .", [["node", "ANATOMY", 18, 22], ["children", "ORGANISM", 4, 12], ["node", "MULTI-TISSUE_STRUCTURE", 18, 22], ["F i", "GENE_OR_GENE_PRODUCT", 229, 232], ["\u03d5| Fi", "GENE_OR_GENE_PRODUCT", 237, 242], ["children", "SPECIES", 4, 12], ["a node", "PROBLEM", 16, 22], ["node", "OBSERVATION", 18, 22], ["minimal", "OBSERVATION_MODIFIER", 54, 61]]], ["Stackelberg Laminar Matroid with One Follower.", [["Laminar Matroid", "OBSERVATION", 12, 27]]], ["The follower is determined by a laminar matroid S based on a laminar family F = {M 1 , . . .", [["laminar matroid S", "CELL_LINE", 32, 49]]], ["M s } with a topological order.Laminar MatroidTo solve the pricing problem, we use a dynamic program whose structure is based on the tree structure of F. First, we compute the optimal revenue for the minimal elements for several configurations.", [["a dynamic program", "TREATMENT", 83, 100]]], ["For an inner node of the tree, the optimal revenue is computed based on the configurations of its direct subsets.Laminar MatroidLet P = {c(e) : e \u2208 E f } be the set of the fixed-costs and P \u221e = P \u222a{\u2212\u221e, \u221e}.", [["inner node", "ANATOMY", 7, 17], ["inner node", "MULTI-TISSUE_STRUCTURE", 7, 17], ["Laminar MatroidLet", "TEST", 113, 131], ["costs", "TEST", 178, 183], ["inner", "OBSERVATION_MODIFIER", 7, 12], ["node", "OBSERVATION", 13, 17], ["tree", "ANATOMY_MODIFIER", 25, 29]]], ["Set S has size x and satisfies the capacity constraint of \u03d5(M i ).", [["size", "OBSERVATION_MODIFIER", 10, 14], ["capacity", "OBSERVATION_MODIFIER", 35, 43]]], ["Q \u2212 is the weight of maximum weight element of S. Adding an element of M i \u00a0S to S such that the capacity constraints are still met increases the weight of S by at least Q + .", [["the capacity constraints", "PROBLEM", 93, 117]]], ["Based on \u0398 Mi x,Q \u2212 ,Q + we define \u03bb Mi x,Q \u2212 ,Q + as follows:Laminar Matroidand for a sound definition max is replaced by sup.", [["Mi", "PROBLEM", 37, 39], ["Laminar Matroidand", "OBSERVATION", 62, 80]]], ["For a practical algorithm, we set \u03bb Mi x,Q \u2212 ,Q + = \u2212\u221e for these cases.", [["a practical algorithm", "TEST", 4, 25]]], ["Note that each basis of a matroid has the same size and that we can compute this size by computing a basis for any price function.Laminar MatroidOur dynamic program computes all values \u03bb Mi x,Q \u2212 ,Q + in reverse order of the topological order.", [["Mi", "TEST", 187, 189], ["size", "OBSERVATION_MODIFIER", 47, 51]]], ["First, we derive a direct formula for the minimal elements of F. Second, we derive a recursive formula for the non-minimal elements of F.Laminar MatroidWe define the set S Mi x,p to contain the x items of M i with the smallest weight under price function p.", [["non-minimal elements", "DNA", 111, 131], ["F.Laminar Matroid", "SPECIES", 135, 152], ["a direct formula", "TREATMENT", 17, 33], ["a recursive formula", "TREATMENT", 83, 102], ["F.Laminar Matroid", "TREATMENT", 135, 152]]], ["The priceable items are preferred in this selection.Laminar MatroidThe set J Mi x,Q \u2212 ,Q + contains the numbers of possible priceable items among the x minimum weight items in M i if their maximum weight item has weight Q \u2212 and the item in M i with the x + 1 largest weight has weight Q + .", [["Laminar Matroid", "TREATMENT", 52, 67], ["The set J Mi", "TREATMENT", 67, 79], ["priceable items", "PROBLEM", 124, 139], ["weight", "TEST", 213, 219], ["weight", "TEST", 267, 273], ["weight", "TEST", 278, 284], ["Matroid", "ANATOMY_MODIFIER", 60, 67]]], ["The set J MiLaminar Matroidotherwise.Laminar MatroidWe show how to compute J Mi x,Q \u2212 ,Q + only in the full version of the paper.", [["J MiLaminar", "OBSERVATION_MODIFIER", 8, 19]]], ["Basically, this can be done by simple routines that inspect the fixed-cost items in M i .Laminar MatroidWith {N 1 , N 2 , . . .}.", [["Laminar MatroidWith", "TEST", 89, 108]]], ["In this case, we add N 1 \u222a N 2 to F and set \u03d5(N 1 \u222a N 2 ) = \u03d5(N 1 ) + \u03d5(N 2 ).", [["\u03d5(N 1 ) + \u03d5(N 2 )", "CHEMICAL", 60, 77]]], ["For a family where the direct subsets of an element are at most 2, the running time of applying the recursion takes times of order O((m + n) 2 \u00b7 n 4 ).", [["O", "CHEMICAL", 131, 132]]], ["It follows that stackelberg partition matroid with one follower can be solved in polynomial time since laminar matroids generalize partition matroids.Partition MatroidFor a ground set E, let A be a partition of E into blocks A 1 , . . . , A s .", [["E", "DNA", 211, 212], ["laminar matroids generalize partition matroids", "TREATMENT", 103, 149], ["partition matroids", "OBSERVATION", 131, 149]]], ["Moreover, there are capacities \u03d5 : A \u2192 N associated with each block of A. The partition matroid S with respect to A and \u03d5 contains a subsets of E if its intersection with each block is at most the block's capacity.", [["\u03d5", "PROTEIN", 120, 121], ["each block", "TREATMENT", 171, 181]]], ["Formally, In this section, we show that stackelberg partition matroid is computationally hard to solve if there are multiple followers.", [["stackelberg partition matroid", "PROBLEM", 40, 69], ["multiple", "OBSERVATION_MODIFIER", 116, 124]]], ["An instance on a ground set E with \u2265 2 followers is given by partition matroids S 1 , . . .", [["a ground set E", "TREATMENT", 15, 29]]], ["S (each with a possibly different partition and capacities).Partition MatroidTheorem 5.1. stackelberg partition matroid with followers is NP-hard, for \u2265 2.Partition MatroidIt follows that stackelberg laminar matroid with multiple followers is also NP-hard since partition matroids are a special case of laminar matroids.Partition MatroidProof (incomplete).", [["laminar matroids", "CANCER", 303, 319], ["Partition MatroidTheorem", "TEST", 60, 84], ["multiple", "OBSERVATION_MODIFIER", 221, 229], ["laminar matroids", "OBSERVATION", 303, 319]]], ["Our reduction is from the hitting set problem which is known to be NP-complete (cf. [14] ).", [["Our reduction", "TREATMENT", 0, 13], ["reduction", "OBSERVATION_MODIFIER", 4, 13]]], ["Here, we are given a set T , a value t \u2208 N and a family of subsets U = {U 1 , . . .", [["U 1", "GENE_OR_GENE_PRODUCT", 72, 75]]], ["The question is if we can find a hitting set H \u2282 T such that H \u2229 U = \u2205 for all U \u2208 U and |H| \u2264 t.Partition MatroidGiven an instance of hitting set, we construct an instance of stackelberg partition matroid as follows:Partition Matroid-We have E f = {g 1 , g 2 } with costs c(g 1 ) = 1 and c(g 2 ) = 2.Partition Matroid-The set of priceable items is E p = T = {h 1 , . . . , h n }.Partition MatroidIn total, there are 2 \u00b7 r + n followers.", [["U \u2208 U", "CELL_LINE", 79, 84], ["Partition", "TEST", 217, 226], ["Matroid", "TEST", 227, 234], ["costs c", "TEST", 267, 274], ["Partition Matroid", "TEST", 301, 318], ["priceable items", "TEST", 330, 345]]], ["The idea of the construction is that the leader chooses a hitting set H by setting p(h) = 1 if h \u2208 H and p(h) = 2 if h \u2208 H. We claim that H is indeed a hitting set of size at most t if p yields revenue at least 2r \u2212 t + 2n.", [["H", "CHEMICAL", 70, 71], ["H", "CHEMICAL", 99, 100]]], ["To gain revenue 2 from a followerF h , the leader has to set p(h) = 2.Partition MatroidTo complete the proof, we show (in the full version of the paper) that our stackelberg partition matroid instance admits revenue of at least 2r\u2212t+2n if and only if the hitting set instance has a hitting set of size at most t.Partition MatroidThe decision version of stackelberg partition matroid is NP-complete since we can compute the leader's revenue for a given price function and compare it to a threshold.", [["stackelberg partition matroid", "TREATMENT", 353, 382]]], ["Moreover, our reduction covers several special cases.", [["our reduction", "TREATMENT", 10, 23], ["reduction", "OBSERVATION_MODIFIER", 14, 23]]], ["Note that we used only two different fixed-cost values and that the partition of each follower contains only 2 blocks.Conclusion and Future WorkWe make progress towards the more general question of determining the complexity of a Stackelberg pricing problem depending on the complexity of the underlying (follower) optimization problem.", [["a Stackelberg pricing problem", "TREATMENT", 228, 257]]]], "PMC7435094": [], "b6f9488bdbe0b8845f70a299a415b6663953fa23": [["IntroductionOn March 11 th , 2020, the World Health Organization (WHO) has declared the novel coronavirus disease (COVID-19) a global pandemic.", [["coronavirus disease", "DISEASE", 94, 113], ["coronavirus", "ORGANISM", 94, 105], ["the novel coronavirus disease", "PROBLEM", 84, 113], ["COVID", "TEST", 115, 120], ["a global pandemic", "PROBLEM", 125, 142], ["coronavirus disease", "OBSERVATION", 94, 113], ["pandemic", "OBSERVATION", 134, 142]]], ["1 The disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 virus) was firstly identified in Wuhan, China, in December 2019 and with a rapid evolving scenario has become a serious threat to global public health.", [["acute respiratory syndrome coronavirus", "DISEASE", 35, 73], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 28, 75], ["SARS-CoV-2 virus", "ORGANISM", 77, 93], ["CoV-2 virus", "SPECIES", 82, 93], ["severe acute respiratory syndrome coronavirus", "SPECIES", 28, 73], ["SARS-CoV-2 virus", "SPECIES", 77, 93], ["The disease", "PROBLEM", 2, 13], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 24, 73], ["SARS", "TEST", 77, 81], ["CoV", "TEST", 82, 85], ["a rapid evolving scenario", "PROBLEM", 161, 186], ["disease", "OBSERVATION", 6, 13], ["severe", "OBSERVATION_MODIFIER", 28, 34], ["acute", "OBSERVATION_MODIFIER", 35, 40], ["respiratory syndrome", "OBSERVATION", 41, 61]]], ["2 As of May 20th, 2020, more than 4,900,000 cases of COVID-19 have been reported, with more than 320,000 deaths.", [["deaths", "DISEASE", 105, 111], ["COVID", "TEST", 53, 58]]], ["Transmission of SARS-CoV-2 mainly occurs in households and other close settings, including nosocomial ones.", [["SARS", "DISEASE", 16, 20], ["SARS-CoV-2", "ORGANISM", 16, 26], ["SARS-CoV", "SPECIES", 16, 24], ["SARS", "PROBLEM", 16, 20], ["CoV", "TEST", 21, 24], ["nosocomial ones", "PROBLEM", 91, 106], ["SARS", "OBSERVATION", 16, 20]]], ["The virus enters the body through mucosal surfaces via droplets, aerosols or hand contact.", [["body", "ANATOMY", 21, 25], ["mucosal", "ANATOMY", 34, 41], ["droplets", "ANATOMY", 55, 63], ["hand", "ANATOMY", 77, 81], ["body", "ORGANISM_SUBDIVISION", 21, 25], ["mucosal surfaces", "TISSUE", 34, 50], ["virus", "OBSERVATION", 4, 9], ["body", "ANATOMY_MODIFIER", 21, 25], ["mucosal", "ANATOMY", 34, 41], ["surfaces", "ANATOMY_MODIFIER", 42, 50], ["droplets", "OBSERVATION_MODIFIER", 55, 63]]], ["Disease presentation can range from no symptoms to acute respiratory distress syndrome (ARDS), multiple organ failure and death.", [["respiratory", "ANATOMY", 57, 68], ["organ", "ANATOMY", 104, 109], ["acute respiratory distress syndrome", "DISEASE", 51, 86], ["ARDS", "DISEASE", 88, 92], ["multiple organ failure", "DISEASE", 95, 117], ["death", "DISEASE", 122, 127], ["organ", "ORGAN", 104, 109], ["Disease presentation", "PROBLEM", 0, 20], ["symptoms", "PROBLEM", 39, 47], ["acute respiratory distress syndrome", "PROBLEM", 51, 86], ["ARDS", "PROBLEM", 88, 92], ["multiple organ failure", "PROBLEM", 95, 117], ["death", "PROBLEM", 122, 127], ["acute", "OBSERVATION_MODIFIER", 51, 56], ["respiratory", "ANATOMY", 57, 68], ["distress", "OBSERVATION", 69, 77], ["ARDS", "OBSERVATION", 88, 92], ["multiple", "OBSERVATION_MODIFIER", 95, 103], ["organ", "ANATOMY", 104, 109], ["failure", "OBSERVATION", 110, 117]]], ["The most common symptoms include fever, dry cough, fatigue, sputum production, shortness of breath, loss of smell and taste, conjunctivitis.", [["sputum", "ANATOMY", 60, 66], ["fever", "DISEASE", 33, 38], ["dry cough", "DISEASE", 40, 49], ["fatigue", "DISEASE", 51, 58], ["shortness of breath", "DISEASE", 79, 98], ["loss of smell", "DISEASE", 100, 113], ["conjunctivitis", "DISEASE", 125, 139], ["The most common symptoms", "PROBLEM", 0, 24], ["fever", "PROBLEM", 33, 38], ["dry cough", "PROBLEM", 40, 49], ["fatigue", "PROBLEM", 51, 58], ["sputum production", "PROBLEM", 60, 77], ["shortness of breath", "PROBLEM", 79, 98], ["loss of smell and taste", "PROBLEM", 100, 123], ["conjunctivitis", "PROBLEM", 125, 139], ["fever", "OBSERVATION", 33, 38], ["cough", "OBSERVATION", 44, 49], ["conjunctivitis", "OBSERVATION", 125, 139]]], ["Severe disease is characterised by dyspnoea, blood oxygen desaturation, respiratory failure and venous thromboembolism.", [["blood", "ANATOMY", 45, 50], ["respiratory", "ANATOMY", 72, 83], ["venous", "ANATOMY", 96, 102], ["dyspnoea", "DISEASE", 35, 43], ["blood oxygen desaturation", "DISEASE", 45, 70], ["respiratory failure", "DISEASE", 72, 91], ["venous thromboembolism", "DISEASE", 96, 118], ["oxygen", "CHEMICAL", 51, 57], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["oxygen", "SIMPLE_CHEMICAL", 51, 57], ["venous", "PATHOLOGICAL_FORMATION", 96, 102], ["Severe disease", "PROBLEM", 0, 14], ["dyspnoea", "PROBLEM", 35, 43], ["blood oxygen desaturation", "PROBLEM", 45, 70], ["respiratory failure", "PROBLEM", 72, 91], ["venous thromboembolism", "PROBLEM", 96, 118], ["disease", "OBSERVATION", 7, 14], ["dyspnoea", "OBSERVATION", 35, 43], ["oxygen desaturation", "OBSERVATION", 51, 70], ["respiratory failure", "OBSERVATION", 72, 91], ["venous", "ANATOMY", 96, 102], ["thromboembolism", "OBSERVATION", 103, 118]]], ["2Materials and methodsWe carried out a review of the English-language literature up to May 20th, 2020, related to the cutaneous manifestation of SARS-CoV-2 virus infection.", [["cutaneous", "ANATOMY", 118, 127], ["SARS-CoV-2 virus infection", "DISEASE", 145, 171], ["SARS-CoV-2 virus", "ORGANISM", 145, 161], ["CoV-2 virus", "SPECIES", 150, 161], ["SARS-CoV-2 virus", "SPECIES", 145, 161], ["SARS", "PROBLEM", 145, 149], ["CoV-2 virus infection", "PROBLEM", 150, 171], ["cutaneous", "ANATOMY", 118, 127]]], ["The research of articles was conducted by using the key term 'COVID-19' or 'SARS-CoV-2' or 'coronavirus' combined with each of the following: 'skin', 'cutaneous', 'dermatologic' or 'dermatology', 'manifestation', 'lesions,' or 'rash.'", [["skin", "ANATOMY", 143, 147], ["cutaneous", "ANATOMY", 151, 160], ["lesions", "ANATOMY", 214, 221], ["SARS", "DISEASE", 76, 80], ["rash", "DISEASE", 228, 232], ["coronavirus", "ORGANISM", 92, 103], ["skin", "ORGAN", 143, 147], ["lesions", "PATHOLOGICAL_FORMATION", 214, 221], ["rash", "PATHOLOGICAL_FORMATION", 228, 232], ["SARS-CoV", "SPECIES", 76, 84], ["the key term 'COVID", "TREATMENT", 48, 67], ["'coronavirus'", "TREATMENT", 91, 104], ["'lesions", "PROBLEM", 213, 221], ["'rash", "PROBLEM", 227, 232], ["skin", "ANATOMY", 143, 147]]], ["For each article, the clinical pattern, type of elementary lesions, localization, early or late onset, age, associated symptoms and number of cases reported were collected.Accepted ArticleThis article is protected by copyright.", [["lesions", "ANATOMY", 59, 66], ["lesions", "PATHOLOGICAL_FORMATION", 59, 66], ["elementary lesions", "PROBLEM", 48, 66], ["associated symptoms", "PROBLEM", 108, 127], ["elementary", "OBSERVATION_MODIFIER", 48, 58], ["lesions", "OBSERVATION", 59, 66]]], ["All rights reservedAccepted ArticleThe patterns of dermatological manifestations associated with SARS-CoV-2 infection are reported in Table 1 .", [["SARS-CoV-2 infection", "DISEASE", 97, 117], ["SARS-CoV-2", "ORGANISM", 97, 107], ["CoV-", "SPECIES", 102, 106], ["SARS-CoV-2", "SPECIES", 97, 107], ["dermatological manifestations", "PROBLEM", 51, 80], ["SARS", "PROBLEM", 97, 101], ["CoV-2 infection", "PROBLEM", 102, 117], ["infection", "OBSERVATION", 108, 117]]], ["The cutaneous manifestations could be classified into the following patterns: exanthema (varicella-like, papulo-vesicular, and morbilliform rash), vascular (chilblain-like, purpuric/petechial and livedoid lesions), urticarial and acro-papular eruption.", [["cutaneous", "ANATOMY", 4, 13], ["papulo", "ANATOMY", 105, 111], ["vesicular", "ANATOMY", 112, 121], ["morbilliform", "ANATOMY", 127, 139], ["vascular", "ANATOMY", 147, 155], ["purpuric", "ANATOMY", 173, 181], ["petechial", "ANATOMY", 182, 191], ["livedoid lesions", "ANATOMY", 196, 212], ["acro-papular", "ANATOMY", 230, 242], ["exanthema", "DISEASE", 78, 87], ["varicella", "DISEASE", 89, 98], ["rash", "DISEASE", 140, 144], ["purpuric", "DISEASE", 173, 181], ["urticarial", "DISEASE", 215, 225], ["acro-papular eruption", "DISEASE", 230, 251], ["vascular", "MULTI-TISSUE_STRUCTURE", 147, 155], ["petechial", "PATHOLOGICAL_FORMATION", 182, 191], ["livedoid lesions", "PATHOLOGICAL_FORMATION", 196, 212], ["The cutaneous manifestations", "PROBLEM", 0, 28], ["exanthema", "PROBLEM", 78, 87], ["varicella", "TEST", 89, 98], ["papulo-vesicular", "PROBLEM", 105, 121], ["morbilliform rash", "PROBLEM", 127, 144], ["vascular (chilblain-like, purpuric/petechial and livedoid lesions", "PROBLEM", 147, 212], ["urticarial", "PROBLEM", 215, 225], ["acro-papular eruption", "PROBLEM", 230, 251], ["cutaneous", "ANATOMY", 4, 13], ["exanthema", "OBSERVATION", 78, 87], ["vesicular", "ANATOMY", 112, 121], ["vascular", "ANATOMY", 147, 155], ["purpuric", "OBSERVATION_MODIFIER", 173, 181], ["petechial", "OBSERVATION_MODIFIER", 182, 191], ["livedoid", "ANATOMY", 196, 204], ["lesions", "OBSERVATION", 205, 212], ["urticarial", "OBSERVATION_MODIFIER", 215, 225], ["acro-papular eruption", "OBSERVATION", 230, 251]]], ["Each pattern is described below.Varicella-like exanthemaThe varicella-like exanthema was firstly described by Marzano et al. 13 and Galv\u00e1n Casas 14 et al. as a specific COVID-19-associated skin manifestation.", [["skin", "ANATOMY", 189, 193], ["Varicella-like exanthema", "DISEASE", 32, 56], ["varicella-like exanthema", "DISEASE", 60, 84], ["Varicella-like exanthema", "ORGANISM", 32, 56], ["skin", "ORGAN", 189, 193], ["Varicella", "PROBLEM", 32, 41], ["like exanthema", "PROBLEM", 42, 56], ["The varicella-like exanthema", "PROBLEM", 56, 84], ["Galv\u00e1n Casas", "TREATMENT", 132, 144], ["a specific COVID", "TEST", 158, 174], ["associated skin manifestation", "PROBLEM", 178, 207], ["exanthema", "OBSERVATION", 47, 56], ["varicella", "OBSERVATION", 60, 69], ["exanthema", "OBSERVATION", 75, 84], ["skin", "ANATOMY", 189, 193], ["manifestation", "OBSERVATION", 194, 207]]], ["It is clinically characterised by widespread monomorphic papulo-vesicular lesions.", [["papulo-vesicular lesions", "ANATOMY", 57, 81], ["papulo-vesicular lesions", "PATHOLOGICAL_FORMATION", 57, 81], ["widespread monomorphic papulo-vesicular lesions", "PROBLEM", 34, 81], ["widespread", "OBSERVATION_MODIFIER", 34, 44], ["monomorphic", "OBSERVATION_MODIFIER", 45, 56], ["papulo", "OBSERVATION_MODIFIER", 57, 63], ["vesicular", "OBSERVATION_MODIFIER", 64, 73], ["lesions", "OBSERVATION", 74, 81]]], ["In the recent prospective nationwide study conducted in Spain 14 this exanthema was described in 9% of the 375 patients studied.", [["exanthema", "DISEASE", 70, 79], ["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["this exanthema", "PROBLEM", 65, 79]]], ["The lesions appear at a median of 3 days after symptoms, and last for a median time of 8 days.", [["lesions", "ANATOMY", 4, 11], ["lesions", "PATHOLOGICAL_FORMATION", 4, 11], ["The lesions", "PROBLEM", 0, 11], ["symptoms", "PROBLEM", 47, 55], ["lesions", "OBSERVATION", 4, 11]]], ["It is associated with moderate disease severity generally in middle-aged patients.", [["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["moderate disease severity", "PROBLEM", 22, 47], ["associated with", "UNCERTAINTY", 6, 21], ["moderate", "OBSERVATION_MODIFIER", 22, 30], ["disease", "OBSERVATION", 31, 38], ["severity", "OBSERVATION_MODIFIER", 39, 47], ["middle", "ANATOMY_MODIFIER", 61, 67]]], ["Trunk is constantly involved, and itching is reported in some, but not all patients.Varicella-like exanthemaHistology shows vacuolar degeneration with disorganized keratinocytes, enlarged and multinucleate keratinocytes with dyskeratotic (apoptotic) cells.", [["Trunk", "ANATOMY", 0, 5], ["vacuolar", "ANATOMY", 124, 132], ["keratinocytes", "ANATOMY", 164, 177], ["multinucleate keratinocytes", "ANATOMY", 192, 219], ["cells", "ANATOMY", 250, 255], ["itching", "DISEASE", 34, 41], ["Varicella-like exanthemaHistology", "DISEASE", 84, 117], ["patients", "ORGANISM", 75, 83], ["Varicella", "ORGANISM", 84, 93], ["vacuolar", "IMMATERIAL_ANATOMICAL_ENTITY", 124, 132], ["keratinocytes", "CELL", 164, 177], ["multinucleate keratinocytes", "CELL", 192, 219], ["dyskeratotic (apoptotic) cells", "CELL", 225, 255], ["disorganized keratinocytes", "CELL_TYPE", 151, 177], ["multinucleate keratinocytes", "CELL_TYPE", 192, 219], ["dyskeratotic (apoptotic) cells", "CELL_TYPE", 225, 255], ["patients", "SPECIES", 75, 83], ["itching", "PROBLEM", 34, 41], ["Varicella", "TEST", 84, 93], ["vacuolar degeneration", "PROBLEM", 124, 145], ["disorganized keratinocytes", "PROBLEM", 151, 177], ["enlarged and multinucleate keratinocytes", "PROBLEM", 179, 219], ["dyskeratotic (apoptotic) cells", "PROBLEM", 225, 255], ["vacuolar degeneration", "OBSERVATION", 124, 145], ["disorganized", "OBSERVATION_MODIFIER", 151, 163], ["keratinocytes", "OBSERVATION", 164, 177], ["enlarged", "OBSERVATION_MODIFIER", 179, 187], ["multinucleate keratinocytes", "OBSERVATION", 192, 219], ["dyskeratotic", "OBSERVATION_MODIFIER", 225, 237], ["apoptotic) cells", "OBSERVATION", 239, 255]]], ["A dense inflammatory infiltrate may be present.Maculo-papular exanthemaA maculo-papular rash, defined also as morbilliform, presenting clinical features that resemble typical viral exanthemas has been also described in COVID-19 patients.", [["rash", "DISEASE", 88, 92], ["viral exanthemas", "DISEASE", 175, 191], ["patients", "ORGANISM", 228, 236], ["patients", "SPECIES", 228, 236], ["A dense inflammatory infiltrate", "PROBLEM", 0, 31], ["Maculo-papular exanthemaA maculo-papular rash", "PROBLEM", 47, 92], ["typical viral exanthemas", "PROBLEM", 167, 191], ["dense", "OBSERVATION_MODIFIER", 2, 7], ["inflammatory", "OBSERVATION_MODIFIER", 8, 20], ["infiltrate", "OBSERVATION", 21, 31], ["may be", "UNCERTAINTY", 32, 38], ["papular", "OBSERVATION_MODIFIER", 54, 61], ["papular", "OBSERVATION_MODIFIER", 80, 87], ["rash", "OBSERVATION", 88, 92], ["typical", "OBSERVATION_MODIFIER", 167, 174], ["viral exanthemas", "OBSERVATION", 175, 191]]], ["[15] [16] [17] [18] It appears concomitantly with the other symptoms of infection, lasts for a short period (3-10 days), and itching is reported in most of the patients.", [["infection", "DISEASE", 72, 81], ["itching", "DISEASE", 125, 132], ["[15] [16] [17] [18]", "SIMPLE_CHEMICAL", 0, 19], ["patients", "ORGANISM", 160, 168], ["patients", "SPECIES", 160, 168], ["the other symptoms of infection", "PROBLEM", 50, 81], ["itching", "PROBLEM", 125, 132], ["infection", "OBSERVATION", 72, 81]]], ["It is associated with severe disease in older patients.", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["severe disease in older patients", "PROBLEM", 22, 54], ["associated with", "UNCERTAINTY", 6, 21], ["severe", "OBSERVATION_MODIFIER", 22, 28], ["disease", "OBSERVATION", 29, 36]]], ["Galvan Casa et al. 14 reported a prevalence of 47% among their 375 patients.", [["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75]]], ["They described a perifollicular distribution in some cases and occasionally scaling.", [["perifollicular", "ANATOMY", 17, 31], ["occasionally scaling", "PROBLEM", 63, 83], ["perifollicular", "OBSERVATION_MODIFIER", 17, 31], ["distribution", "OBSERVATION_MODIFIER", 32, 44], ["occasionally", "OBSERVATION_MODIFIER", 63, 75], ["scaling", "OBSERVATION_MODIFIER", 76, 83]]], ["The erythematous rash may be particularly accentuated on the antecubital fossa and axillary folds.", [["antecubital fossa", "ANATOMY", 61, 78], ["axillary folds", "ANATOMY", 83, 97], ["rash", "DISEASE", 17, 21], ["antecubital fossa", "MULTI-TISSUE_STRUCTURE", 61, 78], ["axillary folds", "MULTI-TISSUE_STRUCTURE", 83, 97], ["The erythematous rash", "PROBLEM", 0, 21], ["erythematous", "OBSERVATION_MODIFIER", 4, 16], ["rash", "OBSERVATION", 17, 21], ["antecubital fossa", "ANATOMY", 61, 78], ["axillary", "ANATOMY", 83, 91], ["folds", "ANATOMY_MODIFIER", 92, 97]]], ["19 Skin biopsy shows some non-specific features of viral-related exanthema, such as slight spongiosis and mild perivascular lymphocytic infiltrate.Accepted ArticleThis article is protected by copyright.", [["Skin biopsy", "ANATOMY", 3, 14], ["perivascular lymphocytic infiltrate", "ANATOMY", 111, 146], ["exanthema", "DISEASE", 65, 74], ["spongiosis", "DISEASE", 91, 101], ["Skin biopsy", "MULTI-TISSUE_STRUCTURE", 3, 14], ["perivascular lymphocytic infiltrate", "PATHOLOGICAL_FORMATION", 111, 146], ["Skin biopsy", "TEST", 3, 14], ["viral-related exanthema", "PROBLEM", 51, 74], ["slight spongiosis", "PROBLEM", 84, 101], ["mild perivascular lymphocytic infiltrate", "PROBLEM", 106, 146], ["Skin", "ANATOMY", 3, 7], ["biopsy", "OBSERVATION", 8, 14], ["some", "OBSERVATION_MODIFIER", 21, 25], ["non-specific", "OBSERVATION_MODIFIER", 26, 38], ["viral", "OBSERVATION", 51, 56], ["exanthema", "OBSERVATION", 65, 74], ["slight", "OBSERVATION_MODIFIER", 84, 90], ["spongiosis", "OBSERVATION", 91, 101], ["mild", "OBSERVATION_MODIFIER", 106, 110], ["perivascular", "ANATOMY_MODIFIER", 111, 123], ["lymphocytic infiltrate", "OBSERVATION", 124, 146]]], ["All rights reserved receptor, which is expressed in several tissues, including endothelial cells.", [["tissues", "ANATOMY", 60, 67], ["endothelial cells", "ANATOMY", 79, 96], ["tissues", "TISSUE", 60, 67], ["endothelial cells", "CELL", 79, 96], ["rights reserved receptor", "PROTEIN", 4, 28], ["endothelial cells", "CELL_TYPE", 79, 96], ["endothelial cells", "PROBLEM", 79, 96], ["endothelial cells", "OBSERVATION", 79, 96]]], ["23 The spectrum of the above mentioned vascular lesions may be due to different possibly overlapping mechanisms, including a direct action of the virus on endothelial cells, 24 an indirect effect involving the triggering of immune or autoimmune reactions as in the case of the immune thrombocytopenic purpura, or to an exaggerated and uncontrolled host response accompanying the well known \"cytokine storm.\"", [["vascular lesions", "ANATOMY", 39, 55], ["endothelial cells", "ANATOMY", 155, 172], ["autoimmune reactions", "DISEASE", 234, 254], ["immune thrombocytopenic purpura", "DISEASE", 277, 308], ["vascular lesions", "PATHOLOGICAL_FORMATION", 39, 55], ["endothelial cells", "CELL", 155, 172], ["endothelial cells", "CELL_TYPE", 155, 172], ["cytokine", "PROTEIN", 391, 399], ["the above mentioned vascular lesions", "PROBLEM", 19, 55], ["different possibly overlapping mechanisms", "PROBLEM", 70, 111], ["the virus on endothelial cells", "PROBLEM", 142, 172], ["autoimmune reactions", "PROBLEM", 234, 254], ["the immune thrombocytopenic purpura", "PROBLEM", 273, 308], ["an exaggerated and uncontrolled host response", "PROBLEM", 316, 361], ["spectrum", "OBSERVATION_MODIFIER", 7, 15], ["vascular", "ANATOMY", 39, 47], ["lesions", "OBSERVATION", 48, 55], ["may be due to", "UNCERTAINTY", 56, 69], ["immune thrombocytopenic purpura", "OBSERVATION", 277, 308]]], ["Whatever the starting mechanism, the consequent microvascular disfunction can lead to increased vasoconstriction and organ ischemia, inflammation and a further pro-coagulation state.", [["microvascular", "ANATOMY", 48, 61], ["organ", "ANATOMY", 117, 122], ["ischemia", "DISEASE", 123, 131], ["inflammation", "DISEASE", 133, 145], ["microvascular", "TISSUE", 48, 61], ["organ", "ORGAN", 117, 122], ["the consequent microvascular disfunction", "PROBLEM", 33, 73], ["increased vasoconstriction", "PROBLEM", 86, 112], ["organ ischemia", "PROBLEM", 117, 131], ["inflammation", "PROBLEM", 133, 145], ["a further pro-coagulation state", "PROBLEM", 150, 181], ["microvascular", "ANATOMY", 48, 61], ["disfunction", "OBSERVATION", 62, 73], ["increased", "OBSERVATION_MODIFIER", 86, 95], ["vasoconstriction", "OBSERVATION", 96, 112], ["organ", "ANATOMY", 117, 122], ["ischemia", "OBSERVATION", 123, 131], ["inflammation", "OBSERVATION", 133, 145]]], ["If skin lesions such as chilblain-like lesions correlate with involvement of internal organs remains to be defined.Chilblain-likeChilblain-like or perniosis-like skin lesions present as erythematous-oedematous manifestations affecting acral sites, mostly toe and soles, with possible bullous evolution.Chilblain-likeThey are usually asymmetrical and mostly itchy and/or painful.", [["skin lesions", "ANATOMY", 3, 15], ["chilblain-like lesions", "ANATOMY", 24, 46], ["internal organs", "ANATOMY", 77, 92], ["skin lesions", "ANATOMY", 162, 174], ["acral sites", "ANATOMY", 235, 246], ["toe", "ANATOMY", 255, 258], ["soles", "ANATOMY", 263, 268], ["Chilblain-likeChilblain", "CHEMICAL", 115, 138], ["skin lesions", "DISEASE", 162, 174], ["Chilblain", "CHEMICAL", 302, 311], ["skin lesions", "PATHOLOGICAL_FORMATION", 3, 15], ["chilblain-like lesions", "PATHOLOGICAL_FORMATION", 24, 46], ["organs", "ORGAN", 86, 92], ["Chilblain", "GENE_OR_GENE_PRODUCT", 115, 124], ["likeChilblain", "GENE_OR_GENE_PRODUCT", 125, 138], ["perniosis", "PATHOLOGICAL_FORMATION", 147, 156], ["skin lesions", "PATHOLOGICAL_FORMATION", 162, 174], ["erythematous-oedematous", "PATHOLOGICAL_FORMATION", 186, 209], ["acral sites", "PATHOLOGICAL_FORMATION", 235, 246], ["toe", "ORGANISM_SUBDIVISION", 255, 258], ["soles", "PATHOLOGICAL_FORMATION", 263, 268], ["Chilblain-likeThey", "GENE_OR_GENE_PRODUCT", 302, 320], ["skin lesions", "PROBLEM", 3, 15], ["chilblain-like lesions", "PROBLEM", 24, 46], ["internal organs", "PROBLEM", 77, 92], ["Chilblain", "TEST", 115, 124], ["likeChilblain", "PROBLEM", 125, 138], ["perniosis", "PROBLEM", 147, 156], ["skin lesions", "PROBLEM", 162, 174], ["erythematous", "PROBLEM", 186, 198], ["oedematous manifestations", "PROBLEM", 199, 224], ["acral sites", "PROBLEM", 235, 246], ["bullous evolution", "PROBLEM", 284, 301], ["itchy", "PROBLEM", 357, 362], ["painful", "PROBLEM", 370, 377], ["skin", "ANATOMY", 3, 7], ["lesions", "OBSERVATION", 8, 15], ["lesions", "OBSERVATION", 39, 46], ["internal", "ANATOMY_MODIFIER", 77, 85], ["organs", "ANATOMY", 86, 92], ["perniosis", "OBSERVATION", 147, 156], ["skin", "ANATOMY", 162, 166], ["lesions", "OBSERVATION", 167, 174], ["erythematous", "OBSERVATION_MODIFIER", 186, 198], ["oedematous", "OBSERVATION_MODIFIER", 199, 209], ["manifestations", "OBSERVATION", 210, 224], ["acral", "ANATOMY", 235, 240], ["sites", "ANATOMY_MODIFIER", 241, 246], ["mostly", "ANATOMY_MODIFIER", 248, 254], ["toe", "ANATOMY", 255, 258], ["soles", "ANATOMY", 263, 268], ["possible", "UNCERTAINTY", 275, 283], ["bullous", "OBSERVATION", 284, 291], ["asymmetrical", "OBSERVATION_MODIFIER", 333, 345], ["mostly", "OBSERVATION_MODIFIER", 350, 356], ["itchy", "OBSERVATION", 357, 362]]], ["25 They typically affect young patients in the absence of systemic symptoms or associated with low-grade disease severity.", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["systemic symptoms", "PROBLEM", 58, 75], ["low-grade disease severity", "PROBLEM", 95, 121], ["low-grade", "OBSERVATION_MODIFIER", 95, 104], ["disease", "OBSERVATION", 105, 112]]], ["Notably, they lack a history of chilblains or Raynaud phenomenon.", [["chilblains", "DISEASE", 32, 42], ["Raynaud phenomenon", "DISEASE", 46, 64], ["chilblains", "GENE_OR_GENE_PRODUCT", 32, 42], ["chilblains", "PROBLEM", 32, 42], ["Raynaud phenomenon", "PROBLEM", 46, 64], ["Raynaud phenomenon", "OBSERVATION", 46, 64]]], ["In the case series reported by Recalcati the eruptions resolved after 2-4 weeks without any treatment.", [["eruptions", "DISEASE", 45, 54], ["the eruptions", "PROBLEM", 41, 54], ["any treatment", "TREATMENT", 88, 101], ["eruptions", "OBSERVATION", 45, 54]]], ["26 Bouaziz et al. described chilblain like lesions in two patients, one presenting also Raynaud's phenomenon.", [["chilblain like lesions", "ANATOMY", 28, 50], ["Raynaud's phenomenon", "DISEASE", 88, 108], ["chilblain like lesions", "CANCER", 28, 50], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["chilblain like lesions", "PROBLEM", 28, 50], ["Raynaud's phenomenon", "PROBLEM", 88, 108], ["lesions", "OBSERVATION", 43, 50], ["two patients", "OBSERVATION_MODIFIER", 54, 66], ["Raynaud", "OBSERVATION", 88, 95]]], ["27 A 19% prevalence of chilblain-like lesions was documented in the Spanish series.", [["chilblain-like lesions", "ANATOMY", 23, 45], ["chilblain-like lesions", "CANCER", 23, 45], ["chilblain-like lesions", "PROBLEM", 23, 45], ["lesions", "OBSERVATION", 38, 45]]], ["14 Histology shows a superficial and deep angiocentric and eccrinotropic lymphocytic infiltrate with some papillary dermal edema, vacuolar degeneration of the basal layer and lymphocytic exocytosis to the epidermis andAccepted ArticleThis article is protected by copyright.", [["angiocentric", "ANATOMY", 42, 54], ["eccrinotropic lymphocytic infiltrate", "ANATOMY", 59, 95], ["papillary dermal edema", "ANATOMY", 106, 128], ["vacuolar", "ANATOMY", 130, 138], ["basal layer", "ANATOMY", 159, 170], ["lymphocytic", "ANATOMY", 175, 186], ["epidermis", "ANATOMY", 205, 214], ["dermal edema", "DISEASE", 116, 128], ["angiocentric", "CANCER", 42, 54], ["papillary dermal edema", "PATHOLOGICAL_FORMATION", 106, 128], ["vacuolar", "CELLULAR_COMPONENT", 130, 138], ["basal layer", "CELLULAR_COMPONENT", 159, 170], ["epidermis", "TISSUE", 205, 214], ["Histology", "TEST", 3, 12], ["a superficial and deep angiocentric and eccrinotropic lymphocytic infiltrate", "PROBLEM", 19, 95], ["some papillary dermal edema", "PROBLEM", 101, 128], ["vacuolar degeneration of the basal layer", "PROBLEM", 130, 170], ["lymphocytic exocytosis", "PROBLEM", 175, 197], ["superficial", "OBSERVATION_MODIFIER", 21, 32], ["deep", "ANATOMY_MODIFIER", 37, 41], ["angiocentric", "OBSERVATION", 42, 54], ["eccrinotropic", "OBSERVATION_MODIFIER", 59, 72], ["lymphocytic infiltrate", "OBSERVATION", 73, 95], ["some", "OBSERVATION_MODIFIER", 101, 105], ["papillary", "OBSERVATION_MODIFIER", 106, 115], ["dermal", "OBSERVATION_MODIFIER", 116, 122], ["edema", "OBSERVATION", 123, 128], ["vacuolar degeneration", "OBSERVATION", 130, 151], ["basal", "ANATOMY_MODIFIER", 159, 164], ["layer", "ANATOMY_MODIFIER", 165, 170], ["lymphocytic exocytosis", "OBSERVATION", 175, 197], ["epidermis", "ANATOMY", 205, 214]]], ["All rights reserved acrosyringia.", [["acrosyringia", "DISEASE", 20, 32], ["acrosyringia", "PROBLEM", 20, 32], ["acrosyringia", "OBSERVATION", 20, 32]]], ["14 A puzzling finding in patients with chilblain-like lesions is the low percentage of positivity to PCR for SARS-CoV-2.", [["chilblain-like lesions", "ANATOMY", 39, 61], ["SARS", "DISEASE", 109, 113], ["patients", "ORGANISM", 25, 33], ["chilblain-like lesions", "CANCER", 39, 61], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 109, 119], ["patients", "SPECIES", 25, 33], ["SARS-CoV", "SPECIES", 109, 117], ["A puzzling finding", "PROBLEM", 3, 21], ["chilblain-like lesions", "PROBLEM", 39, 61], ["PCR", "TEST", 101, 104], ["SARS", "TEST", 109, 113], ["CoV", "TEST", 114, 117], ["lesions", "OBSERVATION", 54, 61], ["low percentage", "OBSERVATION_MODIFIER", 69, 83]]], ["In one study on children and adolescents, only 1 of 19 patients was tested positive.", [["children", "ORGANISM", 16, 24], ["adolescents", "ORGANISM", 29, 40], ["patients", "ORGANISM", 55, 63], ["children", "SPECIES", 16, 24], ["adolescents", "SPECIES", 29, 40], ["patients", "SPECIES", 55, 63]]], ["28 In a similar study on mostly paediatric patients, none of the 19 tested patients resulted positive.", [["patients", "ORGANISM", 43, 51], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 43, 51], ["patients", "SPECIES", 75, 83], ["a similar study", "TEST", 6, 21]]], ["29 This could be explained by the likely lower sensitivity of PCR for SARS-CoV-2 in mild cases and in children, possibly because of a low viral load.", [["SARS", "DISEASE", 70, 74], ["SARS-CoV-2", "ORGANISM", 70, 80], ["children", "ORGANISM", 102, 110], ["children", "SPECIES", 102, 110], ["SARS-CoV", "SPECIES", 70, 78], ["lower sensitivity of PCR", "PROBLEM", 41, 65], ["SARS", "PROBLEM", 70, 74], ["CoV", "TEST", 75, 78], ["mild cases", "PROBLEM", 84, 94], ["a low viral load", "PROBLEM", 132, 148], ["mild", "OBSERVATION_MODIFIER", 84, 88], ["cases", "OBSERVATION", 89, 94], ["low viral load", "OBSERVATION", 134, 148]]], ["30 Otherwise, chilblain-like lesions could represent a late event in the disease course and PCR could become negative when assessed.Purpuric/petechial lesionsA wide spectrum of purpuric and petechial lesions has been described as possible manifestations associated with SARS-CoV-2 infection.", [["chilblain-like lesions", "ANATOMY", 14, 36], ["petechial", "ANATOMY", 141, 150], ["purpuric", "ANATOMY", 177, 185], ["petechial lesions", "ANATOMY", 190, 207], ["purpuric", "DISEASE", 177, 185], ["SARS-CoV-2 infection", "DISEASE", 270, 290], ["chilblain-like lesions", "CANCER", 14, 36], ["petechial lesionsA", "PATHOLOGICAL_FORMATION", 141, 159], ["purpuric", "PATHOLOGICAL_FORMATION", 177, 185], ["petechial lesions", "PATHOLOGICAL_FORMATION", 190, 207], ["SARS-CoV-2", "ORGANISM", 270, 280], ["SARS-CoV", "SPECIES", 270, 278], ["chilblain-like lesions", "PROBLEM", 14, 36], ["a late event", "PROBLEM", 53, 65], ["PCR", "TEST", 92, 95], ["Purpuric/petechial lesionsA", "PROBLEM", 132, 159], ["purpuric", "PROBLEM", 177, 185], ["petechial lesions", "PROBLEM", 190, 207], ["manifestations", "PROBLEM", 239, 253], ["SARS", "PROBLEM", 270, 274], ["CoV-2 infection", "PROBLEM", 275, 290], ["lesions", "OBSERVATION", 29, 36], ["could represent", "UNCERTAINTY", 37, 52], ["late", "OBSERVATION_MODIFIER", 55, 59], ["petechial", "OBSERVATION_MODIFIER", 141, 150], ["purpuric", "OBSERVATION_MODIFIER", 177, 185], ["petechial", "OBSERVATION_MODIFIER", 190, 199], ["lesions", "OBSERVATION", 200, 207], ["SARS", "OBSERVATION", 270, 274], ["CoV", "OBSERVATION_MODIFIER", 275, 278], ["infection", "OBSERVATION", 281, 290]]], ["They appear at any time during the COVID-19 course, they are localized on the trunk, buttock, limbs, typically in adult patients and could be associated with symptoms such as a burning sensation.", [["trunk", "ANATOMY", 78, 83], ["buttock", "ANATOMY", 85, 92], ["limbs", "ANATOMY", 94, 99], ["burning sensation", "DISEASE", 177, 194], ["trunk", "ORGANISM_SUBDIVISION", 78, 83], ["buttock", "ORGANISM_SUBDIVISION", 85, 92], ["limbs", "ORGANISM_SUBDIVISION", 94, 99], ["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128], ["symptoms", "PROBLEM", 158, 166], ["a burning sensation", "PROBLEM", 175, 194], ["trunk", "ANATOMY", 78, 83], ["buttock", "ANATOMY", 85, 92], ["limbs", "ANATOMY", 94, 99]]], ["These lesions may cause difficulties with differential diagnosis.", [["lesions", "ANATOMY", 6, 13], ["lesions", "PATHOLOGICAL_FORMATION", 6, 13], ["These lesions", "PROBLEM", 0, 13], ["lesions", "OBSERVATION", 6, 13]]], ["Indeed, in Thailand a COVID-19 related skin rash with petechiae was initially misdiagnosed as Dengue.", [["skin", "ANATOMY", 39, 43], ["petechiae", "ANATOMY", 54, 63], ["skin rash", "DISEASE", 39, 48], ["petechiae", "DISEASE", 54, 63], ["Dengue", "DISEASE", 94, 100], ["skin", "ORGAN", 39, 43], ["petechiae", "PATHOLOGICAL_FORMATION", 54, 63], ["skin rash", "PROBLEM", 39, 48], ["petechiae", "PROBLEM", 54, 63], ["Dengue", "PROBLEM", 94, 100], ["skin", "ANATOMY", 39, 43], ["rash", "OBSERVATION", 44, 48], ["petechiae", "OBSERVATION", 54, 63]]], ["31 Jimenez-Cauhe et al. 32 described a patient with erythemato-purpuric, millimetric, coalescing macules in flexural regions.", [["millimetric", "ANATOMY", 73, 84], ["macules", "ANATOMY", 97, 104], ["macules", "DISEASE", 97, 104], ["patient", "ORGANISM", 39, 46], ["macules", "PATHOLOGICAL_FORMATION", 97, 104], ["patient", "SPECIES", 39, 46], ["erythemato-purpuric", "PROBLEM", 52, 71], ["coalescing macules in flexural regions", "PROBLEM", 86, 124], ["purpuric", "OBSERVATION", 63, 71], ["coalescing", "OBSERVATION_MODIFIER", 86, 96], ["macules", "OBSERVATION", 97, 104], ["flexural", "ANATOMY_MODIFIER", 108, 116], ["regions", "ANATOMY_MODIFIER", 117, 124]]], ["In this case the rash appeared after three days he had started a therapy with hydroxychloroquine and lopinavr/ritonavir.Kawasaki DiseaseVery recently, an association between SARS-CoV-19 and Kawasaki syndrome has been reported, 37-38 an acute vasculitis of childhood, which can complicate with heart disease, mostly in developed countries.", [["heart", "ANATOMY", 293, 298], ["rash", "DISEASE", 17, 21], ["hydroxychloroquine", "CHEMICAL", 78, 96], ["lopinavr/ritonavir", "CHEMICAL", 101, 119], ["Kawasaki DiseaseVery", "DISEASE", 120, 140], ["Kawasaki syndrome", "DISEASE", 190, 207], ["vasculitis", "DISEASE", 242, 252], ["heart disease", "DISEASE", 293, 306], ["hydroxychloroquine", "CHEMICAL", 78, 96], ["lopinavr", "CHEMICAL", 101, 109], ["ritonavir", "CHEMICAL", 110, 119], ["rash", "PATHOLOGICAL_FORMATION", 17, 21], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 78, 96], ["lopinavr", "SIMPLE_CHEMICAL", 101, 109], ["ritonavir", "SIMPLE_CHEMICAL", 110, 119], ["SARS-CoV-19", "ORGANISM", 174, 185], ["heart", "ORGAN", 293, 298], ["SARS-CoV-19", "SPECIES", 174, 185], ["the rash", "PROBLEM", 13, 21], ["a therapy", "TREATMENT", 63, 72], ["hydroxychloroquine", "TREATMENT", 78, 96], ["lopinavr", "TREATMENT", 101, 109], ["ritonavir", "TREATMENT", 110, 119], ["SARS", "TEST", 174, 178], ["CoV", "TEST", 179, 182], ["Kawasaki syndrome", "PROBLEM", 190, 207], ["an acute vasculitis", "PROBLEM", 233, 252], ["heart disease", "PROBLEM", 293, 306], ["acute", "OBSERVATION_MODIFIER", 236, 241], ["vasculitis", "OBSERVATION", 242, 252], ["heart", "ANATOMY", 293, 298], ["disease", "OBSERVATION", 299, 306]]], ["Such an association may corroborate the occurrence of an endothelial damage associated with SARS-CoV-19 infection.Urticaria-like patternThe urticarial-like pattern has been described as a slightly pruritic disseminated erythematous skin rash that healed in few days.", [["endothelial", "ANATOMY", 57, 68], ["skin", "ANATOMY", 232, 236], ["endothelial damage", "DISEASE", 57, 75], ["SARS-CoV-19 infection", "DISEASE", 92, 113], ["Urticaria", "DISEASE", 114, 123], ["urticarial", "DISEASE", 140, 150], ["skin rash", "DISEASE", 232, 241], ["endothelial", "TISSUE", 57, 68], ["SARS-CoV-19", "ORGANISM", 92, 103], ["skin", "ORGAN", 232, 236], ["SARS-CoV-19", "SPECIES", 92, 103], ["an endothelial damage", "PROBLEM", 54, 75], ["SARS", "PROBLEM", 92, 96], ["CoV-19 infection", "PROBLEM", 97, 113], ["Urticaria", "PROBLEM", 114, 123], ["The urticarial-like pattern", "PROBLEM", 136, 163], ["a slightly pruritic disseminated erythematous skin rash", "PROBLEM", 186, 241], ["endothelial", "ANATOMY", 57, 68], ["damage", "OBSERVATION", 69, 75], ["infection", "OBSERVATION", 104, 113], ["urticarial", "OBSERVATION", 140, 150], ["like pattern", "OBSERVATION_MODIFIER", 151, 163], ["slightly", "OBSERVATION_MODIFIER", 188, 196], ["pruritic", "OBSERVATION_MODIFIER", 197, 205], ["disseminated", "OBSERVATION_MODIFIER", 206, 218], ["erythematous", "OBSERVATION_MODIFIER", 219, 231], ["skin", "ANATOMY", 232, 236], ["rash", "OBSERVATION", 237, 241], ["healed", "OBSERVATION_MODIFIER", 247, 253]]], ["40 In the study by Galvan Casas et al.Accepted ArticleThis article is protected by copyright.", [["the study", "TEST", 6, 15]]], ["All rights reserved Distinct cutaneous clinical patterns have been associated with COVID-19.", [["cutaneous", "ANATOMY", 29, 38], ["COVID-19", "DNA", 83, 91], ["COVID", "TEST", 83, 88], ["Distinct", "OBSERVATION_MODIFIER", 20, 28], ["cutaneous", "OBSERVATION", 29, 38]]], ["They appear at different times in the disease course, and are associated with different duration, severity and prognosis.", [["disease", "OBSERVATION", 38, 45]]], ["The different patterns usually do not coexist in the same patient and patients who develop more than one pattern are very uncommon.", [["patient", "ORGANISM", 58, 65], ["patients", "ORGANISM", 70, 78], ["patient", "SPECIES", 58, 65], ["patients", "SPECIES", 70, 78], ["very", "OBSERVATION_MODIFIER", 117, 121], ["uncommon", "OBSERVATION", 122, 130]]], ["14 Among exanthema patterns, varicella-like type is an early and quite specific skin manifestation of SARS-CoV-2 infection and could therefore represent a useful clue in asymptomatic or mild symptomatic patients.", [["skin", "ANATOMY", 80, 84], ["exanthema", "DISEASE", 9, 18], ["varicella-like type", "DISEASE", 29, 48], ["SARS-CoV-2 infection", "DISEASE", 102, 122], ["skin", "ORGAN", 80, 84], ["SARS-CoV-2", "ORGANISM", 102, 112], ["patients", "ORGANISM", 203, 211], ["patients", "SPECIES", 203, 211], ["SARS-CoV-2", "SPECIES", 102, 112], ["Among exanthema patterns", "PROBLEM", 3, 27], ["varicella", "PROBLEM", 29, 38], ["SARS", "PROBLEM", 102, 106], ["CoV-2 infection", "PROBLEM", 107, 122], ["a useful clue in asymptomatic or mild symptomatic patients", "PROBLEM", 153, 211], ["varicella", "OBSERVATION", 29, 38], ["like type", "OBSERVATION_MODIFIER", 39, 48], ["SARS", "OBSERVATION", 102, 106], ["infection", "OBSERVATION", 113, 122], ["mild", "OBSERVATION_MODIFIER", 186, 190], ["symptomatic", "OBSERVATION_MODIFIER", 191, 202]]], ["13 It may be distinguished from a typical varicella exanthema since it is characterized by the presence of papules (which do not always evolve into vesicles), and histologically is not associated with a large intraepidermal blister, with only few acantholytic keratinocytes showing characteristic viropathic effects.", [["papules", "ANATOMY", 107, 114], ["vesicles", "ANATOMY", 148, 156], ["intraepidermal blister", "ANATOMY", 209, 231], ["keratinocytes", "ANATOMY", 260, 273], ["varicella exanthema", "DISEASE", 42, 61], ["papules", "PATHOLOGICAL_FORMATION", 107, 114], ["vesicles", "CELLULAR_COMPONENT", 148, 156], ["intraepidermal blister", "PATHOLOGICAL_FORMATION", 209, 231], ["keratinocytes", "CELL", 260, 273], ["acantholytic keratinocytes", "CELL_TYPE", 247, 273], ["a typical varicella exanthema", "PROBLEM", 32, 61], ["papules", "PROBLEM", 107, 114], ["a large intraepidermal blister", "PROBLEM", 201, 231], ["few acantholytic keratinocytes", "PROBLEM", 243, 273], ["characteristic viropathic effects", "PROBLEM", 282, 315], ["may be distinguished", "UNCERTAINTY", 6, 26], ["typical", "OBSERVATION_MODIFIER", 34, 41], ["varicella", "OBSERVATION_MODIFIER", 42, 51], ["exanthema", "OBSERVATION", 52, 61], ["papules", "OBSERVATION", 107, 114], ["not associated with", "UNCERTAINTY", 181, 200], ["large", "OBSERVATION_MODIFIER", 203, 208], ["intraepidermal", "OBSERVATION_MODIFIER", 209, 223], ["blister", "OBSERVATION", 224, 231], ["few", "OBSERVATION_MODIFIER", 243, 246], ["acantholytic", "OBSERVATION_MODIFIER", 247, 259], ["keratinocytes", "OBSERVATION", 260, 273], ["characteristic", "OBSERVATION_MODIFIER", 282, 296], ["viropathic effects", "OBSERVATION", 297, 315]]], ["Moreover, itching is only mild or absent.", [["itching", "DISEASE", 10, 17], ["itching", "PROBLEM", 10, 17], ["itching", "OBSERVATION", 10, 17], ["mild", "OBSERVATION_MODIFIER", 26, 30], ["absent", "OBSERVATION", 34, 40]]], ["13 A Tzank test or Varicella-Zoster PCR may be useful for the differential diagnosis.", [["Varicella", "ORGANISM", 19, 28], ["A Tzank test", "TEST", 3, 15], ["Varicella", "PROBLEM", 19, 28], ["Zoster PCR", "TEST", 29, 39], ["Zoster", "OBSERVATION", 29, 35]]], ["Interestingly, PCR for SARS-CoV-2 from vesicle may show negative results.", [["vesicle", "ANATOMY", 39, 46], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 23, 33], ["vesicle", "CELLULAR_COMPONENT", 39, 46], ["SARS-CoV", "SPECIES", 23, 31], ["PCR", "TEST", 15, 18], ["SARS", "TEST", 23, 27], ["CoV", "TEST", 28, 31], ["negative", "OBSERVATION", 56, 64]]], ["37 This may be related to the fact that PCR assays are not standardized for skin testing or the viral load is too low to be detected.", [["skin", "ANATOMY", 76, 80], ["skin", "ORGAN", 76, 80], ["PCR assays", "TEST", 40, 50], ["skin testing", "TEST", 76, 88], ["the viral load", "TEST", 92, 106], ["may be related to", "UNCERTAINTY", 8, 25], ["viral load", "OBSERVATION", 96, 106]]], ["Nonetheless, this finding suggests that varicella-like vesicles in COVID-19 patients are probably not contagious.", [["varicella-like vesicles", "ANATOMY", 40, 63], ["varicella-like vesicles", "DISEASE", 40, 63], ["varicella-like vesicles", "ORGANISM", 40, 63], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["varicella", "PROBLEM", 40, 49], ["COVID", "TEST", 67, 72], ["varicella", "OBSERVATION", 40, 49], ["probably not", "UNCERTAINTY", 89, 101], ["contagious", "OBSERVATION_MODIFIER", 102, 112]]], ["Other than varicella, differential diagnoses may include dermatologic manifestations of herpes simplex, erythema multiforme, autoimmune bullous diseases such as dermatitis herpetiformis and bullous pemphigoid.Accepted ArticleThis article is protected by copyright.", [["erythema multiforme", "ANATOMY", 104, 123], ["varicella", "DISEASE", 11, 20], ["herpes simplex", "DISEASE", 88, 102], ["erythema multiforme", "DISEASE", 104, 123], ["autoimmune bullous diseases", "DISEASE", 125, 152], ["dermatitis herpetiformis", "DISEASE", 161, 185], ["bullous pemphigoid", "DISEASE", 190, 208], ["herpes simplex", "ORGANISM", 88, 102], ["herpes simplex", "SPECIES", 88, 102], ["varicella", "PROBLEM", 11, 20], ["dermatologic manifestations", "PROBLEM", 57, 84], ["herpes simplex", "PROBLEM", 88, 102], ["erythema multiforme", "PROBLEM", 104, 123], ["autoimmune bullous diseases", "PROBLEM", 125, 152], ["dermatitis herpetiformis", "PROBLEM", 161, 185], ["bullous pemphigoid", "PROBLEM", 190, 208], ["varicella", "OBSERVATION", 11, 20], ["may include", "UNCERTAINTY", 45, 56], ["herpes simplex", "OBSERVATION", 88, 102], ["erythema multiforme", "OBSERVATION", 104, 123], ["autoimmune", "OBSERVATION_MODIFIER", 125, 135], ["bullous", "OBSERVATION", 136, 143], ["dermatitis", "OBSERVATION", 161, 171], ["bullous", "OBSERVATION_MODIFIER", 190, 197], ["pemphigoid", "OBSERVATION", 198, 208]]], ["All rights reserved Urticarial and maculopapular exanthema might not be very helpful for diagnosis, as these are common and may have many different causes.", [["maculopapular", "ANATOMY", 35, 48], ["exanthema", "DISEASE", 49, 58], ["Urticarial", "PROBLEM", 20, 30], ["maculopapular exanthema", "PROBLEM", 35, 58], ["Urticarial", "OBSERVATION", 20, 30], ["maculopapular", "OBSERVATION_MODIFIER", 35, 48], ["exanthema", "OBSERVATION", 49, 58]]], ["Drug reactions may be an important and challenging differential diagnosis.", [["Drug reactions", "PROBLEM", 0, 14]]], ["Other differential diagnoses include acute febrile neutrophilic dermatosis (Sweet syndrome), acute urticaria and erythema multiforme.Accepted ArticleAmong vascular patterns, pseudo-chilblain may look like perniosis, and as they appear late in the disease progression and are less commonly associated with virologic confirmation, it is possible that they are not immediately related with COVID-19.", [["erythema multiforme", "ANATOMY", 113, 132], ["vascular", "ANATOMY", 155, 163], ["febrile neutrophilic dermatosis", "DISEASE", 43, 74], ["Sweet syndrome", "DISEASE", 76, 90], ["acute urticaria", "DISEASE", 93, 108], ["erythema multiforme", "DISEASE", 113, 132], ["perniosis", "DISEASE", 205, 214], ["vascular", "MULTI-TISSUE_STRUCTURE", 155, 163], ["acute febrile neutrophilic dermatosis", "PROBLEM", 37, 74], ["Sweet syndrome", "PROBLEM", 76, 90], ["acute urticaria", "PROBLEM", 93, 108], ["erythema multiforme", "PROBLEM", 113, 132], ["perniosis", "PROBLEM", 205, 214], ["the disease progression", "PROBLEM", 243, 266], ["virologic confirmation", "TEST", 305, 327], ["COVID", "TEST", 387, 392], ["differential diagnoses include", "UNCERTAINTY", 6, 36], ["acute", "OBSERVATION_MODIFIER", 37, 42], ["febrile", "OBSERVATION_MODIFIER", 43, 50], ["neutrophilic dermatosis", "OBSERVATION", 51, 74], ["Sweet syndrome", "OBSERVATION", 76, 90], ["acute", "OBSERVATION_MODIFIER", 93, 98], ["urticaria", "OBSERVATION", 99, 108], ["erythema", "OBSERVATION", 113, 121], ["vascular", "ANATOMY", 155, 163], ["perniosis", "OBSERVATION", 205, 214], ["late", "OBSERVATION_MODIFIER", 235, 239]]], ["25 The differential diagnoses include local trauma, Raynaud phenomenon, acrocyanosis, erythromelalgia and purple toe syndrome associated with oral anticoagulant exposure.", [["oral", "ANATOMY", 142, 146], ["trauma", "DISEASE", 44, 50], ["Raynaud phenomenon", "DISEASE", 52, 70], ["acrocyanosis", "DISEASE", 72, 84], ["erythromelalgia", "DISEASE", 86, 101], ["purple toe syndrome", "DISEASE", 106, 125], ["toe", "ORGANISM_SUBDIVISION", 113, 116], ["oral", "ORGANISM_SUBDIVISION", 142, 146], ["local trauma", "PROBLEM", 38, 50], ["Raynaud phenomenon", "PROBLEM", 52, 70], ["acrocyanosis", "PROBLEM", 72, 84], ["erythromelalgia", "PROBLEM", 86, 101], ["purple toe syndrome", "PROBLEM", 106, 125], ["oral anticoagulant exposure", "TREATMENT", 142, 169], ["differential diagnoses include", "UNCERTAINTY", 7, 37], ["local trauma", "OBSERVATION", 38, 50], ["Raynaud phenomenon", "OBSERVATION", 52, 70], ["acrocyanosis", "OBSERVATION", 72, 84], ["erythromelalgia", "OBSERVATION", 86, 101], ["purple toe syndrome", "OBSERVATION", 106, 125]]], ["Overall, pseudo-chilblain and vesicular lesions may represent the most common and characteristic skin manifestations of COVID-19.", [["vesicular lesions", "ANATOMY", 30, 47], ["skin", "ANATOMY", 97, 101], ["vesicular lesions", "DISEASE", 30, 47], ["COVID-19", "CHEMICAL", 120, 128], ["chilblain", "SIMPLE_CHEMICAL", 16, 25], ["vesicular lesions", "CANCER", 30, 47], ["skin", "ORGAN", 97, 101], ["pseudo-chilblain and vesicular lesions", "PROBLEM", 9, 47], ["COVID", "TEST", 120, 125], ["chilblain", "ANATOMY", 16, 25], ["vesicular", "ANATOMY_MODIFIER", 30, 39], ["lesions", "OBSERVATION", 40, 47], ["may represent", "UNCERTAINTY", 48, 61], ["most common", "OBSERVATION_MODIFIER", 66, 77], ["skin", "ANATOMY", 97, 101], ["manifestations", "OBSERVATION", 102, 116]]], ["However, since pseudo-chilblain lesions more commonly appear later during the disease course and are not associated with severe disease, they might be more useful as epidemiological markers than for diagnosis.", [["chilblain lesions", "ANATOMY", 22, 39], ["chilblain lesions", "PATHOLOGICAL_FORMATION", 22, 39], ["pseudo-chilblain lesions", "PROBLEM", 15, 39], ["severe disease", "PROBLEM", 121, 135], ["epidemiological markers", "TEST", 166, 189], ["chilblain", "ANATOMY", 22, 31], ["lesions", "OBSERVATION", 32, 39], ["not associated with", "UNCERTAINTY", 101, 120], ["severe", "OBSERVATION_MODIFIER", 121, 127], ["disease", "OBSERVATION", 128, 135]]], ["All rights reserved Many issues should be addressed including the dynamic of viral load and its relation with the skin rash.", [["skin", "ANATOMY", 114, 118], ["rash", "DISEASE", 119, 123], ["skin", "ORGAN", 114, 118], ["viral load", "PROBLEM", 77, 87], ["the skin rash", "PROBLEM", 110, 123], ["viral load", "OBSERVATION", 77, 87], ["skin", "ANATOMY", 114, 118], ["rash", "OBSERVATION", 119, 123]]], ["The rash may represent an important clue to determine the optimal timing (before, during, or after the skin rash) to collect the samples for molecular identification.Accepted ArticleAn important question is whether the dermatological manifestations in COVID-19 may have any impact on the prognosis and consequent treatment of the disease.", [["skin", "ANATOMY", 103, 107], ["samples", "ANATOMY", 129, 136], ["rash", "DISEASE", 4, 8], ["COVID-19", "CHEMICAL", 252, 260], ["COVID-19", "CHEMICAL", 252, 260], ["skin", "ORGAN", 103, 107], ["The rash", "PROBLEM", 0, 8], ["the skin rash", "PROBLEM", 99, 112], ["the samples", "TEST", 125, 136], ["molecular identification", "TEST", 141, 165], ["the dermatological manifestations", "PROBLEM", 215, 248], ["the disease", "PROBLEM", 326, 337], ["rash", "OBSERVATION", 4, 8], ["may represent", "UNCERTAINTY", 9, 22], ["skin", "ANATOMY", 103, 107], ["disease", "OBSERVATION", 330, 337]]], ["In this regard, it is unclear if the cutaneous manifestations of SARS-CoV-2 infection are the result of an aberrant immune response and consequently could predispose to systemic immune mediated diseases.", [["cutaneous", "ANATOMY", 37, 46], ["SARS", "DISEASE", 65, 69], ["infection", "DISEASE", 76, 85], ["SARS-CoV-2", "ORGANISM", 65, 75], ["SARS-CoV", "SPECIES", 65, 73], ["the cutaneous manifestations", "PROBLEM", 33, 61], ["SARS", "PROBLEM", 65, 69], ["CoV-2 infection", "PROBLEM", 70, 85], ["an aberrant immune response", "PROBLEM", 104, 131], ["systemic immune mediated diseases", "PROBLEM", 169, 202], ["SARS", "OBSERVATION", 65, 69], ["aberrant", "OBSERVATION_MODIFIER", 107, 115], ["immune response", "OBSERVATION", 116, 131]]], ["43 One may argue that the immunological response may sustain, not only an acute inflammatory reaction, but also the development of a late/chronic phase of an autoimmune post-infection process characterized by the absence of the infectious agent.", [["an acute inflammatory reaction", "PROBLEM", 71, 101], ["a late/chronic phase", "PROBLEM", 131, 151], ["an autoimmune post-infection process", "PROBLEM", 155, 191], ["the infectious agent", "PROBLEM", 224, 244], ["acute", "OBSERVATION_MODIFIER", 74, 79], ["inflammatory", "OBSERVATION", 80, 92], ["chronic phase", "OBSERVATION_MODIFIER", 138, 151], ["autoimmune post-infection", "OBSERVATION", 158, 183], ["infectious", "OBSERVATION", 228, 238]]], ["In this case, the mechanisms which might be operative may include molecular mimicry and/or epitope spreading and the induction of an autoimmune process related to concomitant host and environmental factors.", [["molecular mimicry", "PROBLEM", 66, 83], ["epitope spreading", "PROBLEM", 91, 108], ["an autoimmune process", "PROBLEM", 130, 151], ["autoimmune", "OBSERVATION", 133, 143]]], ["45 Lastly, other skin manifestations to be considered are the adverse drug reactions to the drugs prescribed for the treatment of COVID-19 including hydroxychloroquine ( Figure 2 ).Accepted ArticleWhether SARS-CoV-2 infection can directly cause a worsening of pre-existing chronic inflammatory diseases such as psoriasis or atopic dermatitis remains to be determined.Accepted ArticleDermatology's outlook in the COVID-19 pandemic is multidimensional.", [["skin", "ANATOMY", 17, 21], ["COVID-19", "CHEMICAL", 130, 138], ["hydroxychloroquine", "CHEMICAL", 149, 167], ["infection", "DISEASE", 216, 225], ["psoriasis", "DISEASE", 311, 320], ["atopic dermatitis", "DISEASE", 324, 341], ["COVID-19", "CHEMICAL", 130, 138], ["hydroxychloroquine", "CHEMICAL", 149, 167], ["skin", "ORGAN", 17, 21], ["COVID-19", "SIMPLE_CHEMICAL", 130, 138], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 149, 167], ["ArticleWhether SARS-CoV-2", "ORGANISM", 190, 215], ["other skin manifestations", "PROBLEM", 11, 36], ["the adverse drug reactions", "PROBLEM", 58, 84], ["the drugs", "TREATMENT", 88, 97], ["COVID", "TREATMENT", 130, 135], ["hydroxychloroquine ( Figure", "TREATMENT", 149, 176], ["CoV-2 infection", "PROBLEM", 210, 225], ["pre-existing chronic inflammatory diseases", "PROBLEM", 260, 302], ["psoriasis", "PROBLEM", 311, 320], ["atopic dermatitis", "PROBLEM", 324, 341], ["skin", "ANATOMY", 17, 21], ["infection", "OBSERVATION", 216, 225], ["worsening", "OBSERVATION_MODIFIER", 247, 256], ["pre-existing", "OBSERVATION_MODIFIER", 260, 272], ["chronic", "OBSERVATION_MODIFIER", 273, 280], ["inflammatory", "OBSERVATION", 281, 293], ["psoriasis", "OBSERVATION", 311, 320], ["atopic dermatitis", "OBSERVATION", 324, 341]]], ["It is important to make clinicians aware of the spectrum of dermatological manifestations of SARS-CoV-2 infection, improving viral testing and clinical management.", [["SARS-CoV-2 infection", "DISEASE", 93, 113], ["SARS-CoV-2", "ORGANISM", 93, 103], ["SARS-CoV-2", "SPECIES", 93, 103], ["dermatological manifestations", "PROBLEM", 60, 89], ["SARS", "PROBLEM", 93, 97], ["CoV-2 infection", "PROBLEM", 98, 113], ["viral testing", "TEST", 125, 138], ["clinical management", "TREATMENT", 143, 162], ["infection", "OBSERVATION", 104, 113]]]], "PMC7152049": [["IntroductionThe majority of emerging infectious diseases are zoonotic, and most originate in wild animals.1 The rate of emerging disease has increased significantly over the past few decades, and the majority of emerging pathogens are RNA viruses.", [["infectious diseases", "DISEASE", 37, 56], ["emerging infectious diseases", "PROBLEM", 28, 56], ["emerging disease", "PROBLEM", 120, 136], ["emerging pathogens", "PROBLEM", 212, 230], ["RNA viruses", "PROBLEM", 235, 246], ["majority", "OBSERVATION_MODIFIER", 16, 24], ["infectious", "OBSERVATION", 37, 47], ["emerging", "OBSERVATION_MODIFIER", 120, 128], ["disease", "OBSERVATION", 129, 136], ["increased", "OBSERVATION_MODIFIER", 141, 150], ["significantly", "OBSERVATION_MODIFIER", 151, 164], ["pathogens", "OBSERVATION", 221, 230], ["RNA viruses", "OBSERVATION", 235, 246]]], ["These are distinctive in that they have the ability to mutate rapidly compared with DNA viruses and bacteria, allowing them to adapt to new hosts and spread more effectively.2 Little is understood about the dynamics of zoonotic viruses in their natural reservoirs, yet it is becoming clear that anthropogenic environmental change is driving the spillover of pathogens from wildlife populations into domestic livestock and humans.", [["zoonotic viruses", "DISEASE", 219, 235], ["DNA", "CELLULAR_COMPONENT", 84, 87], ["humans", "ORGANISM", 422, 428], ["humans", "SPECIES", 422, 428], ["humans", "SPECIES", 422, 428], ["DNA viruses", "PROBLEM", 84, 95], ["bacteria", "PROBLEM", 100, 108], ["zoonotic viruses", "PROBLEM", 219, 235], ["distinctive", "OBSERVATION_MODIFIER", 10, 21], ["anthropogenic", "OBSERVATION", 295, 308]]], ["Activities such as urbanization, agricultural intensification, and global travel and trade are expanding the interface between people, livestock, and wildlife, providing continuous opportunities for pathogens to spill over into human populations and then move around the world.3 Viral spillover between wildlife and domestic animals or humans probably occurs more frequently than is recognized, owing to limited or poor surveillance systems.4 Zoonotic disease emergence is most likely to occur in regions where biodiversity and human population density are high and where human activities that alter the environment\u2014such as urbanization, agricultural expansion, and deforestation\u2014are most intensive.2, 5", [["people", "ORGANISM", 127, 133], ["human", "ORGANISM", 228, 233], ["humans", "ORGANISM", 336, 342], ["human", "ORGANISM", 528, 533], ["human", "ORGANISM", 572, 577], ["people", "SPECIES", 127, 133], ["human", "SPECIES", 228, 233], ["humans", "SPECIES", 336, 342], ["human", "SPECIES", 528, 533], ["human", "SPECIES", 572, 577], ["human", "SPECIES", 228, 233], ["humans", "SPECIES", 336, 342], ["human", "SPECIES", 528, 533], ["human", "SPECIES", 572, 577], ["agricultural intensification", "TREATMENT", 33, 61], ["pathogens", "PROBLEM", 199, 208], ["Viral spillover", "PROBLEM", 279, 294], ["4 Zoonotic disease emergence", "PROBLEM", 441, 469], ["human population density", "PROBLEM", 528, 552], ["agricultural expansion", "PROBLEM", 638, 660], ["spillover", "OBSERVATION", 285, 294], ["Zoonotic", "OBSERVATION_MODIFIER", 443, 451], ["disease", "OBSERVATION", 452, 459], ["most likely", "UNCERTAINTY", 473, 484], ["high", "OBSERVATION_MODIFIER", 557, 561]]]], "4d161175fd0d94b17314b07edb529f4616af75a6": [["D. T6TH, Limnologieal Institute, Slovak Academy of Sciences, Bratislava.Changes o] Biosynthetic Activity o]Cells of Escherichia coli B labeled during growth in a synthetic medium containing mineral compounds, glucose and ammonium sulphate (SyB) and 14C-valine and transferred after washing to a medium without a carbon source (SyBC-) or without carbon and nitrogen sources (SyBC-N-) increased the number of counts per 1 ml of the suspension during first 8 hours of the exposure.", [["Cells", "ANATOMY", 107, 112], ["glucose", "CHEMICAL", 209, 216], ["ammonium sulphate", "CHEMICAL", 221, 238], ["SyB", "CHEMICAL", 240, 243], ["14C-valine", "CHEMICAL", 249, 259], ["carbon", "CHEMICAL", 312, 318], ["carbon and nitrogen", "CHEMICAL", 345, 364], ["SyBC-N", "CHEMICAL", 374, 380], ["glucose", "CHEMICAL", 209, 216], ["ammonium sulphate", "CHEMICAL", 221, 238], ["SyB", "CHEMICAL", 240, 243], ["14C-valine", "CHEMICAL", 249, 259], ["carbon", "CHEMICAL", 312, 318], ["carbon", "CHEMICAL", 345, 351], ["nitrogen", "CHEMICAL", 356, 364], ["Escherichia coli B", "ORGANISM", 116, 134], ["mineral compounds", "SIMPLE_CHEMICAL", 190, 207], ["glucose", "SIMPLE_CHEMICAL", 209, 216], ["ammonium sulphate", "SIMPLE_CHEMICAL", 221, 238], ["SyB", "SIMPLE_CHEMICAL", 240, 243], ["14C-valine", "SIMPLE_CHEMICAL", 249, 259], ["SyBC", "SIMPLE_CHEMICAL", 327, 331], ["carbon", "SIMPLE_CHEMICAL", 345, 351], ["nitrogen", "SIMPLE_CHEMICAL", 356, 364], ["SyBC-N", "SIMPLE_CHEMICAL", 374, 380], ["Escherichia coli", "SPECIES", 116, 132], ["Escherichia coli", "SPECIES", 116, 132], ["Escherichia coli", "PROBLEM", 116, 132], ["a synthetic medium containing mineral compounds", "TREATMENT", 160, 207], ["glucose and ammonium sulphate", "TREATMENT", 209, 238], ["valine", "TREATMENT", 253, 259], ["a carbon source", "TEST", 310, 325], ["SyBC", "TEST", 327, 331], ["carbon and nitrogen sources", "PROBLEM", 345, 372], ["SyBC", "TEST", 374, 378], ["the suspension", "TREATMENT", 426, 440], ["Escherichia coli", "OBSERVATION", 116, 132]]], ["After this time interval counts per min decrease again at a practically identical rate in both media.", [["interval counts", "TEST", 16, 31], ["decrease", "OBSERVATION_MODIFIER", 40, 48]]], ["A differentiated decrease can be observed after about 48 hours, when the decrease of the number of counts slows down in samples taken from the SyBC-.", [["samples", "ANATOMY", 120, 127], ["SyBC", "GENE_OR_GENE_PRODUCT", 143, 147], ["SyBC", "PROTEIN", 143, 147], ["A differentiated decrease", "PROBLEM", 0, 25], ["the SyBC", "TEST", 139, 147], ["differentiated", "OBSERVATION_MODIFIER", 2, 16], ["decrease", "OBSERVATION", 17, 25], ["decrease", "OBSERVATION_MODIFIER", 73, 81]]], ["After a transfer of cells of Escherichia cell exposed in the mineral medium at 37~ to the SyB medium with radioactive precursors the incorporation of both valine and adenine is decreased, depending on time of the starvation.", [["cells", "ANATOMY", 20, 25], ["cell", "ANATOMY", 41, 45], ["valine", "CHEMICAL", 155, 161], ["adenine", "CHEMICAL", 166, 173], ["valine", "CHEMICAL", 155, 161], ["adenine", "CHEMICAL", 166, 173], ["cells", "CELL", 20, 25], ["Escherichia cell", "CELL", 29, 45], ["valine", "AMINO_ACID", 155, 161], ["adenine", "SIMPLE_CHEMICAL", 166, 173], ["Escherichia cell", "PROBLEM", 29, 45], ["radioactive precursors", "TREATMENT", 106, 128], ["both valine", "TREATMENT", 150, 161], ["adenine", "TREATMENT", 166, 173], ["Escherichia cell", "OBSERVATION", 29, 45], ["radioactive precursors", "OBSERVATION", 106, 128], ["both valine", "OBSERVATION", 150, 161], ["decreased", "OBSERVATION_MODIFIER", 177, 186]]], ["A similar phenomenon was observed even when these cells were transferred to other cultivation media, e.g. meat-peptone broth.Values of radioactivity in individual componentsof the suspension were compared in cells of Escherichia cell B cultivated in the SyB medium and pulse-labeled with 14C-valineo The content of radioactive compounds in the supernatant increases depending on the time of starvation, whereas a decrease is observed in the sediment.", [["cells", "ANATOMY", 50, 55], ["cells", "ANATOMY", 208, 213], ["cell B", "ANATOMY", 229, 235], ["supernatant", "ANATOMY", 344, 355], ["meat-peptone", "CHEMICAL", 106, 118], ["14C-valineo", "CHEMICAL", 288, 299], ["14C-valineo", "CHEMICAL", 288, 299], ["cells", "CELL", 50, 55], ["meat", "ORGANISM_SUBDIVISION", 106, 110], ["cells", "CELL", 208, 213], ["Escherichia cell B", "CELL", 217, 235], ["14C-valineo", "SIMPLE_CHEMICAL", 288, 299], ["Escherichia cell B", "CELL_LINE", 217, 235], ["A similar phenomenon", "PROBLEM", 0, 20], ["Values", "TEST", 125, 131], ["radioactivity", "TEST", 135, 148], ["individual componentsof the suspension", "TREATMENT", 152, 190], ["Escherichia cell B", "PROBLEM", 217, 235], ["pulse", "TEST", 269, 274], ["radioactive compounds", "TREATMENT", 315, 336], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["phenomenon", "OBSERVATION", 10, 20], ["radioactivity", "OBSERVATION_MODIFIER", 135, 148], ["suspension", "OBSERVATION_MODIFIER", 180, 190], ["Escherichia cell", "OBSERVATION", 217, 233], ["content", "OBSERVATION_MODIFIER", 304, 311], ["radioactive compounds", "OBSERVATION", 315, 336], ["sediment", "OBSERVATION", 441, 449]]], ["The sum of both values at a given time is close to the state found in samples of the corresponding suspensions.", [["samples", "ANATOMY", 70, 77]]], ["Labelled compounds of the non-protein nature were found both in the medium and cells.", [["cells", "ANATOMY", 79, 84], ["cells", "CELL", 79, 84]]], ["Comparison of concentrations of labelled compounds found in TCA, precipitates and without precipitation makes it possible to evaluate the extent of degradation of cellular proteins as well as lysis of the studied cells during starvation.Values of radioactivity in individual componentsIt follows from our previous studies that histone added externally to Escherickia cell influences protein synthesis probably at the level of transcription and the mechanism of its action depends on growth phase of the culture.", [["cellular", "ANATOMY", 163, 171], ["cells", "ANATOMY", 213, 218], ["Escherickia cell", "ANATOMY", 355, 371], ["TCA", "CHEMICAL", 60, 63], ["TCA", "CHEMICAL", 60, 63], ["TCA", "SIMPLE_CHEMICAL", 60, 63], ["cellular", "CELL", 163, 171], ["cells", "CELL", 213, 218], ["histone", "GENE_OR_GENE_PRODUCT", 327, 334], ["Escherickia cell", "CELL", 355, 371], ["cellular proteins", "PROTEIN", 163, 180], ["histone", "PROTEIN", 327, 334], ["labelled compounds", "PROBLEM", 32, 50], ["cellular proteins", "PROBLEM", 163, 180], ["lysis", "TREATMENT", 192, 197], ["our previous studies", "TEST", 301, 321], ["Escherickia cell influences protein synthesis", "PROBLEM", 355, 400], ["the culture", "TEST", 499, 510], ["cellular proteins", "OBSERVATION", 163, 180], ["radioactivity", "OBSERVATION_MODIFIER", 247, 260], ["components", "OBSERVATION_MODIFIER", 275, 285]]], ["In this study another model organism, Bacillus cereus, in which individual stages of differentiation are morphologically characterized, was used.", [["Bacillus cereus", "ORGANISM", 38, 53], ["Bacillus cereus", "SPECIES", 38, 53], ["Bacillus cereus", "SPECIES", 38, 53], ["this study", "TEST", 3, 13], ["Bacillus cereus", "PROBLEM", 38, 53], ["Bacillus cereus", "OBSERVATION", 38, 53]]], ["The effect of histone on the early stage of development of the vegetative cell from the spore was studied so far.", [["vegetative cell", "ANATOMY", 63, 78], ["spore", "ANATOMY", 88, 93], ["histone", "GENE_OR_GENE_PRODUCT", 14, 21], ["vegetative cell", "CELL", 63, 78], ["histone", "PROTEIN", 14, 21], ["vegetative cell", "CELL_TYPE", 63, 78], ["the vegetative cell", "PROBLEM", 59, 78], ["histone", "OBSERVATION_MODIFIER", 14, 21], ["vegetative cell", "OBSERVATION", 63, 78]]], ["It was found that during this stage histone inhibits incorporation of 14Cleucine into cellular proteins.", [["cellular", "ANATOMY", 86, 94], ["14Cleucine", "CHEMICAL", 70, 80], ["14Cleucine", "CHEMICAL", 70, 80], ["histone", "GENE_OR_GENE_PRODUCT", 36, 43], ["14Cleucine", "SIMPLE_CHEMICAL", 70, 80], ["cellular", "CELL", 86, 94], ["histone", "PROTEIN", 36, 43], ["14Cleucine", "PROTEIN", 70, 80], ["cellular proteins", "PROTEIN", 86, 103], ["this stage histone", "PROBLEM", 25, 43], ["cellular proteins", "OBSERVATION", 86, 103]]], ["Its effect cannot be removed by adding higher concentrations of certain monovalent or divalent cations.", [["cations", "SIMPLE_CHEMICAL", 95, 102], ["certain monovalent or divalent cations", "TREATMENT", 64, 102], ["divalent cations", "OBSERVATION", 86, 102]]], ["The incorporation of 14C-uracil into the total RNA fraction was substantially inhibited as well.", [["14C-uracil", "CHEMICAL", 21, 31], ["14C-uracil", "CHEMICAL", 21, 31], ["14C-uracil", "SIMPLE_CHEMICAL", 21, 31], ["The incorporation of 14C-uracil", "TREATMENT", 0, 31], ["the total RNA fraction", "TEST", 37, 59]]], ["The results obtained favour the idea that even in this case histone influences protein synthesis at the level of transcription.", [["histone", "GENE_OR_GENE_PRODUCT", 60, 67], ["histone", "PROTEIN", 60, 67], ["protein synthesis", "PROBLEM", 79, 96]]], ["Thus, it can be assumed that the effect of histone in microorganisms is apparently of general validity.", [["histone", "GENE_OR_GENE_PRODUCT", 43, 50], ["histone", "PROTEIN", 43, 50], ["histone in microorganisms", "PROBLEM", 43, 68]]], ["It has already been shown that histone influences protein synthesis in Escherichia eoli and Bacillus cereus.", [["histone", "GENE_OR_GENE_PRODUCT", 31, 38], ["Escherichia eoli", "ORGANISM", 71, 87], ["Bacillus cereus", "ORGANISM", 92, 107], ["histone", "PROTEIN", 31, 38], ["Escherichia eoli", "SPECIES", 71, 87], ["Bacillus cereus", "SPECIES", 92, 107], ["Escherichia eoli", "SPECIES", 71, 87], ["Bacillus cereus", "SPECIES", 92, 107], ["histone influences protein synthesis in Escherichia eoli", "PROBLEM", 31, 87], ["Bacillus cereus", "PROBLEM", 92, 107], ["Escherichia eoli", "OBSERVATION", 71, 87], ["Bacillus cereus", "OBSERVATION", 92, 107]]], ["In addition, it was found that histone can penetrate into the cells of Eseherichia coll.", [["cells", "ANATOMY", 62, 67], ["histone", "GENE_OR_GENE_PRODUCT", 31, 38], ["cells", "CELL", 62, 67], ["histone", "PROTEIN", 31, 38]]], ["Therefore it was of interest to investigate whether the addition of histone to these organisms results also in ultrastructttral changes.", [["histone", "GENE_OR_GENE_PRODUCT", 68, 75], ["histone", "PROTEIN", 68, 75], ["these organisms", "TEST", 79, 94]]], ["Comparison of ultrathin sections of cells of Eseherichia coli in the absence and presence of histone revealed the following differences: (1) In control cells both the cell wall and cytoplasmic membrane are well visible, ribosomes and nuclear structure can be seen in the cytoplasm.Values of radioactivity in individual components(2) Under the influence of histone the inner electron -dense layer of the cell wall is thickned, the cytoplasm is condensed and neither ribosomes nor the nuclear structure are clearly discriminated.", [["sections", "ANATOMY", 24, 32], ["cells", "ANATOMY", 36, 41], ["cells", "ANATOMY", 152, 157], ["cell wall", "ANATOMY", 167, 176], ["cytoplasmic membrane", "ANATOMY", 181, 201], ["ribosomes", "ANATOMY", 220, 229], ["nuclear structure", "ANATOMY", 234, 251], ["cytoplasm", "ANATOMY", 271, 280], ["cell wall", "ANATOMY", 403, 412], ["cytoplasm", "ANATOMY", 430, 439], ["ribosomes", "ANATOMY", 465, 474], ["nuclear", "ANATOMY", 483, 490], ["cells", "CELL", 36, 41], ["Eseherichia coli", "ORGANISM", 45, 61], ["histone", "GENE_OR_GENE_PRODUCT", 93, 100], ["cells", "CELL", 152, 157], ["cell wall", "CELLULAR_COMPONENT", 167, 176], ["cytoplasmic membrane", "CELLULAR_COMPONENT", 181, 201], ["ribosomes", "CELLULAR_COMPONENT", 220, 229], ["nuclear", "CELLULAR_COMPONENT", 234, 241], ["cytoplasm", "ORGANISM_SUBSTANCE", 271, 280], ["histone", "GENE_OR_GENE_PRODUCT", 356, 363], ["cell wall", "CELLULAR_COMPONENT", 403, 412], ["cytoplasm", "ORGANISM_SUBSTANCE", 430, 439], ["ribosomes", "CELLULAR_COMPONENT", 465, 474], ["nuclear", "CELLULAR_COMPONENT", 483, 490], ["histone", "PROTEIN", 93, 100], ["histone", "PROTEIN", 356, 363], ["Eseherichia coli", "SPECIES", 45, 61], ["Eseherichia coli", "SPECIES", 45, 61], ["Eseherichia coli", "PROBLEM", 45, 61], ["histone the inner electron", "TREATMENT", 356, 382], ["cell", "OBSERVATION", 167, 171], ["wall", "ANATOMY_MODIFIER", 172, 176], ["cytoplasmic membrane", "OBSERVATION", 181, 201], ["nuclear structure", "OBSERVATION", 234, 251], ["cytoplasm", "OBSERVATION", 271, 280], ["radioactivity", "OBSERVATION_MODIFIER", 291, 304], ["individual", "OBSERVATION_MODIFIER", 308, 318], ["components", "OBSERVATION_MODIFIER", 319, 329], ["dense", "OBSERVATION_MODIFIER", 384, 389], ["layer", "OBSERVATION_MODIFIER", 390, 395], ["cell wall", "OBSERVATION", 403, 412], ["cytoplasm", "OBSERVATION_MODIFIER", 430, 439], ["condensed", "OBSERVATION_MODIFIER", 443, 452], ["nuclear structure", "OBSERVATION_MODIFIER", 483, 500]]], ["Considerable electron -transparent zones can be observed in this cytoplasm.", [["cytoplasm", "ANATOMY", 65, 74], ["electron", "SIMPLE_CHEMICAL", 13, 21], ["cytoplasm", "ORGANISM_SUBSTANCE", 65, 74], ["Considerable electron -transparent zones", "PROBLEM", 0, 40], ["transparent", "OBSERVATION_MODIFIER", 23, 34], ["zones", "OBSERVATION_MODIFIER", 35, 40]]], ["The following differences were found in Bacillus cereus: (1) After 30 rain of incubation control cells germinate normally and also the beginning of the postgerminative development is normal (i.e. residues of spore envelopes outlast around the swelling protoplast, free exossporium can be clearly seen and individual structures are clearly differentiated in the cytoplasm.Values of radioactivity in individual components(2) In most spores, to which histone was added at the beginning of germination, even the initial phases of germination did not proceed during a 30 rain incubation.", [["cells", "ANATOMY", 97, 102], ["swelling protoplast", "ANATOMY", 243, 262], ["structures", "ANATOMY", 316, 326], ["cytoplasm", "ANATOMY", 361, 370], ["spores", "ANATOMY", 431, 437], ["Bacillus cereus", "ORGANISM", 40, 55], ["cells", "CELL", 97, 102], ["cytoplasm", "ORGANISM_SUBSTANCE", 361, 370], ["histone", "GENE_OR_GENE_PRODUCT", 448, 455], ["histone", "PROTEIN", 448, 455], ["Bacillus cereus", "SPECIES", 40, 55], ["Bacillus cereus", "SPECIES", 40, 55], ["incubation control cells", "TREATMENT", 78, 102], ["spore envelopes outlast", "PROBLEM", 208, 231], ["the swelling protoplast", "PROBLEM", 239, 262], ["a 30 rain incubation", "TREATMENT", 561, 581], ["Bacillus cereus", "OBSERVATION", 40, 55], ["normal", "OBSERVATION", 183, 189], ["swelling protoplast", "OBSERVATION", 243, 262], ["cytoplasm", "OBSERVATION_MODIFIER", 361, 370], ["radioactivity", "OBSERVATION_MODIFIER", 381, 394], ["most spores", "OBSERVATION_MODIFIER", 426, 437]]], ["An undamaged cortex can be observed on the surface of the spore protoplast and the protoplast is not differentiated.", [["cortex", "ANATOMY", 13, 19], ["surface", "ANATOMY", 43, 50], ["spore protoplast", "ANATOMY", 58, 74], ["protoplast", "ANATOMY", 83, 93], ["cortex", "CANCER", 13, 19], ["surface", "CELLULAR_COMPONENT", 43, 50], ["spore protoplast", "CELL", 58, 74], ["undamaged", "OBSERVATION", 3, 12], ["cortex", "ANATOMY_MODIFIER", 13, 19], ["not", "UNCERTAINTY", 97, 100], ["differentiated", "OBSERVATION_MODIFIER", 101, 115]]], ["In a portion of spores the inhibition of germination by histone was not observed.", [["spores", "ANATOMY", 16, 22], ["histone", "GENE_OR_GENE_PRODUCT", 56, 63], ["histone", "PROTEIN", 56, 63]]], ["In both types (non-germinated and partially germinated spores) a fine electron-dense layer at the surface of the exosporium was detected.", [["spores", "ANATOMY", 55, 61], ["surface", "ANATOMY", 98, 105], ["surface", "CELLULAR_COMPONENT", 98, 105], ["exosporium", "GENE_OR_GENE_PRODUCT", 113, 123], ["partially germinated spores", "PROBLEM", 34, 61], ["a fine electron-dense layer", "PROBLEM", 63, 90], ["both types", "OBSERVATION_MODIFIER", 3, 13], ["germinated", "OBSERVATION_MODIFIER", 44, 54], ["spores", "OBSERVATION_MODIFIER", 55, 61], ["fine", "OBSERVATION_MODIFIER", 65, 69], ["electron", "OBSERVATION_MODIFIER", 70, 78], ["dense", "OBSERVATION_MODIFIER", 79, 84], ["layer", "OBSERVATION_MODIFIER", 85, 90], ["surface", "OBSERVATION_MODIFIER", 98, 105], ["exosporium", "OBSERVATION_MODIFIER", 113, 123]]], ["Heat-activated spores (65~ rain) of Bacillus cereus were germinated in a minimal medium which does not facilitate a further development.", [["spores", "ANATOMY", 15, 21], ["Bacillus cereus", "ORGANISM", 36, 51], ["Bacillus cereus", "SPECIES", 36, 51], ["Bacillus cereus", "SPECIES", 36, 51], ["Bacillus cereus", "PROBLEM", 36, 51], ["minimal medium", "OBSERVATION_MODIFIER", 73, 87]]], ["A limited synthesis of proteins and (tested by incorporation of 14C-leucine) and RNA (tested by incorporation of 14C-uracil) took place.", [["14C-leucine", "CHEMICAL", 64, 75], ["14C-uracil", "CHEMICAL", 113, 123], ["14C", "CHEMICAL", 64, 67], ["leucine", "CHEMICAL", 68, 75], ["14C", "CHEMICAL", 113, 116], ["uracil", "CHEMICAL", 117, 123], ["14C-leucine", "SIMPLE_CHEMICAL", 64, 75], ["14C-uracil", "SIMPLE_CHEMICAL", 113, 123], ["A limited synthesis of proteins", "PROBLEM", 0, 31], ["RNA", "TEST", 81, 84]]], ["Synthesis of the cell wall [measured by incorporation of 14C-diaminopimelic acid (dap)] continued for several hours.", [["cell wall", "ANATOMY", 17, 26], ["14C-diaminopimelic acid", "CHEMICAL", 57, 80], ["dap", "CHEMICAL", 82, 85], ["14C-diaminopimelic acid", "CHEMICAL", 57, 80], ["dap", "CHEMICAL", 82, 85], ["cell wall", "TISSUE", 17, 26], ["14C-diaminopimelic acid", "SIMPLE_CHEMICAL", 57, 80], ["dap", "SIMPLE_CHEMICAL", 82, 85], ["the cell wall", "TEST", 13, 26], ["diaminopimelic acid (dap)", "TREATMENT", 61, 86], ["cell", "OBSERVATION", 17, 21], ["wall", "ANATOMY_MODIFIER", 22, 26]]], ["The above mentioned synthetic processes were studied in a medium containing the exudate released during germination of spores and in a fresh medium replacing after the germination the original one.", [["exudate", "ANATOMY", 80, 87], ["spores", "ANATOMY", 119, 125], ["exudate", "ORGANISM_SUBSTANCE", 80, 87], ["the exudate", "PROBLEM", 76, 87], ["a fresh medium", "TREATMENT", 133, 147], ["exudate", "OBSERVATION", 80, 87]]], ["Synthesis of the cell wall was accelerated in the presence of the exudate.", [["cell wall", "ANATOMY", 17, 26], ["exudate", "ANATOMY", 66, 73], ["cell wall", "MULTI-TISSUE_STRUCTURE", 17, 26], ["exudate", "TISSUE", 66, 73], ["Synthesis of the cell wall", "PROBLEM", 0, 26], ["the exudate", "PROBLEM", 62, 73], ["cell wall", "OBSERVATION", 17, 26], ["exudate", "OBSERVATION", 66, 73]]], ["In a limited medium the incorporation of 14C-dap was highly actinomycin D -sensitive and relatively chloramphenicol-resistant.", [["14C-dap", "CHEMICAL", 41, 48], ["actinomycin D", "CHEMICAL", 60, 73], ["chloramphenicol", "CHEMICAL", 100, 115], ["14C", "CHEMICAL", 41, 44], ["actinomycin D", "CHEMICAL", 60, 73], ["chloramphenicol", "CHEMICAL", 100, 115], ["14C-dap", "SIMPLE_CHEMICAL", 41, 48], ["actinomycin D", "SIMPLE_CHEMICAL", 60, 73], ["chloramphenicol", "SIMPLE_CHEMICAL", 100, 115], ["highly actinomycin D -sensitive", "PROBLEM", 53, 84], ["relatively chloramphenicol", "TREATMENT", 89, 115]]], ["The spore exudate accelerated also synthesis of proteins and RNA.", [["spore exudate", "ANATOMY", 4, 17], ["spore exudate", "ORGANISM_SUBSTANCE", 4, 17], ["RNA", "RNA", 61, 64], ["The spore exudate", "PROBLEM", 0, 17], ["synthesis of proteins and RNA", "PROBLEM", 35, 64], ["spore", "OBSERVATION_MODIFIER", 4, 9], ["exudate", "OBSERVATION", 10, 17]]], ["After germination of radioactive spores, the cortical layer of which was prelabeled with 14C-dap, a laC-dap-containing material was released into the medium.", [["spores", "ANATOMY", 33, 39], ["cortical layer", "ANATOMY", 45, 59], ["14C-dap", "CHEMICAL", 89, 96], ["laC-dap", "CHEMICAL", 100, 107], ["14C", "CHEMICAL", 89, 92], ["cortical layer", "MULTI-TISSUE_STRUCTURE", 45, 59], ["14C-dap", "SIMPLE_CHEMICAL", 89, 96], ["laC", "SIMPLE_CHEMICAL", 100, 103], ["germination of radioactive spores", "PROBLEM", 6, 39], ["a laC-dap-containing material", "TREATMENT", 98, 127], ["radioactive spores", "OBSERVATION", 21, 39], ["cortical", "OBSERVATION_MODIFIER", 45, 53], ["layer", "OBSERVATION_MODIFIER", 54, 59], ["laC", "OBSERVATION_MODIFIER", 100, 103], ["medium", "OBSERVATION_MODIFIER", 150, 156]]], ["The incorporation of 14C-dap from the exudate after germination of the labeled spores into germinated unlabeled spores was negligible.", [["exudate", "ANATOMY", 38, 45], ["spores", "ANATOMY", 79, 85], ["spores", "ANATOMY", 112, 118], ["14C-dap", "CHEMICAL", 21, 28], ["14C", "CHEMICAL", 21, 24], ["14C-dap", "SIMPLE_CHEMICAL", 21, 28], ["exudate", "ORGANISM_SUBSTANCE", 38, 45], ["the exudate", "PROBLEM", 34, 45], ["exudate", "OBSERVATION", 38, 45]]], ["The presented results are discussed with respect to a possible reutilization of the exudate components by the germinated spores in a limited medium.On a Possible Rote o] Basic Proteins in Evolution o] the Cell.", [["exudate", "ANATOMY", 84, 91], ["spores", "ANATOMY", 121, 127], ["Cell", "ANATOMY", 205, 209], ["Cell", "CELL", 205, 209], ["the exudate components", "PROBLEM", 80, 102], ["the germinated spores", "PROBLEM", 106, 127], ["exudate", "OBSERVATION", 84, 91], ["germinated", "OBSERVATION_MODIFIER", 110, 120], ["spores", "OBSERVATION_MODIFIER", 121, 127]]], ["V. LIEBL, L. SBJwInstitute of Microbiology, Czechoslovak Academy of Sciences, Prague.On a Possible Rote o] Basic Proteins in Evolution o] the Cell.", [["Cell", "ANATOMY", 142, 146], ["Cell", "CELL", 142, 146]]], ["V. LIEBL, L. SBJwProcaryotic cells, bacterial cells in the first place, are suitable also for studying certain basic yet not fully understood developmental problems.", [["SBJwProcaryotic cells", "ANATOMY", 13, 34], ["cells", "ANATOMY", 46, 51], ["L. SBJwProcaryotic cells", "CELL", 10, 34], ["bacterial cells", "CELL", 36, 51], ["LIEBL, L. SBJwProcaryotic cells", "CELL_LINE", 3, 34], ["bacterial cells", "CELL_TYPE", 36, 51], ["L. SBJwProcaryotic cells", "PROBLEM", 10, 34], ["bacterial cells", "PROBLEM", 36, 51], ["developmental problems", "PROBLEM", 142, 164], ["L.", "OBSERVATION_MODIFIER", 10, 12], ["SBJwProcaryotic cells", "OBSERVATION", 13, 34], ["bacterial cells", "OBSERVATION", 36, 51]]], ["It was found by analysis (mainly electrophoretic) of the bacterial cytoplasm and its components (ribosomes and membranes in particular) that the cytoplasm deprived of ribosomes practically does not contain basic proteins.", [["cytoplasm", "ANATOMY", 67, 76], ["ribosomes", "ANATOMY", 97, 106], ["membranes", "ANATOMY", 111, 120], ["cytoplasm", "ANATOMY", 145, 154], ["ribosomes", "ANATOMY", 167, 176], ["cytoplasm", "ORGANISM_SUBSTANCE", 67, 76], ["ribosomes", "CELLULAR_COMPONENT", 97, 106], ["membranes", "CELLULAR_COMPONENT", 111, 120], ["cytoplasm", "ORGANISM_SUBSTANCE", 145, 154], ["ribosomes", "CELLULAR_COMPONENT", 167, 176], ["ribosomes", "PROTEIN", 97, 106], ["basic proteins", "PROTEIN", 206, 220], ["the bacterial cytoplasm", "PROBLEM", 53, 76], ["its components (ribosomes and membranes", "PROBLEM", 81, 120], ["bacterial cytoplasm", "OBSERVATION", 57, 76], ["components", "OBSERVATION_MODIFIER", 85, 95]]], ["Under physiological conditions cytoplasm thus cannot represent a typical dieomplex coacervate with polyionie linkages.", [["cytoplasm", "ANATOMY", 31, 40], ["polyionie", "CHEMICAL", 99, 108], ["cytoplasm", "ORGANISM_SUBSTANCE", 31, 40], ["polyionie", "SIMPLE_CHEMICAL", 99, 108], ["cannot represent", "UNCERTAINTY", 46, 62]]], ["This coacervate would be unsuitable for complex biochemical processes due to its high viscosity, strong interactions among components, relatively simple structure etc. Cytoplasm is apparently of a more 56 adequate character of a colloid sol of a tricomplex type.", [["This coacervate", "TREATMENT", 0, 15], ["complex biochemical processes", "PROBLEM", 40, 69], ["its high viscosity", "PROBLEM", 77, 95], ["high viscosity", "OBSERVATION_MODIFIER", 81, 95], ["relatively", "OBSERVATION_MODIFIER", 135, 145], ["simple structure", "OBSERVATION_MODIFIER", 146, 162], ["tricomplex type", "OBSERVATION", 246, 261]]], ["Basic proteins are contained in ribosomes and partially in cytoplasmic membranes that can be considered as \"coacervate residues\" in the cell.", [["ribosomes", "ANATOMY", 32, 41], ["cytoplasmic membranes", "ANATOMY", 59, 80], ["cell", "ANATOMY", 136, 140], ["ribosomes", "CELLULAR_COMPONENT", 32, 41], ["cytoplasmic membranes", "CELLULAR_COMPONENT", 59, 80], ["cell", "CELL", 136, 140], ["Basic proteins", "TEST", 0, 14], ["coacervate residues", "PROBLEM", 108, 127], ["proteins", "OBSERVATION", 6, 14], ["cytoplasmic membranes", "OBSERVATION", 59, 80], ["cell", "ANATOMY", 136, 140]]], ["Development of the cell lasting probably for more than four billion years is characterized by a complex developmental differentiation and specialization of both individual macromoleeules, their interactions and functions and multimoleeular systems, cellular structures and the whole cell.", [["cell", "ANATOMY", 19, 23], ["cellular structures", "ANATOMY", 249, 268], ["whole cell", "ANATOMY", 277, 287], ["cell", "CELL", 19, 23], ["macromoleeules", "GENE_OR_GENE_PRODUCT", 172, 186], ["cellular structures", "CELLULAR_COMPONENT", 249, 268], ["cell", "CELL", 283, 287], ["the cell", "PROBLEM", 15, 23], ["a complex developmental differentiation", "PROBLEM", 94, 133], ["both individual macromoleeules", "PROBLEM", 156, 186], ["their interactions and functions and multimoleeular systems", "PROBLEM", 188, 247], ["cell", "OBSERVATION", 19, 23], ["complex", "OBSERVATION_MODIFIER", 96, 103], ["developmental differentiation", "OBSERVATION", 104, 133], ["both", "OBSERVATION_MODIFIER", 156, 160], ["individual macromoleeules", "OBSERVATION", 161, 186], ["whole cell", "OBSERVATION", 277, 287]]], ["Our ideas about the evolution of cellular structures and their coordination functions are experimentally supported by studies on the effect of basic proteins on synthesis of polyadenylie acid by the enzyme polynucleotide-phosphorylase.", [["cellular structures", "ANATOMY", 33, 52], ["polyadenylie acid", "CHEMICAL", 174, 191], ["polynucleotide", "CHEMICAL", 206, 220], ["polyadenylie acid", "CHEMICAL", 174, 191], ["cellular", "CELL", 33, 41], ["polyadenylie acid", "SIMPLE_CHEMICAL", 174, 191], ["polynucleotide-phosphorylase", "GENE_OR_GENE_PRODUCT", 206, 234], ["basic proteins", "PROTEIN", 143, 157], ["enzyme polynucleotide-phosphorylase", "PROTEIN", 199, 234], ["basic proteins", "TREATMENT", 143, 157], ["synthesis of polyadenylie acid", "TREATMENT", 161, 191], ["the enzyme polynucleotide", "TEST", 195, 220], ["cellular structures", "OBSERVATION", 33, 52]]], ["Certain basic proteins, e.g. histone, stimulate synthesis of this polymer forming mostly flocculate or eoacervate complexes that are resistant to ribonuclease.", [["histone", "GENE_OR_GENE_PRODUCT", 29, 36], ["flocculate", "SIMPLE_CHEMICAL", 89, 99], ["ribonuclease", "GENE_OR_GENE_PRODUCT", 146, 158], ["basic proteins", "PROTEIN", 8, 22], ["histone", "PROTEIN", 29, 36], ["flocculate or eoacervate complexes", "PROTEIN", 89, 123], ["ribonuclease", "PROTEIN", 146, 158], ["Certain basic proteins", "PROBLEM", 0, 22], ["this polymer", "PROBLEM", 61, 73], ["eoacervate complexes", "PROBLEM", 103, 123]]], ["In this model multimolecular enzyme system synthesis is favoured and degradation is limited.", [["multimolecular", "OBSERVATION_MODIFIER", 14, 28], ["enzyme system synthesis", "OBSERVATION", 29, 52]]], ["A scheme of a possible evolution from molecules and the coacervate stage to the cell is discussed.", [["cell", "ANATOMY", 80, 84], ["cell", "CELL", 80, 84], ["the coacervate stage", "PROBLEM", 52, 72]]], ["From the evolutionary point of view the cell can be con-~idered as a developed and complex supercoacervate system.", [["cell", "ANATOMY", 40, 44], ["cell", "CELL", 40, 44], ["a developed and complex supercoacervate system", "PROBLEM", 67, 113]]], ["This system retains certain simpler nteractions, relationships and structures from its early, probably coacervate, precellular history.", [["certain", "OBSERVATION_MODIFIER", 20, 27], ["simpler nteractions", "OBSERVATION", 28, 47], ["probably", "UNCERTAINTY", 94, 102], ["coacervate", "OBSERVATION_MODIFIER", 103, 113]]], ["A mixed population of nucleus-containing and nucleus-free protoplasts originates when preparing protopla~ts from logarithmically growing cell of Saccharomyces cerevisiae by means of snail enzymes.Iaol~oplaste and theirThe nucleus-free protoplasts were studied by mean of optical and electron microscopy.", [["nucleus", "ANATOMY", 22, 29], ["protoplasts", "ANATOMY", 58, 69], ["cell", "ANATOMY", 137, 141], ["protoplasts", "ANATOMY", 235, 246], ["Iaol~oplaste", "CHEMICAL", 196, 208], ["nucleus", "CELLULAR_COMPONENT", 22, 29], ["nucleus", "CELLULAR_COMPONENT", 45, 52], ["protoplasts", "CELL", 58, 69], ["cell", "CELL", 137, 141], ["Saccharomyces cerevisiae", "ORGANISM", 145, 169], ["protoplasts", "CELL", 235, 246], ["snail enzymes", "PROTEIN", 182, 195], ["Saccharomyces cerevisiae", "SPECIES", 145, 169], ["Saccharomyces cerevisiae", "SPECIES", 145, 169], ["A mixed population of nucleus-containing and nucleus-free protoplasts", "PROBLEM", 0, 69], ["snail enzymes", "TEST", 182, 195], ["electron microscopy", "TEST", 283, 302], ["mixed", "OBSERVATION_MODIFIER", 2, 7], ["population", "OBSERVATION", 8, 18], ["nucleus", "ANATOMY", 22, 29], ["nucleus", "ANATOMY", 45, 52], ["free protoplasts", "OBSERVATION", 53, 69], ["nucleus", "ANATOMY", 222, 229], ["free protoplasts", "OBSERVATION", 230, 246]]], ["The nucleusfree protoplasts did not synthesize glucan fibrils, in spite of the fact that they contained all basic cytoplasmic structures except for the nucleus and that the structure of their cytoplasmic membrane remained unchanged.", [["protoplasts", "ANATOMY", 16, 27], ["cytoplasmic structures", "ANATOMY", 114, 136], ["nucleus", "ANATOMY", 152, 159], ["cytoplasmic membrane", "ANATOMY", 192, 212], ["glucan", "CHEMICAL", 47, 53], ["nucleusfree protoplasts", "CELL", 4, 27], ["glucan fibrils", "GENE_OR_GENE_PRODUCT", 47, 61], ["cytoplasmic", "ORGANISM_SUBSTANCE", 114, 125], ["nucleus", "CELLULAR_COMPONENT", 152, 159], ["cytoplasmic membrane", "CELLULAR_COMPONENT", 192, 212], ["nucleusfree protoplasts", "CELL_LINE", 4, 27], ["glucan fibrils", "PROTEIN", 47, 61], ["basic cytoplasmic structures", "PROTEIN", 108, 136], ["The nucleusfree protoplasts", "TREATMENT", 0, 27], ["synthesize glucan fibrils", "PROBLEM", 36, 61], ["glucan fibrils", "OBSERVATION", 47, 61], ["cytoplasmic structures", "OBSERVATION", 114, 136], ["nucleus", "ANATOMY", 152, 159], ["cytoplasmic membrane", "OBSERVATION", 192, 212], ["unchanged", "OBSERVATION_MODIFIER", 222, 231]]], ["On the contrary, nucleuscontaining yeast protoplasts synthesize glucan fibrils even after the protein synthesis has been stopped by cycloheximide.", [["protoplasts", "ANATOMY", 41, 52], ["cycloheximide", "CHEMICAL", 132, 145], ["cycloheximide", "CHEMICAL", 132, 145], ["glucan fibrils", "GENE_OR_GENE_PRODUCT", 64, 78], ["cycloheximide", "SIMPLE_CHEMICAL", 132, 145], ["nucleuscontaining yeast protoplasts", "CELL_LINE", 17, 52], ["glucan fibrils", "PROTEIN", 64, 78], ["yeast", "SPECIES", 35, 40], ["yeast", "SPECIES", 35, 40], ["nucleuscontaining yeast protoplasts synthesize glucan fibrils", "TREATMENT", 17, 78], ["the protein synthesis", "TREATMENT", 90, 111], ["cycloheximide", "TREATMENT", 132, 145]]], ["The above-described behaviour of the nucleus-free protoplasts is not clear.", [["nucleus-free protoplasts", "ANATOMY", 37, 61], ["nucleus", "CELLULAR_COMPONENT", 37, 44], ["protoplasts", "CELL", 50, 61], ["nucleus", "ANATOMY", 37, 44], ["free protoplasts", "OBSERVATION", 45, 61], ["not", "UNCERTAINTY", 65, 68], ["clear", "OBSERVATION", 69, 74]]], ["The.nucleus-free yeast protoplasts are the first case when a uniform fraction of nucleus-free fungi was isolated by means of a reproducible method.Ultra, structure o] $he Yeczt Trigono~is variabili~.V. ~NEJDAR, Institute of Microbiology, Czechoslovak Academy of Sciences, Prague.Ultra, structure o] o/ Derivatives o1 Saeeharides on Growth olYeasts.", [["protoplasts", "ANATOMY", 23, 34], ["nucleus", "ANATOMY", 81, 88], ["Saeeharides", "CHEMICAL", 317, 328], ["nucleus", "CELLULAR_COMPONENT", 81, 88], ["o] o/ Derivatives o1 Saeeharides", "SIMPLE_CHEMICAL", 296, 328], ["The.nucleus-free yeast protoplasts", "CELL_LINE", 0, 34], ["yeast", "SPECIES", 17, 22], ["yeast", "SPECIES", 17, 22], ["The.nucleus", "TEST", 0, 11], ["free yeast protoplasts", "PROBLEM", 12, 34], ["free fungi", "PROBLEM", 89, 99], ["a reproducible method", "TREATMENT", 125, 146], ["free", "OBSERVATION", 12, 16], ["yeast protoplasts", "OBSERVATION", 17, 34], ["nucleus", "ANATOMY", 81, 88], ["free fungi", "OBSERVATION", 89, 99]]], ["J. DULA, K. LISEK, Institute of Chemistry, Slovak Academy of Sciences, Bratislava.JEl/ee$ o/ Derivatives o1 Saeeharides on Growth olThe effect of derivatives of saccharides prepared in this institute on growth of some species of yeasts and yeast-like microorganisms was studied.", [["Saeeharides", "CHEMICAL", 108, 119], ["ee", "CHEMICAL", 86, 88], ["Saeeharides", "CHEMICAL", 108, 119], ["Saeeharides", "SIMPLE_CHEMICAL", 108, 119], ["saccharides", "SIMPLE_CHEMICAL", 161, 172], ["yeasts", "CELL", 229, 235], ["yeast", "CELL", 240, 245], ["yeast", "SPECIES", 240, 245], ["yeast", "SPECIES", 240, 245], ["JEl", "TEST", 82, 85], ["Derivatives", "TREATMENT", 93, 104], ["derivatives of saccharides", "TREATMENT", 146, 172], ["some species of yeasts", "PROBLEM", 213, 235], ["yeast-like microorganisms", "PROBLEM", 240, 265]]], ["Out of the tested 30 derivatives of tetroses, D-erythrose (~-nitrophenyl) hydrazone, D-threose (p-nitrophenyl) hydrazone, D-threose (2,5-dichlorophenyl) hydrazone and hexoses, D-glucose phenylhydrazone, D-galactose (p-nitrophenyl) hydrazone, L-rhamnose (:p-nitrophenyl) hydrazone have a strong inhibitory effect on growth of the cultures.", [["tetroses", "CHEMICAL", 36, 44], ["D-erythrose", "CHEMICAL", 46, 57], ["~-nitrophenyl) hydrazone", "CHEMICAL", 59, 83], ["D-threose (p-nitrophenyl) hydrazone", "CHEMICAL", 85, 120], ["D-threose", "CHEMICAL", 122, 131], ["2,5-dichlorophenyl) hydrazone", "CHEMICAL", 133, 162], ["hexoses", "CHEMICAL", 167, 174], ["D-glucose phenylhydrazone", "CHEMICAL", 176, 201], ["D-galactose (p-nitrophenyl) hydrazone", "CHEMICAL", 203, 240], ["-rhamnose", "CHEMICAL", 243, 252], ["hydrazone", "CHEMICAL", 270, 279], ["tetroses", "CHEMICAL", 36, 44], ["D-erythrose (~-nitrophenyl) hydrazone", "CHEMICAL", 46, 83], ["D-threose (p-nitrophenyl) hydrazone", "CHEMICAL", 85, 120], ["D-threose (2,5-dichlorophenyl) hydrazone", "CHEMICAL", 122, 162], ["hexoses", "CHEMICAL", 167, 174], ["D-glucose phenylhydrazone", "CHEMICAL", 176, 201], ["D-galactose", "CHEMICAL", 203, 214], ["p-nitrophenyl) hydrazone", "CHEMICAL", 216, 240], ["L-rhamnose", "CHEMICAL", 242, 252], ["p-nitrophenyl) hydrazone", "CHEMICAL", 255, 279], ["tetroses", "SIMPLE_CHEMICAL", 36, 44], ["D-erythrose (~-nitrophenyl) hydrazone", "SIMPLE_CHEMICAL", 46, 83], ["D-threose (p-nitrophenyl) hydrazone", "SIMPLE_CHEMICAL", 85, 120], ["D-threose (2,5-dichlorophenyl) hydrazone", "SIMPLE_CHEMICAL", 122, 162], ["hexoses", "SIMPLE_CHEMICAL", 167, 174], ["D-glucose phenylhydrazone", "SIMPLE_CHEMICAL", 176, 201], ["D-galactose (p-nitrophenyl) hydrazone", "SIMPLE_CHEMICAL", 203, 240], ["L-rhamnose (:p-nitrophenyl) hydrazone", "SIMPLE_CHEMICAL", 242, 279], ["tetroses", "TREATMENT", 36, 44], ["D-erythrose (~-nitrophenyl) hydrazone", "TREATMENT", 46, 83], ["D-threose (p-nitrophenyl) hydrazone", "TREATMENT", 85, 120], ["D-threose", "TREATMENT", 122, 131], ["dichlorophenyl", "TREATMENT", 137, 151], ["hydrazone", "TREATMENT", 153, 162], ["hexoses", "TREATMENT", 167, 174], ["D-glucose phenylhydrazone", "TREATMENT", 176, 201], ["D-galactose (p-nitrophenyl) hydrazone", "TREATMENT", 203, 240], ["L-rhamnose", "TREATMENT", 242, 252], ["p-nitrophenyl) hydrazone", "TREATMENT", 255, 279], ["the cultures", "TEST", 325, 337]]], ["Derivatives of trioses and pentoses do not substantially influence growth of the cells.", [["cells", "ANATOMY", 81, 86], ["trioses", "CHEMICAL", 15, 22], ["pentoses", "CHEMICAL", 27, 35], ["trioses", "SIMPLE_CHEMICAL", 15, 22], ["pentoses", "SIMPLE_CHEMICAL", 27, 35], ["cells", "CELL", 81, 86], ["Derivatives of trioses and pentoses", "TREATMENT", 0, 35]]], ["Species of the genus Saceharo. myces with a well developed system of glycosidic enzymes are less sensitive, whereas pathogenic species of the genera Candida and Cryptoeoccus, as well as species of the genus Rhodotorula are strongly inhibited by the above-mentioned compounds.JEl/ee$ o/ Derivatives o1 Saeeharides on Growth olComparison o] Cytomorphological Properties o] Cells o1 Candida utilis at Dil]erent Growth Rates.", [["Dil", "CHEMICAL", 398, 401], ["genera Candida", "ORGANISM", 142, 156], ["Cryptoeoccus", "GENE_OR_GENE_PRODUCT", 161, 173], ["genus Rhodotorula", "ORGANISM", 201, 218], ["glycosidic enzymes", "PROTEIN", 69, 87], ["Candida utilis", "SPECIES", 380, 394], ["Candida utilis", "SPECIES", 380, 394], ["glycosidic enzymes", "TEST", 69, 87], ["the genera Candida", "TEST", 138, 156], ["Cryptoeoccus", "TEST", 161, 173], ["the genus Rhodotorula", "PROBLEM", 197, 218], ["JEl/ee$ o/ Derivatives", "TREATMENT", 275, 297], ["Cytomorphological Properties o] Cells", "TREATMENT", 339, 376], ["Candida utilis", "PROBLEM", 380, 394], ["Dil]erent Growth Rates", "TREATMENT", 398, 420], ["genus Saceharo", "OBSERVATION", 15, 29], ["genera Candida", "OBSERVATION", 142, 156], ["genus Rhodotorula", "OBSERVATION", 201, 218]]], ["D. u N./~, J. LYEBLOV.~, K. BERA1% Institute of Microbiology, Czechoslovak Academy of Sciences, Prague, Lengths and widths of mother and daughter ,cells of Candida utilis and Saccharomyces eerevisiae were compared during a single-step continuous cultivation at DI = 0.05, 0.1, 0.25 and 0.35 x h-1.", [["cells", "ANATOMY", 147, 152], ["cells", "CELL", 147, 152], ["Candida utilis", "ORGANISM", 156, 170], ["Saccharomyces eerevisiae", "ORGANISM", 175, 199], ["Candida utilis", "SPECIES", 156, 170], ["Saccharomyces eerevisiae", "SPECIES", 175, 199], ["Candida utilis", "SPECIES", 156, 170], ["Saccharomyces eerevisiae", "SPECIES", 175, 199], ["Candida utilis", "PROBLEM", 156, 170], ["Saccharomyces eerevisiae", "TREATMENT", 175, 199], ["a single-step continuous cultivation", "TREATMENT", 221, 257]]], ["Fluorescence microscopy following \"staining\" of scars by primulin was used to discriminate between mother and daughter cells.", [["scars", "ANATOMY", 48, 53], ["daughter cells", "ANATOMY", 110, 124], ["scars", "PATHOLOGICAL_FORMATION", 48, 53], ["primulin", "SIMPLE_CHEMICAL", 57, 65], ["daughter cells", "CELL", 110, 124], ["primulin", "PROTEIN", 57, 65], ["daughter cells", "CELL_TYPE", 110, 124], ["Fluorescence microscopy", "TEST", 0, 23], ["scars", "PROBLEM", 48, 53], ["scars", "OBSERVATION", 48, 53]]], ["In a population of ~qaccharomyces eerevisiae the average size of mother cells containing one to two scars reaches about 150 ~3 and does not change substantially with increasing growth rate.", [["mother cells", "ANATOMY", 65, 77], ["qaccharomyces eerevisiae", "ORGANISM", 20, 44], ["mother cells", "CELL", 65, 77], ["scars", "PATHOLOGICAL_FORMATION", 100, 105], ["mother cells", "CELL_TYPE", 65, 77], ["qaccharomyces eerevisiae", "SPECIES", 20, 44], ["qaccharomyces eerevisiae", "SPECIES", 20, 44], ["mother cells", "PROBLEM", 65, 77], ["two scars", "PROBLEM", 96, 105], ["increasing growth rate", "PROBLEM", 166, 188], ["average", "OBSERVATION_MODIFIER", 49, 56], ["size", "OBSERVATION_MODIFIER", 57, 61], ["scars", "OBSERVATION", 100, 105], ["increasing", "OBSERVATION_MODIFIER", 166, 176], ["growth rate", "OBSERVATION", 177, 188]]], ["However, the growth rate considerably influences site of the scar-less daughter cells.", [["scar-less daughter cells", "ANATOMY", 61, 85], ["scar", "PATHOLOGICAL_FORMATION", 61, 65], ["cells", "CELL", 80, 85], ["scar-less daughter cells", "CELL_TYPE", 61, 85], ["the growth rate", "PROBLEM", 9, 24], ["the scar", "PROBLEM", 57, 65], ["growth", "OBSERVATION_MODIFIER", 13, 19], ["scar", "OBSERVATION", 61, 65]]], ["At D1 : 0.05 and 0.1 \u2022 h -1 the daughter cells reach about 40% volume of mother cells, at D~ : 0.25 x h -1 this value equals 73% and at D1 : 0.35 \u2022 h -1 the daughter cells are practically of the same size as the mother cells (97%).", [["daughter cells", "ANATOMY", 32, 46], ["mother cells", "ANATOMY", 73, 85], ["daughter cells", "ANATOMY", 157, 171], ["mother cells", "ANATOMY", 212, 224], ["daughter cells", "CELL", 32, 46], ["cells", "CELL", 80, 85], ["daughter cells", "CELL", 157, 171], ["mother cells", "CELL", 212, 224], ["D1", "PROTEIN", 3, 5], ["daughter cells", "CELL_TYPE", 32, 46], ["mother cells", "CELL_TYPE", 73, 85], ["daughter cells", "CELL_TYPE", 157, 171], ["mother cells", "CELL_TYPE", 212, 224], ["D1", "TEST", 136, 138], ["the daughter cells", "TEST", 153, 171], ["size", "OBSERVATION_MODIFIER", 200, 204]]], ["Size of mother cells with four scars was indirectly proportional to the growth \"rate and was apparently a function of the time of delay.", [["mother cells", "ANATOMY", 8, 20], ["scars", "ANATOMY", 31, 36], ["mother cells", "CELL", 8, 20], ["mother cells", "CELL_TYPE", 8, 20], ["four scars", "PROBLEM", 26, 36], ["scars", "OBSERVATION", 31, 36]]], ["In a population of Candida utilis the growth rate is of considerable importance even for the average size of the mother cells ranging from 25 ~3 to 50 ~t 3 at the lowest and highest growth rate, respectively.", [["mother cells", "ANATOMY", 113, 125], ["Candida utilis", "ORGANISM", 19, 33], ["cells", "CELL", 120, 125], ["mother cells", "CELL_TYPE", 113, 125], ["Candida utilis", "SPECIES", 19, 33], ["Candida utilis", "SPECIES", 19, 33], ["Candida utilis", "TREATMENT", 19, 33], ["the mother cells", "TEST", 109, 125], ["Candida utilis", "OBSERVATION", 19, 33], ["growth", "OBSERVATION_MODIFIER", 38, 44], ["size", "OBSERVATION_MODIFIER", 101, 105]]], ["The relative size of the daughter and mother cells was similar as in the population of Saccharomyces cerevisiae.", [["daughter", "ANATOMY", 25, 33], ["mother cells", "ANATOMY", 38, 50], ["mother cells", "CELL", 38, 50], ["Saccharomyces cerevisiae", "ORGANISM", 87, 111], ["daughter and mother cells", "CELL_TYPE", 25, 50], ["Saccharomyces cerevisiae", "SPECIES", 87, 111], ["Saccharomyces cerevisiae", "SPECIES", 87, 111], ["Saccharomyces cerevisiae", "TREATMENT", 87, 111], ["relative", "OBSERVATION_MODIFIER", 4, 12], ["size", "OBSERVATION_MODIFIER", 13, 17], ["Saccharomyces cerevisiae", "OBSERVATION", 87, 111]]], ["The results are discussed with respect to a physiological state conditioning separation of the daughter and mother cells in the populations of yeasts.", [["mother cells", "ANATOMY", 108, 120], ["mother cells", "CELL", 108, 120], ["daughter and mother cells", "CELL_TYPE", 95, 120]]], ["Generally, it can be postulated that the higher the growth rate of the population the more physiologically similar is the daughter cell to its mother cell and the shorter the time interval between its separation and origin of a new bud on its surface.", [["cell", "ANATOMY", 131, 135], ["mother cell", "ANATOMY", 143, 154], ["bud", "ANATOMY", 232, 235], ["surface", "ANATOMY", 243, 250], ["daughter cell", "CELL", 122, 135], ["mother cell", "CELL", 143, 154], ["surface", "CELLULAR_COMPONENT", 243, 250], ["a new bud", "PROBLEM", 226, 235], ["higher", "OBSERVATION_MODIFIER", 41, 47], ["growth", "OBSERVATION_MODIFIER", 52, 58], ["more physiologically", "OBSERVATION_MODIFIER", 86, 106], ["new", "OBSERVATION_MODIFIER", 228, 231], ["bud", "OBSERVATION_MODIFIER", 232, 235], ["surface", "OBSERVATION_MODIFIER", 243, 250]]], ["The specific carrier for monosaecharides in Savcharomyees cerevisiae does not transfer sugars with the axial hydroxyl group at C-4.", [["monosaecharides", "CHEMICAL", 25, 40], ["hydroxyl", "CHEMICAL", 109, 117], ["monosaecharides", "CHEMICAL", 25, 40], ["sugars", "CHEMICAL", 87, 93], ["hydroxyl", "CHEMICAL", 109, 117], ["monosaecharides", "SIMPLE_CHEMICAL", 25, 40], ["Savcharomyees cerevisiae", "ORGANISM", 44, 68], ["hydroxyl", "SIMPLE_CHEMICAL", 109, 117], ["C-4", "SIMPLE_CHEMICAL", 127, 130], ["Savcharomyees cerevisiae", "SPECIES", 44, 68], ["Savcharomyees cerevisiae", "SPECIES", 44, 68], ["monosaecharides in Savcharomyees cerevisiae", "TREATMENT", 25, 68]]], ["The galaetose induced carrier transports these sugars preferentially.", [["galaetose", "CHEMICAL", 4, 13], ["galaetose", "CHEMICAL", 4, 13], ["sugars", "CHEMICAL", 47, 53], ["galaetose", "SIMPLE_CHEMICAL", 4, 13], ["sugars", "SIMPLE_CHEMICAL", 47, 53], ["these sugars", "TEST", 41, 53]]], ["4-Deoxy-glucose (which is simultaneously 4-deoxygalactose) is transferred by both carriers with an activation energy of 40--30 kJ/mol, thus indicating that neither of the carriers requires the presence of the hydroxyl group at C-4.", [["4-Deoxy-glucose", "CHEMICAL", 0, 15], ["4-deoxygalactose", "CHEMICAL", 41, 57], ["hydroxyl", "CHEMICAL", 209, 217], ["4-Deoxy-glucose", "CHEMICAL", 0, 15], ["4-deoxygalactose", "CHEMICAL", 41, 57], ["hydroxyl", "CHEMICAL", 209, 217], ["4-Deoxy-glucose", "SIMPLE_CHEMICAL", 0, 15], ["4-deoxygalactose", "SIMPLE_CHEMICAL", 41, 57], ["hydroxyl", "SIMPLE_CHEMICAL", 209, 217], ["C-4", "SIMPLE_CHEMICAL", 227, 230], ["Deoxy-glucose", "TEST", 2, 15], ["an activation energy", "TEST", 96, 116]]], ["4-Deoxy-D-glucose is apparently oxidized without phosphorylation in yeasts.", [["4-Deoxy-D-glucose", "CHEMICAL", 0, 17], ["4-Deoxy-D-glucose", "CHEMICAL", 0, 17], ["4-Deoxy-D-glucose", "SIMPLE_CHEMICAL", 0, 17], ["Deoxy-D-glucose", "TEST", 2, 17], ["phosphorylation in yeasts", "PROBLEM", 49, 74]]], ["6-Deoxy-D-glueose is also transferred by both transport systems, but it is not further changed inside the ceils.", [["ceils", "ANATOMY", 106, 111], ["6-Deoxy-D-glueose", "CHEMICAL", 0, 17], ["6-Deoxy-D-glueose", "CHEMICAL", 0, 17], ["6-Deoxy-D-glueose", "SIMPLE_CHEMICAL", 0, 17]]], ["None of the sugars can serve as substrate for yeast hexokinase.JEl/ee$ o/ Derivatives o1 Saeeharides on Growth olTransport ol disaccharide8 in the yeast Rhodotorula glutinis.", [["Saeeharides", "CHEMICAL", 89, 100], ["sugars", "CHEMICAL", 12, 18], ["Saeeharides", "CHEMICAL", 89, 100], ["sugars", "SIMPLE_CHEMICAL", 12, 18], ["yeast hexokinase", "GENE_OR_GENE_PRODUCT", 46, 62], ["olTransport ol disaccharide8", "SIMPLE_CHEMICAL", 111, 139], ["yeast Rhodotorula glutinis", "ORGANISM", 147, 173], ["yeast hexokinase", "PROTEIN", 46, 62], ["yeast", "SPECIES", 46, 51], ["yeast", "SPECIES", 147, 152], ["Rhodotorula glutinis", "SPECIES", 153, 173], ["yeast", "SPECIES", 46, 51], ["yeast", "SPECIES", 147, 152], ["Rhodotorula glutinis", "SPECIES", 153, 173], ["the sugars", "TEST", 8, 18], ["yeast hexokinase", "PROBLEM", 46, 62], ["JEl", "TREATMENT", 63, 66], ["o/ Derivatives", "TREATMENT", 71, 85], ["yeast", "OBSERVATION", 147, 152], ["Rhodotorula glutinis", "OBSERVATION", 153, 173]]], ["S. JA~DA, Institute of Microbiology, Czechoslovak Academy of Sciences, Prague.JEl/ee$ o/ Derivatives o1 Saeeharides on Growth olTransport of eight disaceharides and one trisaceharide was followed in the lipid-forming yeast Rhodotorula glutinis.", [["JA", "CHEMICAL", 3, 5], ["DA", "CHEMICAL", 6, 8], ["JEl", "CHEMICAL", 78, 81], ["Saeeharides", "CHEMICAL", 104, 115], ["disaceharides", "CHEMICAL", 147, 160], ["trisaceharide", "CHEMICAL", 169, 182], ["ee", "CHEMICAL", 82, 84], ["Saeeharides", "CHEMICAL", 104, 115], ["disaceharides", "CHEMICAL", 147, 160], ["trisaceharide", "CHEMICAL", 169, 182], ["disaceharides", "SIMPLE_CHEMICAL", 147, 160], ["trisaceharide", "SIMPLE_CHEMICAL", 169, 182], ["lipid", "SIMPLE_CHEMICAL", 203, 208], ["yeast", "ORGANISM", 217, 222], ["Rhodotorula glutinis", "ORGANISM", 223, 243], ["yeast", "SPECIES", 217, 222], ["Rhodotorula glutinis", "SPECIES", 223, 243], ["Rhodotorula glutinis", "SPECIES", 223, 243], ["Derivatives", "TREATMENT", 89, 100], ["eight disaceharides", "TREATMENT", 141, 160], ["the lipid", "TEST", 199, 208], ["yeast Rhodotorula glutinis", "PROBLEM", 217, 243], ["yeast", "OBSERVATION", 217, 222], ["Rhodotorula glutinis", "OBSERVATION", 223, 243]]], ["Sucrose, trehalose, maltose, cellobiose and the trisaccl~ride rafffmose (this sugar only partially} were taken up from the medium.", [["Sucrose", "CHEMICAL", 0, 7], ["trehalose", "CHEMICAL", 9, 18], ["maltose", "CHEMICAL", 20, 27], ["cellobiose", "CHEMICAL", 29, 39], ["rafffmose", "CHEMICAL", 62, 71], ["Sucrose", "CHEMICAL", 0, 7], ["trehalose", "CHEMICAL", 9, 18], ["maltose", "CHEMICAL", 20, 27], ["cellobiose", "CHEMICAL", 29, 39], ["trisaccl~ride rafffmose", "CHEMICAL", 48, 71], ["sugar", "CHEMICAL", 78, 83], ["Sucrose", "SIMPLE_CHEMICAL", 0, 7], ["trehalose", "SIMPLE_CHEMICAL", 9, 18], ["maltose", "SIMPLE_CHEMICAL", 20, 27], ["cellobiose", "SIMPLE_CHEMICAL", 29, 39], ["trisaccl~ride rafffmose", "SIMPLE_CHEMICAL", 48, 71], ["sugar", "SIMPLE_CHEMICAL", 78, 83], ["Sucrose", "TREATMENT", 0, 7], ["trehalose", "TREATMENT", 9, 18], ["maltose", "TREATMENT", 20, 27], ["cellobiose", "TREATMENT", 29, 39], ["this sugar", "TEST", 73, 83]]], ["Lactose, melibiose, isomaltose and gentiobiose were not utilized.", [["Lactose", "CHEMICAL", 0, 7], ["melibiose", "CHEMICAL", 9, 18], ["isomaltose", "CHEMICAL", 20, 30], ["gentiobiose", "CHEMICAL", 35, 46], ["Lactose", "CHEMICAL", 0, 7], ["melibiose", "CHEMICAL", 9, 18], ["isomaltose", "CHEMICAL", 20, 30], ["gentiobiose", "CHEMICAL", 35, 46], ["Lactose", "SIMPLE_CHEMICAL", 0, 7], ["melibiose", "SIMPLE_CHEMICAL", 9, 18], ["isomaltose", "SIMPLE_CHEMICAL", 20, 30], ["gentiobiose", "SIMPLE_CHEMICAL", 35, 46], ["Lactose", "TREATMENT", 0, 7], ["melibiose", "TREATMENT", 9, 18], ["isomaltose", "TREATMENT", 20, 30], ["gentiobiose", "TREATMENT", 35, 46]]], ["Out of the utilized sugars sucrose and trehalose are degraded by periplasmie hydrolases on the cell surface, however, these enzymes are partially released into the medium.", [["cell surface", "ANATOMY", 95, 107], ["sucrose", "CHEMICAL", 27, 34], ["trehalose", "CHEMICAL", 39, 48], ["sugars", "CHEMICAL", 20, 26], ["sucrose", "CHEMICAL", 27, 34], ["trehalose", "CHEMICAL", 39, 48], ["sucrose", "SIMPLE_CHEMICAL", 27, 34], ["trehalose", "SIMPLE_CHEMICAL", 39, 48], ["cell surface", "CELLULAR_COMPONENT", 95, 107], ["periplasmie hydrolases", "PROTEIN", 65, 87], ["enzymes", "PROTEIN", 124, 131], ["trehalose", "TREATMENT", 39, 48], ["periplasmie hydrolases", "PROBLEM", 65, 87], ["these enzymes", "TEST", 118, 131], ["cell surface", "OBSERVATION_MODIFIER", 95, 107]]], ["Glucose (and fructose) are then transported inside the cells.", [["cells", "ANATOMY", 55, 60], ["Glucose", "CHEMICAL", 0, 7], ["fructose", "CHEMICAL", 13, 21], ["Glucose", "CHEMICAL", 0, 7], ["fructose", "CHEMICAL", 13, 21], ["Glucose", "SIMPLE_CHEMICAL", 0, 7], ["fructose", "SIMPLE_CHEMICAL", 13, 21], ["cells", "CELL", 55, 60], ["Glucose", "TEST", 0, 7], ["cells", "ANATOMY", 55, 60]]], ["From raffinose only D-glucose is split off and transported.", [["raffinose", "CHEMICAL", 5, 14], ["D-glucose", "CHEMICAL", 20, 29], ["raffinose", "CHEMICAL", 5, 14], ["D-glucose", "CHEMICAL", 20, 29], ["raffinose", "SIMPLE_CHEMICAL", 5, 14], ["D-glucose", "SIMPLE_CHEMICAL", 20, 29]]], ["Maltose is transported in an unchanged form, probably by means of two transport mechanisms.", [["Maltose", "CHEMICAL", 0, 7], ["Maltose", "CHEMICAL", 0, 7], ["Maltose", "SIMPLE_CHEMICAL", 0, 7], ["unchanged", "OBSERVATION", 29, 38]]], ["Transport of cellobiose has not yet been clarified.", [["cellobiose", "CHEMICAL", 13, 23], ["cellobiose", "CHEMICAL", 13, 23], ["cellobiose", "SIMPLE_CHEMICAL", 13, 23], ["Transport of cellobiose", "TREATMENT", 0, 23]]], ["59 without participation of metabolic energy.", [["metabolic energy", "PROBLEM", 28, 44], ["metabolic energy", "OBSERVATION", 28, 44]]], ["It even appears that uptake of these compounds proceeds without any specific carrier.", [["these compounds", "PROBLEM", 31, 46]]], ["Thus sorbitol is transported roughly to 75~o of cell water within a broad concentration range (from 10 -8 M to l~z), with a negligible temperature dependence, a very broad pH optimum (from 3 to 8) the Km and V of this transport being infinitely high. :No competition with other polyols or sugars was detected, the transport was not influenced by either metabolic (2,4-dinitrophenol, iodoacetamide) or transport (uranyl ions) inhibitors.IntraceUular Level and Rate o/ Transport o/ AminoAcids in Saceharomyees eerevisiae.", [["cell", "ANATOMY", 48, 52], ["sorbitol", "CHEMICAL", 5, 13], ["polyols", "CHEMICAL", 278, 285], ["2,4-dinitrophenol", "CHEMICAL", 364, 381], ["iodoacetamide", "CHEMICAL", 383, 396], ["uranyl ions", "CHEMICAL", 412, 423], ["sorbitol", "CHEMICAL", 5, 13], ["polyols", "CHEMICAL", 278, 285], ["sugars", "CHEMICAL", 289, 295], ["2,4-dinitrophenol", "CHEMICAL", 364, 381], ["iodoacetamide", "CHEMICAL", 383, 396], ["uranyl", "CHEMICAL", 412, 418], ["sorbitol", "SIMPLE_CHEMICAL", 5, 13], ["cell", "CELL", 48, 52], ["Km", "GENE_OR_GENE_PRODUCT", 201, 203], ["polyols", "SIMPLE_CHEMICAL", 278, 285], ["sugars", "SIMPLE_CHEMICAL", 289, 295], ["2,4-dinitrophenol", "SIMPLE_CHEMICAL", 364, 381], ["iodoacetamide", "SIMPLE_CHEMICAL", 383, 396], ["uranyl ions", "SIMPLE_CHEMICAL", 412, 423], ["Saceharomyees eerevisiae", "ORGANISM", 494, 518], ["Saceharomyees eerevisiae", "SPECIES", 494, 518], ["Saceharomyees eerevisiae", "SPECIES", 494, 518], ["sorbitol", "TREATMENT", 5, 13], ["a negligible temperature dependence", "PROBLEM", 122, 157], ["a very broad pH optimum", "PROBLEM", 159, 182], ["this transport", "TEST", 213, 227], ["sugars", "TEST", 289, 295], ["dinitrophenol", "TREATMENT", 368, 381], ["iodoacetamide", "TREATMENT", 383, 396], ["transport (uranyl ions) inhibitors", "TREATMENT", 401, 435], ["AminoAcids", "TREATMENT", 480, 490]]], ["A. KNOTKOVX, A. KOTu Institute of Microbiology, Czechoslovak Academy of Sciences, Prague.IntraceUular Level and Rate o/ Transport o/ AminoThe intensity of transport of amino acids (glycine, methionine, lysine, glutamic acid, cr isobutyric acid) is increased up to 25-fold after previous incubation with some metabolized sugars.", [["amino acids", "CHEMICAL", 168, 179], ["glycine", "CHEMICAL", 181, 188], ["methionine, lysine, glutamic acid", "CHEMICAL", 190, 223], ["cr isobutyric acid", "CHEMICAL", 225, 243], ["amino acids", "CHEMICAL", 168, 179], ["glycine", "CHEMICAL", 181, 188], ["methionine", "CHEMICAL", 190, 200], ["lysine", "CHEMICAL", 202, 208], ["glutamic acid", "CHEMICAL", 210, 223], ["cr isobutyric acid", "CHEMICAL", 225, 243], ["sugars", "CHEMICAL", 320, 326], ["amino acids", "AMINO_ACID", 168, 179], ["glycine", "SIMPLE_CHEMICAL", 181, 188], ["methionine", "SIMPLE_CHEMICAL", 190, 200], ["lysine", "AMINO_ACID", 202, 208], ["glutamic acid", "SIMPLE_CHEMICAL", 210, 223], ["cr isobutyric acid", "SIMPLE_CHEMICAL", 225, 243], ["sugars", "SIMPLE_CHEMICAL", 320, 326], ["amino acids (glycine", "TREATMENT", 168, 188], ["methionine", "TREATMENT", 190, 200], ["lysine", "TREATMENT", 202, 208], ["glutamic acid", "TREATMENT", 210, 223], ["cr isobutyric acid", "TREATMENT", 225, 243], ["previous incubation", "TREATMENT", 278, 297], ["some metabolized sugars", "PROBLEM", 303, 326]]], ["It increases only 10-fold after incubation with substrates of the strictly oxidative metabolism (ethanol, acetate).", [["ethanol, acetate", "CHEMICAL", 97, 113], ["ethanol", "CHEMICAL", 97, 104], ["acetate", "CHEMICAL", 106, 113], ["ethanol", "SIMPLE_CHEMICAL", 97, 104], ["acetate", "SIMPLE_CHEMICAL", 106, 113], ["the strictly oxidative metabolism (ethanol, acetate", "TREATMENT", 62, 113], ["10-fold", "OBSERVATION_MODIFIER", 18, 25]]], ["The increased transport may be explained in two ways: (1) The previous incubation results in the accumulation of energy sources required for the transport of amino acids; (2) the levels of intracellular amino acids decrease during the preincubation due to the proceeding protein synthesis and the trans-inhibitory effect on the transport is thus removed.", [["intracellular", "ANATOMY", 189, 202], ["amino acids", "CHEMICAL", 158, 169], ["amino acids", "CHEMICAL", 203, 214], ["amino acids", "CHEMICAL", 158, 169], ["amino acids", "CHEMICAL", 203, 214], ["amino acids", "AMINO_ACID", 158, 169], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 189, 202], ["amino acids", "AMINO_ACID", 203, 214], ["amino acids", "TREATMENT", 158, 169], ["intracellular amino acids", "TREATMENT", 189, 214], ["the preincubation", "TREATMENT", 231, 248], ["the proceeding protein synthesis", "TREATMENT", 256, 288]]], ["Determination of the total intraeellular level of amino acids after different types of preincubation followed by deprivation show that the second explanation is not likely (after ethanol the total level of amino acids does not change at, all decreasing to about 50% after glucose).", [["amino acids", "CHEMICAL", 50, 61], ["ethanol", "CHEMICAL", 179, 186], ["amino acids", "CHEMICAL", 206, 217], ["glucose", "CHEMICAL", 272, 279], ["amino acids", "CHEMICAL", 50, 61], ["ethanol", "CHEMICAL", 179, 186], ["amino acids", "CHEMICAL", 206, 217], ["glucose", "CHEMICAL", 272, 279], ["amino acids", "AMINO_ACID", 50, 61], ["ethanol", "SIMPLE_CHEMICAL", 179, 186], ["amino acids", "AMINO_ACID", 206, 217], ["glucose", "SIMPLE_CHEMICAL", 272, 279], ["amino acids", "TREATMENT", 50, 61], ["preincubation", "TREATMENT", 87, 100], ["amino acids", "TREATMENT", 206, 217], ["not likely", "UNCERTAINTY", 161, 171]]], ["The direct energy source for the transport of amino acids cannot be identified at present, in spite of the fact that a remarkable agreement between the level of high molecular polyphosphate and capacity of transport systems for amino acids exists.Attempts at Solubilizing Transport Proteins ]romSaccharomyces cerevisiae, g.", [["amino acids", "CHEMICAL", 46, 57], ["polyphosphate", "CHEMICAL", 176, 189], ["amino acids", "CHEMICAL", 228, 239], ["amino acids", "CHEMICAL", 46, 57], ["polyphosphate", "CHEMICAL", 176, 189], ["amino acids", "CHEMICAL", 228, 239], ["amino acids", "AMINO_ACID", 46, 57], ["polyphosphate", "SIMPLE_CHEMICAL", 176, 189], ["amino acids", "AMINO_ACID", 228, 239], ["romSaccharomyces cerevisiae", "SPECIES", 292, 319], ["romSaccharomyces cerevisiae", "SPECIES", 292, 319], ["amino acids", "TREATMENT", 46, 57], ["high molecular polyphosphate", "PROBLEM", 161, 189], ["amino acids", "TREATMENT", 228, 239], ["Solubilizing Transport Proteins", "TREATMENT", 259, 290]]], ["HORAK, M. OPEKA-~OVX, L. lovA, A. KOTYK, Institute of Microbiology, Czechoslovak Academy of Sciences, Prague Solubilization of the plasma membrane of yeasts by means of detergents (Tween 80 in the first place) used for purification of the binding protein for D.glucose and related sugars includes a series of difficulties and the final preparation contains residues of detergents.", [["plasma membrane", "ANATOMY", 131, 146], ["D.glucose", "CHEMICAL", 259, 268], ["Tween 80", "CHEMICAL", 181, 189], ["D.glucose", "CHEMICAL", 259, 268], ["sugars", "CHEMICAL", 281, 287], ["plasma membrane", "CELLULAR_COMPONENT", 131, 146], ["D.glucose", "SIMPLE_CHEMICAL", 259, 268], ["binding protein", "PROTEIN", 239, 254], ["L. lovA", "SPECIES", 22, 29], ["the plasma membrane of yeasts", "TREATMENT", 127, 156], ["detergents (Tween", "TREATMENT", 169, 186], ["the binding protein", "TEST", 235, 254], ["related sugars", "PROBLEM", 273, 287], ["residues of detergents", "TREATMENT", 357, 379]]], ["The use of the osmotic shock described in bacteria avoids these shortcomings, but its application to yeasts requires certain modifications.", [["shock", "DISEASE", 23, 28], ["the osmotic shock", "TREATMENT", 11, 28], ["bacteria", "PROBLEM", 42, 50], ["these shortcomings", "TREATMENT", 58, 76], ["certain modifications", "TREATMENT", 117, 138], ["osmotic shock", "OBSERVATION", 15, 28]]], ["By using a saturated mannitol solution it is possible to release the binding affinity for D-galactose from suitably induced ceils in the stationary phase of growth.", [["mannitol", "CHEMICAL", 21, 29], ["D-galactose", "CHEMICAL", 90, 101], ["mannitol", "CHEMICAL", 21, 29], ["D-galactose", "CHEMICAL", 90, 101], ["mannitol", "SIMPLE_CHEMICAL", 21, 29], ["D-galactose", "SIMPLE_CHEMICAL", 90, 101], ["a saturated mannitol solution", "TREATMENT", 9, 38], ["D-galactose", "TREATMENT", 90, 101]]], ["A peptide with specific binding affinity for L-arginine is released after a simple transfer of the growing cells to distilled water.Prague.The stimulatory effect of glucose and other energy sources on the oxidation of aromatic monomers and more complex compounds (e.g. fulvic acids) described in previous papers was investigated.", [["cells", "ANATOMY", 107, 112], ["glucose", "CHEMICAL", 165, 172], ["fulvic acids", "CHEMICAL", 269, 281], ["L-arginine", "CHEMICAL", 45, 55], ["glucose", "CHEMICAL", 165, 172], ["fulvic acids", "CHEMICAL", 269, 281], ["L-arginine", "SIMPLE_CHEMICAL", 45, 55], ["cells", "CELL", 107, 112], ["glucose", "SIMPLE_CHEMICAL", 165, 172], ["aromatic monomers", "SIMPLE_CHEMICAL", 218, 235], ["fulvic acids", "SIMPLE_CHEMICAL", 269, 281], ["A peptide", "TREATMENT", 0, 9], ["specific binding affinity", "PROBLEM", 15, 40], ["L-arginine", "TREATMENT", 45, 55], ["glucose", "TEST", 165, 172], ["the oxidation of aromatic monomers", "TREATMENT", 201, 235], ["more complex compounds", "PROBLEM", 240, 262], ["fulvic acids", "TREATMENT", 269, 281], ["aromatic monomers", "OBSERVATION", 218, 235]]], ["The effect of glucose on the oxidation of 14COOHvanillic acid by a washed suspension of cells of CeUulomonas sp. was studied by means of respirometric and radiometric methods, cell-free extracts, inhibitors and by adjustment of osmotic conditions.", [["cells", "ANATOMY", 88, 93], ["cell", "ANATOMY", 176, 180], ["extracts", "ANATOMY", 186, 194], ["glucose", "CHEMICAL", 14, 21], ["14COOHvanillic acid", "CHEMICAL", 42, 61], ["glucose", "CHEMICAL", 14, 21], ["14COOHvanillic acid", "CHEMICAL", 42, 61], ["glucose", "SIMPLE_CHEMICAL", 14, 21], ["14COOHvanillic acid", "SIMPLE_CHEMICAL", 42, 61], ["cells", "CELL", 88, 93], ["CeUulomonas sp", "ORGANISM", 97, 111], ["cell", "CELL", 176, 180], ["extracts", "ORGANISM_SUBSTANCE", 186, 194], ["glucose", "TEST", 14, 21], ["the oxidation of 14COOHvanillic acid", "TREATMENT", 25, 61], ["CeUulomonas sp", "PROBLEM", 97, 111], ["radiometric methods", "TEST", 155, 174], ["cell-free extracts", "TREATMENT", 176, 194], ["inhibitors", "TREATMENT", 196, 206], ["osmotic conditions", "TREATMENT", 228, 246], ["osmotic conditions", "OBSERVATION", 228, 246]]], ["The obtained results showed that the lag phase was reduced in the presence of glucose and the oxidation of vanillie acid was thus accelerated.", [["glucose", "CHEMICAL", 78, 85], ["vanillie acid", "CHEMICAL", 107, 120], ["glucose", "CHEMICAL", 78, 85], ["vanillie acid", "CHEMICAL", 107, 120], ["glucose", "SIMPLE_CHEMICAL", 78, 85], ["vanillie acid", "SIMPLE_CHEMICAL", 107, 120], ["the lag phase", "PROBLEM", 33, 46], ["glucose", "TEST", 78, 85], ["the oxidation of vanillie acid", "TREATMENT", 90, 120]]], ["It was further found that the incorporation of the carboxyl carbon of vanillic acid into cellular structures was increased in the presence of glucose and that glucose decreases the inhibitory effect of higher concentrations of vanillic acid on the respiratory activity of bacteria.", [["cellular structures", "ANATOMY", 89, 108], ["respiratory", "ANATOMY", 248, 259], ["carboxyl carbon", "CHEMICAL", 51, 66], ["vanillic acid", "CHEMICAL", 70, 83], ["glucose", "CHEMICAL", 142, 149], ["glucose", "CHEMICAL", 159, 166], ["vanillic acid", "CHEMICAL", 227, 240], ["carboxyl carbon", "CHEMICAL", 51, 66], ["vanillic acid", "CHEMICAL", 70, 83], ["glucose", "CHEMICAL", 142, 149], ["glucose", "CHEMICAL", 159, 166], ["vanillic acid", "CHEMICAL", 227, 240], ["vanillic acid", "SIMPLE_CHEMICAL", 70, 83], ["cellular", "CELL", 89, 97], ["glucose", "SIMPLE_CHEMICAL", 142, 149], ["glucose", "SIMPLE_CHEMICAL", 159, 166], ["vanillic acid", "SIMPLE_CHEMICAL", 227, 240], ["the carboxyl carbon of vanillic acid", "TREATMENT", 47, 83], ["glucose", "TEST", 142, 149], ["glucose", "TEST", 159, 166], ["vanillic acid", "TREATMENT", 227, 240], ["bacteria", "PROBLEM", 272, 280], ["increased", "OBSERVATION_MODIFIER", 113, 122], ["respiratory activity", "OBSERVATION", 248, 268]]], ["It followed from the results that the effect of glucose was due to an increase of biomass or enzymic activity.", [["glucose", "CHEMICAL", 48, 55], ["glucose", "CHEMICAL", 48, 55], ["glucose", "SIMPLE_CHEMICAL", 48, 55], ["glucose", "TEST", 48, 55], ["an increase of biomass", "PROBLEM", 67, 89], ["enzymic activity", "PROBLEM", 93, 109], ["enzymic activity", "OBSERVATION", 93, 109]]], ["Glucose rather served as an energy source for membrane transport mechanisms facilitating contact of the substrate with endoenzymes by the accelerated transport of vanfllic acid inside the cells.", [["membrane", "ANATOMY", 46, 54], ["cells", "ANATOMY", 188, 193], ["Glucose", "CHEMICAL", 0, 7], ["vanfllic acid", "CHEMICAL", 163, 176], ["Glucose", "CHEMICAL", 0, 7], ["vanfllic acid", "CHEMICAL", 163, 176], ["Glucose", "SIMPLE_CHEMICAL", 0, 7], ["membrane", "CELLULAR_COMPONENT", 46, 54], ["endoenzymes", "SIMPLE_CHEMICAL", 119, 130], ["vanfllic acid", "SIMPLE_CHEMICAL", 163, 176], ["cells", "CELL", 188, 193], ["Glucose", "TEST", 0, 7], ["membrane transport mechanisms", "PROBLEM", 46, 75], ["endoenzymes", "TREATMENT", 119, 130]]], ["A similar effect was also observed when using succinic acid and acetate and also in cases when the content of accessible energy substrates in the soil was increased by sterilization by heat or radiation.", [["succinic acid", "CHEMICAL", 46, 59], ["acetate", "CHEMICAL", 64, 71], ["succinic acid", "CHEMICAL", 46, 59], ["acetate", "CHEMICAL", 64, 71], ["succinic acid", "SIMPLE_CHEMICAL", 46, 59], ["acetate", "SIMPLE_CHEMICAL", 64, 71], ["succinic acid and acetate", "TREATMENT", 46, 71], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["effect", "OBSERVATION", 10, 16], ["increased", "OBSERVATION_MODIFIER", 155, 164]]], ["A possible relationship between the above findings and the \"priming effect\" is discussed.Prague.Selection o] Respiratory Mutants in the Basidiomycete Sehizophyllum commune.", [["Respiratory Mutants", "PROBLEM", 109, 128], ["Respiratory Mutants", "OBSERVATION", 109, 128]]], ["J. Nm~VERA, Department of Genetics, Faculty of Sciences, Charles University, Prague.Prague.When basidiospores of Schizophyllum commune are treated with ethyl methanesulfonate for 24 hours, up to 60~ mutants with a decreased growth rate are detected among the surviving population.", [["ethyl methanesulfonate", "CHEMICAL", 152, 174], ["ethyl methanesulfonate", "CHEMICAL", 152, 174], ["Schizophyllum commune", "ORGANISM", 113, 134], ["ethyl methanesulfonate", "SIMPLE_CHEMICAL", 152, 174], ["Schizophyllum commune", "PROBLEM", 113, 134], ["ethyl methanesulfonate", "TREATMENT", 152, 174], ["a decreased growth rate", "PROBLEM", 212, 235], ["Schizophyllum commune", "OBSERVATION", 113, 134]]], ["Out of a total of 75 mutants 15 were selected for further studies.", [["further studies", "TEST", 50, 65]]], ["These mutants grow slowly in a medium containing glucose and do not grow at all even after 7 days in the presence of acetate.", [["glucose", "CHEMICAL", 49, 56], ["acetate", "CHEMICAL", 117, 124], ["glucose", "CHEMICAL", 49, 56], ["acetate", "CHEMICAL", 117, 124], ["glucose", "SIMPLE_CHEMICAL", 49, 56], ["acetate", "SIMPLE_CHEMICAL", 117, 124], ["These mutants", "PROBLEM", 0, 13], ["a medium containing glucose", "PROBLEM", 29, 56], ["acetate", "TREATMENT", 117, 124], ["grow", "OBSERVATION_MODIFIER", 14, 18], ["slowly", "OBSERVATION_MODIFIER", 19, 25]]], ["It was assumed that the decreased growth rate was caused by a defect in the respiratory system and energetic metabolism.", [["respiratory system", "ANATOMY", 76, 94], ["the decreased growth rate", "PROBLEM", 20, 45], ["a defect in the respiratory system", "PROBLEM", 60, 94], ["decreased", "OBSERVATION_MODIFIER", 24, 33], ["growth", "OBSERVATION_MODIFIER", 34, 40], ["defect", "OBSERVATION", 62, 68], ["respiratory system", "ANATOMY", 76, 94], ["energetic metabolism", "OBSERVATION", 99, 119]]], ["The inability to grow in the medium with acetate was recessive in all studied mutants.", [["acetate", "CHEMICAL", 41, 48], ["acetate", "CHEMICAL", 41, 48], ["acetate", "SIMPLE_CHEMICAL", 41, 48], ["The inability", "PROBLEM", 0, 13], ["acetate", "TREATMENT", 41, 48], ["recessive", "PROBLEM", 53, 62]]], ["It was found on the basis of the analysis of segregation of basidiospores after crossing of these mutants with standard strains that in 11 mutants the inability to grow in the acetate medium is due to a mutation in the nuclear gene.", [["nuclear", "ANATOMY", 219, 226], ["acetate", "CHEMICAL", 176, 183], ["acetate", "CHEMICAL", 176, 183], ["acetate", "SIMPLE_CHEMICAL", 176, 183], ["nuclear", "CELLULAR_COMPONENT", 219, 226], ["nuclear gene", "DNA", 219, 231], ["the analysis", "TEST", 29, 41], ["segregation of basidiospores", "PROBLEM", 45, 73], ["these mutants", "PROBLEM", 92, 105], ["standard strains", "PROBLEM", 111, 127], ["the acetate medium", "TREATMENT", 172, 190], ["a mutation in the nuclear gene", "PROBLEM", 201, 231], ["mutation", "OBSERVATION", 203, 211]]], ["An extranuclear mutation can be assumed in 1 mutant.", [["An extranuclear mutation", "PROBLEM", 0, 24], ["extranuclear mutation", "OBSERVATION", 3, 24]]], ["Results of mutual complementation made it possible to estimate a minimum of 8 nuclear loci governing the utilization of acetate.", [["acetate", "CHEMICAL", 120, 127], ["acetate", "CHEMICAL", 120, 127], ["acetate", "SIMPLE_CHEMICAL", 120, 127], ["acetate", "TREATMENT", 120, 127]]], ["Measurement of the respiratory capacity by the oxygen electrode showed that the KCN-sensitive respiration was decreased in one nuclear mutant.", [["respiratory", "ANATOMY", 19, 30], ["nuclear", "ANATOMY", 127, 134], ["oxygen", "CHEMICAL", 47, 53], ["KCN", "CHEMICAL", 80, 83], ["oxygen", "CHEMICAL", 47, 53], ["KCN", "CHEMICAL", 80, 83], ["oxygen", "SIMPLE_CHEMICAL", 47, 53], ["KCN", "SIMPLE_CHEMICAL", 80, 83], ["the respiratory capacity", "TEST", 15, 39], ["the oxygen electrode", "TEST", 43, 63], ["the KCN", "TEST", 76, 83], ["respiratory capacity", "OBSERVATION", 19, 39]]], ["The role of mitochondria in germination of spores of filamentous fungi was investigated.", [["mitochondria", "ANATOMY", 12, 24], ["spores", "ANATOMY", 43, 49], ["filamentous fungi", "ANATOMY", 53, 70], ["mitochondria", "CELLULAR_COMPONENT", 12, 24], ["filamentous fungi", "PROBLEM", 53, 70], ["filamentous fungi", "OBSERVATION", 53, 70]]], ["It was found that strict anacrobiosis, cyanide, azide, oligomyein, bongkrekic acid, acriflavin and ethidium bromide prevent germination of spores of Aapergillus niger and Penicillium itedum in a liquid germination medium.", [["anacrobiosis", "CHEMICAL", 25, 37], ["cyanide", "CHEMICAL", 39, 46], ["azide", "CHEMICAL", 48, 53], ["oligomyein", "CHEMICAL", 55, 65], ["bongkrekic acid", "CHEMICAL", 67, 82], ["acriflavin", "CHEMICAL", 84, 94], ["ethidium bromide", "CHEMICAL", 99, 115], ["germination of spores of Aapergillus niger", "CHEMICAL", 124, 166], ["anacrobiosis", "CHEMICAL", 25, 37], ["cyanide", "CHEMICAL", 39, 46], ["azide", "CHEMICAL", 48, 53], ["oligomyein", "CHEMICAL", 55, 65], ["bongkrekic acid", "CHEMICAL", 67, 82], ["acriflavin", "CHEMICAL", 84, 94], ["ethidium bromide", "CHEMICAL", 99, 115], ["anacrobiosis", "SIMPLE_CHEMICAL", 25, 37], ["cyanide", "SIMPLE_CHEMICAL", 39, 46], ["azide", "SIMPLE_CHEMICAL", 48, 53], ["oligomyein", "SIMPLE_CHEMICAL", 55, 65], ["bongkrekic acid", "SIMPLE_CHEMICAL", 67, 82], ["acriflavin", "SIMPLE_CHEMICAL", 84, 94], ["ethidium bromide", "SIMPLE_CHEMICAL", 99, 115], ["Aapergillus niger", "ORGANISM", 149, 166], ["Penicillium itedum", "ORGANISM", 171, 189], ["Aapergillus niger", "SPECIES", 149, 166], ["Penicillium itedum", "SPECIES", 171, 189], ["Aapergillus niger", "SPECIES", 149, 166], ["Penicillium itedum", "SPECIES", 171, 189], ["strict anacrobiosis", "TREATMENT", 18, 37], ["cyanide", "TREATMENT", 39, 46], ["azide", "TREATMENT", 48, 53], ["oligomyein", "TREATMENT", 55, 65], ["bongkrekic acid", "TREATMENT", 67, 82], ["acriflavin", "TREATMENT", 84, 94], ["ethidium bromide", "TREATMENT", 99, 115], ["germination of spores of Aapergillus niger and Penicillium itedum", "PROBLEM", 124, 189], ["a liquid germination medium", "TREATMENT", 193, 220]]], ["The effect of azide, oligomycin, bongkrekic acid and ethidium bromide was of fungicidal type.", [["azide", "CHEMICAL", 14, 19], ["oligomycin", "CHEMICAL", 21, 31], ["bongkrekic acid", "CHEMICAL", 33, 48], ["ethidium bromide", "CHEMICAL", 53, 69], ["azide", "CHEMICAL", 14, 19], ["oligomycin", "CHEMICAL", 21, 31], ["bongkrekic acid", "CHEMICAL", 33, 48], ["ethidium bromide", "CHEMICAL", 53, 69], ["azide", "SIMPLE_CHEMICAL", 14, 19], ["oligomycin", "SIMPLE_CHEMICAL", 21, 31], ["bongkrekic acid", "SIMPLE_CHEMICAL", 33, 48], ["ethidium bromide", "SIMPLE_CHEMICAL", 53, 69], ["azide", "TREATMENT", 14, 19], ["oligomycin", "TREATMENT", 21, 31], ["bongkrekic acid", "TREATMENT", 33, 48], ["ethidium bromide", "TREATMENT", 53, 69], ["fungicidal type", "OBSERVATION", 77, 92]]], ["Cyanide and azide completely inhibited the incorporation of 14C-leucine and 14C-uracil by germinating conidia of A~pergillus niger.", [["Cyanide", "CHEMICAL", 0, 7], ["azide", "CHEMICAL", 12, 17], ["14C-leucine", "CHEMICAL", 60, 71], ["14C-uracil", "CHEMICAL", 76, 86], ["Cyanide", "CHEMICAL", 0, 7], ["azide", "CHEMICAL", 12, 17], ["14C", "CHEMICAL", 60, 63], ["leucine", "CHEMICAL", 64, 71], ["14C-uracil", "CHEMICAL", 76, 86], ["Cyanide", "SIMPLE_CHEMICAL", 0, 7], ["azide", "SIMPLE_CHEMICAL", 12, 17], ["14C-leucine", "SIMPLE_CHEMICAL", 60, 71], ["14C-uracil", "SIMPLE_CHEMICAL", 76, 86], ["A~pergillus niger", "ORGANISM", 113, 130], ["A~pergillus niger", "SPECIES", 113, 130], ["A~pergillus niger", "SPECIES", 113, 130], ["Cyanide", "TREATMENT", 0, 7], ["azide", "TREATMENT", 12, 17], ["leucine", "TREATMENT", 64, 71], ["uracil", "TREATMENT", 80, 86]]], ["Oligomycin, bongkrekic acid and ethidium bromide reduced the incorporation of both precursors during first hours of the germination of eonidia, inhibiting it completely during further hours of incubation.", [["eonidia", "ANATOMY", 135, 142], ["Oligomycin", "CHEMICAL", 0, 10], ["bongkrekic acid", "CHEMICAL", 12, 27], ["ethidium bromide", "CHEMICAL", 32, 48], ["Oligomycin", "CHEMICAL", 0, 10], ["bongkrekic acid", "CHEMICAL", 12, 27], ["ethidium bromide", "CHEMICAL", 32, 48], ["Oligomycin", "SIMPLE_CHEMICAL", 0, 10], ["bongkrekic acid", "SIMPLE_CHEMICAL", 12, 27], ["ethidium bromide", "SIMPLE_CHEMICAL", 32, 48], ["eonidia", "SIMPLE_CHEMICAL", 135, 142], ["Oligomycin", "TREATMENT", 0, 10], ["bongkrekic acid", "TREATMENT", 12, 27], ["ethidium bromide", "TREATMENT", 32, 48], ["both", "OBSERVATION_MODIFIER", 78, 82], ["precursors", "OBSERVATION_MODIFIER", 83, 93]]], ["The inhibition of the germination of spores as well as the inhibition of synthesis of macromolecules during germination of the conidia of Aspergillus niger were related with the specific inhibitory effect of these compounds on the respiratory activity of dormant conidia and mycelial cells.", [["spores", "ANATOMY", 37, 43], ["respiratory", "ANATOMY", 231, 242], ["conidia", "ANATOMY", 263, 270], ["mycelial cells", "ANATOMY", 275, 289], ["Aspergillus niger", "ORGANISM", 138, 155], ["conidia", "CELL", 263, 270], ["mycelial cells", "CELL", 275, 289], ["mycelial cells", "CELL_TYPE", 275, 289], ["Aspergillus niger", "SPECIES", 138, 155], ["Aspergillus niger", "SPECIES", 138, 155], ["the germination of spores", "PROBLEM", 18, 43], ["synthesis of macromolecules", "TREATMENT", 73, 100], ["Aspergillus niger", "PROBLEM", 138, 155], ["these compounds", "PROBLEM", 208, 223], ["dormant conidia and mycelial cells", "PROBLEM", 255, 289], ["Aspergillus niger", "OBSERVATION", 138, 155], ["respiratory activity", "OBSERVATION_MODIFIER", 231, 251], ["mycelial cells", "OBSERVATION", 275, 289]]], ["The results indicate that the function of the mitochondrial genetic and protein synthesizing system, as well as the function of oxidative phosphorylation are essential for the normal germination of spores and growth of molds.Prague.El/oct el Phaltan on Certain Microorganisms Important ]ram the Point of View el .Food Industry.Prague.V. 0BDR, V. ~icrm, Department of Biochemistry and Microbiology, University of Chemical Technology, Prague.Prague.The effect of phaltan (N-trichloromethyltetrahydrophtalimide), a pesticide, the use of which during storage of sugar beet and some types of fruit and vegetable is considered, was investigated.", [["mitochondrial", "ANATOMY", 46, 59], ["spores", "ANATOMY", 198, 204], ["fruit", "ANATOMY", 587, 592], ["vegetable", "ANATOMY", 597, 606], ["phaltan", "CHEMICAL", 461, 468], ["N-trichloromethyltetrahydrophtalimide", "CHEMICAL", 470, 507], ["phaltan (N-trichloromethyltetrahydrophtalimide", "CHEMICAL", 461, 507], ["sugar", "CHEMICAL", 558, 563], ["mitochondrial", "CELLULAR_COMPONENT", 46, 59], ["phaltan", "SIMPLE_CHEMICAL", 461, 468], ["N-trichloromethyltetrahydrophtalimide", "SIMPLE_CHEMICAL", 470, 507], ["fruit", "ORGANISM_SUBDIVISION", 587, 592], ["vegetable", "ORGANISM_SUBDIVISION", 597, 606], ["beet", "SPECIES", 564, 568], ["oxidative phosphorylation", "TREATMENT", 128, 153], ["phaltan (N-trichloromethyltetrahydrophtalimide)", "TREATMENT", 461, 508], ["sugar beet", "TREATMENT", 558, 568]]], ["The following microorganisms were used throughout: Saccbxtromyces eerevieiae, Bacillus megaterium and several molds belonging to different genera.", [["Saccbxtromyces eerevieiae", "ORGANISM", 51, 76], ["Bacillus megaterium", "ORGANISM", 78, 97], ["Saccbxtromyces eerevieiae", "SPECIES", 51, 76], ["Bacillus megaterium", "SPECIES", 78, 97], ["Saccbxtromyces eerevieiae", "SPECIES", 51, 76], ["Bacillus megaterium", "SPECIES", 78, 97], ["Saccbxtromyces eerevieiae", "TREATMENT", 51, 76], ["Bacillus megaterium", "PROBLEM", 78, 97], ["Bacillus megaterium", "OBSERVATION", 78, 97]]], ["It was found that growth of Saccharomyces cerevisiae is fully inhibited by phaltan at a concentration of 0.03 mg~o.", [["phaltan", "CHEMICAL", 75, 82], ["Saccharomyces cerevisiae", "ORGANISM", 28, 52], ["phaltan", "SIMPLE_CHEMICAL", 75, 82], ["Saccharomyces cerevisiae", "SPECIES", 28, 52], ["Saccharomyces cerevisiae", "SPECIES", 28, 52], ["Saccharomyces cerevisiae", "TREATMENT", 28, 52], ["phaltan", "TREATMENT", 75, 82], ["growth", "OBSERVATION_MODIFIER", 18, 24]]], ["It is difficult to determine accurately the inhibitory concentration of phaltan as this compound is highly unstable in aqueous solutions, at high pH in particular.", [["phaltan", "CHEMICAL", 72, 79], ["phaltan", "CHEMICAL", 72, 79], ["phaltan", "SIMPLE_CHEMICAL", 72, 79], ["phaltan", "TREATMENT", 72, 79], ["highly", "OBSERVATION_MODIFIER", 100, 106], ["unstable", "OBSERVATION_MODIFIER", 107, 115]]], ["Phatfian is rapidly decomposed in worth and other complex media and concentrations higher than 0.1 mg~o are required for the inhibition of rowth.", [["Phatfian", "CHEMICAL", 0, 8], ["Phatfian", "SIMPLE_CHEMICAL", 0, 8], ["the inhibition of rowth", "TREATMENT", 121, 144], ["rapidly", "OBSERVATION_MODIFIER", 12, 19], ["decomposed", "OBSERVATION", 20, 30]]], ["Growth of Bacillus megaterium in a mineral medium with glucose, followed by measuring absorbancy, was inhibited only partially by phaltan at a concentration of 1 mg~o.Prague.Antirmicrobial El]oct el Some Amine-N-oxides.", [["glucose", "CHEMICAL", 55, 62], ["phaltan", "CHEMICAL", 130, 137], ["Amine-N-oxides", "CHEMICAL", 204, 218], ["glucose", "CHEMICAL", 55, 62], ["Amine-N-oxides", "CHEMICAL", 204, 218], ["Bacillus megaterium", "ORGANISM", 10, 29], ["glucose", "SIMPLE_CHEMICAL", 55, 62], ["phaltan", "SIMPLE_CHEMICAL", 130, 137], ["Amine-N-oxides", "SIMPLE_CHEMICAL", 204, 218], ["Bacillus megaterium", "SPECIES", 10, 29], ["Bacillus megaterium", "SPECIES", 10, 29], ["Bacillus megaterium", "PROBLEM", 10, 29], ["glucose", "TEST", 55, 62], ["Antirmicrobial El", "TEST", 174, 191], ["N-oxides", "TREATMENT", 210, 218], ["Bacillus megaterium", "OBSERVATION", 10, 29], ["mineral medium", "OBSERVATION_MODIFIER", 35, 49]]], ["D. YlLYNAR(~iK, D. GEORCH, M. FIGUROV~, L LAC~rO, Pharmaceutical Faculty, Komensk~ University, Bratislava.", [["D.", "SPECIES", 0, 2], ["D.", "SPECIES", 0, 2], ["L", "ANATOMY_MODIFIER", 40, 41], ["LAC", "ANATOMY", 42, 45], ["Pharmaceutical Faculty", "OBSERVATION", 50, 72]]], ["The antimicrobial effect of 14 newly synthesized amitae-N-oxides differing by substitutions on the nitrogen atom was investigated.", [["amitae-N-oxides", "CHEMICAL", 49, 64], ["nitrogen", "CHEMICAL", 99, 107], ["amitae-N-oxides", "CHEMICAL", 49, 64], ["nitrogen", "CHEMICAL", 99, 107], ["amitae-N-oxides", "SIMPLE_CHEMICAL", 49, 64], ["nitrogen atom", "SIMPLE_CHEMICAL", 99, 112], ["newly synthesized amitae", "TREATMENT", 31, 55], ["N-oxides", "TREATMENT", 56, 64], ["the nitrogen atom", "TREATMENT", 95, 112], ["antimicrobial effect", "OBSERVATION_MODIFIER", 4, 24]]], ["The relationship between the chemical structure and effectivity was studied by determining MIC in strains of Staphylo-coccu~ pyoyenes, Bacillus 8ubtilis, Eavherichia cell, Salmonella minnesota, Candida albivans, Tricholahyton terrestre and Mierosperum gypseum.", [["Eavherichia cell", "ANATOMY", 154, 170], ["MIC", "CHEMICAL", 91, 94], ["Staphylo-coccu~ pyoyenes", "ORGANISM", 109, 133], ["Bacillus 8ubtilis", "ORGANISM", 135, 152], ["Eavherichia cell", "CELL", 154, 170], ["Salmonella minnesota", "ORGANISM", 172, 192], ["Candida albivans", "ORGANISM", 194, 210], ["Tricholahyton terrestre", "ORGANISM", 212, 235], ["Mierosperum gypseum", "ORGANISM", 240, 259], ["Bacillus 8ubtilis", "SPECIES", 135, 152], ["Salmonella minnesota", "SPECIES", 172, 192], ["Candida albivans", "SPECIES", 194, 210], ["Tricholahyton terrestre", "SPECIES", 212, 235], ["Mierosperum gypseum", "SPECIES", 240, 259], ["Staphylo-coccu", "SPECIES", 109, 123], ["Bacillus 8ubtilis", "SPECIES", 135, 152], ["Salmonella minnesota", "SPECIES", 172, 192], ["Candida albivans", "SPECIES", 194, 210], ["Tricholahyton terrestre", "SPECIES", 212, 235], ["Mierosperum gypseum", "SPECIES", 240, 259], ["Staphylo", "TEST", 109, 117], ["pyoyenes", "PROBLEM", 125, 133], ["Bacillus 8ubtilis", "PROBLEM", 135, 152], ["Salmonella minnesota", "TREATMENT", 172, 192], ["Candida albivans", "TREATMENT", 194, 210], ["Tricholahyton terrestre and Mierosperum gypseum", "PROBLEM", 212, 259], ["Mierosperum gypseum", "OBSERVATION", 240, 259]]], ["Length of the alkyl chain appears to be the most important factor here.", [["alkyl", "CHEMICAL", 14, 19], ["the alkyl chain", "TREATMENT", 10, 25], ["alkyl chain", "OBSERVATION", 14, 25]]], ["Of the tested compounds 1-pentadccylpiperidine-N-oxide was most effective on Grampositive bacteria and molds, whereas N,N~dimethyldodecylamine-N-oxide was more effective on Gram-negative bacteria.Screening o/ Insecticides Produced by Molds o/ theG/ass Fungi imperfceti.", [["1-pentadccylpiperidine-N-oxide", "CHEMICAL", 24, 54], ["N,N~dimethyldodecylamine-N-oxide", "CHEMICAL", 118, 150], ["1-pentadccylpiperidine-N-oxide", "CHEMICAL", 24, 54], ["N,N~dimethyldodecylamine-N-oxide", "CHEMICAL", 118, 150], ["1-pentadccylpiperidine-N-oxide", "SIMPLE_CHEMICAL", 24, 54], ["N~dimethyldodecylamine-N-oxide", "SIMPLE_CHEMICAL", 120, 150], ["Gram", "SIMPLE_CHEMICAL", 173, 177], ["ass Fungi imperfceti", "ORGANISM", 248, 268], ["Molds o/ theG/ass Fungi imperfceti", "SPECIES", 234, 268], ["pentadccylpiperidine", "TREATMENT", 26, 46], ["N-oxide", "TREATMENT", 47, 54], ["Grampositive bacteria", "PROBLEM", 77, 98], ["molds", "PROBLEM", 103, 108], ["N~dimethyldodecylamine-N-oxide", "TREATMENT", 120, 150], ["Gram", "TEST", 173, 177], ["negative bacteria", "OBSERVATION", 178, 195]]], ["P. NEMEC, J. DOBIAS, KOLT,&ROVs Institute of Biology, Slovak Academy of Sciences, Bratislava.Screening o/ Insecticides Produced by Molds o/ theThe contact insecticide effect of extracts of 193 cultures of the class ~'ungi imper]ecti was investigated.", [["extracts", "ANATOMY", 177, 185], ["extracts", "ORGANISM_SUBSTANCE", 177, 185], ["ungi imper]ecti", "CELL", 217, 232], ["class ~'ungi imper]ecti", "SPECIES", 209, 232]]], ["A method for screening of the contact inseeticides using a model organism Drosophgla melanogaster was described.", [["Drosophgla melanogaster", "ORGANISM", 74, 97], ["Drosophgla melanogaster", "SPECIES", 74, 97], ["Drosophgla melanogaster", "SPECIES", 74, 97], ["a model organism Drosophgla melanogaster", "TREATMENT", 57, 97]]], ["According to the intensity of the insecticide effect the studied molds were divided to 10 groups with the increasing effectivity; each group consists of cultures with the effectivity range within 1()~o mortality of the model organism.Screening o/ Insecticides Produced by Molds o/ theThe results show that molds of the class t~ungi imper/ecti produce effective insecticides.Wild Fungi Produce Attractors and Nematocides.J. BALA~, L. KRIgKOV.~, P. NE~w.C, V. VOL~KDepartment of Technical Microbiology and Biochemistry, Faculty of Chemistry, Bratislava.Wild Fungi Produce Attractors and Nematocides.Wild fungi are little \"known microorganisms belonging mostly to the order Moniliates reacting to the presence of nematodes by the formation of passive or active trapping structures for catching microscopic worms.", [["Moniliates", "CHEMICAL", 671, 681], ["ecti", "GENE_OR_GENE_PRODUCT", 338, 342], ["worms", "SPECIES", 803, 808], ["class t~ungi imper/ecti", "SPECIES", 319, 342], ["the studied molds", "TREATMENT", 53, 70], ["the increasing effectivity", "PROBLEM", 102, 128], ["cultures", "TEST", 153, 161], ["the model organism", "PROBLEM", 215, 233], ["nematodes", "PROBLEM", 710, 719], ["passive or active trapping structures", "PROBLEM", 740, 777], ["catching microscopic worms", "PROBLEM", 782, 808]]], ["It was found that Arthrobotrya conoides, Arthrobotrys dactyloides, Arthrobotrys oligoslaora and Monacrosporium rutgeriensis produce attractors highly effective for nematodes.", [["Arthrobotrya conoides", "ORGANISM", 18, 39], ["Arthrobotrys dactyloides", "ORGANISM", 41, 65], ["Arthrobotrys oligoslaora", "ORGANISM", 67, 91], ["Monacrosporium rutgeriensis", "ORGANISM", 96, 123], ["Arthrobotrya conoides", "SPECIES", 18, 39], ["Arthrobotrys dactyloides", "SPECIES", 41, 65], ["Arthrobotrys oligoslaora", "SPECIES", 67, 91], ["Monacrosporium rutgeriensis", "SPECIES", 96, 123], ["Arthrobotrya conoides", "SPECIES", 18, 39], ["Arthrobotrys dactyloides", "SPECIES", 41, 65], ["Arthrobotrys oligoslaora", "SPECIES", 67, 91], ["Monacrosporium rutgeriensis", "SPECIES", 96, 123], ["Arthrobotrya conoides", "TREATMENT", 18, 39], ["Arthrobotrys dactyloides", "TREATMENT", 41, 65], ["Arthrobotrys oligoslaora", "TREATMENT", 67, 91], ["nematodes", "PROBLEM", 164, 173]]], ["The attracted worms are caught by the trapping structures and killed by the produced toxic compounds.", [["worms", "ANATOMY", 14, 19], ["worms", "ORGANISM", 14, 19], ["worms", "SPECIES", 14, 19], ["toxic compounds", "OBSERVATION", 85, 100]]], ["The presence of worms induces formation of the trapping structures.", [["worms", "SPECIES", 16, 21], ["worms", "PROBLEM", 16, 21], ["worms", "OBSERVATION", 16, 21], ["trapping structures", "OBSERVATION", 47, 66]]], ["In addition, production of attractors and even toxic compounds is induced or stimulated.", [["even toxic compounds", "PROBLEM", 42, 62], ["toxic compounds", "OBSERVATION", 47, 62]]], ["The chemical nature of the produced attractors has not yet been elucidated; however, it has been found that one of the compounds is 3\"5'e-AMP, but this latter compound itself is much less effective than filtrates of media after the submerged cultivation.", [["AMP", "CHEMICAL", 138, 141], ["3\"5'e-AMP", "CHEMICAL", 132, 141], ["5'e-AMP", "SIMPLE_CHEMICAL", 134, 141], ["AMP", "TREATMENT", 138, 141], ["the submerged cultivation", "TREATMENT", 228, 253], ["much less", "OBSERVATION_MODIFIER", 178, 187], ["effective", "OBSERVATION_MODIFIER", 188, 197]]], ["The observed facts indicate that th~ 61 worm may be attacked by the wild fungus as follows: The trapping structures are formed as a morphological reaction to the presence of nematodes, production of the attractors being induced or stimulated at the same time.", [["a morphological reaction", "PROBLEM", 130, 154], ["nematodes", "PROBLEM", 174, 183], ["nematodes", "OBSERVATION", 174, 183]]], ["The concentration gradient of the attractor attracts the worm to the trapping structures and formation of nematocides is induced or stimulated simultaneously. ]=Iyphac of the fungus then enter the body of the nematode which serves as a source of nutrition.", [["worm", "ANATOMY", 57, 61], ["body", "ANATOMY", 197, 201], ["nematocides", "GENE_OR_GENE_PRODUCT", 106, 117], ["body", "ORGANISM_SUBDIVISION", 197, 201], ["nematocides", "PROTEIN", 106, 117], ["The concentration gradient", "TREATMENT", 0, 26], ["nematocides", "PROBLEM", 106, 117], ["Iyphac of the fungus", "PROBLEM", 161, 181], ["concentration", "OBSERVATION_MODIFIER", 4, 17], ["gradient", "OBSERVATION_MODIFIER", 18, 26], ["fungus", "OBSERVATION", 175, 181], ["nematode", "OBSERVATION", 209, 217]]], ["A semiquantitative method for determining the attraction will be briefly described.", [["A semiquantitative method", "TREATMENT", 0, 25]]], ["Many organic dyes degrading photodynamically purine bases or aromatic amino acids during irradiation with light of a suitable wavelength in the presence of oxygen exist.", [["purine", "CHEMICAL", 45, 51], ["aromatic amino acids", "CHEMICAL", 61, 81], ["oxygen", "CHEMICAL", 156, 162], ["purine bases", "CHEMICAL", 45, 57], ["aromatic amino acids", "CHEMICAL", 61, 81], ["oxygen", "CHEMICAL", 156, 162], ["organic dyes", "SIMPLE_CHEMICAL", 5, 17], ["purine", "SIMPLE_CHEMICAL", 45, 51], ["aromatic amino acids", "SIMPLE_CHEMICAL", 61, 81], ["oxygen", "SIMPLE_CHEMICAL", 156, 162], ["Many organic dyes", "PROBLEM", 0, 17], ["purine bases", "TREATMENT", 45, 57], ["aromatic amino acids", "TREATMENT", 61, 81], ["organic dyes", "OBSERVATION", 5, 17], ["bases", "ANATOMY_MODIFIER", 52, 57], ["oxygen exist", "OBSERVATION", 156, 168]]], ["On the other hand, data concerning a similar effect of inorganic ions are only limited.", [["inorganic ions", "CHEMICAL", 55, 69], ["inorganic ions", "SIMPLE_CHEMICAL", 55, 69], ["inorganic ions", "PROBLEM", 55, 69], ["inorganic ions", "OBSERVATION", 55, 69]]], ["Studies of the interaction of metals with DNA showed that the quality of DNA changes with the time of contact with Fo 3+ ions.", [["metals", "CHEMICAL", 30, 36], ["Fo 3+", "CHEMICAL", 115, 120], ["DNA", "CELLULAR_COMPONENT", 42, 45], ["DNA", "CELLULAR_COMPONENT", 73, 76], ["Fo 3+ ions", "SIMPLE_CHEMICAL", 115, 125], ["DNA changes", "PROBLEM", 73, 84]]], ["The effect of light of a wavelength higher than 310 nm on purine and pyrimidine bases in the presence of FeCls and at pH 5, 4, 3, 2, and 1 was hence investigated.", [["purine", "CHEMICAL", 58, 64], ["pyrimidine", "CHEMICAL", 69, 79], ["FeCls", "CHEMICAL", 105, 110], ["purine", "CHEMICAL", 58, 64], ["pyrimidine", "CHEMICAL", 69, 79], ["FeCls", "CHEMICAL", 105, 110], ["purine", "SIMPLE_CHEMICAL", 58, 64], ["pyrimidine", "SIMPLE_CHEMICAL", 69, 79], ["FeCls", "SIMPLE_CHEMICAL", 105, 110], ["purine and pyrimidine bases", "TREATMENT", 58, 85], ["FeCls", "TEST", 105, 110], ["pH", "TEST", 118, 120], ["bases", "ANATOMY_MODIFIER", 80, 85]]], ["Concentration of bases before and after the photoreactivation was studied speetrophotometrically.", [["the photoreactivation", "TREATMENT", 40, 61], ["bases", "ANATOMY_MODIFIER", 17, 22]]], ["The highest decrease of bases was found at pH 3 in the case of pyrimidines.", [["pyrimidines", "CHEMICAL", 63, 74], ["pyrimidines", "CHEMICAL", 63, 74], ["pyrimidines", "SIMPLE_CHEMICAL", 63, 74], ["The highest decrease of bases", "PROBLEM", 0, 29], ["pH", "TEST", 43, 45], ["pyrimidines", "TREATMENT", 63, 74], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["decrease", "OBSERVATION_MODIFIER", 12, 20], ["bases", "ANATOMY_MODIFIER", 24, 29]]], ["Purines are nonreative under these conditions.", [["Purines", "CHEMICAL", 0, 7], ["Purines", "SIMPLE_CHEMICAL", 0, 7]]], ["Kinetic measurements of thymine showed that %he reaction is first order and is decelerated slowed down by formaldehyde, indicating that OH. ions are the active agent here.", [["thymine", "CHEMICAL", 24, 31], ["formaldehyde", "CHEMICAL", 106, 118], ["OH", "CHEMICAL", 136, 138], ["thymine", "CHEMICAL", 24, 31], ["formaldehyde", "CHEMICAL", 106, 118], ["OH", "CHEMICAL", 136, 138], ["thymine", "SIMPLE_CHEMICAL", 24, 31], ["formaldehyde", "SIMPLE_CHEMICAL", 106, 118], ["OH", "SIMPLE_CHEMICAL", 136, 138], ["ions", "SIMPLE_CHEMICAL", 140, 144], ["Kinetic measurements of thymine", "TEST", 0, 31], ["active", "OBSERVATION_MODIFIER", 153, 159]]], ["Paper chromatography revealed the presence of thymine-glycols (cis and trails), thymine -hydroperoxides (cis and trans ), 5-hydroxymethyluracil, 6-hydro-5-hydroxyorotie acid, 6-hydroxy-5-hydrothymine and a product that could not be identified by this technique.", [["thymine-glycols", "CHEMICAL", 46, 61], ["thymine", "CHEMICAL", 80, 87], ["5-hydroxymethyluracil", "CHEMICAL", 122, 143], ["6-hydro-5-hydroxyorotie acid", "CHEMICAL", 145, 173], ["6-hydroxy-5-hydrothymine", "CHEMICAL", 175, 199], ["thymine-glycols", "CHEMICAL", 46, 61], ["thymine", "CHEMICAL", 80, 87], ["hydroperoxides", "CHEMICAL", 89, 103], ["5-hydroxymethyluracil", "CHEMICAL", 122, 143], ["6-hydro-5-hydroxyorotie acid", "CHEMICAL", 145, 173], ["6-hydroxy-5-hydrothymine", "CHEMICAL", 175, 199], ["thymine-glycols", "SIMPLE_CHEMICAL", 46, 61], ["cis", "SIMPLE_CHEMICAL", 63, 66], ["trails", "SIMPLE_CHEMICAL", 71, 77], ["thymine -hydroperoxides", "SIMPLE_CHEMICAL", 80, 103], ["cis and trans )", "SIMPLE_CHEMICAL", 105, 120], ["5-hydroxymethyluracil", "SIMPLE_CHEMICAL", 122, 143], ["6-hydro-5-hydroxyorotie acid", "SIMPLE_CHEMICAL", 145, 173], ["6-hydroxy-5-hydrothymine", "SIMPLE_CHEMICAL", 175, 199], ["Paper chromatography", "TEST", 0, 20], ["thymine-glycols", "TREATMENT", 46, 61], ["hydroxymethyluracil", "TREATMENT", 124, 143], ["hydroxyorotie acid", "TREATMENT", 155, 173], ["hydroxy", "TREATMENT", 177, 184], ["hydrothymine", "TREATMENT", 187, 199], ["a product", "TREATMENT", 204, 213]]], ["Mass spectremerry identified this product as thymine hydrate.", [["thymine hydrate", "CHEMICAL", 45, 60], ["thymine hydrate", "CHEMICAL", 45, 60], ["thymine hydrate", "SIMPLE_CHEMICAL", 45, 60], ["Mass spectremerry", "PROBLEM", 0, 17], ["thymine hydrate", "TREATMENT", 45, 60]]], ["It follows from the in vitro experiments that the irradiation of aqeous solutions of pyrimidine bases with light of wave length higher than 310 nm in the presence of ferric ions results in degradation of bases, independently of the presence of oxygen in the medium.", [["pyrimidine", "CHEMICAL", 85, 95], ["ferric ions", "CHEMICAL", 166, 177], ["oxygen", "CHEMICAL", 244, 250], ["pyrimidine", "CHEMICAL", 85, 95], ["ferric", "CHEMICAL", 166, 172], ["oxygen", "CHEMICAL", 244, 250], ["pyrimidine", "SIMPLE_CHEMICAL", 85, 95], ["ferric ions", "SIMPLE_CHEMICAL", 166, 177], ["oxygen", "SIMPLE_CHEMICAL", 244, 250], ["the irradiation of aqeous solutions of pyrimidine bases", "TREATMENT", 46, 101], ["light of wave length", "TEST", 107, 127], ["ferric ions", "PROBLEM", 166, 177], ["degradation of bases", "PROBLEM", 189, 209], ["oxygen in the medium", "TREATMENT", 244, 264], ["bases", "ANATOMY_MODIFIER", 204, 209], ["oxygen", "OBSERVATION_MODIFIER", 244, 250]]], ["When studying in viva survival of the bacterial strain Escherichia coli K 12, Sm r, ),s we used solutions of Fe a+, v/z.", [["Fe", "CHEMICAL", 109, 111], ["Fe a+", "CHEMICAL", 109, 114], ["Sm r", "GENE_OR_GENE_PRODUCT", 78, 82], ["Fe", "SIMPLE_CHEMICAL", 109, 111], ["Escherichia coli", "SPECIES", 55, 71], ["Escherichia coli", "SPECIES", 55, 71], ["the bacterial strain Escherichia coli K", "TEST", 34, 73], ["Sm r", "TEST", 78, 82]]], ["FeCls-sodium citrate, ferric ammonium citrate, potassium (hexa/cyanoferrate/III) and FeCls-Tris at pH 5.", [["FeCls-", "CHEMICAL", 0, 6], ["sodium citrate", "CHEMICAL", 6, 20], ["ferric ammonium citrate", "CHEMICAL", 22, 45], ["potassium", "CHEMICAL", 47, 56], ["hexa/cyanoferrate", "CHEMICAL", 58, 75], ["FeCls-Tris", "CHEMICAL", 85, 95], ["FeCls", "CHEMICAL", 0, 5], ["sodium citrate", "CHEMICAL", 6, 20], ["ferric ammonium citrate", "CHEMICAL", 22, 45], ["potassium", "CHEMICAL", 47, 56], ["hexa/cyanoferrate/III)", "CHEMICAL", 58, 80], ["FeCls-Tris", "CHEMICAL", 85, 95], ["FeCls", "SIMPLE_CHEMICAL", 0, 5], ["sodium citrate", "SIMPLE_CHEMICAL", 6, 20], ["ferric ammonium citrate", "SIMPLE_CHEMICAL", 22, 45], ["potassium", "SIMPLE_CHEMICAL", 47, 56], ["hexa/cyanoferrate/III", "SIMPLE_CHEMICAL", 58, 79], ["FeCls-Tris", "SIMPLE_CHEMICAL", 85, 95], ["FeCls", "TEST", 0, 5], ["sodium citrate", "TREATMENT", 6, 20], ["ferric ammonium citrate", "TREATMENT", 22, 45], ["potassium", "TEST", 47, 56], ["hexa", "TEST", 58, 62], ["cyanoferrate", "TEST", 63, 75], ["FeCls", "TEST", 85, 90]]], ["The irradiation was performed with light of wave length higher than 31O nm and intensity of 800 erg/mm2/s, tern-perature of samples at the end of the irradiation did not exceed 22~ The highest effect was found with 10-2M FeCls in 10-2M sodium citrate, when a dose of 96 \u2022 104 erg]mm 2 yielded 5.8~o survival, whereas in the control in the absence of Fe a+ a minimum of 90~o bacteria survived.", [["samples", "ANATOMY", 124, 131], ["sodium citrate", "CHEMICAL", 236, 250], ["Fe", "CHEMICAL", 350, 352], ["FeCls", "CHEMICAL", 221, 226], ["sodium citrate", "CHEMICAL", 236, 250], ["Fe a", "CHEMICAL", 350, 354], ["10-2M FeCls", "SIMPLE_CHEMICAL", 215, 226], ["10-2M sodium citrate", "SIMPLE_CHEMICAL", 230, 250], ["Fe", "SIMPLE_CHEMICAL", 350, 352], ["The irradiation", "TREATMENT", 0, 15], ["light of wave length", "TEST", 35, 55], ["tern", "TEST", 107, 111], ["the irradiation", "TREATMENT", 146, 161], ["2M sodium citrate", "TREATMENT", 233, 250]]], ["In the system containing 10-2M ferric ammonium citrate 60% bacteria survived.", [["ferric ammonium citrate", "CHEMICAL", 31, 54], ["ferric ammonium citrate", "CHEMICAL", 31, 54], ["10-2M ferric ammonium citrate", "SIMPLE_CHEMICAL", 25, 54], ["10-2M ferric ammonium citrate", "TREATMENT", 25, 54]]], ["The systems with 10-2~ potassium (hexa/cyanoferrate/III) and FeC13-Tris did not differ from the controls.", [["potassium", "CHEMICAL", 23, 32], ["hexa/cyanoferrate", "CHEMICAL", 34, 51], ["potassium", "CHEMICAL", 23, 32], ["hexa/cyanoferrate/III)", "CHEMICAL", 34, 56], ["FeC13-Tris", "CHEMICAL", 61, 71], ["potassium", "SIMPLE_CHEMICAL", 23, 32], ["hexa/cyanoferrate/III", "SIMPLE_CHEMICAL", 34, 55], ["FeC13-Tris", "SIMPLE_CHEMICAL", 61, 71], ["The systems", "TEST", 0, 11], ["potassium", "TEST", 23, 32], ["hexa", "TEST", 34, 38], ["cyanoferrate", "TEST", 39, 51], ["FeC13", "TEST", 61, 66]]], ["The photosensitization effect of K4Mo(CN)s, MnC12, 0oSO4, UO2(C2HsO2)2 and CuSO4 at concentrations from 10-4~ to 10-2~ was investigated in a similar way.", [["K4Mo", "CHEMICAL", 33, 37], ["MnC12", "CHEMICAL", 44, 49], ["0oSO4", "CHEMICAL", 51, 56], ["UO2", "CHEMICAL", 58, 61], ["C2HsO2", "CHEMICAL", 62, 68], ["CuSO4", "CHEMICAL", 75, 80], ["K4Mo(CN)s", "CHEMICAL", 33, 42], ["MnC12", "CHEMICAL", 44, 49], ["0oSO4", "CHEMICAL", 51, 56], ["UO2(C2HsO2)2", "CHEMICAL", 58, 70], ["CuSO4", "CHEMICAL", 75, 80], ["K4Mo(CN)s", "SIMPLE_CHEMICAL", 33, 42], ["MnC12", "SIMPLE_CHEMICAL", 44, 49], ["0oSO4", "SIMPLE_CHEMICAL", 51, 56], ["UO2(C2HsO2)2", "SIMPLE_CHEMICAL", 58, 70], ["CuSO4", "SIMPLE_CHEMICAL", 75, 80], ["The photosensitization effect", "PROBLEM", 0, 29], ["K4Mo", "TEST", 33, 37], ["MnC12", "TEST", 44, 49], ["0oSO4", "TEST", 51, 56], ["UO2", "TEST", 58, 61], ["CuSO4 at concentrations", "TEST", 75, 98]]], ["It appears that the transition metals behave similarly to the well known organic dyes.", [["organic dyes", "SIMPLE_CHEMICAL", 73, 85], ["the transition metals", "PROBLEM", 16, 37], ["organic dyes", "OBSERVATION", 73, 85]]], ["However, these metals do not require the presence of oxygen, so that rather a clear photosensitization effect than photodynamics is involved here.", [["oxygen", "CHEMICAL", 53, 59], ["oxygen", "CHEMICAL", 53, 59], ["oxygen", "SIMPLE_CHEMICAL", 53, 59], ["oxygen", "TREATMENT", 53, 59], ["a clear photosensitization effect", "PROBLEM", 76, 109]]], ["When the cells of .gscherichia cell B/r Hcr+ thytrp-are. transferred from a complete synthetic glucose medium to a medium without thymine they lose their colony forming ability after 45 min and frequency of trp \u00a7 revertants increases in the surviving fraction.", [["cells", "ANATOMY", 9, 14], [".gscherichia cell", "ANATOMY", 18, 35], ["colony", "ANATOMY", 154, 160], ["glucose", "CHEMICAL", 95, 102], ["thymine", "CHEMICAL", 130, 137], ["glucose", "CHEMICAL", 95, 102], ["thymine", "CHEMICAL", 130, 137], ["cells", "CELL", 9, 14], [".gscherichia cell B", "CELL", 18, 37], ["Hcr", "GENE_OR_GENE_PRODUCT", 40, 43], ["glucose", "SIMPLE_CHEMICAL", 95, 102], ["thymine", "SIMPLE_CHEMICAL", 130, 137], [".gscherichia cell B", "CELL_LINE", 18, 37], ["Hcr", "PROTEIN", 40, 43], ["trp", "DNA", 207, 210], ["thymine", "TREATMENT", 130, 137], ["trp \u00a7 revertants", "TREATMENT", 207, 223], ["increases", "OBSERVATION_MODIFIER", 224, 233]]], ["Thymine starvation lasting up to 40 min (which does not substantially influence viability of cells and frequency of trp + revertants in the non-irradiated culture} decreases resistance and increases mutability of the cells as compared with the control from the exponential phase of growth.", [["cells", "ANATOMY", 93, 98], ["cells", "ANATOMY", 217, 222], ["Thymine", "CHEMICAL", 0, 7], ["Thymine", "CHEMICAL", 0, 7], ["Thymine", "SIMPLE_CHEMICAL", 0, 7], ["cells", "CELL", 93, 98], ["cells", "CELL", 217, 222], ["trp", "DNA", 116, 119], ["Thymine starvation", "PROBLEM", 0, 18], ["trp + revertants", "PROBLEM", 116, 132], ["mutability of the cells", "PROBLEM", 199, 222]]], ["As compared with the control the irradiation of the prestarved culture with a dose of 756 erg. mm -2 results in a delayed DNA synthesis and higher DNA degradation.", [["DNA", "CELLULAR_COMPONENT", 122, 125], ["DNA", "CELLULAR_COMPONENT", 147, 150], ["prestarved culture", "CELL_LINE", 52, 70], ["the prestarved culture", "TEST", 48, 70], ["a delayed DNA synthesis", "PROBLEM", 112, 135], ["higher DNA degradation", "PROBLEM", 140, 162], ["higher DNA degradation", "OBSERVATION", 140, 162]]], ["However, excision of thymine dimers is not influenced.", [["thymine", "CHEMICAL", 21, 28], ["thymine", "CHEMICAL", 21, 28], ["thymine dimers", "SIMPLE_CHEMICAL", 21, 35], ["excision of thymine dimers", "TREATMENT", 9, 35], ["thymine dimers", "OBSERVATION", 21, 35], ["not", "UNCERTAINTY", 39, 42], ["influenced", "OBSERVATION_MODIFIER", 43, 53]]], ["The lower survival of cells after the IYV irradiation can be explained by the increased degradation of DNA after the irradiation, due to the inhibition of DNA ligase.", [["cells", "ANATOMY", 22, 27], ["IYV", "CHEMICAL", 38, 41], ["cells", "CELL", 22, 27], ["DNA", "CELLULAR_COMPONENT", 103, 106], ["DNA", "CELLULAR_COMPONENT", 155, 158], ["DNA ligase", "PROTEIN", 155, 165], ["The lower survival of cells", "TREATMENT", 0, 27], ["the IYV irradiation", "TREATMENT", 34, 53], ["the increased degradation of DNA", "PROBLEM", 74, 106], ["the irradiation", "TREATMENT", 113, 128], ["DNA ligase", "PROBLEM", 155, 165], ["lower", "OBSERVATION_MODIFIER", 4, 9], ["increased", "OBSERVATION_MODIFIER", 78, 87], ["degradation", "OBSERVATION", 88, 99]]], ["As the mutations can be manifested only in the surviving population, the higher frequency of the UV-indueed trp + reyertants in the prestarved culture must be brought about by a complete but a less accurate filling of gaps in DI~A, originating by excision of thymine dimers and other damage caused by the UV radiation.", [["thymine", "CHEMICAL", 259, 266], ["thymine", "CHEMICAL", 259, 266], ["trp", "GENE_OR_GENE_PRODUCT", 108, 111], ["thymine dimers", "SIMPLE_CHEMICAL", 259, 273], ["UV-indueed trp + reyertants", "DNA", 97, 124], ["prestarved culture", "CELL_LINE", 132, 150], ["the UV", "TEST", 93, 99], ["reyertants", "PROBLEM", 114, 124], ["the prestarved culture", "TEST", 128, 150], ["excision of thymine dimers", "TREATMENT", 247, 273], ["other damage", "PROBLEM", 278, 290], ["the UV radiation", "TREATMENT", 301, 317], ["excision", "OBSERVATION", 247, 255], ["thymine dimers", "OBSERVATION", 259, 273], ["UV radiation", "OBSERVATION", 305, 317]]], ["Experimental details: M medium + 2 ~g/ml thymine -b 28 ~zg/ml DLtryptophan served as a complete medium; viability was determined on the same medium solidified with 2%agar; the same plates with a decreased content of DL-tryptophan (1.5 btg. m1-1) served to determine the trp + revertants; synthesis and degradation of DNA labelled with T-2A4C (I~VVR, Prague) was determined in a TCA-preeipitable fraction; DNA used for a radioehromatographic determination of thymine dimers, in the hydrolysate of high molecular DNA, was labelled in the same way.", [["thymine", "CHEMICAL", 41, 48], ["DLtryptophan", "CHEMICAL", 62, 74], ["DL-tryptophan", "CHEMICAL", 216, 229], ["T-2A4C", "CHEMICAL", 335, 341], ["TCA", "CHEMICAL", 378, 381], ["thymine", "CHEMICAL", 458, 465], ["thymine", "CHEMICAL", 41, 48], ["DLtryptophan", "CHEMICAL", 62, 74], ["DL-tryptophan", "CHEMICAL", 216, 229], ["TCA", "CHEMICAL", 378, 381], ["thymine", "CHEMICAL", 458, 465], ["thymine -b", "SIMPLE_CHEMICAL", 41, 51], ["DLtryptophan", "SIMPLE_CHEMICAL", 62, 74], ["DL-tryptophan", "SIMPLE_CHEMICAL", 216, 229], ["m1-1", "GENE_OR_GENE_PRODUCT", 240, 244], ["DNA", "CELLULAR_COMPONENT", 317, 320], ["T-2A4C", "SIMPLE_CHEMICAL", 335, 341], ["TCA", "SIMPLE_CHEMICAL", 378, 381], ["DNA", "CELLULAR_COMPONENT", 405, 408], ["thymine dimers", "SIMPLE_CHEMICAL", 458, 472], ["DNA", "CELLULAR_COMPONENT", 511, 514], ["m1", "DNA", 240, 242], ["trp", "DNA", 270, 273], ["T-2A4C", "SPECIES", 335, 341], ["DLtryptophan", "TREATMENT", 62, 74], ["DNA", "TEST", 317, 320], ["a radioehromatographic determination", "TEST", 418, 454], ["thymine dimers", "PROBLEM", 458, 472], ["high molecular DNA", "PROBLEM", 496, 514], ["DL", "ANATOMY", 216, 218], ["thymine dimers", "OBSERVATION", 458, 472], ["high molecular DNA", "OBSERVATION", 496, 514]]], ["Content of guanine and cytosine (GC) in DNA of two strains of Pasteurella multocida, eight strains of pasteurella pneumotropica and fourteen strains of Pusteurella ureae, isolated from pathological changes or from upper respiratory tract of man and domestic or laboratory animals, was determined.", [["upper respiratory tract", "ANATOMY", 214, 237], ["guanine", "CHEMICAL", 11, 18], ["cytosine", "CHEMICAL", 23, 31], ["Pasteurella multocida", "DISEASE", 62, 83], ["pasteurella pneumotropica", "DISEASE", 102, 127], ["guanine", "CHEMICAL", 11, 18], ["cytosine", "CHEMICAL", 23, 31], ["guanine", "SIMPLE_CHEMICAL", 11, 18], ["cytosine", "SIMPLE_CHEMICAL", 23, 31], ["GC", "SIMPLE_CHEMICAL", 33, 35], ["DNA", "CELLULAR_COMPONENT", 40, 43], ["Pasteurella multocida", "ORGANISM", 62, 83], ["pasteurella pneumotropica", "ORGANISM", 102, 127], ["Pusteurella ureae", "ORGANISM", 152, 169], ["upper", "ORGANISM_SUBDIVISION", 214, 219], ["respiratory tract", "ORGANISM_SUBDIVISION", 220, 237], ["man", "ORGANISM", 241, 244], ["Pasteurella multocida", "SPECIES", 62, 83], ["pasteurella pneumotropica", "SPECIES", 102, 127], ["Pusteurella ureae", "SPECIES", 152, 169], ["man", "SPECIES", 241, 244], ["Pasteurella multocida", "SPECIES", 62, 83], ["pasteurella pneumotropica", "SPECIES", 102, 127], ["Pusteurella ureae", "SPECIES", 152, 169], ["guanine and cytosine (GC)", "TREATMENT", 11, 36], ["Pasteurella multocida", "PROBLEM", 62, 83], ["pasteurella pneumotropica", "PROBLEM", 102, 127], ["Pusteurella ureae", "PROBLEM", 152, 169], ["pathological changes", "PROBLEM", 185, 205], ["upper respiratory tract", "PROBLEM", 214, 237], ["pasteurella pneumotropica", "OBSERVATION", 102, 127], ["upper", "ANATOMY_MODIFIER", 214, 219], ["respiratory tract", "ANATOMY", 220, 237]]], ["The method of Marmur (1961) based on heat denaturation in 10-2M phosphate buffer with 10-aM EDTA, pH 7, was applied.", [["10-2M phosphate", "CHEMICAL", 58, 73], ["phosphate", "CHEMICAL", 64, 73], ["EDTA", "CHEMICAL", 92, 96], ["10-2M phosphate", "SIMPLE_CHEMICAL", 58, 73], ["10-aM EDTA", "SIMPLE_CHEMICAL", 86, 96], ["heat denaturation", "TREATMENT", 37, 54], ["2M phosphate buffer", "TREATMENT", 61, 80], ["pH", "TEST", 98, 100]]], ["Calculation of GC content from the ratio E2~0/E2s0 according to Frederieq (1961) served as the control method.", [["Calculation of GC content", "TEST", 0, 25], ["GC content", "OBSERVATION", 15, 25]]], ["Average values of the GC content in Pasteurella multocida were 38.65~o, the overall range was 38.6--38.7~o.", [["Pasteurella multocida", "ORGANISM", 36, 57], ["Pasteurella multocida", "SPECIES", 36, 57], ["Pasteurella multocida", "SPECIES", 36, 57], ["Average values", "TEST", 0, 14], ["the GC content", "TEST", 18, 32], ["Pasteurella multocida", "TEST", 36, 57], ["GC content", "OBSERVATION", 22, 32]]], ["Corresponding values in Pasteurella pne~tmotropica and Pasteurella ureae were 39.6% (37.1--40.8%) and 41.6% (38.3--45.5~o), respectively.", [["Pasteurella pne~tmotropica", "ORGANISM", 24, 50], ["Pasteurella ureae", "ORGANISM", 55, 72], ["Pasteurella pne~tmotropica", "SPECIES", 24, 50], ["Pasteurella ureae", "SPECIES", 55, 72], ["Pasteurella pne~tmotropica", "SPECIES", 24, 50], ["Pasteurella ureae", "SPECIES", 55, 72], ["Corresponding values in Pasteurella pne~tmotropica", "TEST", 0, 50], ["Pasteurella ureae", "TEST", 55, 72]]], ["The obtained results reveal a close relationship among all studied species and a genetic homogeneity of the whole genus.", [["whole genus", "ANATOMY", 108, 119]]], ["Further classification of the genus Pasteuretla thus consists in existing differences in tbe~r biochemical properties.", [["the genus Pasteuretla", "PROBLEM", 26, 47], ["genus Pasteuretla", "OBSERVATION", 30, 47], ["biochemical properties", "OBSERVATION", 95, 117]]], ["Enzymic degradation of DiNA causes a relatively high radiosensitivity of Acholeplasma laidlawii (Do = 5000 rad).", [["DiNA", "CHEMICAL", 23, 27], ["DiNA", "SIMPLE_CHEMICAL", 23, 27], ["Acholeplasma laidlawii", "ORGANISM", 73, 95], ["DiNA", "PROTEIN", 23, 27], ["Acholeplasma laidlawii", "SPECIES", 73, 95], ["Acholeplasma laidlawii", "SPECIES", 73, 95], ["Enzymic degradation of DiNA", "PROBLEM", 0, 27], ["a relatively high radiosensitivity of Acholeplasma laidlawii", "PROBLEM", 35, 95], ["relatively", "OBSERVATION_MODIFIER", 37, 47], ["high radiosensitivity", "OBSERVATION_MODIFIER", 48, 69], ["Acholeplasma laidlawii", "OBSERVATION", 73, 95]]], ["It follows from the hitherto experiments, in which changes in molecular weight of DNA of irradiated cells of Aeholeplasma laidlawii were followed by means of centrifugation in neutral and alkaline sucrose gradients, that the induction of single and double breaks highly depends on the presence of oxygen during the irradiation.", [["cells", "ANATOMY", 100, 105], ["sucrose", "CHEMICAL", 197, 204], ["oxygen", "CHEMICAL", 297, 303], ["sucrose", "CHEMICAL", 197, 204], ["oxygen", "CHEMICAL", 297, 303], ["DNA", "CELLULAR_COMPONENT", 82, 85], ["cells", "CELL", 100, 105], ["Aeholeplasma laidlawii", "ORGANISM", 109, 131], ["oxygen", "SIMPLE_CHEMICAL", 297, 303], ["irradiated cells", "CELL_TYPE", 89, 105], ["Aeholeplasma laidlawii", "SPECIES", 109, 131], ["Aeholeplasma laidlawii", "SPECIES", 109, 131], ["Aeholeplasma laidlawii", "TREATMENT", 109, 131], ["centrifugation in neutral and alkaline sucrose gradients", "TREATMENT", 158, 214], ["single and double breaks", "TREATMENT", 238, 262], ["oxygen", "TREATMENT", 297, 303], ["the irradiation", "TREATMENT", 311, 326], ["irradiated cells", "OBSERVATION", 89, 105]]], ["The absorption of 58 eV in the presence of O2 at 0~ results in a single break in the DNA molecule, whereas the absorption of 469 eV gives origin to a double break.", [["O2", "CHEMICAL", 43, 45], ["O2", "CHEMICAL", 43, 45], ["O2", "SIMPLE_CHEMICAL", 43, 45], ["DNA", "CELLULAR_COMPONENT", 85, 88], ["DNA molecule", "PROTEIN", 85, 97], ["O2", "TREATMENT", 43, 45], ["a single break in the DNA molecule", "PROBLEM", 63, 97], ["58 eV", "OBSERVATION_MODIFIER", 18, 23]]], ["Removal of oxygen results in an increase of these values to 159 and 1863 eV, respectively.", [["oxygen", "CHEMICAL", 11, 17], ["oxygen", "CHEMICAL", 11, 17], ["oxygen", "SIMPLE_CHEMICAL", 11, 17], ["Removal of oxygen", "TREATMENT", 0, 17], ["oxygen", "OBSERVATION_MODIFIER", 11, 17], ["increase", "OBSERVATION_MODIFIER", 32, 40]]], ["The relationship between the radiation dose and number of single or double breaks in the molecule of DNA cannot be accurately determined, when the enzymic degradation occurring after the irradiation is not excluded or minimized.", [["DNA", "CELLULAR_COMPONENT", 101, 104], ["the radiation dose", "TREATMENT", 25, 43], ["single or double breaks in the molecule of DNA", "PROBLEM", 58, 104], ["the enzymic degradation", "PROBLEM", 143, 166], ["the irradiation", "TREATMENT", 183, 198], ["double breaks", "OBSERVATION", 68, 81], ["not excluded", "UNCERTAINTY", 202, 214]]], ["Repair of breaks in DiNA after the irradiation with gamma rays could not be observed in the studied strain.", [["DiNA", "CHEMICAL", 20, 24], ["DiNA", "SIMPLE_CHEMICAL", 20, 24], ["Repair", "TREATMENT", 0, 6], ["breaks in DiNA", "PROBLEM", 10, 24], ["the irradiation", "TREATMENT", 31, 46], ["gamma rays", "TREATMENT", 52, 62], ["breaks", "OBSERVATION", 10, 16]]], ["In the other group of experiments a question, whether the UV irradiation of Acholeplasma laidlawii results in degradation of DNA, similar to that after the irradiation with ionizing radiation, was investigated.", [["Acholeplasma laidlawii", "ORGANISM", 76, 98], ["DNA", "CELLULAR_COMPONENT", 125, 128], ["Acholeplasma laidlawii", "SPECIES", 76, 98], ["Acholeplasma laidlawii", "SPECIES", 76, 98], ["the UV irradiation of Acholeplasma laidlawii", "TREATMENT", 54, 98], ["DNA", "PROBLEM", 125, 128], ["the irradiation", "TREATMENT", 152, 167], ["ionizing radiation", "TREATMENT", 173, 191]]], ["It was found that the UV radiation does not bring about the enzymic degradation of DNA in Acheleplasma laidlawii.", [["UV", "CHEMICAL", 22, 24], ["DNA", "CELLULAR_COMPONENT", 83, 86], ["Acheleplasma laidlawii", "ORGANISM", 90, 112], ["Acheleplasma laidlawii", "SPECIES", 90, 112], ["Acheleplasma laidlawii", "SPECIES", 90, 112], ["the UV radiation", "TREATMENT", 18, 34], ["Acheleplasma laidlawii", "TREATMENT", 90, 112]]], ["In addition to the enzymic degradation, the occurrence of DNA fragments of low molecular weight was also followed using doses from Do to doses several times higher.", [["DNA", "CELLULAR_COMPONENT", 58, 61], ["DNA fragments", "DNA", 58, 71], ["the enzymic degradation", "PROBLEM", 15, 38], ["DNA fragments", "PROBLEM", 58, 71], ["low molecular weight", "PROBLEM", 75, 95], ["fragments", "OBSERVATION_MODIFIER", 62, 71], ["low molecular", "OBSERVATION_MODIFIER", 75, 88]]], ["A possible repair of the originating damage was also followed.", [["repair", "TREATMENT", 11, 17], ["the originating damage", "PROBLEM", 21, 43], ["possible", "UNCERTAINTY", 2, 10], ["repair", "OBSERVATION", 11, 17], ["originating", "OBSERVATION_MODIFIER", 25, 36], ["damage", "OBSERVATION", 37, 43]]], ["Double auxotrophic mutants were obtained in the prototrophie PA strain of Mycobacterium phlei by treating auxotrophic mutants, induced in the first step by UV radiation or N-methyl-N-nitroso-N'-nitrogxtanidine (nitrosoguanidine), with nitrosoguanidine under standard conditions (concentration 1 mg/ml, pit 6, survival of cells of the basic suspension 5--10~o).", [["cells", "ANATOMY", 321, 326], ["UV", "CHEMICAL", 156, 158], ["N-methyl-N-nitroso-N'-nitrogxtanidine", "CHEMICAL", 172, 209], ["nitrosoguanidine", "CHEMICAL", 211, 227], ["nitrosoguanidine", "CHEMICAL", 235, 251], ["N-methyl-N-nitroso-N'-nitrogxtanidine", "CHEMICAL", 172, 209], ["nitrosoguanidine", "CHEMICAL", 211, 227], ["nitrosoguanidine", "CHEMICAL", 235, 251], ["PA", "GENE_OR_GENE_PRODUCT", 61, 63], ["Mycobacterium phlei", "ORGANISM", 74, 93], ["N-methyl-N-nitroso-N'-nitrogxtanidine", "SIMPLE_CHEMICAL", 172, 209], ["nitrosoguanidine", "SIMPLE_CHEMICAL", 211, 227], ["nitrosoguanidine", "SIMPLE_CHEMICAL", 235, 251], ["cells", "CELL", 321, 326], ["Mycobacterium phlei", "SPECIES", 74, 93], ["Mycobacterium phlei", "SPECIES", 74, 93], ["Double auxotrophic mutants", "PROBLEM", 0, 26], ["Mycobacterium phlei", "PROBLEM", 74, 93], ["auxotrophic mutants", "PROBLEM", 106, 125], ["UV radiation", "TREATMENT", 156, 168], ["N-methyl-N-nitroso", "TREATMENT", 172, 190], ["nitrogxtanidine", "TREATMENT", 194, 209], ["nitrosoguanidine", "TREATMENT", 211, 227], ["nitrosoguanidine", "TREATMENT", 235, 251], ["pit", "TREATMENT", 302, 305], ["the basic suspension", "TREATMENT", 330, 350], ["auxotrophic mutants", "OBSERVATION", 7, 26], ["Mycobacterium phlei", "OBSERVATION", 74, 93]]], ["Four auxotrophic mutants were used: PA met and PA h/s induced by nitrosoguanidine and mutants PA h/s and PA leu induced by UV radiation.", [["nitrosoguanidine", "CHEMICAL", 65, 81], ["UV", "CHEMICAL", 123, 125], ["nitrosoguanidine", "CHEMICAL", 65, 81], ["PA", "GENE_OR_GENE_PRODUCT", 36, 38], ["PA", "GENE_OR_GENE_PRODUCT", 47, 49], ["nitrosoguanidine", "SIMPLE_CHEMICAL", 65, 81], ["PA", "GENE_OR_GENE_PRODUCT", 94, 96], ["PA leu", "SIMPLE_CHEMICAL", 105, 111], ["Four auxotrophic mutants", "TREATMENT", 0, 24], ["PA met", "TEST", 36, 42], ["nitrosoguanidine", "TREATMENT", 65, 81], ["mutants PA h/s", "PROBLEM", 86, 100], ["PA leu", "TREATMENT", 105, 111], ["UV radiation", "TREATMENT", 123, 135], ["auxotrophic mutants", "OBSERVATION", 5, 24], ["UV radiation", "OBSERVATION", 123, 135]]], ["The induction of double auxotrophic mutants was evaluated quantitatively in original single auxotrophie mutants and the results were compared with those obtained with the prototrophic PA strain.", [["PA", "GENE_OR_GENE_PRODUCT", 184, 186], ["double auxotrophic mutants", "PROTEIN", 17, 43], ["double auxotrophic mutants", "TREATMENT", 17, 43], ["the prototrophic PA strain", "PROBLEM", 167, 193]]], ["Only the PA leu mutant retained practically the same sensitivity to a repeated mutagenie treatment (detection of newly induced auxotrophic mutants 0.23~o) as that observed in the original prototrophie PA strain (detection of auxotrophic mutants 0.11~o).", [["mutagenie", "CHEMICAL", 79, 88], ["PA", "GENE_OR_GENE_PRODUCT", 9, 11], ["PA", "GENE_OR_GENE_PRODUCT", 201, 203], ["PA leu mutant", "PROTEIN", 9, 22], ["auxotrophic mutants", "PROTEIN", 225, 244], ["the PA leu mutant", "PROBLEM", 5, 22], ["a repeated mutagenie treatment", "TREATMENT", 68, 98], ["newly induced auxotrophic mutants", "PROBLEM", 113, 146], ["the original prototrophie PA strain", "PROBLEM", 175, 210], ["auxotrophic mutants", "PROBLEM", 225, 244]]], ["On the other hand, the remaining three single auxotrophic mutants exhibited a higher resistance to a repeated treatment with the mutagen (detection of newly induced auxotrophic mutants 0.02--0.03%).", [["mutagen", "CHEMICAL", 129, 136], ["a repeated treatment", "TREATMENT", 99, 119], ["the mutagen", "TREATMENT", 125, 136], ["newly induced auxotrophic mutants", "TREATMENT", 151, 184], ["higher resistance", "OBSERVATION", 78, 95]]], ["It cannot be concluded, whether this fact can be ascribed to changed structural conditions of DkNA previously treated with the mutagen.", [["DkNA", "GENE_OR_GENE_PRODUCT", 94, 98], ["DkNA", "PROTEIN", 94, 98], ["DkNA", "PROBLEM", 94, 98], ["the mutagen", "TREATMENT", 123, 134]]], ["The induction of newly induced phenotypes probably depends to a certain extent on character of an already existing mutational change.", [["newly induced phenotypes", "PROBLEM", 17, 41]]], ["In the mutant PA met we obtained a broad range of phenotypes frequently induced in the prototrophie PA strain (e.g. arg, his, leu, ileu-val, pur, pyr etc.) .", [["PA", "GENE_OR_GENE_PRODUCT", 14, 16], ["PA", "GENE_OR_GENE_PRODUCT", 100, 102], ["leu", "GENE_OR_GENE_PRODUCT", 126, 129], ["a broad range of phenotypes", "PROBLEM", 33, 60], ["the prototrophie PA strain", "PROBLEM", 83, 109]]], ["Completely new phenotypes (co-aminobutyric acid, riboflavin) were also detected.", [["co-aminobutyric acid", "CHEMICAL", 27, 47], ["riboflavin", "CHEMICAL", 49, 59], ["co-aminobutyric acid", "CHEMICAL", 27, 47], ["riboflavin", "CHEMICAL", 49, 59], ["co-aminobutyric acid", "SIMPLE_CHEMICAL", 27, 47], ["riboflavin", "SIMPLE_CHEMICAL", 49, 59], ["Completely new phenotypes", "PROBLEM", 0, 25], ["co-aminobutyric acid", "TREATMENT", 27, 47], ["riboflavin", "TREATMENT", 49, 59], ["new", "OBSERVATION_MODIFIER", 11, 14], ["phenotypes", "OBSERVATION", 15, 25]]], ["In the PA his strain (originally induced by UV radiation) phenotypes leu, ileu, val predominated, whereas in the PA leu strain the phenotype set was most common; the lys phenotype was also detected and the put phenotype was rather rare.", [["PA", "GENE_OR_GENE_PRODUCT", 7, 9], ["PA leu", "GENE_OR_GENE_PRODUCT", 113, 119], ["lys", "GENE_OR_GENE_PRODUCT", 166, 169], ["UV radiation", "TREATMENT", 44, 56], ["phenotypes leu", "PROBLEM", 58, 72], ["ileu", "PROBLEM", 74, 78], ["the lys phenotype", "TEST", 162, 179]]], ["Other changes of the phenotype could not be detected.Constitutive and Inducible Nucleoside Permease inEscherichia coli.", [["Nucleoside", "CHEMICAL", 80, 90], ["Nucleoside", "CHEMICAL", 80, 90], ["Nucleoside Permease inEscherichia coli", "GENE_OR_GENE_PRODUCT", 80, 118], ["inEscherichia coli", "SPECIES", 100, 118], ["inEscherichia coli", "SPECIES", 100, 118], ["the phenotype", "PROBLEM", 17, 30], ["Constitutive and Inducible Nucleoside Permease inEscherichia coli", "PROBLEM", 53, 118], ["could not be detected", "UNCERTAINTY", 31, 52], ["Nucleoside Permease", "OBSERVATION", 80, 99], ["inEscherichia coli", "OBSERVATION", 100, 118]]], ["J. DOSKO(~IL, Institute of Chemistry and Biochemistry, Czechoslovak Academy of Sciences, Prague.Constitutive and Inducible Nucleoside Permease inMutants deficient in nucleoside permease were obtained by selecting for a crossed resistance to 5-az~mytidine and showdomycin.", [["Nucleoside", "CHEMICAL", 123, 133], ["nucleoside", "CHEMICAL", 166, 176], ["5-az~mytidine", "CHEMICAL", 241, 254], ["showdomycin", "CHEMICAL", 259, 270], ["Nucleoside", "CHEMICAL", 123, 133], ["nucleoside", "CHEMICAL", 166, 176], ["5-az", "CHEMICAL", 241, 245], ["mytidine", "CHEMICAL", 246, 254], ["showdomycin", "CHEMICAL", 259, 270], ["Nucleoside Permease inMutants", "GENE_OR_GENE_PRODUCT", 123, 152], ["nucleoside", "SIMPLE_CHEMICAL", 166, 176], ["5-az~mytidine", "SIMPLE_CHEMICAL", 241, 254], ["showdomycin", "SIMPLE_CHEMICAL", 259, 270], ["nucleoside permease", "PROTEIN", 166, 185], ["Constitutive and Inducible Nucleoside Permease inMutants deficient in nucleoside permease", "PROBLEM", 96, 185], ["a crossed resistance", "TREATMENT", 217, 237], ["mytidine", "TREATMENT", 246, 254], ["showdomycin", "TREATMENT", 259, 270]]], ["Out of 20 mutants of the zCyd r type 12 were simultaneously resistant to showdomycin (zCyd r Shmr), the ren~mdor being of the zCyd r Shins type.", [["showdomycin", "CHEMICAL", 73, 84], ["showdomycin", "CHEMICAL", 73, 84], ["showdomycin", "SIMPLE_CHEMICAL", 73, 84], ["zCyd r Shmr", "GENE_OR_GENE_PRODUCT", 86, 97], ["zCyd r type 12", "DNA", 25, 39], ["zCyd r Shmr", "PROTEIN", 86, 97], ["showdomycin", "TREATMENT", 73, 84], ["Shins", "ANATOMY", 133, 138]]], ["The incorporation of 5-aza-cytidine was about eigi]t times slower in both groups as compared w~th wild bacteria, in addition, mutants of Lhe first group exhibited a decreased substrate affinity during metabolic conversion of a number of other nucleosides.", [["5-aza-cytidine", "CHEMICAL", 21, 35], ["Lhe", "CHEMICAL", 137, 140], ["5-aza-cytidine", "CHEMICAL", 21, 35], ["nucleosides", "CHEMICAL", 243, 254], ["5-aza-cytidine", "SIMPLE_CHEMICAL", 21, 35], ["The incorporation of 5-aza-cytidine", "TREATMENT", 0, 35], ["wild bacteria", "PROBLEM", 98, 111], ["a decreased substrate affinity", "PROBLEM", 163, 193], ["other nucleosides", "TREATMENT", 237, 254]]], ["However, all the above-mentioned properties were again comparable with the wild type when the ceils were cultivated in the presence of thymine: they became sensitive to 5-azacytidine but no~ to show d~myein.", [["ceils", "ANATOMY", 94, 99], ["thymine", "CHEMICAL", 135, 142], ["5-azacytidine", "CHEMICAL", 169, 182], ["thymine", "CHEMICAL", 135, 142], ["5-azacytidine", "CHEMICAL", 169, 182], ["thymine", "SIMPLE_CHEMICAL", 135, 142], ["5-azacytidine", "SIMPLE_CHEMICAL", 169, 182], ["d~myein", "SIMPLE_CHEMICAL", 199, 206], ["azacytidine", "TREATMENT", 171, 182]]], ["Resistance of the zCydr Shw s mutants wa~ not changed by the induction.", [["zCydr Shw", "GENE_OR_GENE_PRODUCT", 18, 27], ["zCydr Shw s mutants", "PROTEIN", 18, 37], ["the zCydr", "TREATMENT", 14, 23]]], ["The obtainzd results show that wild type bacteria have two different nucleoside-permeases determined by two different genes; the first is constitutive, whereas the other is a part of the deo-operon and is induced simultaneously with dee-enzymes.", [["nucleoside", "CHEMICAL", 69, 79], ["nucleoside", "CHEMICAL", 69, 79], ["nucleoside", "SIMPLE_CHEMICAL", 69, 79], ["deo-operon", "GENE_OR_GENE_PRODUCT", 187, 197], ["nucleoside-permeases", "PROTEIN", 69, 89], ["deo-operon", "DNA", 187, 197], ["dee-enzymes", "PROTEIN", 233, 244], ["wild type bacteria", "PROBLEM", 31, 49], ["dee-enzymes", "TEST", 233, 244]]], ["The mutants zCyd r Shm r arc defective in the constitutive permease but retain the inducible enzyme.", [["Shm", "GENE_OR_GENE_PRODUCT", 19, 22], ["zCyd", "PROTEIN", 12, 16], ["Shm", "PROTEIN", 19, 22], ["constitutive permease", "PROTEIN", 46, 67], ["inducible enzyme", "PROTEIN", 83, 99], ["The mutants zCyd r Shm r arc defective", "PROBLEM", 0, 38], ["the constitutive permease", "PROBLEM", 42, 67], ["the inducible enzyme", "TEST", 79, 99], ["arc defective", "OBSERVATION", 25, 38], ["constitutive permease", "OBSERVATION", 46, 67]]], ["The inducible permease transports 5-azacytidine almost as effectively as the constitutive component, but it cannob transport showdomycin.", [["5-azacytidine", "CHEMICAL", 34, 47], ["showdomycin", "CHEMICAL", 125, 136], ["5-azacytidine", "CHEMICAL", 34, 47], ["showdomycin", "CHEMICAL", 125, 136], ["5-azacytidine", "SIMPLE_CHEMICAL", 34, 47], ["cannob", "SIMPLE_CHEMICAL", 108, 114], ["showdomycin", "SIMPLE_CHEMICAL", 125, 136], ["The inducible permease transports", "TREATMENT", 0, 33], ["azacytidine", "TREATMENT", 36, 47]]], ["Different character of the two permeascs was verified by their different sensitivity to the inhibitory effect of s)me analogues of nucleosides (J. DoskoSil and A. Hol~, in press).", [["nucleosides", "CHEMICAL", 131, 142], ["nucleosides", "CHEMICAL", 131, 142], ["nucleosides", "SIMPLE_CHEMICAL", 131, 142], ["nucleosides", "TREATMENT", 131, 142]]], ["The inhibitory studies show~d ~; the s~ne t~me that the permease induced in ba .~ria of the w~id type differs from their constitutive permease a-~d is identical with permease of the zCyd r Shm r mutats.63replication (terminal protein --Jones and Donachie, 1973) , the synthesis could not be sensitive even to very high concentrations of chloramphenicol (up to 400 ~g/ml), The antimicrobial effect of 11 derivatives of 3-quinoline carboxylic acid and nalidixic acid on several species of microorganisms was compared.", [["chloramphenicol", "CHEMICAL", 337, 352], ["3-quinoline carboxylic acid", "CHEMICAL", 418, 445], ["nalidixic acid", "CHEMICAL", 450, 464], ["chloramphenicol", "CHEMICAL", 337, 352], ["3-quinoline carboxylic acid", "CHEMICAL", 418, 445], ["nalidixic acid", "CHEMICAL", 450, 464], ["chloramphenicol", "SIMPLE_CHEMICAL", 337, 352], ["3-quinoline carboxylic acid", "SIMPLE_CHEMICAL", 418, 445], ["nalidixic acid", "SIMPLE_CHEMICAL", 450, 464], ["constitutive permease", "PROTEIN", 121, 142], ["-~d", "PROTEIN", 144, 147], ["zCyd r Shm r mutats", "PROTEIN", 182, 201], ["terminal protein", "PROTEIN", 217, 233], ["The inhibitory studies", "TEST", 0, 22], ["chloramphenicol", "TREATMENT", 337, 352], ["The antimicrobial effect of 11 derivatives", "TREATMENT", 372, 414], ["quinoline carboxylic acid", "TREATMENT", 420, 445], ["nalidixic acid", "TREATMENT", 450, 464], ["microorganisms", "PROBLEM", 487, 501], ["antimicrobial effect", "OBSERVATION_MODIFIER", 376, 396]]], ["In addition, the effect of these compounds on DNA synthesis, growth and colony forming ability wan studied in more detail in Escherichia cell 15 TAU.63The most effective was 1-ethyl-4-oxo-l,4-dihydro-6,7 -methylenedioxy-3 -quinoline carboxylic acid (oxolinie acid) completely inhibiting DNA synthesis at a 10 times lower concentration as compared with the commonly used inhibitor, nalidixic acid, or with any of the tested derivatives lacking the methylene bridge bound to ether oxygens in positions 6 and 7 of the quinoline ring.", [["colony", "ANATOMY", 72, 78], ["cell", "ANATOMY", 137, 141], ["1-ethyl-4-oxo-l,4-dihydro-6,7 -methylenedioxy-3 -quinoline carboxylic acid", "CHEMICAL", 174, 248], ["oxolinie acid", "CHEMICAL", 250, 263], ["nalidixic acid", "CHEMICAL", 381, 395], ["methylene", "CHEMICAL", 447, 456], ["ether oxygens", "CHEMICAL", 473, 486], ["quinoline", "CHEMICAL", 515, 524], ["1-ethyl-4-oxo-l,4-dihydro-6,7 -methylenedioxy-3 -quinoline carboxylic acid", "CHEMICAL", 174, 248], ["oxolinie acid", "CHEMICAL", 250, 263], ["nalidixic acid", "CHEMICAL", 381, 395], ["methylene", "CHEMICAL", 447, 456], ["ether oxygens", "CHEMICAL", 473, 486], ["quinoline", "CHEMICAL", 515, 524], ["DNA", "CELLULAR_COMPONENT", 46, 49], ["Escherichia cell", "CELL", 125, 141], ["1-ethyl-4-oxo-l,4-dihydro-6,7 -methylenedioxy-3 -quinoline carboxylic acid", "SIMPLE_CHEMICAL", 174, 248], ["oxolinie acid", "SIMPLE_CHEMICAL", 250, 263], ["DNA", "CELLULAR_COMPONENT", 287, 290], ["nalidixic acid", "SIMPLE_CHEMICAL", 381, 395], ["methylene", "SIMPLE_CHEMICAL", 447, 456], ["ether oxygens", "SIMPLE_CHEMICAL", 473, 486], ["quinoline ring", "SIMPLE_CHEMICAL", 515, 529], ["these compounds", "PROBLEM", 27, 42], ["DNA synthesis", "TREATMENT", 46, 59], ["ethyl", "TEST", 176, 181], ["oxo", "TEST", 184, 187], ["dihydro", "TREATMENT", 192, 199], ["methylenedioxy", "TREATMENT", 205, 219], ["quinoline carboxylic acid (oxolinie acid)", "TREATMENT", 223, 264], ["DNA synthesis", "TREATMENT", 287, 300], ["nalidixic acid", "TREATMENT", 381, 395], ["the tested derivatives", "TREATMENT", 412, 434], ["the methylene bridge", "TREATMENT", 443, 463], ["ether oxygens", "TREATMENT", 473, 486], ["the quinoline ring", "TREATMENT", 511, 529], ["Escherichia cell", "OBSERVATION", 125, 141], ["quinoline ring", "OBSERVATION", 515, 529]]], ["Cells of Escherichia coli 15 TAU synchronized by starvation for arginine and uracil divide after the addition of arginine and uracil only on the condition that synthesis of DNA is not simultaneously inhibited, at least for 5 min, within 35--55 min after termination of the synchronization.", [["Cells", "ANATOMY", 0, 5], ["arginine", "CHEMICAL", 64, 72], ["uracil", "CHEMICAL", 77, 83], ["arginine", "CHEMICAL", 113, 121], ["uracil", "CHEMICAL", 126, 132], ["arginine", "CHEMICAL", 64, 72], ["uracil", "CHEMICAL", 77, 83], ["arginine", "CHEMICAL", 113, 121], ["uracil", "CHEMICAL", 126, 132], ["Cells", "CELL", 0, 5], ["Escherichia coli", "ORGANISM", 9, 25], ["15", "ORGANISM", 26, 28], ["arginine", "AMINO_ACID", 64, 72], ["uracil", "SIMPLE_CHEMICAL", 77, 83], ["arginine", "SIMPLE_CHEMICAL", 113, 121], ["uracil", "SIMPLE_CHEMICAL", 126, 132], ["DNA", "CELLULAR_COMPONENT", 173, 176], ["Escherichia coli", "SPECIES", 9, 25], ["Escherichia coli", "SPECIES", 9, 25], ["Escherichia coli", "PROBLEM", 9, 25], ["arginine and uracil", "TREATMENT", 64, 83], ["arginine and uracil", "TREATMENT", 113, 132], ["synthesis of DNA", "PROBLEM", 160, 176], ["the synchronization", "TREATMENT", 269, 288], ["Escherichia coli", "OBSERVATION", 9, 25]]], ["DNA synthesis was inhibited by thymine starvation, by nalidixic acid and by oxolinic acid.", [["thymine", "CHEMICAL", 31, 38], ["nalidixic acid", "CHEMICAL", 54, 68], ["oxolinic acid", "CHEMICAL", 76, 89], ["thymine", "CHEMICAL", 31, 38], ["nalidixic acid", "CHEMICAL", 54, 68], ["oxolinic acid", "CHEMICAL", 76, 89], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["thymine", "SIMPLE_CHEMICAL", 31, 38], ["nalidixic acid", "SIMPLE_CHEMICAL", 54, 68], ["oxolinic acid", "SIMPLE_CHEMICAL", 76, 89], ["DNA synthesis", "PROBLEM", 0, 13], ["thymine starvation", "TREATMENT", 31, 49], ["nalidixic acid", "TREATMENT", 54, 68], ["oxolinic acid", "TREATMENT", 76, 89]]], ["We assume that the DNA synthesis is necessary for completion of replication cycles that were not fully completed under the conditions of synchronization.", [["DNA", "CELLULAR_COMPONENT", 19, 22], ["the DNA synthesis", "TEST", 15, 32], ["replication cycles", "TREATMENT", 64, 82]]], ["The addition of thymine for 5 min beginning at any time interval within 35--55 rain induces division of a fraction\" of cells beginning with the 60th min of incubation.", [["cells", "ANATOMY", 119, 124], ["thymine", "CHEMICAL", 16, 23], ["thymine", "CHEMICAL", 16, 23], ["thymine", "SIMPLE_CHEMICAL", 16, 23], ["cells", "CELL", 119, 124], ["thymine", "TREATMENT", 16, 23]]], ["It follows that completion of replication of the chromosome is necessary for the division, but it is not a signal of a time process determining the interval, when the subsequent division will take place.", [["chromosome", "ANATOMY", 49, 59], ["chromosome", "CELLULAR_COMPONENT", 49, 59]]], ["As chloramphcnicol added after 45 rain did not inhibit division induced by the addition of thymine 50 rain after the synchronization, it may be assumed that after completion of the replication cycle protein synthesis associated with the division need not proceed.", [["chloramphcnicol", "CHEMICAL", 3, 18], ["thymine", "CHEMICAL", 91, 98], ["chloramphcnicol", "CHEMICAL", 3, 18], ["thymine", "CHEMICAL", 91, 98], ["chloramphcnicol", "SIMPLE_CHEMICAL", 3, 18], ["thymine", "SIMPLE_CHEMICAL", 91, 98], ["chloramphcnicol", "TREATMENT", 3, 18], ["thymine", "TREATMENT", 91, 98], ["the replication cycle protein synthesis", "TREATMENT", 177, 216]]], ["If thus synthesis of a regulatory protein were associated with completion of the blutagenesis of the replication point of auxotrophic mutants of the PA strain of Myeobaeterium phlci was studied from the point of view of induetion of resistance to antitubereulosis agents.", [["PA", "GENE_OR_GENE_PRODUCT", 149, 151], ["Myeobaeterium phlci", "ORGANISM", 162, 181], ["antitubereulosis agents", "SIMPLE_CHEMICAL", 247, 270], ["regulatory protein", "PROTEIN", 23, 41], ["auxotrophic mutants", "PROTEIN", 122, 141], ["Myeobaeterium phlci", "SPECIES", 162, 181], ["a regulatory protein", "PROBLEM", 21, 41], ["auxotrophic mutants", "PROBLEM", 122, 141], ["the PA strain of Myeobaeterium phlci", "PROBLEM", 145, 181], ["antitubereulosis agents", "TREATMENT", 247, 270], ["auxotrophic mutants", "OBSERVATION", 122, 141]]], ["Mutagenic processes were induced by N-methyl-Nnitroso-N'-nitroguanidine, the mutagenic activity of which is maximal in the replicating region of DNA.", [["N-methyl-Nnitroso-N'-nitroguanidine", "CHEMICAL", 36, 71], ["N-methyl-Nnitroso-N'-nitroguanidine", "CHEMICAL", 36, 71], ["N-methyl-Nnitroso-N'-nitroguanidine", "SIMPLE_CHEMICAL", 36, 71], ["DNA", "CELLULAR_COMPONENT", 145, 148], ["Mutagenic processes", "PROBLEM", 0, 19], ["N-methyl-Nnitroso", "TREATMENT", 36, 53], ["nitroguanidine", "TREATMENT", 57, 71], ["mutagenic activity", "OBSERVATION", 77, 95], ["maximal", "OBSERVATION_MODIFIER", 108, 115], ["DNA", "OBSERVATION", 145, 148]]], ["The method of induction of revertants in a synchronized culture, consisting of the synchronization procedure and the mutational process proper, was applied.", [["a synchronized culture", "TEST", 41, 63], ["the synchronization procedure", "TREATMENT", 79, 108], ["the mutational process", "TREATMENT", 113, 135]]], ["The culture was synchronized by a combination of the cold shock with a previous centrifugation.", [["shock", "DISEASE", 58, 63], ["The culture", "TEST", 0, 11], ["the cold shock", "PROBLEM", 49, 63], ["a previous centrifugation", "TREATMENT", 69, 94], ["cold shock", "OBSERVATION", 53, 63]]], ["The procedure of the induction of revertants in the synchronized culture has already been worked out and verified with three auxotrophic mutants of Mycobacterium phlei.", [["Mycobacterium phlei", "ORGANISM", 148, 167], ["Mycobacterium phlei", "SPECIES", 148, 167], ["Mycobacterium phlei", "SPECIES", 148, 167], ["The procedure", "TREATMENT", 0, 13], ["the induction of revertants", "TREATMENT", 17, 44], ["the synchronized culture", "TEST", 48, 72], ["Mycobacterium phlei", "PROBLEM", 148, 167], ["Mycobacterium phlei", "OBSERVATION", 148, 167]]], ["In this work we used double auxotrophic mutants PA leu met, PA met put, PA met arg, in which the induction of reversions was followed, and single mutants PA met and PA leu, in which the induction of resistance to streptomycin, ethionamide, cycloserine and resistomycin was investigated.", [["streptomycin", "CHEMICAL", 213, 225], ["ethionamide", "CHEMICAL", 227, 238], ["cycloserine", "CHEMICAL", 240, 251], ["resistomycin", "CHEMICAL", 256, 268], ["streptomycin", "CHEMICAL", 213, 225], ["ethionamide", "CHEMICAL", 227, 238], ["cycloserine", "CHEMICAL", 240, 251], ["resistomycin", "CHEMICAL", 256, 268], ["PA leu", "SIMPLE_CHEMICAL", 48, 54], ["PA", "GENE_OR_GENE_PRODUCT", 60, 62], ["PA", "GENE_OR_GENE_PRODUCT", 72, 74], ["PA", "GENE_OR_GENE_PRODUCT", 154, 156], ["PA leu", "GENE_OR_GENE_PRODUCT", 165, 171], ["streptomycin", "SIMPLE_CHEMICAL", 213, 225], ["ethionamide", "SIMPLE_CHEMICAL", 227, 238], ["cycloserine", "SIMPLE_CHEMICAL", 240, 251], ["resistomycin", "SIMPLE_CHEMICAL", 256, 268], ["double auxotrophic mutants PA leu", "TREATMENT", 21, 54], ["PA met", "TEST", 60, 66], ["PA met arg", "TEST", 72, 82], ["PA leu", "TREATMENT", 165, 171], ["streptomycin", "TREATMENT", 213, 225], ["ethionamide", "TREATMENT", 227, 238], ["cycloserine", "TREATMENT", 240, 251], ["resistomycin", "TREATMENT", 256, 268]]], ["By calculating maximal induction of the followed mutational changes we determined localization of eight genes on the chromosome of Mycobacterium phlei.", [["chromosome", "ANATOMY", 117, 127], ["chromosome", "CELLULAR_COMPONENT", 117, 127], ["Mycobacterium phlei", "ORGANISM", 131, 150], ["Mycobacterium phlei", "SPECIES", 131, 150], ["Mycobacterium phlei", "SPECIES", 131, 150], ["Mycobacterium phlei", "PROBLEM", 131, 150], ["Mycobacterium phlei", "OBSERVATION", 131, 150]]], ["It was found that D-glucosamine and D-galartosamine form a determinant part of receptors of the competence factor (CF) on the surface of the Pneuraoeoccus (Kohoutovs and Kocourek, l~ature 247, 277 1974) .", [["surface", "ANATOMY", 126, 133], ["D-glucosamine", "CHEMICAL", 18, 31], ["D-galartosamine", "CHEMICAL", 36, 51], ["D-glucosamine", "CHEMICAL", 18, 31], ["D-galartosamine", "CHEMICAL", 36, 51], ["D-glucosamine", "SIMPLE_CHEMICAL", 18, 31], ["D-galartosamine", "SIMPLE_CHEMICAL", 36, 51], ["surface", "CELLULAR_COMPONENT", 126, 133], ["competence factor", "PROTEIN", 96, 113], ["CF", "PROTEIN", 115, 117], ["glucosamine", "TREATMENT", 20, 31], ["D-galartosamine", "TREATMENT", 36, 51]]], ["Binding of CF to the receptors as a function of time was followed biologically in a transformation medium without bovine serum albumin.", [["serum", "ANATOMY", 121, 126], ["CF", "MULTI-TISSUE_STRUCTURE", 11, 13], ["bovine", "ORGANISM", 114, 120], ["serum", "ORGANISM_SUBSTANCE", 121, 126], ["albumin", "GENE_OR_GENE_PRODUCT", 127, 134], ["bovine", "SPECIES", 114, 120], ["bovine serum albumin", "TREATMENT", 114, 134]]], ["This is demonstrated by a loss of activity in the supernataut.", [["a loss of activity in the supernataut", "PROBLEM", 24, 61], ["loss", "OBSERVATION_MODIFIER", 26, 30], ["activity", "OBSERVATION_MODIFIER", 34, 42]]], ["After 10 rain, when the induetion of competence in non-competent ceils roaches its maximum, CF is released from the receptors to the supernatant.", [["supernatant", "ANATOMY", 133, 144]]], ["Under conditions, when the spontaneous competence originates cyclically in the recipient culture, CF is cyclically bound to receptors of non-competent cells.", [["cells", "ANATOMY", 151, 156], ["cells", "CELL", 151, 156], ["non-competent cells", "CELL_TYPE", 137, 156], ["the recipient culture", "TEST", 75, 96], ["non-competent cells", "OBSERVATION", 137, 156]]], ["However, after the induction only a single sharp peak of competence with a maximum after 10 rnin can be detected.Mutagenesis o] the Replication Point inThe first step .of the induction process, i.e. the ability to bind the added CF to the receptors, can be studied in the mutant blocked in the reversible and irreversible binding of DI~A and not producing CF, by means of the described method.", [["the induction process", "TREATMENT", 171, 192]]], ["The effect of NaN3 on. the irreversible binding of the donor DNA by the recipient cell and its transformation was studied in the strains Bacillus subtills 168 trp2 and Bacillus subtili~ trp2 thy.", [["cell", "ANATOMY", 82, 86], ["NaN3", "CHEMICAL", 14, 18], ["NaN3", "CHEMICAL", 14, 18], ["NaN3", "SIMPLE_CHEMICAL", 14, 18], ["DNA", "CELLULAR_COMPONENT", 61, 64], ["cell", "CELL", 82, 86], ["Bacillus subtills 168 trp2", "ORGANISM", 137, 163], ["Bacillus subtili", "ORGANISM", 168, 184], ["donor DNA", "DNA", 55, 64], ["recipient cell", "CELL_TYPE", 72, 86], ["Bacillus subtili", "SPECIES", 168, 184], ["Bacillus subtills 168 trp2", "SPECIES", 137, 163], ["Bacillus subtili", "SPECIES", 168, 184], ["NaN3", "TREATMENT", 14, 18], ["the irreversible binding", "PROBLEM", 23, 47], ["the donor DNA", "TREATMENT", 51, 64], ["the strains Bacillus", "TEST", 125, 145], ["trp2", "TEST", 159, 163], ["Bacillus subtili", "TEST", 168, 184], ["irreversible", "OBSERVATION_MODIFIER", 27, 39], ["donor DNA", "OBSERVATION", 55, 64]]], ["The method of collection of cells on membrane filters was used to follow the amount of irreversibly bound 3H-labelled DNA; the number of transformants was followed by spraying on plates.", [["cells", "ANATOMY", 28, 33], ["membrane", "ANATOMY", 37, 45], ["transformants", "ANATOMY", 137, 150], ["3H", "CHEMICAL", 106, 108], ["3H", "CHEMICAL", 106, 108], ["cells", "CELL", 28, 33], ["membrane", "CELLULAR_COMPONENT", 37, 45], ["DNA", "CELLULAR_COMPONENT", 118, 121], ["transformants", "CELL", 137, 150], ["membrane filters", "TREATMENT", 37, 53], ["labelled DNA", "PROBLEM", 109, 121], ["membrane filters", "OBSERVATION", 37, 53]]], ["The addition of NaNa at a concentration of 5 \u2022 10-2~ inhibited the transformation completely, but did not inhibit the irreversible binding of the all-labelled DI~A by the recipient cell.", [["cell", "ANATOMY", 181, 185], ["NaNa", "CHEMICAL", 16, 20], ["NaNa", "CHEMICAL", 16, 20], ["NaNa", "SIMPLE_CHEMICAL", 16, 20], ["DI~A", "SIMPLE_CHEMICAL", 159, 163], ["cell", "CELL", 181, 185], ["recipient cell", "CELL_TYPE", 171, 185], ["NaNa at a concentration", "TREATMENT", 16, 39], ["the irreversible binding", "PROBLEM", 114, 138], ["NaNa", "OBSERVATION_MODIFIER", 16, 20], ["irreversible", "OBSERVATION", 118, 130], ["recipient cell", "OBSERVATION", 171, 185]]], ["However, a considerable degradation of the irreversibly bound DNA occurs in the presence of the metabolic inhibitor.", [["DNA", "CELLULAR_COMPONENT", 62, 65], ["the irreversibly bound DNA", "PROBLEM", 39, 65], ["the metabolic inhibitor", "TREATMENT", 92, 115], ["irreversibly", "OBSERVATION_MODIFIER", 43, 55], ["bound DNA", "OBSERVATION", 56, 65], ["metabolic inhibitor", "OBSERVATION", 96, 115]]], ["A 40 min incubation of the cells (37~ after the irreversible binding of DNA by the recipient cell showed that in the presence of NaN8 50% of the irreversibly bound DNA is degraded to TCA soluble products, as compared with the control.", [["cells", "ANATOMY", 27, 32], ["cell", "ANATOMY", 93, 97], ["NaN8", "CHEMICAL", 129, 133], ["TCA", "CHEMICAL", 183, 186], ["NaN8", "CHEMICAL", 129, 133], ["TCA", "CHEMICAL", 183, 186], ["cells", "CELL", 27, 32], ["DNA", "CELLULAR_COMPONENT", 72, 75], ["cell", "CELL", 93, 97], ["DNA", "CELLULAR_COMPONENT", 164, 167], ["TCA", "SIMPLE_CHEMICAL", 183, 186], ["TCA soluble products", "PROTEIN", 183, 203], ["the irreversible binding of DNA", "PROBLEM", 44, 75], ["NaN8", "TEST", 129, 133], ["the irreversibly bound DNA", "PROBLEM", 141, 167], ["TCA soluble products", "TREATMENT", 183, 203], ["irreversibly", "OBSERVATION_MODIFIER", 145, 157], ["bound DNA", "OBSERVATION", 158, 167]]], ["A new model of the irreversible binding of the transformation DNA by the recipient cell was postulated on the basis of the obtained results.", [["cell", "ANATOMY", 83, 87], ["DNA", "CELLULAR_COMPONENT", 62, 65], ["cell", "CELL", 83, 87], ["transformation DNA", "DNA", 47, 65], ["the irreversible binding", "PROBLEM", 15, 39], ["the transformation DNA", "PROBLEM", 43, 65], ["new", "OBSERVATION_MODIFIER", 2, 5], ["irreversible", "OBSERVATION_MODIFIER", 19, 31], ["binding", "OBSERVATION_MODIFIER", 32, 39], ["transformation DNA", "OBSERVATION", 47, 65], ["recipient cell", "OBSERVATION", 73, 87]]], ["Nocardia and Streptomycetes.", [["Nocardia", "DISEASE", 0, 8], ["Nocardia", "PROBLEM", 0, 8], ["Streptomycetes", "PROBLEM", 13, 27], ["Streptomycetes", "OBSERVATION", 13, 27]]], ["A high number of attxotrophic mutants requiring amino acids and to a lesser extent components of nucleic acids and vitamins were obtained by induction with N-methyl-N-nitroso-l~'-nitroguanidine C1 mg/ml, pH 6 and survival of the basic suspension of 30% and 5~o).On Conjugation inFQur auxotrophic mutants of ~lycobacterium smeg-mati~ CCM 2300 and eight auxotrophic mutants of Myeobacterium smegmatis My 23/64 that were mutually crossed were used in the experiments proper.", [["amino acids", "CHEMICAL", 48, 59], ["nucleic acids", "CHEMICAL", 97, 110], ["vitamins", "CHEMICAL", 115, 123], ["N-methyl-N-nitroso-l~'-nitroguanidine", "CHEMICAL", 156, 193], ["amino acids", "CHEMICAL", 48, 59], ["N-methyl-N-nitroso-l~'-nitroguanidine", "CHEMICAL", 156, 193], ["amino acids", "AMINO_ACID", 48, 59], ["nucleic acids", "SIMPLE_CHEMICAL", 97, 110], ["vitamins", "SIMPLE_CHEMICAL", 115, 123], ["N-methyl-N-nitroso-l~'-nitroguanidine", "SIMPLE_CHEMICAL", 156, 193], ["Myeobacterium smegmatis", "ORGANISM", 375, 398], ["attxotrophic mutants", "PROTEIN", 17, 37], ["Myeobacterium smegmatis", "SPECIES", 375, 398], ["Myeobacterium smegmatis My 23/64", "SPECIES", 375, 407], ["attxotrophic mutants", "PROBLEM", 17, 37], ["amino acids", "TREATMENT", 48, 59], ["nucleic acids", "TREATMENT", 97, 110], ["vitamins", "TREATMENT", 115, 123], ["N-methyl-N-nitroso", "TREATMENT", 156, 174], ["nitroguanidine", "TREATMENT", 179, 193], ["the basic suspension", "TEST", 225, 245], ["Myeobacterium smegmatis", "PROBLEM", 375, 398], ["high number", "OBSERVATION_MODIFIER", 2, 13]]], ["Prototrophic colonies originating as a result of a simultaneous growth always of two auxotrophic mutants did not exceed substantially in their frequency the frequency of spontaneous reversions of individual auxotrophic mutants.", [["colonies", "ANATOMY", 13, 21], ["Prototrophic colonies", "CELL_LINE", 0, 21], ["auxotrophic mutants", "PROTEIN", 207, 226], ["Prototrophic colonies", "PROBLEM", 0, 21], ["a simultaneous growth", "PROBLEM", 49, 70], ["two auxotrophic mutants", "PROBLEM", 81, 104], ["spontaneous reversions of individual auxotrophic mutants", "PROBLEM", 170, 226], ["colonies", "OBSERVATION", 13, 21], ["auxotrophic mutants", "OBSERVATION", 85, 104], ["auxotrophic mutants", "OBSERVATION", 207, 226]]], ["Negative results are probably caused either by a limited number of used mutants or by unsuitability of the selected strains of Mycobacterium smegmatis.", [["Mycobacterium smegmatis", "ORGANISM", 127, 150], ["Mycobacterium smegmatis", "SPECIES", 127, 150], ["Mycobacterium smegmatis", "SPECIES", 127, 150], ["Mycobacterium smegmatis", "PROBLEM", 127, 150], ["probably caused", "UNCERTAINTY", 21, 36], ["Mycobacterium smegmatis", "OBSERVATION", 127, 150]]], ["Surface layers of the bacterial cell play an important and incompletely understood role in processes of adsorption and inhibitory effect of colicins.", [["cell", "ANATOMY", 32, 36], ["bacterial cell", "CELL", 22, 36], ["colicins", "SIMPLE_CHEMICAL", 140, 148], ["the bacterial cell play", "PROBLEM", 18, 41], ["colicins", "TREATMENT", 140, 148], ["bacterial cell", "OBSERVATION", 22, 36]]], ["Quantitative reanges in these two processes wech hence followed in sensitive bacteria exposed to:Adsorption and E]/eet el Colicins on Sensitive Bac-(1) plasmolysis and deplasmolysis, (2) urea, (3) surface active compounds.", [["surface", "ANATOMY", 197, 204], ["urea", "CHEMICAL", 187, 191], ["urea", "CHEMICAL", 187, 191], ["eet el Colicins", "SIMPLE_CHEMICAL", 115, 130], ["urea", "SIMPLE_CHEMICAL", 187, 191], ["(3) surface active compounds", "SIMPLE_CHEMICAL", 193, 221], ["Quantitative reanges", "PROBLEM", 0, 20], ["sensitive bacteria", "PROBLEM", 67, 85], ["Sensitive Bac", "TEST", 134, 147], ["plasmolysis", "TEST", 152, 163], ["deplasmolysis", "TEST", 168, 181], ["urea", "TEST", 187, 191], ["surface active compounds", "PROBLEM", 197, 221], ["active", "OBSERVATION_MODIFIER", 205, 211], ["compounds", "OBSERVATION", 212, 221]]], ["The experiments were performed with colicins E2 and K. Adsorption capacity of the plasmolyzed bacteria for eolicins is decreased; their inhibitory effect is also proportionally decreased.", [["E2", "CHEMICAL", 45, 47], ["eolicins", "CHEMICAL", 107, 115], ["eolicins", "CHEMICAL", 107, 115], ["colicins E2", "SIMPLE_CHEMICAL", 36, 47], ["eolicins", "SIMPLE_CHEMICAL", 107, 115], ["The experiments", "TEST", 0, 15], ["colicins E2", "TREATMENT", 36, 47], ["the plasmolyzed bacteria", "TREATMENT", 78, 102], ["eolicins", "TREATMENT", 107, 115], ["decreased", "OBSERVATION_MODIFIER", 119, 128], ["proportionally", "OBSERVATION_MODIFIER", 162, 176], ["decreased", "OBSERVATION_MODIFIER", 177, 186]]], ["However, colicin bound to bacteria cannot be released by transfer to a hypertonic solution after the adsorption.", [["colicin", "CHEMICAL", 9, 16], ["colicin", "GENE_OR_GENE_PRODUCT", 9, 16], ["colicin", "PROTEIN", 9, 16], ["colicin bound to bacteria", "PROBLEM", 9, 34], ["a hypertonic solution", "TREATMENT", 69, 90]]], ["The decreased adsorption capacity, as well as the decreased effect of eolicins, remain unchanged even after deplasmolysis (restoration of the physical contact of the cytoplasmic membrane with the wall does not restore its functional integrity).", [["cytoplasmic membrane", "ANATOMY", 166, 186], ["wall", "ANATOMY", 196, 200], ["eolicins", "CHEMICAL", 70, 78], ["eolicins", "SIMPLE_CHEMICAL", 70, 78], ["cytoplasmic membrane", "CELLULAR_COMPONENT", 166, 186], ["The decreased adsorption capacity", "PROBLEM", 0, 33], ["the decreased effect of eolicins", "PROBLEM", 46, 78], ["deplasmolysis", "TREATMENT", 108, 121], ["decreased", "OBSERVATION_MODIFIER", 4, 13], ["adsorption capacity", "OBSERVATION", 14, 33], ["decreased", "OBSERVATION_MODIFIER", 50, 59], ["unchanged", "OBSERVATION_MODIFIER", 87, 96]]], ["The hypertonie medium daes not influence the adsorption capacity of the isolated fraction of the surface structures.", [["surface structures", "ANATOMY", 97, 115], ["hypertonie", "CHEMICAL", 4, 14], ["hypertonie", "CHEMICAL", 4, 14], ["hypertonie", "SIMPLE_CHEMICAL", 4, 14], ["surface structures", "CELLULAR_COMPONENT", 97, 115], ["isolated fraction", "OBSERVATION", 72, 89], ["surface", "OBSERVATION_MODIFIER", 97, 104]]], ["Highest concentrations of urea (highest possible concentration with respect to activity of eolicins) were used; urea did not have any effect either on the adsorption or the effect of both colicins.", [["urea", "CHEMICAL", 26, 30], ["urea", "CHEMICAL", 112, 116], ["urea", "CHEMICAL", 26, 30], ["eolicins", "CHEMICAL", 91, 99], ["urea", "CHEMICAL", 112, 116], ["urea", "SIMPLE_CHEMICAL", 26, 30], ["eolicins", "SIMPLE_CHEMICAL", 91, 99], ["urea", "SIMPLE_CHEMICAL", 112, 116], ["Highest concentrations of urea", "PROBLEM", 0, 30], ["activity of eolicins", "TREATMENT", 79, 99], ["both colicins", "TREATMENT", 183, 196], ["urea", "OBSERVATION_MODIFIER", 26, 30]]], ["On the other hand, the adsorption capacity, as well as the effect on bacteria, were decreased when treating the cells with detergents attacking lipoproteins of the cell surfaces, i.e. dodecylsulphate and sodium deoxycholate.Adsorption and E]/eet el Colicins on Sensitive Bac-However, none of these agents could release eolicins that had already been adsorbed on bacteria or reverse their inhibitory effect.", [["cells", "ANATOMY", 112, 117], ["cell", "ANATOMY", 164, 168], ["dodecylsulphate", "CHEMICAL", 184, 199], ["sodium deoxycholate", "CHEMICAL", 204, 223], ["eolicins", "CHEMICAL", 319, 327], ["dodecylsulphate", "CHEMICAL", 184, 199], ["sodium deoxycholate", "CHEMICAL", 204, 223], ["eolicins", "CHEMICAL", 319, 327], ["cells", "CELL", 112, 117], ["cell", "CELL", 164, 168], ["dodecylsulphate", "SIMPLE_CHEMICAL", 184, 199], ["sodium deoxycholate", "SIMPLE_CHEMICAL", 204, 223], ["eet el Colicins", "SIMPLE_CHEMICAL", 242, 257], ["eolicins", "SIMPLE_CHEMICAL", 319, 327], ["the adsorption capacity", "TEST", 19, 42], ["bacteria", "PROBLEM", 69, 77], ["the cells", "PROBLEM", 108, 117], ["the cell surfaces", "TREATMENT", 160, 177], ["dodecylsulphate", "TREATMENT", 184, 199], ["sodium deoxycholate", "TREATMENT", 204, 223], ["bacteria", "PROBLEM", 362, 370], ["cell surfaces", "OBSERVATION", 164, 177]]], ["Damage of surface structures of bacteria thus increases their resistance to colieins, simultaneously with a decrease of thei r adsorption capacity.Trans/erable Resista~ce in Urinary Strains o]Escheriehia coli.", [["surface structures", "ANATOMY", 10, 28], ["colieins", "CHEMICAL", 76, 84], ["colieins", "CHEMICAL", 76, 84], ["colieins", "SIMPLE_CHEMICAL", 76, 84], ["Escheriehia coli", "ORGANISM", 192, 208], ["Escheriehia coli", "SPECIES", 192, 208], ["Escheriehia coli", "SPECIES", 192, 208], ["Damage of surface structures of bacteria", "PROBLEM", 0, 40], ["a decrease of thei r adsorption capacity", "PROBLEM", 106, 146], ["Urinary Strains", "PROBLEM", 174, 189], ["Escheriehia coli", "PROBLEM", 192, 208], ["surface", "OBSERVATION_MODIFIER", 10, 17], ["bacteria", "OBSERVATION", 32, 40], ["resistance", "OBSERVATION_MODIFIER", 62, 72], ["decrease", "OBSERVATION_MODIFIER", 108, 116], ["adsorption capacity", "OBSERVATION", 127, 146], ["Urinary", "ANATOMY", 174, 181], ["Escheriehia coli", "OBSERVATION", 192, 208]]], ["V. CItALOUPECK~, Institute of Hygiene and Epidemiology, Prague.Trans/erable Resista~ce in Urinary Strains o]Of the strains of Escherichia coli isolated as etiological agents of diseases of the urinary tract 23.5~o were able to transfer resistance to certain antibiotics by conjugation with Citrobacter ]reundii in vitro.", [["urinary tract", "ANATOMY", 193, 206], ["diseases of the urinary tract", "DISEASE", 177, 206], ["Escherichia coli", "ORGANISM", 126, 142], ["urinary tract", "ORGANISM_SUBDIVISION", 193, 206], ["Citrobacter ]reundii", "ORGANISM", 290, 310], ["Escherichia coli", "SPECIES", 126, 142], ["Escherichia coli", "SPECIES", 126, 142], ["Citrobacter ]reundii", "SPECIES", 290, 310], ["Urinary Strains", "PROBLEM", 90, 105], ["Escherichia coli", "PROBLEM", 126, 142], ["diseases", "PROBLEM", 177, 185], ["the urinary tract", "PROBLEM", 189, 206], ["certain antibiotics", "TREATMENT", 250, 269], ["Citrobacter", "PROBLEM", 290, 301], ["Urinary", "ANATOMY", 90, 97], ["Escherichia coli", "OBSERVATION", 126, 142], ["urinary tract", "ANATOMY", 193, 206]]], ["Two R-factors and sometimes R-factor and col-factor were present in cells of some strains.", [["cells", "ANATOMY", 68, 73], ["R-factors", "GENE_OR_GENE_PRODUCT", 4, 13], ["R-factor", "GENE_OR_GENE_PRODUCT", 28, 36], ["col-factor", "GENE_OR_GENE_PRODUCT", 41, 51], ["cells", "CELL", 68, 73], ["R-factors", "PROTEIN", 4, 13], ["R-factor", "PROTEIN", 28, 36], ["col-factor", "PROTEIN", 41, 51], ["sometimes R-factor and col-factor", "PROBLEM", 18, 51], ["some strains", "PROBLEM", 77, 89]]], ["However, the serotype of the strains or an occasional ability to haemolyze red blood cells were not associated with the presence of a col-factor or R-factor of a certain fi character.", [["red blood cells", "ANATOMY", 75, 90], ["red blood cells", "CELL", 75, 90], ["R-factor", "GENE_OR_GENE_PRODUCT", 148, 156], ["haemolyze red blood cells", "CELL_TYPE", 65, 90], ["R-factor", "PROTEIN", 148, 156], ["the strains", "PROBLEM", 25, 36], ["red blood cells", "TEST", 75, 90], ["a col-factor", "PROBLEM", 132, 144]]], ["Degree of resistanee determined by the R-factors differed only insignificantly in the Citrobactsr and Escherichia eoli K 13 Hit.", [["R-factors", "GENE_OR_GENE_PRODUCT", 39, 48], ["R-factors", "PROTEIN", 39, 48], ["Escherichia eoli", "SPECIES", 102, 118], ["Escherichia eoli", "SPECIES", 102, 118], ["Escherichia eoli K", "TEST", 102, 120], ["Hit", "PROBLEM", 124, 127], ["Escherichia eoli", "OBSERVATION", 102, 118]]], ["Resistance was induced to ehloramphenicol (256 ~zg/ml and more), neomycin (126 to 256 [zg/ml), streptomycin (8--512 ~zg/ml and even higher values found in the studied strains were not transferred) and tetracycline (64--512 ptg/ml).", [["ehloramphenicol", "CHEMICAL", 26, 41], ["neomycin", "CHEMICAL", 65, 73], ["streptomycin", "CHEMICAL", 95, 107], ["tetracycline", "CHEMICAL", 201, 213], ["ehloramphenicol", "CHEMICAL", 26, 41], ["neomycin", "CHEMICAL", 65, 73], ["streptomycin", "CHEMICAL", 95, 107], ["tetracycline", "CHEMICAL", 201, 213], ["ehloramphenicol", "SIMPLE_CHEMICAL", 26, 41], ["neomycin", "SIMPLE_CHEMICAL", 65, 73], ["streptomycin", "SIMPLE_CHEMICAL", 95, 107], ["tetracycline", "SIMPLE_CHEMICAL", 201, 213], ["Resistance", "PROBLEM", 0, 10], ["ehloramphenicol", "TEST", 26, 41], ["neomycin", "TREATMENT", 65, 73], ["streptomycin", "TREATMENT", 95, 107], ["tetracycline", "TREATMENT", 201, 213]]], ["Concentrations of chloramphenieol, streptomycin and tetracycline that can be reached in urine are 30 [zg/ml, 1000 ~zg/ml and 300 ~tg/ml, respectively.", [["urine", "ANATOMY", 88, 93], ["chloramphenieol", "CHEMICAL", 18, 33], ["streptomycin", "CHEMICAL", 35, 47], ["tetracycline", "CHEMICAL", 52, 64], ["chloramphenieol", "CHEMICAL", 18, 33], ["streptomycin", "CHEMICAL", 35, 47], ["tetracycline", "CHEMICAL", 52, 64], ["chloramphenieol", "SIMPLE_CHEMICAL", 18, 33], ["streptomycin", "SIMPLE_CHEMICAL", 35, 47], ["tetracycline", "SIMPLE_CHEMICAL", 52, 64], ["urine", "ORGANISM_SUBSTANCE", 88, 93], ["chloramphenieol", "TREATMENT", 18, 33], ["streptomycin", "TREATMENT", 35, 47], ["tetracycline", "TREATMENT", 52, 64]]], ["It follows that the application of the antibiotic does not result in selection of the R + strains of bacteria only in the case of streptomycin.", [["streptomycin", "CHEMICAL", 130, 142], ["streptomycin", "CHEMICAL", 130, 142], ["streptomycin", "SIMPLE_CHEMICAL", 130, 142], ["the antibiotic", "TREATMENT", 35, 49], ["the R + strains of bacteria", "PROBLEM", 82, 109], ["streptomycin", "TREATMENT", 130, 142], ["bacteria", "OBSERVATION", 101, 109]]], ["From the comparison of sensitivity of the R-and R + bacteria concentrations of the antibiotics suitable for the selection of the R + exconjugants can be deduced: 25 ~tg/ml of chloramphenieol, neomycin and tetraeycline and apparently only 5 ~zg/ml of streptomycin with a subsequent control of the presence of the R-factor in this latter case.", [["chloramphenieol", "CHEMICAL", 175, 190], ["neomycin", "CHEMICAL", 192, 200], ["tetraeycline", "CHEMICAL", 205, 217], ["streptomycin", "CHEMICAL", 250, 262], ["chloramphenieol", "CHEMICAL", 175, 190], ["neomycin", "CHEMICAL", 192, 200], ["tetraeycline", "CHEMICAL", 205, 217], ["streptomycin", "CHEMICAL", 250, 262], ["R + bacteria", "SIMPLE_CHEMICAL", 48, 60], ["R + exconjugants", "SIMPLE_CHEMICAL", 129, 145], ["chloramphenieol", "SIMPLE_CHEMICAL", 175, 190], ["neomycin", "SIMPLE_CHEMICAL", 192, 200], ["tetraeycline", "SIMPLE_CHEMICAL", 205, 217], ["streptomycin", "SIMPLE_CHEMICAL", 250, 262], ["R-factor", "GENE_OR_GENE_PRODUCT", 312, 320], ["R-factor", "PROTEIN", 312, 320], ["the R", "TEST", 38, 43], ["the antibiotics", "TREATMENT", 79, 94], ["chloramphenieol", "TREATMENT", 175, 190], ["neomycin", "TREATMENT", 192, 200], ["tetraeycline", "TREATMENT", 205, 217], ["streptomycin", "TREATMENT", 250, 262]]], ["As all strains resistant to streptomycin were also insensitive to spectinomycin, it may be assumed that the mechanism of resistance consists in adenylation of molecules of the above-mentioned antibiotics.", [["streptomycin", "CHEMICAL", 28, 40], ["spectinomycin", "CHEMICAL", 66, 79], ["streptomycin", "CHEMICAL", 28, 40], ["spectinomycin", "CHEMICAL", 66, 79], ["streptomycin", "SIMPLE_CHEMICAL", 28, 40], ["spectinomycin", "SIMPLE_CHEMICAL", 66, 79], ["streptomycin", "TREATMENT", 28, 40], ["spectinomycin", "TREATMENT", 66, 79], ["resistance", "PROBLEM", 121, 131], ["adenylation of molecules", "TREATMENT", 144, 168], ["the above-mentioned antibiotics", "TREATMENT", 172, 203]]], ["In strains Escherichia coli K12 X8011, liK26 and liK66, infected with the Rl-drd 19 plasmid we tested activity of the enzyme chloramphenicol--aeetyl-transferase, coded for by the above-mentioned plasmid.", [["chloramphenicol", "CHEMICAL", 125, 140], ["aeetyl", "CHEMICAL", 142, 148], ["chloramphenicol", "CHEMICAL", 125, 140], ["aeetyl", "CHEMICAL", 142, 148], ["Escherichia coli", "ORGANISM", 11, 27], ["K12 X8011", "ORGANISM", 28, 37], ["liK26", "GENE_OR_GENE_PRODUCT", 39, 44], ["liK66", "GENE_OR_GENE_PRODUCT", 49, 54], ["chloramphenicol", "SIMPLE_CHEMICAL", 125, 140], ["aeetyl-transferase", "GENE_OR_GENE_PRODUCT", 142, 160], ["liK26", "PROTEIN", 39, 44], ["liK66", "PROTEIN", 49, 54], ["Rl-drd 19 plasmid", "DNA", 74, 91], ["enzyme chloramphenicol--aeetyl-transferase", "PROTEIN", 118, 160], ["plasmid", "DNA", 195, 202], ["Escherichia coli", "SPECIES", 11, 27], ["Escherichia coli", "SPECIES", 11, 27], ["Escherichia coli K12", "TEST", 11, 31], ["the Rl-drd 19 plasmid", "TREATMENT", 70, 91], ["the enzyme chloramphenicol", "TREATMENT", 114, 140], ["Escherichia coli", "OBSERVATION", 11, 27]]], ["The enzyme was isolated during different phases of growth of cultures, the activity was measured in supernatants of sonieates by means of a standard spectrophotometric method.", [["supernatants", "ANATOMY", 100, 112], ["The enzyme", "TEST", 0, 10], ["cultures", "TEST", 61, 69], ["a standard spectrophotometric method", "TREATMENT", 138, 174], ["growth", "OBSERVATION_MODIFIER", 51, 57]]], ["The enzyme is synthesized constitutively and its synthesis is regulated by catabolite repression.", [["The enzyme", "TEST", 0, 10], ["synthesized constitutively", "OBSERVATION", 14, 40], ["catabolite repression", "OBSERVATION", 75, 96]]], ["The specific activity is increased 5--10 times during the stationary phase in a complete medium (PNS); the number of enzyme units per cell increases also during this period.", [["cell", "ANATOMY", 134, 138], ["cell", "CELL", 134, 138], ["activity", "OBSERVATION_MODIFIER", 13, 21], ["increased", "OBSERVATION_MODIFIER", 25, 34], ["cell increases", "OBSERVATION", 134, 148]]], ["It was demonstrated that the increase of the specific activity of the enzyme is caused by synthesis of the enzyme de novo, being repressed by higher concentrations of glucose and blocked in the presence of ehlortetracyeline.", [["glucose", "CHEMICAL", 167, 174], ["ehlortetracyeline", "CHEMICAL", 206, 223], ["glucose", "CHEMICAL", 167, 174], ["ehlortetracyeline", "CHEMICAL", 206, 223], ["glucose", "SIMPLE_CHEMICAL", 167, 174], ["ehlortetracyeline", "SIMPLE_CHEMICAL", 206, 223], ["enzyme", "PROTEIN", 107, 113], ["the enzyme", "TEST", 66, 76], ["glucose", "TEST", 167, 174], ["ehlortetracyeline", "TREATMENT", 206, 223], ["increase", "OBSERVATION_MODIFIER", 29, 37]]], ["The apeeifie activity of the enzyme did not increase in the synthetic medium (M9), on the contrary, the number of enzyme units per cell decreased.", [["cell", "ANATOMY", 131, 135], ["cell", "CELL", 131, 135], ["enzyme units", "PROTEIN", 114, 126], ["the enzyme", "TEST", 25, 35], ["increase", "OBSERVATION_MODIFIER", 44, 52], ["cell decreased", "OBSERVATION", 131, 145]]], ["This fact is more pronounced in a medium with glycerol.", [["glycerol", "CHEMICAL", 46, 54], ["glycerol", "CHEMICAL", 46, 54], ["glycerol", "SIMPLE_CHEMICAL", 46, 54], ["glycerol", "TREATMENT", 46, 54], ["more", "OBSERVATION_MODIFIER", 13, 17], ["pronounced", "OBSERVATION_MODIFIER", 18, 28]]], ["The question of preferential synthesis of ehloramphenicol-acetyl-transfcrase during the stationary phase in a rich medium is discussed.", [["ehloramphenicol-acetyl-transfcrase", "CHEMICAL", 42, 76], ["ehloramphenicol", "CHEMICAL", 42, 57], ["acetyl", "CHEMICAL", 58, 64], ["ehloramphenicol-acetyl-transfcrase", "SIMPLE_CHEMICAL", 42, 76], ["acetyl-transfcrase", "PROTEIN", 58, 76], ["preferential synthesis of ehloramphenicol", "PROBLEM", 16, 57], ["acetyl", "TREATMENT", 58, 64], ["transfcrase", "TREATMENT", 65, 76], ["preferential", "OBSERVATION_MODIFIER", 16, 28], ["synthesis", "OBSERVATION_MODIFIER", 29, 38]]], ["Escherichia coli 50 Cot-lily +, Escherichia coli CA 53 and Escherichia coli dispar P 14 as donors of the transfer factor. (a) Out of 30 strains isolated from the feathered utility animals cured with tetracycline 18 strains were T resistant, out of that 8 strains carried the independently mobile T determinant and in 2 strains the independently immobile T determinant of resistance was mobilized at least in one of the used tests of mobilization of plasmids, i.e. 18/812.", [["plasmids", "ANATOMY", 449, 457], ["tetracycline", "CHEMICAL", 199, 211], ["tetracycline", "CHEMICAL", 199, 211], ["Escherichia coli", "ORGANISM", 0, 16], ["Escherichia coli CA 53", "ORGANISM", 32, 54], ["Escherichia coli", "ORGANISM", 59, 75], ["dispar P 14", "ORGANISM", 76, 87], ["donors", "ORGANISM", 91, 97], ["tetracycline", "SIMPLE_CHEMICAL", 199, 211], ["transfer factor", "PROTEIN", 105, 120], ["plasmids", "DNA", 449, 457], ["Escherichia coli", "SPECIES", 0, 16], ["Escherichia coli", "SPECIES", 32, 48], ["Escherichia coli dispar", "SPECIES", 59, 82], ["Escherichia coli", "SPECIES", 0, 16], ["Escherichia coli", "SPECIES", 32, 48], ["Escherichia coli dispar", "SPECIES", 59, 82], ["Escherichia coli", "TEST", 0, 16], ["Escherichia coli CA", "TEST", 32, 51], ["Escherichia coli dispar P", "TREATMENT", 59, 84], ["30 strains", "PROBLEM", 133, 143], ["tetracycline", "TREATMENT", 199, 211], ["8 strains", "PROBLEM", 253, 262], ["mobilization of plasmids", "TREATMENT", 433, 457], ["Escherichia coli", "OBSERVATION", 32, 48]]], ["None of 10 colicinogenie strains carried the independently transferable Col factor; Gol factors of 2 strains could be mobilized, i.e. 10102.Occurrence o/ Individual Categories o] Plasmids inOut of 30 hacmolytie strains only one strain had the independently mobile lily factor; in 4 w the lily factor could be mobilized, i.e. 30/1/4. (b) The following representation of categories of plasmids was found in 30 strains isolated from the feathered vermin animals (without a previous contact with antibiotics): resistance to T --8/5/2, Col factors --9]1/2 and haemolytic activity --30/2/2. (e) The following representation of categories of plasmids was found in 30 strains isolated from deer and hairy utility small animals (without a previous contact with antibiotics): resistance to T --10/6]2, Col factors --5/1/2, haemolytic activity --30[4/4.", [["plasmids", "ANATOMY", 383, 391], ["plasmids", "ANATOMY", 635, 643], ["Col factor", "GENE_OR_GENE_PRODUCT", 72, 82], ["Gol factors", "GENE_OR_GENE_PRODUCT", 84, 95], ["T --8/5/2", "GENE_OR_GENE_PRODUCT", 520, 529], ["Col factors", "GENE_OR_GENE_PRODUCT", 531, 542], ["9]1/2", "GENE_OR_GENE_PRODUCT", 545, 550], ["deer", "ORGANISM", 682, 686], ["T --10/6]2", "GENE_OR_GENE_PRODUCT", 780, 790], ["Col factors", "GENE_OR_GENE_PRODUCT", 792, 803], ["--5/1/2", "GENE_OR_GENE_PRODUCT", 804, 811], ["haemolytic activity --30[4/4", "SIMPLE_CHEMICAL", 813, 841], ["Col factor", "PROTEIN", 72, 82], ["Gol factors", "PROTEIN", 84, 95], ["mobile lily factor", "PROTEIN", 257, 275], ["lily factor", "PROTEIN", 288, 299], ["plasmids", "DNA", 383, 391], ["T --8/5/2", "PROTEIN", 520, 529], ["Col factors", "PROTEIN", 531, 542], ["plasmids", "DNA", 635, 643], ["Col factors", "PROTEIN", 792, 803], ["--5/1/2", "PROTEIN", 804, 811], ["deer", "SPECIES", 682, 686], ["T --10/6]2", "SPECIES", 780, 790], ["10 colicinogenie strains", "PROBLEM", 8, 32], ["2 strains", "PROBLEM", 99, 108], ["categories of plasmids", "TREATMENT", 369, 391], ["antibiotics", "TREATMENT", 492, 503], ["Col factors", "TEST", 531, 542], ["haemolytic activity", "PROBLEM", 555, 574], ["categories of plasmids", "PROBLEM", 621, 643], ["30 strains", "PROBLEM", 657, 667], ["antibiotics", "TREATMENT", 752, 763], ["T", "TEST", 780, 781], ["Col factors", "TEST", 792, 803], ["haemolytic activity", "TEST", 813, 832], ["haemolytic activity", "OBSERVATION", 813, 832]]], ["The results obtained extend the present view on ecology, occurrence and circulation of individual categories of plasmids in Escherichia coli, even without a selection pressure of antibiotics.", [["plasmids", "ANATOMY", 112, 120], ["Escherichia coli", "ORGANISM", 124, 140], ["plasmids", "DNA", 112, 120], ["Escherichia coli", "SPECIES", 124, 140], ["Escherichia coli", "SPECIES", 124, 140], ["plasmids in Escherichia coli", "PROBLEM", 112, 140], ["a selection pressure of antibiotics", "TREATMENT", 155, 190], ["Escherichia coli", "OBSERVATION", 124, 140]]], ["The effect of the peroral application of fiavomycin on the occurrence of markers in Escherichia coli that can be determined by plasmids (resistance to antibiotics, hemolytic activity and eolicinogeny) was followed for 28 days.", [["plasmids", "ANATOMY", 127, 135], ["fiavomycin", "CHEMICAL", 41, 51], ["hemolytic", "DISEASE", 164, 173], ["fiavomycin", "CHEMICAL", 41, 51], ["fiavomycin", "SIMPLE_CHEMICAL", 41, 51], ["Escherichia coli", "ORGANISM", 84, 100], ["plasmids", "DNA", 127, 135], ["Escherichia coli", "SPECIES", 84, 100], ["Escherichia coli", "SPECIES", 84, 100], ["the peroral application", "TREATMENT", 14, 37], ["fiavomycin", "TREATMENT", 41, 51], ["Escherichia coli", "PROBLEM", 84, 100], ["antibiotics", "TREATMENT", 151, 162], ["hemolytic activity", "PROBLEM", 164, 182], ["Escherichia coli", "OBSERVATION", 84, 100]]], ["The following doses were applied: (a) flavomycin 10 mg/kg of diet; (b) flavomyein 10 mg/kg of diet together with the perorally applied eolicinogenie strain Eseherichia cell (a week dose of 5 \u2022 109 of Escherichia cell Ia + per animal); (c) the colicinogenic strain alone (a week dose of 5 \u2022 109 of Eseherichia coli Ia + per animal).", [["cell", "ANATOMY", 168, 172], ["cell", "ANATOMY", 212, 216], ["flavomycin", "CHEMICAL", 38, 48], ["flavomyein", "CHEMICAL", 71, 81], ["eolicinogenie", "CHEMICAL", 135, 148], ["flavomycin", "SIMPLE_CHEMICAL", 38, 48], ["Eseherichia cell", "CELL", 156, 172], ["Escherichia cell Ia", "CELL", 200, 219], ["Eseherichia coli", "ORGANISM", 297, 313], ["Eseherichia coli", "SPECIES", 297, 313], ["Eseherichia coli", "SPECIES", 297, 313], ["flavomycin", "TREATMENT", 38, 48], ["flavomyein", "TREATMENT", 71, 81], ["Escherichia cell Ia", "TREATMENT", 200, 219], ["the colicinogenic strain", "PROBLEM", 239, 263], ["Eseherichia coli Ia", "TREATMENT", 297, 316]]], ["Both experimental and control groups consisted of 25 animals. (a) In the experimental group, in which only flavomycin was added the initial 41.6% incidence of strains of Eseherichia cell with the mobile plasmid decreased to 11.2~o.", [["cell", "ANATOMY", 182, 186], ["plasmid", "ANATOMY", 203, 210], ["flavomycin", "CHEMICAL", 107, 117], ["flavomycin", "CHEMICAL", 107, 117], ["flavomycin", "SIMPLE_CHEMICAL", 107, 117], ["Eseherichia cell", "CELL", 170, 186], ["mobile plasmid", "DNA", 196, 210], ["flavomycin", "TREATMENT", 107, 117], ["Eseherichia cell", "PROBLEM", 170, 186], ["the mobile plasmid", "TEST", 192, 210], ["Eseherichia cell", "OBSERVATION", 170, 186]]], ["The incidence of hemolytic strains of Escherichia cell decreased considerably --from 19.2 to 4%.", [["cell", "ANATOMY", 50, 54], ["Escherichia cell", "CELL", 38, 54], ["hemolytic strains", "PROBLEM", 17, 34], ["Escherichia cell", "PROBLEM", 38, 54], ["hemolytic", "OBSERVATION_MODIFIER", 17, 26], ["strains", "OBSERVATION_MODIFIER", 27, 34], ["Escherichia cell", "OBSERVATION", 38, 54], ["decreased", "OBSERVATION_MODIFIER", 55, 64], ["considerably", "OBSERVATION_MODIFIER", 65, 77], ["19.2 to", "OBSERVATION_MODIFIER", 85, 92]]], ["The initial occurrence of 34.4% of the colicinogenie strains of Eseherichia cell decreased to 14.4%. (b) In the experimental group fed additional fiavomyein together with the colieinogenic strain of Eseherichia cell a considerable decrease of strains with the mobile R plasmid (from 36.8 to 6.4~o), strains with the hemolytic activity {from 18.2 to 2.0~o) but a less considerable decrease of the incidence of the colicinogenic strains (from 34.6 to 18.4%) occurred. (c) In the experimental group, in which only the colicinogenie strain of Eseherichia cell was added, the occurrence of strains with the mobile R factor varied within a narrow range (from 38.4 to 32.0%), the occurrence of strains with the hemolytic activity decreased (from 20 to 14.4%) but the occurrence of the eolicinogenic strains increased (from 28.0 to 49.6~o ). (d) In the control group the occurrence of the followed markers varied within a narrow range --the original incidence of the mobile R plasmid of 38.4~o was decreased by at most 4%, the 17.6% incidence of the hemolytic activity by at most 4% and the 30.4% incidence of colicinogeny by at most 4.2~o.", [["Eseherichia cell", "ANATOMY", 64, 80], ["Eseherichia cell", "ANATOMY", 199, 215], ["Eseherichia cell", "ANATOMY", 539, 555], ["fiavomyein", "CHEMICAL", 146, 156], ["hemolytic", "DISEASE", 316, 325], ["hemolytic", "DISEASE", 704, 713], ["hemolytic", "DISEASE", 1042, 1051], ["colicinogeny", "DISEASE", 1102, 1114], ["fiavomyein", "CHEMICAL", 146, 156], ["Eseherichia cell", "CELL", 64, 80], ["fiavomyein", "SIMPLE_CHEMICAL", 146, 156], ["Eseherichia cell", "CELL", 199, 215], ["Eseherichia cell", "CELL", 539, 555], ["R factor", "GENE_OR_GENE_PRODUCT", 609, 617], ["mobile R plasmid", "DNA", 260, 276], ["mobile R factor", "PROTEIN", 602, 617], ["the colicinogenie strains", "TEST", 35, 60], ["Eseherichia cell", "TEST", 64, 80], ["additional fiavomyein", "TREATMENT", 135, 156], ["the colieinogenic strain", "PROBLEM", 171, 195], ["Eseherichia cell", "PROBLEM", 199, 215], ["strains", "PROBLEM", 243, 250], ["the mobile R plasmid", "TEST", 256, 276], ["strains", "PROBLEM", 299, 306], ["the hemolytic activity", "TEST", 312, 334], ["the colicinogenic strains", "PROBLEM", 409, 434], ["Eseherichia cell", "PROBLEM", 539, 555], ["strains", "PROBLEM", 585, 592], ["the mobile R factor", "PROBLEM", 598, 617], ["strains", "PROBLEM", 687, 694], ["the hemolytic activity", "PROBLEM", 700, 722], ["the eolicinogenic strains", "PROBLEM", 774, 799], ["the mobile R plasmid", "TEST", 955, 975], ["the hemolytic activity", "PROBLEM", 1038, 1060], ["colicinogeny", "TEST", 1102, 1114], ["Eseherichia cell", "OBSERVATION", 199, 215], ["considerable", "OBSERVATION_MODIFIER", 218, 230], ["decrease", "OBSERVATION_MODIFIER", 231, 239], ["hemolytic", "OBSERVATION_MODIFIER", 316, 325], ["less considerable", "OBSERVATION_MODIFIER", 362, 379], ["decrease", "OBSERVATION_MODIFIER", 380, 388], ["colicinogenic strains", "OBSERVATION", 413, 434], ["Eseherichia cell", "OBSERVATION", 539, 555], ["narrow range", "OBSERVATION_MODIFIER", 634, 646], ["hemolytic", "OBSERVATION_MODIFIER", 704, 713], ["activity", "OBSERVATION_MODIFIER", 714, 722], ["decreased", "OBSERVATION_MODIFIER", 723, 732], ["strains", "OBSERVATION_MODIFIER", 792, 799], ["increased", "OBSERVATION_MODIFIER", 800, 809], ["hemolytic activity", "OBSERVATION", 1042, 1060]]], ["The inhibitory effect of flavomycin on the occurrence of all three types of plasmids may be deduced on the basis of the results obtained.", [["plasmids", "ANATOMY", 76, 84], ["flavomycin", "CHEMICAL", 25, 35], ["flavomycin", "CHEMICAL", 25, 35], ["flavomycin", "SIMPLE_CHEMICAL", 25, 35], ["plasmids", "DNA", 76, 84], ["flavomycin", "TREATMENT", 25, 35], ["plasmids", "TREATMENT", 76, 84]]], ["In addition, a possibility of substitution of the strains of Eseherichia cell carrying R plasmids and the Hly factor by the newly accepted strain of Eseherichia cell carrying the Celia factor can be considered.", [["cell", "ANATOMY", 73, 77], ["Eseherichia cell", "ANATOMY", 149, 165], ["Eseherichia cell", "CELL", 61, 77], ["R plasmids", "GENE_OR_GENE_PRODUCT", 87, 97], ["Hly factor", "GENE_OR_GENE_PRODUCT", 106, 116], ["Eseherichia cell", "CELL", 149, 165], ["Celia factor", "GENE_OR_GENE_PRODUCT", 179, 191], ["R plasmids", "DNA", 87, 97], ["Hly factor", "PROTEIN", 106, 116], ["Celia factor", "PROTEIN", 179, 191], ["the strains", "PROBLEM", 46, 57], ["Eseherichia cell carrying R plasmids", "TREATMENT", 61, 97], ["Eseherichia cell", "PROBLEM", 149, 165], ["Eseherichia cell", "OBSERVATION", 149, 165]]], ["In order to determine the relative quantity of plasmid and chromosomal genes and according to that the number of copies of the plasmids in the cell, we transformed the accepter strains of Escherichia cell JC 7623 with DNA isolated from the strain 1100 R1 containing the R1 drd-19 plasmld.", [["plasmid", "ANATOMY", 47, 54], ["chromosomal", "ANATOMY", 59, 70], ["plasmids", "ANATOMY", 127, 135], ["cell", "ANATOMY", 143, 147], ["cell", "ANATOMY", 200, 204], ["chromosomal", "CELLULAR_COMPONENT", 59, 70], ["cell", "CELL", 143, 147], ["Escherichia cell JC 7623", "CELL", 188, 212], ["DNA", "CELLULAR_COMPONENT", 218, 221], ["plasmid", "DNA", 47, 54], ["chromosomal genes", "DNA", 59, 76], ["plasmids", "DNA", 127, 135], ["R1 drd-19 plasmld", "DNA", 270, 287], ["Escherichia cell JC 7623", "SPECIES", 188, 212], ["plasmid and chromosomal genes", "PROBLEM", 47, 76], ["Escherichia cell JC", "TEST", 188, 207], ["DNA", "TEST", 218, 221], ["chromosomal genes", "OBSERVATION", 59, 76], ["Escherichia cell JC", "OBSERVATION", 188, 207]]], ["Synthesis of leucine and resistance to chloramphenicol were transferred as the chromosomal and plasmid markers, respectively.", [["chromosomal", "ANATOMY", 79, 90], ["plasmid", "ANATOMY", 95, 102], ["leucine", "CHEMICAL", 13, 20], ["chloramphenicol", "CHEMICAL", 39, 54], ["leucine", "CHEMICAL", 13, 20], ["chloramphenicol", "CHEMICAL", 39, 54], ["leucine", "AMINO_ACID", 13, 20], ["chloramphenicol", "SIMPLE_CHEMICAL", 39, 54], ["chromosomal", "CELLULAR_COMPONENT", 79, 90], ["chromosomal and plasmid markers", "DNA", 79, 110], ["Synthesis of leucine", "TREATMENT", 0, 20], ["chloramphenicol", "TREATMENT", 39, 54], ["leucine", "OBSERVATION", 13, 20]]], ["The accepter evils were gradually washed with 1OmM CaCl~ in the cold (0--2~ transferred to 30ram CaC12 and DNA at a final concentration of 10--20 Ezg/ml was added to the suspension of cells.", [["cells", "ANATOMY", 184, 189], ["CaCl", "CHEMICAL", 51, 55], ["30ram CaC12", "CHEMICAL", 91, 102], ["CaCl", "CHEMICAL", 51, 55], ["CaC12", "CHEMICAL", 97, 102], ["CaCl", "SIMPLE_CHEMICAL", 51, 55], ["CaC12", "SIMPLE_CHEMICAL", 97, 102], ["DNA", "CELLULAR_COMPONENT", 107, 110], ["cells", "CELL", 184, 189], ["1OmM CaCl", "TREATMENT", 46, 55], ["the suspension of cells", "TREATMENT", 166, 189]]], ["The cells were sprayed on selective media and the frequency of both markers was followed separately.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["selective media", "TREATMENT", 26, 41]]], ["The frequency of transformants for the chromosomal marker varied from 1.0\u2022 10 -7 to 4.0\u2022 10 -7 9 The frequency of transformants for the plasmid gone represents 2 to 5~o of the frequency of transformants of the chromosomal gone.", [["transformants", "ANATOMY", 17, 30], ["chromosomal", "ANATOMY", 39, 50], ["transformants", "ANATOMY", 114, 127], ["plasmid", "ANATOMY", 136, 143], ["transformants", "ANATOMY", 189, 202], ["chromosomal", "ANATOMY", 210, 221], ["transformants", "CELL", 17, 30], ["chromosomal", "CELLULAR_COMPONENT", 39, 50], ["transformants", "CELL", 114, 127], ["transformants", "CELL", 189, 202], ["chromosomal", "CELLULAR_COMPONENT", 210, 221], ["plasmid", "DNA", 136, 143], ["the chromosomal marker", "TEST", 35, 57], ["the plasmid", "TREATMENT", 132, 143]]], ["The frequency of the chromosomal gone.", [["chromosomal", "ANATOMY", 21, 32], ["chromosomal", "CELLULAR_COMPONENT", 21, 32]]], ["The frequency of the chromosomal and plasmid markers was roughly the same when using the accepter strain Eseherichia cell C600.", [["chromosomal", "ANATOMY", 21, 32], ["plasmid", "ANATOMY", 37, 44], ["cell", "ANATOMY", 117, 121], ["chromosomal", "CELLULAR_COMPONENT", 21, 32], ["Eseherichia cell C600", "CELL", 105, 126], ["chromosomal and plasmid markers", "DNA", 21, 52], ["Eseherichia cell C600", "CELL_LINE", 105, 126], ["the chromosomal and plasmid markers", "TEST", 17, 52], ["Eseherichia cell", "OBSERVATION", 105, 121]]], ["Sensitivity to antibiotics of 800 strains of Shigella sonnei was tested during 1971--1972.", [["Shigella sonnei", "ORGANISM", 45, 60], ["Shigella sonnei", "SPECIES", 45, 60], ["Shigella sonnei", "SPECIES", 45, 60], ["antibiotics", "TREATMENT", 15, 26], ["Shigella sonnei", "PROBLEM", 45, 60]]], ["Out of the strains 463 were resistant to one or more antibiotics.", [["more antibiotics", "TREATMENT", 48, 64]]], ["Monoresistance (TC, CM or SU) was found roughly in one half of the strains, 13% of strains were biresistant, 23% of the strains were resistant to 3 antibiotics and 14% of the strains were resistant to 4 and even more antibiotics.", [["Monoresistance", "DISEASE", 0, 14], ["CM", "DISEASE", 20, 22], ["strains", "PROBLEM", 83, 90], ["biresistant", "PROBLEM", 96, 107], ["the strains", "PROBLEM", 116, 127], ["3 antibiotics", "TREATMENT", 146, 159], ["the strains", "PROBLEM", 171, 182], ["antibiotics", "TREATMENT", 217, 228]]], ["Types of the resistance change: whereas in 1971 strains resistant to tetracycline predominated, in 1972 the relative frequency of chloramphenicol resistant strains increased.", [["tetracycline", "CHEMICAL", 69, 81], ["chloramphenicol", "CHEMICAL", 130, 145], ["tetracycline", "CHEMICAL", 69, 81], ["chloramphenicol", "CHEMICAL", 130, 145], ["tetracycline", "SIMPLE_CHEMICAL", 69, 81], ["chloramphenicol", "SIMPLE_CHEMICAL", 130, 145], ["the resistance change", "PROBLEM", 9, 30], ["tetracycline", "TREATMENT", 69, 81], ["chloramphenicol resistant strains", "PROBLEM", 130, 163], ["resistance", "OBSERVATION", 13, 23], ["increased", "OBSERVATION_MODIFIER", 164, 173]]], ["Changes of the type of resistance could be observed also during individual epidemics, namely in strains belonging to a single lysotype and eolicin type.", [["eolicin", "GENE_OR_GENE_PRODUCT", 139, 146], ["a single lysotype and eolicin type", "TREATMENT", 117, 151], ["resistance", "OBSERVATION", 23, 33]]], ["Conjugation experiments performed in 13.0 strains with a recipient strain of Citrobacter revealed the transferable character of the l~-faetors in 77%.", [["Conjugation experiments", "TEST", 0, 23], ["Citrobacter", "PROBLEM", 77, 88], ["Citrobacter", "OBSERVATION", 77, 88]]], ["Changes of R factors were detected in strains of Shigella sonnei during dysentery epidemics.", [["dysentery", "DISEASE", 72, 81], ["R factors", "GENE_OR_GENE_PRODUCT", 11, 20], ["Shigella sonnei", "ORGANISM", 49, 64], ["R factors", "PROTEIN", 11, 20], ["Shigella sonnei", "SPECIES", 49, 64], ["Shigella sonnei", "SPECIES", 49, 64], ["R factors", "PROBLEM", 11, 20], ["Shigella sonnei", "PROBLEM", 49, 64], ["dysentery epidemics", "PROBLEM", 72, 91]]], ["These changes can occur by accepting R factors from the resistant physiological flora, or by segregation of R factors in strains that were originally resistant, leading to a complete loss of resistance.", [["R factors", "GENE_OR_GENE_PRODUCT", 37, 46], ["R factors", "GENE_OR_GENE_PRODUCT", 108, 117], ["R factors", "PROTEIN", 37, 46], ["R factors", "PROTEIN", 108, 117], ["R factors", "PROBLEM", 37, 46], ["the resistant physiological flora", "PROBLEM", 52, 85], ["R factors in strains", "PROBLEM", 108, 128], ["a complete loss of resistance", "PROBLEM", 172, 201], ["flora", "OBSERVATION", 80, 85]]], ["Changes can be observed both during the followed epidemic and in repeatedly isolated ShigeUa strains in individuals.", [["repeatedly isolated ShigeUa strains in individuals", "PROBLEM", 65, 115]]], ["A possibility of a mutual interaction between pathogens and non-pathogens is in several cases supported by demonstration of transferability of the R factors in strains of Shigella and ~Tseheriehia cell isolated simultaneously from the same person.", [["cell", "ANATOMY", 197, 201], ["R factors", "GENE_OR_GENE_PRODUCT", 147, 156], ["Tseheriehia cell", "CELL", 185, 201], ["R factors", "PROTEIN", 147, 156], ["person", "SPECIES", 240, 246], ["a mutual interaction between pathogens", "PROBLEM", 17, 55], ["the R factors", "PROBLEM", 143, 156], ["Shigella", "PROBLEM", 171, 179], ["possibility of", "UNCERTAINTY", 2, 16]]], ["Junkalor industrial gas analysers, adjusted for laboratory use, were employed to determine the consumption of oxygen and the formation of carbon dioxide during the synthesis of yeast biomass from ethanol.", [["oxygen", "CHEMICAL", 110, 116], ["carbon dioxide", "CHEMICAL", 138, 152], ["ethanol", "CHEMICAL", 196, 203], ["oxygen", "CHEMICAL", 110, 116], ["carbon dioxide", "CHEMICAL", 138, 152], ["ethanol", "CHEMICAL", 196, 203], ["oxygen", "SIMPLE_CHEMICAL", 110, 116], ["carbon dioxide", "SIMPLE_CHEMICAL", 138, 152], ["ethanol", "SIMPLE_CHEMICAL", 196, 203], ["yeast", "SPECIES", 177, 182], ["yeast", "SPECIES", 177, 182], ["Junkalor industrial gas analysers", "TEST", 0, 33], ["oxygen", "TREATMENT", 110, 116], ["carbon dioxide", "TREATMENT", 138, 152], ["yeast biomass", "PROBLEM", 177, 190], ["gas analysers", "OBSERVATION", 20, 33], ["carbon dioxide", "OBSERVATION", 138, 152], ["yeast biomass", "OBSERVATION", 177, 190]]], ["In the first phase of batch cultivation the oxygen consumption attains 1.11 g O2/g yeast dry wt., during the following phase it reaches a value of 1.76 g O2/g yeast dry wt.", [["oxygen", "CHEMICAL", 44, 50], ["oxygen", "CHEMICAL", 44, 50], ["O2", "CHEMICAL", 78, 80], ["O2", "CHEMICAL", 154, 156], ["oxygen", "SIMPLE_CHEMICAL", 44, 50], ["yeast", "SPECIES", 83, 88], ["yeast", "SPECIES", 159, 164], ["yeast", "SPECIES", 83, 88], ["yeast", "SPECIES", 159, 164], ["batch cultivation", "TREATMENT", 22, 39], ["the oxygen consumption", "TREATMENT", 40, 62]]], ["The formation of CO2 also increases but its increase is relatively more rapid; this is reflected in an increasing respiration coefficient during the cultivation.", [["CO2", "CHEMICAL", 17, 20], ["CO2", "CHEMICAL", 17, 20], ["CO2", "SIMPLE_CHEMICAL", 17, 20], ["The formation of CO2", "PROBLEM", 0, 20], ["an increasing respiration coefficient", "PROBLEM", 100, 137], ["the cultivation", "TREATMENT", 145, 160], ["CO2", "OBSERVATION_MODIFIER", 17, 20], ["increases", "OBSERVATION_MODIFIER", 26, 35], ["increase", "OBSERVATION_MODIFIER", 44, 52], ["relatively", "OBSERVATION_MODIFIER", 56, 66], ["more", "OBSERVATION_MODIFIER", 67, 71], ["rapid", "OBSERVATION_MODIFIER", 72, 77], ["increasing", "OBSERVATION_MODIFIER", 103, 113], ["respiration coefficient", "OBSERVATION", 114, 137]]], ["Mass balance was established for both cultivation phases; it yielded stoiehiometric relationships which were found to fit the experimental data in all respects.", [["Mass balance", "PROBLEM", 0, 12], ["stoiehiometric relationships", "PROBLEM", 69, 97]]], ["The characteristic features of the two cultivation phases are the accumulation of acetic acid during the first phase and its subsequent consumption during the second one.", [["acetic acid", "CHEMICAL", 82, 93], ["acetic acid", "CHEMICAL", 82, 93], ["acetic acid", "SIMPLE_CHEMICAL", 82, 93], ["acetic acid", "TREATMENT", 82, 93], ["acetic acid", "OBSERVATION", 82, 93]]], ["This second phase coincides with increased oxygen consumption, production of carbon dioxide and the RQ .value; a calculation shows that the accumulated acetic acid is oxidized to CO2 and H~O.SECTION OF APPLIED MICROBIOLOGYCultivation of Yeasts on l~lethanol.", [["oxygen", "CHEMICAL", 43, 49], ["carbon dioxide", "CHEMICAL", 77, 91], ["acetic acid", "CHEMICAL", 152, 163], ["CO2", "CHEMICAL", 179, 182], ["H~O.", "CHEMICAL", 187, 191], ["l~lethanol", "CHEMICAL", 247, 257], ["oxygen", "CHEMICAL", 43, 49], ["carbon dioxide", "CHEMICAL", 77, 91], ["acetic acid", "CHEMICAL", 152, 163], ["CO2", "CHEMICAL", 179, 182], ["l~lethanol", "CHEMICAL", 247, 257], ["oxygen", "SIMPLE_CHEMICAL", 43, 49], ["carbon dioxide", "SIMPLE_CHEMICAL", 77, 91], ["acetic acid", "SIMPLE_CHEMICAL", 152, 163], ["CO2", "SIMPLE_CHEMICAL", 179, 182], ["l~lethanol", "SIMPLE_CHEMICAL", 247, 257], ["H~O.", "SPECIES", 187, 191], ["increased oxygen consumption", "PROBLEM", 33, 61], ["carbon dioxide", "TREATMENT", 77, 91], ["a calculation", "TEST", 111, 124], ["the accumulated acetic acid", "PROBLEM", 136, 163], ["Yeasts", "PROBLEM", 237, 243], ["l~lethanol", "TREATMENT", 247, 257], ["increased", "OBSERVATION_MODIFIER", 33, 42], ["oxygen consumption", "OBSERVATION", 43, 61], ["carbon dioxide", "OBSERVATION", 77, 91], ["acetic acid", "OBSERVATION", 152, 163], ["Yeasts", "OBSERVATION", 237, 243]]], ["O. VOLFOV~-, P. PrLXT, J. PANOg, Institute of Microbiology, Czechoslovak Academy of Sciences, Prague.SECTION OF APPLIED MICROBIOLOGYA total of 10 yeast strains, utilizing methanol as the only source of carbon and energy, were isolated from soil.", [["methanol", "CHEMICAL", 171, 179], ["methanol", "CHEMICAL", 171, 179], ["carbon", "CHEMICAL", 202, 208], ["methanol", "SIMPLE_CHEMICAL", 171, 179], ["carbon", "SIMPLE_CHEMICAL", 202, 208], ["yeast", "SPECIES", 146, 151], ["yeast", "SPECIES", 146, 151], ["10 yeast strains", "PROBLEM", 143, 159], ["methanol", "TREATMENT", 171, 179]]], ["Their growth was studied at 30~ in a mineral medium with a small amount of yeast extract, NH +, and with 1% methanol.", [["extract", "ANATOMY", 81, 88], ["NH", "CHEMICAL", 90, 92], ["methanol", "CHEMICAL", 108, 116], ["NH", "CHEMICAL", 90, 92], ["methanol", "CHEMICAL", 108, 116], ["NH +", "SIMPLE_CHEMICAL", 90, 94], ["methanol", "SIMPLE_CHEMICAL", 108, 116], ["yeast", "SPECIES", 75, 80], ["yeast", "SPECIES", 75, 80], ["1% methanol", "TREATMENT", 105, 116], ["growth", "OBSERVATION_MODIFIER", 6, 12], ["small", "OBSERVATION_MODIFIER", 59, 64], ["yeast extract", "OBSERVATION", 75, 88]]], ["The strain yielding the highest percentage of biomass on tivation in flasks (Y 33%) was further studied as to the growth parameters and biomass composition.", [["The strain", "PROBLEM", 0, 10], ["tivation in flasks", "TREATMENT", 57, 75], ["the growth parameters", "TEST", 110, 131], ["highest", "OBSERVATION_MODIFIER", 24, 31], ["percentage", "OBSERVATION_MODIFIER", 32, 42], ["biomass", "OBSERVATION", 46, 53], ["biomass composition", "OBSERVATION", 136, 155]]], ["The biomass was found to consist of 44% crude proteins, 2--3~o esterified fatty acids, 1--2% free fatty acids, 5.7--6.0~o RNA and 0.25~o DNA.", [["fatty acids", "CHEMICAL", 74, 85], ["fatty acids", "CHEMICAL", 98, 109], ["fatty acids", "CHEMICAL", 74, 85], ["fatty acids", "CHEMICAL", 98, 109], ["2--3~o esterified fatty acids", "SIMPLE_CHEMICAL", 56, 85], ["free fatty acids", "SIMPLE_CHEMICAL", 93, 109], ["DNA", "CELLULAR_COMPONENT", 137, 140], ["The biomass", "TEST", 0, 11], ["crude proteins", "TEST", 40, 54], ["esterified fatty acids", "TEST", 63, 85], ["free fatty acids", "TEST", 93, 109], ["RNA", "TEST", 122, 125]]], ["Amino acid analysis revealed a high content of aspartic acid, glutamic acid, lysine, leucine, valine and threonine.", [["Amino acid", "CHEMICAL", 0, 10], ["aspartic acid", "CHEMICAL", 47, 60], ["glutamic acid", "CHEMICAL", 62, 75], ["lysine", "CHEMICAL", 77, 83], ["leucine", "CHEMICAL", 85, 92], ["valine", "CHEMICAL", 94, 100], ["threonine", "CHEMICAL", 105, 114], ["Amino acid", "CHEMICAL", 0, 10], ["aspartic acid", "CHEMICAL", 47, 60], ["glutamic acid", "CHEMICAL", 62, 75], ["lysine", "CHEMICAL", 77, 83], ["leucine", "CHEMICAL", 85, 92], ["valine", "CHEMICAL", 94, 100], ["threonine", "CHEMICAL", 105, 114], ["Amino acid", "AMINO_ACID", 0, 10], ["aspartic acid", "AMINO_ACID", 47, 60], ["glutamic acid", "AMINO_ACID", 62, 75], ["lysine", "AMINO_ACID", 77, 83], ["leucine", "AMINO_ACID", 85, 92], ["valine", "AMINO_ACID", 94, 100], ["threonine", "AMINO_ACID", 105, 114], ["Amino acid analysis", "TEST", 0, 19], ["aspartic acid", "TREATMENT", 47, 60], ["glutamic acid", "TREATMENT", 62, 75], ["lysine", "TREATMENT", 77, 83], ["leucine, valine", "TREATMENT", 85, 100], ["threonine", "TREATMENT", 105, 114]]], ["The composition of fatty acids in the cell lipids of this strain was similar to that found in lipids formed during the growth of the cells on glucose and ethanol (the strain grows better on these substrates than on methanol).", [["cell", "ANATOMY", 38, 42], ["cells", "ANATOMY", 133, 138], ["fatty acids", "CHEMICAL", 19, 30], ["glucose", "CHEMICAL", 142, 149], ["ethanol", "CHEMICAL", 154, 161], ["fatty acids", "CHEMICAL", 19, 30], ["glucose", "CHEMICAL", 142, 149], ["ethanol", "CHEMICAL", 154, 161], ["methanol", "CHEMICAL", 215, 223], ["fatty acids", "SIMPLE_CHEMICAL", 19, 30], ["cell lipids", "CELLULAR_COMPONENT", 38, 49], ["lipids", "SIMPLE_CHEMICAL", 94, 100], ["cells", "CELL", 133, 138], ["glucose", "SIMPLE_CHEMICAL", 142, 149], ["ethanol", "SIMPLE_CHEMICAL", 154, 161], ["methanol", "SIMPLE_CHEMICAL", 215, 223], ["fatty acids", "PROBLEM", 19, 30], ["this strain", "PROBLEM", 53, 64], ["glucose", "TEST", 142, 149], ["ethanol", "TREATMENT", 154, 161], ["the strain", "PROBLEM", 163, 173], ["methanol", "TREATMENT", 215, 223], ["fatty acids", "OBSERVATION", 19, 30]]], ["The lipids contained 96% fatty acids with even number of carbon atoms and 4% of acids with odd number of C atoms in the molecule.", [["fatty acids", "CHEMICAL", 25, 36], ["carbon atoms", "CHEMICAL", 57, 69], ["fatty acids", "CHEMICAL", 25, 36], ["carbon", "CHEMICAL", 57, 63], ["C", "CHEMICAL", 105, 106], ["lipids", "SIMPLE_CHEMICAL", 4, 10], ["fatty acids", "SIMPLE_CHEMICAL", 25, 36], ["carbon atoms", "SIMPLE_CHEMICAL", 57, 69], ["C atoms", "SIMPLE_CHEMICAL", 105, 112], ["The lipids", "TEST", 0, 10], ["fatty acids", "TEST", 25, 36], ["carbon atoms", "TREATMENT", 57, 69], ["acids", "TEST", 80, 85], ["C atoms in the molecule", "PROBLEM", 105, 128]]], ["Oleic acid was found to have the highest relative content.", [["Oleic acid", "CHEMICAL", 0, 10], ["Oleic acid", "CHEMICAL", 0, 10], ["Oleic acid", "SIMPLE_CHEMICAL", 0, 10], ["Oleic acid", "TEST", 0, 10], ["acid", "OBSERVATION_MODIFIER", 6, 10], ["content", "OBSERVATION", 50, 57]]], ["The suitability of application of this strain for the production of SCP from methanol is discussed.", [["methanol", "CHEMICAL", 77, 85], ["methanol", "CHEMICAL", 77, 85], ["SCP", "SIMPLE_CHEMICAL", 68, 71], ["methanol", "SIMPLE_CHEMICAL", 77, 85], ["this strain", "TREATMENT", 34, 45]]], ["The consumption of oxygen during fermentation may be measured by balance method as the product of the air flow and the difference in its partial pressure between the fermenter inlet and outlet air stream.", [["oxygen", "CHEMICAL", 19, 25], ["oxygen", "CHEMICAL", 19, 25], ["oxygen", "SIMPLE_CHEMICAL", 19, 25], ["oxygen during fermentation", "TREATMENT", 19, 45], ["the air flow", "PROBLEM", 98, 110], ["outlet air stream", "PROBLEM", 186, 203], ["air flow", "OBSERVATION", 102, 110], ["partial", "OBSERVATION_MODIFIER", 137, 144], ["pressure", "OBSERVATION_MODIFIER", 145, 153], ["fermenter inlet", "OBSERVATION", 166, 181], ["outlet", "ANATOMY", 186, 192], ["air stream", "OBSERVATION", 193, 203]]], ["The content of oxygen, carbon dioxide and nitrogen was measured by gas chromatography.", [["oxygen", "CHEMICAL", 15, 21], ["carbon dioxide", "CHEMICAL", 23, 37], ["nitrogen", "CHEMICAL", 42, 50], ["oxygen", "CHEMICAL", 15, 21], ["carbon dioxide", "CHEMICAL", 23, 37], ["nitrogen", "CHEMICAL", 42, 50], ["oxygen", "SIMPLE_CHEMICAL", 15, 21], ["carbon dioxide", "SIMPLE_CHEMICAL", 23, 37], ["nitrogen", "SIMPLE_CHEMICAL", 42, 50], ["oxygen, carbon dioxide", "TREATMENT", 15, 37], ["nitrogen", "TREATMENT", 42, 50], ["gas chromatography", "TEST", 67, 85], ["oxygen", "OBSERVATION_MODIFIER", 15, 21]]], ["Nitrogen served also as an internal standard for calculating the air flow rate at the fermenter outlet as this differed from the inlet value.", [["Nitrogen", "CHEMICAL", 0, 8], ["Nitrogen", "CHEMICAL", 0, 8], ["Nitrogen", "SIMPLE_CHEMICAL", 0, 8], ["Nitrogen", "TREATMENT", 0, 8], ["calculating the air flow rate", "TEST", 49, 78], ["the inlet value", "TEST", 125, 140], ["air flow", "OBSERVATION", 65, 73], ["fermenter outlet", "OBSERVATION", 86, 102]]], ["The example of fermentation of n-alkanes by the yeast Gandida lipolytica 4-1 served to demonstrate the calculation of the specific oxygen consumption rate in mmol/g, h and the oxygen demand per biomass unit (g O2]g biomass) obtained by dividing the former value by productivity.", [["n-alkanes", "CHEMICAL", 31, 40], ["oxygen", "CHEMICAL", 131, 137], ["oxygen", "CHEMICAL", 176, 182], ["n-alkanes", "CHEMICAL", 31, 40], ["oxygen", "CHEMICAL", 131, 137], ["oxygen", "CHEMICAL", 176, 182], ["O2", "CHEMICAL", 210, 212], ["n-alkanes", "SIMPLE_CHEMICAL", 31, 40], ["yeast Gandida lipolytica", "ORGANISM", 48, 72], ["oxygen", "SIMPLE_CHEMICAL", 131, 137], ["oxygen", "SIMPLE_CHEMICAL", 176, 182], ["yeast", "SPECIES", 48, 53], ["Gandida lipolytica", "SPECIES", 54, 72], ["yeast", "SPECIES", 48, 53], ["Gandida lipolytica", "SPECIES", 54, 72], ["fermentation of n-alkanes", "PROBLEM", 15, 40], ["the yeast Gandida lipolytica", "TEST", 44, 72], ["the oxygen demand", "TREATMENT", 172, 189], ["g O2]g biomass", "TREATMENT", 208, 222]]], ["At initial growth stages, the specific oxygen consumption rate and oxygen demand are in a correlation with an enhanced production of fatty acids present in both the oil and water phases.", [["oil", "ANATOMY", 165, 168], ["oxygen", "CHEMICAL", 39, 45], ["oxygen", "CHEMICAL", 67, 73], ["fatty acids", "CHEMICAL", 133, 144], ["oxygen", "CHEMICAL", 39, 45], ["oxygen", "CHEMICAL", 67, 73], ["fatty acids", "CHEMICAL", 133, 144], ["oxygen", "SIMPLE_CHEMICAL", 39, 45], ["oxygen", "SIMPLE_CHEMICAL", 67, 73], ["fatty acids", "SIMPLE_CHEMICAL", 133, 144], ["oil", "ORGANISM_SUBSTANCE", 165, 168], ["the specific oxygen consumption rate", "TEST", 26, 62], ["oxygen demand", "TREATMENT", 67, 80], ["fatty acids", "TEST", 133, 144], ["growth", "OBSERVATION_MODIFIER", 11, 17], ["oxygen demand", "OBSERVATION", 67, 80], ["fatty acids", "OBSERVATION", 133, 144]]], ["At this time the biomass yield is also lower.", [["the biomass yield", "TEST", 13, 30], ["biomass yield", "OBSERVATION", 17, 30], ["lower", "OBSERVATION_MODIFIER", 39, 44]]], ["The results of this study may serve to the optimization of biomass production.", [["this study", "TEST", 15, 25], ["biomass production", "PROBLEM", 59, 77]]], ["The generally low growth rates (productivities) of microorganisms growing on solid n-alkanes hint at a different type of uptake of these substrates from that found with liquid hydrocarbons.", [["n-alkanes", "CHEMICAL", 83, 92], ["n-alkanes", "CHEMICAL", 83, 92], ["hydrocarbons", "CHEMICAL", 176, 188], ["solid n-alkanes", "SIMPLE_CHEMICAL", 77, 92], ["The generally low growth rates", "PROBLEM", 0, 30], ["microorganisms", "PROBLEM", 51, 65], ["solid n-alkanes hint", "PROBLEM", 77, 97], ["liquid hydrocarbons", "PROBLEM", 169, 188], ["low", "OBSERVATION_MODIFIER", 14, 17], ["growth", "OBSERVATION_MODIFIER", 18, 24], ["solid n-alkanes", "OBSERVATION_MODIFIER", 77, 92], ["different type", "OBSERVATION_MODIFIER", 103, 117], ["liquid hydrocarbons", "OBSERVATION", 169, 188]]], ["To obtain higher productivities, the solid substrate may be dissolved either in liquid hydrocarbons (n-deeane) or in highly branched inert hydrocarbons (pristane, squalane) or deparaffinated gas oil.", [["n-deeane", "CHEMICAL", 101, 109], ["inert hydrocarbons", "CHEMICAL", 133, 151], ["pristane", "CHEMICAL", 153, 161], ["squalane", "CHEMICAL", 163, 171], ["hydrocarbons", "CHEMICAL", 87, 99], ["n-deeane", "CHEMICAL", 101, 109], ["hydrocarbons", "CHEMICAL", 139, 151], ["pristane", "CHEMICAL", 153, 161], ["squalane", "CHEMICAL", 163, 171], ["liquid hydrocarbons", "SIMPLE_CHEMICAL", 80, 99], ["n-deeane", "SIMPLE_CHEMICAL", 101, 109], ["branched inert hydrocarbons", "SIMPLE_CHEMICAL", 124, 151], ["pristane", "SIMPLE_CHEMICAL", 153, 161], ["squalane", "SIMPLE_CHEMICAL", 163, 171], ["oil", "ORGANISM_SUBSTANCE", 195, 198], ["the solid substrate", "TREATMENT", 33, 52], ["highly branched inert hydrocarbons (pristane, squalane)", "TREATMENT", 117, 172], ["deparaffinated gas oil", "TREATMENT", 176, 198], ["higher productivities", "OBSERVATION_MODIFIER", 10, 31]]], ["The last technique was used for comparing the substrate specificity of two strains of Gandida lipolytica; strain 4-1, already used for preparing biomass from gas oil, and strain K capable of removing paraffin from mineral oil.", [["oil", "ANATOMY", 222, 225], ["K", "CHEMICAL", 178, 179], ["paraffin", "CHEMICAL", 200, 208], ["Gandida lipolytica", "ORGANISM", 86, 104], ["strain 4-1", "ORGANISM", 106, 116], ["oil", "ORGANISM_SUBSTANCE", 162, 165], ["mineral oil", "SIMPLE_CHEMICAL", 214, 225], ["Gandida lipolytica", "SPECIES", 86, 104], ["Gandida lipolytica", "SPECIES", 86, 104], ["The last technique", "TREATMENT", 0, 18], ["Gandida lipolytica", "TREATMENT", 86, 104], ["gas oil", "TEST", 158, 165], ["paraffin from mineral oil", "TREATMENT", 200, 225]]], ["The substrate was a model mixture of C10--C32 n-alkanes.", [["C10--C32 n-alkanes", "CHEMICAL", 37, 55], ["C10--C32 n-alkanes", "CHEMICAL", 37, 55], ["C10--C32 n-alkanes", "SIMPLE_CHEMICAL", 37, 55], ["C10", "TEST", 37, 40]]], ["The consumption of individual n-alkanes, as determined by gas chromatography, was considerably different with each of the two strains.", [["n-alkanes", "CHEMICAL", 30, 39], ["n-alkanes", "CHEMICAL", 30, 39], ["n-alkanes", "SIMPLE_CHEMICAL", 30, 39], ["gas chromatography", "TEST", 58, 76]]], ["The substrate specificity of strain K was found to be shifted to higher n-alkanes, the relative utilization of individual alkanes being also different from the strain 4-1.", [["K", "CHEMICAL", 36, 37], ["n-alkanes", "CHEMICAL", 72, 81], ["alkanes", "CHEMICAL", 122, 129], ["n-alkanes", "CHEMICAL", 72, 81], ["alkanes", "CHEMICAL", 122, 129], ["n-alkanes", "SIMPLE_CHEMICAL", 72, 81], ["alkanes", "SIMPLE_CHEMICAL", 122, 129], ["strain K", "TEST", 29, 37], ["individual alkanes", "PROBLEM", 111, 129], ["alkanes", "OBSERVATION", 122, 129]]], ["The results were verified with crude oil (melting point 33~ n-alkanes C8--C36).", [["n-alkanes C8--C36", "CHEMICAL", 60, 77], ["n-alkanes C8--C36", "CHEMICAL", 60, 77], ["oil", "ORGANISM_SUBSTANCE", 37, 40], ["n-alkanes C8--C36", "SIMPLE_CHEMICAL", 60, 77], ["crude oil", "TEST", 31, 40]]], ["The results obtained with the utilization ofn-alkanes from gas and mineral oils (previous data), from model mixture and from the crude oil point at an adaptation of the two strains to higher n-alkanes.", [["ofn-alkanes", "CHEMICAL", 42, 53], ["n-alkanes", "CHEMICAL", 191, 200], ["ofn-alkanes", "CHEMICAL", 42, 53], ["n-alkanes", "CHEMICAL", 191, 200], ["ofn-alkanes", "SIMPLE_CHEMICAL", 42, 53], ["gas and mineral oils", "TEST", 59, 79], ["previous data", "TEST", 81, 94], ["higher n-alkanes", "OBSERVATION", 184, 200]]], ["The substrate specificity depends thus to a certain extent on the substrate used, its spectrum of n-alkanes and the fashion and form of its application.", [["n-alkanes", "CHEMICAL", 98, 107], ["n-alkanes", "SIMPLE_CHEMICAL", 98, 107], ["the substrate", "TREATMENT", 62, 75], ["its application", "TREATMENT", 136, 151]]], ["Changes in drop size distribution are typical for the onset of hydrocarbon fermentation.", [["hydrocarbon", "CHEMICAL", 63, 74], ["hydrocarbon", "SIMPLE_CHEMICAL", 63, 74], ["Changes in drop size distribution", "PROBLEM", 0, 33], ["hydrocarbon fermentation", "PROBLEM", 63, 87], ["drop", "OBSERVATION_MODIFIER", 11, 15], ["size", "OBSERVATION_MODIFIER", 16, 20], ["typical for", "UNCERTAINTY", 38, 49], ["hydrocarbon fermentation", "OBSERVATION", 63, 87]]], ["Expermential data on the distribution of hydrocarbon droplets at different times during the fermentation, when plotted in non-dimensionalized plots, show that the distribution has a tendency towards selfpreservation; the non-dimensionalized plots are obtained by normalizing the distribution according to the Sauter-mean diameter.", [["hydrocarbon", "CHEMICAL", 41, 52], ["hydrocarbon droplets", "PROBLEM", 41, 61], ["a tendency towards selfpreservation", "PROBLEM", 180, 215], ["the non-dimensionalized plots", "TEST", 217, 246], ["hydrocarbon droplets", "OBSERVATION", 41, 61], ["tendency", "OBSERVATION_MODIFIER", 182, 190], ["mean diameter", "OBSERVATION", 316, 329]]], ["Also, the curves so obtained for different initial dispersed phase fractions and for two different kinds of substrates (gas oil and a model dispersed.phase system --n-hexadeeane dissolved in biologically dewaxed gas oil) were found to have similar shapes.", [["n-hexadeeane", "CHEMICAL", 165, 177], ["n-hexadeeane", "CHEMICAL", 165, 177], ["n-hexadeeane", "SIMPLE_CHEMICAL", 165, 177], ["oil", "ORGANISM_SUBSTANCE", 216, 219], ["the curves", "TEST", 6, 16], ["substrates (gas oil", "TREATMENT", 108, 127], ["n-hexadeeane dissolved", "TREATMENT", 165, 187], ["similar", "OBSERVATION_MODIFIER", 240, 247], ["shapes", "OBSERVATION_MODIFIER", 248, 254]]], ["Using this selfpreserving property, an empirical (signle parameter) equation was set up for the drop size distributions.", [["this selfpreserving property", "TREATMENT", 6, 34], ["an empirical (signle parameter) equation", "TREATMENT", 36, 76], ["the drop size distributions", "PROBLEM", 92, 119], ["drop", "OBSERVATION_MODIFIER", 96, 100], ["size", "OBSERVATION_MODIFIER", 101, 105]]], ["The proposed empirical distribution was found to hold for different reactor sizes (working volumes of 1.5--850 1).", [["different reactor sizes", "PROBLEM", 58, 81], ["working volumes", "TEST", 83, 98], ["sizes", "OBSERVATION_MODIFIER", 76, 81]]], ["An attempt was made to correlate the parameter, the Sauter mean diameter, with the operating conditions.", [["diameter", "OBSERVATION_MODIFIER", 64, 72]]], ["Oxygen limitation of the growth of a bacterial culture may be accomplished either by changing the partial oxygen pressure in the intake air or by altering the volumetric oxygen transfer coefficient (KLI) which is a function of agitator speed, aeration intensity and the physical properties of the liquid medium.", [["Oxygen", "CHEMICAL", 0, 6], ["oxygen", "CHEMICAL", 106, 112], ["oxygen", "CHEMICAL", 170, 176], ["Oxygen", "CHEMICAL", 0, 6], ["oxygen", "CHEMICAL", 106, 112], ["oxygen", "CHEMICAL", 170, 176], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["oxygen", "SIMPLE_CHEMICAL", 106, 112], ["oxygen", "SIMPLE_CHEMICAL", 170, 176], ["Oxygen limitation", "PROBLEM", 0, 17], ["a bacterial culture", "TEST", 35, 54], ["the partial oxygen pressure", "TREATMENT", 94, 121], ["aeration intensity", "PROBLEM", 243, 261], ["the liquid medium", "TREATMENT", 293, 310], ["growth", "OBSERVATION_MODIFIER", 25, 31], ["partial", "OBSERVATION_MODIFIER", 98, 105], ["oxygen pressure", "OBSERVATION", 106, 121]]], ["Experiments were doric with the organism Klebsiella aerogenes CCM 2318 grown on a minimal glucose medium at constant pH.", [["CCM 2318", "CHEMICAL", 62, 70], ["glucose", "CHEMICAL", 90, 97], ["glucose", "CHEMICAL", 90, 97], ["Klebsiella aerogenes CCM 2318", "CELL", 41, 70], ["glucose", "SIMPLE_CHEMICAL", 90, 97], ["Klebsiella aerogenes", "SPECIES", 41, 61], ["Klebsiella aerogenes CCM 2318", "SPECIES", 41, 70], ["the organism Klebsiella aerogenes CCM", "PROBLEM", 28, 65], ["a minimal glucose medium", "PROBLEM", 80, 104]]], ["Oxygen supply was controlled by changing KLa; this coefficient was measured during the cultivation by a dynamic method using a membrane electrode and also calculated from both the differential and the integral form of the oxygen transfer equation.", [["membrane", "ANATOMY", 127, 135], ["Oxygen", "CHEMICAL", 0, 6], ["oxygen", "CHEMICAL", 222, 228], ["Oxygen", "CHEMICAL", 0, 6], ["oxygen", "CHEMICAL", 222, 228], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["KLa", "GENE_OR_GENE_PRODUCT", 41, 44], ["oxygen", "SIMPLE_CHEMICAL", 222, 228], ["Oxygen supply", "TREATMENT", 0, 13], ["a membrane electrode", "TREATMENT", 125, 145], ["the oxygen transfer equation", "TREATMENT", 218, 246], ["oxygen transfer", "OBSERVATION", 222, 237]]], ["The experimental data provided a basis for an analysis of the factors affecting the accuracy of the determination of KLa by the two methods.", [["KLa", "GENE_OR_GENE_PRODUCT", 117, 120], ["KLa", "PROTEIN", 117, 120], ["an analysis", "TEST", 43, 54]]], ["On studying the effect of KLa on specific cell growth rate in batch cultivations the value of tz was found to be in the range of 0.68--1.1 h -1 throughout the region from anaerobic to aerobic conditions.", [["cell", "ANATOMY", 42, 46], ["KLa", "CHEMICAL", 26, 29], ["tz", "CHEMICAL", 94, 96], ["KLa", "SIMPLE_CHEMICAL", 26, 29], ["cell", "CELL", 42, 46], ["KLa", "PROTEIN", 26, 29], ["specific cell growth rate", "TEST", 33, 58], ["batch cultivations", "TEST", 62, 80], ["tz", "TEST", 94, 96], ["aerobic conditions", "OBSERVATION", 184, 202]]], ["Changes were found in biomass yield {23.4--47.3%)and in the production of acid products (difference of 26~o).", [["acid products", "TREATMENT", 74, 87], ["acid products", "OBSERVATION", 74, 87]]], ["Continuous cultivations were carried out at dilution rates of 0.96 h -1 and 0.178 h -1 under otherwise identical conditions.", [["Continuous cultivations", "TEST", 0, 23], ["dilution rates", "TEST", 44, 58]]], ["During the transition from * UNESCO Scholar, Indian Institute of Technology, Kanpur, India; ** Department of Chemical Engineering, IIT, Kanpur, India. anaerobic to aerobic conditions, the steady-state changes in biomass yields were considerably higher than with batch cultivations (9--51~o).", [["anaerobic to aerobic conditions", "PROBLEM", 151, 182], ["batch cultivations", "TEST", 262, 280], ["aerobic conditions", "OBSERVATION", 164, 182]]], ["At otherwise identical values of the physical parameters affecting the oxygen supply, a change in the dilution rate was found to bring about not only a change in the specific oxygen uptake rate, but also a change in the coefficient KLa.Study o! the Growth o] Microorganisms on Fermenter Walls and o/ its E]/ect on the Dynamic8Characteristics o] the Chemostat.", [["oxygen", "CHEMICAL", 71, 77], ["oxygen", "CHEMICAL", 175, 181], ["oxygen", "CHEMICAL", 71, 77], ["oxygen", "CHEMICAL", 175, 181], ["oxygen", "SIMPLE_CHEMICAL", 71, 77], ["oxygen", "SIMPLE_CHEMICAL", 175, 181], ["the oxygen supply", "TREATMENT", 67, 84], ["the dilution rate", "TEST", 98, 115], ["a change in the coefficient KLa", "PROBLEM", 204, 235], ["Study", "TEST", 236, 241], ["Fermenter Walls", "TEST", 277, 292], ["the Chemostat", "TREATMENT", 345, 358], ["oxygen supply", "OBSERVATION", 71, 84], ["oxygen uptake", "OBSERVATION", 175, 188]]], ["M. II V. G, Department of Fermentation Chemistry and Technology, Institute of Chemical Technology, Prague.Study o! the Growth o] Microorganisms on Fermenter Walls and o/ its E]/ect on the Dynamic8To assess its maximum production of itaeonie acid, Aspergiltus terreus ATCC 10020 was cultivated on a glucose synthetic medium.", [["itaeonie acid", "CHEMICAL", 232, 245], ["Aspergiltus terreus ATCC 10020", "CHEMICAL", 247, 277], ["glucose", "CHEMICAL", 298, 305], ["itaeonie acid", "CHEMICAL", 232, 245], ["glucose", "CHEMICAL", 298, 305], ["Dynamic8To", "SIMPLE_CHEMICAL", 188, 198], ["itaeonie acid", "SIMPLE_CHEMICAL", 232, 245], ["Aspergiltus terreus ATCC 10020", "CELL", 247, 277], ["glucose", "SIMPLE_CHEMICAL", 298, 305], ["Aspergiltus terreus", "SPECIES", 247, 266], ["Aspergiltus terreus ATCC 10020", "SPECIES", 247, 277], ["Study", "TEST", 106, 111], ["Fermenter Walls", "TEST", 147, 162], ["the Dynamic8To", "TEST", 184, 198], ["itaeonie acid", "TEST", 232, 245], ["Aspergiltus terreus ATCC", "PROBLEM", 247, 271], ["a glucose synthetic medium", "TREATMENT", 296, 322]]], ["Prolonged cultivation, especially at pH above 2.9, gives rise to a very intense growth of the microorganism on fermenter walls, above the surface of the agitated liquid.", [["surface", "ANATOMY", 138, 145], ["Prolonged cultivation", "PROBLEM", 0, 21], ["the agitated liquid", "PROBLEM", 149, 168], ["cultivation", "OBSERVATION_MODIFIER", 10, 21], ["very", "OBSERVATION_MODIFIER", 67, 71], ["intense", "OBSERVATION_MODIFIER", 72, 79], ["growth", "OBSERVATION_MODIFIER", 80, 86], ["microorganism", "OBSERVATION", 94, 107], ["surface", "OBSERVATION_MODIFIER", 138, 145]]], ["The adhesion of the microorganism depends both on its properties and on the properties of the fermenter walls.", [["The adhesion of the microorganism", "PROBLEM", 0, 33], ["adhesion", "OBSERVATION_MODIFIER", 4, 12], ["microorganism", "OBSERVATION", 20, 33], ["both", "OBSERVATION_MODIFIER", 42, 46], ["fermenter walls", "OBSERVATION", 94, 109]]], ["In contrast to bacteria or yeasts, the cultivation of mycelar forms gives rise not to a thin film, but to a thick layer (thickness 3--5 mm) The fermenter thus represents a continttous agitated biological reactor and, at the same time, a continuous film reactor with no regulation of the thickness of the biologically active layer.", [["mycelar", "ANATOMY", 54, 61], ["bacteria", "PROBLEM", 15, 23], ["yeasts", "PROBLEM", 27, 33], ["a thin film", "TEST", 86, 97], ["a thick layer (thickness", "TEST", 106, 130], ["a continttous agitated biological reactor", "PROBLEM", 170, 211], ["a continuous film reactor", "TEST", 235, 260], ["bacteria", "OBSERVATION", 15, 23], ["yeasts", "OBSERVATION", 27, 33], ["active", "OBSERVATION_MODIFIER", 317, 323], ["layer", "OBSERVATION_MODIFIER", 324, 329]]], ["Under experimental conditions the system cannot be flushed out completely.", [["flushed", "OBSERVATION", 51, 58]]], ["The surface-growing microorganisms differed considerably from the actual submerged culture.", [["surface", "ANATOMY", 4, 11], ["The surface", "TEST", 0, 11], ["growing microorganisms", "PROBLEM", 12, 34], ["the actual submerged culture", "TEST", 62, 90], ["surface", "OBSERVATION_MODIFIER", 4, 11], ["growing", "OBSERVATION_MODIFIER", 12, 19], ["microorganisms", "OBSERVATION", 20, 34]]], ["The effect of dilution rate (0.2--0.4 h-l), pH (2.3--3.6) and phosphorus concentration (0.002 to 0.05% P) on the behaviour of the culture were studied.", [["phosphorus", "CHEMICAL", 62, 72], ["phosphorus", "CHEMICAL", 62, 72], ["phosphorus", "SIMPLE_CHEMICAL", 62, 72], ["dilution rate", "TEST", 14, 27], ["pH", "TEST", 44, 46], ["phosphorus concentration", "TEST", 62, 86], ["the culture", "TEST", 126, 137]]], ["The results obtained with the wall growth differ considerably from those obtained when the wall growth was almost completely removed.", [["wall", "ANATOMY", 30, 34], ["wall", "ANATOMY", 91, 95], ["wall", "TISSUE", 91, 95], ["the wall growth", "TEST", 26, 41], ["the wall growth", "PROBLEM", 87, 102]]], ["The model was verified on a large number of experiments.", [["large", "OBSERVATION_MODIFIER", 28, 33]]], ["The knowledge of quantitative relationships during the growth of microorganisms on the walls of biological reactors is of a grea~b importance for the study of the behaviour and stability of continuous cultivations, especially for the application of small-scale results on a larger scale.", [["microorganisms", "PROBLEM", 65, 79], ["the study", "TEST", 146, 155], ["continuous cultivations", "TREATMENT", 190, 213], ["a larger scale", "TREATMENT", 272, 286], ["growth", "OBSERVATION_MODIFIER", 55, 61]]], ["Experiments were carried out with 3 wine yeast strains, Saccharomyces bayanus Saeeardo 1895 (Bratislava 0 and 1), and Sac~haromyces cerevisiae (Hlirdk 1), in an automatic-intake functional fermeter model.", [["Saccharomyces bayanus Saeeardo 1895", "ORGANISM", 56, 91], ["Bratislava 0", "ORGANISM", 93, 105], ["Sac~haromyces cerevisiae", "ORGANISM", 118, 142], ["Hlirdk 1", "ORGANISM", 144, 152], ["yeast", "SPECIES", 41, 46], ["Saccharomyces bayanus", "SPECIES", 56, 77], ["Sac~haromyces cerevisiae", "SPECIES", 118, 142], ["yeast", "SPECIES", 41, 46], ["Saccharomyces bayanus", "SPECIES", 56, 77], ["Sac~haromyces cerevisiae", "SPECIES", 118, 142], ["Sac~haromyces cerevisiae (Hlirdk", "TREATMENT", 118, 150]]], ["The nutrient medium was a concentrated grape must diluted prior to the fermentation.", [["grape", "ORGANISM_SUBDIVISION", 39, 44], ["The nutrient medium", "TREATMENT", 0, 19], ["a concentrated grape", "TREATMENT", 24, 44], ["nutrient medium", "OBSERVATION", 4, 19]]], ["The experiments included both continuous and period-ieal fermentations with irregular dosage.", [["period-ieal fermentations", "TREATMENT", 45, 70], ["irregular dosage", "TREATMENT", 76, 92]]], ["On evaluating the interrelationships between the rate of substrate consumption and biomass concentration during the propagation from an inoeulum (neglecting the effect of the alcohol formed) we found that at higher concentrations of yeast biomass the rate of multiplication declines.", [["alcohol", "CHEMICAL", 175, 182], ["alcohol", "CHEMICAL", 175, 182], ["alcohol", "SIMPLE_CHEMICAL", 175, 182], ["yeast", "SPECIES", 233, 238], ["yeast", "SPECIES", 233, 238], ["biomass concentration", "TREATMENT", 83, 104], ["yeast biomass", "PROBLEM", 233, 246], ["multiplication declines", "PROBLEM", 259, 282], ["biomass concentration", "OBSERVATION", 83, 104], ["yeast biomass", "OBSERVATION", 233, 246], ["multiplication declines", "OBSERVATION", 259, 282]]], ["When taking into account the effect of alcohol (using an equation similar in form to that for noncompetitive inhibition) its inhibiting effect on the multiplication rate may be demonstrated.", [["alcohol", "CHEMICAL", 39, 46], ["alcohol", "CHEMICAL", 39, 46], ["alcohol", "SIMPLE_CHEMICAL", 39, 46], ["an equation", "TREATMENT", 54, 65], ["noncompetitive inhibition)", "TREATMENT", 94, 120], ["the multiplication rate", "TEST", 146, 169]]], ["The appraisal of experimental data on the propagation of yeast biomass obtained by anaerobic fermentation shows that the yeast multiplication rate grows until a certain maximum concentration of the biomass is attained.", [["yeast", "SPECIES", 57, 62], ["yeast", "SPECIES", 121, 126], ["yeast", "SPECIES", 57, 62], ["yeast", "SPECIES", 121, 126], ["yeast biomass", "PROBLEM", 57, 70], ["anaerobic fermentation", "TEST", 83, 105], ["the yeast multiplication rate", "TEST", 117, 146], ["yeast biomass", "OBSERVATION", 57, 70], ["yeast multiplication", "OBSERVATION", 121, 141], ["biomass", "OBSERVATION", 198, 205]]], ["A 20% replacement of the grape must by beet sugar is permissible for technological purposes.", [["sugar", "CHEMICAL", 44, 49], ["sugar", "SIMPLE_CHEMICAL", 44, 49], ["beet", "SPECIES", 39, 43], ["A 20% replacement of the grape", "TREATMENT", 0, 30], ["technological purposes", "TEST", 69, 91]]], ["The propagation of yeast biomass on grape must is suitable only when the must is complemented by nutrients lost during the technological treatment of the concentrated must.", [["grape", "ORGANISM_SUBDIVISION", 36, 41], ["yeast", "SPECIES", 19, 24], ["yeast", "SPECIES", 19, 24], ["yeast biomass", "PROBLEM", 19, 32], ["grape", "TREATMENT", 36, 41], ["the technological treatment", "TREATMENT", 119, 146], ["propagation", "OBSERVATION_MODIFIER", 4, 15], ["yeast biomass", "OBSERVATION", 19, 32]]], ["In various fields of technology, an attention has recently centered on the application of polysaccharities produced by microorganisms and accumulated in the cultivation medium.", [["polysaccharities", "SIMPLE_CHEMICAL", 90, 106], ["polysaccharities", "PROBLEM", 90, 106], ["microorganisms", "PROBLEM", 119, 133], ["various", "OBSERVATION_MODIFIER", 3, 10], ["fields", "OBSERVATION_MODIFIER", 11, 17], ["cultivation medium", "OBSERVATION", 157, 175]]], ["The substrates used are for the most part glucose or sucrose which are, however, relatively expensive.", [["glucose", "CHEMICAL", 42, 49], ["sucrose", "CHEMICAL", 53, 60], ["glucose", "CHEMICAL", 42, 49], ["sucrose", "CHEMICAL", 53, 60], ["glucose", "SIMPLE_CHEMICAL", 42, 49], ["sucrose", "SIMPLE_CHEMICAL", 53, 60], ["The substrates", "TREATMENT", 0, 14]]], ["As synthetic ethanol has become accessible in large amot~nts, a special attention has been paid to microorganisms capable of producing polysaccharide from this substrafe on a minimal medium.", [["ethanol", "CHEMICAL", 13, 20], ["ethanol", "CHEMICAL", 13, 20], ["ethanol", "SIMPLE_CHEMICAL", 13, 20], ["polysaccharide", "SIMPLE_CHEMICAL", 135, 149], ["substrafe", "SIMPLE_CHEMICAL", 160, 169], ["a special attention", "TREATMENT", 62, 81], ["polysaccharide", "PROBLEM", 135, 149], ["large", "OBSERVATION_MODIFIER", 46, 51]]], ["We carried out experiments of this type with nonidentifled bacteria isolated from compost soil.", [["nonidentifled bacteria", "PROBLEM", 45, 67], ["compost soil", "OBSERVATION", 82, 94]]], ["Cultivation conditions were tested in laboratory fermenters.", [["Cultivation conditions", "TEST", 0, 22]]], ["Increased amount of oxygen promoted the decomposition of polysaccharides and the formation of acetic acid at later growth stages.", [["oxygen", "CHEMICAL", 20, 26], ["acetic acid", "CHEMICAL", 94, 105], ["oxygen", "CHEMICAL", 20, 26], ["acetic acid", "CHEMICAL", 94, 105], ["oxygen", "SIMPLE_CHEMICAL", 20, 26], ["polysaccharides", "SIMPLE_CHEMICAL", 57, 72], ["acetic acid", "SIMPLE_CHEMICAL", 94, 105], ["oxygen", "TREATMENT", 20, 26], ["the decomposition of polysaccharides", "TREATMENT", 36, 72], ["acetic acid", "PROBLEM", 94, 105], ["amount", "OBSERVATION_MODIFIER", 10, 16], ["oxygen promoted", "OBSERVATION", 20, 35]]], ["Organic nitrogen, in the form of peptone and yeast extract, suppressed the formation of polysaecharide.", [["extract", "ANATOMY", 51, 58], ["Organic nitrogen", "CHEMICAL", 0, 16], ["peptone", "CHEMICAL", 33, 40], ["polysaecharide", "CHEMICAL", 88, 102], ["nitrogen", "CHEMICAL", 8, 16], ["peptone", "CHEMICAL", 33, 40], ["polysaecharide", "CHEMICAL", 88, 102], ["Organic nitrogen", "SIMPLE_CHEMICAL", 0, 16], ["peptone", "SIMPLE_CHEMICAL", 33, 40], ["polysaecharide", "SIMPLE_CHEMICAL", 88, 102], ["yeast", "SPECIES", 45, 50], ["yeast", "SPECIES", 45, 50], ["Organic nitrogen", "TREATMENT", 0, 16], ["peptone", "TREATMENT", 33, 40], ["yeast extract", "TREATMENT", 45, 58], ["polysaecharide", "TREATMENT", 88, 102]]], ["In cultures without any limitation by inorganic nitrogen source (e.g. KNO3) the polysaccharide yield was half that in limited cultures even though the limitation decreased the final concentration of cells.", [["cells", "ANATOMY", 199, 204], ["inorganic nitrogen", "CHEMICAL", 38, 56], ["KNO3", "CHEMICAL", 70, 74], ["nitrogen", "CHEMICAL", 48, 56], ["KNO3", "CHEMICAL", 70, 74], ["inorganic", "SIMPLE_CHEMICAL", 38, 47], ["KNO3", "SIMPLE_CHEMICAL", 70, 74], ["polysaccharide", "SIMPLE_CHEMICAL", 80, 94], ["cells", "CELL", 199, 204], ["cultures", "TEST", 3, 11], ["inorganic nitrogen source", "PROBLEM", 38, 63], ["the polysaccharide yield", "TEST", 76, 100], ["limited cultures", "TEST", 118, 134]]], ["2% glucose yielded 0.3--0.5~o polysaccharide while 2~o ethanol gave only 0.06 --0.1 ~o of the product.", [["glucose", "CHEMICAL", 3, 10], ["ethanol", "CHEMICAL", 55, 62], ["glucose", "CHEMICAL", 3, 10], ["ethanol", "CHEMICAL", 55, 62], ["glucose", "SIMPLE_CHEMICAL", 3, 10], ["ethanol", "SIMPLE_CHEMICAL", 55, 62], ["glucose", "TEST", 3, 10], ["polysaccharide", "TEST", 30, 44], ["ethanol", "TEST", 55, 62]]], ["Increase in ethanol concentration to 5% did not result in any increase of polysaccharide production.", [["ethanol", "CHEMICAL", 12, 19], ["ethanol", "CHEMICAL", 12, 19], ["ethanol", "SIMPLE_CHEMICAL", 12, 19], ["polysaccharide", "SIMPLE_CHEMICAL", 74, 88], ["Increase in ethanol concentration", "TREATMENT", 0, 33], ["polysaccharide production", "PROBLEM", 74, 99], ["ethanol concentration", "OBSERVATION", 12, 33], ["increase", "OBSERVATION_MODIFIER", 62, 70], ["polysaccharide production", "OBSERVATION", 74, 99]]], ["The highest yield was observed with 1-2 ~o ethanol.", [["ethanol", "CHEMICAL", 43, 50], ["ethanol", "CHEMICAL", 43, 50], ["ethanol", "SIMPLE_CHEMICAL", 43, 50]]], ["Respiratory nitrate reduetase (NR) and tetrathionate reductase (TTR) catalyse the reduction of terminal electron accepters, nitrate or tetrathionate (anaerobic respiration).", [["nitrate", "CHEMICAL", 12, 19], ["tetrathionate", "CHEMICAL", 39, 52], ["nitrate", "CHEMICAL", 124, 131], ["tetrathionate", "CHEMICAL", 135, 148], ["nitrate", "CHEMICAL", 12, 19], ["tetrathionate", "CHEMICAL", 39, 52], ["nitrate", "CHEMICAL", 124, 131], ["tetrathionate", "CHEMICAL", 135, 148], ["nitrate reduetase", "SIMPLE_CHEMICAL", 12, 29], ["tetrathionate reductase", "GENE_OR_GENE_PRODUCT", 39, 62], ["TTR", "GENE_OR_GENE_PRODUCT", 64, 67], ["nitrate", "SIMPLE_CHEMICAL", 124, 131], ["tetrathionate", "SIMPLE_CHEMICAL", 135, 148], ["Respiratory nitrate reduetase", "PROTEIN", 0, 29], ["NR", "PROTEIN", 31, 33], ["tetrathionate reductase", "PROTEIN", 39, 62], ["TTR", "PROTEIN", 64, 67], ["Respiratory nitrate reduetase", "TREATMENT", 0, 29], ["tetrathionate reductase (TTR)", "TREATMENT", 39, 68], ["terminal electron accepters", "TREATMENT", 95, 122], ["nitrate", "TREATMENT", 124, 131], ["tetrathionate (anaerobic respiration", "TREATMENT", 135, 171]]], ["The presence of oxygen both inhibits the activities of the two enzymes and represses their synthesis.", [["oxygen", "CHEMICAL", 16, 22], ["oxygen", "CHEMICAL", 16, 22], ["oxygen", "SIMPLE_CHEMICAL", 16, 22], ["enzymes", "PROTEIN", 63, 70], ["the two enzymes", "TEST", 55, 70], ["oxygen both", "OBSERVATION", 16, 27]]], ["Washed ungrowing Citrobaeter cells possessing NR synthetize TTR inductively in the presence of K2SaOe, the NR activity being not affected by this synthesis.", [["Citrobaeter cells", "ANATOMY", 17, 34], ["K2SaOe", "CHEMICAL", 95, 101], ["K2SaOe", "CHEMICAL", 95, 101], ["Citrobaeter cells", "CELL", 17, 34], ["TTR", "GENE_OR_GENE_PRODUCT", 60, 63], ["K2SaOe", "SIMPLE_CHEMICAL", 95, 101], ["ungrowing Citrobaeter cells", "CELL_LINE", 7, 34], ["NR", "PROTEIN", 46, 48], ["TTR", "PROTEIN", 60, 63], ["Citrobaeter cells", "TREATMENT", 17, 34], ["NR synthetize TTR", "TREATMENT", 46, 63], ["NR activity", "OBSERVATION", 107, 118]]], ["On the other hand, the induction of NR in cells possessing TTR causes a reduction in the TTR activity.", [["cells", "ANATOMY", 42, 47], ["NR", "GENE_OR_GENE_PRODUCT", 36, 38], ["cells", "CELL", 42, 47], ["TTR", "GENE_OR_GENE_PRODUCT", 59, 62], ["TTR", "GENE_OR_GENE_PRODUCT", 89, 92], ["NR", "PROTEIN", 36, 38], ["TTR", "PROTEIN", 59, 62], ["TTR", "PROTEIN", 89, 92], ["NR in cells", "TREATMENT", 36, 47], ["TTR", "PROBLEM", 59, 62], ["a reduction", "PROBLEM", 70, 81], ["the TTR activity", "PROBLEM", 85, 101], ["reduction", "OBSERVATION_MODIFIER", 72, 81], ["TTR activity", "OBSERVATION", 89, 101]]], ["The NR induction having been completed, the TTR activity is gradually restored to its original level.", [["TTR", "GENE_OR_GENE_PRODUCT", 44, 47], ["TTR", "PROTEIN", 44, 47], ["The NR induction", "TREATMENT", 0, 16], ["the TTR activity", "TEST", 40, 56]]], ["If the same experiment is carried out in the presence of KCN, which inhibits the :NR activity but does not repress its synthesis and does not affect the TTR activity, the temporary decrease does not occur.", [["KCN", "CHEMICAL", 57, 60], ["KCN", "CHEMICAL", 57, 60], ["KCN", "SIMPLE_CHEMICAL", 57, 60], ["TTR", "GENE_OR_GENE_PRODUCT", 153, 156], ["TTR", "PROTEIN", 153, 156], ["KCN", "PROBLEM", 57, 60]]], ["If KCN is added it the moment of the most pronounced decrease, an instantaneous restoration of the :NR activity to the original level follows.", [["KCN", "CHEMICAL", 3, 6], ["KCN", "CHEMICAL", 3, 6], ["KCN", "SIMPLE_CHEMICAL", 3, 6], ["KCN", "TREATMENT", 3, 6]]], ["If chloramphenicol is added in the same way, no activity restoration is observed.", [["chloramphenicol", "CHEMICAL", 3, 18], ["chloramphenicol", "CHEMICAL", 3, 18], ["chloramphenicol", "SIMPLE_CHEMICAL", 3, 18], ["chloramphenicol", "TREATMENT", 3, 18], ["activity restoration", "PROBLEM", 48, 68], ["no", "UNCERTAINTY", 45, 47], ["activity restoration", "OBSERVATION", 48, 68]]], ["Hence, the temporary decrease in the TTR activity is due to the action of the already existing NR and not to its synthesis; protein synthesis is thus required for the renewal of the activity.", [["TTR", "GENE_OR_GENE_PRODUCT", 37, 40], ["TTR", "PROTEIN", 37, 40], ["NR", "PROTEIN", 95, 97], ["the temporary decrease", "PROBLEM", 7, 29], ["the TTR activity", "PROBLEM", 33, 49], ["protein synthesis", "PROBLEM", 124, 141], ["temporary", "OBSERVATION_MODIFIER", 11, 20], ["decrease", "OBSERVATION_MODIFIER", 21, 29]]], ["The two reduetases were simultaneously induced in growing cells.", [["cells", "ANATOMY", 58, 63], ["cells", "CELL", 58, 63], ["growing cells", "CELL_TYPE", 50, 63], ["The two reduetases", "PROBLEM", 0, 18], ["growing cells", "OBSERVATION", 50, 63]]], ["While the TTR synthesis was repressed, the :NR synthesis was not influenced.", [["TTR", "GENE_OR_GENE_PRODUCT", 10, 13], ["TTR", "PROTEIN", 10, 13], ["the TTR synthesis", "TEST", 6, 23], ["NR synthesis", "TEST", 44, 56]]], ["In the presence of KCN, which inhibited the :NR activity, however, the repression did not occur and the two enzymes were synthetized simultaneously.", [["KCN", "CHEMICAL", 19, 22], ["KCN", "CHEMICAL", 19, 22], ["KCN", "SIMPLE_CHEMICAL", 19, 22], ["NR", "PROTEIN", 45, 47], ["enzymes", "PROTEIN", 108, 115], ["KCN", "PROBLEM", 19, 22], ["the two enzymes", "TEST", 100, 115], ["KCN", "OBSERVATION", 19, 22], ["NR activity", "OBSERVATION", 45, 56]]], ["Thus it may be concluded that the TTR synthesis is repressed by the activity and not by the synthesis of NR.", [["TTR", "GENE_OR_GENE_PRODUCT", 34, 37], ["TTR", "PROTEIN", 34, 37], ["NR", "PROTEIN", 105, 107], ["the TTR synthesis", "PROBLEM", 30, 47], ["may be concluded", "UNCERTAINTY", 8, 24]]], ["Citrobacter was cultivated aerobically in a ehemostat at 30~ in a minimal mineral medium under the following conditions: with glucose at glucose limitation; with galactose at galactose limitation; with glucose at NHaC1 limitation; with galactose at :NH4C1 limitation.", [["Citrobacter", "CHEMICAL", 0, 11], ["glucose", "CHEMICAL", 126, 133], ["glucose", "CHEMICAL", 137, 144], ["galactose", "CHEMICAL", 162, 171], ["galactose", "CHEMICAL", 175, 184], ["glucose", "CHEMICAL", 202, 209], ["galactose", "CHEMICAL", 236, 245], ["glucose", "CHEMICAL", 126, 133], ["glucose", "CHEMICAL", 137, 144], ["galactose", "CHEMICAL", 162, 171], ["galactose", "CHEMICAL", 175, 184], ["glucose", "CHEMICAL", 202, 209], ["galactose", "CHEMICAL", 236, 245], ["NH4C1", "CHEMICAL", 250, 255], ["Citrobacter", "SIMPLE_CHEMICAL", 0, 11], ["glucose", "SIMPLE_CHEMICAL", 126, 133], ["glucose", "SIMPLE_CHEMICAL", 137, 144], ["galactose", "SIMPLE_CHEMICAL", 162, 171], ["galactose", "SIMPLE_CHEMICAL", 175, 184], ["glucose", "SIMPLE_CHEMICAL", 202, 209], ["NHaC1", "SIMPLE_CHEMICAL", 213, 218], ["galactose", "SIMPLE_CHEMICAL", 236, 245], ["NH4C1", "SIMPLE_CHEMICAL", 250, 255], ["Citrobacter", "PROBLEM", 0, 11], ["a minimal mineral medium", "TREATMENT", 64, 88], ["glucose at glucose limitation", "PROBLEM", 126, 155], ["galactose at galactose limitation", "PROBLEM", 162, 195], ["glucose", "TEST", 202, 209], ["galactose", "TEST", 236, 245]]], ["The culture was analysed in the steady state at different dilution rates D (10--85~o ~Zmax) and the following parameters were determined: growth yield K, specific metabolic rate q, intracellular concentration of pyruvate, ATP, ADP and AMP.", [["intracellular", "ANATOMY", 181, 194], ["pyruvate", "CHEMICAL", 212, 220], ["ATP", "CHEMICAL", 222, 225], ["ADP", "CHEMICAL", 227, 230], ["AMP", "CHEMICAL", 235, 238], ["pyruvate", "CHEMICAL", 212, 220], ["ATP", "CHEMICAL", 222, 225], ["ADP", "CHEMICAL", 227, 230], ["AMP", "CHEMICAL", 235, 238], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 181, 194], ["pyruvate", "SIMPLE_CHEMICAL", 212, 220], ["ATP", "SIMPLE_CHEMICAL", 222, 225], ["ADP", "SIMPLE_CHEMICAL", 227, 230], ["AMP", "SIMPLE_CHEMICAL", 235, 238], ["The culture", "TEST", 0, 11], ["K", "TEST", 151, 152], ["specific metabolic rate", "TEST", 154, 177], ["intracellular concentration of pyruvate", "TREATMENT", 181, 220], ["ATP", "TREATMENT", 222, 225], ["ADP", "TREATMENT", 227, 230], ["AMP", "TREATMENT", 235, 238]]], ["A change in the physiology of the culture was found to occur at D = 70(~) ~Zmax and near DM; the value of K dropped, q increased, as also did the intraeelhilar concentrations of pyruvate, ATP, ADP and AMP.", [["pyruvate", "CHEMICAL", 178, 186], ["ATP", "CHEMICAL", 188, 191], ["ADP", "CHEMICAL", 193, 196], ["AMP", "CHEMICAL", 201, 204], ["pyruvate", "CHEMICAL", 178, 186], ["ATP", "CHEMICAL", 188, 191], ["ADP", "CHEMICAL", 193, 196], ["AMP", "CHEMICAL", 201, 204], ["pyruvate", "SIMPLE_CHEMICAL", 178, 186], ["ATP", "SIMPLE_CHEMICAL", 188, 191], ["ADP", "SIMPLE_CHEMICAL", 193, 196], ["AMP", "SIMPLE_CHEMICAL", 201, 204], ["A change", "PROBLEM", 0, 8], ["the culture", "TEST", 30, 41], ["Zmax", "TEST", 75, 79], ["near DM", "PROBLEM", 84, 91], ["the value", "TEST", 93, 102], ["K", "TEST", 106, 107], ["ATP", "PROBLEM", 188, 191], ["ADP", "TEST", 193, 196], ["AMP", "TEST", 201, 204], ["change", "OBSERVATION_MODIFIER", 2, 8]]], ["The reason for this was taken to be a partial uncoupling of catabolism from anabolism or a decrease in the efficiency of oxidative phosporylation.", [["a partial uncoupling of catabolism", "PROBLEM", 36, 70], ["anabolism", "PROBLEM", 76, 85], ["a decrease", "PROBLEM", 89, 99], ["oxidative phosporylation", "TREATMENT", 121, 145], ["decrease", "OBSERVATION_MODIFIER", 91, 99], ["oxidative phosporylation", "OBSERVATION", 121, 145]]], ["The above criteria served to compare ja culture growing with the same growth rate but (a) with D lower than D~ and D higher than DM; (b) cultures growing on glucose or on galactose; (c) at carbon limitation and nitrogen source limitation;Study o/ the Propagation o] Yeast Biomass ]or the(d) E. coli instead of Citrobacter.", [["glucose", "CHEMICAL", 157, 164], ["galactose", "CHEMICAL", 171, 180], ["nitrogen", "CHEMICAL", 211, 219], ["glucose", "CHEMICAL", 157, 164], ["galactose", "CHEMICAL", 171, 180], ["carbon", "CHEMICAL", 189, 195], ["nitrogen", "CHEMICAL", 211, 219], ["glucose", "SIMPLE_CHEMICAL", 157, 164], ["galactose", "SIMPLE_CHEMICAL", 171, 180], ["E. coli", "ORGANISM", 291, 298], ["Citrobacter.", "ORGANISM", 310, 322], ["Yeast", "SPECIES", 266, 271], ["E. coli", "SPECIES", 291, 298], ["E. coli", "SPECIES", 291, 298], ["The above criteria", "TEST", 0, 18], ["ja culture", "TEST", 37, 47], ["D lower than D~ and D higher than DM", "PROBLEM", 95, 131], ["b) cultures", "TEST", 134, 145], ["glucose", "TEST", 157, 164], ["galactose", "TEST", 171, 180], ["c) at carbon limitation", "PROBLEM", 183, 206], ["nitrogen source limitation", "PROBLEM", 211, 237], ["Yeast Biomass", "PROBLEM", 266, 279], ["the(d) E. coli", "PROBLEM", 284, 298], ["Citrobacter", "PROBLEM", 310, 321], ["Yeast Biomass", "OBSERVATION", 266, 279], ["Citrobacter", "OBSERVATION", 310, 321]]], ["Stable m.RNA /or ce-amyla, se in B. subtilis.", [["ce-amyla", "GENE_OR_GENE_PRODUCT", 17, 25], ["B. subtilis", "ORGANISM", 33, 44], ["B. subtilis", "SPECIES", 33, 44], ["B. subtilis", "SPECIES", 33, 44], ["RNA", "TEST", 9, 12], ["ce-amyla", "PROBLEM", 17, 25]]], ["In the process of waste water treatment bacteria arc transferred into the atmosphere with water droplets and the sedimentation of the bacterial aerosol results in a contamination of the working environment.", [["waste water treatment bacteria", "TREATMENT", 18, 48], ["water droplets", "TREATMENT", 90, 104], ["the bacterial aerosol", "TREATMENT", 130, 151], ["bacterial aerosol", "OBSERVATION", 134, 151]]], ["Quantitative determination os psychrophyllie, mesophyllie and coliform bacteria in the air of the plants was carried out using Aeroscope.", [["psychrophyllie", "SIMPLE_CHEMICAL", 30, 44], ["mesophyllie", "SIMPLE_CHEMICAL", 46, 57], ["Quantitative determination os psychrophyllie", "PROBLEM", 0, 44], ["mesophyllie", "PROBLEM", 46, 57], ["coliform bacteria", "PROBLEM", 62, 79], ["Aeroscope", "TREATMENT", 127, 136], ["air", "OBSERVATION_MODIFIER", 87, 90]]], ["Replica microbiotests served to take samples for the determination of coli --aerogenes bacteria, fungi and enterococei.", [["samples", "ANATOMY", 37, 44], ["coli", "ORGANISM", 70, 74], ["Replica microbiotests", "TREATMENT", 0, 21], ["coli --aerogenes bacteria", "PROBLEM", 70, 95], ["fungi", "PROBLEM", 97, 102], ["enterococei", "PROBLEM", 107, 118]]], ["Samples were taken from the rack house, pumping station, aeration tanks, biofilters, workshops, laboratories and offices.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["aeration tanks", "TREATMENT", 57, 71]]], ["To have a standard of the degree of air contamination, samples were also taken in a place with a heavy traffic in the centre, in laboratories of a drinking water processing plant and in a wood.", [["samples", "ANATOMY", 55, 62], ["wood", "ANATOMY", 188, 192], ["air contamination", "PROBLEM", 36, 53], ["air contamination", "OBSERVATION", 36, 53]]], ["The effect of UV-radiation on the bacterial air contamination was studied by a Microlux; the working place was irradiated for 15 min and samples were then taken from a distance of 1 m from the radiation source.", [["samples", "ANATOMY", 137, 144], ["UV", "CHEMICAL", 14, 16], ["UV-radiation", "TREATMENT", 14, 26], ["the bacterial air contamination", "PROBLEM", 30, 61], ["bacterial", "OBSERVATION_MODIFIER", 34, 43], ["air contamination", "OBSERVATION", 44, 61], ["radiation source", "OBSERVATION", 193, 209]]], ["The most sensitive towards the radiation were coliform bacteria and enterococei which were almost annihilated, more resistant are psychrophyllic bacteria, mesophyllic bacteria and fungi.", [["coliform bacteria", "PROBLEM", 46, 63], ["enterococei", "PROBLEM", 68, 79], ["psychrophyllic bacteria", "PROBLEM", 130, 153], ["mesophyllic bacteria", "PROBLEM", 155, 175], ["fungi", "PROBLEM", 180, 185], ["most sensitive", "OBSERVATION_MODIFIER", 4, 18]]], ["The effect of the radiation was rapidly abolished due to proceeding transfer of bacteria from waste water into the atmosphere and stirring up of the sedimented bacterial dust.", [["the radiation", "TREATMENT", 14, 27], ["bacteria", "PROBLEM", 80, 88], ["the sedimented bacterial dust", "PROBLEM", 145, 174], ["sedimented bacterial dust", "OBSERVATION", 149, 174]]], ["One of the best methods for decreasing the concentration of microorganisms in the air is an effective ventilation which may reduce the number of bacteria by 50~o.", [["an effective ventilation", "TREATMENT", 89, 113], ["bacteria", "PROBLEM", 145, 153], ["air", "OBSERVATION", 82, 85], ["effective", "OBSERVATION_MODIFIER", 92, 101], ["ventilation", "OBSERVATION", 102, 113], ["bacteria", "OBSERVATION", 145, 153]]], ["The experimental values of the bacterial contamination in individual places formed a basis for a proposed system of evaluation of the life environment with respect to bacteriology.SECTION OF ENVIRONMENTAL MICROBIOLOGYNitri]ication by Heterotrophs.", [["the bacterial contamination", "PROBLEM", 27, 54], ["evaluation", "TEST", 116, 126], ["bacterial contamination", "OBSERVATION", 31, 54]]], ["E. B~RGEROV2k, Department of Microbiology, Faculty of Sciences, Commenius University, Bratislava.SECTION OF ENVIRONMENTAL MICROBIOLOGYThe existence of heterotrophic nitrifiers has long been denied, the results concerning heterotrophic nitrification being taken to be erroneous.", [["heterotrophic nitrifiers", "TREATMENT", 151, 175], ["heterotrophic nitrification", "TREATMENT", 221, 248], ["heterotrophic nitrifiers", "OBSERVATION", 151, 175], ["heterotrophic nitrification", "OBSERVATION", 221, 248]]], ["Though the existence of heterotrophic nitrifiers --bacteria, actinomyeetes and fungi --is no longer doubted, the biochemistry of the process is not yet clear.", [["heterotrophic nitrifiers --bacteria", "PROBLEM", 24, 59], ["actinomyeetes", "PROBLEM", 61, 74], ["fungi", "PROBLEM", 79, 84], ["heterotrophic nitrifiers --bacteria", "OBSERVATION", 24, 59], ["no longer", "UNCERTAINTY", 90, 99], ["not yet", "UNCERTAINTY", 144, 151], ["clear", "OBSERVATION", 152, 157]]], ["Heterotrophie microorganisms do not belong to a single taxonomic group; apart from fungi, oxidizing avidly NFIa + to NO2-or Nee-, bacteria and astinomyeetes form also these substances, though to a lesser extent.", [["NFIa", "CHEMICAL", 107, 111], ["NO2", "CHEMICAL", 117, 120], ["Nee-", "CHEMICAL", 124, 128], ["NFIa +", "CHEMICAL", 107, 113], ["NO2", "CHEMICAL", 117, 120], ["Nee-", "CHEMICAL", 124, 128], ["NFIa +", "SIMPLE_CHEMICAL", 107, 113], ["NO2", "SIMPLE_CHEMICAL", 117, 120], ["Nee-", "SIMPLE_CHEMICAL", 124, 128], ["astinomyeetes", "SIMPLE_CHEMICAL", 143, 156], ["Heterotrophie microorganisms", "PROBLEM", 0, 28], ["fungi", "PROBLEM", 83, 88], ["NO2", "TEST", 117, 120], ["Nee-", "PROBLEM", 124, 128], ["bacteria", "PROBLEM", 130, 138], ["astinomyeetes", "TEST", 143, 156], ["bacteria", "OBSERVATION", 130, 138], ["substances", "OBSERVATION", 173, 183], ["lesser extent", "OBSERVATION_MODIFIER", 197, 210]]], ["The capability to oxidize NH4 + seems to be possessed also by other, not yet identified bacteria and fungi.", [["NH4", "CHEMICAL", 26, 29], ["NH4 +", "CHEMICAL", 26, 31], ["NH4 +", "SIMPLE_CHEMICAL", 26, 31], ["oxidize NH4", "TREATMENT", 18, 29], ["bacteria", "PROBLEM", 88, 96], ["fungi", "PROBLEM", 101, 106], ["bacteria", "OBSERVATION", 88, 96], ["fungi", "OBSERVATION", 101, 106]]], ["The ability of heterotrophic nitrification was tested in micromyeetes Aspergillus ]lavus Wehmer, Aspergillus ]lavua Link, Chafemium globosum Kunze and Penicillium solium Westling.", [["Aspergillus ]lavua", "ORGANISM", 97, 115], ["Link", "ORGANISM", 116, 120], ["Chafemium globosum Kunze", "ORGANISM", 122, 146], ["Penicillium solium", "ORGANISM", 151, 169], ["Aspergillus ]lavus", "SPECIES", 70, 88], ["Aspergillus ]lavua", "SPECIES", 97, 115], ["Chafemium globosum", "SPECIES", 122, 140], ["Penicillium solium", "SPECIES", 151, 169], ["Aspergillus ]lavus", "SPECIES", 70, 88], ["Aspergillus ]lavua", "SPECIES", 97, 115], ["Chafemium globosum", "SPECIES", 122, 140], ["Penicillium solium", "SPECIES", 151, 169], ["heterotrophic nitrification", "TREATMENT", 15, 42], ["Aspergillus", "PROBLEM", 70, 81], ["Wehmer", "TEST", 89, 95], ["Aspergillus", "TEST", 97, 108], ["Penicillium solium Westling", "TREATMENT", 151, 178], ["heterotrophic nitrification", "OBSERVATION", 15, 42]]], ["All of them oxidized NHa + if grown on a medium with reduced nitrogen forms.", [["NHa", "CHEMICAL", 21, 24], ["nitrogen", "CHEMICAL", 61, 69], ["NHa +", "CHEMICAL", 21, 26], ["nitrogen", "CHEMICAL", 61, 69], ["NHa +", "SIMPLE_CHEMICAL", 21, 26], ["NHa", "PROTEIN", 21, 24], ["reduced nitrogen forms", "PROBLEM", 53, 75]]], ["Various amino acids and ammonium sulphate served as nitrogen sources for the formation of hydroxylamine, nitrite and nitrate.", [["amino acids", "CHEMICAL", 8, 19], ["ammonium sulphate", "CHEMICAL", 24, 41], ["nitrogen", "CHEMICAL", 52, 60], ["hydroxylamine", "CHEMICAL", 90, 103], ["nitrite", "CHEMICAL", 105, 112], ["nitrate", "CHEMICAL", 117, 124], ["amino acids", "CHEMICAL", 8, 19], ["ammonium sulphate", "CHEMICAL", 24, 41], ["nitrogen", "CHEMICAL", 52, 60], ["hydroxylamine", "CHEMICAL", 90, 103], ["nitrite", "CHEMICAL", 105, 112], ["nitrate", "CHEMICAL", 117, 124], ["amino acids", "AMINO_ACID", 8, 19], ["ammonium sulphate", "SIMPLE_CHEMICAL", 24, 41], ["hydroxylamine", "SIMPLE_CHEMICAL", 90, 103], ["nitrite", "SIMPLE_CHEMICAL", 105, 112], ["nitrate", "SIMPLE_CHEMICAL", 117, 124], ["Various amino acids", "TREATMENT", 0, 19], ["ammonium sulphate", "TREATMENT", 24, 41], ["nitrogen sources", "TREATMENT", 52, 68], ["hydroxylamine", "TREATMENT", 90, 103], ["nitrite", "TREATMENT", 105, 112], ["nitrate", "TREATMENT", 117, 124]]], ["The intensity of NO2and NOa-formation depends on the species, substrate, and the C :57 ratio, which is one of the limiting factors in the release of the NHa + ions and, consequently, one of the decisive factors in heterotrophie nitrification.", [["NOa-", "CHEMICAL", 24, 28], ["NHa", "CHEMICAL", 153, 156], ["NO2and NOa-", "CHEMICAL", 17, 28], ["NHa +", "CHEMICAL", 153, 158], ["NO2and", "SIMPLE_CHEMICAL", 17, 23], ["NOa-", "SIMPLE_CHEMICAL", 24, 28], ["NHa + ions", "SIMPLE_CHEMICAL", 153, 163], ["heterotrophie", "SIMPLE_CHEMICAL", 214, 227], ["NO2and NOa-formation", "PROBLEM", 17, 37], ["heterotrophie nitrification", "TREATMENT", 214, 241], ["intensity", "OBSERVATION_MODIFIER", 4, 13], ["heterotrophie nitrification", "OBSERVATION", 214, 241]]], ["The course of the process is also strongly dependent on the pH of the medium, the optimum being at pH 7--9.", [["pH", "TEST", 99, 101]]], ["The intensity of NHa + oxidation is not directly proportional to growth intensity.", [["NHa", "CHEMICAL", 17, 20], ["NHa +", "CHEMICAL", 17, 22], ["NHa +", "SIMPLE_CHEMICAL", 17, 22], ["NHa", "PROTEIN", 17, 20]]], ["Further experiments aimed at determining the effect of some metals on heterotrophic nitrification in the above mieromyeetes and in the cell extract from Ghaetomium globosum Kunze.SECTION OF ENVIRONMENTAL MICROBIOLOGYThe problem of the utilization of energy formed by the process Under natural conditions has not yet been elucidated.Regulation o] Enzymes Participating in Utilization o/ Glutamic Acid by Soil Micro]Iota.", [["cell extract", "ANATOMY", 135, 147], ["metals", "CHEMICAL", 60, 66], ["Glutamic Acid", "CHEMICAL", 386, 399], ["Glutamic Acid", "CHEMICAL", 386, 399], ["metals", "SIMPLE_CHEMICAL", 60, 66], ["cell", "CELL", 135, 139], ["Ghaetomium globosum Kunze", "ORGANISM", 153, 178], ["Glutamic Acid", "SIMPLE_CHEMICAL", 386, 399], ["Ghaetomium globosum", "SPECIES", 153, 172], ["Ghaetomium globosum", "SPECIES", 153, 172], ["some metals", "PROBLEM", 55, 66], ["heterotrophic nitrification", "TREATMENT", 70, 97], ["Glutamic Acid", "TREATMENT", 386, 399], ["heterotrophic nitrification", "OBSERVATION", 70, 97], ["above mieromyeetes", "ANATOMY", 105, 123]]], ["J. MACRO,Institute of Microbiology, Czechoslovak Academy of Sciences, Prague.Regulation o] Enzymes Participating in Utilization o/ Glutamic Acid by Soil Micro]Iota.", [["Glutamic Acid", "CHEMICAL", 131, 144], ["Glutamic Acid", "CHEMICAL", 131, 144], ["Glutamic Acid", "SIMPLE_CHEMICAL", 131, 144], ["Glutamic Acid", "TREATMENT", 131, 144]]], ["J. MACRO,Mechanisms were studied which control the synthesis and activity of enzymes participating in the degradation and utilization of amino acids by soil microflora.", [["amino acids", "CHEMICAL", 137, 148], ["amino acids", "CHEMICAL", 137, 148], ["amino acids", "AMINO_ACID", 137, 148], ["enzymes", "PROTEIN", 77, 84], ["the synthesis and activity of enzymes", "PROBLEM", 47, 84], ["amino acids", "TREATMENT", 137, 148]]], ["Enzyme synthesis and activity were assessed from the rate of disappearance of glutamie acid present in a nitrogen-free mineral solution inoculated by a medium preincubated with glu-77 ramie acid or with glucose.", [["glutamie acid", "CHEMICAL", 78, 91], ["nitrogen", "CHEMICAL", 105, 113], ["glu-77 ramie acid", "CHEMICAL", 177, 194], ["glucose", "CHEMICAL", 203, 210], ["glutamie acid", "CHEMICAL", 78, 91], ["nitrogen", "CHEMICAL", 105, 113], ["glu-77 ramie acid", "CHEMICAL", 177, 194], ["glucose", "CHEMICAL", 203, 210], ["glutamie acid", "SIMPLE_CHEMICAL", 78, 91], ["nitrogen", "SIMPLE_CHEMICAL", 105, 113], ["glu-77 ramie acid", "SIMPLE_CHEMICAL", 177, 194], ["glucose", "SIMPLE_CHEMICAL", 203, 210], ["Enzyme synthesis", "TEST", 0, 16], ["glutamie acid", "TREATMENT", 78, 91], ["a nitrogen-free mineral solution", "TREATMENT", 103, 135], ["glu", "TEST", 177, 180], ["glucose", "TEST", 203, 210]]], ["Enzymes catabolizing glutamie acid were synthetized in the medium enriched by this acid, and the glutamic acid present in the mineral medium disappeared at a constant rate.", [["glutamie acid", "CHEMICAL", 21, 34], ["glutamic acid", "CHEMICAL", 97, 110], ["glutamie acid", "CHEMICAL", 21, 34], ["glutamic acid", "CHEMICAL", 97, 110], ["glutamie acid", "SIMPLE_CHEMICAL", 21, 34], ["glutamic acid", "SIMPLE_CHEMICAL", 97, 110], ["Enzymes", "TEST", 0, 7], ["glutamie acid", "PROBLEM", 21, 34], ["this acid", "TREATMENT", 78, 87], ["the glutamic acid", "TEST", 93, 110], ["glutamie acid", "OBSERVATION", 21, 34]]], ["In glucose-enriched medium, on the other hand, the activity of these enzymes was low; the glutamic acid present in the mineral medium was initially utilized at a low rate, which increased appreciably after 2--3 h.", [["glucose", "CHEMICAL", 3, 10], ["glutamic acid", "CHEMICAL", 90, 103], ["glucose", "CHEMICAL", 3, 10], ["glutamic acid", "CHEMICAL", 90, 103], ["glucose", "SIMPLE_CHEMICAL", 3, 10], ["glutamic acid", "SIMPLE_CHEMICAL", 90, 103], ["enzymes", "PROTEIN", 69, 76], ["these enzymes", "TEST", 63, 76], ["the glutamic acid", "TEST", 86, 103], ["enriched", "OBSERVATION_MODIFIER", 11, 19], ["medium", "OBSERVATION_MODIFIER", 20, 26]]], ["The results indicated that the glucose-enriched medium allowed only very low constitutive synthesis of appropriate enzymes or that these enzymes were repressed or inhibited by glucose.", [["glucose", "CHEMICAL", 31, 38], ["glucose", "CHEMICAL", 176, 183], ["glucose", "CHEMICAL", 31, 38], ["glucose", "CHEMICAL", 176, 183], ["glucose", "SIMPLE_CHEMICAL", 31, 38], ["glucose", "SIMPLE_CHEMICAL", 176, 183], ["enzymes", "PROTEIN", 115, 122], ["enzymes", "PROTEIN", 137, 144], ["the glucose", "TEST", 27, 38], ["very low constitutive synthesis of appropriate enzymes", "PROBLEM", 68, 122], ["these enzymes", "TEST", 131, 144], ["glucose", "TEST", 176, 183]]], ["The increase in the glutamie acid degradation would then be due either to inductive enzyme synthesis or to derepression.", [["glutamie acid", "CHEMICAL", 20, 33], ["glutamie acid", "CHEMICAL", 20, 33], ["glutamie acid", "SIMPLE_CHEMICAL", 20, 33], ["the glutamie acid degradation", "PROBLEM", 16, 45], ["inductive enzyme synthesis", "PROBLEM", 74, 100], ["increase", "OBSERVATION_MODIFIER", 4, 12]]], ["Glucose was found to repress the synthesis of the enzymes catabolizing glutamic acid and to inhibit their activity.", [["Glucose", "CHEMICAL", 0, 7], ["glutamic acid", "CHEMICAL", 71, 84], ["Glucose", "CHEMICAL", 0, 7], ["glutamic acid", "CHEMICAL", 71, 84], ["Glucose", "SIMPLE_CHEMICAL", 0, 7], ["glutamic acid", "SIMPLE_CHEMICAL", 71, 84], ["Glucose", "TEST", 0, 7], ["the enzymes", "TEST", 46, 57], ["glutamic acid", "TEST", 71, 84]]], ["The activity of the enzymes was also inhibited in the presence of ammonium ions; this inhibitory effect of ammonium ions decreased in the presence of glucose, and vice versa.", [["ammonium ions", "CHEMICAL", 66, 79], ["ammonium ions", "CHEMICAL", 107, 120], ["glucose", "CHEMICAL", 150, 157], ["ammonium", "CHEMICAL", 66, 74], ["ammonium", "CHEMICAL", 107, 115], ["glucose", "CHEMICAL", 150, 157], ["ammonium ions", "SIMPLE_CHEMICAL", 66, 79], ["ammonium ions", "SIMPLE_CHEMICAL", 107, 120], ["glucose", "SIMPLE_CHEMICAL", 150, 157], ["the enzymes", "TEST", 16, 27], ["ammonium ions", "PROBLEM", 66, 79], ["ammonium ions", "PROBLEM", 107, 120], ["glucose", "TEST", 150, 157]]], ["The results con~rmed the existence of regulatory mechanisms and pointed at the significance of nutritional conditions in the synthesis and activity control of enzymes in mixed soil populations.Biochemical Evaluation o/the E]]ect o/ Fertilization on the Utilization o/ Nitrogen in Soil.", [["o/ Nitrogen", "CHEMICAL", 265, 276], ["Nitrogen", "CHEMICAL", 268, 276], ["enzymes", "PROTEIN", 159, 166], ["nutritional conditions", "PROBLEM", 95, 117], ["the synthesis", "TREATMENT", 121, 134], ["activity control of enzymes", "TREATMENT", 139, 166], ["mixed soil populations", "PROBLEM", 170, 192], ["Biochemical Evaluation", "TEST", 193, 215], ["ect o/ Fertilization", "TREATMENT", 225, 245], ["Nitrogen", "TREATMENT", 268, 276], ["mixed", "OBSERVATION_MODIFIER", 170, 175], ["soil populations", "OBSERVATION", 176, 192]]], ["B. NOVAE,Research Institutes for Crop Production, Prague-Ruzyn~.Biochemical Evaluation o/the E]]ect o/ Fertilization on the Utilization o/ Nitrogen in Soil.", [["o/ Nitrogen", "CHEMICAL", 136, 147], ["Nitrogen", "CHEMICAL", 139, 147], ["Biochemical Evaluation", "TEST", 64, 86], ["ect o/ Fertilization", "TREATMENT", 96, 116], ["Nitrogen", "TREATMENT", 139, 147]]], ["B. NOVAE,Two-culture crop rotating system (sugar beet, spring wheat) was systematically fertilized by both organic and mineral fertilizers.", [["wheat", "SPECIES", 62, 67], ["beet", "SPECIES", 49, 53], ["wheat", "SPECIES", 62, 67], ["both organic and mineral fertilizers", "TREATMENT", 102, 138], ["mineral fertilizers", "OBSERVATION", 119, 138]]], ["All fertilizing variants included also plots of black-soil fallow.", [["All fertilizing variants", "PROBLEM", 0, 24], ["black-soil fallow", "TREATMENT", 48, 65], ["fertilizing variants", "OBSERVATION", 4, 24]]], ["The physiological utilizability of nitrogen was evaluated from the values of respirometric test, N :B, NG :G, and those obtained by eellulolytic test, CN :CB.", [["nitrogen", "CHEMICAL", 35, 43], ["NG", "CHEMICAL", 103, 105], ["nitrogen", "CHEMICAL", 35, 43], ["nitrogen", "SIMPLE_CHEMICAL", 35, 43], ["N :B", "SIMPLE_CHEMICAL", 97, 101], ["NG :G", "SIMPLE_CHEMICAL", 103, 108], ["respirometric test", "TEST", 77, 95]]], ["The value N : B indicates the actual shortage of utilizable nitrogen in the soil while the quotients NG : G and CN : CB indicate its potential shortage.", [["utilizable nitrogen", "CHEMICAL", 49, 68], ["NG", "CHEMICAL", 101, 103], ["nitrogen", "CHEMICAL", 60, 68], ["nitrogen", "SIMPLE_CHEMICAL", 60, 68], ["utilizable nitrogen", "TREATMENT", 49, 68]]], ["The physiological utilizability of nitrogen is enhanced by fertilizers, especially mineral.", [["nitrogen", "CHEMICAL", 35, 43], ["nitrogen", "CHEMICAL", 35, 43], ["nitrogen", "SIMPLE_CHEMICAL", 35, 43]]], ["It decreases partially spontaneously with time, and partially due to the crop growth.", [["the crop growth", "PROBLEM", 69, 84]]], ["The compost used prevented, to a considerable extent, the losses in nitrogen utilizability, particularly in fallow soil.", [["nitrogen", "CHEMICAL", 68, 76], ["nitrogen", "CHEMICAL", 68, 76], ["nitrogen", "SIMPLE_CHEMICAL", 68, 76], ["The compost", "TREATMENT", 0, 11], ["the losses in nitrogen utilizability", "PROBLEM", 54, 90], ["nitrogen utilizability", "OBSERVATION", 68, 90]]], ["The use of manure brought about conspicuous changes in the nitrogen utilization, especially in soil with growing crops.", [["nitrogen", "CHEMICAL", 59, 67], ["nitrogen", "CHEMICAL", 59, 67], ["nitrogen", "SIMPLE_CHEMICAL", 59, 67], ["manure", "TREATMENT", 11, 17], ["conspicuous changes", "PROBLEM", 32, 51], ["the nitrogen utilization", "TREATMENT", 55, 79]]], ["Epidermal root surface is covered by a layer of viscous material, the so-called mucigel.", [["Epidermal root surface", "ANATOMY", 0, 22], ["Epidermal root surface", "TISSUE", 0, 22], ["root", "OBSERVATION_MODIFIER", 10, 14], ["surface", "OBSERVATION_MODIFIER", 15, 22], ["layer", "OBSERVATION_MODIFIER", 39, 44], ["viscous material", "OBSERVATION", 48, 64]]], ["It is formed even on the surface of sterile roots.", [["surface", "ANATOMY", 25, 32], ["roots", "ANATOMY", 44, 49], ["surface", "CELLULAR_COMPONENT", 25, 32], ["roots", "ORGAN", 44, 49], ["formed", "OBSERVATION", 6, 12], ["surface", "OBSERVATION_MODIFIER", 25, 32], ["sterile roots", "ANATOMY", 36, 49]]], ["We studied the formation of this polymer by wheat roots during the first four weeks of plant growth in Robinson medium under sterile and controlled conditions.", [["roots", "ANATOMY", 50, 55], ["wheat", "ORGANISM", 44, 49], ["roots", "DEVELOPING_ANATOMICAL_STRUCTURE", 50, 55], ["wheat", "SPECIES", 44, 49], ["wheat", "SPECIES", 44, 49], ["this polymer", "TREATMENT", 28, 40], ["plant growth", "PROBLEM", 87, 99], ["sterile and controlled conditions", "TREATMENT", 125, 158], ["growth", "OBSERVATION_MODIFIER", 93, 99]]], ["The dynamics of the formation of polysaceharides exuded by plant roots is similar to that of excretion of other exudates.", [["roots", "ANATOMY", 65, 70], ["exudates", "ANATOMY", 112, 120], ["polysaceharides", "CHEMICAL", 33, 48], ["polysaceharides", "CHEMICAL", 33, 48], ["polysaceharides", "SIMPLE_CHEMICAL", 33, 48], ["roots", "ORGAN", 65, 70], ["polysaceharides exuded", "PROBLEM", 33, 55], ["other exudates", "PROBLEM", 106, 120], ["plant roots", "OBSERVATION", 59, 70], ["exudates", "OBSERVATION", 112, 120]]], ["When referred to 1 plant/1 day, the values show a decrease in the second week of growth, followed by rise in the third week which continues probably till the flowering phase.", [["the values", "TEST", 32, 42], ["a decrease", "PROBLEM", 48, 58], ["decrease", "OBSERVATION_MODIFIER", 50, 58]]], ["During the first week the germinating plant has sufficient energy from seed storage substances and the seeds themselves exude also a certain amount of polysaccharides.", [["seeds", "ANATOMY", 103, 108], ["seed storage substances", "TREATMENT", 71, 94], ["polysaccharides", "PROBLEM", 151, 166], ["amount", "OBSERVATION_MODIFIER", 141, 147], ["polysaccharides", "OBSERVATION", 151, 166]]], ["In the second week the nutrition of the germinating plant is switched mainly to photosynthesis and the amount of exuded polysaceharides declines as compared with the first week.", [["polysaceharides", "CHEMICAL", 120, 135], ["polysaceharides", "SIMPLE_CHEMICAL", 120, 135], ["the germinating plant", "TREATMENT", 36, 57], ["photosynthesis", "TREATMENT", 80, 94], ["exuded polysaceharides", "PROBLEM", 113, 135], ["amount", "OBSERVATION_MODIFIER", 103, 109], ["exuded", "OBSERVATION_MODIFIER", 113, 119], ["polysaceharides", "OBSERVATION", 120, 135]]], ["In the following weeks the amount of exuded polysaceharides increases, amounting to 30 mg/day/1 g dry root weight, or 7.5 mg/day/1 g dry wt. of whole wheat plants.", [["root", "ANATOMY", 102, 106], ["polysaceharides", "CHEMICAL", 44, 59], ["polysaceharides", "CHEMICAL", 44, 59], ["polysaceharides", "SIMPLE_CHEMICAL", 44, 59], ["root", "ORGANISM_SUBDIVISION", 102, 106], ["wheat plants", "ORGANISM", 150, 162], ["wheat", "SPECIES", 150, 155], ["wheat", "SPECIES", 150, 155], ["exuded polysaceharides", "PROBLEM", 37, 59], ["whole wheat plants", "TREATMENT", 144, 162], ["amount", "OBSERVATION_MODIFIER", 27, 33], ["exuded", "OBSERVATION_MODIFIER", 37, 43], ["polysaceharides", "OBSERVATION", 44, 59], ["wheat plants", "OBSERVATION", 150, 162]]], ["Similar values were obtained also with maize.", [["maize", "SPECIES", 39, 44]]], ["If the nutrient solution is not replaced, the formation of polysaceharides decreases.", [["polysaceharides", "CHEMICAL", 59, 74], ["polysaceharides", "CHEMICAL", 59, 74], ["polysaceharides", "SIMPLE_CHEMICAL", 59, 74], ["the nutrient solution", "TREATMENT", 3, 24], ["polysaceharides", "PROBLEM", 59, 74]]], ["The composition of acid hydrolysates of polysaccharides was determined by paper and gas chromatography; wheat root polysaceharides contained uronic acid, galactose, glucose, arabinose, mannose and xylose.", [["polysaceharides", "CHEMICAL", 115, 130], ["uronic acid", "CHEMICAL", 141, 152], ["galactose", "CHEMICAL", 154, 163], ["glucose", "CHEMICAL", 165, 172], ["arabinose", "CHEMICAL", 174, 183], ["mannose", "CHEMICAL", 185, 192], ["xylose", "CHEMICAL", 197, 203], ["uronic acid", "CHEMICAL", 141, 152], ["galactose", "CHEMICAL", 154, 163], ["glucose", "CHEMICAL", 165, 172], ["arabinose", "CHEMICAL", 174, 183], ["mannose", "CHEMICAL", 185, 192], ["xylose", "CHEMICAL", 197, 203], ["polysaccharides", "SIMPLE_CHEMICAL", 40, 55], ["polysaceharides", "SIMPLE_CHEMICAL", 115, 130], ["uronic acid", "SIMPLE_CHEMICAL", 141, 152], ["galactose", "SIMPLE_CHEMICAL", 154, 163], ["glucose", "SIMPLE_CHEMICAL", 165, 172], ["arabinose", "SIMPLE_CHEMICAL", 174, 183], ["mannose", "SIMPLE_CHEMICAL", 185, 192], ["xylose", "SIMPLE_CHEMICAL", 197, 203], ["wheat", "SPECIES", 104, 109], ["wheat", "SPECIES", 104, 109], ["acid hydrolysates of polysaccharides", "TREATMENT", 19, 55], ["gas chromatography", "TEST", 84, 102], ["wheat root polysaceharides", "TEST", 104, 130], ["uronic acid", "TEST", 141, 152], ["galactose", "TEST", 154, 163], ["glucose", "TEST", 165, 172], ["xylose", "TREATMENT", 197, 203], ["uronic acid", "OBSERVATION", 141, 152]]], ["Maize root polysaccharides contained, in addition, fueose.Changes in Microbial Population of Bean PlantRhizosphere alter Colonization of the Root Su'rface by the Bacterium Xanthomonas fuscans.", [["root polysaccharides", "ANATOMY", 6, 26], ["fueose", "SIMPLE_CHEMICAL", 51, 57], ["Xanthomonas fuscans", "ORGANISM", 172, 191], ["Maize", "SPECIES", 0, 5], ["Xanthomonas fuscans", "SPECIES", 172, 191], ["Maize", "SPECIES", 0, 5], ["Xanthomonas fuscans", "SPECIES", 172, 191], ["Maize root polysaccharides", "PROBLEM", 0, 26], ["Bean PlantRhizosphere", "TREATMENT", 93, 114], ["the Bacterium Xanthomonas fuscans", "TEST", 158, 191], ["root", "OBSERVATION_MODIFIER", 6, 10], ["polysaccharides contained", "OBSERVATION", 11, 36], ["Microbial Population", "OBSERVATION", 69, 89], ["Bean PlantRhizosphere", "OBSERVATION", 93, 114], ["Root", "ANATOMY", 141, 145]]], ["J. Lxsix, M. STAN~K, Institute of Microbiology, Czechoslovak Academy of Sciences, Prague.Changes in Microbial Population of Bean PlantIn a preceding communication, the possibility was outlined to study the interaction of root plants with bacteria colonizing the rhizosphere and the factors limiting the occurrence of individual species on root surface, by means of the bacterium Xanthomonas ]uscans.", [["rhizosphere", "ANATOMY", 262, 273], ["root surface", "ANATOMY", 339, 351], ["root surface", "MULTI-TISSUE_STRUCTURE", 339, 351], ["Xanthomonas ]uscans", "SPECIES", 379, 398], ["root plants", "PROBLEM", 221, 232], ["bacteria colonizing the rhizosphere", "PROBLEM", 238, 273], ["individual species on root surface", "PROBLEM", 317, 351]]], ["When the bacterium was artificially inoculated on bean seeds, and thus colonized the roots of germinating plants, the species P. fluorescens and some other species originally inhabiting the germinating seeds disappeared within the first month of vegetation.", [["seeds", "ANATOMY", 55, 60], ["roots", "ANATOMY", 85, 90], ["seeds", "ANATOMY", 202, 207], ["bean", "ORGANISM", 50, 54], ["roots", "ORGANISM_SUBDIVISION", 85, 90], ["P. fluorescens", "ORGANISM", 126, 140], ["bean", "SPECIES", 50, 54], ["P. fluorescens", "SPECIES", 126, 140], ["bean", "SPECIES", 50, 54], ["P. fluorescens", "SPECIES", 126, 140], ["the bacterium", "PROBLEM", 5, 18], ["bean seeds", "TREATMENT", 50, 60], ["the species P. fluorescens", "PROBLEM", 114, 140], ["some other species", "PROBLEM", 145, 163], ["the germinating seeds", "PROBLEM", 186, 207], ["vegetation", "PROBLEM", 246, 256], ["bean seeds", "OBSERVATION", 50, 60], ["germinating plants", "OBSERVATION", 94, 112], ["germinating seeds", "OBSERVATION", 190, 207], ["vegetation", "OBSERVATION", 246, 256]]], ["The concomitant decrease in the total bacterial count on the root surface was due to altered nutritional conditions in this phase and the transition from cotyledon nutrition (heterotrophic type) to leaf-and-root nutrition (autotrophie type).", [["root surface", "ANATOMY", 61, 73], ["cotyledon", "ANATOMY", 154, 163], ["leaf", "ANATOMY", 198, 202], ["root", "ANATOMY", 207, 211], ["root surface", "MULTI-TISSUE_STRUCTURE", 61, 73], ["cotyledon", "ORGANISM_SUBDIVISION", 154, 163], ["The concomitant decrease", "PROBLEM", 0, 24], ["the total bacterial count", "TEST", 28, 53], ["altered nutritional conditions", "PROBLEM", 85, 115], ["cotyledon nutrition", "TREATMENT", 154, 173], ["leaf", "TEST", 198, 202], ["concomitant", "OBSERVATION_MODIFIER", 4, 15], ["decrease", "OBSERVATION_MODIFIER", 16, 24], ["total", "OBSERVATION_MODIFIER", 32, 37], ["bacterial count", "OBSERVATION", 38, 53], ["root surface", "OBSERVATION_MODIFIER", 61, 73], ["altered", "OBSERVATION_MODIFIER", 85, 92], ["nutritional conditions", "OBSERVATION", 93, 115], ["root", "ANATOMY", 207, 211]]], ["In the period of leaf formation the rootsurface count of X. ]uscans decreased but the total bacterial count was considerably higher.", [["leaf", "ANATOMY", 17, 21], ["rootsurface", "ANATOMY", 36, 47], ["leaf", "ORGAN", 17, 21], ["leaf formation", "PROBLEM", 17, 31], ["the total bacterial count", "TEST", 82, 107], ["leaf formation", "OBSERVATION", 17, 31]]], ["Physiological properties (e.g. nutritional requirements) of bacteria colonizing the roots after the disappacranee of X. ]uscans differed from those of the bacteria inhabiting the roots of control plants.", [["roots", "ANATOMY", 84, 89], ["roots", "ANATOMY", 179, 184], ["roots", "ORGAN", 84, 89], ["roots", "ORGAN", 179, 184], ["Physiological properties (e.g. nutritional requirements", "PROBLEM", 0, 55], ["bacteria colonizing the roots", "PROBLEM", 60, 89], ["the bacteria", "PROBLEM", 151, 163], ["roots", "OBSERVATION_MODIFIER", 84, 89]]], ["The bacteria also decomposed polysaceharide produced in the rhizosphere by Xanthomenas cells.", [["Xanthomenas cells", "ANATOMY", 75, 92], ["polysaceharide", "CHEMICAL", 29, 43], ["polysaceharide", "CHEMICAL", 29, 43], ["polysaceharide", "SIMPLE_CHEMICAL", 29, 43], ["Xanthomenas cells", "CELL", 75, 92], ["Xanthomenas cells", "CELL_LINE", 75, 92], ["The bacteria", "PROBLEM", 0, 12], ["bacteria", "OBSERVATION", 4, 12], ["Xanthomenas cells", "OBSERVATION", 75, 92]]], ["The rhizosphere microorganisms were thus showr~ to be able to utilize, apart from root exudates, also the metabelites of bacteria previously colonizing the surface of the roots.E]]ect ot ~oliar Application of Urea in Combinationwith Pesticides on Oxygen Gonsum2ation in Rhizosphere Soil.", [["root exudates", "ANATOMY", 82, 95], ["surface", "ANATOMY", 156, 163], ["roots", "ANATOMY", 171, 176], ["Urea", "CHEMICAL", 209, 213], ["Oxygen", "CHEMICAL", 247, 253], ["Urea", "CHEMICAL", 209, 213], ["Oxygen", "CHEMICAL", 247, 253], ["root exudates", "PATHOLOGICAL_FORMATION", 82, 95], ["roots", "ORGAN", 171, 176], ["Urea", "SIMPLE_CHEMICAL", 209, 213], ["Oxygen", "SIMPLE_CHEMICAL", 247, 253], ["The rhizosphere microorganisms", "PROBLEM", 0, 30], ["root exudates", "PROBLEM", 82, 95], ["bacteria", "PROBLEM", 121, 129], ["ect ot ~oliar Application of Urea", "TREATMENT", 180, 213], ["Oxygen", "TREATMENT", 247, 253], ["root", "ANATOMY", 82, 86], ["exudates", "OBSERVATION", 87, 95], ["bacteria", "OBSERVATION", 121, 129], ["surface", "OBSERVATION_MODIFIER", 156, 163], ["roots", "ANATOMY", 171, 176]]], ["J. VnA~2, Institute of Microbiology, Czechoslovak Academy of Sciences, Prague.E]]ect ot ~oliar Application of Urea in CombinationWinter wheat was grown in soil in pots.", [["Urea", "CHEMICAL", 110, 114], ["Urea", "CHEMICAL", 110, 114], ["Urea", "SIMPLE_CHEMICAL", 110, 114], ["CombinationWinter wheat", "ORGANISM", 118, 141], ["wheat", "SPECIES", 136, 141], ["wheat", "SPECIES", 136, 141], ["ect ot ~oliar Application of Urea", "TREATMENT", 81, 114]]], ["In the phase of 2--3 proper leaves the above-ground parts were treated 4--5 tiines with 2% solution of urea, 0.4% Ben]ate (methyl-l(earbamoyl)-2-benzimidazole earbamate), 0.6~/o Aminex (4-ehloro-2-methylphenoxyacetic acid), or a combination of these compounds.", [["leaves", "ANATOMY", 28, 34], ["4--5 tiines", "CHEMICAL", 71, 82], ["urea", "CHEMICAL", 103, 107], ["methyl-l(earbamoyl)-2-benzimidazole earbamate", "CHEMICAL", 123, 168], ["Aminex", "CHEMICAL", 178, 184], ["4-ehloro-2-methylphenoxyacetic acid", "CHEMICAL", 186, 221], ["urea", "CHEMICAL", 103, 107], ["methyl-l(earbamoyl)-2-benzimidazole earbamate", "CHEMICAL", 123, 168], ["Aminex", "CHEMICAL", 178, 184], ["4-ehloro-2-methylphenoxyacetic acid", "CHEMICAL", 186, 221], ["urea", "SIMPLE_CHEMICAL", 103, 107], ["Ben]ate", "SIMPLE_CHEMICAL", 114, 121], ["methyl-l(earbamoyl)-2-benzimidazole earbamate", "SIMPLE_CHEMICAL", 123, 168], ["Aminex", "SIMPLE_CHEMICAL", 178, 184], ["4-ehloro-2-methylphenoxyacetic acid", "SIMPLE_CHEMICAL", 186, 221], ["2% solution of urea", "TREATMENT", 88, 107], ["methyl-l(earbamoyl)", "TREATMENT", 123, 142], ["benzimidazole earbamate", "TREATMENT", 145, 168], ["Aminex", "TREATMENT", 178, 184], ["ehloro", "TREATMENT", 188, 194], ["methylphenoxyacetic acid", "TREATMENT", 197, 221], ["these compounds", "TREATMENT", 244, 259]]], ["Oxygen consumption was then measured in rhizosphere soils (RS) of control and treated plants 1--8 weeks after the last application.", [["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["Oxygen consumption", "TREATMENT", 0, 18]]], ["Approximately 0.2 g RS was suspended in 0.90/0 buffered :NaC1 and measured by conventional Warburg technique.", [["NaC1", "CHEMICAL", 57, 61], ["NaC1", "CHEMICAL", 57, 61], ["NaC1", "SIMPLE_CHEMICAL", 57, 61], ["NaC1", "TREATMENT", 57, 61]]], ["The oxygen consumption in RS was 3--7 times higher than that in control soil without plants, taken from parallel pots.", [["oxygen", "CHEMICAL", 4, 10], ["oxygen", "CHEMICAL", 4, 10], ["oxygen", "SIMPLE_CHEMICAL", 4, 10], ["The oxygen consumption", "TEST", 0, 22], ["RS", "TEST", 26, 28], ["oxygen", "OBSERVATION_MODIFIER", 4, 10], ["consumption", "OBSERVATION_MODIFIER", 11, 22]]], ["The respiratiort rate in RS of urea-treated plants was enhanced, the oxygen consumption during a 3-h period being higher by 50~o.", [["urea", "CHEMICAL", 31, 35], ["oxygen", "CHEMICAL", 69, 75], ["urea", "CHEMICAL", 31, 35], ["oxygen", "CHEMICAL", 69, 75], ["urea", "SIMPLE_CHEMICAL", 31, 35], ["oxygen", "SIMPLE_CHEMICAL", 69, 75], ["The respiratiort rate", "TEST", 0, 21], ["the oxygen consumption", "TREATMENT", 65, 87]]], ["In RS of plants treated with Aminex or Ben]ate the oxygen consumption fell below that found in controls.", [["Aminex", "CHEMICAL", 29, 35], ["oxygen", "CHEMICAL", 51, 57], ["Aminex", "CHEMICAL", 29, 35], ["oxygen", "CHEMICAL", 51, 57], ["Aminex", "SIMPLE_CHEMICAL", 29, 35], ["oxygen", "SIMPLE_CHEMICAL", 51, 57], ["Aminex", "TREATMENT", 29, 35], ["the oxygen consumption", "TREATMENT", 47, 69]]], ["When the two agents were applied together with urea, the O2 consumption was also lower than with untreated plants.", [["urea", "CHEMICAL", 47, 51], ["O2", "CHEMICAL", 57, 59], ["urea", "CHEMICAL", 47, 51], ["O2", "CHEMICAL", 57, 59], ["urea", "SIMPLE_CHEMICAL", 47, 51], ["O2", "SIMPLE_CHEMICAL", 57, 59], ["urea", "TREATMENT", 47, 51], ["the O2 consumption", "TEST", 53, 71]]], ["With combination urea-Ben]ate, however, the Oz consumption was higher than with Benlate alone.", [["urea", "CHEMICAL", 17, 21], ["Benlate", "CHEMICAL", 80, 87], ["urea", "CHEMICAL", 17, 21], ["Benlate", "CHEMICAL", 80, 87], ["urea-Ben", "SIMPLE_CHEMICAL", 17, 25], ["Oz", "SIMPLE_CHEMICAL", 44, 46], ["Benlate", "SIMPLE_CHEMICAL", 80, 87], ["combination urea", "TEST", 5, 21], ["the Oz consumption", "TEST", 40, 58]]], ["The bacterial counts in the RS of both treated and untreated plants were in correlation with the experimentally assessed oxygen consumption by the soil.", [["oxygen", "CHEMICAL", 121, 127], ["oxygen", "CHEMICAL", 121, 127], ["oxygen", "SIMPLE_CHEMICAL", 121, 127], ["The bacterial counts", "TEST", 0, 20], ["bacterial counts", "OBSERVATION", 4, 20]]], ["An attempt was made to relate these results to the data on the effect of urea and pesticides on the microbial counts in the RS, with the aim to obtain a suitable criterion for evaluating the effect of pesticides on the microfiora and the treated plant.", [["urea", "CHEMICAL", 73, 77], ["pesticides", "CHEMICAL", 82, 92], ["urea", "CHEMICAL", 73, 77], ["urea", "SIMPLE_CHEMICAL", 73, 77], ["urea and pesticides", "TREATMENT", 73, 92], ["the microbial counts", "TEST", 96, 116], ["pesticides", "TREATMENT", 201, 211], ["the microfiora", "TREATMENT", 215, 229]]], ["The effect of 7 strains of R. tri]olii was tested at 3 levels of mineral nitrogen (14, 70, 140 p.p.m.", [["mineral nitrogen", "CHEMICAL", 65, 81], ["nitrogen", "CHEMICAL", 73, 81], ["R. tri]olii", "ORGANISM", 27, 38], ["mineral nitrogen", "SIMPLE_CHEMICAL", 65, 81], ["R. tri]olii", "SPECIES", 27, 38], ["R. tri]olii", "SPECIES", 27, 38], ["R. tri]olii", "TREATMENT", 27, 38], ["mineral nitrogen", "TREATMENT", 65, 81]]], ["N) in plants of red clover by greenhouse agar tests on Jcnsen medium.", [["clover", "ORGANISM_SUBDIVISION", 20, 26], ["red clover", "SPECIES", 16, 26], ["red clover", "TREATMENT", 16, 26], ["greenhouse agar tests", "TEST", 30, 51], ["Jcnsen medium", "TREATMENT", 55, 68], ["red clover", "OBSERVATION", 16, 26]]], ["The parameters tested were nodulation, rate of nodule setting and plant dry weight.", [["nodule", "ANATOMY", 47, 53], ["dry", "ORGANISM_SUBDIVISION", 72, 75], ["The parameters", "TEST", 0, 14], ["nodulation", "PROBLEM", 27, 37], ["nodule setting", "PROBLEM", 47, 61], ["plant dry weight", "TEST", 66, 82], ["nodule", "OBSERVATION", 47, 53]]], ["With the last parameter, a significant difference was found between the nitrogen-less variant and the variants with nitrogen; no significant difference existed between the 70 and 140 p.p.m.", [["nitrogen", "CHEMICAL", 72, 80], ["nitrogen", "CHEMICAL", 116, 124], ["nitrogen", "CHEMICAL", 72, 80], ["nitrogen", "CHEMICAL", 116, 124], ["a significant difference", "PROBLEM", 25, 49], ["the nitrogen", "TEST", 68, 80], ["nitrogen", "TREATMENT", 116, 124], ["significant", "OBSERVATION_MODIFIER", 27, 38], ["difference", "OBSERVATION", 39, 49], ["significant", "OBSERVATION_MODIFIER", 129, 140], ["difference", "OBSERVATION", 141, 151]]], ["Individual strains responded differently to the addition of KNO3; the highest plant mass yield was in a symbiosis with the strain S 190.", [["KNO3", "CHEMICAL", 60, 64], ["KNO3", "CHEMICAL", 60, 64], ["KNO3", "SIMPLE_CHEMICAL", 60, 64], ["Individual strains", "PROBLEM", 0, 18], ["KNO3", "TREATMENT", 60, 64], ["the highest plant mass yield", "PROBLEM", 66, 94], ["the strain S", "TEST", 119, 131], ["mass", "OBSERVATION", 84, 88]]], ["N increased the yield as compared to the nitrogen-less variant, further increase in nitrogen level did not affect the yield.", [["nitrogen", "CHEMICAL", 41, 49], ["nitrogen", "CHEMICAL", 84, 92], ["nitrogen", "CHEMICAL", 41, 49], ["nitrogen", "CHEMICAL", 84, 92], ["nitrogen", "SIMPLE_CHEMICAL", 84, 92], ["the nitrogen", "TEST", 37, 49], ["further increase in nitrogen level", "PROBLEM", 64, 98], ["increased", "OBSERVATION_MODIFIER", 2, 11], ["less variant", "OBSERVATION_MODIFIER", 50, 62], ["increase", "OBSERVATION_MODIFIER", 72, 80]]], ["Concerning nodule formation, a significant difference was found between the nitrogen-less variant and those with up to 70 p.p.m.", [["nodule", "ANATOMY", 11, 17], ["nitrogen", "CHEMICAL", 76, 84], ["nitrogen", "CHEMICAL", 76, 84], ["nodule", "PATHOLOGICAL_FORMATION", 11, 17], ["nitrogen", "SIMPLE_CHEMICAL", 76, 84], ["nodule formation", "PROBLEM", 11, 27], ["the nitrogen", "TEST", 72, 84], ["nodule", "OBSERVATION", 11, 17], ["significant", "OBSERVATION_MODIFIER", 31, 42], ["difference", "OBSERVATION_MODIFIER", 43, 53], ["less variant", "OBSERVATION_MODIFIER", 85, 97]]], ["N inhibited the nodulation.", [["the nodulation", "PROBLEM", 12, 26], ["nodulation", "OBSERVATION", 16, 26]]], ["The decomposition of cellulose was studied in three variants of eleven-year-old culture after nine years of herbicide application: control without herbicides (B1), classical treatment (B2) and yearly treatment with a mixture of Zeazine and Selectine (2.5 kg/ha).", [["herbicide", "CHEMICAL", 108, 117], ["Zeazine", "CHEMICAL", 228, 235], ["Selectine", "CHEMICAL", 240, 249], ["Zeazine", "CHEMICAL", 228, 235], ["Selectine", "CHEMICAL", 240, 249], ["cellulose", "SIMPLE_CHEMICAL", 21, 30], ["Zeazine", "SIMPLE_CHEMICAL", 228, 235], ["Selectine", "SIMPLE_CHEMICAL", 240, 249], ["The decomposition of cellulose", "TREATMENT", 0, 30], ["old culture", "TEST", 76, 87], ["herbicide application", "TREATMENT", 108, 129], ["herbicides (B1)", "TREATMENT", 147, 162], ["classical treatment (B2)", "TREATMENT", 164, 188], ["Zeazine", "TREATMENT", 228, 235], ["Selectine", "TREATMENT", 240, 249]]], ["In 1972 we used prcemergently a dose of 7.5 1/ha Oleogesaprine.", [["Oleogesaprine", "CHEMICAL", 49, 62], ["Oleogesaprine", "CHEMICAL", 49, 62], ["Oleogesaprine", "SIMPLE_CHEMICAL", 49, 62], ["ha Oleogesaprine", "TREATMENT", 46, 62]]], ["Chemically treated variant (B3) was given 8 kg/ha Zeazine, lower since 1964 to 4 kg/ha.", [["Zeazine", "CHEMICAL", 50, 57], ["Zeazine", "SIMPLE_CHEMICAL", 50, 57], ["Chemically treated variant (B3)", "TREATMENT", 0, 31], ["ha Zeazine", "TREATMENT", 47, 57]]], ["In 1969 the dose given to B2 and Bs was supplemented by 7 kg/ha Ramrod against Echinochloa crues gaul (L.)", [["Echinochloa crues", "SPECIES", 79, 96], ["Echinochloa crues gaul", "SPECIES", 79, 101], ["Bs", "TEST", 33, 35]]], ["Fertilizing was identical in all variants.", [["Fertilizing", "TREATMENT", 0, 11], ["all variants", "OBSERVATION", 29, 41]]], ["Cellulose decomposition was determined by the method of Pokorng~ and Kozovs (1965) .", [["Cellulose", "CHEMICAL", 0, 9], ["Cellulose", "SIMPLE_CHEMICAL", 0, 9], ["Cellulose decomposition", "TREATMENT", 0, 23]]], ["Prolonged application of herbicides suppressed the relative occurrence of cellulolyric microorganisms and thus also the basic cellulose decomposition.", [["herbicides", "CHEMICAL", 25, 35], ["cellulose", "SIMPLE_CHEMICAL", 126, 135], ["Prolonged application of herbicides", "TREATMENT", 0, 35], ["cellulolyric microorganisms", "PROBLEM", 74, 101], ["the basic cellulose decomposition", "TREATMENT", 116, 149]]], ["The potential decomposition of cellulose with the addition of nitrogen increased significantly during the prolonged herbicide application.", [["nitrogen", "CHEMICAL", 62, 70], ["nitrogen", "CHEMICAL", 62, 70], ["cellulose", "SIMPLE_CHEMICAL", 31, 40], ["nitrogen", "SIMPLE_CHEMICAL", 62, 70], ["cellulose", "TREATMENT", 31, 40], ["nitrogen", "TREATMENT", 62, 70], ["the prolonged herbicide application", "TREATMENT", 102, 137]]], ["The control without herbicides showed a higher basic decomposition and a lower potential decomposition of cellulose as compared with chemically treated variant.", [["herbicides", "CHEMICAL", 20, 30], ["cellulose", "SIMPLE_CHEMICAL", 106, 115], ["chemically treated variant", "CELL_LINE", 133, 159], ["a higher basic decomposition", "PROBLEM", 38, 66], ["a lower potential decomposition of cellulose", "PROBLEM", 71, 115], ["chemically treated variant", "PROBLEM", 133, 159]]], ["Under natural conditions, the cellulose decomposition is in a correlation with the amount of rainfall and with soil humidity.E/leer o/ Allylisothiocyanate on Soil Mieroflora.", [["Allylisothiocyanate", "CHEMICAL", 135, 154], ["Allylisothiocyanate", "CHEMICAL", 135, 154], ["cellulose", "SIMPLE_CHEMICAL", 30, 39], ["Allylisothiocyanate", "SIMPLE_CHEMICAL", 135, 154], ["the cellulose decomposition", "TREATMENT", 26, 53], ["soil humidity", "TREATMENT", 111, 124], ["natural conditions", "OBSERVATION", 6, 24]]], ["V. DROBNiKOVi, Z. P~rAgricultural Soil Research Institute and Faculty of Sciences, Charles University, Prague.E/leer o/ Allylisothiocyanate on Soil Mieroflora.", [["Allylisothiocyanate", "CHEMICAL", 120, 139], ["Allylisothiocyanate", "CHEMICAL", 120, 139], ["Allylisothiocyanate", "SIMPLE_CHEMICAL", 120, 139]]], ["V. DROBNiKOVi, Z. P~rThe effect of allylisothiocyanate (AITC), in the form of aqueous solution or vapour, on soil bacteria, actinomycetes and micromyeetes was studied by Warburg method and by plating technique.", [["micromyeetes", "ANATOMY", 142, 154], ["allylisothiocyanate", "CHEMICAL", 35, 54], ["AITC", "CHEMICAL", 56, 60], ["allylisothiocyanate", "CHEMICAL", 35, 54], ["AITC", "CHEMICAL", 56, 60], ["allylisothiocyanate", "SIMPLE_CHEMICAL", 35, 54], ["AITC", "SIMPLE_CHEMICAL", 56, 60], ["allylisothiocyanate (AITC", "TREATMENT", 35, 60], ["aqueous solution", "TREATMENT", 78, 94], ["soil bacteria", "PROBLEM", 109, 122], ["actinomycetes", "TREATMENT", 124, 137], ["micromyeetes", "TREATMENT", 142, 154]]], ["The solution of AITC exhibited an inhibitory effect on soil microflora only at high concentrations (400 p.p.m.); this inhibition was short and was followed by a stimulation.", [["AITC", "CHEMICAL", 16, 20], ["AITC", "CHEMICAL", 16, 20], ["AITC", "SIMPLE_CHEMICAL", 16, 20], ["The solution of AITC", "TREATMENT", 0, 20], ["soil microflora", "TREATMENT", 55, 70]]], ["The fungicide effects of the selution, which were observed also with lower concentrations (40 p.p.m.) were also transient.", [["fungicide effects", "OBSERVATION", 4, 21]]], ["The inhibitory effects of AITC vapours, on the other hand, are more ponounced, the length of inhibition being directly proportional to the length of exposure.", [["AITC", "CHEMICAL", 26, 30], ["AITC", "CHEMICAL", 26, 30], ["AITC", "SIMPLE_CHEMICAL", 26, 30], ["AITC vapours", "TREATMENT", 26, 38], ["AITC vapours", "OBSERVATION", 26, 38]]], ["After a certain exposure both the physiological activity and the count of bacteria increase, this stimulation being again directly proportional to the length of action of AITC vapours.", [["AITC", "CHEMICAL", 171, 175], ["AITC", "CHEMICAL", 171, 175], ["AITC", "SIMPLE_CHEMICAL", 171, 175], ["bacteria", "PROBLEM", 74, 82], ["this stimulation", "TREATMENT", 93, 109], ["AITC vapours", "TREATMENT", 171, 183], ["activity", "OBSERVATION_MODIFIER", 48, 56], ["bacteria", "OBSERVATION_MODIFIER", 74, 82], ["increase", "OBSERVATION_MODIFIER", 83, 91], ["AITC vapours", "OBSERVATION", 171, 183]]], ["24-h exposure to AITC-saturated atmosphere resulted in a complete abolishment of the growth of micromycetes in soil sample.", [["soil sample", "ANATOMY", 111, 122], ["AITC", "CHEMICAL", 17, 21], ["AITC", "CHEMICAL", 17, 21], ["AITC", "SIMPLE_CHEMICAL", 17, 21], ["AITC", "TREATMENT", 17, 21], ["growth", "OBSERVATION_MODIFIER", 85, 91]]], ["Even at lower partial pressures of the AITC vapour the fungicide effect was high.", [["AITC", "CHEMICAL", 39, 43], ["AITC", "CHEMICAL", 39, 43], ["AITC", "SIMPLE_CHEMICAL", 39, 43], ["the AITC vapour", "TREATMENT", 35, 50], ["partial", "OBSERVATION_MODIFIER", 14, 21], ["pressures", "OBSERVATION_MODIFIER", 22, 31], ["AITC vapour", "OBSERVATION", 39, 50], ["fungicide effect", "OBSERVATION", 55, 71], ["high", "OBSERVATION_MODIFIER", 76, 80]]], ["At a required degree of fungicide effect, the length of necessary exposure to AITC vapour increases with increasing soil layer.", [["AITC", "CHEMICAL", 78, 82], ["AITC", "CHEMICAL", 78, 82], ["AITC", "SIMPLE_CHEMICAL", 78, 82], ["fungicide effect", "PROBLEM", 24, 40], ["AITC vapour", "TREATMENT", 78, 89], ["increasing soil layer", "TREATMENT", 105, 126], ["fungicide effect", "OBSERVATION", 24, 40], ["AITC vapour", "OBSERVATION", 78, 89], ["increasing", "OBSERVATION_MODIFIER", 105, 115], ["soil layer", "OBSERVATION", 116, 126]]], ["Fungicide properties of AITC vapour were found also with phytopathogenic micromycetes isolated from infected plants and soil.", [["AITC", "CHEMICAL", 24, 28], ["AITC", "CHEMICAL", 24, 28], ["AITC", "SIMPLE_CHEMICAL", 24, 28], ["AITC vapour", "PROBLEM", 24, 35], ["phytopathogenic micromycetes", "PROBLEM", 57, 85], ["AITC vapour", "OBSERVATION", 24, 35], ["infected plants", "OBSERVATION", 100, 115], ["soil", "OBSERVATION_MODIFIER", 120, 124]]], ["The effect was studied of straw and pig manure on soil processes in a two-crop rotation system and in black-soil fallow.", [["pig", "ORGANISM", 36, 39], ["pig", "SPECIES", 36, 39], ["pig", "SPECIES", 36, 39], ["straw", "TREATMENT", 26, 31], ["pig manure", "TREATMENT", 36, 46], ["a two-crop rotation system", "TREATMENT", 68, 94], ["soil fallow", "OBSERVATION", 108, 119]]], ["In comparison with both control variant and with variant fertilized by mineral NPK fertilizers, both the organic fertilizers enhance the respiration activity of soil and the counts of soil microorganisms.", [["NPK", "CHEMICAL", 79, 82], ["NPK", "SIMPLE_CHEMICAL", 79, 82], ["variant fertilized by mineral NPK fertilizers", "TREATMENT", 49, 94], ["the organic fertilizers", "TREATMENT", 101, 124], ["soil microorganisms", "PROBLEM", 184, 203]]], ["Specific mineralization intensity (referred to the number of microorganisms) decreases in the presence of easily utilizable organic substances (pig manure root exudates) and the assimilation and synthetic ability of the microbes increases.", [["root exudates", "ANATOMY", 155, 168], ["pig", "ORGANISM", 144, 147], ["root exudates", "MULTI-TISSUE_STRUCTURE", 155, 168], ["pig", "SPECIES", 144, 147], ["pig", "SPECIES", 144, 147], ["Specific mineralization intensity", "PROBLEM", 0, 33], ["easily utilizable organic substances", "PROBLEM", 106, 142], ["pig manure root exudates", "PROBLEM", 144, 168], ["the assimilation", "TREATMENT", 174, 190], ["mineralization", "OBSERVATION_MODIFIER", 9, 23], ["intensity", "OBSERVATION_MODIFIER", 24, 33], ["organic substances", "OBSERVATION", 124, 142]]], ["The straw brings about an immobilization of soil nitrogen and a drop in its actual and potential utilizability, especially in cultivated plots.", [["soil nitrogen", "CHEMICAL", 44, 57], ["nitrogen", "CHEMICAL", 49, 57], ["an immobilization of soil nitrogen", "TREATMENT", 23, 57], ["a drop", "PROBLEM", 62, 68]]], ["It prevents, to a great extent, the losses of nitrogen from the fallow soil.", [["nitrogen", "CHEMICAL", 46, 54], ["nitrogen", "CHEMICAL", 46, 54], ["nitrogen", "SIMPLE_CHEMICAL", 46, 54], ["the losses of nitrogen", "PROBLEM", 32, 54], ["great extent", "OBSERVATION_MODIFIER", 18, 30]]], ["Pig manure accelerates the dynamics of soil nitrogen turnover; its nitrogen is physiologically more utilizable than the nitrogen of mineral fertilizers.", [["nitrogen", "CHEMICAL", 44, 52], ["nitrogen", "CHEMICAL", 67, 75], ["nitrogen", "CHEMICAL", 44, 52], ["nitrogen", "CHEMICAL", 67, 75], ["nitrogen", "CHEMICAL", 120, 128], ["Pig", "ORGANISM", 0, 3], ["nitrogen", "SIMPLE_CHEMICAL", 44, 52], ["nitrogen", "SIMPLE_CHEMICAL", 67, 75], ["mineral fertilizers", "SIMPLE_CHEMICAL", 132, 151], ["Pig", "SPECIES", 0, 3], ["Pig", "SPECIES", 0, 3], ["Pig manure", "TREATMENT", 0, 10], ["soil nitrogen turnover", "TREATMENT", 39, 61], ["its nitrogen", "TREATMENT", 63, 75], ["the nitrogen of mineral fertilizers", "TREATMENT", 116, 151]]], ["In two plots in highland meadows and one in a lowland meadow in southern Slovakia, the intensity of ammonization and nitrification was studied.", [["ammonization", "TREATMENT", 100, 112], ["nitrification", "TREATMENT", 117, 130], ["plots", "OBSERVATION_MODIFIER", 7, 12], ["highland meadows", "OBSERVATION", 16, 32]]], ["The soils of the meadow phytocoenoses in question were characterized by a low level of mineral nitrogen forms.", [["mineral nitrogen", "CHEMICAL", 87, 103], ["nitrogen", "CHEMICAL", 95, 103], ["the meadow phytocoenoses", "TREATMENT", 13, 37], ["soils", "OBSERVATION_MODIFIER", 4, 9]]], ["The proportion of nitrate nitrogen was lower than that of ammonium nitrogen.", [["nitrate nitrogen", "CHEMICAL", 18, 34], ["ammonium nitrogen", "CHEMICAL", 58, 75], ["nitrate nitrogen", "CHEMICAL", 18, 34], ["ammonium nitrogen", "CHEMICAL", 58, 75], ["nitrate", "SIMPLE_CHEMICAL", 18, 25], ["ammonium nitrogen", "SIMPLE_CHEMICAL", 58, 75], ["nitrate nitrogen", "TREATMENT", 18, 34], ["ammonium nitrogen", "TREATMENT", 58, 75], ["nitrate nitrogen", "OBSERVATION", 18, 34]]], ["On applying a maximum dose of nitrogen (480 kg N/ha) it was accumulated predominantly as NOn-, especially in the period of decreased biological sorption, which indicated low utilization of this form by the herbage and by soil microflora, and a better utilization of NH4 +.", [["nitrogen", "CHEMICAL", 30, 38], ["NOn", "CHEMICAL", 89, 92], ["NH4", "CHEMICAL", 266, 269], ["nitrogen", "CHEMICAL", 30, 38], ["NOn", "CHEMICAL", 89, 92], ["NH4 +", "CHEMICAL", 266, 271], ["NOn", "SIMPLE_CHEMICAL", 89, 92], ["NH4 +", "SIMPLE_CHEMICAL", 266, 271], ["a maximum dose of nitrogen", "TREATMENT", 12, 38], ["decreased biological sorption", "PROBLEM", 123, 152], ["decreased", "OBSERVATION", 123, 132]]], ["After the application of nitrogen fertilizers considerable proportion of N became immobilized by soil microflora.", [["nitrogen fertilizers", "CHEMICAL", 25, 45], ["nitrogen", "CHEMICAL", 25, 33], ["N", "CHEMICAL", 73, 74], ["nitrogen fertilizers", "TREATMENT", 25, 45]]], ["The mineralization of organic nitrogenous substances was significantly affected by soil and climatic factors, developmental stage of the herbage and the fertilization with maximum doses.", [["organic nitrogenous substances", "PROBLEM", 22, 52], ["the herbage", "TREATMENT", 133, 144], ["the fertilization", "TREATMENT", 149, 166], ["maximum doses", "TREATMENT", 172, 185], ["mineralization", "OBSERVATION_MODIFIER", 4, 18], ["organic", "OBSERVATION_MODIFIER", 22, 29], ["nitrogenous substances", "OBSERVATION", 30, 52], ["herbage", "OBSERVATION", 137, 144]]], ["In plots with acid soil reaction the proportion of nitrified nitrogen was low and generally directly proportional to the productivity of the plots.", [["nitrified nitrogen", "CHEMICAL", 51, 69], ["nitrogen", "CHEMICAL", 61, 69], ["acid soil reaction", "PROBLEM", 14, 32], ["nitrified nitrogen", "TREATMENT", 51, 69]]], ["At high levels of superficially applied nitrogen the soil reaction changed, which resulted in heavy losses by denitrifieation and volatilization.", [["nitrogen", "CHEMICAL", 40, 48], ["nitrogen", "CHEMICAL", 40, 48], ["nitrogen", "SIMPLE_CHEMICAL", 40, 48], ["nitrogen", "TREATMENT", 40, 48], ["the soil reaction", "PROBLEM", 49, 66], ["heavy losses", "OBSERVATION", 94, 106]]], ["The results show that the dose 480 kg N/ha and, in arid years, even 240 kg N/ha are unsuitable.", [["ha", "PROBLEM", 40, 42]]], ["In view of the heavy losses of nitrogen by way of microorganisms, the fertilizers used for meadow eoenoses should be supplemented by compounds inhibiting the nitrification and retarding the ammonization of urea.", [["nitrogen", "CHEMICAL", 31, 39], ["eoenoses", "CHEMICAL", 98, 106], ["urea", "CHEMICAL", 206, 210], ["nitrogen", "CHEMICAL", 31, 39], ["urea", "CHEMICAL", 206, 210], ["nitrogen", "SIMPLE_CHEMICAL", 31, 39], ["eoenoses", "SIMPLE_CHEMICAL", 98, 106], ["urea", "SIMPLE_CHEMICAL", 206, 210], ["the heavy losses of nitrogen", "PROBLEM", 11, 39], ["microorganisms", "PROBLEM", 50, 64], ["the fertilizers", "TREATMENT", 66, 81], ["meadow eoenoses", "TREATMENT", 91, 106], ["the nitrification", "TREATMENT", 154, 171], ["the ammonization of urea", "TREATMENT", 186, 210], ["heavy", "OBSERVATION_MODIFIER", 15, 20]]], ["The utilization of carbon and nitrogen from the fulvoacid (FK~) and humine acid (HKa), isolated from podzolie soil according to Roehus, by soil mieromycetes was studied.", [["carbon and nitrogen", "CHEMICAL", 19, 38], ["fulvoacid", "CHEMICAL", 48, 57], ["FK~) and humine acid", "CHEMICAL", 59, 79], ["HKa", "CHEMICAL", 81, 84], ["podzolie", "CHEMICAL", 101, 109], ["Roehus", "CHEMICAL", 128, 134], ["carbon", "CHEMICAL", 19, 25], ["nitrogen", "CHEMICAL", 30, 38], ["fulvoacid", "CHEMICAL", 48, 57], ["FK", "CHEMICAL", 59, 61], ["humine acid", "CHEMICAL", 68, 79], ["HKa", "CHEMICAL", 81, 84], ["carbon", "SIMPLE_CHEMICAL", 19, 25], ["nitrogen", "SIMPLE_CHEMICAL", 30, 38], ["fulvoacid", "SIMPLE_CHEMICAL", 48, 57], ["FK~)", "SIMPLE_CHEMICAL", 59, 63], ["humine acid", "SIMPLE_CHEMICAL", 68, 79], ["HKa", "SIMPLE_CHEMICAL", 81, 84], ["carbon and nitrogen", "TREATMENT", 19, 38], ["the fulvoacid (FK", "TREATMENT", 44, 61], ["humine acid (HKa", "TREATMENT", 68, 84], ["podzolie soil", "TREATMENT", 101, 114]]], ["The cultures included Aspergillus versieolor, Absidia glauea, PenieiUium citrinum and P. lilacinum, all of them being previously found to utilize carbon and nitrogen uniformly from all fractions of fulvoacid.", [["carbon and nitrogen", "CHEMICAL", 146, 165], ["fulvoacid", "CHEMICAL", 198, 207], ["carbon", "CHEMICAL", 146, 152], ["nitrogen", "CHEMICAL", 157, 165], ["fulvoacid", "CHEMICAL", 198, 207], ["Aspergillus versieolor", "ORGANISM", 22, 44], ["Absidia glauea", "ORGANISM", 46, 60], ["PenieiUium citrinum", "ORGANISM", 62, 81], ["P. lilacinum", "ORGANISM", 86, 98], ["carbon", "SIMPLE_CHEMICAL", 146, 152], ["nitrogen", "SIMPLE_CHEMICAL", 157, 165], ["fulvoacid", "SIMPLE_CHEMICAL", 198, 207], ["Aspergillus versieolor", "SPECIES", 22, 44], ["Absidia glauea", "SPECIES", 46, 60], ["PenieiUium citrinum", "SPECIES", 62, 81], ["P. lilacinum", "SPECIES", 86, 98], ["Aspergillus versieolor", "SPECIES", 22, 44], ["Absidia glauea", "SPECIES", 46, 60], ["PenieiUium citrinum", "SPECIES", 62, 81], ["P. lilacinum", "SPECIES", 86, 98], ["The cultures", "TEST", 0, 12], ["Aspergillus versieolor", "PROBLEM", 22, 44], ["PenieiUium citrinum", "TREATMENT", 62, 81], ["P. lilacinum", "TREATMENT", 86, 98], ["carbon and nitrogen", "TREATMENT", 146, 165], ["fulvoacid", "TREATMENT", 198, 207], ["Aspergillus versieolor", "OBSERVATION", 22, 44]]], ["C and N utilization was determined from increased myeelium dry weight; the level of carbon and the optical density were measured also in repreeipitated fractions of humus acids.", [["humus acids", "CHEMICAL", 165, 176], ["N", "CHEMICAL", 6, 7], ["carbon", "CHEMICAL", 84, 90], ["C", "SIMPLE_CHEMICAL", 0, 1], ["N", "SIMPLE_CHEMICAL", 6, 7], ["carbon", "SIMPLE_CHEMICAL", 84, 90], ["humus acids", "SIMPLE_CHEMICAL", 165, 176], ["increased myeelium dry weight", "PROBLEM", 40, 69], ["the optical density", "TEST", 95, 114], ["humus acids", "TREATMENT", 165, 176], ["humus acids", "OBSERVATION", 165, 176]]], ["The comparison of these data with the original ones gives a fairly accurate measure of the degree of decomposition of the acids and of carbon utilization.", [["carbon", "CHEMICAL", 135, 141], ["carbon", "CHEMICAL", 135, 141], ["carbon", "SIMPLE_CHEMICAL", 135, 141], ["these data", "TEST", 18, 28], ["the acids", "TREATMENT", 118, 127], ["carbon utilization", "TREATMENT", 135, 153]]], ["The decomposition of the above fractions of humus acids was measured after 1 and 2 months of cultivation.", [["humus acids", "CHEMICAL", 44, 55], ["humus acids", "CHEMICAL", 44, 55], ["humus acids", "SIMPLE_CHEMICAL", 44, 55], ["humus acids", "TEST", 44, 55], ["cultivation", "TREATMENT", 93, 104], ["humus acids", "OBSERVATION", 44, 55]]], ["The increment of myeelium dry weight was found to vary with the variant used (humus acid, C or N source) and species of mieromyeotes, no correlation being revealed between the increment and the loss of carbon from the humus acid fractions used.", [["humus acid", "CHEMICAL", 78, 88], ["carbon", "CHEMICAL", 202, 208], ["humus acid", "CHEMICAL", 218, 228], ["humus acid", "CHEMICAL", 78, 88], ["C", "CHEMICAL", 90, 91], ["N", "CHEMICAL", 95, 96], ["carbon", "CHEMICAL", 202, 208], ["humus acid", "CHEMICAL", 218, 228], ["humus acid", "SIMPLE_CHEMICAL", 78, 88], ["C", "SIMPLE_CHEMICAL", 90, 91], ["carbon", "SIMPLE_CHEMICAL", 202, 208], ["myeelium dry weight", "TEST", 17, 36], ["humus acid", "TEST", 78, 88], ["the loss of carbon", "PROBLEM", 190, 208], ["the humus acid fractions", "TREATMENT", 214, 238]]], ["Total amount of FK2 decreased, during the cultivation, by 54% at most, the maximum loss of HK3 being 64%.", [["FK2", "CHEMICAL", 16, 19], ["FK2", "GENE_OR_GENE_PRODUCT", 16, 19], ["HK3", "GENE_OR_GENE_PRODUCT", 91, 94], ["FK2", "PROTEIN", 16, 19], ["the maximum loss of HK3", "PROBLEM", 71, 94], ["amount", "OBSERVATION_MODIFIER", 6, 12], ["FK2", "OBSERVATION_MODIFIER", 16, 19], ["decreased", "OBSERVATION_MODIFIER", 20, 29]]], ["The loss of C from FK2 after 30 and 60 days of cultivation was 10--45%, similar data for HK3 were 12--38% depending on micromycetes species.", [["FK2", "GENE_OR_GENE_PRODUCT", 19, 22], ["HK3", "GENE_OR_GENE_PRODUCT", 89, 92], ["The loss of C", "PROBLEM", 0, 13], ["cultivation", "TEST", 47, 58], ["HK3", "TEST", 89, 92], ["micromycetes species", "PROBLEM", 119, 139], ["loss", "OBSERVATION_MODIFIER", 4, 8]]], ["The utilization of humus acids by soil micromycetes may also be characterized by decrease in the optical density of appropriate fractions.", [["humus acids", "CHEMICAL", 19, 30], ["humus acids", "CHEMICAL", 19, 30], ["humus acids", "SIMPLE_CHEMICAL", 19, 30], ["humus acids", "TREATMENT", 19, 30], ["decrease", "OBSERVATION_MODIFIER", 81, 89], ["optical density", "OBSERVATION_MODIFIER", 97, 112], ["appropriate fractions", "OBSERVATION", 116, 137]]], ["The rabe of cellulose decomposition (RCD) was studied for several years in three different phytoeoenoses; a tight relation was found between the RCD and the type of phytocoenosis.", [["RCD", "DISEASE", 145, 148], ["phytocoenosis", "DISEASE", 165, 178], ["cellulose", "SIMPLE_CHEMICAL", 12, 21], ["cellulose decomposition", "TREATMENT", 12, 35], ["phytocoenosis", "PROBLEM", 165, 178], ["cellulose decomposition", "OBSERVATION", 12, 35], ["RCD", "OBSERVATION", 145, 148]]], ["This may be derived from the following findings: (1) The study of the dependence of RCD o~n time and phytocoenosis type as the sources of its variability in soil showed that the primary source of variability is the type of phytoeoenosis; (2) A tight correlation was found between the RCD in soil and the increasing production of plant biomass; (3) From the three soil profiles tested, 0--5 era, 5--15 em, and 15--25 em the highest RCD was found in the depth of 5--15 em, i.e. in the place of accumulation of plant root mass.", [["root mass", "ANATOMY", 514, 523], ["RCD", "DISEASE", 84, 87], ["phytoeoenosis", "DISEASE", 223, 236], ["RCD", "DISEASE", 284, 287], ["RCD", "DISEASE", 431, 434], ["root", "TISSUE", 514, 518], ["The study", "TEST", 53, 62], ["the increasing production of plant biomass", "PROBLEM", 300, 342], ["the three soil profiles", "TEST", 353, 376], ["plant root mass", "PROBLEM", 508, 523], ["RCD", "OBSERVATION", 284, 287], ["increasing", "OBSERVATION_MODIFIER", 304, 314], ["production", "OBSERVATION_MODIFIER", 315, 325], ["plant biomass", "OBSERVATION", 329, 342], ["highest", "OBSERVATION_MODIFIER", 423, 430], ["RCD", "OBSERVATION", 431, 434], ["plant root mass", "OBSERVATION", 508, 523]]], ["The differences between RCD values obtained at corresponding soil profile depths with individual phytocoenoses were statistically evaluated; the coenoses were found to differ in the values corresponding to the depth of 5--15 cm; (4) The soil of phytocoenoses with broader spectrum of plant species gave a more heterogeneous cellulolyric microflora.IOV~, E. VAwInstitute of Botany, Czechoslovak Academy of Sciences, Brno.IOV~, E. VAwThe levels of mineral nutrients and microbial colonization of a number of materials were studied at 1-month intervals in a cross-section of typical coastal vegetation zones of the pond ~esyt in southern Moravia in 1972.", [["phytocoenoses", "SIMPLE_CHEMICAL", 245, 258], ["cellulolyric microflora", "PATHOLOGICAL_FORMATION", 324, 347], ["RCD", "PROTEIN", 24, 27], ["RCD values", "TEST", 24, 34], ["individual phytocoenoses", "TEST", 86, 110], ["The soil of phytocoenoses", "PROBLEM", 233, 258], ["plant species", "PROBLEM", 284, 297], ["a more heterogeneous cellulolyric microflora", "PROBLEM", 303, 347], ["mineral nutrients", "TREATMENT", 446, 463], ["microbial colonization", "PROBLEM", 468, 490], ["typical coastal vegetation zones", "PROBLEM", 572, 604], ["depth", "OBSERVATION_MODIFIER", 210, 215], ["5--15 cm", "OBSERVATION_MODIFIER", 219, 227], ["plant species", "OBSERVATION", 284, 297], ["mineral nutrients", "OBSERVATION", 446, 463], ["microbial colonization", "OBSERVATION", 468, 490], ["coastal vegetation", "OBSERVATION", 580, 598]]], ["In the terrestrial eeophase standing dead parts of main macrophytes, plant material strewn on the ground and semi-decomposed material mixed with soil were analysed.", [["terrestrial", "ANATOMY_MODIFIER", 7, 18], ["main macrophytes", "OBSERVATION", 51, 67], ["plant material strewn", "OBSERVATION", 69, 90]]], ["The hydrophase gave data on standing dead parts of main maerophytes, floating decomposing material, material lying on the bottom, and sapropel.", [["maerophytes", "ANATOMY", 56, 67], ["main maerophytes", "PROBLEM", 51, 67], ["floating decomposing material", "PROBLEM", 69, 98], ["sapropel", "TREATMENT", 134, 142], ["main maerophytes", "ANATOMY", 51, 67], ["floating", "OBSERVATION_MODIFIER", 69, 77], ["decomposing material", "OBSERVATION", 78, 98]]], ["All materials studied differed considerably in both chemical composition and microbial colonization.", [["microbial colonization", "PROBLEM", 77, 99], ["chemical composition", "OBSERVATION_MODIFIER", 52, 72], ["microbial colonization", "OBSERVATION", 77, 99]]], ["The terrestrial ecophase was characterized by mineralization of plant material, enrichment by mineral substances, especially Ca; K and P were readily released during the decomposition.", [["Ca", "CHEMICAL", 125, 127], ["K", "CHEMICAL", 129, 130], ["Ca", "CHEMICAL", 125, 127], ["K", "CHEMICAL", 129, 130], ["P", "CHEMICAL", 135, 136], ["The terrestrial ecophase", "TEST", 0, 24], ["mineralization of plant material", "PROBLEM", 46, 78], ["Ca", "TEST", 125, 127], ["K", "TEST", 129, 130], ["terrestrial ecophase", "OBSERVATION", 4, 24], ["mineralization", "OBSERVATION", 46, 60], ["plant material", "OBSERVATION", 64, 78]]], ["The decomposing plant material exhibited a gradually increasing level of N, providing apparently conditions favourable to its fixation.", [["N", "CHEMICAL", 73, 74], ["The decomposing plant material", "PROBLEM", 0, 30], ["its fixation", "TREATMENT", 122, 134], ["plant material", "OBSERVATION", 16, 30], ["gradually", "OBSERVATION_MODIFIER", 43, 52], ["increasing", "OBSERVATION_MODIFIER", 53, 63], ["fixation", "OBSERVATION", 126, 134]]], ["In the hydrophase, the predominant process was humifieation, the level of C remaining high even in sapropel.", [["C", "SIMPLE_CHEMICAL", 74, 75], ["predominant", "OBSERVATION_MODIFIER", 23, 34], ["process", "OBSERVATION", 35, 42], ["high", "OBSERVATION_MODIFIER", 86, 90]]], ["Some accumulation of mineral materials was also observed.", [["Some accumulation of mineral materials", "PROBLEM", 0, 38], ["accumulation", "OBSERVATION_MODIFIER", 5, 17], ["mineral materials", "OBSERVATION", 21, 38]]], ["The level of N and P of floating material increased strikingly, probably owing to colonization by periphyton.", [["floating material", "PROBLEM", 24, 41], ["floating", "OBSERVATION_MODIFIER", 24, 32], ["material", "OBSERVATION", 33, 41], ["increased", "OBSERVATION_MODIFIER", 42, 51], ["probably owing to", "UNCERTAINTY", 64, 81], ["colonization", "OBSERVATION", 82, 94], ["periphyton", "OBSERVATION", 98, 108]]], ["The microbial populations in standing, decomposing and finally degraded materials differed both qualitatively and quantitatively.", [["microbial", "OBSERVATION_MODIFIER", 4, 13], ["populations", "OBSERVATION_MODIFIER", 14, 25]]], ["The most abundant ones were in decomposing materials, the poorest in the standing ones, with higher proportion of micromycetes.Comparison o/ the E/]cct o/ Bentonite and Kaolinite on the Mineralization o] Various Concentrations o]Glucose.", [["Glucose", "CHEMICAL", 229, 236], ["Kaolinite", "CHEMICAL", 169, 178], ["o]Glucose", "CHEMICAL", 227, 236], ["Kaolinite", "SIMPLE_CHEMICAL", 169, 178], ["o]Glucose", "SIMPLE_CHEMICAL", 227, 236], ["cct o/ Bentonite", "TREATMENT", 148, 164], ["Kaolinite", "TREATMENT", 169, 178], ["Glucose", "TEST", 229, 236], ["most", "OBSERVATION_MODIFIER", 4, 8], ["abundant", "OBSERVATION_MODIFIER", 9, 17]]], ["J. Nov/~KovX, College of Agriculture, Prague.Comparison o/ the E/]cct o/ Bentonite and Kaolinite on the Mineralization o] Various Concentrations o]Sand containing a mineral nutrient solution, 3% bentonine or kaolinite and inoculated by soil microflora was supplemented with 0; 0.1; 0.2; 0.5 or 1.0% glucose.", [["bentonine", "CHEMICAL", 195, 204], ["kaolinite", "CHEMICAL", 208, 217], ["glucose", "CHEMICAL", 299, 306], ["bentonine", "CHEMICAL", 195, 204], ["kaolinite", "CHEMICAL", 208, 217], ["glucose", "CHEMICAL", 299, 306], ["Kaolinite", "SIMPLE_CHEMICAL", 87, 96], ["bentonine", "SIMPLE_CHEMICAL", 195, 204], ["kaolinite", "SIMPLE_CHEMICAL", 208, 217], ["glucose", "SIMPLE_CHEMICAL", 299, 306], ["cct o/ Bentonite", "TREATMENT", 66, 82], ["Kaolinite", "TREATMENT", 87, 96], ["a mineral nutrient solution", "TREATMENT", 163, 190], ["3% bentonine", "TREATMENT", 192, 204], ["kaolinite", "TREATMENT", 208, 217]]], ["The production of CO2 during the incubation was determined.", [["CO2", "CHEMICAL", 18, 21], ["CO2", "CHEMICAL", 18, 21], ["CO2", "SIMPLE_CHEMICAL", 18, 21], ["the incubation", "TREATMENT", 29, 43], ["CO2", "OBSERVATION_MODIFIER", 18, 21]]], ["Both clays suppressed the mineralization of glucose at all concentrations~ caolinite being more effective.", [["glucose", "CHEMICAL", 44, 51], ["caolinite", "CHEMICAL", 75, 84], ["glucose", "CHEMICAL", 44, 51], ["caolinite", "CHEMICAL", 75, 84], ["glucose", "SIMPLE_CHEMICAL", 44, 51], ["caolinite", "SIMPLE_CHEMICAL", 75, 84], ["the mineralization of glucose", "PROBLEM", 22, 51], ["caolinite", "TREATMENT", 75, 84], ["clays suppressed", "OBSERVATION", 5, 21], ["mineralization", "OBSERVATION_MODIFIER", 26, 40], ["more effective", "OBSERVATION_MODIFIER", 91, 105]]], ["The oxidation at the beginning of incubation was enhanced by bentonite and suppressed by kaolinite.", [["bentonite", "CHEMICAL", 61, 70], ["kaolinite", "CHEMICAL", 89, 98], ["bentonite", "CHEMICAL", 61, 70], ["kaolinite", "CHEMICAL", 89, 98], ["bentonite", "SIMPLE_CHEMICAL", 61, 70], ["kaolinite", "SIMPLE_CHEMICAL", 89, 98], ["The oxidation", "TREATMENT", 0, 13]]], ["With rising glucose concentration the number of secondary respiration peaks increased; these peaks were entirely eliminated by the addition of bentonite.", [["glucose", "CHEMICAL", 12, 19], ["bentonite", "CHEMICAL", 143, 152], ["glucose", "CHEMICAL", 12, 19], ["bentonite", "CHEMICAL", 143, 152], ["glucose", "SIMPLE_CHEMICAL", 12, 19], ["bentonite", "SIMPLE_CHEMICAL", 143, 152], ["rising glucose concentration", "PROBLEM", 5, 33], ["secondary respiration peaks", "PROBLEM", 48, 75], ["bentonite", "TREATMENT", 143, 152], ["rising", "OBSERVATION_MODIFIER", 5, 11], ["glucose concentration", "OBSERVATION", 12, 33], ["secondary respiration", "OBSERVATION", 48, 69], ["peaks", "OBSERVATION_MODIFIER", 70, 75], ["increased", "OBSERVATION_MODIFIER", 76, 85]]], ["The smoothing--out of the respiration curves by kaolinite was less pronounced than with bentonite.", [["kaolinite", "CHEMICAL", 48, 57], ["bentonite", "CHEMICAL", 88, 97], ["kaolinite", "CHEMICAL", 48, 57], ["bentonite", "CHEMICAL", 88, 97], ["kaolinite", "SIMPLE_CHEMICAL", 48, 57], ["bentonite", "SIMPLE_CHEMICAL", 88, 97], ["the respiration curves", "TEST", 22, 44], ["smoothing", "OBSERVATION_MODIFIER", 4, 13], ["less pronounced", "OBSERVATION_MODIFIER", 62, 77]]], ["These phenomena are explained on the basis of a different adsorption of the primary substrate and its metabolites by bentonite and by kaolinite.", [["bentonite", "CHEMICAL", 117, 126], ["kaolinite", "CHEMICAL", 134, 143], ["bentonite", "CHEMICAL", 117, 126], ["kaolinite", "CHEMICAL", 134, 143], ["bentonite", "SIMPLE_CHEMICAL", 117, 126], ["kaolinite", "SIMPLE_CHEMICAL", 134, 143], ["phenomena", "OBSERVATION", 6, 15]]], ["The droplet method was used to determine the effect of clay minerals on spore germination and sprout length of some microscopic soil fungi of the class Deuteromycetes.", [["spore", "ANATOMY", 72, 77], ["sprout", "ANATOMY", 94, 100], ["clay minerals", "CHEMICAL", 55, 68], ["clay minerals", "SIMPLE_CHEMICAL", 55, 68], ["The droplet method", "TREATMENT", 0, 18], ["clay minerals", "TREATMENT", 55, 68], ["spore germination", "TREATMENT", 72, 89]]], ["Both germination percentage and sprout length were affected particularly by minerals of the montmorine type, the effect being positive or negative depending on the fungal species.", [["sprout", "ANATOMY", 32, 38], ["Both germination percentage", "TEST", 0, 27], ["the fungal species", "PROBLEM", 160, 178], ["germination", "OBSERVATION_MODIFIER", 5, 16], ["percentage", "OBSERVATION_MODIFIER", 17, 27], ["sprout", "OBSERVATION_MODIFIER", 32, 38], ["length", "OBSERVATION_MODIFIER", 39, 45], ["fungal species", "OBSERVATION", 164, 178]]], ["For instance, the presence of montmorillonite (Wyoming) caused an increase in the length of sprouts of the fungus Stachybotrys atra by 0.25% and increased the germination capacity by 6% as compared to control while with Macor hiemali, s and .Fusarium exysporum the spore germination capacity dropped by 20~/o, the length of sprouts being only 0.2 that of the control.", [["sprouts", "ANATOMY", 92, 99], ["spore", "ANATOMY", 265, 270], ["sprouts", "ANATOMY", 324, 331], ["montmorillonite", "CHEMICAL", 30, 45], ["montmorillonite", "CHEMICAL", 30, 45], ["montmorillonite", "SIMPLE_CHEMICAL", 30, 45], ["Fusarium exysporum", "ORGANISM", 242, 260], ["sprouts", "TISSUE", 324, 331], ["Fusarium exysporum", "SPECIES", 242, 260], ["Stachybotrys atra", "SPECIES", 114, 131], ["Macor hiemali", "SPECIES", 220, 233], ["Fusarium exysporum", "SPECIES", 242, 260], ["the fungus Stachybotrys atra", "TREATMENT", 103, 131], ["the germination capacity", "TEST", 155, 179], ["Fusarium exysporum", "TEST", 242, 260], ["the spore germination capacity", "TEST", 261, 291], ["increase", "OBSERVATION_MODIFIER", 66, 74], ["length", "OBSERVATION_MODIFIER", 82, 88], ["sprouts", "OBSERVATION_MODIFIER", 92, 99], ["fungus Stachybotrys", "OBSERVATION", 107, 126], ["spore", "OBSERVATION_MODIFIER", 265, 270], ["germination capacity", "OBSERVATION", 271, 291]]], ["The results indicate that the lower occurrence of some microscopic fun~, e.g. Fusarium sp., known from the literature, may be due not only to the effect of clays on soil environment, but also to a direct fungistatic effect of some clay minerals.", [["Fusarium sp.", "DISEASE", 78, 90], ["Fusarium sp.", "ORGANISM", 78, 90], ["clay minerals", "SIMPLE_CHEMICAL", 231, 244], ["some microscopic fun~", "PROBLEM", 50, 71], ["Fusarium sp.", "PROBLEM", 78, 90], ["some clay minerals", "TREATMENT", 226, 244]]], ["The mechanism of this effect deserved a further study.SECTION OF IMMUNOLOGYThe Preparation and Characterization ol AnSi.", [["a further study", "TEST", 38, 53]]], ["Intracellular proteases (cathepsins) participate in the destruction of phagocytosed material, and their relationship to immunogenicity of antigens is thought.", [["Intracellular", "ANATOMY", 0, 13], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 13], ["cathepsins", "GENE_OR_GENE_PRODUCT", 25, 35], ["Intracellular proteases", "PROTEIN", 0, 23], ["cathepsins", "PROTEIN", 25, 35], ["antigens", "PROTEIN", 138, 146], ["Intracellular proteases (cathepsins)", "TREATMENT", 0, 36], ["the destruction of phagocytosed material", "PROBLEM", 52, 92], ["phagocytosed material", "OBSERVATION", 71, 92]]], ["As besides pepstatin, no other suitable inhibitors of these enzymes are known, we prepared antiserum against chicken and rabbit cathepsin D. Antiserum to chicken cathepsin D was prepared by a repeated immunization of rabbits with purified cathepsin D isolated from chicken spleens, whereas serum to rabbit cathepsin was prepared by immunization of sheep with highly purified preparation of cathepsin D from rabbit spleens.", [["spleens", "ANATOMY", 273, 280], ["serum", "ANATOMY", 290, 295], ["spleens", "ANATOMY", 414, 421], ["pepstatin", "CHEMICAL", 11, 20], ["pepstatin", "CHEMICAL", 11, 20], ["pepstatin", "SIMPLE_CHEMICAL", 11, 20], ["antiserum", "ORGANISM_SUBSTANCE", 91, 100], ["chicken", "ORGANISM", 109, 116], ["rabbit", "ORGANISM", 121, 127], ["cathepsin D.", "ORGANISM", 128, 140], ["Antiserum", "ORGANISM_SUBSTANCE", 141, 150], ["chicken", "ORGANISM", 154, 161], ["cathepsin D", "GENE_OR_GENE_PRODUCT", 162, 173], ["rabbits", "ORGANISM", 217, 224], ["cathepsin D", "GENE_OR_GENE_PRODUCT", 239, 250], ["chicken", "ORGANISM", 265, 272], ["spleens", "ORGAN", 273, 280], ["serum", "ORGANISM_SUBSTANCE", 290, 295], ["rabbit", "ORGANISM", 299, 305], ["cathepsin", "GENE_OR_GENE_PRODUCT", 306, 315], ["sheep", "ORGANISM", 348, 353], ["cathepsin D", "GENE_OR_GENE_PRODUCT", 390, 401], ["rabbit", "ORGANISM", 407, 413], ["spleens", "ORGAN", 414, 421], ["enzymes", "PROTEIN", 60, 67], ["chicken and rabbit cathepsin D. Antiserum to chicken cathepsin D", "PROTEIN", 109, 173], ["cathepsin D", "PROTEIN", 239, 250], ["rabbit cathepsin", "PROTEIN", 299, 315], ["cathepsin D", "PROTEIN", 390, 401], ["chicken", "SPECIES", 109, 116], ["rabbit", "SPECIES", 121, 127], ["chicken", "SPECIES", 154, 161], ["rabbits", "SPECIES", 217, 224], ["chicken", "SPECIES", 265, 272], ["rabbit", "SPECIES", 299, 305], ["sheep", "SPECIES", 348, 353], ["rabbit", "SPECIES", 407, 413], ["chicken", "SPECIES", 109, 116], ["rabbit", "SPECIES", 121, 127], ["chicken", "SPECIES", 154, 161], ["rabbits", "SPECIES", 217, 224], ["chicken", "SPECIES", 265, 272], ["rabbit", "SPECIES", 299, 305], ["sheep", "SPECIES", 348, 353], ["rabbit", "SPECIES", 407, 413], ["pepstatin", "TREATMENT", 11, 20], ["these enzymes", "TEST", 54, 67], ["chicken and rabbit cathepsin D. Antiserum", "TREATMENT", 109, 150], ["chicken cathepsin D", "TREATMENT", 154, 173], ["a repeated immunization of rabbits", "TREATMENT", 190, 224], ["purified cathepsin D", "TREATMENT", 230, 250], ["chicken spleens", "TREATMENT", 265, 280], ["serum to rabbit cathepsin", "TREATMENT", 290, 315], ["cathepsin D from rabbit spleens", "TREATMENT", 390, 421], ["spleens", "ANATOMY", 273, 280]]], ["The activity of antisera was determined on the basis of inhibition of cathepsin degradation of bovine haemoglobin at pH 5.0 using immunoelectrophoresis with subsequent detection of cathepsin D activity using bovine haemoglobin (pI~ 3.0) as a substrate.", [["cathepsin", "GENE_OR_GENE_PRODUCT", 70, 79], ["bovine", "ORGANISM", 95, 101], ["haemoglobin", "SIMPLE_CHEMICAL", 102, 113], ["cathepsin D", "GENE_OR_GENE_PRODUCT", 181, 192], ["bovine", "ORGANISM", 208, 214], ["haemoglobin", "GENE_OR_GENE_PRODUCT", 215, 226], ["cathepsin", "PROTEIN", 70, 79], ["cathepsin D", "PROTEIN", 181, 192], ["bovine", "SPECIES", 95, 101], ["bovine", "SPECIES", 208, 214], ["cathepsin degradation", "TREATMENT", 70, 91], ["bovine haemoglobin", "TEST", 95, 113], ["pH", "TEST", 117, 119], ["immunoelectrophoresis", "TEST", 130, 151], ["cathepsin D activity", "TREATMENT", 181, 201], ["bovine haemoglobin", "TREATMENT", 208, 226], ["pI", "TEST", 228, 230]]], ["All antisera possessed a significant inhibitory effect on the activity of cathepsin D. The most active serum inhibited completely the activity of 1 unit of chicken cathepsin in the amount of 8 ~1.", [["serum", "ANATOMY", 103, 108], ["cathepsin D.", "GENE_OR_GENE_PRODUCT", 74, 86], ["serum", "ORGANISM_SUBSTANCE", 103, 108], ["chicken", "ORGANISM", 156, 163], ["cathepsin", "GENE_OR_GENE_PRODUCT", 164, 173], ["chicken cathepsin", "PROTEIN", 156, 173], ["chicken", "SPECIES", 156, 163], ["chicken", "SPECIES", 156, 163], ["All antisera", "TREATMENT", 0, 12], ["cathepsin D.", "TREATMENT", 74, 86], ["chicken cathepsin", "TREATMENT", 156, 173], ["significant", "OBSERVATION_MODIFIER", 25, 36]]], ["One unit of rabbit cathepsin D was fully inhibited with approximately 15 [zl of specific antiserum.", [["rabbit", "ORGANISM", 12, 18], ["cathepsin D", "GENE_OR_GENE_PRODUCT", 19, 30], ["antiserum", "ORGANISM_SUBSTANCE", 89, 98], ["rabbit cathepsin D", "PROTEIN", 12, 30], ["rabbit", "SPECIES", 12, 18], ["rabbit", "SPECIES", 12, 18], ["rabbit cathepsin D", "TREATMENT", 12, 30]]], ["The fractionation of antisera on a DEAE cellulose column revealed that the anti-cathepsin D activity was localised in the IgG fraction of the serum.", [["serum", "ANATOMY", 142, 147], ["anti-cathepsin D", "CHEMICAL", 75, 91], ["anti-cathepsin D", "CHEMICAL", 75, 91], ["anti-cathepsin D", "SIMPLE_CHEMICAL", 75, 91], ["IgG", "GENE_OR_GENE_PRODUCT", 122, 125], ["serum", "ORGANISM_SUBSTANCE", 142, 147], ["anti-cathepsin D", "PROTEIN", 75, 91], ["The fractionation of antisera", "TREATMENT", 0, 29], ["a DEAE cellulose column", "TEST", 33, 56], ["the anti-cathepsin D activity", "PROBLEM", 71, 100], ["the IgG fraction", "TEST", 118, 134], ["IgG fraction", "OBSERVATION", 122, 134]]], ["Rabbit and chicken PMN leucocytes were homogenized in 0.34M saccharose.", [["PMN leucocytes", "ANATOMY", 19, 33], ["Rabbit", "ORGANISM", 0, 6], ["chicken", "ORGANISM", 11, 18], ["PMN leucocytes", "CELL", 19, 33], ["saccharose", "SIMPLE_CHEMICAL", 60, 70], ["Rabbit and chicken PMN leucocytes", "CELL_TYPE", 0, 33], ["Rabbit", "SPECIES", 0, 6], ["chicken", "SPECIES", 11, 18], ["Rabbit", "SPECIES", 0, 6], ["chicken", "SPECIES", 11, 18], ["Rabbit", "TEST", 0, 6], ["chicken PMN leucocytes", "TEST", 11, 33], ["PMN leucocytes", "OBSERVATION", 19, 33]]], ["The homogenate was submitted to differential centrifugation at 150, 800, 10,000 and 50,000 g.", [["homogenate", "ANATOMY", 4, 14]]], ["In the fractions, both the overall bactericidal activity and activity of myeloperoxidase (EC 1.11.I.7.), catalase (EC 1.11.1.6.1, lysozyme (EC 3.2.1.17.), eathepsin D (EC 3.4.4.23.) and E, beta glucuronidase (EC 3.2.1.31.", [["eathepsin D", "CHEMICAL", 155, 166], ["myeloperoxidase", "SIMPLE_CHEMICAL", 73, 88], ["EC", "CELL", 90, 92], ["catalase", "GENE_OR_GENE_PRODUCT", 105, 113], ["EC", "CELL", 115, 117], ["lysozyme", "GENE_OR_GENE_PRODUCT", 130, 138], ["eathepsin D", "SIMPLE_CHEMICAL", 155, 166], ["beta glucuronidase", "GENE_OR_GENE_PRODUCT", 189, 207], ["myeloperoxidase", "PROTEIN", 73, 88], ["catalase", "PROTEIN", 105, 113], ["lysozyme", "PROTEIN", 130, 138], ["beta glucuronidase", "PROTEIN", 189, 207], ["myeloperoxidase", "TEST", 73, 88], ["EC", "TEST", 90, 92], ["lysozyme (EC", "TEST", 130, 142], ["beta glucuronidase (EC", "TEST", 189, 211], ["fractions", "OBSERVATION_MODIFIER", 7, 16], ["overall", "OBSERVATION_MODIFIER", 27, 34], ["bactericidal activity", "OBSERVATION", 35, 56]]], ["I and acid phosphatase (EC 3.1.3.2.) were determined.", [["acid phosphatase", "PROTEIN", 6, 22], ["acid phosphatase", "TEST", 6, 22], ["EC", "TEST", 24, 26]]], ["Antibacterial activity was found in all fractions from rabbit leucocytes with the exception of the last one (above 50,000 g), whereas in chicken leukocytes, the activity was localised in the first fraction (150 g) only.", [["leucocytes", "ANATOMY", 62, 72], ["leukocytes", "ANATOMY", 145, 155], ["rabbit", "ORGANISM", 55, 61], ["leucocytes", "CELL", 62, 72], ["chicken", "ORGANISM", 137, 144], ["leukocytes", "CELL", 145, 155], ["rabbit leucocytes", "CELL_TYPE", 55, 72], ["chicken leukocytes", "CELL_TYPE", 137, 155], ["rabbit", "SPECIES", 55, 61], ["chicken", "SPECIES", 137, 144], ["rabbit", "SPECIES", 55, 61], ["chicken", "SPECIES", 137, 144], ["Antibacterial activity", "TEST", 0, 22], ["rabbit leucocytes", "TEST", 55, 72], ["rabbit leucocytes", "OBSERVATION", 55, 72], ["chicken leukocytes", "ANATOMY", 137, 155]]], ["The content of above mentioned enzymes in individual fractions of rabbit and chicken leucocytes was also different.", [["fractions", "ANATOMY", 53, 62], ["leucocytes", "ANATOMY", 85, 95], ["rabbit", "ORGANISM", 66, 72], ["chicken", "ORGANISM", 77, 84], ["leucocytes", "CELL", 85, 95], ["enzymes", "PROTEIN", 31, 38], ["rabbit and chicken leucocytes", "CELL_TYPE", 66, 95], ["rabbit", "SPECIES", 66, 72], ["chicken", "SPECIES", 77, 84], ["rabbit", "SPECIES", 66, 72], ["chicken", "SPECIES", 77, 84], ["above mentioned enzymes", "TEST", 15, 38], ["chicken leucocytes", "PROBLEM", 77, 95], ["chicken leucocytes", "OBSERVATION", 77, 95], ["different", "OBSERVATION_MODIFIER", 105, 114]]], ["Contrary to rabbit leucocytes, in chicken peritoneal leukocytes, myeloperoxidase, catalase and cathepsin E could not be detected.", [["leucocytes", "ANATOMY", 19, 29], ["peritoneal leukocytes", "ANATOMY", 42, 63], ["rabbit", "ORGANISM", 12, 18], ["leucocytes", "CELL", 19, 29], ["chicken", "ORGANISM", 34, 41], ["peritoneal leukocytes", "CELL", 42, 63], ["myeloperoxidase", "SIMPLE_CHEMICAL", 65, 80], ["catalase", "GENE_OR_GENE_PRODUCT", 82, 90], ["cathepsin E", "GENE_OR_GENE_PRODUCT", 95, 106], ["rabbit leucocytes", "CELL_TYPE", 12, 29], ["chicken peritoneal leukocytes", "CELL_TYPE", 34, 63], ["myeloperoxidase", "PROTEIN", 65, 80], ["catalase", "PROTEIN", 82, 90], ["cathepsin E", "PROTEIN", 95, 106], ["rabbit", "SPECIES", 12, 18], ["chicken", "SPECIES", 34, 41], ["rabbit", "SPECIES", 12, 18], ["chicken", "SPECIES", 34, 41], ["rabbit leucocytes", "TEST", 12, 29], ["chicken peritoneal leukocytes", "TEST", 34, 63], ["myeloperoxidase", "TEST", 65, 80], ["catalase", "TEST", 82, 90], ["cathepsin E", "TREATMENT", 95, 106], ["rabbit leucocytes", "OBSERVATION", 12, 29], ["peritoneal leukocytes", "ANATOMY", 42, 63], ["myeloperoxidase", "OBSERVATION", 65, 80], ["could not be", "UNCERTAINTY", 107, 119]]], ["However, despite the absence of the myeloperoxidase system, which is one of main intracellular microbicidal mechanisms in mamals, the overall antibacterial activity of chicken leucocytes was comparable to that found in rabbit leucocytes.", [["intracellular", "ANATOMY", 81, 94], ["leucocytes", "ANATOMY", 176, 186], ["leucocytes", "ANATOMY", 226, 236], ["myeloperoxidase", "GENE_OR_GENE_PRODUCT", 36, 51], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 81, 94], ["chicken", "ORGANISM", 168, 175], ["leucocytes", "CELL", 176, 186], ["rabbit", "ORGANISM", 219, 225], ["leucocytes", "CELL", 226, 236], ["myeloperoxidase", "PROTEIN", 36, 51], ["chicken leucocytes", "CELL_TYPE", 168, 186], ["rabbit leucocytes", "CELL_TYPE", 219, 236], ["chicken", "SPECIES", 168, 175], ["rabbit", "SPECIES", 219, 225], ["chicken", "SPECIES", 168, 175], ["rabbit", "SPECIES", 219, 225], ["the myeloperoxidase system", "TEST", 32, 58], ["chicken leucocytes", "PROBLEM", 168, 186], ["myeloperoxidase", "OBSERVATION", 36, 51], ["microbicidal mechanisms", "OBSERVATION", 95, 118], ["overall", "OBSERVATION_MODIFIER", 134, 141], ["antibacterial activity", "OBSERVATION", 142, 164], ["chicken leucocytes", "OBSERVATION", 168, 186], ["rabbit leucocytes", "OBSERVATION", 219, 236]]], ["These findings seem to suggest the presence of more antibacterial mechanisms in phagocytes and differences among animal species, the variances being not necessarily accompanied by different final antibacterial activity.The E fleet of Hydroeortisone on the Plaqueforming Activity of Peripheral AT-Lymphocytes.A Administration of hydroeortisone elicits in experimental animals decrease of metabolic activity or even degeneration and lysis of thymocytes and proportion of lymphocytes.", [["phagocytes", "ANATOMY", 80, 90], ["Peripheral AT-Lymphocytes", "ANATOMY", 282, 307], ["thymocytes", "ANATOMY", 440, 450], ["lymphocytes", "ANATOMY", 469, 480], ["Hydroeortisone", "CHEMICAL", 234, 248], ["hydroeortisone", "CHEMICAL", 328, 342], ["Hydroeortisone", "CHEMICAL", 234, 248], ["hydroeortisone", "CHEMICAL", 328, 342], ["phagocytes", "CELL", 80, 90], ["Hydroeortisone", "SIMPLE_CHEMICAL", 234, 248], ["Peripheral AT-Lymphocytes", "CELL", 282, 307], ["hydroeortisone", "SIMPLE_CHEMICAL", 328, 342], ["thymocytes", "CELL", 440, 450], ["lymphocytes", "CELL", 469, 480], ["phagocytes", "CELL_TYPE", 80, 90], ["Peripheral AT-Lymphocytes", "CELL_TYPE", 282, 307], ["thymocytes", "CELL_TYPE", 440, 450], ["lymphocytes", "CELL_TYPE", 469, 480], ["more antibacterial mechanisms in phagocytes", "PROBLEM", 47, 90], ["animal species", "PROBLEM", 113, 127], ["Hydroeortisone", "TREATMENT", 234, 248], ["A Administration of hydroeortisone elicits", "TREATMENT", 308, 350], ["metabolic activity", "PROBLEM", 387, 405], ["even degeneration", "PROBLEM", 409, 426], ["lysis of thymocytes", "PROBLEM", 431, 450], ["lymphocytes", "PROBLEM", 469, 480], ["more", "OBSERVATION_MODIFIER", 47, 51], ["antibacterial mechanisms", "OBSERVATION", 52, 76], ["antibacterial activity", "OBSERVATION", 196, 218], ["Peripheral", "ANATOMY_MODIFIER", 282, 292], ["Lymphocytes", "ANATOMY", 296, 307], ["decrease", "OBSERVATION_MODIFIER", 375, 383], ["metabolic activity", "OBSERVATION", 387, 405], ["degeneration", "OBSERVATION", 414, 426], ["thymocytes", "ANATOMY", 440, 450], ["lymphocytes", "ANATOMY", 469, 480]]], ["This phenomenon is caused by the inhibitory effect of glueocorticoids on synthesis of RNA, DNA and proteins, particularly on the RNA-and DNA-polymerase, as well as on membrane transport proteins.", [["membrane", "ANATOMY", 167, 175], ["glueocorticoids", "CHEMICAL", 54, 69], ["glueocorticoids", "CHEMICAL", 54, 69], ["glueocorticoids", "SIMPLE_CHEMICAL", 54, 69], ["DNA", "CELLULAR_COMPONENT", 91, 94], ["DNA", "CELLULAR_COMPONENT", 137, 140], ["membrane", "CELLULAR_COMPONENT", 167, 175], ["RNA", "RNA", 86, 89], ["DNA-polymerase", "PROTEIN", 137, 151], ["membrane transport proteins", "PROTEIN", 167, 194], ["This phenomenon", "PROBLEM", 0, 15], ["glueocorticoids", "PROBLEM", 54, 69], ["synthesis of RNA", "TREATMENT", 73, 89], ["DNA and proteins", "PROBLEM", 91, 107], ["the RNA", "TEST", 125, 132], ["DNA-polymerase", "TEST", 137, 151], ["membrane transport proteins", "TREATMENT", 167, 194]]], ["Lymphocytes, withdrawn from the organism in activated state (ATL), after incubation in the microehamber attached to glass and released a soluble factor which pushed off erythroeytes; thus a cell-free space -a plaque --was generated.", [["Lymphocytes", "ANATOMY", 0, 11], ["ATL", "ANATOMY", 61, 64], ["cell", "ANATOMY", 190, 194], ["plaque", "ANATOMY", 209, 215], ["Lymphocytes", "CELL", 0, 11], ["ATL", "CANCER", 61, 64], ["cell", "CELL", 190, 194], ["plaque", "PATHOLOGICAL_FORMATION", 209, 215], ["Lymphocytes", "CELL_TYPE", 0, 11], ["soluble factor", "PROTEIN", 137, 151], ["Lymphocytes", "TEST", 0, 11], ["incubation", "TREATMENT", 73, 83], ["a soluble factor", "TREATMENT", 135, 151], ["erythroeytes", "TREATMENT", 169, 181], ["a plaque", "PROBLEM", 207, 215], ["free space", "OBSERVATION", 195, 205], ["plaque", "OBSERVATION", 209, 215]]], ["The number of activated, plaque-forming lymphocytes was studied in guinea pigs (a) after a single injection; {b) after flve intraperitoneal injections of hydrocortisone for four and/or five days.", [["plaque", "ANATOMY", 25, 31], ["lymphocytes", "ANATOMY", 40, 51], ["intraperitoneal", "ANATOMY", 124, 139], ["hydrocortisone", "CHEMICAL", 154, 168], ["hydrocortisone", "CHEMICAL", 154, 168], ["lymphocytes", "CELL", 40, 51], ["guinea", "ORGANISM", 67, 73], ["pigs", "ORGANISM", 74, 78], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 124, 139], ["hydrocortisone", "SIMPLE_CHEMICAL", 154, 168], ["activated, plaque-forming lymphocytes", "CELL_TYPE", 14, 51], ["guinea pigs", "SPECIES", 67, 78], ["guinea pigs", "SPECIES", 67, 78], ["a single injection", "TREATMENT", 89, 107], ["flve intraperitoneal injections", "TREATMENT", 119, 150], ["hydrocortisone", "TREATMENT", 154, 168], ["plaque", "OBSERVATION", 25, 31], ["forming lymphocytes", "OBSERVATION", 32, 51]]], ["The blood differential count and cortisol level were determined quantitatively.", [["blood", "ANATOMY", 4, 9], ["cortisol", "CHEMICAL", 33, 41], ["cortisol", "CHEMICAL", 33, 41], ["blood", "ORGANISM_SUBSTANCE", 4, 9], ["cortisol", "SIMPLE_CHEMICAL", 33, 41], ["The blood differential count", "TEST", 0, 28], ["cortisol level", "TEST", 33, 47]]], ["Thsnnus and peripheral lymph nodes of control and experimental animals wore examined histologically.", [["Thsnnus", "ANATOMY", 0, 7], ["peripheral lymph nodes", "ANATOMY", 12, 34], ["Thsnnus", "CELL", 0, 7], ["peripheral lymph nodes", "MULTI-TISSUE_STRUCTURE", 12, 34], ["animals", "ORGANISM", 63, 70], ["Thsnnus", "TREATMENT", 0, 7], ["peripheral lymph nodes of control", "TREATMENT", 12, 45], ["peripheral", "ANATOMY_MODIFIER", 12, 22], ["lymph nodes", "OBSERVATION", 23, 34]]], ["After a single hydroeortisone administration, no change in the number of plaque-forming active lymphoeytes was recorded in the blood with high level of cortisol; however, the number temporarily slightly increased following the decrease of the cortisol level.", [["plaque", "ANATOMY", 73, 79], ["lymphoeytes", "ANATOMY", 95, 106], ["blood", "ANATOMY", 127, 132], ["hydroeortisone", "CHEMICAL", 15, 29], ["plaque", "DISEASE", 73, 79], ["cortisol", "CHEMICAL", 152, 160], ["cortisol", "CHEMICAL", 243, 251], ["hydroeortisone", "CHEMICAL", 15, 29], ["cortisol", "CHEMICAL", 152, 160], ["cortisol", "CHEMICAL", 243, 251], ["hydroeortisone", "SIMPLE_CHEMICAL", 15, 29], ["plaque", "PATHOLOGICAL_FORMATION", 73, 79], ["lymphoeytes", "CANCER", 95, 106], ["blood", "ORGANISM_SUBSTANCE", 127, 132], ["cortisol", "GENE_OR_GENE_PRODUCT", 152, 160], ["cortisol", "GENE_OR_GENE_PRODUCT", 243, 251], ["a single hydroeortisone administration", "TREATMENT", 6, 44], ["plaque", "PROBLEM", 73, 79], ["active lymphoeytes", "PROBLEM", 88, 106], ["the blood", "TEST", 123, 132], ["cortisol", "TEST", 152, 160], ["the cortisol level", "TEST", 239, 257], ["no", "UNCERTAINTY", 46, 48], ["change", "OBSERVATION_MODIFIER", 49, 55], ["number", "OBSERVATION_MODIFIER", 63, 69], ["plaque", "OBSERVATION", 73, 79], ["active", "OBSERVATION_MODIFIER", 88, 94], ["lymphoeytes", "OBSERVATION", 95, 106], ["slightly", "OBSERVATION_MODIFIER", 194, 202], ["increased", "OBSERVATION", 203, 212]]], ["After the five-fold hydrocortisone administration, the number of plaque--forming active cells did not change again during the period of high level of cortisol, however, it increased abruptly following the decrease of the eortisol level.", [["plaque", "ANATOMY", 65, 71], ["cells", "ANATOMY", 88, 93], ["hydrocortisone", "CHEMICAL", 20, 34], ["cortisol", "CHEMICAL", 150, 158], ["hydrocortisone", "CHEMICAL", 20, 34], ["cortisol", "CHEMICAL", 150, 158], ["eortisol", "CHEMICAL", 221, 229], ["hydrocortisone", "SIMPLE_CHEMICAL", 20, 34], ["plaque", "PATHOLOGICAL_FORMATION", 65, 71], ["cells", "CELL", 88, 93], ["cortisol", "GENE_OR_GENE_PRODUCT", 150, 158], ["eortisol", "SIMPLE_CHEMICAL", 221, 229], ["plaque--forming active cells", "CELL_TYPE", 65, 93], ["the five-fold hydrocortisone administration", "TREATMENT", 6, 49], ["plaque", "PROBLEM", 65, 71], ["active cells", "PROBLEM", 81, 93], ["plaque", "OBSERVATION", 65, 71], ["active cells", "OBSERVATION", 81, 93], ["increased", "OBSERVATION_MODIFIER", 172, 181], ["decrease", "OBSERVATION_MODIFIER", 205, 213]]], ["Based on the contemporary knowledge on the biphasic respons6 of the organism to glucocorticoids, as well as on the results of our present study we may assume that the adherence, release of soluble factors (activators) into the microenvironment and the pushing off of erythrocytes, i.e. the plaque-forming capacity, do require not only the activated state of the given AT lymphocyte, but also appropriate conditions for realization of directed metabolic events (synthesis of RNA, DNA and membrane transport proteins).", [["erythrocytes", "ANATOMY", 267, 279], ["plaque", "ANATOMY", 290, 296], ["AT lymphocyte", "ANATOMY", 368, 381], ["membrane", "ANATOMY", 487, 495], ["glucocorticoids", "CHEMICAL", 80, 95], ["glucocorticoids", "SIMPLE_CHEMICAL", 80, 95], ["erythrocytes", "CELL", 267, 279], ["AT lymphocyte", "CELL", 368, 381], ["DNA", "CELLULAR_COMPONENT", 479, 482], ["membrane", "CELLULAR_COMPONENT", 487, 495], ["soluble factors", "PROTEIN", 189, 204], ["erythrocytes", "CELL_TYPE", 267, 279], ["AT lymphocyte", "CELL_TYPE", 368, 381], ["RNA", "RNA", 474, 477], ["membrane transport proteins", "PROTEIN", 487, 514], ["our present study", "TEST", 126, 143], ["erythrocytes", "PROBLEM", 267, 279], ["the plaque", "PROBLEM", 286, 296], ["directed metabolic events", "PROBLEM", 434, 459], ["synthesis of RNA", "TREATMENT", 461, 477], ["membrane transport proteins", "TEST", 487, 514], ["plaque", "OBSERVATION", 290, 296]]], ["The function and cooperation of A-, T-, and B-cells is discussed.The Influence o] D~'ase, RNase and Trypsin on the Plaque.]orming Capacity o] Peripheral Lymphocytes.", [["A-, T-", "ANATOMY", 32, 38], ["B-cells", "ANATOMY", 44, 51], ["Peripheral Lymphocytes", "ANATOMY", 142, 164], ["A", "GENE_OR_GENE_PRODUCT", 32, 33], ["T-", "CELL", 36, 38], ["B-cells", "CELL", 44, 51], ["RNase", "GENE_OR_GENE_PRODUCT", 90, 95], ["Trypsin", "GENE_OR_GENE_PRODUCT", 100, 107], ["Peripheral Lymphocytes", "CELL", 142, 164], ["A-, T-, and B-cells", "CELL_TYPE", 32, 51], ["RNase", "PROTEIN", 90, 95], ["Trypsin", "PROTEIN", 100, 107], ["Peripheral Lymphocytes", "CELL_TYPE", 142, 164], ["A", "TEST", 32, 33], ["RNase", "TEST", 90, 95], ["the Plaque", "PROBLEM", 111, 121], ["Peripheral Lymphocytes", "TEST", 142, 164], ["Peripheral", "ANATOMY_MODIFIER", 142, 152], ["Lymphocytes", "ANATOMY", 153, 164]]], ["M. KUNAY, A. SOKOL Department ofMicrobiology, Faculty Hospital, School of Microbiology and Zoohygiene, Veterinary Faculty, Kow An increased number of peripheral blood lymphoeytes, withdrawn from patients 24 h after surgery, possessed the plaque-forming capacity in microchamber in vitro.", [["peripheral blood lymphoeytes", "ANATOMY", 150, 178], ["plaque", "ANATOMY", 238, 244], ["peripheral blood lymphoeytes", "DISEASE", 150, 178], ["blood lymphoeytes", "ORGANISM_SUBSTANCE", 161, 178], ["patients", "ORGANISM", 195, 203], ["microchamber", "CANCER", 265, 277], ["patients", "SPECIES", 195, 203], ["peripheral blood lymphoeytes", "PROBLEM", 150, 178], ["surgery", "TREATMENT", 215, 222], ["the plaque", "PROBLEM", 234, 244], ["increased", "OBSERVATION_MODIFIER", 130, 139], ["peripheral", "ANATOMY_MODIFIER", 150, 160], ["blood", "ANATOMY", 161, 166], ["plaque", "OBSERVATION", 238, 244], ["capacity", "OBSERVATION_MODIFIER", 253, 261]]], ["The plaque-forming activity of lymphocytes was influenced by various concentrations of DN-aso, RN-ase and trypsin, added to buffered physiological saline used for dilutions of blood samples.", [["plaque", "ANATOMY", 4, 10], ["lymphocytes", "ANATOMY", 31, 42], ["blood samples", "ANATOMY", 176, 189], ["DN-aso, RN-ase", "CHEMICAL", 87, 101], ["plaque", "PATHOLOGICAL_FORMATION", 4, 10], ["lymphocytes", "CELL", 31, 42], ["DN-aso", "SIMPLE_CHEMICAL", 87, 93], ["RN-ase", "SIMPLE_CHEMICAL", 95, 101], ["trypsin", "SIMPLE_CHEMICAL", 106, 113], ["saline", "SIMPLE_CHEMICAL", 147, 153], ["blood samples", "ORGANISM_SUBSTANCE", 176, 189], ["lymphocytes", "CELL_TYPE", 31, 42], ["trypsin", "PROTEIN", 106, 113], ["The plaque", "PROBLEM", 0, 10], ["DN-aso", "TREATMENT", 87, 93], ["trypsin", "TREATMENT", 106, 113], ["buffered physiological saline", "TREATMENT", 124, 153], ["blood samples", "TEST", 176, 189], ["plaque", "OBSERVATION", 4, 10], ["activity", "OBSERVATION_MODIFIER", 19, 27], ["lymphocytes", "ANATOMY", 31, 42]]], ["DN-ase at concentration of 0.1 mg (18 U. Kunitz) and higher per 1 ml of diluted blood, inhibited completely the formation of plaques, whereas at concentrations of 0.1--0.02 nag/ ml yielded a partial inhibition of the plaqueforming mass.", [["blood", "ANATOMY", 80, 85], ["plaques", "ANATOMY", 125, 132], ["DN-ase", "CHEMICAL", 0, 6], ["plaques", "DISEASE", 125, 132], ["DN-ase", "SIMPLE_CHEMICAL", 0, 6], ["blood", "ORGANISM_SUBSTANCE", 80, 85], ["plaques", "PATHOLOGICAL_FORMATION", 125, 132], ["DN", "PROBLEM", 0, 2], ["diluted blood", "PROBLEM", 72, 85], ["plaques", "PROBLEM", 125, 132], ["concentrations", "TEST", 145, 159], ["a partial inhibition of the plaqueforming mass", "PROBLEM", 189, 235], ["plaques", "OBSERVATION", 125, 132], ["plaqueforming", "OBSERVATION_MODIFIER", 217, 230], ["mass", "OBSERVATION", 231, 235]]], ["On the other hand, l~N-ase could not inhibit the plaque-formation at concentrations 0.5 mg (20 U. Kunitz) and higher per 1 ml of diluted blood.", [["plaque", "ANATOMY", 49, 55], ["blood", "ANATOMY", 137, 142], ["N-ase", "CHEMICAL", 21, 26], ["plaque", "DISEASE", 49, 55], ["N-ase", "SIMPLE_CHEMICAL", 21, 26], ["plaque", "PATHOLOGICAL_FORMATION", 49, 55], ["blood", "ORGANISM_SUBSTANCE", 137, 142], ["the plaque", "PROBLEM", 45, 55], ["diluted blood", "PROBLEM", 129, 142], ["plaque", "OBSERVATION", 49, 55]]], ["Trypsin (1:150) at concentrations above 15 mg]ml of diluted blood inhibited completely the plaque formation, whereas at coneentrations 0.5--10 mg/ml inhibited partially not only the formation of the plaque-forming mass but decreased the number of plaque-forming active cells at the same time.", [["blood", "ANATOMY", 60, 65], ["plaque", "ANATOMY", 91, 97], ["plaque", "ANATOMY", 199, 205], ["plaque", "ANATOMY", 247, 253], ["cells", "ANATOMY", 269, 274], ["Trypsin", "CHEMICAL", 0, 7], ["plaque", "DISEASE", 91, 97], ["plaque", "DISEASE", 199, 205], ["plaque", "DISEASE", 247, 253], ["Trypsin", "GENE_OR_GENE_PRODUCT", 0, 7], ["blood", "ORGANISM_SUBSTANCE", 60, 65], ["plaque", "PATHOLOGICAL_FORMATION", 91, 97], ["plaque", "PATHOLOGICAL_FORMATION", 199, 205], ["plaque", "PATHOLOGICAL_FORMATION", 247, 253], ["cells", "CELL", 269, 274], ["plaque-forming active cells", "CELL_TYPE", 247, 274], ["Trypsin", "TREATMENT", 0, 7], ["diluted blood", "PROBLEM", 52, 65], ["the plaque formation", "PROBLEM", 87, 107], ["coneentrations", "TEST", 120, 134], ["the plaque", "PROBLEM", 195, 205], ["mass", "PROBLEM", 214, 218], ["plaque", "PROBLEM", 247, 253], ["plaque", "OBSERVATION", 91, 97], ["plaque", "OBSERVATION", 199, 205], ["mass", "OBSERVATION", 214, 218], ["decreased", "OBSERVATION_MODIFIER", 223, 232], ["number", "OBSERVATION_MODIFIER", 237, 243], ["plaque", "OBSERVATION", 247, 253], ["active cells", "OBSERVATION", 262, 274]]], ["We therefore assume that only DN-ase exerts a specific effect on the production of the plaque-forming mass in activated lymphoeytes.", [["plaque", "ANATOMY", 87, 93], ["lymphoeytes", "ANATOMY", 120, 131], ["DN-ase", "CHEMICAL", 30, 36], ["DN-ase", "GENE_OR_GENE_PRODUCT", 30, 36], ["plaque", "PATHOLOGICAL_FORMATION", 87, 93], ["lymphoeytes", "CANCER", 120, 131], ["DN", "PROBLEM", 30, 32], ["the plaque", "PROBLEM", 83, 93], ["mass in activated lymphoeytes", "PROBLEM", 102, 131], ["plaque", "OBSERVATION", 87, 93], ["mass", "OBSERVATION", 102, 106]]], ["In the course of the local primary immune response to intraperitoneally administered horse raddish peroxydase together with endotoxin, several types of arrangement of rer, containing specific antiporoxydaso antibodies in the channels, were found in omentum of mice: on the 3rd day after immunizatione (1) short, narrow irregular tubules ;The Development and Degradation o] Rough Endoplasmic Ret~culum (rer) System in Maturing(2) irregular convolute of narrow tubules; (3) \"whirls\" of concentric narrow tubules.", [["omentum", "ANATOMY", 249, 256], ["tubules", "ANATOMY", 329, 336], ["tubules", "ANATOMY", 459, 466], ["tubules", "ANATOMY", 502, 509], ["endotoxin", "CHEMICAL", 124, 133], ["horse", "ORGANISM", 85, 90], ["raddish peroxydase", "SIMPLE_CHEMICAL", 91, 109], ["endotoxin", "SIMPLE_CHEMICAL", 124, 133], ["rer", "GENE_OR_GENE_PRODUCT", 167, 170], ["antiporoxydaso antibodies", "GENE_OR_GENE_PRODUCT", 192, 217], ["omentum", "ORGAN", 249, 256], ["mice", "ORGANISM", 260, 264], ["tubules", "TISSUE", 329, 336], ["tubules", "TISSUE", 459, 466], ["tubules", "TISSUE", 502, 509], ["endotoxin", "PROTEIN", 124, 133], ["rer", "PROTEIN", 167, 170], ["antiporoxydaso antibodies", "PROTEIN", 192, 217], ["horse", "SPECIES", 85, 90], ["mice", "SPECIES", 260, 264], ["horse", "SPECIES", 85, 90], ["mice", "SPECIES", 260, 264], ["horse raddish peroxydase", "TREATMENT", 85, 109], ["endotoxin", "TREATMENT", 124, 133], ["specific antiporoxydaso antibodies", "TREATMENT", 183, 217], ["short, narrow irregular tubules", "PROBLEM", 305, 336], ["irregular convolute of narrow tubules", "PROBLEM", 429, 466], ["concentric narrow tubules", "PROBLEM", 484, 509], ["omentum", "ANATOMY", 249, 256], ["irregular", "OBSERVATION_MODIFIER", 429, 438], ["narrow tubules", "OBSERVATION", 452, 466], ["narrow tubules", "OBSERVATION", 495, 509]]], ["On the 5th and 7th day after immunization, majority of produetive plasma cells contained already rer system, which was arranged typically in dense parallel lameral tubules, filling up almost entirely the protoplasm.", [["plasma cells", "ANATOMY", 66, 78], ["rer system", "ANATOMY", 97, 107], ["lameral tubules", "ANATOMY", 156, 171], ["protoplasm", "ANATOMY", 204, 214], ["plasma cells", "CELL", 66, 78], ["lameral tubules", "TISSUE", 156, 171], ["protoplasm", "CANCER", 204, 214], ["produetive plasma cells", "CELL_TYPE", 55, 78], ["immunization", "TREATMENT", 29, 41], ["produetive plasma cells", "PROBLEM", 55, 78], ["plasma cells", "OBSERVATION", 66, 78], ["dense", "OBSERVATION_MODIFIER", 141, 146], ["parallel", "OBSERVATION_MODIFIER", 147, 155], ["lameral tubules", "OBSERVATION", 156, 171], ["protoplasm", "OBSERVATION", 204, 214]]], ["In addition, certain mature plasma cells contained anti-peroxidase antibodies in spherical dilated eysternae of rer, in which condensation or even crystallization of antibodies took place.", [["plasma cells", "ANATOMY", 28, 40], ["eysternae", "ANATOMY", 99, 108], ["plasma cells", "CELL", 28, 40], ["anti-peroxidase antibodies", "GENE_OR_GENE_PRODUCT", 51, 77], ["mature plasma cells", "CELL_TYPE", 21, 40], ["anti-peroxidase antibodies", "PROTEIN", 51, 77], ["antibodies", "PROTEIN", 166, 176], ["certain mature plasma cells", "PROBLEM", 13, 40], ["anti-peroxidase antibodies in spherical dilated eysternae of rer", "PROBLEM", 51, 115], ["crystallization of antibodies", "PROBLEM", 147, 176], ["plasma cells", "OBSERVATION", 28, 40], ["spherical", "OBSERVATION_MODIFIER", 81, 90], ["dilated", "OBSERVATION", 91, 98]]], ["On the basis of our findings we assume that the arrangement of the rcr system within the plasma cells develops from short disarranged narrow tubules found in blast elements up to dense parallel lamellae of rer in mature plasma cells or even up to the stadium of large lacunar eysternac.", [["plasma cells", "ANATOMY", 89, 101], ["tubules", "ANATOMY", 141, 148], ["plasma cells", "ANATOMY", 220, 232], ["lacunar", "DISEASE", 268, 275], ["rcr", "GENE_OR_GENE_PRODUCT", 67, 70], ["plasma cells", "CELL", 89, 101], ["tubules", "TISSUE", 141, 148], ["plasma cells", "CELL", 220, 232], ["rcr", "PROTEIN", 67, 70], ["plasma cells", "CELL_TYPE", 89, 101], ["blast elements", "DNA", 158, 172], ["mature plasma cells", "CELL_TYPE", 213, 232], ["the plasma cells", "TEST", 85, 101], ["short disarranged narrow tubules", "PROBLEM", 116, 148], ["blast elements", "PROBLEM", 158, 172], ["dense parallel lamellae of rer in mature plasma cells", "PROBLEM", 179, 232], ["large lacunar eysternac", "PROBLEM", 262, 285], ["plasma cells", "OBSERVATION", 89, 101], ["short", "OBSERVATION_MODIFIER", 116, 121], ["narrow tubules", "OBSERVATION", 134, 148], ["blast elements", "OBSERVATION", 158, 172], ["dense", "OBSERVATION_MODIFIER", 179, 184], ["parallel", "OBSERVATION_MODIFIER", 185, 193], ["lamellae", "OBSERVATION_MODIFIER", 194, 202], ["mature plasma cells", "OBSERVATION", 213, 232], ["large", "OBSERVATION_MODIFIER", 262, 267], ["lacunar eysternac", "OBSERVATION", 268, 285]]], ["The occurrence of sometimes even bizarre forms of the rer system could be attributed to the specific action of mitogens used, and we consider them transitional and fully functional proteosynthetic structures which could be \"reorganised\" into an arrangement, typical for mature plasma cells.", [["proteosynthetic structures", "ANATOMY", 181, 207], ["plasma cells", "ANATOMY", 277, 289], ["plasma cells", "CELL", 277, 289], ["mitogens", "PROTEIN", 111, 119], ["mature plasma cells", "CELL_TYPE", 270, 289], ["mitogens", "TREATMENT", 111, 119], ["them transitional and fully functional proteosynthetic structures", "PROBLEM", 142, 207], ["mature plasma cells", "PROBLEM", 270, 289], ["bizarre", "OBSERVATION", 33, 40], ["plasma cells", "OBSERVATION", 277, 289]]], ["The discontinuation of the limiting membrane unit of rer during gradual crystallization of antibodies within the cysternae can be considered as one of possible modes of degradation of the rer system.", [["membrane", "ANATOMY", 36, 44], ["cysternae", "ANATOMY", 113, 122], ["membrane", "CELLULAR_COMPONENT", 36, 44], ["cysternae", "CANCER", 113, 122], ["antibodies", "PROTEIN", 91, 101], ["gradual crystallization of antibodies", "TREATMENT", 64, 101], ["degradation of the rer system", "PROBLEM", 169, 198]]], ["The effect of intraperitoneal administration of protease peptone on the composition of peritoneal exudate of CBA mice was studied using light and electron microscopy.", [["intraperitoneal", "ANATOMY", 14, 29], ["peritoneal exudate", "ANATOMY", 87, 105], ["peptone", "CHEMICAL", 57, 64], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 14, 29], ["protease peptone", "GENE_OR_GENE_PRODUCT", 48, 64], ["peritoneal exudate", "MULTI-TISSUE_STRUCTURE", 87, 105], ["CBA mice", "ORGANISM", 109, 117], ["mice", "SPECIES", 113, 117], ["mice", "SPECIES", 113, 117], ["intraperitoneal administration of protease peptone", "TREATMENT", 14, 64], ["peritoneal exudate of CBA mice", "TREATMENT", 87, 117], ["electron microscopy", "TEST", 146, 165], ["intraperitoneal", "ANATOMY", 14, 29], ["peritoneal", "ANATOMY", 87, 97], ["exudate", "OBSERVATION", 98, 105]]], ["The enzymatic activity of cells was tested by histoehemical and biochemical assays on acid phosphatase.", [["cells", "ANATOMY", 26, 31], ["cells", "CELL", 26, 31], ["acid phosphatase", "PROTEIN", 86, 102], ["The enzymatic activity of cells", "PROBLEM", 0, 31], ["acid phosphatase", "TEST", 86, 102], ["enzymatic activity", "OBSERVATION", 4, 22]]], ["As compared with control animals, an increase in the number of nmno-histioeytic forms from 50~/o to 80~o was found three days after peptone injection.", [["peptone", "SIMPLE_CHEMICAL", 132, 139], ["nmno-histioeytic forms", "RNA", 63, 85], ["peptone injection", "TREATMENT", 132, 149], ["increase", "OBSERVATION_MODIFIER", 37, 45]]], ["Besides quantitative changes, an activation of cells of the macrophage type was detected: faster and firmer adherence to glass and ultrastructural changes that are characteristic for activated macrophages, particularly the enhanced content of lysosomes in correlation to increased level of acid phosphatase.", [["cells", "ANATOMY", 47, 52], ["macrophage", "ANATOMY", 60, 70], ["macrophages", "ANATOMY", 193, 204], ["lysosomes", "ANATOMY", 243, 252], ["cells", "CELL", 47, 52], ["macrophage type", "CELL", 60, 75], ["macrophages", "CELL", 193, 204], ["lysosomes", "CELLULAR_COMPONENT", 243, 252], ["activated macrophages", "CELL_TYPE", 183, 204], ["acid phosphatase", "PROTEIN", 290, 306], ["quantitative changes", "PROBLEM", 8, 28], ["ultrastructural changes", "PROBLEM", 131, 154], ["activated macrophages", "PROBLEM", 183, 204], ["increased level of acid phosphatase", "PROBLEM", 271, 306], ["macrophage", "OBSERVATION_MODIFIER", 60, 70], ["characteristic for", "UNCERTAINTY", 164, 182], ["macrophages", "OBSERVATION", 193, 204]]], ["The increased activity of peritoneal cells -adherence and enzymatic activity--was also found in mice following an intraperitoneal administration of Bor-deteUa pertussis vaccine.", [["peritoneal cells", "ANATOMY", 26, 42], ["intraperitoneal", "ANATOMY", 114, 129], ["Bor-deteUa pertussis", "CHEMICAL", 148, 168], ["peritoneal cells", "CELL", 26, 42], ["mice", "ORGANISM", 96, 100], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 114, 129], ["Bor-deteUa pertussis", "ORGANISM", 148, 168], ["peritoneal cells", "CELL_TYPE", 26, 42], ["mice", "SPECIES", 96, 100], ["mice", "SPECIES", 96, 100], ["The increased activity of peritoneal cells", "PROBLEM", 0, 42], ["enzymatic activity", "PROBLEM", 58, 76], ["an intraperitoneal administration", "TREATMENT", 111, 144], ["Bor-deteUa pertussis vaccine", "TREATMENT", 148, 176], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["activity", "OBSERVATION_MODIFIER", 14, 22], ["peritoneal cells", "OBSERVATION", 26, 42], ["enzymatic activity", "OBSERVATION", 58, 76], ["intraperitoneal", "ANATOMY", 114, 129]]], ["The morphological heterogeneity of cells of the peritoneal exudate after activation with substances which influence the cells of the maerophage series is discussed as regards their origin, differentiation and functions performed by these cells.", [["cells", "ANATOMY", 35, 40], ["peritoneal exudate", "ANATOMY", 48, 66], ["cells", "ANATOMY", 120, 125], ["cells", "ANATOMY", 238, 243], ["cells", "CELL", 35, 40], ["peritoneal exudate", "MULTI-TISSUE_STRUCTURE", 48, 66], ["cells", "CELL", 120, 125], ["cells", "CELL", 238, 243], ["the peritoneal exudate", "PROBLEM", 44, 66], ["activation with substances", "TREATMENT", 73, 99], ["the maerophage series", "TEST", 129, 150], ["morphological", "OBSERVATION_MODIFIER", 4, 17], ["heterogeneity", "OBSERVATION_MODIFIER", 18, 31], ["cells", "OBSERVATION_MODIFIER", 35, 40], ["peritoneal", "ANATOMY", 48, 58], ["exudate", "OBSERVATION", 59, 66]]], ["Opsonizing activity detected by intravascular clearance of bacteria in newborn precolostral piglets, and bactericidal effect to Escherichia cell 0 55 of immune pig IgM, its peptic Fab ~ and F(e)5 fragments and tryptic Fab ~ fragment were studied.", [["intravascular", "ANATOMY", 32, 45], ["precolostral piglets", "ANATOMY", 79, 99], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 32, 45], ["piglets", "ORGANISM", 92, 99], ["Escherichia cell 0 55", "ORGANISM", 128, 149], ["pig", "ORGANISM", 160, 163], ["IgM", "GENE_OR_GENE_PRODUCT", 164, 167], ["F(e)5", "GENE_OR_GENE_PRODUCT", 190, 195], ["immune pig IgM", "PROTEIN", 153, 167], ["peptic Fab ~ and F(e)5 fragments", "DNA", 173, 205], ["tryptic Fab ~ fragment", "PROTEIN", 210, 232], ["piglets", "SPECIES", 92, 99], ["pig", "SPECIES", 160, 163], ["pig", "SPECIES", 160, 163], ["Opsonizing activity", "PROBLEM", 0, 19], ["intravascular clearance", "TEST", 32, 55], ["bacteria", "PROBLEM", 59, 67], ["newborn precolostral piglets", "TREATMENT", 71, 99], ["bactericidal effect", "PROBLEM", 105, 124], ["Escherichia cell", "TEST", 128, 144], ["immune pig IgM", "TEST", 153, 167], ["its peptic Fab", "TEST", 169, 183], ["5 fragments", "PROBLEM", 194, 205], ["tryptic Fab ~ fragment", "TREATMENT", 210, 232], ["bacteria", "OBSERVATION", 59, 67], ["Escherichia cell", "OBSERVATION", 128, 144], ["peptic Fab", "OBSERVATION", 173, 183]]], ["Total reductmn and carboxymethylation of disulphide bonds of the immune IgM molecule completely abolished its in rive opsonizing activity, suggesting thus the importance of a tertiary structure stabilized by disluphide bonds.", [["reductmn", "CHEMICAL", 6, 14], ["disulphide", "CHEMICAL", 41, 51], ["disluphide", "CHEMICAL", 208, 218], ["disluphide bonds", "SIMPLE_CHEMICAL", 208, 224], ["immune IgM molecule", "PROTEIN", 65, 84], ["Total reductmn", "TREATMENT", 0, 14], ["carboxymethylation of disulphide bonds", "TREATMENT", 19, 57], ["the immune IgM molecule", "PROBLEM", 61, 84], ["immune IgM", "OBSERVATION", 65, 75], ["opsonizing activity", "OBSERVATION", 118, 137]]], ["Tryptic and peptic Fab tz fragments differed significantly in biological activities.", [["Tryptic", "TREATMENT", 0, 7], ["peptic Fab tz fragments", "PROBLEM", 12, 35], ["peptic", "OBSERVATION_MODIFIER", 12, 18], ["Fab tz", "OBSERVATION", 19, 25]]], ["Unlike the tryptie Fab {z fragment, the 4,200 dalton larger peptic Fab ~t fragment possessed both opsonizing and bactericidal activity.", [["tryptie Fab {z fragment", "PROTEIN", 11, 34], ["4,200 dalton larger peptic Fab ~t fragment", "PROTEIN", 40, 82], ["the tryptie Fab {z fragment", "PROBLEM", 7, 34], ["the 4,200 dalton larger peptic Fab ~t fragment", "TREATMENT", 36, 82], ["peptic Fab", "OBSERVATION", 60, 70], ["opsonizing", "OBSERVATION_MODIFIER", 98, 108], ["bactericidal activity", "OBSERVATION", 113, 134]]], ["On the other hand, the peptic :F(c)5 ~z fragment opsonized bacteria without any bactericidal effect.", [["5 ~z fragment opsonized bacteria", "PROBLEM", 35, 67], ["any bactericidal effect", "PROBLEM", 76, 99], ["peptic", "OBSERVATION", 23, 29], ["bactericidal effect", "OBSERVATION", 80, 99]]], ["The possible participation of complement as well as the nature of nonspeeifie binding of the peptic F(c)5 ~t fragment to bacteria is discussed.", [["peptic F(c)5 ~t fragment", "DNA", 93, 117], ["the peptic F(c)5 ~t fragment to bacteria", "PROBLEM", 89, 129], ["peptic", "OBSERVATION", 93, 99]]], ["The antibody response and immunoglobulin synthesis was studied in piglets, reared under germfree conditions after monoeontamination with gramnegative intestinal bacteria and after a long-term peroral administration of massive doses of killed bacteria.", [["intestinal", "ANATOMY", 150, 160], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 26, 40], ["piglets", "ORGANISM", 66, 73], ["immunoglobulin", "PROTEIN", 26, 40], ["piglets", "SPECIES", 66, 73], ["The antibody response", "TEST", 0, 21], ["immunoglobulin synthesis", "TEST", 26, 50], ["gramnegative intestinal bacteria", "PROBLEM", 137, 169], ["a long-term peroral administration", "TREATMENT", 180, 214], ["killed bacteria", "PROBLEM", 235, 250], ["intestinal", "ANATOMY", 150, 160]]], ["The antibody formation and immuneglobulin synthesis wa s significantly higher in monocontaminated piglets in comparison with the vaccinated group.", [["immuneglobulin", "CHEMICAL", 27, 41], ["immuneglobulin", "SIMPLE_CHEMICAL", 27, 41], ["piglets", "ORGANISM", 98, 105], ["piglets", "SPECIES", 98, 105], ["The antibody formation", "TEST", 0, 22], ["immuneglobulin synthesis", "TEST", 27, 51], ["antibody formation", "OBSERVATION", 4, 22]]], ["These results are compatible with the finding that non-pathogenic gramnegative bacteria penetrate in high numbers into the regional lymph nodes which results in much higher antigennic stimulation.", [["lymph nodes", "ANATOMY", 132, 143], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 132, 143], ["non-pathogenic gramnegative bacteria", "PROBLEM", 51, 87], ["compatible with", "UNCERTAINTY", 18, 33], ["non-pathogenic", "OBSERVATION_MODIFIER", 51, 65], ["gramnegative", "OBSERVATION_MODIFIER", 66, 78], ["bacteria", "OBSERVATION_MODIFIER", 79, 87], ["penetrate", "OBSERVATION_MODIFIER", 88, 97], ["high", "OBSERVATION_MODIFIER", 101, 105], ["numbers", "OBSERVATION_MODIFIER", 106, 113], ["regional", "ANATOMY_MODIFIER", 123, 131], ["lymph nodes", "OBSERVATION", 132, 143], ["much", "OBSERVATION_MODIFIER", 161, 165], ["higher", "OBSERVATION_MODIFIER", 166, 172], ["antigennic stimulation", "OBSERVATION", 173, 195]]], ["Using the germfree piglet model, the effect of the immune colostrum, serum and immunoglobulins IgA, IgM and IgG on the antibacterial and antienterotoxie local resistance of the small intestine to enteropathogenie Escherichia cell 0 55 was studied.", [["immune colostrum", "ANATOMY", 51, 67], ["serum", "ANATOMY", 69, 74], ["small intestine", "ANATOMY", 177, 192], ["germfree piglet", "ORGANISM", 10, 25], ["colostrum", "ORGANISM_SUBSTANCE", 58, 67], ["serum", "ORGANISM_SUBSTANCE", 69, 74], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 79, 94], ["IgA", "GENE_OR_GENE_PRODUCT", 95, 98], ["IgM", "GENE_OR_GENE_PRODUCT", 100, 103], ["IgG", "GENE_OR_GENE_PRODUCT", 108, 111], ["antienterotoxie", "SIMPLE_CHEMICAL", 137, 152], ["small intestine", "ORGAN", 177, 192], ["serum and immunoglobulins IgA", "PROTEIN", 69, 98], ["IgM", "PROTEIN", 100, 103], ["IgG", "PROTEIN", 108, 111], ["the germfree piglet model", "TREATMENT", 6, 31], ["the immune colostrum", "TEST", 47, 67], ["serum", "TEST", 69, 74], ["immunoglobulins IgA", "TEST", 79, 98], ["IgM", "TEST", 100, 103], ["IgG", "TEST", 108, 111], ["the antibacterial", "TREATMENT", 115, 132], ["antienterotoxie", "TREATMENT", 137, 152], ["Escherichia cell", "TEST", 213, 229], ["small intestine", "ANATOMY", 177, 192]]], ["The in vivo assay, ligated intestinal loop of piglets, was employed for determination of enterotoxic activity and penetration of bacteria through the intestinal wall.", [["intestinal loop", "ANATOMY", 27, 42], ["piglets", "ANATOMY", 46, 53], ["intestinal wall", "ANATOMY", 150, 165], ["intestinal loop", "MULTI-TISSUE_STRUCTURE", 27, 42], ["piglets", "ORGANISM", 46, 53], ["intestinal wall", "MULTI-TISSUE_STRUCTURE", 150, 165], ["piglets", "SPECIES", 46, 53], ["The in vivo assay", "TEST", 0, 17], ["ligated intestinal loop of piglets", "TREATMENT", 19, 53], ["enterotoxic activity", "PROBLEM", 89, 109], ["penetration of bacteria through the intestinal wall", "PROBLEM", 114, 165], ["intestinal loop", "ANATOMY", 27, 42], ["enterotoxic activity", "OBSERVATION", 89, 109], ["intestinal wall", "ANATOMY", 150, 165]]], ["The results demonstrated the protective effect of all three immuneglobulin classes used, the IgA being the most effective.The Protective E]]ect o] Antibodies toComparison o] the Adjuvant E]/ect ~ Lipopolysaccharide with its Toxicity and Chemical Structure.", [["immuneglobulin", "CHEMICAL", 60, 74], ["Lipopolysaccharide", "CHEMICAL", 196, 214], ["Toxicity", "DISEASE", 224, 232], ["immuneglobulin", "CHEMICAL", 60, 74], ["immuneglobulin", "SIMPLE_CHEMICAL", 60, 74], ["IgA", "GENE_OR_GENE_PRODUCT", 93, 96], ["Lipopolysaccharide", "SIMPLE_CHEMICAL", 196, 214], ["IgA", "PROTEIN", 93, 96], ["all three immuneglobulin classes", "TREATMENT", 50, 82], ["the IgA", "TREATMENT", 89, 96], ["the Adjuvant E", "TREATMENT", 174, 188], ["ect", "TREATMENT", 190, 193], ["Lipopolysaccharide", "TREATMENT", 196, 214], ["its Toxicity", "PROBLEM", 220, 232], ["most effective", "OBSERVATION_MODIFIER", 107, 121], ["Chemical Structure", "OBSERVATION", 237, 255]]], ["J. HOFMAN, B. lovk, V. DLAB_~, Department of Immunology, Institute of Microbiology, Czechoslovak Academy of Science~, Prague.The Protective E]]ect o] Antibodies toLipopolysaccharide of Salmonella typhimurium LT2 increases significantly both the primary and secondary antibody response if administered together with a low molecular haptene bound to a protein carrier ARS-BGG into inbred mice which do not responde to the antigen alone.", [["Salmonella typhimurium", "ORGANISM", 185, 207], ["LT2", "ORGANISM", 208, 211], ["mice", "ORGANISM", 386, 390], ["protein carrier ARS-BGG", "DNA", 350, 373], ["Salmonella typhimurium LT2", "SPECIES", 185, 211], ["mice", "SPECIES", 386, 390], ["Salmonella typhimurium", "SPECIES", 185, 207], ["LT2", "SPECIES", 208, 211], ["mice", "SPECIES", 386, 390], ["The Protective E", "TEST", 125, 141], ["ect o", "TEST", 143, 148], ["Antibodies", "TEST", 150, 160], ["Salmonella typhimurium LT2", "PROBLEM", 185, 211], ["a low molecular haptene bound", "PROBLEM", 315, 344], ["a protein carrier ARS", "PROBLEM", 348, 369]]], ["The enhancement involves both 7S and 19S antibodies.", [["7S", "GENE_OR_GENE_PRODUCT", 30, 32], ["19S antibodies", "GENE_OR_GENE_PRODUCT", 37, 51], ["7S and 19S antibodies", "PROTEIN", 30, 51], ["enhancement", "OBSERVATION_MODIFIER", 4, 15], ["both", "ANATOMY_MODIFIER", 25, 29], ["7S", "ANATOMY", 30, 32], ["19S antibodies", "OBSERVATION", 37, 51]]], ["Mild alcali hydrolysis, which splits esterifically and amidically bound fatty acids in the lipidic portion, lowers the toxicity and adjuvant capacity of lipopolysacehaxide.", [["fatty acids", "CHEMICAL", 72, 83], ["toxicity", "DISEASE", 119, 127], ["lipopolysacehaxide", "CHEMICAL", 153, 171], ["fatty acids", "CHEMICAL", 72, 83], ["lipopolysacehaxide", "CHEMICAL", 153, 171], ["alcali", "SIMPLE_CHEMICAL", 5, 11], ["fatty acids", "SIMPLE_CHEMICAL", 72, 83], ["lipopolysacehaxide", "SIMPLE_CHEMICAL", 153, 171], ["Mild alcali hydrolysis", "PROBLEM", 0, 22], ["amidically bound fatty acids in the lipidic portion", "PROBLEM", 55, 106], ["the toxicity", "PROBLEM", 115, 127], ["adjuvant capacity of lipopolysacehaxide", "TREATMENT", 132, 171], ["alcali hydrolysis", "OBSERVATION", 5, 22], ["fatty acids", "OBSERVATION", 72, 83], ["lipidic portion", "ANATOMY_MODIFIER", 91, 106], ["toxicity", "OBSERVATION_MODIFIER", 119, 127], ["capacity", "OBSERVATION_MODIFIER", 141, 149]]], ["Therefore it seems that there is certain relationship between the adjuvant effect and certain other biological activities of the lipopolysaccharide, which axe bound to the lipid portion of the molecule.Puri]ication o] Interteron.", [["lipopolysaccharide", "CHEMICAL", 129, 147], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 129, 147], ["the adjuvant effect", "TREATMENT", 62, 81], ["the lipopolysaccharide", "TREATMENT", 125, 147], ["Interteron", "TREATMENT", 218, 228], ["molecule", "ANATOMY", 193, 201]]], ["N. FUCIISBERGER, V.HAJNICKk, L. BORECK'2, Institute of Virology, Slovak Academy of Sciences, Bratislava.Puri]ication o] Interteron.", [["Interteron", "TREATMENT", 120, 130]]], ["N. FUCIISBERGER, V.The disadvantage of purification procedures of interferon published so far is that in the process of purification great losses of interferon activity take place.", [["interferon", "GENE_OR_GENE_PRODUCT", 149, 159], ["interferon", "PROTEIN", 66, 76], ["interferon", "PROTEIN", 149, 159], ["purification procedures", "TREATMENT", 39, 62], ["interferon", "TREATMENT", 66, 76], ["interferon activity", "TREATMENT", 149, 168], ["interferon activity", "OBSERVATION", 149, 168]]], ["We therefore modified the purification procedure in order to obtain a sufficient amount of highly purified material for its further testing.", [["the purification procedure", "TREATMENT", 22, 48], ["its further testing", "TEST", 120, 139]]], ["We concentrated on a fast and effective concentration of the preparation obtained from mouse L-cells, and, furthermore, on the possible shortening of a time .period, at which the material is exposed to possible inactivation.", [["L-cells", "ANATOMY", 93, 100], ["mouse", "ORGANISM", 87, 92], ["L-cells", "CELL", 93, 100], ["mouse L-cells", "CELL_LINE", 87, 100], ["mouse", "SPECIES", 87, 92], ["mouse", "SPECIES", 87, 92], ["inactivation", "PROBLEM", 211, 223], ["possible", "UNCERTAINTY", 202, 210], ["inactivation", "OBSERVATION", 211, 223]]], ["The procedure includes formation of interferon in a minimal amount of serumfree medium, precipitation with zinc acetate, dialysis, centrifugation in a ionexchanger, pressure dialysis and electrophoresis in polyacrylamide gel.", [["zinc acetate", "CHEMICAL", 107, 119], ["zinc acetate", "CHEMICAL", 107, 119], ["polyacrylamide", "CHEMICAL", 206, 220], ["interferon", "GENE_OR_GENE_PRODUCT", 36, 46], ["zinc acetate", "SIMPLE_CHEMICAL", 107, 119], ["interferon", "PROTEIN", 36, 46], ["The procedure", "TREATMENT", 0, 13], ["interferon", "TREATMENT", 36, 46], ["a minimal amount of serumfree medium", "TREATMENT", 50, 86], ["zinc acetate", "TREATMENT", 107, 119], ["dialysis", "TREATMENT", 121, 129], ["centrifugation", "TREATMENT", 131, 145], ["a ionexchanger, pressure dialysis", "TREATMENT", 149, 182], ["electrophoresis in polyacrylamide gel", "TREATMENT", 187, 224], ["interferon", "OBSERVATION", 36, 46]]], ["Using this procedure, no addition of stabilizing protein to the interferon preparation was needed.", [["interferon", "PROTEIN", 64, 74], ["this procedure", "TREATMENT", 6, 20], ["stabilizing protein", "TREATMENT", 37, 56], ["the interferon preparation", "TREATMENT", 60, 86]]], ["Thus we obtained in one purification 2 \u2022 l0 s unit.s of highly purified mouse interferon with a specific activity of > 108 units/rag of protein, which permits further testing of its properties.", [["mouse", "ORGANISM", 72, 77], ["interferon", "GENE_OR_GENE_PRODUCT", 78, 88], ["highly purified mouse interferon", "PROTEIN", 56, 88], ["mouse", "SPECIES", 72, 77], ["mouse", "SPECIES", 72, 77], ["highly purified mouse interferon", "TREATMENT", 56, 88], ["further testing", "TEST", 159, 174]]], ["Using the model of peritoneal cells, the authors studied the onset of hyporeactivity after intravenous, subcutaneous and oral administration of lipopolysaccharide.", [["peritoneal cells", "ANATOMY", 19, 35], ["intravenous", "ANATOMY", 91, 102], ["subcutaneous", "ANATOMY", 104, 116], ["oral", "ANATOMY", 121, 125], ["hyporeactivity", "DISEASE", 70, 84], ["lipopolysaccharide", "CHEMICAL", 144, 162], ["peritoneal cells", "CELL", 19, 35], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 91, 102], ["oral", "ORGANISM_SUBDIVISION", 121, 125], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 144, 162], ["peritoneal cells", "CELL_TYPE", 19, 35], ["peritoneal cells", "TREATMENT", 19, 35], ["hyporeactivity", "PROBLEM", 70, 84], ["intravenous", "TREATMENT", 91, 102], ["subcutaneous", "TREATMENT", 104, 116], ["oral administration of lipopolysaccharide", "TREATMENT", 121, 162], ["peritoneal cells", "ANATOMY", 19, 35], ["hyporeactivity", "OBSERVATION", 70, 84]]], ["We took advantage of the fact that cells of the peritoneal cavity play a central role in the production of interferon in the organism after the endotoxin stimulus, and that the stimulation of interferon formation occurs shortly after the intravenous, subcutaneous or oral administration.", [["cells", "ANATOMY", 35, 40], ["peritoneal cavity", "ANATOMY", 48, 65], ["intravenous", "ANATOMY", 238, 249], ["subcutaneous", "ANATOMY", 251, 263], ["oral", "ANATOMY", 267, 271], ["cells", "CELL", 35, 40], ["peritoneal cavity", "MULTI-TISSUE_STRUCTURE", 48, 65], ["interferon", "GENE_OR_GENE_PRODUCT", 107, 117], ["interferon", "GENE_OR_GENE_PRODUCT", 192, 202], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 238, 249], ["oral", "ORGANISM_SUBDIVISION", 267, 271], ["interferon", "PROTEIN", 107, 117], ["interferon", "PROTEIN", 192, 202], ["the peritoneal cavity", "TREATMENT", 44, 65], ["interferon", "TREATMENT", 107, 117], ["the endotoxin stimulus", "TEST", 140, 162], ["the stimulation of interferon formation", "TREATMENT", 173, 212], ["the intravenous", "TREATMENT", 234, 249], ["oral administration", "TREATMENT", 267, 286], ["peritoneal", "ANATOMY", 48, 58], ["cavity", "OBSERVATION", 59, 65], ["central", "OBSERVATION_MODIFIER", 73, 80], ["interferon", "OBSERVATION", 107, 117]]], ["Liberation of interferon or an attempt to restimulate peritoneal cells was performed after their explanation in vitro.", [["peritoneal cells", "ANATOMY", 54, 70], ["interferon", "GENE_OR_GENE_PRODUCT", 14, 24], ["peritoneal cells", "CELL", 54, 70], ["interferon", "PROTEIN", 14, 24], ["peritoneal cells", "CELL_TYPE", 54, 70], ["interferon", "TREATMENT", 14, 24], ["peritoneal cells", "TREATMENT", 54, 70], ["interferon", "OBSERVATION", 14, 24], ["peritoneal", "ANATOMY", 54, 64]]], ["We found that: (1) Peritoneal ceils became hyporeactive already within 30--60 mira after intravenous administration of lipopolysaccharide, i.e. at time, when the serum interferon level has not reached the maximum;Studies on Hyporcaetivity o/ Mouse Peritoneal GsUs to the lnter]eron.inducing Gapacity o]I, ipopolysaccharide ]ram(2) after the subcutaneous administration of lipopolysaccharide, the hyporeactivity stadium was preceded by a phase of enhanced reactivity (30 to 60 min after administration); (3) oral administration of 1,000 ~tg of lipopolysaccharide stimulated the formation of interferon in peritoneal cells, however, did not induce the hyporeactivity state.", [["Peritoneal ceils", "ANATOMY", 19, 35], ["intravenous", "ANATOMY", 89, 100], ["serum", "ANATOMY", 162, 167], ["subcutaneous", "ANATOMY", 341, 353], ["oral", "ANATOMY", 507, 511], ["peritoneal cells", "ANATOMY", 604, 620], ["lipopolysaccharide", "CHEMICAL", 119, 137], ["lipopolysaccharide", "CHEMICAL", 372, 390], ["lipopolysaccharide", "CHEMICAL", 543, 561], ["Peritoneal ceils", "CELL", 19, 35], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 89, 100], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 119, 137], ["serum", "ORGANISM_SUBSTANCE", 162, 167], ["interferon", "GENE_OR_GENE_PRODUCT", 168, 178], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 372, 390], ["oral", "ORGANISM_SUBDIVISION", 507, 511], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 543, 561], ["interferon", "GENE_OR_GENE_PRODUCT", 590, 600], ["peritoneal cells", "CELL", 604, 620], ["serum interferon", "PROTEIN", 162, 178], ["interferon", "PROTEIN", 590, 600], ["peritoneal cells", "CELL_TYPE", 604, 620], ["Mouse", "SPECIES", 242, 247], ["Peritoneal ceils", "TEST", 19, 35], ["hyporeactive", "PROBLEM", 43, 55], ["lipopolysaccharide", "TREATMENT", 119, 137], ["the serum interferon level", "TEST", 158, 184], ["Studies", "TEST", 213, 220], ["Hyporcaetivity", "TEST", 224, 238], ["the subcutaneous administration of lipopolysaccharide", "TREATMENT", 337, 390], ["the hyporeactivity stadium", "PROBLEM", 392, 418], ["oral administration", "TREATMENT", 507, 526], ["lipopolysaccharide", "TREATMENT", 543, 561], ["interferon in peritoneal cells", "TREATMENT", 590, 620], ["the hyporeactivity state", "PROBLEM", 646, 670], ["Peritoneal", "ANATOMY", 19, 29], ["Peritoneal", "ANATOMY", 248, 258], ["peritoneal cells", "ANATOMY", 604, 620], ["hyporeactivity", "OBSERVATION", 650, 664]]], ["These results support the author's view, that interferon released in the organism of mice by endotoxin, is originated from presensitised peritoneal leukoeytes.", [["peritoneal leukoeytes", "ANATOMY", 137, 158], ["endotoxin", "CHEMICAL", 93, 102], ["interferon", "GENE_OR_GENE_PRODUCT", 46, 56], ["mice", "ORGANISM", 85, 89], ["endotoxin", "GENE_OR_GENE_PRODUCT", 93, 102], ["peritoneal leukoeytes", "MULTI-TISSUE_STRUCTURE", 137, 158], ["interferon", "PROTEIN", 46, 56], ["mice", "SPECIES", 85, 89], ["mice", "SPECIES", 85, 89], ["interferon", "TREATMENT", 46, 56], ["presensitised peritoneal leukoeytes", "PROBLEM", 123, 158], ["peritoneal", "ANATOMY", 137, 147]]], ["This reaction was found in lymphoeytes of all animal species tested, i.e. rabbit, mouse, man and it possessed characteristics of non-specific stimulation, comparable to the response of lymphocytes to PHA.", [["lymphoeytes", "ANATOMY", 27, 38], ["lymphocytes", "ANATOMY", 185, 196], ["PHA", "CHEMICAL", 200, 203], ["PHA", "CHEMICAL", 200, 203], ["lymphoeytes", "CANCER", 27, 38], ["rabbit", "ORGANISM", 74, 80], ["mouse", "ORGANISM", 82, 87], ["man", "ORGANISM", 89, 92], ["lymphocytes", "CELL", 185, 196], ["PHA", "SIMPLE_CHEMICAL", 200, 203], ["lymphocytes", "CELL_TYPE", 185, 196], ["PHA", "PROTEIN", 200, 203], ["rabbit", "SPECIES", 74, 80], ["mouse", "SPECIES", 82, 87], ["man", "SPECIES", 89, 92], ["rabbit", "SPECIES", 74, 80], ["mouse", "SPECIES", 82, 87], ["This reaction", "PROBLEM", 0, 13], ["non-specific stimulation", "PROBLEM", 129, 153], ["lymphocytes to PHA", "PROBLEM", 185, 203], ["non-specific stimulation", "OBSERVATION", 129, 153], ["lymphocytes", "OBSERVATION", 185, 196]]], ["The mitogenic effect of ET, depending on the dose used, can be inhibited specifically in viw by an induced pyrogenic tolerance to a given ET type; cross tolerance was used as an evidence that the carrier of mitegenic activity as virtually the pyrogenic exotoxin.", [["ET", "SIMPLE_CHEMICAL", 24, 26], ["exotoxin", "GENE_OR_GENE_PRODUCT", 253, 261], ["pyrogenic exotoxin", "PROTEIN", 243, 261], ["an induced pyrogenic tolerance", "PROBLEM", 96, 126], ["ET type", "PROBLEM", 138, 145], ["mitegenic activity", "PROBLEM", 207, 225], ["the pyrogenic exotoxin", "PROBLEM", 239, 261], ["pyrogenic tolerance", "OBSERVATION", 107, 126]]], ["The significance of mitogcnie activity of ET for the pathogenicity of streptococcal infections is discussed.", [["streptococcal infections", "DISEASE", 70, 94], ["mitogcnie", "GENE_OR_GENE_PRODUCT", 20, 29], ["streptococcal infections", "PROBLEM", 70, 94], ["mitogcnie activity", "OBSERVATION", 20, 38], ["streptococcal", "OBSERVATION_MODIFIER", 70, 83], ["infections", "OBSERVATION", 84, 94]]], ["Antibodies were detected on the basis of decrease in immunoglobulin IgG, IgM and IgA levels after absorption with purified O, Vi and H antigens.", [["immunoglobulin IgG", "GENE_OR_GENE_PRODUCT", 53, 71], ["IgM", "GENE_OR_GENE_PRODUCT", 73, 76], ["IgA", "GENE_OR_GENE_PRODUCT", 81, 84], ["H antigens", "GENE_OR_GENE_PRODUCT", 133, 143], ["immunoglobulin IgG", "PROTEIN", 53, 71], ["IgM", "PROTEIN", 73, 76], ["IgA", "PROTEIN", 81, 84], ["O, Vi and H antigens", "PROTEIN", 123, 143], ["Antibodies", "TEST", 0, 10], ["immunoglobulin IgG", "TEST", 53, 71], ["IgM", "TEST", 73, 76], ["IgA levels", "TEST", 81, 91], ["decrease", "OBSERVATION_MODIFIER", 41, 49]]], ["The method according to Nash and Heremans was employed.", [["The method", "TREATMENT", 0, 10], ["Nash", "OBSERVATION", 24, 28]]], ["The immunoglobulln levels were determined using the IDP Sevac kit.", [["immunoglobulln", "GENE_OR_GENE_PRODUCT", 4, 18], ["The immunoglobulln levels", "TEST", 0, 25]]], ["The results showed a significant decrease of IgA in sera of typhoid carriers and of IgM in sera of typhoid patients and reconvalescents.", [["sera", "ANATOMY", 52, 56], ["sera", "ANATOMY", 91, 95], ["typhoid", "DISEASE", 60, 67], ["typhoid", "DISEASE", 99, 106], ["IgA", "GENE_OR_GENE_PRODUCT", 45, 48], ["sera", "ORGANISM_SUBSTANCE", 52, 56], ["IgM", "GENE_OR_GENE_PRODUCT", 84, 87], ["sera", "ORGANISM_SUBSTANCE", 91, 95], ["patients", "ORGANISM", 107, 115], ["IgA", "PROTEIN", 45, 48], ["IgM", "PROTEIN", 84, 87], ["patients", "SPECIES", 107, 115], ["a significant decrease of IgA", "PROBLEM", 19, 48], ["typhoid carriers", "PROBLEM", 60, 76], ["IgM", "TEST", 84, 87], ["typhoid patients", "TREATMENT", 99, 115], ["significant", "OBSERVATION_MODIFIER", 21, 32], ["decrease", "OBSERVATION_MODIFIER", 33, 41]]], ["The amount of Absorbed IgA antibodies from sera of carriers was 1.5 times higher as compared with individuals with positive typhoid anamnesis but without a carrier state.", [["sera", "ANATOMY", 43, 47], ["typhoid anamnesis", "DISEASE", 124, 141], ["IgA antibodies", "GENE_OR_GENE_PRODUCT", 23, 37], ["sera", "ORGANISM_SUBSTANCE", 43, 47], ["Absorbed IgA antibodies", "PROTEIN", 14, 37], ["Absorbed IgA antibodies", "TEST", 14, 37], ["sera of carriers", "TEST", 43, 59], ["positive typhoid anamnesis", "PROBLEM", 115, 141], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["Absorbed", "OBSERVATION_MODIFIER", 14, 22], ["IgA antibodies", "OBSERVATION", 23, 37]]], ["In sera of typhoid patients and reconvalescents, the IgM antibodies level was 1.5 times higher than in sera of carriers.", [["sera", "ANATOMY", 3, 7], ["sera", "ANATOMY", 103, 107], ["typhoid", "DISEASE", 11, 18], ["sera", "ORGANISM_SUBSTANCE", 3, 7], ["patients", "ORGANISM", 19, 27], ["IgM antibodies", "GENE_OR_GENE_PRODUCT", 53, 67], ["sera", "ORGANISM_SUBSTANCE", 103, 107], ["IgM antibodies", "PROTEIN", 53, 67], ["patients", "SPECIES", 19, 27], ["reconvalescents", "TEST", 32, 47], ["the IgM antibodies level", "TEST", 49, 73]]], ["No major changes were observed in the IgG levels.", [["IgG", "GENE_OR_GENE_PRODUCT", 38, 41], ["IgG", "PROTEIN", 38, 41], ["major changes", "PROBLEM", 3, 16], ["the IgG levels", "TEST", 34, 48], ["major", "OBSERVATION_MODIFIER", 3, 8], ["changes", "OBSERVATION", 9, 16]]], ["These results were confronted with the specific bactericidal activity of corresponding sera.", [["sera", "ANATOMY", 87, 91], ["sera", "ORGANISM_SUBSTANCE", 87, 91]]], ["Lipopolysaccharide antigens of four strains of NAG vihrios isolated from patients suffering from diarrhoea, and of two strains from surface water were analysed.", [["Lipopolysaccharide", "CHEMICAL", 0, 18], ["diarrhoea", "DISEASE", 97, 106], ["Lipopolysaccharide antigens", "GENE_OR_GENE_PRODUCT", 0, 27], ["NAG vihrios", "ORGANISM", 47, 58], ["patients", "ORGANISM", 73, 81], ["Lipopolysaccharide antigens", "PROTEIN", 0, 27], ["patients", "SPECIES", 73, 81], ["Lipopolysaccharide antigens", "TEST", 0, 27], ["NAG vihrios", "TREATMENT", 47, 58], ["diarrhoea", "PROBLEM", 97, 106], ["four strains", "OBSERVATION_MODIFIER", 31, 43]]], ["The purified antigens formed with homologous rabbit antisera 1--3 precipitin lines.", [["rabbit", "ORGANISM", 45, 51], ["purified antigens", "PROTEIN", 4, 21], ["rabbit", "SPECIES", 45, 51], ["rabbit", "SPECIES", 45, 51], ["homologous rabbit antisera", "TREATMENT", 34, 60]]], ["The immunoelectrophoretic patterns of these antigens differed mutually and also differred from patterns which arc typical for lipopolysaccharides of S-forms of Escherichia cell and Salmonella.", [["Escherichia cell", "ANATOMY", 160, 176], ["Escherichia cell", "CELL", 160, 176], ["Salmonella", "CELL", 181, 191], ["lipopolysaccharides", "PROBLEM", 126, 145], ["Escherichia cell", "PROBLEM", 160, 176], ["Salmonella", "PROBLEM", 181, 191], ["Escherichia cell", "OBSERVATION", 160, 176], ["Salmonella", "OBSERVATION_MODIFIER", 181, 191]]], ["The mild alcali hydrolysis of purified lipopolysaccharides altered their antigenic properties.", [["alcali", "SIMPLE_CHEMICAL", 9, 15], ["lipopolysaccharides", "SIMPLE_CHEMICAL", 39, 58], ["The mild alcali hydrolysis", "PROBLEM", 0, 26], ["purified lipopolysaccharides", "PROBLEM", 30, 58], ["mild", "OBSERVATION_MODIFIER", 4, 8], ["alcali hydrolysis", "OBSERVATION", 9, 26], ["lipopolysaccharides", "OBSERVATION_MODIFIER", 39, 58], ["antigenic properties", "OBSERVATION", 73, 93]]], ["According to altered reactions in gel, the lipopolysaceharides could be divided into three types: (a) antigens, in which determinant groups were inactivated by the mild alcali hydrolysis and therefore did not react with homologous antisera; (b) antigens, in which only certain determinant groups were inactivated and therefore yielded semiidentieal reactions with homologous antisera or formed new prccipitin lines; (e) antigens, gaining new determinants after mild alcali hydrolysis which react with homologous antisera. ~he mild alcali hydrolysis modified such antigenic determinants, in which the structure was based on 0-acetyl group and monosaccharides, bound by a alcali-labile bond.", [["alcali", "CHEMICAL", 169, 175], ["alcali", "CHEMICAL", 466, 472], ["alcali", "CHEMICAL", 531, 537], ["0-acetyl", "CHEMICAL", 623, 631], ["monosaccharides", "CHEMICAL", 642, 657], ["lipopolysaceharides", "CHEMICAL", 43, 62], ["alcali", "CHEMICAL", 531, 537], ["0-acetyl", "CHEMICAL", 623, 631], ["monosaccharides", "CHEMICAL", 642, 657], ["lipopolysaceharides", "SIMPLE_CHEMICAL", 43, 62], ["alcali", "SIMPLE_CHEMICAL", 169, 175], ["prccipitin lines", "CELL", 398, 414], ["alcali", "SIMPLE_CHEMICAL", 466, 472], ["alcali", "SIMPLE_CHEMICAL", 531, 537], ["0-acetyl group", "SIMPLE_CHEMICAL", 623, 637], ["monosaccharides", "SIMPLE_CHEMICAL", 642, 657], ["antigens", "PROTEIN", 102, 110], ["homologous antisera; (b) antigens", "PROTEIN", 220, 253], ["prccipitin lines", "CELL_LINE", 398, 414], ["antigens", "PROTEIN", 420, 428], ["altered reactions in gel", "PROBLEM", 13, 37], ["the mild alcali hydrolysis", "PROBLEM", 160, 186], ["homologous antisera", "TEST", 220, 239], ["semiidentieal reactions", "PROBLEM", 335, 358], ["homologous antisera", "TREATMENT", 364, 383], ["new prccipitin lines", "PROBLEM", 394, 414], ["mild alcali hydrolysis", "PROBLEM", 461, 483], ["homologous antisera", "TREATMENT", 501, 520], ["mild alcali hydrolysis", "PROBLEM", 526, 548], ["0-acetyl group and monosaccharides", "TREATMENT", 623, 657], ["mild", "OBSERVATION_MODIFIER", 164, 168], ["alcali hydrolysis", "OBSERVATION", 169, 186], ["new", "OBSERVATION_MODIFIER", 394, 397], ["prccipitin lines", "OBSERVATION", 398, 414], ["mild", "OBSERVATION_MODIFIER", 461, 465], ["alcali hydrolysis", "OBSERVATION", 466, 483], ["mild", "OBSERVATION_MODIFIER", 526, 530], ["alcali hydrolysis", "OBSERVATION", 531, 548]]], ["The causative agent of Q-fever, Coxiel~ burneti, is a gram-labile rickettsia.", [["Q-fever", "DISEASE", 23, 30], ["Coxiel~ burneti", "DISEASE", 32, 47], ["rickettsia", "DISEASE", 66, 76], ["Q-fever", "ORGANISM", 23, 30], ["Coxiel~ burneti", "ORGANISM", 32, 47], ["Q-fever", "SPECIES", 23, 30], ["Coxiel~ burneti", "SPECIES", 32, 47], ["Q-fever", "SPECIES", 23, 30], ["Coxiel~ burneti", "SPECIES", 32, 47], ["fever", "PROBLEM", 25, 30], ["a gram", "TEST", 52, 58], ["labile rickettsia", "PROBLEM", 59, 76], ["labile", "OBSERVATION_MODIFIER", 59, 65], ["rickettsia", "OBSERVATION", 66, 76]]], ["Using the methods for isolation of lipopolysaeeharide of gram-negative bacteria, we isolated from purified suSpensions of phase I a soluble antigen, possessing the serologic activity of antigen of phase I and immunogenie activity of antigens of phase II and III.", [["lipopolysaeeharide", "CHEMICAL", 35, 53], ["lipopolysaeeharide", "SIMPLE_CHEMICAL", 35, 53], ["phase I", "PROTEIN", 122, 129], ["soluble antigen", "PROTEIN", 132, 147], ["antigens", "PROTEIN", 233, 241], ["phase II and III", "PROTEIN", 245, 261], ["the methods", "TEST", 6, 17], ["gram-negative bacteria", "PROBLEM", 57, 79], ["a soluble antigen", "TEST", 130, 147], ["negative bacteria", "OBSERVATION", 62, 79]]], ["The chemical analysis of isolated antigens showed that these are lipopolysaceharideprotein complexes with various proportion of these components, depending on the isolation method used.", [["lipopolysaceharideprotein", "CHEMICAL", 65, 90], ["lipopolysaceharideprotein", "GENE_OR_GENE_PRODUCT", 65, 90], ["lipopolysaceharideprotein complexes", "PROTEIN", 65, 100], ["The chemical analysis", "TEST", 0, 21], ["isolated antigens", "TEST", 25, 42], ["lipopolysaceharideprotein complexes", "PROBLEM", 65, 100], ["the isolation method", "TREATMENT", 159, 179], ["components", "OBSERVATION_MODIFIER", 134, 144]]], ["The method of isolation (extraction with trichloroacetic acid or phenol), purification, chemical composition, physieo-ehemical properties (thermostability, sedimentation) and biological properties (toxicity, pyrogenicity) showed that isolated soluble antigen of Coxlella burneti of phase I has typical properties of endotoxic lipopolysaceharide of gram-negative bacteria.Endotoxic Lipopolysaecharide o[Chemovaccine Against Q-t:ever.", [["trichloroacetic acid", "CHEMICAL", 41, 61], ["phenol", "CHEMICAL", 65, 71], ["toxicity", "DISEASE", 198, 206], ["lipopolysaceharide", "CHEMICAL", 326, 344], ["trichloroacetic acid", "CHEMICAL", 41, 61], ["phenol", "CHEMICAL", 65, 71], ["lipopolysaceharide", "CHEMICAL", 326, 344], ["trichloroacetic acid", "SIMPLE_CHEMICAL", 41, 61], ["phenol", "SIMPLE_CHEMICAL", 65, 71], ["Coxlella burneti", "ORGANISM", 262, 278], ["lipopolysaceharide", "SIMPLE_CHEMICAL", 326, 344], ["Coxlella burneti", "SPECIES", 262, 278], ["Coxlella burneti", "SPECIES", 262, 278], ["isolation (extraction", "TREATMENT", 14, 35], ["trichloroacetic acid", "TREATMENT", 41, 61], ["phenol)", "TREATMENT", 65, 72], ["purification", "TREATMENT", 74, 86], ["chemical composition", "TEST", 88, 108], ["endotoxic lipopolysaceharide of gram-negative bacteria", "PROBLEM", 316, 370], ["Endotoxic Lipopolysaecharide", "TREATMENT", 371, 399], ["endotoxic lipopolysaceharide", "OBSERVATION", 316, 344], ["negative bacteria", "OBSERVATION", 353, 370]]], ["R. B~EZnCA, ~.", [["EZnCA", "GENE_OR_GENE_PRODUCT", 5, 10], ["B", "ANATOMY", 3, 4], ["~EZnCA", "OBSERVATION", 4, 10]]], ["SCHRAMEK, J. KAZXR, J. URV6LOu Institute of Virology, Slovak Academy of Sciences, Bratislava.Endotoxic Lipopolysaecharide o[The protective antigen, obtained by extraction with trichloroacetic acid from a highly purified suspension of phase I Coxiella burneti, represents a new type of vaccine against Q-fever in men.", [["trichloroacetic acid", "CHEMICAL", 176, 196], ["Q-fever", "DISEASE", 301, 308], ["trichloroacetic acid", "CHEMICAL", 176, 196], ["trichloroacetic acid", "SIMPLE_CHEMICAL", 176, 196], ["Coxiella burneti", "ORGANISM", 242, 258], ["men", "ORGANISM", 312, 315], ["Coxiella burneti", "SPECIES", 242, 258], ["men", "SPECIES", 312, 315], ["Coxiella burneti", "SPECIES", 242, 258], ["Endotoxic Lipopolysaecharide", "TREATMENT", 93, 121], ["The protective antigen", "TREATMENT", 124, 146], ["trichloroacetic acid", "TREATMENT", 176, 196], ["phase I Coxiella burneti", "PROBLEM", 234, 258], ["a new type of vaccine", "TREATMENT", 271, 292], ["fever", "PROBLEM", 303, 308]]], ["The immunogenicity of the vaccine was tested in laboratory animals and in group of 46 laboratory workers, potentially exposed to infection during laboratory work.", [["infection", "DISEASE", 129, 138], ["the vaccine", "TREATMENT", 22, 33], ["infection", "PROBLEM", 129, 138], ["infection", "OBSERVATION", 129, 138]]], ["23 individuals were vaccinated with a single dose, another 23 people received 2 doses of the vaccine.", [["individuals", "ORGANISM", 3, 14], ["people", "ORGANISM", 62, 68], ["people", "SPECIES", 62, 68], ["the vaccine", "TREATMENT", 89, 100]]], ["The serological conversion was found in 23 persons with a single vaccination and in 21 with double vaccination.", [["persons", "ORGANISM", 43, 50], ["persons", "SPECIES", 43, 50], ["a single vaccination", "TREATMENT", 56, 76], ["double vaccination", "TREATMENT", 92, 110]]], ["Antibodies against phase I (alone or together with antibodies to phase II) were formed in 16 persons belonging to the first group; antibodies to phase II only were found in 11 individuals.", [["Antibodies against phase I", "GENE_OR_GENE_PRODUCT", 0, 26], ["persons", "ORGANISM", 93, 100], ["phase I", "PROTEIN", 19, 26], ["antibodies", "PROTEIN", 51, 61], ["phase II", "PROTEIN", 65, 73], ["antibodies", "PROTEIN", 131, 141], ["persons", "SPECIES", 93, 100], ["Antibodies", "TEST", 0, 10], ["antibodies to phase II", "TEST", 131, 153]]], ["After two doses of the vaccine, phase I antibodies (alone or together with phase II antibodies) were found in 19 vaccinated and in 2 persons antibodies only to phase II occurred.", [["phase I antibodies", "GENE_OR_GENE_PRODUCT", 32, 50], ["phase II antibodies", "GENE_OR_GENE_PRODUCT", 75, 94], ["persons", "ORGANISM", 133, 140], ["phase I antibodies", "PROTEIN", 32, 50], ["phase II antibodies", "PROTEIN", 75, 94], ["persons", "SPECIES", 133, 140], ["the vaccine", "TREATMENT", 19, 30], ["phase I antibodies", "TEST", 32, 50], ["phase II antibodies", "TEST", 75, 94]]], ["No one of vaccinated persons, exposed daily to infection during work, contracted a clinically manifest Q-fever.", [["infection", "DISEASE", 47, 56], ["Q-fever", "DISEASE", 103, 110], ["persons", "ORGANISM", 21, 28], ["persons", "SPECIES", 21, 28], ["infection", "PROBLEM", 47, 56], ["fever", "PROBLEM", 105, 110], ["infection", "OBSERVATION", 47, 56]]], ["Listeria complex Ei was used for sensitization of experimental animals and for liberation of mediatots of cell-mediated hypersensitivity.", [["cell", "ANATOMY", 106, 110], ["hypersensitivity", "DISEASE", 120, 136], ["cell", "CELL", 106, 110], ["Listeria complex Ei", "PROTEIN", 0, 19], ["Listeria complex Ei", "PROBLEM", 0, 19], ["experimental animals", "PROBLEM", 50, 70], ["cell-mediated hypersensitivity", "PROBLEM", 106, 136], ["hypersensitivity", "OBSERVATION", 120, 136]]], ["For evaluation of the cell-mediated hypersensitivity and immunity, method of a direct inhibition of cells of the macrophage type was employed.", [["cell", "ANATOMY", 22, 26], ["cells", "ANATOMY", 100, 105], ["macrophage", "ANATOMY", 113, 123], ["hypersensitivity", "DISEASE", 36, 52], ["cell", "CELL", 22, 26], ["cells", "CELL", 100, 105], ["macrophage type", "CELL", 113, 128], ["evaluation", "TEST", 4, 14], ["the cell-mediated hypersensitivity", "PROBLEM", 18, 52], ["a direct inhibition of cells of the macrophage type", "TREATMENT", 77, 128]]], ["Groups of rabbits were sensitised with factor Ei in incomplete Freund' adjuvant (20 mg in divided doses into fore and hind foot pads).", [["hind foot pads", "ANATOMY", 118, 132], ["rabbits", "ORGANISM", 10, 17], ["hind foot", "ORGANISM_SUBDIVISION", 118, 127], ["pads", "ORGANISM_SUBDIVISION", 128, 132], ["factor Ei", "PROTEIN", 39, 48], ["rabbits", "SPECIES", 10, 17], ["rabbits", "SPECIES", 10, 17], ["factor Ei", "TREATMENT", 39, 48], ["incomplete Freund' adjuvant", "TREATMENT", 52, 79], ["hind foot", "ANATOMY", 118, 127]]], ["Spleens were removed 4--5 weeks after immunization.", [["Spleens", "ANATOMY", 0, 7], ["Spleens", "ORGAN", 0, 7], ["immunization", "TREATMENT", 38, 50]]], ["Complex Ei was added to the tissue culture medium in various amounts.", [["tissue", "ANATOMY", 28, 34], ["tissue", "TISSUE", 28, 34], ["Complex Ei", "PROTEIN", 0, 10], ["the tissue culture", "TEST", 24, 42], ["tissue", "ANATOMY", 28, 34]]], ["The lymphocytes, present in the spleen fragments, release under the influence of antigen a number of activities; the factor inhibiting macrophage migration was chosen for our study.", [["lymphocytes", "ANATOMY", 4, 15], ["spleen fragments", "ANATOMY", 32, 48], ["macrophage", "ANATOMY", 135, 145], ["lymphocytes", "CELL", 4, 15], ["spleen", "ORGAN", 32, 38], ["macrophage", "CELL", 135, 145], ["lymphocytes", "CELL_TYPE", 4, 15], ["the spleen fragments", "PROBLEM", 28, 48], ["the factor inhibiting macrophage migration", "PROBLEM", 113, 155], ["our study", "TEST", 171, 180], ["lymphocytes", "OBSERVATION", 4, 15], ["spleen", "ANATOMY", 32, 38], ["fragments", "OBSERVATION", 39, 48]]], ["The degree of inhibition of migration was determined by the migration index.", [["inhibition of migration", "PROBLEM", 14, 37], ["the migration index", "TEST", 56, 75], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["inhibition", "OBSERVATION_MODIFIER", 14, 24], ["migration", "OBSERVATION", 28, 37], ["migration index", "OBSERVATION", 60, 75]]], ["After addition of 100 ~tg of Ei/1 ml of medium, the values of inhibition indexes were found to be 0.67, 0.64, 0.67 and after 1 ~g of Ei/1 ml of medium, the values were: 0.80, 0.83, and 0.85.", [["inhibition indexes", "TEST", 62, 80]]], ["The statistical evaluation of the results revealed that values under 0.9 represent inhibition of migration.", [["The statistical evaluation", "TEST", 0, 26], ["migration", "OBSERVATION", 97, 106]]], ["Similar results were obtained in experiments with rabbits, sensitised with Ei complex in complete Freund's adjuvant.", [["rabbits", "ORGANISM", 50, 57], ["Ei complex", "GENE_OR_GENE_PRODUCT", 75, 85], ["Freund", "ORGANISM", 98, 104], ["Ei complex", "PROTEIN", 75, 85], ["rabbits", "SPECIES", 50, 57], ["rabbits", "SPECIES", 50, 57], ["complete Freund's adjuvant", "TREATMENT", 89, 115]]], ["The effect of the Listeria factor Ei can be demonstrated even in the indirect migration test.", [["Listeria factor Ei", "GENE_OR_GENE_PRODUCT", 18, 36], ["Listeria factor Ei", "PROTEIN", 18, 36], ["the Listeria factor Ei", "PROBLEM", 14, 36], ["the indirect migration test", "TEST", 65, 92]]], ["At present, the activity of the medium is being tested, which contains MIF produced by peripheral blood lymphoeytes, influenced by Ei.", [["peripheral blood lymphoeytes", "ANATOMY", 87, 115], ["peripheral blood lymphoeytes", "DISEASE", 87, 115], ["MIF", "GENE_OR_GENE_PRODUCT", 71, 74], ["peripheral blood lymphoeytes", "ORGANISM_SUBSTANCE", 87, 115], ["MIF", "PROTEIN", 71, 74], ["peripheral blood lymphoeytes", "PROBLEM", 87, 115], ["peripheral", "ANATOMY_MODIFIER", 87, 97], ["blood", "ANATOMY", 98, 103]]], ["During bacteriological examination of material from pigs from slaughter houses, we isolated from swollen and highly oedematous submandibular lymphnodes strains of beta haemolytic streptococci of serologic groups C, L, S, U, and further haemolytic strains, which could not be calssified to any of so far known serologic groups A--U.", [["submandibular lymphnodes", "ANATOMY", 127, 151], ["pigs", "ORGANISM", 52, 56], ["submandibular", "ORGAN", 127, 140], ["U", "GENE_OR_GENE_PRODUCT", 221, 222], ["pigs", "SPECIES", 52, 56], ["pigs", "SPECIES", 52, 56], ["bacteriological examination", "TEST", 7, 34], ["swollen", "PROBLEM", 97, 104], ["highly oedematous submandibular lymphnodes strains", "PROBLEM", 109, 159], ["beta haemolytic streptococci of serologic groups C", "PROBLEM", 163, 213], ["further haemolytic strains", "PROBLEM", 228, 254], ["swollen", "OBSERVATION_MODIFIER", 97, 104], ["highly", "OBSERVATION_MODIFIER", 109, 115], ["oedematous", "OBSERVATION_MODIFIER", 116, 126], ["submandibular", "ANATOMY", 127, 140], ["lymphnodes", "OBSERVATION", 141, 151], ["beta haemolytic streptococci", "OBSERVATION", 163, 191], ["haemolytic strains", "OBSERVATION", 236, 254]]], ["Antisera against isolated strains contained antibodies which were active in the homologous system, different from groups A--U.", [["strains", "ANATOMY", 26, 33], ["Antisera", "ORGANISM_SUBSTANCE", 0, 8], ["antibodies", "PROTEIN", 44, 54], ["Antisera", "TREATMENT", 0, 8], ["isolated strains contained antibodies", "PROBLEM", 17, 54], ["active", "OBSERVATION_MODIFIER", 66, 72]]], ["As regards certain biological properties of these strains (particularly the CAMP test), and with respect to their origin, it is necessary to differentiate them from groups B, P, U, E and Str. uberis.", [["B", "GENE_OR_GENE_PRODUCT", 172, 173], ["U", "GENE_OR_GENE_PRODUCT", 178, 179], ["Str. uberis", "ORGANISM", 187, 198], ["Str. uberis", "SPECIES", 187, 198], ["these strains", "PROBLEM", 44, 57], ["the CAMP test", "TEST", 72, 85], ["Str. uberis", "PROBLEM", 187, 198]]], ["For differential diagnosis, following combination of properties is important: splitting of l~a hippurate (--), splitting of aeseulin (--), growth in 4% l~/aC1 (-p).", [["l~a hippurate", "CHEMICAL", 91, 104], ["l~a hippurate", "CHEMICAL", 91, 104], ["aeseulin", "CHEMICAL", 124, 132], ["l~a hippurate", "SIMPLE_CHEMICAL", 91, 104], ["aeseulin", "GENE_OR_GENE_PRODUCT", 124, 132], ["aeseulin", "PROTEIN", 124, 132], ["l~a hippurate", "TREATMENT", 91, 104]]], ["On the basis of immunological antigenic studies we assume that the isolated strains belong into a new, so far not described serological group of haemolytic streptococci.", [["haemolytic streptococci", "DISEASE", 145, 168], ["haemolytic streptococci", "CELL", 145, 168], ["immunological antigenic studies", "TEST", 16, 47], ["the isolated strains", "PROBLEM", 63, 83], ["haemolytic streptococci", "PROBLEM", 145, 168], ["haemolytic streptococci", "OBSERVATION", 145, 168]]], ["We therefore propose to designate this group with the letter \"T\".Some Properties o] Enterococci o/ Human Origin.Z. MATYhw District Hygiene Centre, LuSenee.Some Properties o] Enterococci o/ Human Origin.The results of studies of 256 strains of enterococci isolated within a period of one year from clinical material in the District hygiene Centre-LuSenec, permit to draw following conclusions: For isolation and identification of enteroeocei from clinical material, the use of blood agar (pH 9.6 with 6.5O/o NaC1, supplemented with 40% bile), appears to be the most advantageous.", [["blood", "ANATOMY", 476, 481], ["bile", "ANATOMY", 535, 539], ["NaC1", "CHEMICAL", 507, 511], ["Human", "ORGANISM", 99, 104], ["Human", "ORGANISM", 189, 194], ["blood", "ORGANISM_SUBSTANCE", 476, 481], ["bile", "MULTI-TISSUE_STRUCTURE", 535, 539], ["Human", "SPECIES", 99, 104], ["Human", "SPECIES", 189, 194], ["Enterococci", "PROBLEM", 84, 95], ["Enterococci", "PROBLEM", 174, 185], ["studies", "TEST", 217, 224], ["enterococci", "PROBLEM", 243, 254], ["isolation", "TREATMENT", 397, 406], ["blood agar", "TEST", 476, 486], ["pH", "TEST", 488, 490], ["NaC1", "TEST", 507, 511], ["Enterococci", "OBSERVATION", 84, 95], ["Enterococci", "OBSERVATION", 174, 185], ["Human Origin", "OBSERVATION_MODIFIER", 189, 201], ["enterococci", "OBSERVATION", 243, 254]]], ["For detection of varlets of Str. zymogenes and Str. durans, human or rabbit blood is required (not sheep), temperature 37~ In the stools of healthy individuals, Str. boris was found most frequently (40O/o); in patients suffering from dyspepsia, Sir. ]aeeium (52%), and in 19% of cases Str. zymogenes was found, the majority of strains being non-proteolytic.", [["blood", "ANATOMY", 76, 81], ["stools", "ANATOMY", 130, 136], ["dyspepsia", "DISEASE", 234, 243], ["Str. zymogenes", "ORGANISM", 28, 42], ["Str. durans", "ORGANISM", 47, 58], ["human", "ORGANISM", 60, 65], ["rabbit", "ORGANISM", 69, 75], ["blood", "ORGANISM_SUBSTANCE", 76, 81], ["sheep", "ORGANISM_SUBDIVISION", 99, 104], ["stools", "ORGANISM_SUBSTANCE", 130, 136], ["Str. boris", "ORGANISM", 161, 171], ["patients", "ORGANISM", 210, 218], ["human", "SPECIES", 60, 65], ["rabbit", "SPECIES", 69, 75], ["sheep", "SPECIES", 99, 104], ["Str. boris", "SPECIES", 161, 171], ["patients", "SPECIES", 210, 218], ["Str. zymogenes", "SPECIES", 28, 42], ["Str. durans", "SPECIES", 47, 58], ["human", "SPECIES", 60, 65], ["rabbit", "SPECIES", 69, 75], ["sheep", "SPECIES", 99, 104], ["Str. boris", "SPECIES", 161, 171], ["Str. zymogenes", "SPECIES", 285, 299], ["Str. zymogenes", "PROBLEM", 28, 42], ["Str. durans", "TREATMENT", 47, 58], ["temperature", "TEST", 107, 118], ["dyspepsia", "PROBLEM", 234, 243], ["strains", "PROBLEM", 327, 334], ["stools", "ANATOMY", 130, 136]]], ["From infectious loci, localised outside the digestive tract, Str. ]aecalis was isolated most frequently (48%), then ~tr. lique]aciens (23%) and Str. zymogenes (19~o) .", [["digestive tract", "ANATOMY", 44, 59], ["digestive tract", "ORGAN", 44, 59], ["Str. ]aecalis", "ORGANISM", 61, 74], ["Str. ]aecalis", "SPECIES", 61, 74], ["Str. ]aecalis", "SPECIES", 61, 74], ["Str. zymogenes", "SPECIES", 144, 158], ["aciens", "TEST", 127, 133], ["infectious loci", "OBSERVATION", 5, 20], ["digestive tract", "ANATOMY", 44, 59]]], ["A significantly higher proportion of proteolytie and haemolytic enterococci in this group suggests their important role in the pathogenesis of the infectious process.", [["proteolytie", "GENE_OR_GENE_PRODUCT", 37, 48], ["haemolytic enterococci", "GENE_OR_GENE_PRODUCT", 53, 75], ["A significantly higher proportion of proteolytie", "PROBLEM", 0, 48], ["haemolytic enterococci", "PROBLEM", 53, 75], ["the infectious process", "PROBLEM", 143, 165], ["significantly", "OBSERVATION_MODIFIER", 2, 15], ["higher", "OBSERVATION_MODIFIER", 16, 22], ["haemolytic enterococci", "OBSERVATION", 53, 75], ["infectious", "OBSERVATION", 147, 157]]], ["The determination of sensitivity of enterococci to five basic antibiotics revealed two types of dependence: according to the species and according to the origin of the strain.", [["enterococci", "PROBLEM", 36, 47], ["basic antibiotics", "TREATMENT", 56, 73]]], ["The most sensitive strain was Str. bovis; in Str. zymogenes and Str. liqus-/aciene, high differences in sensitivity to individual antibiotics were observed.", [["aciene", "CHEMICAL", 76, 82], ["Str. bovis", "ORGANISM", 30, 40], ["Str. zymogenes", "ORGANISM", 45, 59], ["Str. liqus-/aciene", "ORGANISM", 64, 82], ["Str. bovis", "SPECIES", 30, 40], ["Str. bovis", "SPECIES", 30, 40], ["Str. zymogenes", "SPECIES", 45, 59], ["The most sensitive strain", "PROBLEM", 0, 25], ["Str. bovis", "PROBLEM", 30, 40], ["individual antibiotics", "TREATMENT", 119, 141]]], ["On the contrary, lowest differences were found in Str. ]aecium; most of all multiresistent strains belonged to this strain.", [["Str. ]aecium", "ORGANISM", 50, 62], ["all multiresistent strains", "PROBLEM", 72, 98], ["this strain", "PROBLEM", 111, 122]]], ["Most sensitive strains were found in the stools of healthy individuals, most resistent strains were isolated from infectious processes outside the digestive tract.Contribution to the Type Determination o] Germs o] Genus Bacillus.", [["stools", "ANATOMY", 41, 47], ["digestive tract", "ANATOMY", 147, 162], ["infectious processes outside the digestive tract", "DISEASE", 114, 162], ["stools", "ORGANISM_SUBDIVISION", 41, 47], ["digestive tract", "ORGANISM_SUBDIVISION", 147, 162], ["Most sensitive strains", "PROBLEM", 0, 22], ["most resistent strains", "PROBLEM", 72, 94], ["Germs", "PROBLEM", 205, 210], ["Genus Bacillus", "PROBLEM", 214, 228], ["stools", "ANATOMY", 41, 47], ["infectious", "OBSERVATION", 114, 124], ["digestive tract", "ANATOMY", 147, 162], ["Genus Bacillus", "OBSERVATION", 214, 228]]], ["M. BAwCentral State Veterinary Institute, Prague.Contribution to the Type Determination o] Germs o] Genus Bacillus.", [["Germs", "PROBLEM", 91, 96], ["Genus Bacillus", "PROBLEM", 100, 114], ["Genus Bacillus", "OBSERVATION", 100, 114]]], ["M. BAwMore accurate classification of germs of genus Bacillus can be done using agglutination (droplet method or in test tubes) or precipitation; spore antigens and antisera to these antigens are used in the first place.", [["germs", "ORGAN", 38, 43], ["spore antigens", "PROTEIN", 146, 160], ["antigens", "PROTEIN", 183, 191], ["germs of genus Bacillus", "PROBLEM", 38, 61], ["agglutination (droplet method", "TREATMENT", 80, 109], ["test tubes", "TREATMENT", 116, 126], ["precipitation", "PROBLEM", 131, 144], ["spore antigens", "PROBLEM", 146, 160], ["these antigens", "TREATMENT", 177, 191], ["genus Bacillus", "OBSERVATION", 47, 61]]], ["Sera can be relatively easily produced and absorbed.", [["Sera", "ORGANISM_SUBSTANCE", 0, 4]]], ["For serological determinations of strains, mostly the methods according to Norris and ~Volf (1961) were employed in our experiments.", [["serological determinations", "TEST", 4, 30], ["strains", "PROBLEM", 34, 41]]], ["In addition, the gross appearance of colonies (morphology), microscopy of sporangium and spores and certain physiological and biochemical properties were evaluated.", [["colonies", "ANATOMY", 37, 45], ["sporangium", "ANATOMY", 74, 84], ["spores", "ANATOMY", 89, 95], ["microscopy of sporangium and spores and certain physiological and biochemical properties", "PROBLEM", 60, 148], ["gross", "OBSERVATION_MODIFIER", 17, 22], ["colonies", "OBSERVATION", 37, 45]]], ["The determination key of Smith et al. (1952) , modified by Wolf and Barker (1968) was used for evaluation of these properties.", [["evaluation", "TEST", 95, 105]]], ["The number of false determinations which were done on the basis of biochemical, physiological and mor-phological criteria as compared to serological examination, comprised one fourth of all complex determinations of strains (alltogether 84).", [["false determinations", "TEST", 14, 34], ["serological examination", "TEST", 137, 160], ["strains", "PROBLEM", 216, 223], ["false determinations", "OBSERVATION", 14, 34]]], ["In studies on the effect of banana in meat--peptone agar on Escherichia cell and Proteus, various effects on monocultures and on association were observed in the correlation to the concentration used.", [["Escherichia cell", "ANATOMY", 60, 76], ["banana in meat--peptone", "CHEMICAL", 28, 51], ["banana", "ORGANISM_SUBDIVISION", 28, 34], ["meat", "ORGANISM_SUBDIVISION", 38, 42], ["Escherichia cell", "CELL", 60, 76], ["banana", "SPECIES", 28, 34], ["banana in meat", "TREATMENT", 28, 42], ["peptone agar", "TREATMENT", 44, 56], ["Escherichia cell", "PROBLEM", 60, 76], ["Proteus", "PROBLEM", 81, 88], ["various effects on monocultures", "PROBLEM", 90, 121], ["Escherichia cell", "OBSERVATION", 60, 76], ["Proteus", "OBSERVATION", 81, 88]]], ["A 5% dried banana mass in MPA suppressed the growth of bacteria in monoeultures.", [["MPA", "CHEMICAL", 26, 29], ["MPA", "CHEMICAL", 26, 29], ["banana", "ORGANISM_SUBDIVISION", 11, 17], ["MPA", "SIMPLE_CHEMICAL", 26, 29], ["A 5% dried banana mass in MPA", "TREATMENT", 0, 29], ["bacteria in monoeultures", "PROBLEM", 55, 79], ["mass", "OBSERVATION", 18, 22], ["MPA suppressed", "OBSERVATION_MODIFIER", 26, 40], ["growth", "OBSERVATION_MODIFIER", 45, 51], ["bacteria", "OBSERVATION", 55, 63]]], ["In association, the growth of Proteu~ was significantly inhibited, whereas Escherichia cell exhibited normal growth.", [["cell", "ANATOMY", 87, 91], ["Proteu", "GENE_OR_GENE_PRODUCT", 30, 36], ["Escherichia cell", "CELL", 75, 91], ["Escherichia cell", "PROBLEM", 75, 91], ["growth", "OBSERVATION_MODIFIER", 20, 26], ["Escherichia cell", "OBSERVATION", 75, 91], ["normal", "OBSERVATION_MODIFIER", 102, 108], ["growth", "OBSERVATION_MODIFIER", 109, 115]]], ["The described effect of banana was also studied quantitatively.", [["banana", "ORGANISM", 24, 30], ["banana", "SPECIES", 24, 30], ["banana", "TREATMENT", 24, 30]]], ["If bacteria were transferred from a 8 h broth culture containing 5% of dry banana mass on MPA agar plates, no typical _Proteus colonies were observed; on the other hand, the number of colonies of Escherichia cell corresponded to that obtained in broth culture without banana.", [["colonies", "ANATOMY", 127, 135], ["colonies", "ANATOMY", 184, 192], ["cell", "ANATOMY", 208, 212], ["MPA", "CHEMICAL", 90, 93], ["MPA", "CHEMICAL", 90, 93], ["banana", "ORGANISM_SUBDIVISION", 75, 81], ["MPA", "SIMPLE_CHEMICAL", 90, 93], ["Escherichia cell", "CELL", 196, 212], ["banana", "ORGANISM_SUBDIVISION", 268, 274], ["Escherichia cell", "CELL_LINE", 196, 212], ["bacteria", "PROBLEM", 3, 11], ["a 8 h broth culture", "TEST", 34, 53], ["dry banana mass", "PROBLEM", 71, 86], ["MPA agar plates", "TEST", 90, 105], ["typical _Proteus colonies", "PROBLEM", 110, 135], ["Escherichia cell", "PROBLEM", 196, 212], ["broth culture", "TEST", 246, 259], ["banana", "TREATMENT", 268, 274], ["banana mass", "OBSERVATION", 75, 86], ["no", "UNCERTAINTY", 107, 109], ["Proteus colonies", "OBSERVATION", 119, 135], ["Escherichia cell", "OBSERVATION", 196, 212]]], ["After a 24 h cultivation in broth, no growth of _proteus was observed, whereas the number of Morbidity rates for acute respiratory diseases (ARD) were analysed in seven different Railway Apprentice Centers in Czechoslovakia.", [["respiratory", "ANATOMY", 119, 130], ["acute respiratory diseases", "DISEASE", 113, 139], ["ARD", "DISEASE", 141, 144], ["a 24 h cultivation in broth", "TREATMENT", 6, 33], ["growth of _proteus", "PROBLEM", 38, 56], ["Morbidity rates", "PROBLEM", 93, 108], ["acute respiratory diseases (ARD)", "PROBLEM", 113, 145], ["no", "UNCERTAINTY", 35, 37], ["growth", "OBSERVATION_MODIFIER", 38, 44], ["acute", "OBSERVATION_MODIFIER", 113, 118], ["respiratory diseases", "OBSERVATION", 119, 139]]], ["The study lasted for 3 school years and covered 9,400 apprentices mostly aged 15 to 17 being based on doctors' diagnoses.", [["The study", "TEST", 0, 9]]], ["It was shown that ARD is the main cause of absenteeism from work and school in adolescents: it accounted for 42.5% of the lost days, whereas injuries contributed 17.1 ~ and all the remaining diagnoses together 40.4%.", [["ARD", "DISEASE", 18, 21], ["injuries", "DISEASE", 141, 149], ["ARD", "PROBLEM", 18, 21], ["absenteeism", "PROBLEM", 43, 54], ["injuries", "PROBLEM", 141, 149], ["ARD", "OBSERVATION", 18, 21], ["main", "OBSERVATION_MODIFIER", 29, 33], ["absenteeism", "OBSERVATION", 43, 54]]], ["The ratio between acute tonsillitis and/or pharyngitis (ATPH) on the one hand and any other form of ARD on the other was approximately 1 : 2.", [["hand", "ANATOMY", 73, 77], ["tonsillitis", "DISEASE", 24, 35], ["pharyngitis", "DISEASE", 43, 54], ["ATPH", "CHEMICAL", 56, 60], ["ARD", "DISEASE", 100, 103], ["The ratio", "TEST", 0, 9], ["acute tonsillitis", "PROBLEM", 18, 35], ["pharyngitis (ATPH)", "PROBLEM", 43, 61], ["ARD", "PROBLEM", 100, 103], ["acute", "OBSERVATION_MODIFIER", 18, 23], ["tonsillitis", "OBSERVATION", 24, 35], ["pharyngitis", "OBSERVATION", 43, 54], ["ARD", "OBSERVATION", 100, 103]]], ["Each year boarders displayed a higher ATPH attack rate than expected: life in dormitories seems to favour the incidence of ATPH as compared with other forms of ARD.", [["ATPH", "DISEASE", 123, 127], ["ARD", "DISEASE", 160, 163], ["ATPH", "SIMPLE_CHEMICAL", 38, 42], ["ATPH", "SIMPLE_CHEMICAL", 123, 127], ["a higher ATPH attack rate", "PROBLEM", 29, 54], ["ATPH", "PROBLEM", 123, 127], ["ARD", "PROBLEM", 160, 163], ["ARD", "OBSERVATION", 160, 163]]], ["It is highly probable that under these conditions the spread of beta-haemolyric streptococci is enhanced more than that of viral agents. year, we determined in 115 strains of Shigella ,onnei 12 lysotypes and 11 eolieinogenotypes.", [["beta-haemolyric streptococci", "SIMPLE_CHEMICAL", 64, 92], ["beta-haemolyric streptococci", "PROBLEM", 64, 92], ["viral agents", "TREATMENT", 123, 135], ["Shigella", "PROBLEM", 175, 183], ["highly probable", "UNCERTAINTY", 6, 21], ["spread", "OBSERVATION_MODIFIER", 54, 60], ["beta-haemolyric streptococci", "OBSERVATION", 64, 92]]], ["Using the combination of both methods, the number of types increased to 23.", [["both methods", "TREATMENT", 25, 37]]], ["Out of these 23 strains, 39% were sensitive to drugs, 52% possessed the R-factor, 9% had a non-transferable resistance and 13% were non-colicinogenic.", [["R-factor", "GENE_OR_GENE_PRODUCT", 72, 80], ["R-factor", "PROTEIN", 72, 80], ["drugs", "TREATMENT", 47, 52], ["the R-factor", "TEST", 68, 80], ["a non-transferable resistance", "PROBLEM", 89, 118], ["non-colicinogenic", "PROBLEM", 132, 149]]], ["Furthermore, we found that the lysotype 23 (XII-) colicinogenotypo 4 (col Ib) keeps constantly in the Broumov region, probably as a carrier strain.", [["XII-) colicinogenotypo 4", "GENE_OR_GENE_PRODUCT", 44, 68], ["col Ib", "GENE_OR_GENE_PRODUCT", 70, 76], ["lysotype 23 (XII-) colicinogenotypo 4", "DNA", 31, 68], ["col Ib", "PROTEIN", 70, 76], ["Broumov region", "DNA", 102, 116], ["the lysotype", "TEST", 27, 39], ["XII", "TEST", 44, 47], ["colicinogenotypo", "TEST", 50, 66], ["a carrier strain", "PROBLEM", 130, 146]]], ["During that time the change of the colicinogenotype to type 14 (eel Ib + col E3) to type 2 (col Is) and to further undefined type took place.", [["eel", "ORGANISM", 64, 67], ["Ib + col E3", "GENE_OR_GENE_PRODUCT", 68, 79], ["type 2", "GENE_OR_GENE_PRODUCT", 84, 90], ["col Is", "GENE_OR_GENE_PRODUCT", 92, 98], ["eel Ib", "PROTEIN", 64, 70], ["col E3", "PROTEIN", 73, 79], ["the colicinogenotype to type 14 (eel Ib + col E3", "TREATMENT", 31, 79]]], ["In further ease, one colicinogenotype 8 (col E2) changed in one epidemic to lysotype N.C. (III-IV-VIII) probably by acquiring the l~-factor to lysetype N.C. (I-III-IV-VIII) and finally by acquisition of a col V factor to lysetype 2rTypes of(LIILIV-VII-VIII-).", [["E2", "CHEMICAL", 45, 47], ["col E2", "GENE_OR_GENE_PRODUCT", 41, 47], ["III-IV-VIII", "GENE_OR_GENE_PRODUCT", 91, 102], ["I-III-IV-VIII", "GENE_OR_GENE_PRODUCT", 158, 171], ["col V factor", "GENE_OR_GENE_PRODUCT", 205, 217], ["LIILIV-VII-VIII", "GENE_OR_GENE_PRODUCT", 241, 256], ["col E2", "PROTEIN", 41, 47], ["VIII", "PROTEIN", 98, 102], ["IV", "PROTEIN", 164, 166], ["VIII", "PROTEIN", 167, 171], ["col V factor", "PROTEIN", 205, 217], ["lysetype 2rTypes", "PROTEIN", 221, 237], ["VII", "PROTEIN", 248, 251], ["VIII", "PROTEIN", 252, 256], ["one colicinogenotype 8 (col E2)", "TREATMENT", 17, 48], ["a col V factor", "PROBLEM", 203, 217], ["LIILIV", "TEST", 241, 247]]], ["Our lysotypes 65 were probably connected with the production of colicino E1 in colicinogenotypes 11 (eel El), 6 (col El) and 13 (colE1 + celia).", [["colicino E1", "GENE_OR_GENE_PRODUCT", 64, 75], ["eel", "ORGANISM", 101, 104], ["colE1 + celia", "GENE_OR_GENE_PRODUCT", 129, 142], ["colicino E1", "PROTEIN", 64, 75], ["colE1", "PROTEIN", 129, 134], ["Our lysotypes", "TEST", 0, 13], ["colicino E1 in colicinogenotypes", "PROBLEM", 64, 96], ["eel El", "TEST", 101, 107]]], ["Sometimes identical types could be differentiated by a different colicinogenotype and vice versa. }Ve recommend combination of both methods.Types ofAraehnia propioniea --a Causative Agent o] Aetinomycosis faciei.", [["Araehnia propioniea", "ORGANISM", 148, 167], ["Aetinomycosis faciei", "ORGANISM", 191, 211], ["Araehnia propioniea", "SPECIES", 148, 167], ["Aetinomycosis faciei", "SPECIES", 191, 211], ["Araehnia propioniea", "SPECIES", 148, 167], ["Aetinomycosis faciei", "SPECIES", 191, 211], ["both methods", "TREATMENT", 127, 139], ["Aetinomycosis faciei", "PROBLEM", 191, 211]]], ["J. SCFEX, Reference Laboratory for Pathogenic Actinomycactae, Department of Microbiology, District Hygiene Centre, Trutnov.Types ofThe genus Araehnia, represented by a single species Arachnia propionica (A.p.) is classified together with genera Actinomyees, t~othia, Bacterionema and Bi/idobacterium into the family Acti~wmycetaeeae.", [["Arachnia propionica", "ORGANISM", 183, 202], ["Bacterionema", "ORGANISM", 267, 279], ["Bi/idobacterium", "ORGANISM", 284, 299], ["Arachnia propionica", "SPECIES", 183, 202], ["Arachnia propionica", "SPECIES", 183, 202], ["Bi/idobacterium", "SPECIES", 284, 299], ["The genus Araehnia", "PROBLEM", 131, 149], ["genera Actinomyees", "PROBLEM", 238, 256], ["t~othia", "PROBLEM", 258, 265], ["Bacterionema", "PROBLEM", 267, 279], ["genus Araehnia", "OBSERVATION", 135, 149]]], ["A. propionica is defined as a microaerophil, catalase-negative G + filamentous organism that is able to form mycelium of a transitional type.", [["microaerophil", "ANATOMY", 30, 43], ["mycelium", "ANATOMY", 109, 117], ["A. propionica", "ORGANISM", 0, 13], ["microaerophil", "CANCER", 30, 43], ["catalase", "GENE_OR_GENE_PRODUCT", 45, 53], ["G", "GENE_OR_GENE_PRODUCT", 63, 64], ["catalase", "PROTEIN", 45, 53], ["A. propionica", "SPECIES", 0, 13], ["A. propionica", "SPECIES", 0, 13], ["a microaerophil, catalase", "TEST", 28, 53], ["filamentous organism", "PROBLEM", 67, 87], ["filamentous organism", "OBSERVATION", 67, 87], ["transitional type", "OBSERVATION", 123, 140]]], ["A. propionica does not split urea but ferments glucose and propionic acid and contains in its peptideglycane LL-diaminopimelic acid.", [["urea", "CHEMICAL", 29, 33], ["glucose", "CHEMICAL", 47, 54], ["propionic acid", "CHEMICAL", 59, 73], ["peptideglycane LL-diaminopimelic acid", "CHEMICAL", 94, 131], ["urea", "CHEMICAL", 29, 33], ["glucose", "CHEMICAL", 47, 54], ["propionic acid", "CHEMICAL", 59, 73], ["peptideglycane LL-diaminopimelic acid", "CHEMICAL", 94, 131], ["A. propionica", "ORGANISM", 0, 13], ["urea", "SIMPLE_CHEMICAL", 29, 33], ["glucose", "SIMPLE_CHEMICAL", 47, 54], ["propionic acid", "SIMPLE_CHEMICAL", 59, 73], ["peptideglycane LL-diaminopimelic acid", "SIMPLE_CHEMICAL", 94, 131], ["A. propionica", "SPECIES", 0, 13], ["A. propionica", "SPECIES", 0, 13], ["split urea", "PROBLEM", 23, 33], ["glucose", "TEST", 47, 54], ["propionic acid", "TEST", 59, 73], ["diaminopimelic acid", "TREATMENT", 112, 131]]], ["A. propionica is pathogenic for man --the disease is manifested as actinomycose --and experimentally for mice.", [["A. propionica", "ORGANISM", 0, 13], ["man", "ORGANISM", 32, 35], ["mice", "ORGANISM", 105, 109], ["A. propionica", "SPECIES", 0, 13], ["man", "SPECIES", 32, 35], ["mice", "SPECIES", 105, 109], ["A. propionica", "SPECIES", 0, 13], ["mice", "SPECIES", 105, 109], ["pathogenic", "PROBLEM", 17, 27], ["the disease", "PROBLEM", 38, 49], ["disease", "OBSERVATION", 42, 49]]], ["A. propionica is sensitive to penicillin.", [["penicillin", "CHEMICAL", 30, 40], ["penicillin", "CHEMICAL", 30, 40], ["A. propionica", "ORGANISM", 0, 13], ["penicillin", "SIMPLE_CHEMICAL", 30, 40], ["A. propionica", "SPECIES", 0, 13], ["A. propionica", "SPECIES", 0, 13], ["penicillin", "TREATMENT", 30, 40]]], ["A well-documented isolation of A. propionica from such localisation which is typical for actinomyeosis, is unique in our country.", [["actinomyeosis", "DISEASE", 89, 102], ["A. propionica", "ORGANISM", 31, 44], ["A. propionica", "SPECIES", 31, 44], ["A. propionica", "SPECIES", 31, 44], ["A. propionica", "PROBLEM", 31, 44], ["actinomyeosis", "PROBLEM", 89, 102], ["typical for", "UNCERTAINTY", 77, 88]]], ["In this respect, A. propionica belongs together with Aetinomyces naeslundi and Aetinomyces viscosue to mieroaerophfl actinomycotic organisms, which were reported to be pathogenic only recently and exceptionally.", [["A. propionica", "ORGANISM", 17, 30], ["Aetinomyces naeslundi", "ORGANISM", 53, 74], ["Aetinomyces viscosue", "ORGANISM", 79, 99], ["A. propionica", "SPECIES", 17, 30], ["Aetinomyces naeslundi", "SPECIES", 53, 74], ["A. propionica", "SPECIES", 17, 30], ["Aetinomyces naeslundi", "SPECIES", 53, 74], ["Aetinomyces viscosue", "SPECIES", 79, 99], ["Aetinomyces naeslundi", "TREATMENT", 53, 74], ["Aetinomyces", "TREATMENT", 79, 90], ["mieroaerophfl actinomycotic organisms", "PROBLEM", 103, 140]]], ["The proteus-like nature of actinomycosis almost excludes its clinical diagnosis.", [["actinomycosis", "ANATOMY", 27, 40], ["actinomycosis", "DISEASE", 27, 40], ["actinomycosis", "CANCER", 27, 40], ["The proteus", "TEST", 0, 11], ["actinomycosis", "PROBLEM", 27, 40], ["proteus", "OBSERVATION", 4, 11], ["like nature", "OBSERVATION_MODIFIER", 12, 23], ["actinomycosis", "OBSERVATION", 27, 40]]], ["However, the aimed laboratory diagnostic shows that microaerophilic actinomycaetac participate in morbidity of our population in an unexpected large scale.", [["actinomycaetac", "SIMPLE_CHEMICAL", 68, 82], ["microaerophilic actinomycaetac", "PROBLEM", 52, 82], ["our population", "PROBLEM", 111, 125], ["microaerophilic actinomycaetac", "OBSERVATION", 52, 82], ["large", "OBSERVATION_MODIFIER", 143, 148]]], ["Relative diffieulties which are connected with isolation and identification of the causati;ce agent of aotinomycotic diseases could be solved provided this 87 problem will be submitted to careful studies and the diagnostic will be available for all laboratories.", [["aotinomycotic diseases", "DISEASE", 103, 125], ["Relative diffieulties", "PROBLEM", 0, 21], ["isolation", "TREATMENT", 47, 56], ["the causati", "PROBLEM", 79, 90], ["aotinomycotic diseases", "PROBLEM", 103, 125], ["careful studies", "TEST", 188, 203]]], ["The analysis of the mucopeptido component of the cell wall was used for differentiation of anaerobic corynebacteria and strictly anaerobic actinoraycetes.", [["cell wall", "ANATOMY", 49, 58], ["cell wall", "TISSUE", 49, 58], ["mucopeptido component", "PROTEIN", 20, 41], ["The analysis", "TEST", 0, 12], ["the cell wall", "PROBLEM", 45, 58], ["anaerobic corynebacteria", "PROBLEM", 91, 115], ["strictly anaerobic actinoraycetes", "PROBLEM", 120, 153], ["cell wall", "OBSERVATION", 49, 58], ["anaerobic corynebacteria", "OBSERVATION", 91, 115], ["anaerobic actinoraycetes", "OBSERVATION", 129, 153]]], ["Mueopeptide of the genus Actinomyces (Actinobacterium) meyeri belongs to the lysine type with a following proportion of components in its mucopeptide: lys: glu : ala: N-ac-glN : N-ac-mur = 1.19 : 1.00 : 1.26 : 0.93 : 0.75.", [["Mueopeptide", "CHEMICAL", 0, 11], ["lysine", "CHEMICAL", 77, 83], ["lysine", "CHEMICAL", 77, 83], ["mucopeptide", "CHEMICAL", 138, 149], ["Actinomyces (", "ORGANISM", 25, 38], ["Actinobacterium) meyeri", "ORGANISM", 38, 61], ["mucopeptide", "SIMPLE_CHEMICAL", 138, 149], ["lys: glu", "SIMPLE_CHEMICAL", 151, 159], ["N-ac-glN", "SIMPLE_CHEMICAL", 167, 175], ["Actinobacterium) meyeri", "SPECIES", 38, 61], ["Actinobacterium) meyeri", "SPECIES", 38, 61], ["the genus Actinomyces", "PROBLEM", 15, 36], ["N-ac", "TEST", 167, 171], ["N-ac-mur", "TEST", 178, 186], ["genus Actinomyces", "OBSERVATION", 19, 36]]], ["Mueopeptide of Corynebacterium granulosum contains diaminopimelic acid.", [["Mueopeptide", "CHEMICAL", 0, 11], ["diaminopimelic acid", "CHEMICAL", 51, 70], ["diaminopimelic acid", "CHEMICAL", 51, 70], ["Mueopeptide", "SIMPLE_CHEMICAL", 0, 11], ["Corynebacterium granulosum", "ORGANISM", 15, 41], ["diaminopimelic acid", "SIMPLE_CHEMICAL", 51, 70], ["Corynebacterium granulosum", "SPECIES", 15, 41], ["Corynebacterium granulosum", "SPECIES", 15, 41], ["Corynebacterium granulosum", "PROBLEM", 15, 41], ["diaminopimelic acid", "TREATMENT", 51, 70], ["Corynebacterium granulosum", "OBSERVATION", 15, 41], ["diaminopimelic acid", "OBSERVATION", 51, 70]]], ["The proportion of components of its cell wall is charactorised by following numbers: dap : glu : ale : N-ac-glN : N-ac-mur : (gly : ser) = 0.59 : 1.00 : 1.38 : 0.77 : 0.85 : (0.92 : 0.51).", [["cell wall", "ANATOMY", 36, 45], ["cell wall", "MULTI-TISSUE_STRUCTURE", 36, 45], ["ale : N-ac-glN", "SIMPLE_CHEMICAL", 97, 111], ["N-ac-mur", "SIMPLE_CHEMICAL", 114, 122], ["gly : ser", "SIMPLE_CHEMICAL", 126, 135], ["glu", "TEST", 91, 94], ["N-ac-mur", "TEST", 114, 122], ["cell wall", "OBSERVATION", 36, 45]]], ["In the d/agnostic praxis, it is sufficient to use the method according to Park and Hancock (1960) which is based on gradual extraction of cells with hot TCA, ethanol, ethanolether and acetone and digestion of solid residue by trypsin.", [["cells", "ANATOMY", 138, 143], ["TCA", "CHEMICAL", 153, 156], ["ethanol", "CHEMICAL", 158, 165], ["ethanolether", "CHEMICAL", 167, 179], ["acetone", "CHEMICAL", 184, 191], ["TCA", "CHEMICAL", 153, 156], ["ethanol", "CHEMICAL", 158, 165], ["ethanolether", "CHEMICAL", 167, 179], ["acetone", "CHEMICAL", 184, 191], ["cells", "CELL", 138, 143], ["TCA", "SIMPLE_CHEMICAL", 153, 156], ["ethanol", "SIMPLE_CHEMICAL", 158, 165], ["ethanolether", "SIMPLE_CHEMICAL", 167, 179], ["acetone", "SIMPLE_CHEMICAL", 184, 191], ["trypsin", "GENE_OR_GENE_PRODUCT", 226, 233], ["trypsin", "PROTEIN", 226, 233], ["the method", "TREATMENT", 50, 60], ["gradual extraction of cells", "TREATMENT", 116, 143], ["hot TCA", "TREATMENT", 149, 156], ["ethanol", "TREATMENT", 158, 165], ["ethanolether", "TREATMENT", 167, 179], ["acetone", "TREATMENT", 184, 191], ["solid residue", "PROBLEM", 209, 222], ["solid residue", "OBSERVATION", 209, 222]]], ["In case the analysed sample of extracted mueopeptide contains both diaminopimelie acid and lysine, one can presume that the presence of lysine indicates contamination of the cell wall by traces of protein.", [["cell wall", "ANATOMY", 174, 183], ["mueopeptide", "CHEMICAL", 41, 52], ["diaminopimelie acid", "CHEMICAL", 67, 86], ["lysine", "CHEMICAL", 91, 97], ["lysine", "CHEMICAL", 136, 142], ["mueopeptide", "CHEMICAL", 41, 52], ["diaminopimelie acid", "CHEMICAL", 67, 86], ["lysine", "CHEMICAL", 91, 97], ["lysine", "CHEMICAL", 136, 142], ["mueopeptide", "SIMPLE_CHEMICAL", 41, 52], ["diaminopimelie acid", "SIMPLE_CHEMICAL", 67, 86], ["lysine", "AMINO_ACID", 91, 97], ["lysine", "AMINO_ACID", 136, 142], ["cell wall", "CELLULAR_COMPONENT", 174, 183], ["both diaminopimelie acid and lysine", "TREATMENT", 62, 97], ["lysine", "PROBLEM", 136, 142], ["lysine", "OBSERVATION", 136, 142], ["contamination", "OBSERVATION", 153, 166], ["cell", "OBSERVATION", 174, 178], ["wall", "ANATOMY_MODIFIER", 179, 183]]], ["This work presents the results of electronmicroscopic studies of Mycobaeteriem emegmatis during three periods of cultivation: (1) on Youmnas medium; (2) subsequent cultivation in physiological solution or (3) cultivation in physiological solution supplemented with 1% glycerol.", [["Mycobaeteriem", "CHEMICAL", 65, 78], ["glycerol", "CHEMICAL", 268, 276], ["glycerol", "CHEMICAL", 268, 276], ["Mycobaeteriem emegmatis", "ORGANISM", 65, 88], ["glycerol", "SIMPLE_CHEMICAL", 268, 276], ["Mycobaeteriem emegmatis", "SPECIES", 65, 88], ["Mycobaeteriem emegmatis", "SPECIES", 65, 88], ["electronmicroscopic studies", "TEST", 34, 61], ["Mycobaeteriem emegmatis", "TREATMENT", 65, 88], ["subsequent cultivation in physiological solution", "TREATMENT", 153, 201], ["cultivation in physiological solution", "TREATMENT", 209, 246], ["1% glycerol", "TREATMENT", 265, 276]]], ["During the longterm cultivation, samples were withdrawn, fixed with OsO4, embedded in agar and Durcupan and ultrathin sections were prepared.", [["samples", "ANATOMY", 33, 40], ["sections", "ANATOMY", 118, 126], ["OsO4", "CHEMICAL", 68, 72], ["OsO4", "SIMPLE_CHEMICAL", 68, 72], ["Durcupan", "SIMPLE_CHEMICAL", 95, 103], ["the longterm cultivation", "TREATMENT", 7, 31], ["OsO4", "TREATMENT", 68, 72], ["Durcupan and ultrathin sections", "TREATMENT", 95, 126]]], ["The electronmicroscopic pictures showed heavy degranulation of cytoplasm and widening of the space between the eytoplasmatic membrane and outer coat in mycobacteria that were cultivated for 30 days in a nutritionally deIficient medium.", [["cytoplasm", "ANATOMY", 63, 72], ["eytoplasmatic membrane", "ANATOMY", 111, 133], ["outer coat", "ANATOMY", 138, 148], ["cytoplasm", "ORGANISM_SUBSTANCE", 63, 72], ["eytoplasmatic membrane", "CELLULAR_COMPONENT", 111, 133], ["outer coat", "CELLULAR_COMPONENT", 138, 148], ["The electronmicroscopic pictures", "TEST", 0, 32], ["heavy degranulation of cytoplasm", "PROBLEM", 40, 72], ["widening of the space", "PROBLEM", 77, 98], ["the eytoplasmatic membrane", "TREATMENT", 107, 133], ["outer coat in mycobacteria", "PROBLEM", 138, 164], ["heavy", "OBSERVATION_MODIFIER", 40, 45], ["degranulation", "OBSERVATION", 46, 59], ["cytoplasm", "OBSERVATION_MODIFIER", 63, 72], ["widening", "OBSERVATION_MODIFIER", 77, 85], ["space", "ANATOMY_MODIFIER", 93, 98], ["eytoplasmatic membrane", "ANATOMY", 111, 133], ["outer coat", "ANATOMY_MODIFIER", 138, 148], ["mycobacteria", "OBSERVATION", 152, 164]]], ["On the other hand, the characteristic appearance was mainrained in the membrane structure of the eell wall, cytoplasmatie membrane, as well as in the membrane which envelops the lipid granules.", [["membrane", "ANATOMY", 71, 79], ["eell wall", "ANATOMY", 97, 106], ["cytoplasmatie membrane", "ANATOMY", 108, 130], ["membrane", "ANATOMY", 150, 158], ["lipid granules", "ANATOMY", 178, 192], ["membrane", "CELLULAR_COMPONENT", 71, 79], ["eell wall", "CELLULAR_COMPONENT", 97, 106], ["cytoplasmatie membrane", "CELLULAR_COMPONENT", 108, 130], ["membrane", "CELLULAR_COMPONENT", 150, 158], ["lipid granules", "CELLULAR_COMPONENT", 178, 192], ["cytoplasmatie membrane", "PROBLEM", 108, 130], ["the lipid granules", "PROBLEM", 174, 192], ["membrane structure", "OBSERVATION", 71, 89], ["eell wall", "ANATOMY", 97, 106], ["cytoplasmatie membrane", "OBSERVATION", 108, 130], ["membrane", "ANATOMY_MODIFIER", 150, 158], ["lipid granules", "OBSERVATION", 178, 192]]], ["In each of three mentioned alternatives, regardless from the length of cultivation, a sporadic occurrence of individuals with an unusual rough lamelar structure and dense polymorph granule in the cytoplasm could be observed.", [["polymorph granule", "ANATOMY", 171, 188], ["cytoplasm", "ANATOMY", 196, 205], ["lamelar", "CANCER", 143, 150], ["polymorph granule", "CELLULAR_COMPONENT", 171, 188], ["cytoplasm", "ORGANISM_SUBSTANCE", 196, 205], ["cultivation", "TREATMENT", 71, 82], ["a sporadic occurrence of individuals", "PROBLEM", 84, 120], ["an unusual rough lamelar structure", "PROBLEM", 126, 160], ["dense polymorph granule in the cytoplasm", "PROBLEM", 165, 205], ["unusual", "OBSERVATION_MODIFIER", 129, 136], ["rough", "OBSERVATION_MODIFIER", 137, 142], ["lamelar structure", "OBSERVATION", 143, 160], ["dense", "OBSERVATION_MODIFIER", 165, 170], ["polymorph granule", "OBSERVATION", 171, 188], ["could be observed", "UNCERTAINTY", 206, 223]]], ["The scanning microscope showed differences in the regularity of surfaces and roughness of bacteria from individual cultivations.", [["The scanning microscope", "TEST", 0, 23], ["roughness of bacteria", "PROBLEM", 77, 98], ["individual cultivations", "PROBLEM", 104, 127], ["surfaces", "OBSERVATION_MODIFIER", 64, 72], ["roughness", "OBSERVATION_MODIFIER", 77, 86], ["bacteria", "OBSERVATION_MODIFIER", 90, 98], ["individual cultivations", "OBSERVATION", 104, 127]]], ["The pictures from the scanning microscope and the ultrathin sections revealed that the irregular roughness was in connection with the formation of giant vacuoles.", [["sections", "ANATOMY", 60, 68], ["giant vacuoles", "ANATOMY", 147, 161], ["giant vacuoles", "CELLULAR_COMPONENT", 147, 161], ["the scanning microscope", "TEST", 18, 41], ["the ultrathin sections", "TEST", 46, 68], ["the irregular roughness", "PROBLEM", 83, 106], ["giant vacuoles", "PROBLEM", 147, 161], ["irregular", "OBSERVATION_MODIFIER", 87, 96], ["roughness", "OBSERVATION_MODIFIER", 97, 106], ["giant vacuoles", "OBSERVATION", 147, 161]]], ["It was also of interest that great irregularities of the surface were characteristic for cultures grown in physiological solution with 1~o glycerol.", [["surface", "ANATOMY", 57, 64], ["glycerol", "CHEMICAL", 139, 147], ["glycerol", "CHEMICAL", 139, 147], ["surface", "CELLULAR_COMPONENT", 57, 64], ["1~o", "SIMPLE_CHEMICAL", 135, 138], ["glycerol", "SIMPLE_CHEMICAL", 139, 147], ["great irregularities of the surface", "PROBLEM", 29, 64], ["cultures", "TEST", 89, 97], ["1~o glycerol", "TREATMENT", 135, 147], ["great", "OBSERVATION_MODIFIER", 29, 34], ["irregularities", "OBSERVATION", 35, 49], ["surface", "OBSERVATION_MODIFIER", 57, 64]]], ["Cultures grown in physiological solution without glycerol had a relatively regular surface similarly as the control culture grown in complete nutrient medium.", [["surface", "ANATOMY", 83, 90], ["glycerol", "CHEMICAL", 49, 57], ["glycerol", "CHEMICAL", 49, 57], ["glycerol", "SIMPLE_CHEMICAL", 49, 57], ["Cultures", "TEST", 0, 8], ["glycerol", "TREATMENT", 49, 57], ["the control culture", "TEST", 104, 123], ["nutrient medium", "OBSERVATION", 142, 157]]], ["Mycobacterium smegmatis was studied in the aim to investigate their effect in biosynthestic processes.", [["Mycobacterium smegmatis", "GENE_OR_GENE_PRODUCT", 0, 23], ["Mycobacterium smegmatis", "SPECIES", 0, 23], ["Mycobacterium smegmatis", "SPECIES", 0, 23], ["Mycobacterium smegmatis", "PROBLEM", 0, 23], ["biosynthestic processes", "PROBLEM", 78, 101], ["smegmatis", "OBSERVATION", 14, 23]]], ["These involve proteosynthesis indicated by the rate of incorporation of leucine-14C into the TCA-insoluble fraction of cells and synthesis of nucleic acids using adenine-14C.", [["cells", "ANATOMY", 119, 124], ["leucine-14C", "CHEMICAL", 72, 83], ["TCA", "CHEMICAL", 93, 96], ["nucleic acids", "CHEMICAL", 142, 155], ["adenine-14C", "CHEMICAL", 162, 173], ["leucine", "CHEMICAL", 72, 79], ["14C", "CHEMICAL", 80, 83], ["TCA", "CHEMICAL", 93, 96], ["adenine", "CHEMICAL", 162, 169], ["14C", "CHEMICAL", 170, 173], ["leucine-14C", "SIMPLE_CHEMICAL", 72, 83], ["TCA", "SIMPLE_CHEMICAL", 93, 96], ["cells", "CELL", 119, 124], ["nucleic acids", "SIMPLE_CHEMICAL", 142, 155], ["adenine-14C", "SIMPLE_CHEMICAL", 162, 173], ["leucine", "TEST", 72, 79], ["synthesis of nucleic acids", "TREATMENT", 129, 155], ["adenine", "TREATMENT", 162, 169]]], ["The rate of incorporation was studied using the Merill's synthetic medium with glucose which proved to be the most advantageous for this purpose.", [["glucose", "CHEMICAL", 79, 86], ["glucose", "CHEMICAL", 79, 86], ["glucose", "SIMPLE_CHEMICAL", 79, 86], ["the Merill's synthetic medium with glucose", "TREATMENT", 44, 86]]], ["The effectiveness of tested substances was considered mainly on the basis of changes in the rate if incorporation of precursors used, and therefore it was followed in a relatively short time interval.", [["tested substances", "TEST", 21, 38]]], ["As the concentration dependence of tested substances was used, we could determine graphically the Ins0 value, i.e. such concentration of the substance, which was required for a 50~o decrease of the incorporation rate into corresponding macromolecules of the cell.", [["cell", "ANATOMY", 258, 262], ["Ins0", "SIMPLE_CHEMICAL", 98, 102], ["cell", "CELL", 258, 262], ["the incorporation rate", "TEST", 194, 216], ["cell", "ANATOMY", 258, 262]]], ["In addition, by expressing the ratio of radioactivity of incorporated adenine to radioactivity of incorporated leucine, different data were obtained which were suitable for evaluation of the effect of the substance under study on the metabolism of the cell.", [["cell", "ANATOMY", 252, 256], ["adenine", "CHEMICAL", 70, 77], ["leucine", "CHEMICAL", 111, 118], ["adenine", "CHEMICAL", 70, 77], ["leucine", "CHEMICAL", 111, 118], ["adenine", "SIMPLE_CHEMICAL", 70, 77], ["leucine", "AMINO_ACID", 111, 118], ["cell", "CELL", 252, 256], ["evaluation", "TEST", 173, 183]]], ["From the data obtained it follows that streptomycin, gentamyein, kanamycin and r'ffampicin influenced significantly incorporation ofprecursors-14C into corresponding macromolecules in Mycobacterium smegmatis cells.", [["Mycobacterium smegmatis cells", "ANATOMY", 184, 213], ["streptomycin", "CHEMICAL", 39, 51], ["gentamyein", "CHEMICAL", 53, 63], ["kanamycin", "CHEMICAL", 65, 74], ["r'ffampicin", "CHEMICAL", 79, 90], ["ofprecursors-14C", "CHEMICAL", 130, 146], ["streptomycin", "CHEMICAL", 39, 51], ["gentamyein", "CHEMICAL", 53, 63], ["kanamycin", "CHEMICAL", 65, 74], ["r'ffampicin", "CHEMICAL", 79, 90], ["14C", "CHEMICAL", 143, 146], ["streptomycin", "SIMPLE_CHEMICAL", 39, 51], ["gentamyein", "SIMPLE_CHEMICAL", 53, 63], ["kanamycin", "SIMPLE_CHEMICAL", 65, 74], ["r'ffampicin", "SIMPLE_CHEMICAL", 79, 90], ["ofprecursors-14C", "SIMPLE_CHEMICAL", 130, 146], ["Mycobacterium smegmatis cells", "CELL", 184, 213], ["Mycobacterium smegmatis cells", "CELL_TYPE", 184, 213], ["Mycobacterium smegmatis", "SPECIES", 184, 207], ["Mycobacterium smegmatis", "SPECIES", 184, 207], ["streptomycin", "TREATMENT", 39, 51], ["gentamyein", "TREATMENT", 53, 63], ["kanamycin", "TREATMENT", 65, 74], ["r'ffampicin", "TREATMENT", 79, 90], ["incorporation ofprecursors", "TEST", 116, 142], ["Mycobacterium smegmatis cells", "PROBLEM", 184, 213], ["Mycobacterium smegmatis cells", "OBSERVATION", 184, 213]]], ["The endocetlular parasitism is characteristic for pathogenic mycobaeteria.", [["endocetlular", "ANATOMY", 4, 16], ["mycobaeteria", "DISEASE", 61, 73], ["endocetlular", "CANCER", 4, 16], ["The endocetlular parasitism", "PROBLEM", 0, 27], ["pathogenic mycobaeteria", "PROBLEM", 50, 73], ["endocetlular", "ANATOMY", 4, 16], ["parasitism", "OBSERVATION", 17, 27], ["characteristic for", "UNCERTAINTY", 31, 49], ["pathogenic mycobaeteria", "OBSERVATION", 50, 73]]], ["Atypical mycobacteria like Mycobacterium avium, elicit the Yersin-type of a lethal disease without typical symptoms of tuberculosis.", [["Mycobacterium avium", "DISEASE", 27, 46], ["lethal disease", "DISEASE", 76, 90], ["tuberculosis", "DISEASE", 119, 131], ["Mycobacterium avium", "ORGANISM", 27, 46], ["Mycobacterium avium", "SPECIES", 27, 46], ["Mycobacterium avium", "SPECIES", 27, 46], ["Atypical mycobacteria", "PROBLEM", 0, 21], ["Mycobacterium avium", "PROBLEM", 27, 46], ["a lethal disease", "PROBLEM", 74, 90], ["typical symptoms", "PROBLEM", 99, 115], ["tuberculosis", "PROBLEM", 119, 131], ["mycobacteria", "OBSERVATION", 9, 21], ["Mycobacterium avium", "OBSERVATION", 27, 46], ["lethal disease", "OBSERVATION", 76, 90], ["tuberculosis", "OBSERVATION", 119, 131]]], ["We studied the course of infection in situ in the rabbit liver.", [["liver", "ANATOMY", 57, 62], ["infection", "DISEASE", 25, 34], ["rabbit", "ORGANISM", 50, 56], ["liver", "ORGAN", 57, 62], ["rabbit", "SPECIES", 50, 56], ["rabbit", "SPECIES", 50, 56], ["infection", "PROBLEM", 25, 34], ["infection", "OBSERVATION", 25, 34], ["rabbit", "ANATOMY_MODIFIER", 50, 56], ["liver", "ANATOMY", 57, 62]]], ["Mycobacteria were found only within phagosomes of Kupffer cells, or eventually at later stages of infection, within phagosomes of giant multinuelear cells, which can be detected approximately in the half of the process.", [["phagosomes", "ANATOMY", 36, 46], ["Kupffer cells", "ANATOMY", 50, 63], ["phagosomes", "ANATOMY", 116, 126], ["giant multinuelear cells", "ANATOMY", 130, 154], ["infection", "DISEASE", 98, 107], ["phagosomes", "CELLULAR_COMPONENT", 36, 46], ["Kupffer cells", "CELL", 50, 63], ["phagosomes", "CELLULAR_COMPONENT", 116, 126], ["giant multinuelear cells", "CELL", 130, 154], ["Kupffer cells", "CELL_TYPE", 50, 63], ["giant multinuelear cells", "CELL_TYPE", 130, 154], ["Mycobacteria", "PROBLEM", 0, 12], ["infection", "PROBLEM", 98, 107], ["giant multinuelear cells", "PROBLEM", 130, 154], ["Kupffer cells", "OBSERVATION", 50, 63], ["infection", "OBSERVATION", 98, 107], ["giant", "OBSERVATION_MODIFIER", 130, 135], ["multinuelear cells", "OBSERVATION", 136, 154]]], ["In the course of the process of infection, the enlargement of the volume of cytoplasm and an increase in the number of cellular organella in the Kupffer cells could be observed.", [["cytoplasm", "ANATOMY", 76, 85], ["cellular organella", "ANATOMY", 119, 137], ["Kupffer cells", "ANATOMY", 145, 158], ["infection", "DISEASE", 32, 41], ["cytoplasm", "ORGANISM_SUBSTANCE", 76, 85], ["cellular organella", "CELL", 119, 137], ["Kupffer cells", "CELL", 145, 158], ["Kupffer cells", "CELL_TYPE", 145, 158], ["infection", "PROBLEM", 32, 41], ["the enlargement of the volume of cytoplasm", "PROBLEM", 43, 85], ["an increase", "PROBLEM", 90, 101], ["cellular organella in the Kupffer cells", "PROBLEM", 119, 158], ["infection", "OBSERVATION", 32, 41], ["enlargement", "OBSERVATION_MODIFIER", 47, 58], ["volume", "OBSERVATION_MODIFIER", 66, 72], ["cytoplasm", "OBSERVATION_MODIFIER", 76, 85], ["increase", "OBSERVATION_MODIFIER", 93, 101], ["number", "OBSERVATION_MODIFIER", 109, 115], ["cellular organella", "OBSERVATION", 119, 137], ["Kupffer cells", "OBSERVATION", 145, 158]]], ["The cells could be seen in vast agglomerations around sinusoids.", [["cells", "ANATOMY", 4, 9], ["sinusoids", "ANATOMY", 54, 63], ["cells", "CELL", 4, 9], ["sinusoids", "TISSUE", 54, 63], ["vast agglomerations around sinusoids", "PROBLEM", 27, 63], ["could be seen", "UNCERTAINTY", 10, 23], ["vast", "OBSERVATION_MODIFIER", 27, 31], ["agglomerations", "OBSERVATION", 32, 46]]], ["Mycobaeteria maintained unchanged morphology and the structure of cell coats was undamaged as compared with mycobacteria cultivated in vitro.", [["cell coats", "ANATOMY", 66, 76], ["Mycobaeteria", "CHEMICAL", 0, 12], ["Mycobaeteria", "SIMPLE_CHEMICAL", 0, 12], ["cell coats", "ORGANISM_SUBSTANCE", 66, 76], ["cell coats", "PROBLEM", 66, 76], ["mycobacteria", "PROBLEM", 108, 120], ["unchanged", "OBSERVATION_MODIFIER", 24, 33], ["morphology", "OBSERVATION_MODIFIER", 34, 44], ["cell coats", "OBSERVATION", 66, 76]]], ["Only exceptionally lysed cells could be found.", [["cells", "ANATOMY", 25, 30], ["cells", "CELL", 25, 30], ["exceptionally lysed cells", "PROBLEM", 5, 30], ["lysed cells", "OBSERVATION", 19, 30]]], ["However, qnite frequently the polymorph structures occurred in the plasma of mycobacteria and phagosomes.", [["plasma", "ANATOMY", 67, 73], ["phagosomes", "ANATOMY", 94, 104], ["plasma", "ORGANISM_SUBSTANCE", 67, 73], ["phagosomes", "CELLULAR_COMPONENT", 94, 104], ["the polymorph structures", "PROBLEM", 26, 50], ["mycobacteria", "PROBLEM", 77, 89], ["phagosomes", "PROBLEM", 94, 104], ["mycobacteria", "OBSERVATION", 77, 89]]], ["These structures were characterisod by a high density and their morphology, size and frequency of occurrence did not correspond to volutine granules and, furthermore, they were never found in avian mycobacteria cultivated in vitro under standard laboratory conditions.", [["volutine granules", "ANATOMY", 131, 148], ["volutine", "SIMPLE_CHEMICAL", 131, 139], ["granules", "ORGANISM_SUBSTANCE", 140, 148], ["a high density", "PROBLEM", 39, 53], ["volutine granules", "PROBLEM", 131, 148], ["avian mycobacteria", "PROBLEM", 192, 210], ["high", "OBSERVATION_MODIFIER", 41, 45], ["density", "OBSERVATION", 46, 53], ["morphology", "OBSERVATION_MODIFIER", 64, 74], ["size", "OBSERVATION_MODIFIER", 76, 80], ["granules", "OBSERVATION", 140, 148]]], ["Within certain mycobaeteria, and further within myeobacteria that were released into the sinusoid lumen probably by a secondary disruption of cells, vacuolisation of plasma was observed probably as a consequence of inadequate cultivation conditions.", [["sinusoid lumen", "ANATOMY", 89, 103], ["cells", "ANATOMY", 142, 147], ["plasma", "ANATOMY", 166, 172], ["myeobacteria", "GENE_OR_GENE_PRODUCT", 48, 60], ["sinusoid lumen", "MULTI-TISSUE_STRUCTURE", 89, 103], ["cells", "CELL", 142, 147], ["plasma", "ORGANISM_SUBSTANCE", 166, 172], ["a secondary disruption of cells", "PROBLEM", 116, 147], ["vacuolisation of plasma", "PROBLEM", 149, 172], ["inadequate cultivation conditions", "PROBLEM", 215, 248], ["sinusoid lumen", "OBSERVATION", 89, 103], ["secondary", "OBSERVATION_MODIFIER", 118, 127], ["disruption of cells", "OBSERVATION", 128, 147], ["cultivation conditions", "OBSERVATION", 226, 248]]], ["Dense structures occurred even within these cells.", [["Dense structures", "ANATOMY", 0, 16], ["cells", "ANATOMY", 44, 49], ["cells", "CELL", 44, 49], ["Dense structures", "PROBLEM", 0, 16], ["structures", "OBSERVATION", 6, 16]]], ["Presumably, we were also dealing with a regressive change which might reflect the lack of oxygen or lack of some essential nutrient in the infected tissue.", [["tissue", "ANATOMY", 148, 154], ["oxygen", "CHEMICAL", 90, 96], ["oxygen", "CHEMICAL", 90, 96], ["oxygen", "SIMPLE_CHEMICAL", 90, 96], ["tissue", "TISSUE", 148, 154], ["a regressive change", "PROBLEM", 38, 57], ["the infected tissue", "PROBLEM", 135, 154], ["essential", "OBSERVATION_MODIFIER", 113, 122], ["nutrient", "OBSERVATION", 123, 131], ["infected tissue", "OBSERVATION", 139, 154]]], ["Macrophages obviously lack the capacity to degrade mycobacteria.", [["Macrophages", "ANATOMY", 0, 11], ["Macrophages", "CELL", 0, 11], ["Macrophages", "CELL_TYPE", 0, 11], ["Macrophages", "PROBLEM", 0, 11], ["the capacity", "PROBLEM", 27, 39], ["mycobacteria", "PROBLEM", 51, 63], ["mycobacteria", "OBSERVATION", 51, 63]]], ["The basic chemical composition of S-and Rendotoxins (lipopolysaccharide-protein complexes) of Shigella dysenteriae 1 (Shiga), partially purified by a two-step column chromatography on Sephadex G 200 and Sepharose 4B, was studied.", [["S-", "CHEMICAL", 34, 36], ["Rendotoxins", "CHEMICAL", 40, 51], ["lipopolysaccharide", "CHEMICAL", 53, 71], ["Shiga", "CHEMICAL", 118, 123], ["Rendotoxins", "CHEMICAL", 40, 51], ["S-", "SIMPLE_CHEMICAL", 34, 36], ["Rendotoxins", "SIMPLE_CHEMICAL", 40, 51], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 53, 71], ["Shigella dysenteriae 1", "ORGANISM", 94, 116], ["Shiga)", "ORGANISM", 118, 124], ["Sephadex G 200", "SIMPLE_CHEMICAL", 184, 198], ["lipopolysaccharide-protein complexes", "PROTEIN", 53, 89], ["Shigella dysenteriae", "SPECIES", 94, 114], ["Shigella dysenteriae 1", "SPECIES", 94, 116], ["S-", "TEST", 34, 36], ["Rendotoxins (lipopolysaccharide-protein complexes", "TREATMENT", 40, 89], ["Shigella dysenteriae", "PROBLEM", 94, 114], ["a two-step column chromatography", "TREATMENT", 148, 180], ["Sephadex G", "TREATMENT", 184, 194], ["Sepharose 4B", "TREATMENT", 203, 215]]], ["As an original raw extract, we used the preparation obtained by treatment of cells with hypertonic solution of NaC1 (1M) and Na citrate (0.1M) according to Reynaud.", [["extract", "ANATOMY", 19, 26], ["cells", "ANATOMY", 77, 82], ["NaC1", "CHEMICAL", 111, 115], ["Na citrate", "CHEMICAL", 125, 135], ["NaC1", "CHEMICAL", 111, 115], ["Na citrate", "CHEMICAL", 125, 135], ["cells", "CELL", 77, 82], ["NaC1", "SIMPLE_CHEMICAL", 111, 115], ["Na citrate", "SIMPLE_CHEMICAL", 125, 135], ["hypertonic solution of NaC1", "TREATMENT", 88, 115], ["Na citrate", "TREATMENT", 125, 135]]], ["The complexes consisted of 23--35% of lipids, 40--50% of sugars and 14--24~o of aminoacids.", [["sugars", "CHEMICAL", 57, 63], ["aminoacids", "CHEMICAL", 80, 90], ["lipids", "SIMPLE_CHEMICAL", 38, 44], ["sugars", "SIMPLE_CHEMICAL", 57, 63], ["aminoacids", "SIMPLE_CHEMICAL", 80, 90], ["lipids", "TEST", 38, 44], ["sugars", "TEST", 57, 63], ["aminoacids", "TREATMENT", 80, 90]]], ["Main part of the total lipid content formed the behenie acid 22 : 0 (about 50% for both growth forms).", [["behenie acid", "CHEMICAL", 48, 60], ["behenie acid", "CHEMICAL", 48, 60], ["lipid", "SIMPLE_CHEMICAL", 23, 28], ["behenie acid", "SIMPLE_CHEMICAL", 48, 60], ["the total lipid content", "TEST", 13, 36], ["the behenie acid", "TEST", 44, 60], ["total", "OBSERVATION_MODIFIER", 17, 22], ["lipid content", "OBSERVATION", 23, 36]]], ["The value above 10~o was recorded in fatty acid 16 : 0; within the range of 5--10% were detected 14 : 0 and OH 14 : 0.", [["fatty acid", "CHEMICAL", 37, 47], ["fatty acid", "CHEMICAL", 37, 47], ["OH", "CHEMICAL", 108, 110], ["fatty acid", "SIMPLE_CHEMICAL", 37, 47], ["The value", "TEST", 0, 9], ["fatty acid", "TEST", 37, 47]]], ["None of the odd fatty acids possessed a significant per cent proportion-in the total lipid.", [["fatty acids", "CHEMICAL", 16, 27], ["fatty acids", "CHEMICAL", 16, 27], ["odd fatty acids", "SIMPLE_CHEMICAL", 12, 27], ["lipid", "SIMPLE_CHEMICAL", 85, 90], ["the odd fatty acids", "TEST", 8, 27], ["the total lipid", "TREATMENT", 75, 90]]], ["The carbohydrate component contained following sugars: galactose (for S-30~o/for R-30%), glucose (5/35), glucosamin (10/3), rham-nose (40/0) and aldoheptose (0/25).", [["galactose", "CHEMICAL", 55, 64], ["glucose", "CHEMICAL", 89, 96], ["glucosamin", "CHEMICAL", 105, 115], ["rham-nose", "CHEMICAL", 124, 133], ["aldoheptose", "CHEMICAL", 145, 156], ["carbohydrate", "CHEMICAL", 4, 16], ["sugars", "CHEMICAL", 47, 53], ["galactose", "CHEMICAL", 55, 64], ["glucose", "CHEMICAL", 89, 96], ["glucosamin", "CHEMICAL", 105, 115], ["rham-nose", "CHEMICAL", 124, 133], ["aldoheptose", "CHEMICAL", 145, 156], ["sugars", "SIMPLE_CHEMICAL", 47, 53], ["galactose", "SIMPLE_CHEMICAL", 55, 64], ["glucose", "SIMPLE_CHEMICAL", 89, 96], ["glucosamin", "SIMPLE_CHEMICAL", 105, 115], ["rham-nose", "SIMPLE_CHEMICAL", 124, 133], ["aldoheptose", "SIMPLE_CHEMICAL", 145, 156], ["galactose", "TEST", 55, 64], ["S", "TEST", 70, 71], ["glucose", "TEST", 89, 96], ["glucosamin", "TREATMENT", 105, 115], ["aldoheptose", "TREATMENT", 145, 156], ["nose", "ANATOMY", 129, 133]]], ["Sixteen aminoacids were found in both forms in an identical composition; only in S-cndotoxin less aminoacids were found quantitatively.", [["aminoacids", "CHEMICAL", 8, 18], ["aminoacids", "CHEMICAL", 8, 18], ["aminoacids", "CHEMICAL", 98, 108], ["S-cndotoxin", "SIMPLE_CHEMICAL", 81, 92], ["Sixteen aminoacids", "TREATMENT", 0, 18], ["S-cndotoxin less aminoacids", "TREATMENT", 81, 108]]], ["The ratio of individual aminoaeids between R/S endotoxins was maintamed within the range 1.7 \u2022 0.2.", [["aminoaeids", "CHEMICAL", 24, 34], ["aminoaeids", "SIMPLE_CHEMICAL", 24, 34], ["R/S endotoxins", "GENE_OR_GENE_PRODUCT", 43, 57], ["The ratio", "TEST", 0, 9], ["R/S endotoxins", "TEST", 43, 57]]], ["The preparation of a given purification step contained 3.8--4.8% of N, 2--3~o of P and traces of S. The kete-deoxyoctulonic acid (KD0) was found under 0.5%, 0-phosphoryl-ethanolamine could not be detected The presence of several trace elements (inorganic cations) was demonstrated in both S-and R-forms (Cu, Zn, Ca, Mg, Fe, Mn).", [["N, 2--3~o", "CHEMICAL", 68, 77], ["kete-deoxyoctulonic acid", "CHEMICAL", 104, 128], ["KD0", "CHEMICAL", 130, 133], ["0-phosphoryl-ethanolamine", "CHEMICAL", 157, 182], ["inorganic cations", "CHEMICAL", 245, 262], ["Cu", "CHEMICAL", 304, 306], ["Zn", "CHEMICAL", 308, 310], ["Ca", "CHEMICAL", 312, 314], ["Mg", "CHEMICAL", 316, 318], ["Fe", "CHEMICAL", 320, 322], ["Mn", "CHEMICAL", 324, 326], ["N", "CHEMICAL", 68, 69], ["P", "CHEMICAL", 81, 82], ["kete-deoxyoctulonic acid", "CHEMICAL", 104, 128], ["KD0", "CHEMICAL", 130, 133], ["0-phosphoryl-ethanolamine", "CHEMICAL", 157, 182], ["Cu", "CHEMICAL", 304, 306], ["Zn", "CHEMICAL", 308, 310], ["Ca", "CHEMICAL", 312, 314], ["Mg", "CHEMICAL", 316, 318], ["Fe", "CHEMICAL", 320, 322], ["Mn", "CHEMICAL", 324, 326], ["2--3~o of P", "SIMPLE_CHEMICAL", 71, 82], ["kete-deoxyoctulonic acid", "SIMPLE_CHEMICAL", 104, 128], ["KD0", "SIMPLE_CHEMICAL", 130, 133], ["0-phosphoryl-ethanolamine", "SIMPLE_CHEMICAL", 157, 182], ["inorganic cations", "SIMPLE_CHEMICAL", 245, 262], ["R-forms", "SIMPLE_CHEMICAL", 295, 302], ["Cu, Zn", "SIMPLE_CHEMICAL", 304, 310], ["Ca, Mg", "SIMPLE_CHEMICAL", 312, 318], ["Fe, Mn", "SIMPLE_CHEMICAL", 320, 326], ["purification step", "TEST", 27, 44], ["N", "TEST", 68, 69], ["phosphoryl-ethanolamine", "TREATMENT", 159, 182], ["several trace elements (inorganic cations", "PROBLEM", 221, 262], ["Ca", "TEST", 312, 314], ["several", "OBSERVATION_MODIFIER", 221, 228], ["trace elements", "OBSERVATION", 229, 243], ["inorganic cations", "OBSERVATION", 245, 262]]], ["The results of the analysis of chemical composition should be taken as preliminary mean values which should serve as a guide for further steps of purification and isolation of active components of bacterial endotoxins.", [["the analysis", "TEST", 15, 27], ["chemical composition", "TEST", 31, 51], ["preliminary mean values", "TEST", 71, 94], ["further steps of purification", "TREATMENT", 129, 158], ["isolation", "TREATMENT", 163, 172], ["bacterial endotoxins", "PROBLEM", 197, 217], ["active", "OBSERVATION_MODIFIER", 176, 182], ["bacterial endotoxins", "OBSERVATION", 197, 217]]], ["It turns out that the sugar ratio, which represents a different structure both quantitatively and qualitatively, is the main cause of different immunological behaviour of both types of endotoxin and therefore its immunodominant role is fully acceptable.Some Chemical and Immunochemical Aspects o/ Sand R-Endotoxins elThe Base Composition o/ Rickettsial Deoxyribonucleic Acids. ~.", [["endotoxin", "CHEMICAL", 185, 194], ["sugar", "CHEMICAL", 22, 27], ["sugar", "SIMPLE_CHEMICAL", 22, 27], ["endotoxin", "SIMPLE_CHEMICAL", 185, 194], ["the sugar ratio", "TEST", 18, 33], ["endotoxin", "TREATMENT", 185, 194], ["Immunochemical Aspects", "TEST", 271, 293], ["Endotoxins el", "TREATMENT", 304, 317], ["Rickettsial Deoxyribonucleic Acids", "TREATMENT", 341, 375], ["different", "OBSERVATION_MODIFIER", 54, 63], ["structure", "OBSERVATION", 64, 73], ["main", "OBSERVATION_MODIFIER", 120, 124], ["different", "OBSERVATION_MODIFIER", 134, 143], ["immunological behaviour", "OBSERVATION", 144, 167], ["both types", "OBSERVATION_MODIFIER", 171, 181], ["endotoxin", "OBSERVATION", 185, 194]]], ["SCHRA~EK, Institute of Virology, Slovak Academy of Sciences, Bratislava.Some Chemical and Immunochemical Aspects o/ Sand R-Endotoxins elRickettsiae possess relatively little phenotypie characteristics suitable for classification.", [["Immunochemical Aspects", "TEST", 90, 112]]], ["Until now, the classification of rickettsiae was based mainly on antigenic differences, epidemiological and ecological criteria and on comparatively few biological properties.", [["rickettsiae", "DISEASE", 33, 44], ["rickettsiae", "ORGANISM", 33, 44], ["rickettsiae", "PROBLEM", 33, 44], ["rickettsiae", "OBSERVATION", 33, 44]]], ["For determination of an objective index of genetic relationships among rickettsiae, we established the molar content of bases from various strains of rickettsiae using the thermal denaturation method.", [["rickettsiae", "PROBLEM", 150, 161], ["the thermal denaturation method", "TREATMENT", 168, 199], ["bases", "ANATOMY_MODIFIER", 120, 125]]], ["The average molar content of fuanin and cytosin was in the genus Rickettsia within the range of 29--*39~Some Chemical and Immunochemical Aspects o/ Sand R-Endotoxins elIn subgenera following values were found: Rickettsia 29%, Dermacentroxenous 33~o, Roehalimaea 39%.", [["fuanin", "CHEMICAL", 29, 35], ["cytosin", "CHEMICAL", 40, 47], ["fuanin", "CHEMICAL", 29, 35], ["cytosin", "CHEMICAL", 40, 47], ["fuanin", "SIMPLE_CHEMICAL", 29, 35], ["cytosin", "GENE_OR_GENE_PRODUCT", 40, 47], ["Immunochemical Aspects", "TEST", 122, 144], ["Rickettsia", "PROBLEM", 210, 220], ["Roehalimaea", "TEST", 250, 261], ["average", "OBSERVATION_MODIFIER", 4, 11], ["molar", "OBSERVATION_MODIFIER", 12, 17], ["content", "OBSERVATION_MODIFIER", 18, 25], ["genus Rickettsia", "OBSERVATION", 59, 75]]], ["In the genus Goxiella, the average base composition was '43% for guanin and cytosin.", [["guanin", "CHEMICAL", 65, 71], ["cytosin", "CHEMICAL", 76, 83], ["guanin", "GENE_OR_GENE_PRODUCT", 65, 71], ["cytosin", "SIMPLE_CHEMICAL", 76, 83], ["guanin", "PROTEIN", 65, 71], ["cytosin", "PROTEIN", 76, 83], ["the average base composition", "TREATMENT", 23, 51], ["guanin", "TREATMENT", 65, 71], ["cytosin", "TREATMENT", 76, 83], ["genus Goxiella", "ANATOMY", 7, 21]]], ["The differences among species and strains within one subgenus were not significant.", [["strains", "PROBLEM", 34, 41], ["not", "UNCERTAINTY", 67, 70], ["significant", "OBSERVATION_MODIFIER", 71, 82]]], ["On the basis of the analysis of base composition of deoxyribonucleic asld in newly isolated rickettsiae in We studied antigen-binding and antigen-inducing properties, virulence for mice and guinea pigs of strains of Coxiella burneti 48 and Nine Mile, serelogically in phase II during transfers in normal and immunologically suppressed mice.", [["deoxyribonucleic asld", "CHEMICAL", 52, 73], ["Coxiella burneti", "DISEASE", 216, 232], ["deoxyribonucleic asld", "SIMPLE_CHEMICAL", 52, 73], ["mice", "ORGANISM", 181, 185], ["guinea pigs", "ORGANISM", 190, 201], ["Coxiella burneti 48", "ORGANISM", 216, 235], ["mice", "ORGANISM", 335, 339], ["mice", "SPECIES", 181, 185], ["guinea pigs", "SPECIES", 190, 201], ["Coxiella burneti", "SPECIES", 216, 232], ["mice", "SPECIES", 335, 339], ["mice", "SPECIES", 181, 185], ["guinea pigs", "SPECIES", 190, 201], ["Coxiella burneti", "SPECIES", 216, 232], ["mice", "SPECIES", 335, 339], ["the analysis", "TEST", 16, 28], ["deoxyribonucleic asld", "PROBLEM", 52, 73], ["newly isolated rickettsiae", "PROBLEM", 77, 103], ["antigen", "TEST", 138, 145], ["virulence", "PROBLEM", 167, 176], ["Coxiella burneti", "TEST", 216, 232], ["rickettsiae", "OBSERVATION", 92, 103], ["normal", "OBSERVATION", 297, 303]]], ["The strain 48 (50 transfers on yolk sac of chicken embryos) could be transfered in normal mice; in immunosuppressed mice it changed to phase I during 4 passages.", [["yolk sac", "ANATOMY", 31, 39], ["embryos", "ANATOMY", 51, 58], ["yolk sac", "MULTI-TISSUE_STRUCTURE", 31, 39], ["chicken", "ORGANISM", 43, 50], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 51, 58], ["mice", "ORGANISM", 90, 94], ["mice", "ORGANISM", 116, 120], ["chicken", "SPECIES", 43, 50], ["mice", "SPECIES", 90, 94], ["mice", "SPECIES", 116, 120], ["chicken", "SPECIES", 43, 50], ["mice", "SPECIES", 90, 94], ["mice", "SPECIES", 116, 120], ["yolk sac of chicken embryos", "TREATMENT", 31, 58], ["immunosuppressed mice", "TREATMENT", 99, 120]]], ["The Nine Mile strain (an undefined number of several hundreds of transfers on yolk sac of chicken embryos) could not be transfered in normal mice, however, it could be changed to phase I during 8 passages in immunosuppressed mice.", [["yolk sac", "ANATOMY", 78, 86], ["embryos", "ANATOMY", 98, 105], ["yolk sac", "MULTI-TISSUE_STRUCTURE", 78, 86], ["chicken", "ORGANISM", 90, 97], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 98, 105], ["mice", "ORGANISM", 141, 145], ["mice", "ORGANISM", 225, 229], ["chicken", "SPECIES", 90, 97], ["mice", "SPECIES", 141, 145], ["mice", "SPECIES", 225, 229], ["chicken", "SPECIES", 90, 97], ["mice", "SPECIES", 141, 145], ["mice", "SPECIES", 225, 229], ["yolk sac of chicken embryos", "TREATMENT", 78, 105], ["immunosuppressed mice", "TREATMENT", 208, 229]]], ["These results invalidate the hypothesis on the significance of antibodies for conversion of phase II to phase I of The virus of classical plague of fowl, strain Dobson, was grown in 10--11 day-old chicken embryos.", [["embryos", "ANATOMY", 205, 212], ["fowl", "ORGANISM", 148, 152], ["chicken", "ORGANISM", 197, 204], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 205, 212], ["antibodies", "PROTEIN", 63, 73], ["fowl", "SPECIES", 148, 152], ["chicken", "SPECIES", 197, 204], ["fowl", "SPECIES", 148, 152], ["chicken", "SPECIES", 197, 204], ["antibodies", "TREATMENT", 63, 73], ["old chicken embryos", "PROBLEM", 193, 212]]], ["The virus was then concentrated using the 2\u2022 zinc acetate and further purified on a DEAE cellulose.", [["zinc acetate", "CHEMICAL", 45, 57], ["zinc acetate", "CHEMICAL", 45, 57], ["\u2022 zinc acetate", "SIMPLE_CHEMICAL", 43, 57], ["cellulose", "SIMPLE_CHEMICAL", 89, 98], ["The virus", "PROBLEM", 0, 9], ["the 2\u2022 zinc acetate", "TREATMENT", 38, 57], ["a DEAE cellulose", "TREATMENT", 82, 98], ["virus", "OBSERVATION", 4, 9]]], ["The sediment was dissolved in a minimal volume of 0.141~ NaC1.", [["NaC1", "CHEMICAL", 57, 61], ["NaC1", "CHEMICAL", 57, 61], ["NaC1", "SIMPLE_CHEMICAL", 57, 61], ["sediment", "OBSERVATION", 4, 12], ["dissolved", "OBSERVATION_MODIFIER", 17, 26], ["minimal", "OBSERVATION_MODIFIER", 32, 39], ["volume", "OBSERVATION_MODIFIER", 40, 46]]], ["The purified virus (concentration 106-l07 HU/ml) was dissociated in phosphate buffer, pH 7.2, using a 2~o sodium dodecylsulphate and 1~o 2-mercaptoethanol.", [["phosphate", "CHEMICAL", 68, 77], ["sodium dodecylsulphate", "CHEMICAL", 106, 128], ["1~o 2-mercaptoethanol", "CHEMICAL", 133, 154], ["phosphate", "CHEMICAL", 68, 77], ["sodium dodecylsulphate", "CHEMICAL", 106, 128], ["1~o 2-mercaptoethanol", "CHEMICAL", 133, 154], ["phosphate", "SIMPLE_CHEMICAL", 68, 77], ["o sodium dodecylsulphate", "SIMPLE_CHEMICAL", 104, 128], ["1~o 2-mercaptoethanol", "SIMPLE_CHEMICAL", 133, 154], ["The purified virus", "TEST", 0, 18], ["concentration", "TEST", 20, 33], ["phosphate buffer", "TREATMENT", 68, 84], ["pH", "TEST", 86, 88], ["a 2~o sodium dodecylsulphate", "TREATMENT", 100, 128], ["mercaptoethanol", "TREATMENT", 139, 154], ["virus", "OBSERVATION", 13, 18]]], ["Eleetrophoresis was performed in 8% polyaerylamide gel.", [["Eleetrophoresis", "DISEASE", 0, 15], ["polyaerylamide", "CHEMICAL", 36, 50], ["polyaerylamide", "CHEMICAL", 36, 50], ["polyaerylamide", "SIMPLE_CHEMICAL", 36, 50], ["Eleetrophoresis", "TREATMENT", 0, 15], ["8% polyaerylamide gel", "TREATMENT", 33, 54]]], ["The polymerization took place in glass tubes 10X 0.6 em.", [["The polymerization", "TREATMENT", 0, 18], ["glass tubes", "TREATMENT", 33, 44], ["glass tubes", "OBSERVATION", 33, 44]]], ["Seven polypeptides could be clearly demonstrated electrophoretically in the virus studied.", [["Seven polypeptides", "PROBLEM", 0, 18], ["virus", "OBSERVATION", 76, 81]]], ["In some experiments, the SH groups were found to be carboxymethylated.", [["SH", "CHEMICAL", 25, 27]]], ["Differences in the number of polypeptide chains were nob observed.", [["polypeptide chains", "PROTEIN", 29, 47], ["polypeptide chains", "PROBLEM", 29, 47]]], ["In four polypeptides the presence of glyeoproteins could be demonstrated.", [["glyeoproteins", "GENE_OR_GENE_PRODUCT", 37, 50], ["glyeoproteins", "PROTEIN", 37, 50], ["glyeoproteins", "TREATMENT", 37, 50]]], ["The antigenic characteristic of the localisation of virus polypeptides was in agreement with data of Klenk et al. (1972) .", [["virus polypeptides", "PROBLEM", 52, 70], ["virus polypeptides", "OBSERVATION", 52, 70]]], ["Polypeptidos designated HA, HA1, NA and HA2 are glycoproteins, originating in the capsule of the virion.", [["capsule", "ANATOMY", 82, 89], ["virion", "ANATOMY", 97, 103], ["Polypeptidos", "CHEMICAL", 0, 12], ["Polypeptidos", "GENE_OR_GENE_PRODUCT", 0, 12], ["HA", "GENE_OR_GENE_PRODUCT", 24, 26], ["HA1", "GENE_OR_GENE_PRODUCT", 28, 31], ["NA", "GENE_OR_GENE_PRODUCT", 33, 35], ["HA2", "GENE_OR_GENE_PRODUCT", 40, 43], ["capsule", "CANCER", 82, 89], ["virion", "CELLULAR_COMPONENT", 97, 103], ["HA", "PROTEIN", 24, 26], ["HA1", "PROTEIN", 28, 31], ["NA", "PROTEIN", 33, 35], ["HA2", "PROTEIN", 40, 43], ["glycoproteins", "PROTEIN", 48, 61], ["Polypeptidos designated HA", "PROBLEM", 0, 26], ["HA1", "PROBLEM", 28, 31], ["NA and HA2 are glycoproteins", "PROBLEM", 33, 61], ["HA", "OBSERVATION_MODIFIER", 24, 26], ["glycoproteins", "OBSERVATION", 48, 61], ["capsule", "ANATOMY_MODIFIER", 82, 89], ["virion", "ANATOMY", 97, 103]]], ["If virus was treated with bromelain, all glycoproteins were split off the virus.", [["bromelain", "GENE_OR_GENE_PRODUCT", 26, 35], ["virus", "PROBLEM", 3, 8], ["bromelain", "TREATMENT", 26, 35], ["all glycoproteins", "TREATMENT", 37, 54], ["the virus", "PROBLEM", 70, 79]]], ["Polypeptides P, NP and MP were detected by polyaerylamide electrophoresis even in this case.", [["polyaerylamide", "CHEMICAL", 43, 57], ["MP", "GENE_OR_GENE_PRODUCT", 23, 25], ["polyaerylamide", "SIMPLE_CHEMICAL", 43, 57], ["NP", "DNA", 16, 18], ["polyaerylamide electrophoresis", "TEST", 43, 73]]], ["Using the protein markers, the molecular weight of individual virion polypeptides was established; the values vary within the range 26,000 to 91,000 daltons.", [["protein markers", "PROTEIN", 10, 25], ["virion polypeptides", "PROTEIN", 62, 81], ["the protein markers", "TEST", 6, 25], ["individual virion polypeptides", "TEST", 51, 81], ["the values", "TEST", 99, 109]]], ["The origin of HA polypeptide in the virus under study and in viruses in general, is discussed.", [["HA polypeptide", "GENE_OR_GENE_PRODUCT", 14, 28], ["HA polypeptide", "PROTEIN", 14, 28], ["HA polypeptide", "TREATMENT", 14, 28], ["the virus under study", "TEST", 32, 53], ["origin", "ANATOMY_MODIFIER", 4, 10], ["virus", "OBSERVATION", 36, 41], ["viruses", "OBSERVATION", 61, 68]]], ["L-forms were induced by penicillin in three strains of Listeria monocytogenes out of 20 strains.", [["penicillin", "CHEMICAL", 24, 34], ["penicillin", "CHEMICAL", 24, 34], ["penicillin", "SIMPLE_CHEMICAL", 24, 34], ["Listeria monocytogenes", "ORGANISM", 55, 77], ["Listeria monocytogenes", "SPECIES", 55, 77], ["Listeria monocytogenes", "SPECIES", 55, 77], ["penicillin", "TREATMENT", 24, 34], ["Listeria monocytogenes", "PROBLEM", 55, 77]]], ["These were stabilised after 5 passages on solid medium and did not revert into the bacterial form during subsequent 60 passages on media without an antibiotic.", [["5 passages on solid medium", "TREATMENT", 28, 54], ["an antibiotic", "TREATMENT", 145, 158]]], ["The colonies possessed characteristic morphology of L-forms.", [["colonies", "ANATOMY", 4, 12], ["morphology", "OBSERVATION_MODIFIER", 38, 48], ["L-forms", "OBSERVATION_MODIFIER", 52, 59]]], ["They were osmotically labile, did not grow at :NaC1 concentration below 1.5%.", [["NaC1", "CHEMICAL", 47, 51], ["NaC1", "CHEMICAL", 47, 51], ["NaC1", "SIMPLE_CHEMICAL", 47, 51], ["osmotically labile", "PROBLEM", 10, 28], ["NaC1 concentration", "TEST", 47, 65], ["labile", "OBSERVATION_MODIFIER", 22, 28]]], ["They required at least 1~o of native serum, the optimum concentration being 10%.", [["serum", "ANATOMY", 37, 42], ["serum", "ORGANISM_SUBSTANCE", 37, 42], ["native serum", "TREATMENT", 30, 42], ["the optimum concentration", "TREATMENT", 44, 69]]], ["All strains produced weak haemolysis in a blood-containing me-dium similarly as original bacteria.", [["blood", "ANATOMY", 42, 47], ["haemolysis", "DISEASE", 26, 36], ["blood", "ORGANISM_SUBSTANCE", 42, 47], ["me-dium", "SIMPLE_CHEMICAL", 59, 66], ["All strains", "PROBLEM", 0, 11], ["weak haemolysis", "PROBLEM", 21, 36], ["a blood", "TEST", 40, 47], ["original bacteria", "PROBLEM", 80, 97], ["weak", "OBSERVATION_MODIFIER", 21, 25], ["haemolysis", "OBSERVATION", 26, 36], ["bacteria", "OBSERVATION", 89, 97]]], ["In the liquid medium, the L-forms grew in the form of a fine sediment.", [["a fine sediment", "PROBLEM", 54, 69], ["liquid medium", "OBSERVATION_MODIFIER", 7, 20], ["fine", "OBSERVATION_MODIFIER", 56, 60], ["sediment", "OBSERVATION", 61, 69]]], ["The growth of colonies on solid medium was inhibited by antisera against L/ater/a monocytogenes.", [["colonies", "ANATOMY", 14, 22], ["L/ater/a monocytogenes", "ORGANISM", 73, 95], ["monocytogenes", "SPECIES", 82, 95], ["L/ater/a monocytogenes", "SPECIES", 73, 95], ["solid medium", "TREATMENT", 26, 38], ["a monocytogenes", "PROBLEM", 80, 95], ["growth", "OBSERVATION_MODIFIER", 4, 10], ["colonies", "OBSERVATION_MODIFIER", 14, 22], ["solid medium", "OBSERVATION_MODIFIER", 26, 38], ["monocytogenes", "OBSERVATION", 82, 95]]], ["L-forms are highly resistant to antibodies influencing the synthesis of the cell wall, however, to antibodies, which inhibit proteosynthesis, they arc more sensitive than bacterial forms.", [["cell wall", "ANATOMY", 76, 85], ["cell wall", "CELLULAR_COMPONENT", 76, 85], ["antibodies", "PROTEIN", 32, 42], ["antibodies", "PROTEIN", 99, 109], ["highly resistant to antibodies", "PROBLEM", 12, 42], ["antibodies", "TEST", 99, 109], ["highly", "OBSERVATION_MODIFIER", 12, 18], ["resistant", "OBSERVATION", 19, 28], ["cell wall", "ANATOMY", 76, 85]]], ["A number of properties of mycoplasmatales viruses belonging to types MV-L2 and MV-Lg-L 172 were found to be identical to thos~ of myxoviruses and kindred animal viruses which indicates the relation or identical origin of these groups of viruses.", [["mycoplasmatales viruses", "ORGANISM", 26, 49], ["MV-L2", "ORGANISM", 69, 74], ["MV-Lg-L 172", "ORGANISM", 79, 90], ["L 172", "DNA", 85, 90], ["MV-L2", "SPECIES", 69, 74], ["MV-Lg-L 172", "SPECIES", 79, 90], ["mycoplasmatales viruses", "PROBLEM", 26, 49], ["types MV", "TEST", 63, 71], ["MV", "TEST", 79, 81], ["Lg", "TEST", 82, 84], ["myxoviruses", "PROBLEM", 130, 141], ["kindred animal viruses", "PROBLEM", 146, 168], ["L2", "ANATOMY", 72, 74], ["Lg", "ANATOMY", 82, 84], ["animal viruses", "OBSERVATION", 154, 168], ["viruses", "OBSERVATION", 237, 244]]], ["The properties are: (1) structure ~of particles, containing nucleic acid enclosed in the three layer lipoproteinic, biological unit-membrane; (2) heterogeneity in the size of virus particles; the particles are not rigid but rather of pliant consistency;Morphological, Biochemical and Developmental(3) electron microscopic studies show that mature particles are not present inside the ceils but they can mature either at the moment of lysis of the host cell or by budding and become enveloped by the membrane at this final stage.", [["membrane", "ANATOMY", 132, 140], ["ceils", "ANATOMY", 384, 389], ["cell", "ANATOMY", 452, 456], ["membrane", "ANATOMY", 499, 507], ["nucleic acid", "CHEMICAL", 60, 72], ["nucleic acid", "SIMPLE_CHEMICAL", 60, 72], ["membrane", "CELLULAR_COMPONENT", 132, 140], ["host cell", "CELL", 447, 456], ["membrane", "CELLULAR_COMPONENT", 499, 507], ["nucleic acid", "TEST", 60, 72], ["heterogeneity in the size of virus particles", "PROBLEM", 146, 190], ["rigid", "PROBLEM", 214, 219], ["electron microscopic studies", "TEST", 301, 329], ["mature particles", "PROBLEM", 340, 356], ["lysis", "TREATMENT", 434, 439], ["nucleic acid", "OBSERVATION", 60, 72], ["three", "ANATOMY_MODIFIER", 89, 94], ["layer", "ANATOMY_MODIFIER", 95, 100], ["membrane", "OBSERVATION_MODIFIER", 132, 140], ["size", "OBSERVATION_MODIFIER", 167, 171], ["virus particles", "OBSERVATION", 175, 190], ["mature", "OBSERVATION_MODIFIER", 340, 346], ["particles", "OBSERVATION", 347, 356], ["lysis", "OBSERVATION", 434, 439], ["host cell", "OBSERVATION", 447, 456]]], ["Since mycoplasmas themselves are close to mammalian cells as to surface structure and they are elementary self-reproducing microorganisms, parasiting in plant and animal tissues where they can live together with their viruses, in many cases inside the cells, it is possible that these viruses could get adapted to the host cells of higher organisms or the viruses of the~ organisms could be taken over by royceplasmas.", [["cells", "ANATOMY", 52, 57], ["surface structure", "ANATOMY", 64, 81], ["tissues", "ANATOMY", 170, 177], ["cells", "ANATOMY", 252, 257], ["cells", "ANATOMY", 323, 328], ["mammalian cells", "CELL", 42, 57], ["tissues", "TISSUE", 170, 177], ["cells", "CELL", 252, 257], ["host cells", "CELL", 318, 328], ["royceplasmas", "SIMPLE_CHEMICAL", 405, 417], ["mammalian cells", "CELL_TYPE", 42, 57], ["host cells", "CELL_TYPE", 318, 328], ["mycoplasmas themselves", "PROBLEM", 6, 28], ["their viruses", "PROBLEM", 212, 225], ["these viruses", "PROBLEM", 279, 292], ["higher organisms", "PROBLEM", 332, 348], ["the viruses", "PROBLEM", 352, 363], ["mammalian cells", "OBSERVATION", 42, 57], ["viruses", "OBSERVATION", 285, 292]]], ["The former of the two possibilities is very probable in view of the relation of the morphogenesis of these viruses to the characteristic features of mycoplasmal structure and development.", [["mycoplasmal structure", "PROBLEM", 149, 170], ["very probable", "UNCERTAINTY", 39, 52], ["mycoplasmal structure", "OBSERVATION", 149, 170]]], ["The difference in the nucleic acid type of globular viruses of mycoplasmas hitherto described and of myxoviruses cannot be explained on the basis of present knowledge of mycoplasmatales viruses, but a number of processes arc l~mwn which could take part in this conversion and the similarity of other properties of these viruses shows their obvious relationship.", [["nucleic acid", "CHEMICAL", 22, 34], ["mycoplasmatales viruses", "ORGANISM", 170, 193], ["the nucleic acid type of globular viruses of mycoplasmas", "PROBLEM", 18, 74], ["mycoplasmatales viruses", "PROBLEM", 170, 193], ["these viruses", "PROBLEM", 314, 327], ["difference", "OBSERVATION_MODIFIER", 4, 14], ["nucleic acid", "OBSERVATION", 22, 34], ["globular", "OBSERVATION_MODIFIER", 43, 51], ["viruses", "OBSERVATION", 52, 59], ["mycoplasmatales viruses", "OBSERVATION", 170, 193], ["viruses", "OBSERVATION", 320, 327]]], ["Antibody inhibition of neuraminidase activity was studied by using influenza A virus recombinants containing haemagglutinin and different neuraminidase subtypes.", [["neuraminidase", "GENE_OR_GENE_PRODUCT", 23, 36], ["influenza A virus", "ORGANISM", 67, 84], ["haemagglutinin", "GENE_OR_GENE_PRODUCT", 109, 123], ["neuraminidase", "PROTEIN", 23, 36], ["haemagglutinin", "PROTEIN", 109, 123], ["neuraminidase subtypes", "PROTEIN", 138, 160], ["influenza A virus", "SPECIES", 67, 84], ["influenza A virus", "SPECIES", 67, 84], ["Antibody inhibition", "TEST", 0, 19], ["neuraminidase activity", "PROBLEM", 23, 45], ["influenza A virus recombinants", "TREATMENT", 67, 97], ["haemagglutinin", "TREATMENT", 109, 123], ["different neuraminidase subtypes", "TREATMENT", 128, 160], ["neuraminidase activity", "OBSERVATION", 23, 45], ["neuraminidase subtypes", "OBSERVATION", 138, 160]]], ["Neuraminidase was inhibited in every case tested, even when hyperimmuno serum containing antibodies only to the relevant haemagglutinin was used.", [["hyperimmuno serum", "ANATOMY", 60, 77], ["Neuraminidase", "GENE_OR_GENE_PRODUCT", 0, 13], ["serum", "ORGANISM_SUBSTANCE", 72, 77], ["haemagglutinin", "GENE_OR_GENE_PRODUCT", 121, 135], ["antibodies", "PROTEIN", 89, 99], ["haemagglutinin", "PROTEIN", 121, 135], ["Neuraminidase", "TREATMENT", 0, 13], ["hyperimmuno serum containing antibodies", "PROBLEM", 60, 99], ["the relevant haemagglutinin", "PROBLEM", 108, 135]]], ["This steric inhibition of virus neuraminidase was not observed if the inhibition test was carried out in the presence of a non-ionic detergent (Triton-X-100), however.", [["Triton-X-100", "CHEMICAL", 144, 156], ["Triton-X-100", "SIMPLE_CHEMICAL", 144, 156], ["virus neuraminidase", "PROBLEM", 26, 45], ["the inhibition test", "TEST", 66, 85], ["a non-ionic detergent", "TREATMENT", 121, 142], ["virus", "OBSERVATION", 26, 31]]], ["Inhibition of neuraminidase by serum containing antibodies to the neuraminidase in question was not influenced by the presence of Triten-X-100.", [["serum", "ANATOMY", 31, 36], ["Triten-X-100", "CHEMICAL", 130, 142], ["Triten-X-100", "CHEMICAL", 130, 142], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 14, 27], ["serum", "ORGANISM_SUBSTANCE", 31, 36], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 66, 79], ["neuraminidase", "PROTEIN", 14, 27], ["antibodies", "PROTEIN", 48, 58], ["neuraminidase", "PROTEIN", 66, 79], ["neuraminidase", "TREATMENT", 14, 27], ["serum containing antibodies", "TEST", 31, 58], ["the neuraminidase", "TEST", 62, 79]]], ["The use of Triton-X-100 allows very simple and quick detection of sterie inhibition of virus neuraminidase by antihaemagglutinin antibodies.Characterization of Influenza Virus ts Mutants.E. Tu~Kovi, E. AlOV&, V. VONKA, Institute of Scra and Vaccines, Prague.Characterization of Influenza Virus ts Mutants.After 5-fluorouracil induction, 2 ts mutants were isolated from a recombinant obtained in our laboratory by crossing the viruses A2/Singaporc and A0/NWS.", [["Triton-X-100", "CHEMICAL", 11, 23], ["5-fluorouracil", "CHEMICAL", 311, 325], ["5-fluorouracil", "CHEMICAL", 311, 325], ["Triton-X-100", "SIMPLE_CHEMICAL", 11, 23], ["antihaemagglutinin antibodies", "GENE_OR_GENE_PRODUCT", 110, 139], ["Influenza Virus", "ORGANISM", 160, 175], ["Influenza Virus", "ORGANISM", 278, 293], ["5-fluorouracil", "SIMPLE_CHEMICAL", 311, 325], ["Singaporc", "GENE_OR_GENE_PRODUCT", 437, 446], ["virus neuraminidase", "PROTEIN", 87, 106], ["antihaemagglutinin antibodies", "PROTEIN", 110, 139], ["A2", "PROTEIN", 434, 436], ["Influenza Virus", "SPECIES", 160, 175], ["Influenza Virus", "SPECIES", 278, 293], ["Influenza Virus ts", "SPECIES", 160, 178], ["Influenza Virus ts", "SPECIES", 278, 296], ["Triton", "TREATMENT", 11, 17], ["sterie inhibition", "TREATMENT", 66, 83], ["virus neuraminidase", "TREATMENT", 87, 106], ["antihaemagglutinin antibodies", "PROBLEM", 110, 139], ["Influenza Virus ts Mutants", "PROBLEM", 160, 186], ["Scra", "TREATMENT", 232, 236], ["Vaccines", "TREATMENT", 241, 249], ["Influenza Virus ts Mutants", "PROBLEM", 278, 304], ["5-fluorouracil induction", "TREATMENT", 311, 335], ["2 ts mutants", "PROBLEM", 337, 349], ["A0/NWS", "TREATMENT", 451, 457], ["Influenza Virus", "OBSERVATION", 160, 175], ["Influenza Virus", "OBSERVATION", 278, 293], ["viruses", "OBSERVATION", 426, 433]]], ["The mutants were characterized by growth tests at a permissive (35~ and a nonpermissive (39~ temperature.", [["growth tests", "TEST", 34, 46]]], ["Haemadsorptive, haemagglutinating and neuraminidase activity, RNP antigen formation and ultrastructural changes in the cells were studied and infectious virus production at both temperatures was determined.", [["cells", "ANATOMY", 119, 124], ["RNP antigen", "GENE_OR_GENE_PRODUCT", 62, 73], ["cells", "CELL", 119, 124], ["neuraminidase", "PROTEIN", 38, 51], ["RNP antigen", "PROTEIN", 62, 73], ["Haemadsorptive", "TREATMENT", 0, 14], ["haemagglutinating", "PROBLEM", 16, 33], ["neuraminidase activity", "PROBLEM", 38, 60], ["RNP antigen formation", "PROBLEM", 62, 83], ["ultrastructural changes in the cells", "PROBLEM", 88, 124], ["infectious virus production", "PROBLEM", 142, 169], ["neuraminidase activity", "OBSERVATION", 38, 60], ["infectious", "OBSERVATION_MODIFIER", 142, 152]]], ["The results, including those of the temperature tests,Characterization of Influenza Virus ts Mutants.show that ts defects of the given mutants involve various virus functions.", [["Influenza Virus", "DISEASE", 74, 89], ["Influenza Virus", "ORGANISM", 74, 89], ["Influenza Virus", "SPECIES", 74, 89], ["Influenza Virus ts", "SPECIES", 74, 92], ["the temperature tests", "TEST", 32, 53], ["Influenza Virus ts Mutants", "PROBLEM", 74, 100], ["ts defects", "PROBLEM", 111, 121], ["various virus functions", "PROBLEM", 151, 174], ["defects", "OBSERVATION", 114, 121]]], ["Neurotropism of strain A0/NWS thermoresistant mutant obtained by successive adaptation to high temperatures was tested in monkeys (Maccaeus rhesus).", [["strain A0/NWS thermoresistant mutant", "ORGANISM", 16, 52], ["monkeys", "ORGANISM", 122, 129], ["Maccaeus rhesus", "ORGANISM", 131, 146], ["monkeys", "SPECIES", 122, 129], ["Maccaeus rhesus", "SPECIES", 131, 146], ["Maccaeus rhesus", "SPECIES", 131, 146], ["strain A0/NWS thermoresistant mutant", "PROBLEM", 16, 52], ["high temperatures", "PROBLEM", 90, 107]]], ["The monkeys were infected intranasally, intracerebrally and by a combination of the two methods.", [["intranasally", "ANATOMY", 26, 38], ["monkeys", "ORGANISM", 4, 11], ["monkeys", "SPECIES", 4, 11], ["the two methods", "TREATMENT", 80, 95], ["infected", "OBSERVATION", 17, 25]]], ["Histological changes in their brain, lungs and spleen were studied and the presence of virus in the organs was determined by cultivating organ suspensions.", [["brain", "ANATOMY", 30, 35], ["lungs", "ANATOMY", 37, 42], ["spleen", "ANATOMY", 47, 53], ["organs", "ANATOMY", 100, 106], ["organ", "ANATOMY", 137, 142], ["brain", "ORGAN", 30, 35], ["lungs", "ORGAN", 37, 42], ["spleen", "ORGAN", 47, 53], ["organs", "ORGAN", 100, 106], ["organ", "ORGAN", 137, 142], ["Histological changes in their brain, lungs and spleen", "PROBLEM", 0, 53], ["virus in the organs", "PROBLEM", 87, 106], ["brain", "ANATOMY", 30, 35], ["lungs", "ANATOMY", 37, 42], ["spleen", "ANATOMY", 47, 53], ["virus", "OBSERVATION", 87, 92], ["organs", "ANATOMY", 100, 106]]], ["Specific antibodies were determined in a haemagglutination inhibition test.", [["antibodies", "PROTEIN", 9, 19], ["Specific antibodies", "TEST", 0, 19], ["a haemagglutination inhibition test", "TEST", 39, 74]]], ["CNS lesions were found only in i.e. infected monkeys.", [["CNS lesions", "ANATOMY", 0, 11], ["CNS lesions", "PATHOLOGICAL_FORMATION", 0, 11], ["monkeys", "ORGANISM", 45, 52], ["monkeys", "SPECIES", 45, 52], ["CNS lesions", "PROBLEM", 0, 11], ["lesions", "OBSERVATION", 4, 11], ["infected", "OBSERVATION", 36, 44]]], ["Most of the findings support the hypothesis of a single, defective influenza virus replication cycle, but the fact that a brain suspension from i.e. infected monkeys produces typical influenzal meningoencephalitis in mice still remains unexplained.", [["brain", "ANATOMY", 122, 127], ["meningoencephalitis", "DISEASE", 194, 213], ["influenza virus", "ORGANISM", 67, 82], ["brain", "ORGAN", 122, 127], ["monkeys", "ORGANISM", 158, 165], ["mice", "ORGANISM", 217, 221], ["mice", "SPECIES", 217, 221], ["mice", "SPECIES", 217, 221], ["a single, defective influenza virus replication cycle", "PROBLEM", 47, 100], ["a brain suspension", "TREATMENT", 120, 138], ["typical influenzal meningoencephalitis", "PROBLEM", 175, 213], ["influenza virus", "OBSERVATION", 67, 82], ["brain", "ANATOMY", 122, 127], ["infected", "OBSERVATION", 149, 157], ["influenzal", "OBSERVATION_MODIFIER", 183, 193], ["meningoencephalitis", "OBSERVATION", 194, 213]]], ["The question of the elongate structures released from the surface of monkey ependymal cells after i.c. infection is likewise still unresolved.Bratislava.For removing nonspecific inhibitors of myxoviruses, WHO experts recommend preparing the sera with RDE.", [["structures", "ANATOMY", 29, 39], ["surface", "ANATOMY", 58, 65], ["ependymal cells", "ANATOMY", 76, 91], ["sera", "ANATOMY", 241, 245], ["infection", "DISEASE", 103, 112], ["surface", "CELLULAR_COMPONENT", 58, 65], ["monkey", "ORGANISM", 69, 75], ["ependymal cells", "CELL", 76, 91], ["i.c.", "IMMATERIAL_ANATOMICAL_ENTITY", 98, 102], ["sera", "ORGANISM_SUBSTANCE", 241, 245], ["monkey ependymal cells", "CELL_TYPE", 69, 91], ["the elongate structures", "PROBLEM", 16, 39], ["i.c. infection", "PROBLEM", 98, 112], ["nonspecific inhibitors of myxoviruses", "TREATMENT", 166, 203], ["elongate", "OBSERVATION_MODIFIER", 20, 28], ["surface", "OBSERVATION_MODIFIER", 58, 65], ["monkey", "OBSERVATION_MODIFIER", 69, 75], ["ependymal cells", "OBSERVATION", 76, 91], ["infection", "OBSERVATION", 103, 112]]], ["We tested this method, using RDE cholera filtrate preparations (Czechoslovak and foreign produced) and recent and prototype strains of influenza, parainfluenza and parotitis virus.", [["influenza, parainfluenza and parotitis virus", "DISEASE", 135, 179], ["influenza", "ORGANISM", 135, 144], ["parainfluenza", "ORGANISM", 146, 159], ["parotitis virus", "ORGANISM", 164, 179], ["parainfluenza", "SPECIES", 146, 159], ["parotitis virus", "SPECIES", 164, 179], ["this method", "TREATMENT", 10, 21], ["RDE cholera filtrate preparations", "TREATMENT", 29, 62], ["influenza", "PROBLEM", 135, 144], ["parainfluenza", "PROBLEM", 146, 159], ["parotitis virus", "PROBLEM", 164, 179], ["influenza", "OBSERVATION", 135, 144]]], ["We found that crude cholera filtrate preparations did not adequately remove nonspecifie inhibitors of recent, epidemiologically important, influenza A virus strains and that semlpuritled RDE preparations (RBC eluates) were needed.", [["influenza A virus", "ORGANISM", 139, 156], ["RDE", "SIMPLE_CHEMICAL", 187, 190], ["influenza A virus", "SPECIES", 139, 156], ["influenza A virus", "SPECIES", 139, 156], ["crude cholera filtrate preparations", "TREATMENT", 14, 49], ["influenza A virus strains", "PROBLEM", 139, 164], ["semlpuritled RDE preparations", "TREATMENT", 174, 203], ["RBC eluates", "TEST", 205, 216]]], ["Czechoslovak preparations were more potent than those produced by Messrs Duphar (Holland); they reliably removed nonspecific inhibitors without significantly impairing specific antibodies.", [["specific antibodies", "PROTEIN", 168, 187], ["Czechoslovak preparations", "TREATMENT", 0, 25], ["nonspecific inhibitors", "PROBLEM", 113, 135], ["significantly impairing specific antibodies", "PROBLEM", 144, 187], ["more potent", "OBSERVATION_MODIFIER", 31, 42]]], ["The RDE preparations were produced, in principle, according to the method of Burner and Stone, using developing chick embryos for the propagation of V. choleras and all-glass G5 filters for filtering the cleared allantoic fluid.", [["embryos", "ANATOMY", 118, 125], ["allantoic fluid", "ANATOMY", 212, 227], ["chick", "ORGANISM", 112, 117], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 118, 125], ["allantoic fluid", "ORGANISM_SUBSTANCE", 212, 227], ["V. choleras", "SPECIES", 149, 160], ["The RDE preparations", "TREATMENT", 0, 20], ["Stone", "PROBLEM", 88, 93], ["developing chick embryos", "TREATMENT", 101, 125], ["V. choleras", "TREATMENT", 149, 160], ["all-glass G5 filters", "TREATMENT", 165, 185], ["the cleared allantoic fluid", "PROBLEM", 200, 227], ["Stone", "OBSERVATION", 88, 93], ["allantoic fluid", "OBSERVATION", 212, 227]]], ["The enzymatic activity (neuraminidase content) and RDE titre of the preparations and their ability to destroy inhibitors in standard sera were tested.", [["sera", "ANATOMY", 133, 137], ["neuraminidase", "SIMPLE_CHEMICAL", 24, 37], ["RDE", "SIMPLE_CHEMICAL", 51, 54], ["sera", "ORGANISM_SUBSTANCE", 133, 137], ["neuraminidase", "PROTEIN", 24, 37], ["The enzymatic activity (neuraminidase content", "PROBLEM", 0, 45], ["the preparations", "TREATMENT", 64, 80], ["enzymatic", "OBSERVATION_MODIFIER", 4, 13], ["activity", "OBSERVATION_MODIFIER", 14, 22]]], ["The RDE preparations were supplied to Czechoslovak virology laboratories, ust~lly in the lyophilized form.", [["The RDE preparations", "TREATMENT", 0, 20]]], ["Another final way of preparing RDE was also tested.", [["RDE", "SIMPLE_CHEMICAL", 31, 34], ["RDE", "DNA", 31, 34]]], ["In this, the preparation was dried by atomization and the resultant powder was compressed into dry tablets.", [["atomization", "TREATMENT", 38, 49], ["the resultant powder", "TREATMENT", 54, 74]]], ["The distribution of the virus particle and of its antigenic components was studied in virus preparations from embryonic mouse brain tissue by zonal centrifugation in a sucrose density gradient, by electron microscopy identification of the resultant fractions and by serological tests.", [["embryonic", "ANATOMY", 110, 119], ["brain tissue", "ANATOMY", 126, 138], ["sucrose", "CHEMICAL", 168, 175], ["sucrose", "CHEMICAL", 168, 175], ["mouse", "ORGANISM", 120, 125], ["brain tissue", "TISSUE", 126, 138], ["sucrose", "SIMPLE_CHEMICAL", 168, 175], ["mouse", "SPECIES", 120, 125], ["mouse", "SPECIES", 120, 125], ["the virus particle", "PROBLEM", 20, 38], ["its antigenic components", "PROBLEM", 46, 70], ["virus preparations", "TREATMENT", 86, 104], ["embryonic mouse brain tissue", "PROBLEM", 110, 138], ["zonal centrifugation", "TREATMENT", 142, 162], ["a sucrose density gradient", "PROBLEM", 166, 192], ["electron microscopy", "TEST", 197, 216], ["the resultant fractions", "PROBLEM", 235, 258], ["serological tests", "TEST", 266, 283], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["virus particle", "OBSERVATION", 24, 38], ["embryonic mouse brain tissue", "OBSERVATION", 110, 138], ["zonal centrifugation", "OBSERVATION", 142, 162], ["sucrose density", "OBSERVATION_MODIFIER", 168, 183], ["resultant fractions", "OBSERVATION", 239, 258]]], ["Strain OC 43 v'irions were found in the 1.16 density zone.", [["OC", "CHEMICAL", 7, 9], ["Strain OC 43 v'irions", "TEST", 0, 21], ["1.16 density", "OBSERVATION_MODIFIER", 40, 52], ["zone", "ANATOMY_MODIFIER", 53, 57]]], ["Haemagglutinating activity was associated mainly with complete virus, whereas complement-fixing activity was found in the ribosomal fraction (sp. density 1.14).", [["ribosomal", "ANATOMY", 122, 131], ["ribosomal", "CELLULAR_COMPONENT", 122, 131], ["Haemagglutinating activity", "PROBLEM", 0, 26], ["complete virus", "PROBLEM", 54, 68], ["fixing activity", "PROBLEM", 89, 104], ["ribosomal fraction", "ANATOMY", 122, 140]]], ["Conditions for storing the isolated fractions so as to preserve their biological activity were determined.", [["the isolated fractions", "PROBLEM", 23, 45]]], ["During an epidemic caused by type A2/Hongkong and A2/England influenza virus, the authors systematically examined postmortem material from 9l subjects who died during an acute im~luenza infection.", [["influenza virus", "DISEASE", 61, 76], ["im~luenza infection", "DISEASE", 176, 195], ["A2/England influenza virus", "ORGANISM", 50, 76], ["influenza virus", "SPECIES", 61, 76], ["type A2/Hongkong and A2/England influenza virus", "SPECIES", 29, 76], ["type A2/Hongkong and A2/England influenza virus", "PROBLEM", 29, 76], ["an acute im~luenza infection", "PROBLEM", 167, 195], ["influenza virus", "OBSERVATION", 61, 76], ["acute", "OBSERVATION_MODIFIER", 170, 175], ["im~luenza", "OBSERVATION_MODIFIER", 176, 185], ["infection", "OBSERVATION", 186, 195]]], ["In fve, they demonstrated influenza virus in organs other thaw those of the respiratory tract (heart, liver, spleen).", [["organs", "ANATOMY", 45, 51], ["respiratory tract", "ANATOMY", 76, 93], ["heart", "ANATOMY", 95, 100], ["liver", "ANATOMY", 102, 107], ["spleen", "ANATOMY", 109, 115], ["influenza virus", "ORGANISM", 26, 41], ["organs", "ORGAN", 45, 51], ["respiratory tract", "ORGANISM_SUBDIVISION", 76, 93], ["heart", "ORGAN", 95, 100], ["liver", "ORGAN", 102, 107], ["spleen", "ORGAN", 109, 115], ["influenza virus in organs", "PROBLEM", 26, 51], ["influenza virus", "OBSERVATION", 26, 41], ["respiratory tract", "ANATOMY", 76, 93], ["heart", "ANATOMY", 95, 100], ["liver", "ANATOMY", 102, 107], ["spleen", "ANATOMY", 109, 115]]], ["These were all subjects with lowered resistance: three were over the age of 70, one was a young woman who had given birth five days previously and one was an infant aged four months.", [["woman", "ORGANISM", 96, 101], ["woman", "SPECIES", 96, 101], ["infant", "SPECIES", 158, 164]]], ["The virus was demonstrated by isolation and by examining cryoteme sections of the organs by the immunofluoreseence method.Study o] the Prevalence o/ Adenoviruses and HerpesVirus in an Infant Community.", [["cryoteme sections", "ANATOMY", 57, 74], ["organs", "ANATOMY", 82, 88], ["cryoteme sections", "MULTI-TISSUE_STRUCTURE", 57, 74], ["organs", "ORGAN", 82, 88], ["The virus", "PROBLEM", 0, 9], ["the immunofluoreseence method", "TEST", 92, 121], ["virus", "OBSERVATION", 4, 9], ["organs", "ANATOMY", 82, 88]]], ["J. ioL~, K. VA-SEK, Z. PAVLIK, Department of Child Development Research, Faculty of Paediatrics, Prag~m; Department of Economic and Regional Geography, Faculty of Science, Charles University, Prague.Study o] the Prevalence o/ Adenoviruses and HerpesVirus infections of the respiratory system present clinically similar signs despite antigenic diversity of the virus pathogens.", [["respiratory system", "ANATOMY", 273, 291], ["HerpesVirus infections", "DISEASE", 243, 265], ["o/ Adenoviruses", "TREATMENT", 223, 238], ["HerpesVirus infections of the respiratory system", "PROBLEM", 243, 291], ["the virus pathogens", "PROBLEM", 356, 375], ["HerpesVirus infections", "OBSERVATION", 243, 265], ["respiratory system", "ANATOMY", 273, 291], ["virus pathogens", "OBSERVATION", 360, 375]]], ["When evaluating the incidence of serum conversions against adenoviruses and four human herpes viruses among the infants in an infants' home, the authors used the statistical method employed in demography.", [["serum", "ANATOMY", 33, 38], ["herpes viruses", "DISEASE", 87, 101], ["serum", "ORGANISM_SUBSTANCE", 33, 38], ["adenoviruses", "ORGANISM", 59, 71], ["human", "ORGANISM", 81, 86], ["herpes viruses", "ORGANISM", 87, 101], ["infants", "ORGANISM", 112, 119], ["infants", "ORGANISM", 126, 133], ["human", "SPECIES", 81, 86], ["infants", "SPECIES", 112, 119], ["infants", "SPECIES", 126, 133], ["human herpes viruses", "SPECIES", 81, 101], ["serum conversions", "TREATMENT", 33, 50], ["adenoviruses", "PROBLEM", 59, 71], ["four human herpes viruses", "TREATMENT", 76, 101]]], ["This method is suitable for studying the progressive prevalence of different viruses in a child community, with or without clinical signs.", [["different viruses", "PROBLEM", 67, 84], ["clinical signs", "TEST", 123, 137], ["different", "OBSERVATION_MODIFIER", 67, 76], ["viruses", "OBSERVATION", 77, 84]]], ["The cross reactivity of the viruses A/England/ 42/72 and A/Hongkong/68 was studied by means of hyperimmune rabbit sera, the sera of subjects who had influenza in 1969 or 1972 and the sera of subjects of different ages vaccinated with inactivated vaccine prepared from the strain A/England/42/72.", [["sera", "ANATOMY", 114, 118], ["sera", "ANATOMY", 124, 128], ["sera", "ANATOMY", 183, 187], ["influenza", "DISEASE", 149, 158], ["England/ 42/72", "ORGANISM", 38, 52], ["A/Hongkong/68", "ORGANISM", 57, 70], ["hyperimmune", "ORGANISM", 95, 106], ["rabbit", "ORGANISM", 107, 113], ["sera", "ORGANISM_SUBSTANCE", 114, 118], ["sera", "ORGANISM_SUBSTANCE", 124, 128], ["sera", "ORGANISM_SUBSTANCE", 183, 187], ["rabbit", "SPECIES", 107, 113], ["A/England/ 42/72", "SPECIES", 36, 52], ["A/Hongkong/68", "SPECIES", 57, 70], ["rabbit", "SPECIES", 107, 113], ["A/England/42/72", "SPECIES", 279, 294], ["hyperimmune rabbit sera", "TREATMENT", 95, 118], ["influenza", "PROBLEM", 149, 158], ["inactivated vaccine", "TREATMENT", 234, 253], ["viruses", "OBSERVATION", 28, 35]]], ["The results show that, according to its haemagglutinin, the virus A/England/42/72 is the \"prime\" strain in relation to the virus A/Hongkong/68.", [["haemagglutinin", "GENE_OR_GENE_PRODUCT", 40, 54], ["England/42/72", "ORGANISM", 68, 81], ["Hongkong/68", "ORGANISM", 131, 142], ["A/England/42/72", "SPECIES", 66, 81], ["virus A/Hongkong/68", "SPECIES", 123, 142]]], ["Some evidence was likewise obtained indicating that the reverse applies to the neuraminidase antigens of the two viruses.", [["neuraminidase antigens", "GENE_OR_GENE_PRODUCT", 79, 101], ["neuraminidase antigens", "PROTEIN", 79, 101], ["the neuraminidase antigens", "TREATMENT", 75, 101]]], ["The permanent cell line MDBK and a primary calf kidney cell culture were infected with two strains of IBR virus.", [["cell line MDBK", "ANATOMY", 14, 28], ["kidney cell culture", "ANATOMY", 48, 67], ["cell line MDBK", "CELL", 14, 28], ["calf", "ORGANISM", 43, 47], ["kidney cell", "CELL", 48, 59], ["IBR virus", "ORGANISM", 102, 111], ["permanent cell line MDBK", "CELL_LINE", 4, 28], ["primary calf kidney cell culture", "CELL_LINE", 35, 67], ["calf", "SPECIES", 43, 47], ["MDBK", "SPECIES", 24, 28], ["calf", "SPECIES", 43, 47], ["IBR virus", "SPECIES", 102, 111], ["The permanent cell line MDBK", "TREATMENT", 0, 28], ["a primary calf kidney cell culture", "TEST", 33, 67], ["IBR virus", "PROBLEM", 102, 111], ["permanent cell line MDBK", "OBSERVATION", 4, 28], ["calf", "ANATOMY_MODIFIER", 43, 47], ["kidney", "ANATOMY", 48, 54], ["cell", "OBSERVATION", 55, 59], ["IBR virus", "OBSERVATION", 102, 111]]], ["It was found that: (1) The outer envelope of virus particles in the cytoplasm canals and the extracellular space has a distinct membrane unit structure and processes or globular formations on its surface, while the envelope of intranuclear particles and particles in the perinuclear cisterna consists of only a single dark layer.Electron Microscopy Study o/ the Structure o/ the Envelopes o/In]ectious Bovine Rhinotraeheitis ( IBR) Virus in Ultrathiv~(2) The outer envelope of cytoplasmic and extracellular virus particles is often pleomorphous compared with that of intranuelear particles and the space between the eapsid and the outer envelope is filled with varying amounts of a dark substance.", [["cytoplasm canals", "ANATOMY", 68, 84], ["extracellular space", "ANATOMY", 93, 112], ["membrane unit", "ANATOMY", 128, 141], ["surface", "ANATOMY", 196, 203], ["intranuclear particles", "ANATOMY", 227, 249], ["perinuclear cisterna", "ANATOMY", 271, 291], ["cytoplasmic", "ANATOMY", 477, 488], ["extracellular", "ANATOMY", 493, 506], ["outer envelope", "ANATOMY", 631, 645], ["cytoplasm canals", "MULTI-TISSUE_STRUCTURE", 68, 84], ["extracellular space", "CELLULAR_COMPONENT", 93, 112], ["membrane unit", "CELLULAR_COMPONENT", 128, 141], ["surface", "CELLULAR_COMPONENT", 196, 203], ["intranuclear particles", "CELLULAR_COMPONENT", 227, 249], ["perinuclear", "CELLULAR_COMPONENT", 271, 282], ["cisterna", "IMMATERIAL_ANATOMICAL_ENTITY", 283, 291], ["Bovine", "ORGANISM", 402, 408], ["cytoplasmic", "ORGANISM_SUBSTANCE", 477, 488], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 493, 506], ["Bovine", "SPECIES", 402, 408], ["The outer envelope of virus particles", "TREATMENT", 23, 60], ["globular formations on its surface", "PROBLEM", 169, 203], ["a single dark layer", "PROBLEM", 309, 328], ["Electron Microscopy", "TEST", 329, 348], ["ectious Bovine Rhinotraeheitis ( IBR) Virus in Ultrathiv~", "TREATMENT", 394, 451], ["cytoplasmic and extracellular virus particles", "PROBLEM", 477, 522], ["virus particles", "OBSERVATION", 45, 60], ["cytoplasm canals", "OBSERVATION", 68, 84], ["extracellular", "ANATOMY_MODIFIER", 93, 106], ["distinct", "OBSERVATION_MODIFIER", 119, 127], ["membrane unit structure", "OBSERVATION", 128, 151], ["globular", "OBSERVATION_MODIFIER", 169, 177], ["formations", "OBSERVATION", 178, 188], ["surface", "OBSERVATION_MODIFIER", 196, 203], ["intranuclear particles", "OBSERVATION", 227, 249], ["particles", "OBSERVATION_MODIFIER", 254, 263], ["perinuclear cisterna", "ANATOMY", 271, 291], ["single", "OBSERVATION_MODIFIER", 311, 317], ["dark", "OBSERVATION_MODIFIER", 318, 322], ["layer", "OBSERVATION_MODIFIER", 323, 328], ["cytoplasmic", "OBSERVATION_MODIFIER", 477, 488], ["extracellular virus", "OBSERVATION", 493, 512], ["outer", "ANATOMY_MODIFIER", 631, 636], ["envelope", "OBSERVATION_MODIFIER", 637, 645], ["filled", "OBSERVATION", 649, 655], ["varying", "OBSERVATION_MODIFIER", 661, 668], ["amounts", "OBSERVATION_MODIFIER", 669, 676], ["dark substance", "OBSERVATION", 682, 696]]], ["The substance is contiguous to the inner aspect of the outer envelope, but is separated from the capsid by a light zone.", [["inner aspect", "ANATOMY", 35, 47], ["outer envelope", "ANATOMY", 55, 69], ["outer envelope", "CELLULAR_COMPONENT", 55, 69], ["substance", "OBSERVATION", 4, 13], ["inner", "ANATOMY_MODIFIER", 35, 40], ["outer", "ANATOMY_MODIFIER", 55, 60], ["envelope", "OBSERVATION", 61, 69], ["capsid", "OBSERVATION", 97, 103]]], ["The dark substance, which is linked to the membranes of the cytoplasm canals, enters the virion, together with a nucleocapsid acquiring an outer envelope, by being forced into these canals.", [["membranes", "ANATOMY", 43, 52], ["cytoplasm canals", "ANATOMY", 60, 76], ["virion", "ANATOMY", 89, 95], ["outer envelope", "ANATOMY", 139, 153], ["canals", "ANATOMY", 182, 188], ["membranes", "CELLULAR_COMPONENT", 43, 52], ["cytoplasm canals", "CELLULAR_COMPONENT", 60, 76], ["virion", "CELLULAR_COMPONENT", 89, 95], ["The dark substance", "PROBLEM", 0, 18], ["a nucleocapsid", "PROBLEM", 111, 125], ["an outer envelope", "TREATMENT", 136, 153], ["dark substance", "OBSERVATION", 4, 18], ["membranes", "ANATOMY_MODIFIER", 43, 52], ["cytoplasm canals", "ANATOMY", 60, 76], ["virion", "ANATOMY", 89, 95], ["nucleocapsid", "OBSERVATION", 113, 125], ["outer", "OBSERVATION_MODIFIER", 139, 144], ["envelope", "OBSERVATION_MODIFIER", 145, 153], ["canals", "ANATOMY_MODIFIER", 182, 188]]], ["The origin, chemical composition and function of the substance are still obscure.", [["origin", "ANATOMY_MODIFIER", 4, 10], ["chemical", "OBSERVATION_MODIFIER", 12, 20], ["composition", "OBSERVATION_MODIFIER", 21, 32]]], ["(3) A light zone can clearly be seen round some intranuclear nuclcoeapsids.", [["intranuclear nuclcoeapsids", "PROTEIN", 48, 74], ["intranuclear nuclcoeapsids", "OBSERVATION", 48, 74]]], ["The same zone separates the capsids of cytoplasmic and extracellular virious from the dark substance lying on the inner wall of the outer envelope.", [["cytoplasmic", "ANATOMY", 39, 50], ["extracellular", "ANATOMY", 55, 68], ["inner wall", "ANATOMY", 114, 124], ["outer envelope", "ANATOMY", 132, 146], ["cytoplasmic", "ORGANISM_SUBSTANCE", 39, 50], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 55, 68], ["inner wall", "TISSUE", 114, 124], ["outer envelope", "CELLULAR_COMPONENT", 132, 146], ["cytoplasmic and extracellular virious", "PROBLEM", 39, 76], ["the dark substance", "PROBLEM", 82, 100], ["zone", "OBSERVATION_MODIFIER", 9, 13], ["capsids", "OBSERVATION_MODIFIER", 28, 35], ["cytoplasmic", "OBSERVATION_MODIFIER", 39, 50], ["extracellular", "OBSERVATION_MODIFIER", 55, 68], ["dark substance", "OBSERVATION", 86, 100], ["inner", "ANATOMY_MODIFIER", 114, 119], ["wall", "ANATOMY_MODIFIER", 120, 124], ["outer envelope", "ANATOMY_MODIFIER", 132, 146]]], ["It is probably the inner envelope of the virion.Action o1 Some Inhibitors on Influenza Virus.S. HAVI&ROVX, G. Russ, Institute of Virology, Slovak Academy of Sciences, Bratislava.Action o1 Some Inhibitors on Influenza Virus.The authors studied inhibition of the replication of influenza virus and neuraminidase synthesis by N-tosyl-L-phenylalanyl ehloromethane, an inhibitor of prot~olytic enzymes, in influenza virus-infected cells.", [["virion", "ANATOMY", 41, 47], ["cells", "ANATOMY", 426, 431], ["Influenza Virus", "DISEASE", 207, 222], ["influenza", "DISEASE", 276, 285], ["N-tosyl-L-phenylalanyl ehloromethane", "CHEMICAL", 323, 359], ["influenza virus-infected", "DISEASE", 401, 425], ["N-tosyl-L-phenylalanyl ehloromethane", "CHEMICAL", 323, 359], ["inner envelope", "CELLULAR_COMPONENT", 19, 33], ["virion", "CELLULAR_COMPONENT", 41, 47], ["Influenza Virus", "ORGANISM", 207, 222], ["influenza virus", "ORGANISM", 276, 291], ["neuraminidase", "SIMPLE_CHEMICAL", 296, 309], ["N-tosyl-L-phenylalanyl ehloromethane", "SIMPLE_CHEMICAL", 323, 359], ["influenza virus", "ORGANISM", 401, 416], ["cells", "CELL", 426, 431], ["prot~olytic enzymes", "PROTEIN", 377, 396], ["influenza virus-infected cells", "CELL_TYPE", 401, 431], ["Influenza", "SPECIES", 77, 86], ["Influenza", "SPECIES", 207, 216], ["influenza virus", "SPECIES", 276, 291], ["influenza virus", "SPECIES", 401, 416], ["Influenza Virus", "SPECIES", 207, 222], ["influenza virus", "SPECIES", 276, 291], ["influenza virus", "SPECIES", 401, 416], ["o1 Some Inhibitors", "TREATMENT", 185, 203], ["Influenza Virus", "PROBLEM", 207, 222], ["influenza virus", "PROBLEM", 276, 291], ["neuraminidase synthesis", "TREATMENT", 296, 319], ["phenylalanyl ehloromethane", "TREATMENT", 333, 359], ["an inhibitor", "TREATMENT", 361, 373], ["prot~olytic enzymes", "TEST", 377, 396], ["influenza virus", "PROBLEM", 401, 416], ["infected cells", "PROBLEM", 417, 431], ["inner", "OBSERVATION_MODIFIER", 19, 24], ["envelope", "OBSERVATION_MODIFIER", 25, 33], ["virion", "OBSERVATION", 41, 47], ["influenza virus", "OBSERVATION", 401, 416], ["infected cells", "OBSERVATION", 417, 431]]], ["Influenza virus replication was found to be inhibited; neuraminidase synthesis in the infected cells was inhibited at the same time.", [["cells", "ANATOMY", 95, 100], ["Influenza virus", "ORGANISM", 0, 15], ["neuraminidase", "SIMPLE_CHEMICAL", 55, 68], ["cells", "CELL", 95, 100], ["neuraminidase", "PROTEIN", 55, 68], ["infected cells", "CELL_TYPE", 86, 100], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus replication", "TREATMENT", 0, 27], ["neuraminidase synthesis", "TREATMENT", 55, 78], ["the infected cells", "PROBLEM", 82, 100], ["infected cells", "OBSERVATION", 86, 100]]], ["These results are in agreement with the concept that large protein molecule precursors are synthesized in influenza virus-infected cells and that they are then broken down to virus structural proteins by proteolysis.", [["cells", "ANATOMY", 131, 136], ["influenza virus-infected", "DISEASE", 106, 130], ["influenza virus", "ORGANISM", 106, 121], ["cells", "CELL", 131, 136], ["infected cells", "CELL_TYPE", 122, 136], ["virus structural proteins", "PROTEIN", 175, 200], ["influenza virus", "SPECIES", 106, 121], ["influenza virus", "SPECIES", 106, 121], ["large protein molecule precursors", "PROBLEM", 53, 86], ["influenza virus", "PROBLEM", 106, 121], ["infected cells", "PROBLEM", 122, 136], ["large", "OBSERVATION_MODIFIER", 53, 58], ["protein molecule precursors", "OBSERVATION", 59, 86], ["influenza virus", "OBSERVATION", 106, 121], ["infected cells", "OBSERVATION", 122, 136]]], ["The influenza virus envelope proteins contain a large quantity of eysteine residues and the effect of S-methyl-L-eysteine on the replication of influenza virus was therefore tested.", [["S-methyl-L-eysteine", "CHEMICAL", 102, 121], ["eysteine", "CHEMICAL", 66, 74], ["S-methyl-L-eysteine", "CHEMICAL", 102, 121], ["influenza virus", "ORGANISM", 4, 19], ["S-methyl-L-eysteine", "SIMPLE_CHEMICAL", 102, 121], ["influenza virus", "ORGANISM", 144, 159], ["influenza virus envelope proteins", "PROTEIN", 4, 37], ["influenza virus", "SPECIES", 4, 19], ["influenza virus", "SPECIES", 144, 159], ["influenza virus", "SPECIES", 4, 19], ["influenza virus", "SPECIES", 144, 159], ["The influenza virus envelope proteins", "PROBLEM", 0, 37], ["eysteine residues", "PROBLEM", 66, 83], ["S-methyl-L-eysteine", "TREATMENT", 102, 121], ["influenza virus", "PROBLEM", 144, 159], ["influenza virus", "OBSERVATION", 4, 19], ["large", "OBSERVATION_MODIFIER", 48, 53], ["quantity", "OBSERVATION_MODIFIER", 54, 62], ["eysteine residues", "OBSERVATION", 66, 83], ["influenza virus", "OBSERVATION", 144, 159]]], ["Influenza virus replication was found to be inhibited.", [["Influenza virus", "ORGANISM", 0, 15], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus replication", "TREATMENT", 0, 27]]], ["The influence of temperature on the stability of the neuraminidase of influenza virus replicating in the presence of S-methyl-L-cysteine and on control virus neuraminidase was also compared.", [["S-methyl-L-cysteine", "CHEMICAL", 117, 136], ["S-methyl-L-cysteine", "CHEMICAL", 117, 136], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 53, 66], ["influenza virus", "ORGANISM", 70, 85], ["S-methyl-L-cysteine", "SIMPLE_CHEMICAL", 117, 136], ["control virus neuraminidase", "ORGANISM", 144, 171], ["neuraminidase", "PROTEIN", 53, 66], ["influenza virus", "SPECIES", 70, 85], ["influenza virus", "SPECIES", 70, 85], ["influenza virus", "PROBLEM", 70, 85], ["S-methyl-L-cysteine", "TREATMENT", 117, 136], ["control virus neuraminidase", "TREATMENT", 144, 171]]], ["The cysteine analogue was not found to have any effect on the thermostability of neuraminidase.E]]ect o1 l~Phage 812 The glucose oxidase activity of cells of S. aureus S/k 812, NCTC 8511, S 26 and SA 66 in the presence of the polyvalent and virulent staphylococcal phage 812 is reduced to 85.3--66.6% of the activity of cells not exposed to the action of the phage.", [["cells", "ANATOMY", 149, 154], ["cells", "ANATOMY", 320, 325], ["cysteine", "CHEMICAL", 4, 12], ["glucose", "CHEMICAL", 121, 128], ["NCTC 8511, S 26 and SA 66", "CHEMICAL", 177, 202], ["cysteine", "CHEMICAL", 4, 12], ["glucose", "CHEMICAL", 121, 128], ["cysteine", "AMINO_ACID", 4, 12], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 81, 94], ["glucose oxidase", "GENE_OR_GENE_PRODUCT", 121, 136], ["cells", "CELL", 149, 154], ["S. aureus S/k 812", "ORGANISM", 158, 175], ["NCTC 8511", "CELL", 177, 186], ["S 26", "CELL", 188, 192], ["SA 66", "ORGANISM", 197, 202], ["staphylococcal phage 812", "ORGANISM", 250, 274], ["cells", "CELL", 320, 325], ["neuraminidase", "PROTEIN", 81, 94], ["glucose oxidase", "PROTEIN", 121, 136], ["S. aureus", "SPECIES", 158, 167], ["S. aureus S/k 812", "SPECIES", 158, 175], ["NCTC 8511", "SPECIES", 177, 186], ["The cysteine analogue", "TEST", 0, 21], ["the thermostability of neuraminidase", "PROBLEM", 58, 94], ["ect o1", "TEST", 98, 104], ["The glucose oxidase activity", "TEST", 117, 145], ["S. aureus S", "TEST", 158, 169], ["k", "TEST", 170, 171], ["NCTC", "TEST", 177, 181], ["S", "TEST", 188, 189], ["SA", "TEST", 197, 199], ["the polyvalent", "TREATMENT", 222, 236], ["virulent staphylococcal phage", "TEST", 241, 270], ["aureus", "OBSERVATION", 161, 167]]], ["Oxidase activity was determined by the standard manometric Warburg method in 0.05M Tris medium at an input ratio of 10 -1.", [["Oxidase", "GENE_OR_GENE_PRODUCT", 0, 7], ["an input ratio", "TEST", 98, 112]]], ["The smallest drop in glucose oxidase activity was recorded in SA 66 cells (by 14.7~ to which a large proportion (92.3%) of phage 812 is adsorbed, but does not replicate.", [["SA 66 cells", "ANATOMY", 62, 73], ["glucose", "CHEMICAL", 21, 28], ["glucose", "CHEMICAL", 21, 28], ["glucose", "SIMPLE_CHEMICAL", 21, 28], ["oxidase", "GENE_OR_GENE_PRODUCT", 29, 36], ["SA 66 cells", "CELL", 62, 73], ["glucose oxidase", "PROTEIN", 21, 36], ["SA 66 cells", "CELL_LINE", 62, 73], ["The smallest drop in glucose oxidase activity", "PROBLEM", 0, 45], ["smallest", "OBSERVATION_MODIFIER", 4, 12], ["drop", "OBSERVATION_MODIFIER", 13, 17], ["glucose oxidase activity", "OBSERVATION", 21, 45]]], ["In the other organisms studied, the decrease in oxidase activity was roughly the same (29.3--33.4o/0) and was uncorrelated to the number of phage virious adsorbed and to their ability to replicate.", [["oxidase", "GENE_OR_GENE_PRODUCT", 48, 55], ["oxidase", "PROTEIN", 48, 55], ["the decrease in oxidase activity", "PROBLEM", 32, 64], ["decrease", "OBSERVATION_MODIFIER", 36, 44], ["oxidase activity", "OBSERVATION", 48, 64]]], ["The presence of phage 812 likewise has a negative effect on oxidation of the endogenous substrates of strains SA 812, NCTC 8511 and S 26, whereas 02 consumption by strain SA 66 cells for the oxidation of endogenous substrate does not alter significantly in the presence of phage 812.", [["SA 66 cells", "ANATOMY", 171, 182], ["phage 812", "CHEMICAL", 16, 25], ["SA 812", "CHEMICAL", 110, 116], ["NCTC 8511 and S 26", "CHEMICAL", 118, 136], ["SA 812", "ORGANISM", 110, 116], ["NCTC 8511", "CELL", 118, 127], ["S 26", "ORGANISM", 132, 136], ["SA 66 cells", "CELL", 171, 182], ["NCTC 8511", "SPECIES", 118, 127], ["strains SA", "TEST", 102, 112], ["NCTC", "TEST", 118, 122], ["S", "TEST", 132, 133], ["02 consumption", "TEST", 146, 160], ["the oxidation of endogenous substrate", "PROBLEM", 187, 224], ["negative effect", "OBSERVATION_MODIFIER", 41, 56]]], ["The drop in the glucose oxidase activity of the cells and in the oxidation of endogenous substrate is uneorrelated to the input ratio (IR), which is specific for the individual strains.", [["cells", "ANATOMY", 48, 53], ["glucose", "CHEMICAL", 16, 23], ["glucose", "CHEMICAL", 16, 23], ["glucose oxidase", "GENE_OR_GENE_PRODUCT", 16, 31], ["cells", "CELL", 48, 53], ["glucose oxidase", "PROTEIN", 16, 31], ["The drop in the glucose oxidase activity of the cells", "PROBLEM", 0, 53], ["the individual strains", "PROBLEM", 162, 184], ["drop", "OBSERVATION_MODIFIER", 4, 8], ["glucose oxidase activity", "OBSERVATION", 16, 40], ["endogenous substrate", "OBSERVATION", 78, 98]]], ["Strain SA 66 again forms an exception, since its oxidative activity is influenced irrespective of the number of virions present in the phage-bacteria mixture.Isolation o] Ph Item Coagulase-negative Staphy~ lococc~l Strains Isolated Item Clinical Martial.J. PrLLIC~, J. I-IAxLOVh, Institute of Biophysics, Czechoslovak Academy of Sciences, Brno.Isolation o] Ph Item Coagulase-negative Staphy~ lococc~l Strains Isolated Item Clinical Martial.Today there is an increase in the number of infections caused by eoagulase-negative staphylococci, which were once all regarded as saprophytes and contaminants of a primary pathogen.", [["SA 66", "CHEMICAL", 7, 12], ["infections", "DISEASE", 484, 494], ["eoagulase", "GENE_OR_GENE_PRODUCT", 505, 514], ["Strain SA", "TEST", 0, 9], ["Isolation", "TEST", 158, 167], ["Ph Item", "TEST", 171, 178], ["Coagulase", "TEST", 179, 188], ["Staphy", "TEST", 198, 204], ["Ph Item", "TEST", 357, 364], ["Coagulase", "TEST", 365, 374], ["Staphy", "TEST", 384, 390], ["infections", "PROBLEM", 484, 494], ["eoagulase-negative staphylococci", "PROBLEM", 505, 537], ["saprophytes", "PROBLEM", 571, 582], ["a primary pathogen", "PROBLEM", 603, 621], ["oxidative activity", "OBSERVATION", 49, 67], ["virions", "OBSERVATION", 112, 119], ["increase", "OBSERVATION_MODIFIER", 458, 466], ["number", "OBSERVATION_MODIFIER", 474, 480], ["infections", "OBSERVATION", 484, 494], ["negative staphylococci", "OBSERVATION", 515, 537]]], ["This group of bacteria now frequently causes chronic inflammations of the urinary passages, endocarditis, osteomyelitis and a number of other diseases.", [["urinary", "ANATOMY", 74, 81], ["inflammations of the urinary passages", "DISEASE", 53, 90], ["endocarditis", "DISEASE", 92, 104], ["osteomyelitis", "DISEASE", 106, 119], ["urinary", "ORGANISM_SUBDIVISION", 74, 81], ["bacteria", "PROBLEM", 14, 22], ["chronic inflammations", "PROBLEM", 45, 66], ["the urinary passages", "PROBLEM", 70, 90], ["endocarditis", "PROBLEM", 92, 104], ["osteomyelitis", "PROBLEM", 106, 119], ["other diseases", "PROBLEM", 136, 150], ["bacteria", "OBSERVATION", 14, 22], ["chronic", "OBSERVATION_MODIFIER", 45, 52], ["inflammations", "OBSERVATION", 53, 66], ["urinary passages", "ANATOMY", 74, 90], ["endocarditis", "OBSERVATION", 92, 104], ["osteomyelitis", "OBSERVATION", 106, 119], ["diseases", "OBSERVATION", 142, 150]]], ["We have concentrated, in our laboratory, over 150 of these strains from different laboratories in other countries, where they were isolated from a wide variety of infections.", [["infections", "DISEASE", 163, 173], ["these strains", "PROBLEM", 53, 66], ["infections", "PROBLEM", 163, 173], ["concentrated", "OBSERVATION_MODIFIER", 8, 20], ["wide", "OBSERVATION_MODIFIER", 147, 151], ["variety", "OBSERVATION_MODIFIER", 152, 159], ["infections", "OBSERVATION", 163, 173]]], ["Using mitomyein C and UV radiation, we suceeded in isolating phage strains with more or less specific effects in relation to the staphylococcal host.", [["mitomyein C", "CHEMICAL", 6, 17], ["mitomyein C", "CHEMICAL", 6, 17], ["mitomyein C", "SIMPLE_CHEMICAL", 6, 17], ["mitomyein C", "TREATMENT", 6, 17], ["UV radiation", "TREATMENT", 22, 34], ["isolating phage strains", "TREATMENT", 51, 74], ["the staphylococcal host", "TREATMENT", 125, 148], ["staphylococcal host", "OBSERVATION", 129, 148]]], ["So far we have observed definite relationships between coagulase-positive and coagulase-negative staphylococci isolated from clinical material, which can be expressed in terms of their sensitivity to individual phages.Autolytic Phenomenon in Pseudomonas aeruginosa.A. KAZDOV~, J. PILLICIt, Institute of Biophysics, Czechoslovak Academy of Sciences, Brno.Autolytic Phenomenon in Pseudomonas aeruginosa.One of the properties of Pseudomonas aeruginosa are the spontaneous lyric manifestations which can be observed on solid media.", [["coagulase-positive", "GENE_OR_GENE_PRODUCT", 55, 73], ["coagulase-negative staphylococci", "GENE_OR_GENE_PRODUCT", 78, 110], ["Pseudomonas aeruginosa", "ORGANISM", 378, 400], ["Pseudomonas aeruginosa", "ORGANISM", 426, 448], ["coagulase", "PROTEIN", 55, 64], ["coagulase", "PROTEIN", 78, 87], ["Pseudomonas aeruginosa", "SPECIES", 242, 264], ["Pseudomonas aeruginosa", "SPECIES", 378, 400], ["Pseudomonas aeruginosa", "SPECIES", 426, 448], ["Pseudomonas aeruginosa", "SPECIES", 242, 264], ["Pseudomonas aeruginosa", "SPECIES", 378, 400], ["Pseudomonas aeruginosa", "SPECIES", 426, 448], ["coagulase", "TEST", 55, 64], ["coagulase", "TEST", 78, 87], ["staphylococci", "PROBLEM", 97, 110], ["Autolytic Phenomenon in Pseudomonas aeruginosa", "PROBLEM", 218, 264], ["Autolytic Phenomenon in Pseudomonas aeruginosa", "PROBLEM", 354, 400], ["Pseudomonas aeruginosa", "PROBLEM", 426, 448], ["the spontaneous lyric manifestations", "PROBLEM", 453, 489], ["negative staphylococci", "OBSERVATION_MODIFIER", 88, 110], ["Pseudomonas aeruginosa", "OBSERVATION", 242, 264], ["Pseudomonas aeruginosa", "OBSERVATION", 378, 400], ["Pseudomonas", "OBSERVATION_MODIFIER", 426, 437], ["aeruginosa", "OBSERVATION", 438, 448], ["spontaneous", "OBSERVATION_MODIFIER", 457, 468], ["lyric manifestations", "OBSERVATION", 469, 489]]], ["AP), which closely resemble phage plaques.", [["plaques", "ANATOMY", 34, 41], ["AP", "GENE_OR_GENE_PRODUCT", 0, 2], ["phage plaques", "PROBLEM", 28, 41], ["phage", "OBSERVATION_MODIFIER", 28, 33], ["plaques", "OBSERVATION", 34, 41]]], ["About two thirds of Ps. aeruginosa strains are capable of forming AP.", [["Ps. aeruginosa strains", "ORGANISM", 20, 42], ["AP", "GENE_OR_GENE_PRODUCT", 66, 68], ["Ps. aeruginosa", "SPECIES", 20, 34], ["Ps. aeruginosa", "SPECIES", 20, 34], ["Ps. aeruginosa strains", "PROBLEM", 20, 42]]], ["An analysis of 150 colonies of strain whose AP production can be influenced by passaging showed that it is composed of colonies both producing and not producing AP, whereas AP production by strains not influenced by passaging is uniform.", [["colonies", "ANATOMY", 19, 27], ["colonies", "ANATOMY", 119, 127], ["AP", "GENE_OR_GENE_PRODUCT", 44, 46], ["AP", "GENE_OR_GENE_PRODUCT", 161, 163], ["AP", "GENE_OR_GENE_PRODUCT", 173, 175], ["AP", "PROTEIN", 173, 175], ["An analysis", "TEST", 0, 11], ["strain", "PROBLEM", 31, 37], ["colonies", "PROBLEM", 119, 127], ["strains", "PROBLEM", 190, 197], ["uniform", "OBSERVATION_MODIFIER", 229, 236]]], ["Ultracentrifugation of a culture of the autolytic strain Ps 170003 unh in a CsC1 density gradient showed the presence of phage in l0 s concentration in the zone corresponding to a density of 1,500 g/ec.", [["Ps 170003", "CHEMICAL", 57, 66], ["Ps 170003", "SPECIES", 57, 66], ["a culture", "TEST", 23, 32], ["the autolytic strain Ps", "TEST", 36, 59], ["a CsC1 density gradient", "TEST", 74, 97], ["phage", "PROBLEM", 121, 126], ["zone", "ANATOMY_MODIFIER", 156, 160], ["density", "OBSERVATION", 180, 187]]], ["The phage displayed normal morphology in the EM.", [["normal", "OBSERVATION", 20, 26], ["morphology", "OBSERVATION_MODIFIER", 27, 37]]], ["Direct, evidence that it induced AP formation was not obtained.", [["AP", "PATHOLOGICAL_FORMATION", 33, 35], ["AP formation", "PROBLEM", 33, 45]]], ["If AP are of phagic origin, the relationship between bacteriophage and host is evidently a specific, atypical one.Autolytic Phenomenon in Pseudomonas aeruginosa.Utilization o] the Agar Di//usion Method ]or Testing Radiomimetics.", [["AP", "GENE_OR_GENE_PRODUCT", 3, 5], ["Pseudomonas aeruginosa", "ORGANISM", 138, 160], ["AP", "PROTEIN", 3, 5], ["Pseudomonas aeruginosa", "SPECIES", 138, 160], ["Pseudomonas aeruginosa", "SPECIES", 138, 160], ["Autolytic Phenomenon in Pseudomonas aeruginosa", "PROBLEM", 114, 160], ["the Agar Di", "TEST", 176, 187], ["//usion Method", "TREATMENT", 187, 201], ["Pseudomonas aeruginosa", "OBSERVATION", 138, 160]]], ["Z. MALINKA, D. TouF.~ovk, Z.Autolytic Phenomenon in Pseudomonas aeruginosa.HnADk, Institute of Biophysics, Czechoslovak Academy of Sciences, Brno.Autolytic Phenomenon in Pseudomonas aeruginosa.The authors' aim was to verify the suitability of using the agar diffusion method to test radiomitactics and substances whose action has not, so far, been explained.", [["Pseudomonas aeruginosa", "ORGANISM", 52, 74], ["Pseudomonas aeruginosa", "ORGANISM", 170, 192], ["Pseudomonas aeruginosa", "SPECIES", 52, 74], ["Pseudomonas aeruginosa", "SPECIES", 170, 192], ["Pseudomonas aeruginosa", "SPECIES", 52, 74], ["Pseudomonas aeruginosa", "SPECIES", 170, 192], ["Z.Autolytic Phenomenon in Pseudomonas aeruginosa", "PROBLEM", 26, 74], ["Autolytic Phenomenon in Pseudomonas aeruginosa", "PROBLEM", 146, 192], ["the agar diffusion method", "TREATMENT", 249, 274], ["Pseudomonas aeruginosa", "OBSERVATION", 52, 74], ["Pseudomonas aeruginosa", "OBSERVATION", 170, 192]]], ["Hydroxylamine, the monofunetional alkylating agents ethylmethane sulphonate, 2-chloroethylamine and N,N-dimethyl-2-chloroethylamine and the bifunctional agents ypenyl and mitomycin C were used for testing.", [["Hydroxylamine", "CHEMICAL", 0, 13], ["ethylmethane sulphonate", "CHEMICAL", 52, 75], ["2-chloroethylamine", "CHEMICAL", 77, 95], ["N,N-dimethyl-2-chloroethylamine", "CHEMICAL", 100, 131], ["ypenyl", "CHEMICAL", 160, 166], ["mitomycin C", "CHEMICAL", 171, 182], ["Hydroxylamine", "CHEMICAL", 0, 13], ["ethylmethane sulphonate", "CHEMICAL", 52, 75], ["2-chloroethylamine", "CHEMICAL", 77, 95], ["N,N-dimethyl-2-chloroethylamine", "CHEMICAL", 100, 131], ["ypenyl", "CHEMICAL", 160, 166], ["mitomycin C", "CHEMICAL", 171, 182], ["Hydroxylamine", "SIMPLE_CHEMICAL", 0, 13], ["ethylmethane sulphonate", "SIMPLE_CHEMICAL", 52, 75], ["2-chloroethylamine", "SIMPLE_CHEMICAL", 77, 95], ["N,N-dimethyl-2-chloroethylamine", "SIMPLE_CHEMICAL", 100, 131], ["bifunctional agents ypenyl", "SIMPLE_CHEMICAL", 140, 166], ["mitomycin C", "SIMPLE_CHEMICAL", 171, 182], ["Hydroxylamine", "TREATMENT", 0, 13], ["the monofunetional alkylating agents ethylmethane sulphonate", "TREATMENT", 15, 75], ["chloroethylamine", "TREATMENT", 79, 95], ["N", "TREATMENT", 100, 101], ["N", "TREATMENT", 102, 103], ["dimethyl", "TREATMENT", 104, 112], ["chloroethylamine", "TREATMENT", 115, 131], ["the bifunctional agents ypenyl", "TREATMENT", 136, 166], ["mitomycin C", "TREATMENT", 171, 182], ["testing", "TEST", 197, 204]]], ["Several nitrofurans, sugar analogues and microbial metabelites were also employed.", [["nitrofurans", "CHEMICAL", 8, 19], ["nitrofurans", "CHEMICAL", 8, 19], ["sugar", "CHEMICAL", 21, 26], ["nitrofurans", "SIMPLE_CHEMICAL", 8, 19], ["sugar analogues", "SIMPLE_CHEMICAL", 21, 36], ["Several nitrofurans", "TREATMENT", 0, 19], ["sugar analogues", "TREATMENT", 21, 36], ["microbial metabelites", "TREATMENT", 41, 62]]], ["The lysogenic strain E. cell C 600 lambda was used to study the inductive effect of the substances.", [["E. cell C", "CELL", 21, 30], ["The lysogenic strain E. cell C 600 lambda", "TREATMENT", 0, 41], ["lysogenic", "OBSERVATION_MODIFIER", 4, 13], ["strain", "OBSERVATION_MODIFIER", 14, 20], ["E. cell", "OBSERVATION_MODIFIER", 21, 28]]], ["Phage inactivation was studied in phage lambda cb2.", [["phage lambda cb2", "GENE_OR_GENE_PRODUCT", 34, 50], ["phage lambda cb2", "DNA", 34, 50], ["Phage inactivation", "TREATMENT", 0, 18]]], ["In both cases the indicator organism was E. cell C 600.", [["cell", "ANATOMY", 44, 48], ["E. cell C", "CELL", 41, 50]]], ["An inductive effect was manifested in an increase in the number of plaques, an antiviral effect in a distinct decrease in the number of plaques in the diffusion zone of the substance.", [["plaques", "ANATOMY", 67, 74], ["plaques", "ANATOMY", 136, 143], ["plaques", "DISEASE", 67, 74], ["plaques", "DISEASE", 136, 143], ["plaques", "PATHOLOGICAL_FORMATION", 67, 74], ["An inductive effect", "PROBLEM", 0, 19], ["plaques", "PROBLEM", 67, 74], ["an antiviral effect", "PROBLEM", 76, 95], ["a distinct decrease", "PROBLEM", 99, 118], ["plaques", "PROBLEM", 136, 143], ["inductive effect", "OBSERVATION", 3, 19], ["increase", "OBSERVATION_MODIFIER", 41, 49], ["number", "OBSERVATION_MODIFIER", 57, 63], ["plaques", "OBSERVATION", 67, 74], ["antiviral effect", "OBSERVATION", 79, 95], ["distinct", "OBSERVATION_MODIFIER", 101, 109], ["decrease", "OBSERVATION_MODIFIER", 110, 118], ["number", "OBSERVATION_MODIFIER", 126, 132], ["plaques", "OBSERVATION", 136, 143], ["diffusion zone", "ANATOMY_MODIFIER", 151, 165], ["substance", "OBSERVATION", 173, 182]]], ["None of the three monofunctional alkylating agents was found to influence prophage induction.", [["alkylating agents", "CHEMICAL", 33, 50], ["the three monofunctional alkylating agents", "TREATMENT", 8, 50], ["prophage induction", "TREATMENT", 74, 92]]], ["With the two bifunctional akylating agents, induction occurred in both cases.", [["the two bifunctional akylating agents", "TREATMENT", 5, 42], ["induction", "TREATMENT", 44, 53]]], ["Some of the other test substances also had an inductive effect, but it was significantly weaker.", [["the other test substances", "TEST", 8, 33]]], ["2-ehloroethylamine and some sugar analogues, nitrefurans and microbial metabolites displayed an antiviral effect.", [["2-ehloroethylamine", "CHEMICAL", 0, 18], ["nitrefurans", "CHEMICAL", 45, 56], ["2-ehloroethylamine", "CHEMICAL", 0, 18], ["sugar", "CHEMICAL", 28, 33], ["nitrefurans", "CHEMICAL", 45, 56], ["2-ehloroethylamine", "SIMPLE_CHEMICAL", 0, 18], ["sugar analogues", "SIMPLE_CHEMICAL", 28, 43], ["nitrefurans", "SIMPLE_CHEMICAL", 45, 56], ["ehloroethylamine", "TREATMENT", 2, 18], ["some sugar analogues", "TREATMENT", 23, 43], ["nitrefurans", "TREATMENT", 45, 56], ["microbial metabolites", "TEST", 61, 82], ["an antiviral effect", "PROBLEM", 93, 112], ["antiviral effect", "OBSERVATION", 96, 112]]], ["The electrophoretic profiles of the doublestranded RNA formed in large amounts in nonpermissive host bacteria infected with phage f2 sns 11 were determined.", [["doublestranded RNA", "RNA", 36, 54], ["phage f2 sns 11", "DNA", 124, 139], ["phage f2 sns 11", "SPECIES", 124, 139], ["The electrophoretic profiles", "TEST", 0, 28], ["the doublestranded RNA", "TREATMENT", 32, 54], ["large amounts", "PROBLEM", 65, 78], ["nonpermissive host bacteria", "PROBLEM", 82, 109], ["phage f2 sns", "TREATMENT", 124, 136], ["large", "OBSERVATION_MODIFIER", 65, 70], ["amounts", "OBSERVATION_MODIFIER", 71, 78], ["nonpermissive host", "OBSERVATION_MODIFIER", 82, 100], ["bacteria", "OBSERVATION_MODIFIER", 101, 109], ["infected", "OBSERVATION_MODIFIER", 110, 118]]], ["Short-term labelling at different intervals of the defective replication cycle shows that the molecular weight of the newly formed RNA is not progressively reduced, but that the dnuble-strandcd RNA formed soon after infection is progressively degraded to low molecular weight fragments.", [["infection", "DISEASE", 216, 225], ["dnuble-strandcd", "GENE_OR_GENE_PRODUCT", 178, 193], ["newly formed RNA", "RNA", 118, 134], ["dnuble-strandcd RNA", "RNA", 178, 197], ["the defective replication cycle", "TREATMENT", 47, 78], ["the newly formed RNA", "PROBLEM", 114, 134], ["the dnuble-strandcd RNA", "TREATMENT", 174, 197], ["infection", "PROBLEM", 216, 225], ["low molecular weight fragments", "PROBLEM", 255, 285], ["defective replication", "OBSERVATION", 51, 72], ["RNA", "OBSERVATION", 131, 134], ["not", "UNCERTAINTY", 138, 141], ["progressively", "OBSERVATION_MODIFIER", 142, 155], ["reduced", "OBSERVATION_MODIFIER", 156, 163], ["infection", "OBSERVATION", 216, 225], ["low molecular", "OBSERVATION_MODIFIER", 255, 268], ["weight fragments", "OBSERVATION", 269, 285]]], ["On using a strain deficient in RNAse III, which specifically breaks down double-stranded RNA, degradation does not occur and an intact replicating form is obtained.", [["RNAse III", "GENE_OR_GENE_PRODUCT", 31, 40], ["RNAse III", "PROTEIN", 31, 40], ["double-stranded RNA", "RNA", 73, 92], ["a strain deficient in RNAse III", "PROBLEM", 9, 40], ["double-stranded RNA", "PROBLEM", 73, 92], ["RNAse III", "OBSERVATION_MODIFIER", 31, 40], ["stranded RNA", "OBSERVATION_MODIFIER", 80, 92], ["intact", "OBSERVATION", 128, 134]]], ["The results show that the greater part of the hyperproppced complementary RNA already forms a bihelical structure in the cells, i.e. prior to isolation, so that it loses its template function and undergoes gradual degradation by RNAse III.", [["cells", "ANATOMY", 121, 126], ["cells", "CELL", 121, 126], ["RNAse III", "GENE_OR_GENE_PRODUCT", 229, 238], ["hyperproppced complementary RNA", "RNA", 46, 77], ["RNAse III", "PROTEIN", 229, 238], ["a bihelical structure in the cells", "PROBLEM", 92, 126], ["isolation", "TREATMENT", 142, 151], ["greater", "OBSERVATION_MODIFIER", 26, 33], ["gradual", "OBSERVATION_MODIFIER", 206, 213], ["degradation", "OBSERVATION_MODIFIER", 214, 225]]], ["Only a small portion of the RNA keeps its monohelical-stranded structure and template function.", [["monohelical-stranded structure", "PROTEIN", 42, 72], ["a small portion of the RNA", "PROBLEM", 5, 31], ["small", "OBSERVATION_MODIFIER", 7, 12], ["portion", "OBSERVATION_MODIFIER", 13, 20], ["RNA", "OBSERVATION", 28, 31], ["stranded structure", "OBSERVATION", 54, 72], ["template function", "OBSERVATION", 77, 94]]], ["This part of the RNA does not undergo intracellular degradation.Virulent Mutants o/Salmonella typhimurium Phage\"L\".", [["intracellular", "ANATOMY", 38, 51], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 38, 51], ["Salmonella typhimurium", "ORGANISM", 83, 105], ["Salmonella typhimurium", "SPECIES", 83, 105], ["Salmonella typhimurium", "SPECIES", 83, 105], ["intracellular degradation", "PROBLEM", 38, 63], ["does not undergo", "UNCERTAINTY", 21, 37], ["intracellular degradation", "OBSERVATION", 38, 63]]], ["J. SowVirulent Mutants o/Salmonella typhimurium PhageInstitute of Biophysics, Czechoslovak Academy of Sciences, Brno.Virulent Mutants o/Salmonella typhimurium PhageA series of \"clear\" mutants of Salmonella typhimurium phage \"L\", different from the typical type ex, cn and ciii mutants, was isolated.", [["Salmonella typhimurium", "ORGANISM", 25, 47], ["Mutants o/Salmonella typhimurium", "ORGANISM", 126, 158], ["Salmonella typhimurium", "ORGANISM", 195, 217], ["phage", "ORGANISM", 218, 223], ["cn", "GENE_OR_GENE_PRODUCT", 265, 267], ["ciii", "GENE_OR_GENE_PRODUCT", 272, 276], ["Salmonella typhimurium", "SPECIES", 25, 47], ["Salmonella typhimurium", "SPECIES", 136, 158], ["Salmonella typhimurium", "SPECIES", 195, 217], ["Salmonella typhimurium", "SPECIES", 25, 47], ["Salmonella typhimurium", "SPECIES", 136, 158], ["Salmonella typhimurium", "SPECIES", 195, 217], ["Salmonella typhimurium", "TEST", 136, 158], ["Salmonella typhimurium phage", "PROBLEM", 195, 223], ["ciii mutants", "PROBLEM", 272, 284], ["ciii", "ANATOMY", 272, 276]]], ["The properties of the mutant designated as B 14 were studied in detail.", [["B 14", "ORGANISM", 43, 47], ["B 14", "PROTEIN", 43, 47]]], ["The mutant was localized by means of crosses in the zone between the genes cII (the gene for the represser) and ci (the gene for the activator of the repressorl.", [["cII", "GENE_OR_GENE_PRODUCT", 75, 78], ["ci", "GENE_OR_GENE_PRODUCT", 112, 114], ["cII", "DNA", 75, 78], ["represser", "DNA", 97, 106], ["ci", "DNA", 112, 114], ["repressorl", "DNA", 150, 160], ["the represser)", "TREATMENT", 93, 107]]], ["This mutant, like other, similar, independently isolated mutants, is remarkable in that it produces phenotypically virulent mutants capable of vegetative growth on lysogen LT2 (L) with relatively high frequency.", [["phenotypically virulent mutants", "PROBLEM", 100, 131], ["vegetative growth", "PROBLEM", 143, 160], ["vegetative", "OBSERVATION_MODIFIER", 143, 153], ["growth", "OBSERVATION_MODIFIER", 154, 160], ["relatively", "OBSERVATION_MODIFIER", 185, 195], ["high", "OBSERVATION", 196, 200]]], ["The nature of the other mutation leading to virulence has not yet been determined.", [["the other mutation", "PROBLEM", 14, 32], ["virulence", "PROBLEM", 44, 53]]], ["According to the fregueney of back-recombinations, it is likewise in thB \"c\" zone of the phage chromosome, however, \"Virulent\" mutants are complementary with ci and clix mutants.", [["chromosome", "ANATOMY", 95, 105], ["phage chromosome", "CELLULAR_COMPONENT", 89, 105], ["ci", "GENE_OR_GENE_PRODUCT", 158, 160], ["clix", "GENE_OR_GENE_PRODUCT", 165, 169], ["phage chromosome", "DNA", 89, 105], ["ci and clix mutants", "PROTEIN", 158, 177], ["back", "ANATOMY", 30, 34]]], ["The initial B 14 mutant is capable of lysogenizing an infected cell.", [["cell", "ANATOMY", 63, 67], ["B 14 mutant", "ORGANISM", 12, 23], ["cell", "CELL", 63, 67], ["B 14 mutant", "PROTEIN", 12, 23], ["lysogenizing an infected cell", "PROBLEM", 38, 67], ["infected cell", "OBSERVATION", 54, 67]]], ["Some of the resultant lysogens are defective.", [["the resultant lysogens", "PROBLEM", 8, 30], ["defective", "PROBLEM", 35, 44], ["resultant", "OBSERVATION_MODIFIER", 12, 21], ["lysogens", "OBSERVATION", 22, 30]]], ["The biological effect of o-methylhydroxylamine (OMHA)-modified adenine on phage T4 was studied by means of a non-sense phage T4 mutant.", [["o-methylhydroxylamine", "CHEMICAL", 25, 46], ["OMHA", "CHEMICAL", 48, 52], ["adenine", "CHEMICAL", 63, 70], ["o-methylhydroxylamine", "CHEMICAL", 25, 46], ["OMHA", "CHEMICAL", 48, 52], ["adenine", "CHEMICAL", 63, 70], ["o-methylhydroxylamine", "SIMPLE_CHEMICAL", 25, 46], ["OMHA", "SIMPLE_CHEMICAL", 48, 52], [")-modified adenine", "SIMPLE_CHEMICAL", 52, 70], ["phage T4", "SIMPLE_CHEMICAL", 74, 82], ["non-sense phage T4 mutant", "PROTEIN", 109, 134], ["o-methylhydroxylamine (OMHA)", "TREATMENT", 25, 53], ["modified adenine on phage T4", "TREATMENT", 54, 82], ["a non-sense phage", "TREATMENT", 107, 124]]], ["The rate of OMHA modification of adenine was 50 to I00 times lower than the rate for cytosine.", [["adenine", "CHEMICAL", 33, 40], ["cytosine", "CHEMICAL", 85, 93], ["adenine", "CHEMICAL", 33, 40], ["cytosine", "CHEMICAL", 85, 93], ["OMHA", "SIMPLE_CHEMICAL", 12, 16], ["adenine", "SIMPLE_CHEMICAL", 33, 40], ["cytosine", "SIMPLE_CHEMICAL", 85, 93], ["OMHA modification of adenine", "TREATMENT", 12, 40], ["cytosine", "TREATMENT", 85, 93]]], ["Modified adenine derivatives display very low activity in the RNA-polymerase system and their biological activity is therefore presumably also low.", [["adenine", "CHEMICAL", 9, 16], ["adenine", "CHEMICAL", 9, 16], ["Modified adenine derivatives", "SIMPLE_CHEMICAL", 0, 28], ["Modified adenine derivatives", "TREATMENT", 0, 28], ["very low activity in the RNA-polymerase system", "PROBLEM", 37, 83], ["very", "OBSERVATION_MODIFIER", 37, 41], ["low activity", "OBSERVATION", 42, 54], ["low", "OBSERVATION_MODIFIER", 143, 146]]], ["In the ease of phage T4, however, study of reversions of amber and ochre mutants shows that OMHA also caused type A--G transitions.", [["OMHA", "CHEMICAL", 92, 96], ["OMHA", "SIMPLE_CHEMICAL", 92, 96], ["OMHA", "PROTEIN", 92, 96], ["type A--G transitions", "PROBLEM", 109, 130]]], ["Unlike other systems, this transition accounts for a relatively large proportion of the total mutagenic effect of OMHA on phage T4.El/ect o/ O-methylhydroxylamine on Lambda Phage.L. DOBIk~, Z. HRADES~rk, I. KoR~kKOVk, Institute of Biophysics, Czechoslovak Academy of Sciences, Brno.El/ect o/ O-methylhydroxylamine on Lambda Phage.Raised non-exponential inactivation of lambda phage was demonstrated during short-term exposure to 1~ o-methylhydroxylamine.", [["OMHA", "CHEMICAL", 114, 118], ["El/ect o/ O-methylhydroxylamine", "CHEMICAL", 131, 162], ["El/ect o/ O-methylhydroxylamine", "CHEMICAL", 282, 313], ["1~ o-methylhydroxylamine", "CHEMICAL", 429, 453], ["OMHA", "CHEMICAL", 114, 118], ["ect o/ O-methylhydroxylamine", "CHEMICAL", 134, 162], ["ect o/ O-methylhydroxylamine", "CHEMICAL", 285, 313], ["1~ o-methylhydroxylamine", "CHEMICAL", 429, 453], ["OMHA", "SIMPLE_CHEMICAL", 114, 118], ["phage T4", "GENE_OR_GENE_PRODUCT", 122, 130], ["ect o/ O-methylhydroxylamine", "SIMPLE_CHEMICAL", 134, 162], ["ect o/ O-methylhydroxylamine", "SIMPLE_CHEMICAL", 285, 313], ["Lambda Phage", "GENE_OR_GENE_PRODUCT", 317, 329], ["lambda phage", "GENE_OR_GENE_PRODUCT", 369, 381], ["1~ o-methylhydroxylamine", "SIMPLE_CHEMICAL", 429, 453], ["Lambda Phage", "DNA", 317, 329], ["lambda phage", "DNA", 369, 381], ["OMHA on phage T4", "TREATMENT", 114, 130], ["methylhydroxylamine", "TREATMENT", 143, 162], ["Lambda Phage", "TREATMENT", 166, 178], ["methylhydroxylamine", "TREATMENT", 294, 313], ["Lambda Phage", "TREATMENT", 317, 329], ["Raised non-exponential inactivation of lambda phage", "PROBLEM", 330, 381], ["-methylhydroxylamine", "TREATMENT", 433, 453], ["mutagenic effect", "OBSERVATION", 94, 110], ["lambda phage", "OBSERVATION", 369, 381], ["short-term", "OBSERVATION_MODIFIER", 406, 416]]], ["Under these conditions, the lethal effect is probably caused by bonds between the phage DNA and protein.", [["DNA", "CELLULAR_COMPONENT", 88, 91], ["phage DNA and protein", "PROTEIN", 82, 103], ["the lethal effect", "PROBLEM", 24, 41]]], ["Phage DNA damage can be repaired by the host cell's enzymatic system, as in UV inactivation.", [["cell", "ANATOMY", 45, 49], ["DNA", "CELLULAR_COMPONENT", 6, 9], ["host cell", "CELL", 40, 49], ["Phage DNA damage", "PROBLEM", 0, 16], ["UV inactivation", "OBSERVATION", 76, 91]]], ["Phage DNA repair is stimulated either by the host cell alone, or by sublethal doses of UV radiation, to which the host cell is exposed prior to infection with phage.", [["cell", "ANATOMY", 50, 54], ["cell", "ANATOMY", 119, 123], ["UV", "CHEMICAL", 87, 89], ["infection", "DISEASE", 144, 153], ["DNA", "CELLULAR_COMPONENT", 6, 9], ["host cell", "CELL", 45, 54], ["host cell", "CELL", 114, 123], ["Phage DNA repair", "TREATMENT", 0, 16], ["UV radiation", "TREATMENT", 87, 99], ["infection", "PROBLEM", 144, 153], ["phage", "TREATMENT", 159, 164], ["repair", "OBSERVATION", 10, 16], ["host cell", "OBSERVATION", 114, 123], ["infection", "OBSERVATION", 144, 153]]]], "2cbcf01c6c380106e7f2031eaa82f5052058d15e": [["Sir, Since a group of unknown pneumonia patients were found in December 2019 in Wuhan, China, a novel coronavirus (nCoV), suddenly came into our sight [1] .", [["pneumonia", "DISEASE", 30, 39], ["patients", "ORGANISM", 40, 48], ["coronavirus", "ORGANISM", 102, 113], ["patients", "SPECIES", 40, 48], ["unknown pneumonia", "PROBLEM", 22, 39], ["a novel coronavirus", "PROBLEM", 94, 113], ["pneumonia", "OBSERVATION", 30, 39]]], ["Although WHO noted in 2003 that no cases of SARS-CoV have been reported due to transfusion of blood products, there is still a theoretical risk of transmission of SARS-CoV-2 through blood transfusion.", [["blood", "ANATOMY", 94, 99], ["blood", "ANATOMY", 182, 187], ["SARS-CoV", "DISEASE", 44, 52], ["SARS", "DISEASE", 163, 167], ["SARS-CoV", "ORGANISM", 44, 52], ["blood", "ORGANISM_SUBSTANCE", 94, 99], ["SARS-CoV-2", "ORGANISM", 163, 173], ["blood", "ORGANISM_SUBSTANCE", 182, 187], ["SARS-CoV", "SPECIES", 44, 52], ["SARS-CoV", "SPECIES", 163, 171], ["SARS", "PROBLEM", 44, 48], ["CoV", "PROBLEM", 49, 52], ["transfusion of blood products", "TREATMENT", 79, 108], ["SARS", "PROBLEM", 163, 167], ["CoV", "TEST", 168, 171], ["blood transfusion", "TREATMENT", 182, 199]]], ["Additionally, with more asymptomatic carriers of the COVID-19, blood safety is worthy of consideration.", [["blood", "ANATOMY", 63, 68], ["blood", "ORGANISM_SUBSTANCE", 63, 68], ["COVID-19", "DNA", 53, 61], ["the COVID", "TEST", 49, 58], ["blood safety", "TEST", 63, 75]]], ["The current recommendations are based largely on the new guidelines released by AABB, and a precautionary approach includes vigilant blood donor surveillance which is the desirable need of the hour [5].", [["blood", "ANATOMY", 133, 138], ["blood", "ORGANISM_SUBSTANCE", 133, 138], ["a precautionary approach", "TREATMENT", 90, 114], ["vigilant blood donor surveillance", "TEST", 124, 157]]]], "1516bf34fa269684379b443f4b82d3de53db7160": [["Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide, resulting in a pandemic [1] .", [["Coronavirus disease", "DISEASE", 0, 19], ["COVID-19", "CHEMICAL", 26, 34], ["acute respiratory syndrome coronavirus", "DISEASE", 53, 91], ["SARS-CoV-2)", "CHEMICAL", 95, 106], ["COVID-19", "ORGANISM", 26, 34], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 46, 93], ["SARS-CoV-2", "ORGANISM", 95, 105], ["Coronavirus disease 2019 (COVID-19", "SPECIES", 0, 34], ["severe acute respiratory syndrome coronavirus", "SPECIES", 46, 91], ["SARS-CoV-2", "SPECIES", 95, 105], ["Coronavirus disease", "PROBLEM", 0, 19], ["COVID", "TEST", 26, 31], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 46, 91], ["severe", "OBSERVATION_MODIFIER", 46, 52], ["acute", "OBSERVATION_MODIFIER", 53, 58], ["respiratory syndrome", "OBSERVATION", 59, 79]]], ["Since there is no proven effective treatment for severe COVID-19, combining antiviral and antiinflammatory agents may be an alternative to improve patient outcomes [2] .", [["COVID-19", "CHEMICAL", 56, 64], ["patient", "ORGANISM", 147, 154], ["patient", "SPECIES", 147, 154], ["severe COVID", "PROBLEM", 49, 61], ["combining antiviral", "TREATMENT", 66, 85], ["antiinflammatory agents", "TREATMENT", 90, 113], ["no proven", "UNCERTAINTY", 15, 24], ["effective", "OBSERVATION_MODIFIER", 25, 34]]], ["Here, we report five patients with severe COVID-19 pneumonia who improved with triple combination therapy, with lopinavir/ritonavir (LPV/r), hydroxychloroquine, and interferon \u03b2-1b.", [["COVID", "DISEASE", 42, 47], ["pneumonia", "DISEASE", 51, 60], ["lopinavir/ritonavir", "CHEMICAL", 112, 131], ["LPV", "CHEMICAL", 133, 136], ["hydroxychloroquine", "CHEMICAL", 141, 159], ["interferon \u03b2-1b", "CHEMICAL", 165, 180], ["lopinavir", "CHEMICAL", 112, 121], ["ritonavir", "CHEMICAL", 122, 131], ["LPV", "CHEMICAL", 133, 136], ["hydroxychloroquine", "CHEMICAL", 141, 159], ["patients", "ORGANISM", 21, 29], ["lopinavir", "SIMPLE_CHEMICAL", 112, 121], ["ritonavir", "SIMPLE_CHEMICAL", 122, 131], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 141, 159], ["interferon \u03b2-1b", "GENE_OR_GENE_PRODUCT", 165, 180], ["interferon", "PROTEIN", 165, 175], ["patients", "SPECIES", 21, 29], ["severe COVID-19 pneumonia", "PROBLEM", 35, 60], ["triple combination therapy", "TREATMENT", 79, 105], ["lopinavir", "TREATMENT", 112, 121], ["ritonavir", "TREATMENT", 122, 131], ["LPV/r)", "TREATMENT", 133, 139], ["hydroxychloroquine", "TREATMENT", 141, 159], ["interferon", "TREATMENT", 165, 175], ["pneumonia", "OBSERVATION", 51, 60]]], ["Lowdose, short term corticosteroids were also used to reduce excessive inflammation.", [["inflammation", "DISEASE", 71, 83], ["corticosteroids", "CHEMICAL", 20, 35], ["Lowdose", "TREATMENT", 0, 7], ["short term corticosteroids", "TREATMENT", 9, 35], ["excessive inflammation", "PROBLEM", 61, 83], ["short term", "OBSERVATION_MODIFIER", 9, 19], ["excessive", "OBSERVATION_MODIFIER", 61, 70], ["inflammation", "OBSERVATION", 71, 83]]], ["The clinical courses of the patients are summarized in Figure 1 .", [["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36]]]]}